Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof

Abstract

The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

Description

FIELD OF THE INVENTION

The present invention relates to compounds which act as antagonists for MCH receptors and to the use of these compounds in pharmaceutical compositions.

BACKGROUND OF THE INVENTION

Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/neuromodulator to alter a number of behavioral responses such as feeding habits. For example, injection of MCH into rats has been reported to increase their consumption of food. Reports indicate that genetically engineered mice which lack MCH show lower body weight and increased metabolism. See Saito et al., TEM, vol. 11, 299 (2000). As such, the literature suggests that discovery of MCH antagonists that interact with SCL-1 expressing cells will be useful in developing obesity treatments. See Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999).

G protein-coupled receptors (GPCRs) share a common structural motif. All these receptors have seven sequences of between 22 to 24 hydrophobic amino acids that form seven alpha helices, each of which spans the membrane. The fourth and fifth transmembrane helices are joined on the extracellular side of the membrane by a strand of amino acids that forms a relatively large loop. Another larger loop, composed primarily of hydrophilic amino acids, joins transmembrane helices five and six on the intracellular side of the membrane. The carboxy terminus of the receptor lies intracellularly, and the amino terminus lies in the extracellular space. It is thought that the loop joining helices five and six, as well as the carboxy terminus, interact with the G protein. Currently, Gq, Gs, Gi, and Go are G proteins that have been identified as possible proteins that interact with the receptor.

Under physiological conditions, GPCRs exist in the cell membrane in equilibrium between two different states or conformations: an “inactive” state and an “active” state. A receptor in an inactive state is unable to link to the intracellular transduction pathway to produce a biological response. Changing the receptor conformation to the active state allows linkage to the transduction pathway and produces a biological response.

A receptor may be stabilized in an active state by an endogenous ligand or an exogenous agonist ligand. Recent discoveries, including but not exclusively limited to, modifications to the amino acid sequence of the receptor, provide alternative mechanisms other than ligands to stabilize the active state conformation. These approaches effectively stabilize the receptor in an active state by simulating the effect of a ligand binding to the receptor. Stabilization by such ligand-independent approaches is termed “constitutive receptor activation.” In contrast, antagonists can competitively bind to the receptor at the same site as agonists, but do not activate the intracellular response initiated by the active form of the receptor, and therefore inhibit the intracellular responses by agonists.

Certain 2-aminoquinazoline derivatives have been reported to be NPY antagonists which are said to be effective in the treatment of disorders and diseases associated with the NPY receptor subtype Y5. See PCT Patent Application 97/20823. Quinazoline derivatives have also been found to be useful by enhancing antitumor activity. See PCT Patent Application 92/07844. And also the quinoline derivatives which have an antagonist activity for MCH receptor are known in these patents, WO03/070244, WO03/105850, WO03/45313, WO03/045920, and WO04/04726.

Recently, our current knowledge of human obesity has advanced dramatically. Previously, obesity was viewed as an oppugnant behavior of inappropriate eating in the setting of appealing foods. Studies of animal models of obesity, biochemical alterations in both humans and animals, and the complex interactions of psychosocial and cultural factors that create receptiveness to human obesity indicate that this disease in humans is multifaceted and deeply entrenched in biologic systems. Thus, it is almost certain that obesity has multiple causes and that there are different types of obesity. Not only does MCHR1 antagonist have potent and durable anti-obesity effects in rodents, it has surprising antidepressant and anxiolytic properties as well (Borowsky et al., Nature Medicine, 8, 825-830, 2002). MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models such as social interaction, forced swimming test and ultrasonic vocalization. These findings indicate that MCHR1 antagonists could be useful for treatment of obesity patients with multiple causes. Moreover, MCHR1 antagonists could be used to treat subjects not only with obesity, but also those with depression and anxiety. These advantages make it different from NPY receptor antagonists, with which anxiogenic-like activity can be expected, as NPY itself has anxiolytic-like effect.

Obesity is also regarded as a chronic disease and the possibly of long-term treatment is a concept that is receiving more attention. In this context, it is noteworthy that the depletion of MCH leads to hypophagia as well as leanness (Shimada et al., Nature, 396, 670-674, 1998). By contrast, NPY (Erickson et al., Nature, 381, 415-418, 1996), as well as the Y1 (Pedrazzini et al., Nature Medicine, 4, 722-726, 1998) and Y5 receptors (Marsh et al., Nature Medicine, 4, 718-721, 1998), disrupted mice maintained a stable body weight or rather became obese. Considering the above reports, MCHR1 antagonists can be more attractive than Y1 or Y5 receptor antagonists in terms of long-term treatment of obese patients.

Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals and human. However, the molecular mechanisms that are involved in obesity-diabetes syndromes are not clear. During early development of obesity, increase insulin secretion balances insulin resistance and protects patients from hyperglycemia (Le Stunff, et al. Diabetes 43, 696-702 (1989)). However, after several decades, β cell function deteriorates and non-insulin-dependent diabetes develops in about 20% of the obese population (Pederson, P. Diab. Metab. Rev. 5, 505-509 (1989)) and (Brancati, F. L., et al., Arch. Intern. Med. 159, 957-963 (1999)). Given its high prevalence in modern societies, obesity has thus become the leading risk factor for NIDDM (Hill, J. O., et al., Science 280, 1371-1374 (1998)). However, the factors which predispose a fraction of patients to alteration of insulin secretion in response to fat accumulation remain unknown.

Whether someone is classified as overweight or obese is generally determined on the basis of their body mass index (BMI) which is calculated by dividing body weight (kg) by height squared (m²). Thus, the units of BMI are kg/m² and it is possible to calculate the BMI range associated with minimum mortality in each decade of life. Overweight is defined as a BMI in the range 25-30 kg/M², and obesity as a BMI greater than 30 kg/m² (see TABLE below). There are problems with this definition in that it does not take into account the proportion of body mass that is muscle in relation to fat (adipose tissue). To account for this, obesity can also be defined on the basis of body fat content: greater than 25% and 30% in males and females, respectively.

CLASSIFICATION OF WEIGHT BY
BODY MASS INDEX (BMI)
BMI       CLASSIFICATION
<18.5     Underweight
18.5-24.9 Normal
25.0-29.9 Overweight
30.0-34.9 Obesity (Class I)
35.0-39.9 Obesity (Class II)
>40       Extreme Obesity (Class III)

As the BMI increases there is an increased risk of death from a variety of causes that is independent of other risk factors. The most common diseases with obesity are cardiovascular disease (particularly hypertension), diabetes (obesity aggravates the development of diabetes), gall bladder disease (particularly cancer) and diseases of reproduction. Research has shown that even a modest reduction in body weight can correspond to a significant reduction in the risk of developing coronary heart disease.

Compounds marketed as anti-obesity agents include Orlistat (XENICAL™) and Sibutramine. Orlistat (a lipase inhibitor) inhibits fat absorption directly and tends to produce a high incidence of unpleasant (though relatively harmless) side-effects such as diarrhea. Sibutramine (a mixed 5-HT/noradrenaline reuptake inhibitor) can increase blood pressure and heart rate in some patients. The serotonin releaser/reuptake inhibitors fenfluramine (Pondimin™) and dexfenfluramine (Redux™) have been reported to decrease food intake and body weight over a prolonged period (greater than 6 months). However, both products were withdrawn after reports of preliminary evidence of heart valve abnormalities associated with their use. Accordingly, there is a need for the development of a safer anti-obesity agent.

Obesity considerably increases the risk of developing cardiovascular diseases as well. Coronary insufficiency, atheromatous disease, and cardiac insufficiency are at the forefront of the cardiovascular complication induced by obesity. It is estimated that if the entire population had an ideal weight, the risk of coronary insufficiency would decrease by 25% and the risk of cardiac insufficiency and of cerebral vascular accidents by 35%. The incidence of coronary diseases is doubled in subjects less than 50 years of age who are 30% overweight. The diabetes patient faces a 30% reduced lifespan. After age 45, people with diabetes are about three times more likely than people without diabetes to have significant heart disease and up to five times more likely to have a stroke. These findings emphasize the inter-relations between risks factors for NIDDM and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of these conditions based on the prevention of obesity (Perry, I. J., et al., BMJ 310, 560-564 (1995)).

An increasing number of children and adolescents are overweight. Although not all overweight children will necessarily become overweight adults, the growing occurrence of obesity in childhood is likely to be reflected in increasing obesity in adult years. The high prevalence of obesity in our adult population and the likelihood that the nation of the future will be even more obese demands a re-examination of the health implications of this disease. See, Health Implications of Obesity. NIH Consens. Statement Online 1985 Feb. 11-13; 5(9):1-7.

“Clinical obesity” is a measurement of the excess body fat relative to lean body mass and is defined as a body weight more than 20% above the ideal body weight. Recent estimates suggest that 1 in 2 adults in the United States is clinically obese, an increase of more than 25% over the past decades. Flegal M. D. et al., 22 Int. J. Obes. Relat. Metab. Disor. 39 (1998). Both overweight conditions and clinical obesity are a major health concerns worldwide, in particular because clinical obesity is often accompanied by numerous complications, i.e., hypertension and Type II diabetes, which in turn can cause coronary artery disease, stroke, late-stage complications of diabetes and premature death. (See, e.g., Nishina P. M. et al., 43 Metab. 554 (1994)).

Although the etiologic mechanisms underlying obesity require further clarification, the net effect of such mechanisms leads to an imbalance between energy intake and expenditure. Both genetic and environmental factors are likely to be involved in the pathogenesis of obesity. These include excess caloric intake, decreased physical activity, and metabolic and endocrine abnormalities.

Treatment of overweight conditions and clinical obesity via pharmaceutical agents are not only of importance with respect to the conditions themselves, but also with respect to the possibility of preventing other diseases that are associated with, e.g., clinical obesity, as well as enhancement of the positive feeling of “self” that often accompanies those who are overweight or clinically obese and who encounter a significant reduction in body weight. Given the foregoing discussion, it is apparent that compounds which help in the treatment of such disorders would be useful and would provide an advance in both research and clinical medicine. The present invention is directed to these, as well as other, important ends.

SUMMARY OF THE INVENTION

The present invention is drawn to compounds, which bind to and modulate the activity of a GPCR referred to herein as MCH, and uses thereof. The term MCH, as used herein, includes the human sequences found in GeneBank accession number NM_—005297, naturally-occurring allelic variants, mammalian orthologs, biologically active fragments and recombinant mutants thereof.

One aspect of the present invention relates to certain substituted heterocyclic compounds represented by Formula (I):

• wherein Q is:
• R₁ is selected from the group consisting of:
• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl,
    • heterocyclyl, and
    • heterocyclyl substituted by C_1-5 alkyl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy,
      • oxo,
      • mono-C_1-5 alkylamino,
      • di-C_1-5 alkylamino,
      • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
      • di-C_1-5 alkylamino substituted by carbocyclic aryl,
      • mono-C_1-5 alkylamino substituted by halogenated carbocyclic aryl,
      • di-C_1-5 alkylamino substituted by halogenated carbocyclic aryl,
      • carbocyclic arylcarbonylamino, and
      • carbocyclic arylcarbonylamino substituted by halogen,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
  • substituted heterocyclyl-ethylideneaminooxy,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl substituted by carbocyclic aryl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • mono-C₁₅ alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano,
    • carbocyclic aryl, and
    • heterocyclyl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano,
    • carbocyclic aryl, and
    • heterocyclyl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
  • di-carbocyclic arylamino,
  • di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
  • mono-heterocyclylamino,
  • mono-heterocyclylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of
      • halogen,
      • hydroxy, and
      • carboxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
  • di-heterocyclylamino,
  • di-heterocyclylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • nitro,
    • cyano,
    • amino,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by C_1-5 alkoxy,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy, and
      • carboxy,
  • C_1-5 alkylcarbonylamino,
  • C_1-5 alkylcarbonylamino substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkylcarbonylamino,
    • carbocyclic arylcarbonylamino, and
    • heterocyclyl,
  • C_1-5 alkoxycarbonylamino,
  • carbocyclic arylcarbonylamino,
  • heterocyclyl carbonylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by substituent(s) independently selected from the group consisting of:
    • nitro,
    • C_1-5 alkyl,
    • mono-C_1-5 alkylamino, and
    • di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • mono-carbocyclic arylamino,
    • mono-carbocyclic arylamino substituted by halogen,
    • di-carbocyclic arylamino,
    • di-carbocyclic arylamino substituted by halogen,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • heterocyclylthio,
  • heterocyclylthio substituted by substituent(s) independently selected from the group consisting of:
    • nitro, and
    • C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkyl substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl substituted by carbocyclic aryl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • cyano,
    • nitro,
    • amino,
    • C_1-5 alkylcarbonylamino,
    • C_3-6 cycloalkylcarbonylamino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy,
      • carbamoyl,
      • oxo,
      • carbocyclic aryl,
      • heterocyclyl,
      • mono-carbocyclic arylamino,
      • di-carbocyclic arylamino,
      • mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
        • halogen,
        • nitro,
        • C_1-5 alkyl,
        • C_1-5 alkoxy, and
        • C_1-5 alkoxy substituted by halogen,
      • di-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
        • halogen,
        • nitro,
        • C_1-5 alkyl,
        • C_1-5 alkoxy, and
        • C_1-5 alkoxy substituted by halogen,
    • C_2-5 alkenyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • carbocyclic aryl,
    • carbocyclic aryloxy,
    • C_1-5 alkoxycarbonyl,
    • C_1-5 alkylcarbonyloxy,
    • mono-C_1-5 alkylamino,
    • di-C_1-5 alkylamino,
    • mono-carbocyclic arylamino,
    • mono-carbocyclic arylamino substituted by halogen,
    • di-carbocyclic arylamino,
    • di-carbocyclic arylamino substituted by halogen,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:
      • halogen,
      • nitro,
      • C_1-5 alkyl,
      • C_1-5 alkoxy, and
      • C_1-5 alkoxy substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by substituent(s) selected from the group consisting of:
      • halogen,
      • nitro,
      • C_1-5 alkyl,
      • C_1-5 alkoxy, and
      • C_1-5 alkoxy substituted by halogen,
    • mercapto,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by halogen,
    • C_1-5 alkylsulfonyl,
    • C_3-6 cycloalkyl,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • cyano,
    • nitro,
    • amino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy, and
      • carbamoyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-8 alkenyl, and
  • C_2-8 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • hydroxy,
    • nitro,
  • C_1-5 alkyl, and
    • C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • hydroxy,
    • oxo, and
    • carbocyclic aryl,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by carbocyclic aryl,
  • carbocyclic arylcarbonylamino,
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (v) C_3-6 cycloalkenyl, and
  • C_3-6 cycloalkenyl substituted by C_1-5 alkyl,
• (vi) carbocyclyl, and
  • carbocyclyl substituted by substitutent(s) independently selected from the group consisting of:
  • hydroxy, and
  • nitro,
• (vii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • oxo,
    • C_1-5 alkoxy,
    • carbocyclic aryloxy,
    • mono-C_1-5 alkylamino-N-oxy,
    • di-C_1-5 alkylamino-N-oxy,
    • mono-C_1-5 alkylamino,
    • di-C_1-5 alkylamino,
    • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
    • di-C_1-5 alkylamino substituted by carbocyclic aryl,
    • mono-carbocyclic arylamino,
    • di-carbocyclic arylamino,
    • carbocyclylimino,
    • carbocyclylimino substituted by carbocyclic aryl,
    • mono-carbocyclic arylamino,
    • di-carbocyclic arylamino,
    • mono-carbocyclic arylamino substituted by C_1-5 alkoxy,
    • di-carbocyclic arylamino substituted by C_1-5 alkoxy,
    • mono-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by C_1-5 alkoxy,
    • di-carbocyclic arylaminocarbonyl substituted by C_1-5 alkoxy,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • C_1-5 alkyl, and
      • C_1-5 alkyl substituted by halogen,
    • heterocyclyl, and
    • heterocyclyl substituted by C_1-5 alkyl,
  • C_2-5 alkenyl,
  • C_2-5 alkenyl substituted by carbocyclic aryl,
  • C_1-9 alkoxy,
  • C_1-9 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • hydroxy,
    • halogen,
    • carboxy,
    • mono-C_1-5 alkylamino,
    • di-C_1-5 alkylamino,
    • carbocyclic aryl,
    • halogenated carbocyclic aryl,
    • heterocyclyl,
    • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • heterocyclyl, and
      • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
        • halogen,
        • C_1-5 alkyl, and
        • C_1-5 alkyl substituted by halogen,
  • C_2-5 alkenyloxy,
  • C_3-6 cycloalkoxy,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • cyano,
    • nitro,
    • amino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy, and
      • carbamoyl,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • cyano,
    • nitro,
    • amino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy, and
      • carbamoyl,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • (carbocyclic aryl)S(O)₂O,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • mono-carbocyclic arylaminocarbonyl,
  • di-carbocyclic arylaminocarbonyl,
  • mono-carbocyclic arylaminocarbonyl substituted by C_1-5 alkyl,
  • di-carbocyclic arylaminocarbonyl substituted by C_1-5 alkyl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • C_1-5 alkylcarbonylamino,
  • C_3-6 cycloalkylcarbonylamino,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • C_1-5 alkoxycarbonylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by C_1-5 alkyl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • carbocyclic aryl azo,
  • carbocyclic aryl azo substituted by mono-C_1-5 alkylamino,
  • carbocyclic aryl azo substituted by di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • cyano, and
    • C_1-5 alkyl,
  • aminosulfonyl,
  • heterocyclylthio,
  • C_1-5 alkylsulfonyl,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl,
  • heterocyclylsulfonyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-7 alkyl, and
    • C_1-7 alkyl substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
  • C_1-5 alkoxycarbonyl substituted by carbocyclic aryl, and
• (viii) heterocyclyl, and
  • • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • carboxy,
  • carbamoyl,
  • cyano,
  • nitro,
  • amino,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • oxo,
    • C_1-5 alkylcarbonyloxy,
    • carbocyclic arylcarbonylamino,
    • carbocyclic arylcarbonylamino substituted by halogen,
    • C_1-5 alkoxycarbonyl,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • nitro,
    • heterocyclyl, and
    • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • C_1-5 alkyl, and
      • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • cyano,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • amino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy, and
      • carbamoyl,
    • mono-C_1-5 alkylamino,
    • di-C_1-5 alkylamino,
    • C_1-5 alkylcarbonylamino,
    • C_3-6 cycloalkycarbonylamino,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_3-6 cycloalkyl,
    • C_2-5 alkenyl,
    • C_2-5alkynyl,
    • carboxy,
    • C_1-5 alkoxycarbonyl,
    • mono-C_1-5 alkylaminocarbonyl,
    • di-C_1-5 alkylaminocarbonyl,
    • mono-C_3-6 cycloalkylaminocarbonyl,
    • di-C_3-6 cycloalkylaminocarbonyl,
    • mono-C_1-5 alkylaminocarbonylamino,
    • di-C_1-5 alkylaminocarbonylamaino,
    • mono-C_3-6 cycloalkylaminocarbonylamino,
    • di-C_3-6 cycloalkylaminocarbonylamino,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by halogen,
    • C_1-5 alkylsulfinyl,
    • C_1-5 alkylsulfinyl substituted by halogen,
    • C_1-5 alkylsulfonyl, and
    • C_1-5 alkylsulfonyl substituted by halogen,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • hydroxy,
    • carboxy,
    • carbamoyl,
    • cyano,
    • amino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • halogen,
      • hydroxy,
      • carboxy, and
      • carbamoyl,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • C_1-5 alkylcarbonylamino,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by halogen,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_1-5 alkylsulfinyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl substituted by carbocyclic aryl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxycarbonyl;
• R₂ is selected from the group consisting of:
  • hydrogen, halogen, hydroxy, carboxy, carbamoyl, amino, C_1-5 alkyl, C_1-5 alkyl substituted by halogen, C_1-5 alkyl substituted by hydroxy, C_1-5 alkyl substituted by carboxy, C_1-5 alkyl substituted by carbamoyl, C_1-5 alkoxy, C_1-5 alkoxy substituted by halogen, —NHNH₂, —NHNHBoc, —N(R_2a)(R_2b), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl,
• wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl, C_3-6 cycloalkyl, or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkoxy,
  • amino,
  • —NHBoc,
  • C_3-6 cycloalkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • —SO₂NH₂,
  • heterocyclyl, and
• C_3-6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkoxy, and
  • a group of Formula (V):
• wherein Boc is carbamic acid tert-butyl ester and G is C_1-5 alkyl or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • halogenated carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy;
• or R₂ is methylamino or dimethylamino when Q is Formula (II) and Y is a single bond or —CH₂—;
• Each T is independently selected from the group consisting of: halogen, hydroxy, carboxy, carbamoyl, amino, cyano, nitro, C_1-5 alkyl, C_1-5 alkyl substituted by halogen, C_1-5 alkyl substituted by hydroxy, C_1-5 alkyl substituted by carboxy, C_1-5 alkyl substituted by carbamoyl, C_2-5 alkenyl, C_2-5 alkynyl, C_3-6 cycloalkyl, C_1-5 alkoxy, C_1-5 alkoxy substituted by halogen, carbocyclic aryl, heterocyclyl, and —N(R_2a)(R_2b); p is 0, 1, 2, 3, 4 or 5;
• L is selected from the group consisting of Formulae (VI) to (XXI):
  • wherein R₃ and R₄ are independently hydrogen or C_1-5 alkyl; and A and B are independently a single bond, —CH₂—, or —(CH₂)₂—; and
• Y represents:
• (i) —C(O)NR₅—, —C(S)NR₅—, —C(O)O—, —S(O))₂—, —C(O)—, —C(S)—, a single bond, or —CH₂— when L is selected from the group consisting of Formulae (VI) to (XIII); or
• (ii) —C(O)NR₅—, —C(S)NR₅—, —C(O)O— or —OC(O))— when L is selected from the group consisting of Formulae (XIV) to (XXI);
• wherein R₅ is hydrogen or C_1-5 alkyl, or when Y is —C(O)NR₅— then R₅ and R₁ together with the nitrogen they are bonded form a heterocyclyl group;
• wherein carbocyclic aryl is phenyl, naphthyl, anthranyl, phenanthryl, or biphenyl;
  • carbocyclyl is 10,11-dihydro-5-oxo-dibenzo[a,d]cycloheptyl, 1-oxo-indanyl, 7,7-dimethyl-2-oxo-bicyclo[2.2.1]heptyl, 9H-fluorenyl, 9-oxo-fluorenyl, acenaphthyl, anthraquinonyl, C-fluoren-9-ylidene, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthyl, or bicyclo[2.2.1]heptenyl;
  • heterocyclyl is 1,2,3,4-tetrahydro-isoquinolyl, 1,2,3-thiadiazolyl, 1,2,3-triazolyl, 1,2dihydro-3-oxo-pyrazolyl, 1,3,4-thiadiazolyl, 1,3-dioxo-isoindolyl, 1,3-dioxolanyl, 1H-indolyl, 1H-pyrrolo[2,3-c]pyridyl, 1H-pyrrolyl, 1-oxo-3H-isobenzofuranyl, 2,2′,5′,2″-terthiophenyl, 2,2′-bithiophenyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3dihydro-benzofuryl, 2,4dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 2-oxo-pyrrolidinyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, 4H-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-3,4-dihydro-phthalazinyl, 4-oxo-benzopyranyl, 9,10,10-trioxo-thioxanthenyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzimidazolyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, cinnolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, oxolanyl, piperazyl, piperidyl, piridyl, pyrazolo[5,1-b]thiazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, pyrrolidyl, quinolyl, quinoxalyl, thiazolidyl, thiazolyl, thienyl, thiolanyl, 2,3-dihydro-benzofuryl, tetrahydro-thienyl, or benzofuranyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

One aspect of the present invention pertains to pharmaceutical compositions comprising at least one compound, as described herein, in combination with a pharmaceutically acceptable carrier.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of treatment of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

One aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to the individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of modulating a MCH receptor in an individual comprising contacting the receptor with a compound, as described herein. In some embodiments, the compound is an antagonist. In some embodiments, the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder. In some embodiments, the modulation of the MCH receptor reduces food intake of the individual. In some embodiments, the modulation of the MCH receptor induces satiety in the individual. In some embodiments, the modulation of the MCH receptor controls or reduces weight gain of the individual. In some embodiments, the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

In some embodiments, the individual is a mammal.

In some embodiments, the mammal is a human.

In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.

One aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing a compound, as described herein, and a pharmaceutically acceptable carrier.

This application claims priority to US Provisional Patent Applications, Ser. No. 60/458,530, filed Mar. 31, 2003; Ser. No. 60/495,911, filed Aug. 19, 2003; Ser. 60/510,186, filed Oct. 9,2003; and Ser. No. 60/530,360, filed Dec, 16,2003; all of which are incorporated herein by reference in their entirety.

DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to certain substituted heterocyclic compounds represented by Formula (I): or a pharmaceutically acceptable salt, hydrate or solvate therefo, wherein Q, L, Y, and R₁ are as described herein, supra and infra.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.

In some embodiments of the present invention, R₂ is selected from the group consisting of:

hydrogen, halogen, hydroxy, carboxy, carbamoyl, amino, C_1-5 alkyl substituted by hydroxy, C_1-5 alkyl substituted by carboxy, C_1-5 alkyl substituted by carbamoyl, C_1-5 alkoxy, C_1-5 alkoxy substituted by halogen, —NHNH₂, —NHNHBoc, —N(R_2a)(R_2b), morpholino, 4-acetyl-piperazyl, or 4-phenyl-piperazyl,

wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl, C_3-6 cycloalkyl, or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:

• • halogen,
  • hydroxy,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkoxy,
  • amino,
  • —NHBoc,
  • C_3-6 cycloalkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • —SO₂NH₂,
  • heterocyclyl, and

C_3-6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

• • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkoxy, and
  • a group of Formula (V):

wherein Boc is carbamic acid tert-butyl ester and G is C_1-5 alkyl or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:

• • carbocyclic aryl,
  • halogenated carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy.

In some embodiments of the present invention, R₂ is —N(R_2a)(R_2b), wherein R_2a, is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl, C_3-6 cycloalkyl, or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:

• • halogen,
  • hydroxy,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkoxy,
  • amino,
  • —NHBoc,
  • C_3-6 cycloalkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • —SO₂NH₂,
  • heterocyclyl, and

C_3-6 cycloalkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:

• • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkoxy, and
  • a group of Formula (V):

wherein Boc is carbamic acid tert-butyl ester and G is C_1-5 alkyl or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:

• • carbocyclic aryl,
  • halogenated carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy.

In some embodiments of the present invention, R₂ is —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl or C_3-6 cycloalkyl.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino,
  • di-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonylamino,
  • carbocyclic arylcarbonylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • carbocyclic aryl substituted by C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by nitro,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_2-5 alkenyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by oxo,
  • C_1-5 alkyl substituted by carbocyclic aryl, and
  • carbocyclic aryl,
• (v) carbocyclyl,
• (vi) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • carboxy,
  • carbamoyl,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-7 alkoxy,
  • C_1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
  • C_2-5 alkenyloxy,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by nitro,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • C_1-5 alkoxycarbonylamino,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • carbocyclic aryl azo,
  • carbocyclic aryl azo substituted by mono-C_1-5 alkylamino,
  • carbocyclic aryl azo substituted by di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by nitro,
  • carbocyclic arylthio substituted by cyano,
  • aminosulfonyl,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl,
  • heterocyclylsulfonyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
• (vii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • amino,
  • hydroxy,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl substituted by carbocyclic aryl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantly, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, indanyl, indenyl, or menthyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, 4oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, tetrahydrofuryl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, Q is Formula (II);

• R₁ is selected from the group consisting of:
• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by nitro,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • C_1-5 alkoxycarbonylamino,
  • carbocyclic arylcarbonylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • carbocyclic aryl substituted by C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_2-5 alkenyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by oxo,
  • C_1-5 alkyl substituted by carbocyclic aryl, and
  • carbocyclic aryl,
• (v) carbocyclyl,
• (vi) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
  • C_2-5 alkenyloxy,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by cyano,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl, and
  • carbocyclic aryl,
• (vii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • heterocyclyl;
  • R₂ is methylamino or dimethylamino when Y is a single bond or —CH₂—;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, bicyclo[2.2.1]heptyl, indenyl, or menthyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-7 alkyl, and
  • C_1-7 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo, and
      • carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyl,
  • heterocyclyl substituted by carbocyclic aryl, and
  • heterocyclyl substituted by halogen,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl, and
  • C_1-5 alkyl substituted by carbocyclic aryl,
• (v) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen,
  • C_2-5 alkenyloxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_1-5 alkylthio, and
  • C_1-5 alkylthio substituted by halogen,
• (vi) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • hydroxy, and
    • carbocyclic aryl,
  • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • L is Formula (VII);
  • Y is a single bond or —CH₂—;
  • R₂ is methylamino or dimethylamino;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, azetidinyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 0; R₃ and R₄ are hydrogen; A is a single bond or —CH₂—; and B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkil, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • C_1-5 alkoxy,
  • heterocyclyl, and
  • heterocyclyl substituted by carbocyclic aryl,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen, and
  • C_2-5 alkenyloxy,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by carbocyclic aryl,
  • C_1-5 alkoxy, and
  • C_1-5 alkoxycarbonyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, azetidinyl, or benzo[1,3]dioxolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)amino]-methyl}-1H-indole-2-carboxylate;
• 3-[{2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]ethyl}(phenyl)-amino]propanenitrile;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[2-(2-phenyl-1H-indol-3-yl)ethyl]amino}-cyclohexyl)quinoline-2,4-diamine;
• N²-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-[cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• 4-bromo-2-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]amino)}-methyl)-6-methoxyphenol;
• N²-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine;
• N²-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine;
• N²-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylquinoline-2,4-diamine;
• N²-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}methyl)-cyclohexyl]-N⁴, N⁴-dimethylquinoline-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine;
• N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N⁴,N⁴-dimethyl-quinoline-2,4-diamine;
• N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N⁴-methyl-quinoline-2,4-diamine;
• N²-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-quinoline-2,4-diamine;
• N⁴-methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴-methyl-quinoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine;
• cis-N-(3,5-dimethoxybenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine; and
• cis-N-(3,5-dichlorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • hydroxy,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkoxycarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • nitro,
• (iii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • oxo, and
    • carbocyclic aryl, and
  • carbocyclic aryl,
• (iv) carbocyclyl,
• (v) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
  • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by cyano,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl, and
  • carbocyclic aryl,
• (vi) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • hydroxy,
  • amino,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkyl,
  • heterocyclyl;
  • L is Formula (VII);
  • Y is —C(O)—;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is hydrogen, halogen, methyl, trifluoromethyl, methoxy, carbamoyl, amino, methylamino, or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • C_3-6 cycloalkyl,
  • carbocyclic aryl,
  • carbocyclic aryl by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • carbocyclic aryl,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • nitro,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • carbamoyl,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkyl substituted by hydroxy,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy, and
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • amino,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by halogen,
  • carbocyclic aryl substituted by nitro, and
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, pyridyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • carbocyclic aryl,
  • carbocyclic aryl by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy, and
  • heterocyclyl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • hydroxy,
  • cyano,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • carbocyclic aryloxy, and
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by halogen,
  • carbocyclic aryl substituted by nitro, and
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, pyridyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxypropanamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-iodobenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide;
• (2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(4-nitrophenyl)-acrylamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiophene-3-carboxamide;
• 2-(4chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-acetamide;
• 3-(2chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-cyclopentanecarboxamide;
• 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)quinoxaline-2-carboxamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)-nicotinamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)-acetamide;
• 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide;
• (2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)-acrylamide;
• 2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)-acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,4,6-trichlorophenoxy)-acetamide;
• 3-benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methoxy-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide;
• 5chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-hydroxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxybenzamide;
• 3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-nitrobenzamide;
• 3-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide;
• 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-5-(trifluoromethyl)benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide;
• 4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-iodobenzamide;
• 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2,4-difluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide;
• 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-4-fluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide;
• 2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-thiophene-3-carboxamide;
• 2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-2,4,6-trimethylbenzamide;
• 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• (2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]acrylamide;
• 5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]thiophene-2-carboxamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide;
• 5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-2-furamide;
• 5-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]thiophene-2-carboxamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2-iodophenyl)-acetamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide;
• 2,2-bis(4chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• 3,4-difluoro-N-[cis-4-4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,5-dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4-dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 9H-xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-(4chloro-phenyl)-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-nitro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-trifluoromethyl-benzamide;
• N-[cis-4-4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;
• 3,4-dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-bromo-furan-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• N-[cis-4-(4-methylquinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide;
• N-[cis-4-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide;
• 2,2-diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 5-bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide;
• 2-(4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3,4-difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide;
• 2-(4-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide;
• 2-(3-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-4-fluorophenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-dichloro-phenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 3-hydroxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-bis-trifluoromethyl-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide;
• N-[cis-4-4-amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;
• C-(ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 3-hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-amino-N-[cis-4-4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2,3-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2,6-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 4-chloro-3-fluoro-N-[cis -4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester;
• 3,5-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 6-dimethylamino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-hydroxymethyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamide;
• 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4,5-trifluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 4-chloro-pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide;
• 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide;
• N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide;
• 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide;
• 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide;
• 4-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide;
• 2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide;
• 3,4,5-triethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide;
• 2-(3,4-difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide;
• 2-(2-bromo-4,5-dimethoxyphenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide;
• 2,6-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide;
• N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-4-(trifluoromethoxy)benzamide;
• 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; and
• 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• 3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-phenoxybutanamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-phenoxypropanamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-methylbenzamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-acetamide;
• 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide;
• 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)-nicotinamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)-acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide;
• 3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-nitrobenzamide;
• 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide;
• 4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide;
• 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-4-fluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide;
• 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,5-dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4-dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• benzo[2,3,1 ]oxadiazole-5-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 9H-xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-nitro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-trifluoromethyl-benzamide;
• N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;
• 3,4-dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-3-methyl-N-[cis-4-4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 5-bromo-furan-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide;
• 2,2-diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 5-bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide;
• benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide;
• 3-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide;
• 2-(4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3,4-difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide;
• 2-(4-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide;
• 2-(3-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide;
• N-[cis-4-(4-amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide;
• C-(ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• C-(ethyl-phenyl-amino)-N-[cis-4-4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 3-hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 2,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester;
• 3,5-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide;
• C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide;
• 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 3,4,5-trifluoro-N-[cis-4-4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide;
• 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide;
• 4-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide;
• 2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide;
• 3,4,5-trimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide;
• 2-(3,4-difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide;
• 2-(2-bromo-4,5-dimethoxyphenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]-cyclohexyl}-acetamide;
• 2,6-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide;
• N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-4-(trifluoromethoxy)-benzamide;
• 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; and
• 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• • C_1-6 alkyl, and
  • C_1-6 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • L is Formula (XV);
  • Y is —C(O)NR₅—;
  • wherein carbocyclic aryl is phenyl; and
  • halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• • C_1-6 alkyl, and
  • C_1-6 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • wherein carbocyclic aryl is phenyl; and
  • halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methyl; p is 0; R₃ and R₄ are both hydrogen; A and B are both single bonds; and R₅ is hydrogen: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-N-[(1R)-1-(2-fluorophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-N-[(1S)-1-(2-fluorophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}-cyclohexanecarboxamide;
• cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}-cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide; and
• cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-N-[(1S)-1-(2-fluorophenyl)ethyl]-4-[(4-methylquinolin-2-yl)amino]-cyclohexanecarboxamide;
• cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}-cyclohexanecarboxamide; and
• cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}-cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkylthio,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_2-5 alkenyl,
• (ii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • C_1-5 alkylthio, and
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • carbocyclic aryl;
  • L is Formula (VII);
  • Y is —C(O)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]-dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is hydrogen, methyl, methylamino, or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by halogen,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • C_1-5 alkoxy,
• (iii) heterocyclyl, heterocyclyl substituted by C_1-5 alkyl, and heterocyclyl substituted by carbocyclic aryl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is isoxazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(2chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2-ethyl-6-methylphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-mesitylurea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)-urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)-urea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino-cyclohexyl)urea;
• N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2-isopropyl-6-methylphenyl)urea;
• N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(diphenylmethyl)urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(3-methyl-5-phenylisoxazol-4-yl)urea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-1-naphthylurea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-[1-(1-naphthyl)ethyl]-urea;
• methyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]carbonyl}-phenylalaninate;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea;
• N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-mesitylurea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-methyl]urea;
• N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-quinolin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-[(cis-4-I [4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea;
• N-(2-tert-butyl-6-methylphenyl-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}-cyclohexyl)methyl]urea;
• 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea; and
• 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • C_1-5 alkoxy,
• (ii) carbocyclyl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy carbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino, and
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkoxy carbonyl, and
  • carbocyclic aryl;
  • L is Formula (VII);
  • Y is —C(S)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is bicyclo[2.2.1]heptyl;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • mono-C_1-5 alkylamino, and
  • di-C_1-5 alkylamino,
• (ii) heterocyclyl, and
  • heterocyclyl substituted by C_1-5 alkyl, and
  • heterocyclyl substituted by C_1-5 alkoxy carbonyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)-thiourea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea;
• N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)-thiourea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)-thiourea;
• N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-N′-mesitylthiourea;
• N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-thiourea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea;
• N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea;
• N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-quinolin-2-yl]-amino}cyclohexyl)thiourea;
• N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea;
• N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea; and
• methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]-carbonothioyl}amino)-4-methylthiophene-2-carboxylate; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (ii) C_2-5 alkenyl,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • C_1-5 alkoxy;
  • L is Formula (VII);
  • Y is —C(O)O—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is 9H-fluorenyl or menthyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, Q is Formula (III);

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by nitro,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • carbocyclic aryl substituted by C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_2-5 alkenyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (iii) C_2-5 alkynyl,
• (iv) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by oxo,
  • C_1-5 alkyl substituted by carbocyclic aryl, and
  • carbocyclic aryl,
• (v) carbocyclyl,
• (vi) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-7 alkoxy,
  • C_1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
  • C_2-5 alkenyloxy,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by nitro,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • carboxy,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • C_1-5 alkoxycarbonylamino,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • carbocyclic aryl azo,
  • carbocyclic aryl azo substituted by mono-C_1-5 alkylamino,
  • carbocyclic aryl azo substituted by di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by nitro,
  • carbocyclic arylthio substituted by cyano,
  • aminosulfonyl,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl,
  • heterocyclylsulfonyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
• (vii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl substituted by carbocyclic aryl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9oxo-9H-fluorenyl, adamantly, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, indanyl, indenyl, or menthyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[2, 1,3]thiadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, tetrahydrofuryl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-7 alkyl, and
  • C_1-7 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo, and
      • carbocyclic aryl,
    • C_1-5 alkoxy,
  • heterocyclyl, and
  • heterocyclyl substituted by carbocyclic aryl,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy,
• (iii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl, and
  • C_1-5 alkyl substituted by carbocyclic aryl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen,
  • C_2-5 alkenyloxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_1-5 alkylthio, and
  • C_1-5 alkylthio substituted by halogen,
• (v) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • hydroxy, and
    • carbocyclic aryl,
  • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen;
  • L is Formula (VII);
  • Y is a single bond or —CH₂—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, azetidinyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by C_1-5 alkyl,
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • mono-C_1-5 alkylamino, and
  • di-C_1-5 alkylamino,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by carbocyclic aryl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 4-oxo-benzopyranyl, azetidinyl, benzo[1,3]dioxolyl, or pyrazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • carbocyclic arylsulfonylamino,
  • carbocyclic arylsulfonylamino substituted by C_1-5 alkyl, and
  • carbocyclic aryl,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • C_1-5 alkoxy, and
  • C_1-5 alkoxy substituted by halogen,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by carbocyclic aryl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by halogen;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is 1H-indolyl, azetidinyl, or pyrazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N²-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-bromo-2-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)amino]methyl}-6-methoxyphenol;
• N²-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-{[(cis-4-{[4(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]methyl}-2,6-dimethoxyphenol;
• N²-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N₄-dimethyl-N²-{cis-4-[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)-amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-{cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-{cis-4-[(pentamethylbenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]methyl}-2-iodomethoxyphenol;
• 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]methyl}-2,6-dimethylphenol;
• 3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]methyl}-6,8-dimethyl-4H-chromen-4-one;
• ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate;
• N²-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}amino)cyclohexyl]-N⁴, N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-[4-(pentamethylphenylmethyl-amino)-cyclohexyl]-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-amino]ethyl}(3-methylphenyl)amino]propanenitrile;
• 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-amino]ethyl}(phenyl)amino]propanenitrile;
• N-{(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide;
• N²-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N⁴,N⁴-dimethyl -5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-({[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-bromo-2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]amino}methyl)-6-methoxyphenol;
• N²-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(1 3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)-amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]-methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-iodo-6-methoxyphenol;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2,6-dimethylphenol;
• 3-chloro-4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]amino}methyl)phenol;
• N²-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl--5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-ethoxyphenol;
• N²-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol;
• N²-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-({[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}methyl)-cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-methylphenol;
• N²-(cis-4-({[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-fluoro-6-methoxyphenol;
• N⁴,N⁴-dimethyl-N²-[cis-4-({[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino}methyl)-cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[({[1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-yl]methyl}-amino)methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; and
• N⁴-methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N²-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate;
• N²-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}amino)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-amino]ethyl}(phenyl)amino]propanenitrile;
• N-{(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide;
• N²-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-({[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,8-tetrahydroquinazoline-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-iodo-6-methoxyphenol;
• N²-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-({[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-[cis-4-({[(1-phenyl-5-propyl-1H-pyrazol-4-yl)methyl]amino}methyl)-cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[({[1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-yl]methyl{-amino)methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine;
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; and
• N⁴,N⁴-dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl{-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by nitro,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • mono-carbocyclic arylaminocarbonyl,
    • mono-carbocyclic arylaminocarbonyl substituted by halogen,
    • di-carbocyclic arylaminocarbonyl,
    • di-carbocyclic arylaminocarbonyl substituted by halogen,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • nitro,
• (iii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • oxo, and
    • carbocyclic aryl,
  • carbocyclic aryl,
• (iv) carbocyclyl,
• (v) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_2-5 alkynylcarbonylamino, -C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by cyano,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl,
  • carbocyclic aryl,
  • heterocyclyl,
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
• (vi) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkyl,
  • heterocyclyl;
  • L is Formula (VII);
  • Y is —C(O)—;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo, and
      • heterocyclyl,
    • C_1-5 alkoxy,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • carbocyclic aryl,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by nitro,
• (iii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by carbocyclic aryl,
• (iv) carbocyclyl,
• (v) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo, and
    • carbocyclic aryl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy, and
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
• (vi) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl, and
    • heterocyclyl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkyl,
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl;
  • carbocyclyl is 1-oxo-indanyl or indenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2-oxo-benzopyranyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl;
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • carbocyclic arylcarbonylamino,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • carbocyclic aryl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy, and
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkyl substituted by heterocyclyl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by halogen, and
  • carbocyclic aryl substituted by nitro;
  • wherein carbocyclic aryl is phenyl;
  • carbocyclyl is indenyl;
  • heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2-oxo-benzopyranyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, morpholino, pyridyl, quinoxalyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxybenzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-nitrobenzamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• 3-cyano-N-cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(diethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-hexanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methyl-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-nitrobenzamide;
• (2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxypropanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethoxy)benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-iodobenzamide;
• 2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(3-methoxyphenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,5-dimethyl-3-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-methylbenzarride;
• 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)thiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(propylthio)nicotinamide;
• 1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}-cyclohexyl)-1H-pyrazole-5-carboxamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)nicotinamide;
• 2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]-2-oxo-1-phenylethyl acetate;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-benzamide;
• 2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)acetamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• 3-(2-chlorophenyl)-N-cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)cyclopentanecarboxamide;
• 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitro-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-quinoxaline-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethyl)benzamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxynicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methylphenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide;
• 2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide;
• 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,3-diphenylpropanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(2-hydroxyphenyl)propanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-iodo-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-iodophenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-oxoindane-1-carboxamide;
• 2-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-2-carboxamide;
• N-cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 3-acetyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2yl]amino}-cyclohexyl)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide;
• 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-2-furamide;
• 2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• N²,N⁶-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)lysinamide;
• 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)benzamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H -indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H -indol-3-yl)-4-oxo-4-phenylbutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy)phenyl]amino}carbonyl)amino]-benzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide;
• 4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-nitrophenyl)butanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(3-phenoxyphenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-phenoxyphenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;
• N²-benzoyl-N⁵-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N¹,N¹-dipropylglutamamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-phenoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide;
• N¹-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide;
• (2S)-N-(cis-4-{[4-(dimethylamino}-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide;
• 2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-}(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide;
• 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide;
• 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenylquinoline-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-(3-nitrophenyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-methoxy-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-methoxy-2-phenylacetamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-hydroxybenzamide;
• 3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(ethylthio)nicotinamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(4-methoxyphenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-4-fluoro-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(propylthio)nicotinamide;
• 2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2,4,6-trimethylbenzamide;
• 2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]-6-fluorobenzamide;
• 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(2,3,6-trichlorophenyl)acetamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide; and
• N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxybenzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 4chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-nitrobenzamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methyl-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxypropanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-iodobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,5-dimethyl-3-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-methylbenzamide;
• 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)thiophene-3-carboxamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2yl]amino}-cyclohexyl)nicotinamide;
• 2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-amino]-2-oxo-1-phenylethyl acetate;
• 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitro-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-quinoxaline-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethyl)benzamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methylphenoxy)nicotinamide;
• 2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide;
• 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• N-(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-iodo-2-furamide;
• 2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 3-acetyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-furamide;
• 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-2-furamide;
• 2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H -indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy)phenyl]amino}carbonyl)amino]-benzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide;
• 4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-nitrophenyl)butanamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;
• N²-benzoyl-N⁵-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N¹,N¹-dipropylglutamamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-phenoxybenzamide;
• N¹-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N,N -bis[(1S)-1-phenylethyl]phthalamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide;
• 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• 5chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-hydroxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(ethylthio)nicotinamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(4-methoxyphenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-5-methyl-2-(trifluoromethyl)-3-furamide;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-2-(propylthio)nicotinamide; and
• 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)methyl]benzamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • C_1-5 alkoxy carbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_2-5 alkenyl, and
    • C_1-5 alkoxy,
  • C_1-5 alkylthio, and
  • heterocyclyl,
• (ii) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by carbocyclic aryl,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo, and
    • carbocyclic aryl,
  • C_1-5 alkoxy carbonyl,
  • C_1-7 alkoxy,
  • C_1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen, and
  • carbocyclic aryl,
• (v) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy carbonyl
  • C_1-5 alkoxy carbonyl substituted by carbocyclic aryl, and
  • carbocyclic aryl;
  • L is Formula (VII);
  • Y is —(O)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is indanyl, adamantly, or 9H-fluorenyl;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl;
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—: R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxy carbonyl,
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by halogen,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy, and
  • C_1-5 alkoxy substituted by halogen,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by C_1-5 alkyl, and
  • heterocyclyl substituted by carbocyclic aryl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is isoxazolyl;
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethyl-6-methylphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-fluorophenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-mesitylurea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4,6-tribromophenyl)urea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)urea;
• N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethylphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-isopropyl-6-methylphenyl)urea;
• N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(diphenylmethyl)urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(3-methyl-5-phenylisoxazol-4-yl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-1-naphthylurea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-[1-(1-naphthyl)ethyl]urea;
• N-(2,4-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)urea;
• N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)urea;
• N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethoxyphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-fluorobenzyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea;
• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-fluorobenzyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-methoxy-2-methylphenyl)urea;
• N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-({[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-[1-(4-bromophenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(5-methyl-3-phenylisoxazol-4-yl)urea;
• N-(2,3-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-methylphenyl)urea;
• N-(2,6-diisopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4,5-trichlorophenyl)urea;
• N-(2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(4-bromo-2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2,6-dimethylphenyl)urea;
• N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2-ethyl-6-methylphenyl)urea;
• ethyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}-cyclohexyl)methyl]amino}carbonyl)leucinate;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(4-fluorophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-mesitylurea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2,4,6-trichlorophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2,4,6-tribromophenyl)urea;
• N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2-ethyl-6-isopropylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2-isopropyl-6-methylphenyl)urea;
• N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7, 8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea;
• N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea;
• N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea; and
• 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy,
  • heterocyclyl,
• (ii) C_2-5 alkynyl,
• (iii) C_2-5 alkenyl,
• (iv) C_3-12 cycloalkyl,
• (v) carbocyclyl,
• (vi) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • oxo,
  • carboxy,
  • C_1-5 alkoxy carbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by nitro,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_1-5 alkoxy carbonylamino,
  • carbocyclic aryl azo,
  • carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of:
    • mono-C_1-5 alkylamino, and
    • di-C_1-5 alkylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by nitro,
  • amino sulfonyl,
  • heterocyclyl sulfonyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkyl substituted by C_1-5 alkyl,
  • carbocyclic aryl, and
  • heterocyclyl,
• (vii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkoxy carbonyl,
  • carbocyclic aryloxy,
  • carbocyclic aryl, and
  • heterocyclyl;
  • L is Formula (VII);
  • Y is —C(S)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or adamantly;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—: R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by carbocyclic aryl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • mono-C_1-5 alkylamino, and
  • di-C_1-5 alkylamino;
  • wherein carbocyclic aryl is phenyl or naphthyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl}-N′-(3,4,5-trimethoxyphenyl)thiourea;
• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-methoxy-5-methylphenyl)thiourea;
• N-(4-bromo-2chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-iodophenyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4,6-tribromophenyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4,6-trichlorophenyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-mesitylthiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4-dimethylphenyl)thiourea;
• N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]-amino}cyclohexyl)thiourea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-fluoro-2-methylphenyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-methoxy-2-methylphenyl)thiourea;
• N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethoxyphenyl)thiourea;
• N-[4-bromo-2-(trifluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea;
• N-(4-chloro-2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea; and
• N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,2-diphenylethyl)thiourea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (ii) C_2-5 alkenyl,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • C_1-5 alkoxy;
  • L is Formula (VII);
  • Y is —C(O)O—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is 9H-fluorenyl or menthyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, Q is Formula (IV); p is 0; R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl, -C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by nitro,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • mono-C_1-5 alkylamino substituted by carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonylamino,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • carbocyclic aryl substituted by C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by nitro,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_2-5 alkenyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) C_3-6 cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by oxo,
  • C_1-5 alkyl substituted by carbocyclic aryl, and
  • carbocyclic aryl,
• (v) carbocyclyl,
• (vi) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
  • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
  • C_2-5 alkenyloxy,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • mono-C_1-5 alkylaminocarbonyl, -di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by cyano,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl,
  • carbocyclic aryl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
• (vii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, bicyclo[2.2 1]heptyl, indenyl, or menthyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-7 alkyl, and
  • C_1-7 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • mono-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • di-C_1-5 alkylamino,
  • di-C_1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of:
    • cyano, and
    • carbocyclic aryl,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by C_1-5 alkyl,
  • di-carbocyclic arylamino substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkoxy,
• (ii) C_2-7 alkenyl, and
  • C_2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by C_1-5 alkoxy,
• (iii) C_2-5 alkynyl, and
  • C_2-5 alkynyl substituted by carbocyclic aryl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
  • C_2-5 alkenyloxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano,
  • di-C_1-5 alkylamino substituted by cyano,
  • C_1-5 alkylthio, and
  • C_1-5 alkylthio substituted by halogen,
• (v) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by hydroxy,
  • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by C_1-5 alkoxycarbonyl,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen;
  • L is Formula (VII);
  • Y is a single bond or —CH₂—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino, or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by carbocyclic aryl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
  • C_2-5 alkenyloxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-C_1-5 alkylamino substituted by cyano, and
  • di-C_1-5 alkylamino substituted by cyano,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 9H-carbazolyl, benzo[1,3]dioxolyl, pyrazolyl, or pyridyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by carbocyclic aryl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • C_2-5 alkenyloxy,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxycarbonyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by C_1-5 alkyl, and
  • carbocyclic aryl substituted by halogenated C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 1H-indolyl, 9H-carbazolyl, benzo[1,3]dioxolyl, or pyrazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N²-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[5(4-fluorophenyl)pyridin-3-yl]methyl}amino)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• ethyl 4,6-dichloro-3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-amino]methyl -1H-indole-2-carboxylate;
• N²-(cis-4-({[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-({[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• 4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-amino}methyl)-6-methoxyphenol;
• N²-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-({[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-({[(2,3,4-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N²-(cis-4-j [(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)-amino]methyl}cyclohexyl)pyrimidin-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-iodo-6-methoxyphenol;
• 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2,6-dimethylphenol;
• N²-(cis-4-({[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(9-ethyl-9H-carbazolyl-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-({[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2-ethoxyphenol;
• N²-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)methyl]-cyclohexyl}-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine-2,4-diamine;
• N²-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-({[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-({[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N²-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-[cis-4-({[(1-methyl-1H-indol-3-yl)methyl]amino}-methyl)cyclohexyl]-pyrimidin-2,4-diamine;
• N²-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino{methyl)-cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-({[(2-bromo-4,5-dimethoxybenzyl)amino]methyl cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• 3-[[4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]amino}-methyl)phenyl](methyl)amino]propanenitrile;
• N²-{cis-4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]cyclohexyl}-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine; and
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-amino]methyl}-1H-indole-2-carboxylate;
• N²-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• 4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-amino}methyl)-6-methoxyphenol;
• N²-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[(2,3,4-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N²-(cis-4-({[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)-amino]methyl}cyclohexyl)pyrimidin-2,4-diamine;
• 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2-iodo-6-methoxyphenol;
• 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2,6-dimethylphenol;
• N²-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(9-ethyl-9H-carbazolyl-3-yl)methyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴N⁴-dimethyl-N²-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N²-(cis-4-{[1(5-bromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N⁴,N⁴-dimethyl-N²-(cis-4-({[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidin-2,4-diamine;
• N²-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}methyl)-cyclohexyl]-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N⁴,N⁴-dimethylpyrimidine-2,4-diamine;
• N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidin-2,4-diamine; and
• N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidin-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • C_1-5 alkylcarbonyloxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by nitro,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by C_1-5 alkyl,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkoxycarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of:
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
      • halogen, and
      • C_1-5 alkoxy,
  • carbocyclic arylthio,
  • heterocyclylthio,
  • heterocyclylthio substituted by C_1-5 alkyl,
  • heterocyclylthio substituted by nitro,
  • C_3-6 cycloalkyl,
  • C_3-6 cycloalkenyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkoxy,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • heterocyclyl,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by carbocyclic aryl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by carbocyclic aryl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • nitro,
• (iii) C cycloalkyl, and
  • C_3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • oxo, and
    • carbocyclic aryl, and
  • carbocyclic aryl,
• (iv) carbocyclyl,
• (v) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo,
    • carbocyclic aryloxy,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by C_1-5 alkyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • amino,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • (carbocyclic aryl)NHC(O)NH,
  • (carbocyclic aryl)NHC(O)NH substituted by C_1-5 alkoxy,
  • (carbocyclic aryl)NHC(O)NH substituted by haloganated C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • C_1-5 alkylthio substituted by halogen,
  • carbocyclic arylthio,
  • carbocyclic arylthio substituted by cyano,
  • mono-C_1-5 alkylaminosulfonyl,
  • di-C_1-5 alkylaminosulfonyl, and
  • carbocyclic aryl,
  • carbocyclic aryl substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • halogenated carbocyclic aryl,
• (vi) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_2-5 alkenylthio,
  • carbocyclic arylthio,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkyl,
  • heterocyclyl;
  • L is Formula (VII);
  • Y is —C(O)—;
  • wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl;
  • carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9oxo-9H-fluorenyl, or indenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is hydrogen, trifluoromethyl, methoxy, methylamino, dimethylamino, ethylamino, ethylmethylamino, or hydroxylethylmethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • carbocyclic arylcarbonylamino,
  • C_1-5 alkylthio,
  • C_3-6 cycloalkyl,
  • carbocyclyl,
  • carbocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_2-5 alkenyl, and
    • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
      • carbocyclic aryl, and
      • carbocyclic aryl substituted by C_1-5 alkylsulfinyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
      • oxo,
      • carbocyclic aryl, and
      • heterocyclyl,
    • C_1-5 alkoxy,
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • nitro,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • oxo, and
    • carbocyclic aryl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • C_2-5 alkynylcarbonylamino,
  • C_2-5 alkynylcarbonylamino substituted by carbocyclic aryl,
  • mono-C_1-5 alkylaminosulfonyl, and
  • di-C_1-5 alkylaminosulfonyl,
• (v) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl,
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
    • carbocyclic aryl,
    • carbocyclic aryl substituted by halogen, and
    • heterocyclyl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • C_1-5 alkylthio,
  • C_1-5 alkylsulfonyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkyl,
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl;
  • heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydrobenzofuryl, 2H-benzopyranyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino,
  • mono-carbocyclic arylamino,
  • di-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • di-carbocyclic arylamino substituted by halogen,
  • C_1-5 alkylthio,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • hydroxy,
    • C_1-5 alkyl,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
  • heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl,
    • carbocyclic aryl, and
    • carbocyclic aryl substituted by halogen,
• (ii) C_2-5 alkenyl, and
  • C_2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by nitro,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by C_1-5 alkoxy,
  • mono-C_1-5 alkylaminocarbonyl,
  • di-C_1-5 alkylaminocarbonyl,
  • mono-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • di-C_1-5 alkylaminocarbonyl substituted by carbocyclic aryl,
  • mono-C_1-5 alkylaminosulfonyl, and
  • di-C_1-5 alkylaminosulfonyl,
• (v) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkylthio,
    • C_1-5 alkylthio substituted by carbocyclic aryl, and
    • C_1-5 alkylthio substituted by halogenated carbocyclic aryl,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by halogen,
  • carbocyclic aryloxy substituted by C_1-5 alkyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by halogen,
  • carbocyclic aryl substituted by nitro, and
  • heterocyclyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is 1-oxo-indanyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzofuryl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, pyridyl, quinoxalyl, thiazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-3-iodobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene-3-carboxamide;
• 1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1H -pyrazole-5-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-acetamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl) -cyclopentanecarboxamide;
• 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(pentafluorophenoxy)-acetamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)-nicotinamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)-sulfonyl]benzamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide;
• 2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1,3-thiazole-4-carboxamide;
• 3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1H-pyrazole-5-carboxamide;
• 6-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;
• 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 1-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide;
• 3-acetyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene-2-carboxamide;
• 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide;
• N²,N⁶-dibenzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-lysinamide;
• 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-benzamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide;

4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-(1H -indol-3-yl)-4-oxobutanamide;

• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide;
• N-(cis-4-{[4{(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-nitrophenyl)-butanamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;
• N²-benzoyl-N⁵cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-N¹,N¹-dipropylglutamamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide;
• 3-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-[(1R)-1-(1-naphthyl)ethyl]phthalamide;
• (2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl) -propanamide;
• N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[4-(2-thienylcarbonyl) -phenyl]propanamide;
• 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H -pyrrole-3-carboxamide;
• 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl-1)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide;
• 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-[(4-methylphenyl)-sulfonyl]-1H-pyrrole-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide;
• 3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hydroxybenzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-phenylacrylamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-nitrobenzamide;
• 2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-methyl]acetamide;
• 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide;
• 2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-5-fluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;
• 2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-methyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(propylthio)-nicotinamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)-acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide;
• 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-benzamide;
• (2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl) -methyl]acrylamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide;
• 2-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-benzamide;
• 2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide;
• 2(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl) -methyl]acetamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide;
• C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;
• 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• 5-bromo-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide;
• 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide;
• 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide; and
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• 3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodobenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2-carboxamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-acetamide;
• 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)-nicotinamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)-sulfonyl]benzamide;
• 2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1,3-thiazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide;
• 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;
• 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide;
• N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide;
• 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H -pyrrole-3-carboxamide;
• 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide;
• 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide;
• 3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hydroxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)-acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide;
• (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide;
• 2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide;
• 2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl) -methyl]acetamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide;
• C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide;
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide; and
• N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkoxy carbonyl,
  • C_1-5 alkylthio,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_2-5 alkenyl,
• (ii) C_3-6 cycloalkyl, C_3-6 cycloalkyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy carbonyl,
  • C_1-5 alkoxy,
  • C_3-6 cycloalkoxy,
  • carbocyclic aryloxy,
  • C_1-5 alkylthio, and
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • carbocyclic aryl;
  • L is Formula (VII);
  • Y is C(O)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond;.B is a single bond or —CH₂—: R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by carbocyclic aryl,
• (ii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy, and
  • C_3-6 cycloalkoxy,
• (iii) heterocyclyl, and
  • heterocyclyl substituted by C_1-5 alkyl, and
  • heterocyclyl substituted by carbocyclic aryl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is isoxazolyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-mesitylurea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)-urea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)-urea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-[1-(1-naphthyl)ethyl]-urea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea;
• N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(2,6-dibromo-4-isopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea;
• N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(4-fluorophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-mesitylurea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]urea;
• N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-propylphenyl)urea;
• N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]urea;
• N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(4-bromo-2,6-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(3-methyl-5-phenylisoxazol-4-yl)urea;
• N-(3,5-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}-cyclohexyl)methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea;
• N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea;
• N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methoxy-5-methylphenyl)urea;
• N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-6-nitrophenyl)urea;
• N-(3,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)-methyl]urea;
• N-(3,5-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)-methyl]urea; and
• N-(3-chloro-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-5 alkyl, and
  • C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
  • C_1-5 alkoxy,
• (ii) carbocyclyl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy carbonyl,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by halogen,
  • mono-C_1-5 alkylamino,
  • di-C_1-5 alkylamino, and
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • C_1-5 alkyl,
  • C_1-5 alkoxy carbonyl, and
  • carbocyclic aryl;
  • L is Formula (VII);
  • Y is —C(S)NR₅—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is bicyclo[2.2.1]heptyl;
  • heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino, or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; R₅ is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• • carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • C_1-5 alkyl,
  • C_1-5 alkoxy,
  • mono-C_1-5 alkylamino, and
  • di-C_1-5 alkylamino;
  • wherein carbocyclic aryl is phenyl or naphthyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-thiourea;
• N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}-cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea;
• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}-cyclohexyl)thiourea;
• N-[4-dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}-cyclohexyl)thiourea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)-thiourea;
• N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-mesitylthiourea;
• N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiourea;
• N-(5chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}-cyclohexyl)thiourea;
• N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiourea; and
• N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiourea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-8 alkyl, and
  • C_1-8 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkoxy,
  • C_1-5 alkoxy substituted by carbocyclic aryl,
  • carbocyclyl,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro, and
    • C_1-5 alkoxy,
• (ii) C_2-5 alkenyl,
• (iii) carbocyclyl,
• (iv) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen, and
  • C_1-5 alkoxy;
  • L is Formula (VII);
  • Y is —C(O)O—;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • carbocyclyl is 9H-fluorenyl or menthyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₂ is methylamino or dimethylamino; p is 0; R₃ and R₄ are hydrogen; A is a single bond; B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, Q is Formula (IV); p is 1 or 2;

• R₁ is selected from the group consisting of:
• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • hydroxy,
  • oxo,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkylcarbonylamino,
    • C_3-6 cycloalkylcarbonylamino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen, and
  • heterocyclyl,
• (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:
    • C_1-5 alkoxy,
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • hydroxy,
  • C_1-9 alkoxy,
  • C_1-9 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
  • carboxy,
  • C_1-5 alkoxycarbonyl,
  • di-C_1-5 alkylamino,
  • C_1-5 alkylcarbonylamino,
  • C_3-6 cycloalkylcarbonylamino,
  • C_1-5 alkylthio,
  • C_1-5 alkylsulfinyl,
  • C_1-5 alkylsulfonyl,
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • amino,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by halogen,
  • heterocyclyl sulfonyl,
  • heterocyclyl sulfonyl substituted by C_1-5 alkyl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • C_1-5 alkylthio,
  • C_1-5 alkylsulfinyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• R₂ is selected from the group consisting of:
• amino, C_1-5 alkyl, C_1-5 alkoxy, —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl or C_3-6 cycloalkyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 3,4-dihydro-1H-isoquinolinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • oxo,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
• (ii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic arylsulfinyl, and
  • carbocyclic arylsulfinyl substituted by halogen,
• L is Formula (VII);
• Y is a single bond or —CH₂—;
• R₂ is —N(R_2a)(R_2b), wherein R_2a is C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • carbocyclic aryl is phenyl;
  • heterocyclyl is pyrazinyl; and
  • halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted-by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • C_1-5 alkoxy,
• (ii) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic arylsulfinyl, and
  • carbocyclic arylsulfinyl substituted by halogen,
• R₂ is —N(R_2a)(R_2b), wherein R_2a is C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • carbocyclic aryl is phenyl;
  • heterocyclyl is pyrazinyl; and
  • halogen is fluoro or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• • heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic arylsulfinyl, and
  • carbocyclic arylsulfinyl substituted by halogen,
• R₂ is —N(R_2a)(R_2b), wherein R_2a is C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • carbocyclic aryl is phenyl;
  • heterocyclyl is pyrazinyl; and
  • halogen is fluoro; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 and T is C_1-5 alkyl; R₃ and R₄ are both hydrogen; A and B are both single bonds: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N²-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine;
• N²-{cis-4-[(3-bromobenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine;
• N²-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine -2,4-diamine; and
• N²-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino)cyclohexyl]-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is:

• N²-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino)cyclohexyl]-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-6 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • hydroxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
• (ii) C_3-12 cycloalyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:
    • C_1-5 alkoxy,
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • hydroxy,
  • C_1-9 alkoxy,
  • C_1-9 alkoxy substituted by halogen,
  • carboxy,
  • C_1-5 alkoxycarbonyl,
  • di-C_1-5 alkylamino,
  • C_1-5 alkylcarbonylamino,
  • C_3-6 cycloalkylcarbonylamino,
  • C_1-5 alkylsulfonyl, and
  • carbocyclic aryl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • amino,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by halogen,
  • heterocyclyl sulfonyl,
  • heterocyclyl sulfonyl substituted by C_1-5 alkyl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • C_1-5 alkylthio,
  • C_1-5 alkylsulfinyl,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• L is Formula (VII);
• Y is —C(O)—;
• R₂ is selected from the group consisting of:
• amino, C_1-5 alkyl, C_1-5 alkoxy, —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and
  • R_2b is C_1-5 alkyl or C_3-6 cycloalkyl;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • hydroxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by halogen,
  • mono-arbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of:
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:
    • C_1-5 alkoxy,
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • hydroxy,
  • C_1-9 alkoxy,
  • C_1-9 alkoxy substituted by halogen,
  • carboxy,
  • C_1-5 alkoxycarbonyl, and
  • C_1-5 alkylsulfonyl,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by halogen,
  • heterocyclyl sulfonyl,
  • heterocyclyl sulfonyl substituted by C_1-5 alkyl,
  • mono-carbocyclic arylamino,
  • mono-carbocyclic arylamino substituted by halogen,
  • C_1-5 alkylthio,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• R₂ is selected from the group consisting of:
• C_1-5 alkoxy, —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • hydroxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • heterocyclyloxy,
  • heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • monocarbocyclic arylamino,
  • monocarbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkoxy, and
  • C_1-5 alkyl,
  • carbocyclic arylsulfinyl,
  • carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of:
    • C_1-5 alkoxy,
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • cyano,
  • nitro,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by halogen,
  • C_1-9 alkoxy, and
  • C_1-9 alkoxy substituted by halogen,
• (iv) heterocyclyl, and
  • heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-5 alkyl,
  • C_1-5 alkyl substituted by halogen,
  • C_1-5 alkoxy,
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen, and
    • C_1-5 alkoxy,
  • C_1-5 alkylthio,
  • carbocyclic arylsulfonyl,
  • carbocyclic arylsulfonyl substituted by halogen,
• R₂ is selected from the group consisting of:
• —(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl;
  • heterocyclyl is benzo[1,3]dioxolyl, furyl, pyrazolyl, pyridyl, or thienyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 and T is C_1-5 alkyl; R₃ and R₄ are both hydrogen; A is a single bond and B is a single bond or —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;
• N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;
• N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide;
• 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide;
• 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-methylbenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-4-(trifluoromethyl)benzamide;
• 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide;
• 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide;
• 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide;
• N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide;
• 4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide;
• 4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-methylbenzamide;
• 3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide;
• 3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide;
• N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide;

N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide;

• 4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide;
• 4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide;
• N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide;
• 2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide;
• 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide;
• 2-(3,4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;
• 2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide;
• 2-[(3,4-difluorophenyl)sulfonyl[-N-cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-ethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-[cis-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide;
• 2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• 2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• 2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide;
• 2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]sulfinyl}acetamide;
• 2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;
• 2-[(3,4-difluorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide;
• 1-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 2-[(3,4-dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide;
• 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)-benzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-3-carboxamide;
• 2-(3,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,3-oxazole-4-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylthiophene-2-carboxamide
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-6-(trifluoromethyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-flourobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-methylpropanamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclobutanecarboxamide;
• 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-methylpropanamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclobutanecarboxamide;
• 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide;
• 2-4-chlorophenyl)-N-cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)propanamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide;
• N²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N²-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methyl-N²-(3-methylphenyl)glycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(3-fluorophenyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(4-fluorophenyl)-N²-methylglycinamide;
• N²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N²-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(3-methoxyphenyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(4-methoxyphenyl)-N²-methylglycinamide;
• 2-[(3,4-difluorophenyl)amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• 2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)cyclopropanecarboxamide;
• trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;
• 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• 2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• 2-[(4-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}acetamide;
• 2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• 2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• 3,4-dichloro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl}-benzamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide; and
• 2-(3,4-difluoro-phenyl)-N-[cis-4(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide;
• N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide;
• 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide;
• 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide;
• 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide;
• 3,5-dichloro-N-[cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)-cyclohexyl]benzamide;
• N-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide;
• N-(4-{[4-(dimethylamino)-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide;
• 2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide;
• 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide;
• 2-(3,4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• N-[cis-4-(4-[ethyl(methyl)amino]-5-methylpyrimidin-2-ylamino)cyclohexyl]-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide;
• 2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• 2-(3-bromophenoxy)-N-cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxylacetamide;
• 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide;
• 2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]sulfinyl}acetamide;
• 2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• 2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino cyclohexyl)-3-fluorobenzamide;
• 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;
• N-(cis-t [4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5-difluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• 3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• 3-cyano-N-(cis-4-{[4-dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-bromo-N-(cis-4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}cyclohexyl)-3-methoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5 ,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylthiophene-2-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide;
• N-(cis-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide;
• N-(cis-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide;
• 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide;
• 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethylbenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• 5-chloro-N-(cis-4-{[4-(dimethylamino)-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide;
• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide;
• 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide;
• 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide;
• 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide;
• N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-methylpropanamide
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclobutanecarboxamide;
• 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-methylpropanamide
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclobutanecarboxamide;
• 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide;
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)propanamide
• 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxyacetamide;
• N-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide;
• N²-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N²-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methyl-N²-(3-methylphenyl)glycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(3-fluorophenyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino ]cyclohexyl)-N²-(4-fluorophenyl)-N²-methylglycinamide;
• N²-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N²-methylglycinamide;
• N²-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methylglycinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-(3-methoxyphenyl)-N²-methylglycinamide;
• 2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide;
• trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)cyclopropanecarboxamide;
• trans-2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)cyclopropanecarboxamide;
• trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide;
• 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)nicotinamide;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}acetamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pydin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide;
• 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide;
• 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide;
• N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide; and
• 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkylcarbonylamino,
    • C_3-6 cycloalkylcarbonylamino,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen, p0 (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by halogen,
  • C_1-9 alkoxy, and
  • C_1-5 alkylthio,
• (iv) heterocyclyl,
• L is Formula (XV);
• Y is —C(O)NR₅—;
• R₂ is selected from the group consisting of:
• —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • nitro,
    • C_1-5 alkyl,
    • C_1-5 alkyl substituted by halogen,
    • C_1-5 alkoxy, and
    • C_1-5 alkoxy substituted by halogen,
• (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by carbocyclic aryl,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by halogen, and
  • C_1-9 alkoxy,
• R₂ is selected from the group consisting of:
• —N(R_2a)(R_2b), wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 and T is C_1-5 alkyl; R₃ and R₄ are both hydrogen; and A and B are both single bonds; R₅ is hydrogen: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide;
• cis-N-2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)-cyclohexanecarboxamide;
• cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide;
• cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide;
• cis-N-(4-chlorobenzyl)A-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1 R)-1-phenylethyl]-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-fluorophenyl)cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)-cyclohexanecarboxamide;
• cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxypheny)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2yl]-amino}cyclohexanecarboxamide;
• cis-N-benzyl4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-fluorobenzyl)-cyclohexanecarboxamaide;
• cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]-cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(2-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;
• 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[3-(trifluoromethyl)-phenyl]ethyl}cyclohexanecarboxamide;
• 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[2-(trifluoromethyl)-phenyl]ethyl}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide;
• cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide; and
• cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)-cyclohexanecarboxamide;
• cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)-cyclohexanecarboxamide;
• cis-N-(3,5-dichlorobenzyl)-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3,5-dimethoxybenzyl)-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)-cyclohexanecarboxamide;
• cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino)-N-[(1R)-1-(4-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide;
• cis-N-[l -(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)-cyclohexanecarboxamide;
• cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-phenylcyclopropyl]-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]-cyclohexanecarboxamide;
• cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino)-N-[(1S)-1-(1-naphthyl)-ethyl]cyclohexanecarboxamide;
• cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide;
• cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(2-fluorophenyl)-ethyl]cyclohexanecarboxamide;
• cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide;
• 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[3-(trifluoromethyl)-phenyl]ethyl}cyclohexanecarboxamide;
• 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[2-(trifluoromethyl)-phenyl]ethyl}cyclohexanecarboxamide; and
• cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) C_1-16 alkyl, and
  • C_1-16 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl,
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
    • halogen,
    • C_1-5 alkyl, and
    • C_1-5 alkyl substituted by halogen,
• (ii) C_3-12 cycloalkyl, and
  • C_3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryl, and
  • carbocyclic aryl substituted by halogen,
• (iii) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-10 alkyl,
  • C_1-10 alkyl substituted by halogen,
  • C_1-9 alkoxy,
  • C_1-9 alkoxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • carbocyclic aryl,
• L is Formula (VII);
• Y is —C(O)NR₅—;
• R₂ is —N(R_2a)(R_2b) wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 or 2 and each T is independently C_1-5 alkyl; R₃ is hydrogen; R₄ is hydrogen or C_1-5 alkyl; A and B are both single bonds; R₅ is hydrogen: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]-amino}cyclohexyl)urea;
• N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea;
• N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea;
• N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino]cyclohexyl)urea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;
• N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2-methoxyphenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)urea;
• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea;
• N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea;
• N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclohexyl)urea;
• N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2-methylphenyl)urea;
• N-benzyl-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl}amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea;
• N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea;
• N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-ethylurea;
• N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(2-fluorophenyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy)phenyl]urea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-phenylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and
• 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, compounds of the present invention are of Formula (I) wherein the compound is selected from the group consisting of:

• N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]-amino}cyclohexyl)urea;
• N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea;
• N-(4-chlorophenyl)-N′-(cis-([4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N-(3,4-difluorophenyl)-N′-(cis-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea;
• N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea;
• N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-2-methylphenyl)urea;
• N-cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea;
• N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-methylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea;
• N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-N-ethylurea;
• N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-phenylurea;
• N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and
• 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• • heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of:
  • carbocyclic aryloxy,
  • carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of:
    • halogen, and
    • C_1-5 alkoxy,
• L is Formula (X) or (XI);
• Y is —C(O)—;
• R₂ is —N(R_2a)(R_2b) wherein R_2a is C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • • wherein carbocyclic aryl is phenyl;
    • heterocyclyl is pyridyl; and
    • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 and T is C_1-5 alkyl; R₃ and R₄ are both hydrogen; A is a single bond and B is —CH₂—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, R₁ is selected from the group consisting of:

• (i) carbocyclic aryl, and
  • carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • C_1-10 alkyl, and
  • C_1-10 alkyl substituted by halogen,
• (ii) heterocyclyl,
• L is Formula (VII); and
• Y is —S(O)₂—;
• R₂ is —N(R_2a)(R_2b) wherein R_2a is C_1-5 alkyl and R_2b is C_1-5 alkyl;
  • wherein carbocyclic aryl is phenyl or naphthyl;
  • heterocyclyl is furyl; and
  • halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, p is 1 and T is C_1-5 alkyl; R₃ and R₄ are both hydrogen, and A and B are both single bonds; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments, a compound of the present invention is:

• 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzenesulfonamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

In some embodiments of the present invention, wherein R₁ is selected from hydrogen, —CO₂^tBu, or —CO₂Bn (Bn is a benzyl group);

• R₂ is selected from the group consisting of:
  • hydrogen, halogen, hydroxy, carboxy, carbamoyl, amino, C_1-5 alkyl, C_1-5 alkyl substituted by halogen, C_1-5 alkyl substituted by hydroxy, C_1-5 alkyl substituted by carboxy, C_1-5 alkyl substituted by carbamoyl, C_1-5 alkoxy, C_1-5 alkoxy substituted by halogen, —N(R_2a)(R_2b);
• wherein R_2a is hydrogen or C_1-5 alkyl and R_2b is C_1-5 alkyl, C_3-6 cycloalkyl, or C_1-5 alkyl substituted by substituent(s) independently selected from the group consisting of:
  • halogen,
  • hydroxy,
  • carboxy,
  • carbamoyl,
  • C_1-5 alkoxy,
  • amino,
  • C_3-6 cycloalkyl,
• or R₂ is methylamino or dimethylamino when Q is Formula (II);
• Each T is independently selected from the group consisting of halogen, hydroxy, carboxy, carbamoyl, amino, cyano, nitro, C_1-5 alkyl, C_1-5 alkyl substituted by halogen, C_1-5 alkyl substituted by hydroxy, C_1-5 alkyl substituted by carboxy, C_1-5 alkyl substituted by carbamoyl, C_2-5 alkenyl, C_2-5 alkynyl, C_3-6 cycloalkyl, C_1-5 alkoxy, C_1-5 alkoxy substituted by halogen, carbocyclic aryl, heterocyclyl, and —N(R_2a)(R_2b);
  • p is 0, 1, 2, 3, 4 or 5;
• L is selected from the group consisting of: Formula (VII), (X), (XI), (XV), (XVIII), or (XIX): wherein R₃ and R₄ are independently hydrogen or C_1-5 alkyl; and A and B are independently a single bond or —CH₂—; and
• Y is a single bond; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

One aspect of the present invention pertains to pharmaceutical compositions comprising at least one compound, as described herein, in combination with a pharmaceutically acceptable carrier.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from the condition a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of treatment of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, or a pharmaceutical composition thereof, for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

One aspect of the present invention pertains to compounds of the present invention, as described herein, for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

One aspect of the present invention pertains to methods of decreasing food intake of an individual comprising administering to the individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of controlling or reducing weight gain in an individual comprising administering to said individual a therapeutically effective amount of a compound, as described herein, or a pharmaceutical composition thereof.

One aspect of the present invention pertains to methods of modulating a MCH receptor in an individual comprising contacting the receptor with a compound, as described herein. In some embodiments, the compound is an antagonist. In some embodiments, the modulation of the MCH receptor is for the prophylaxis or treatment of an eating disorder, obesity or obesity related disorder. In some embodiments, the modulation of the MCH receptor reduces food intake of the individual. In some embodiments, the modulation of the MCH receptor induces satiety in the individual. In some embodiments, the modulation of the MCH receptor controls or reduces weight gain of the individual. In some embodiments, the modulation of the MCH receptor is for prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

In some embodiments, the individual is a mammal.

In some embodiments, the mammal is a human.

In some embodiments, the human has a body mass index of about 18.5 to about 45. In some embodiments, the human has a body mass index of about 25 to about 45. In some embodiments, the human has a body mass index of about 30 to about 45. In some embodiments, the human has a body mass index of about 35 to about 45.

One aspect of the present invention pertains to methods of producing a pharmaceutical composition comprising admixing a compound, as described herein, and a pharmaceutically acceptable carrier.

One aspect of the present invention pertains to methods for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction in mammals in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound, as described herein, or pharmaceutical composition thereof.

One embodiment of the invention includes any compound of the invention which selectively binds an MCH receptor, such selective binding is preferably demonstrated by a Ki for one or more other GPCR(s), preferably NPY, being at least 10-fold greater than the Ki for any particular MCH receptor, preferable MCHR1.

As used herein, the term “alkyl” is intended to denote hydrocarbon compounds including straight chain and branched chain, including for example but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, tert-pentyl, n-hexyl, and the like.

The term “alkoxy” is intended to denote substituents of the formula —O-alkyl.

At various places in the present specification substituents of compounds of the invention are disclosed in groups. It is specifically intended that the invention include each and every individual subcombination of the members of such groups.

G-protein coupled receptors (GPCRs) represent a major class of cell surface receptors with which many neurotransmitters interact to mediate their effects. GPCRs are predicted to have seven membrane-spanning domains and are coupled to their effectors via G-proteins linking receptor activation with intracellular biochemical sequelae such as stimulation of adenylyl cyclase. Melanin Concentrating Hormone (MCH), a cyclic peptide, has been identified as the endogenous ligand of the orphan G-protein coupled receptor SLC-1. See, for example, Shimomura et al., Biochem. Biophys. Res. Commun. 261, 622-26 (1999). Studies have indicated that MCH acts as a neurotransmitter/modulator/regulator to alter a number of behavioral responses.

Mammalian MCH (19 amino acids) is highly conserved between rat, mouse, and human, exhibiting 100% amino acid identity, but its physiological roles are less clear. MCH has been reported to participate in a variety of processes including feeding, water balance, energy metabolism, general arousal/attention state, memory and cognitive functions, and psychiatric disorders. For reviews, see 1. Baker, Int. Rev. Cytol. 126:1-47 (1991); 2. Baker, TEM 5:120-126 (1994); 3. Nahon, Critical Rev. in Neurobiol 221:221-262, (1994); 4. Knigge et al., Peptides 18(7):1095-1097, (1996). The role of MCH in feeding or body weight regulation is supported by Qu et al., Nature 380:243-247, (1996), demonstrating that MCH is over expressed in the hypothalamus of ob/ob mice compared with ob/+mice, and that fasting further increased MCH mRNA in both obese and normal mice during fasting. MCH also stimulated feeding in normal rats when injected into the lateral ventricles as reported by Rossi et al., Endocrinology 138:351-355, (1997). MCH also has been reported to functionally antagonize the behavioral effects of α-MSH; see: Miller et al., Peptides 14:1-10, (1993); Gonzalez et al, Peptides 17:171-177, (1996); and Sanchez et al., Peptides 18:3933-396, (1997). In addition, stress has been shown to increase POMC mRNA levels while decreasing the MCH precursor preproMCH (ppMCH) mRNA levels; Presse et al., Endocrinology 131:1241-1250, (1992). Thus MCH can serve as an integrative neuropeptide involved in the reaction to stress, as well as in the regulation of feeding and sexual activity; Baker, Int. Rev. Cytol. 126:1-47, (1991); Knigge et al., Peptides 17:1063-1073, (1996).

The localization and biological activities of MCH peptide suggest that the modulation of MCH receptor activity can be useful in a number of therapeutic applications. MCH is expressed in the lateral hypothalamus, a brain area implicated in the regulation of thirst and hunger: Grillon et al., Neuropeptides 31:131-136, (1997); recently orexins A and B, which are potent orexigenic agents, have been shown to have very similar localization to MCH in the lateral hypothalamus; Sakurai et al., Cell 92:573-585 (1998). MCH mRNA levels in this brain region are increased in rats after 24 hours of food-deprivation; Herve and Fellmann, Neurpeptides 31:237-242 (1997); after insulin injection, a significant increase in the abundance and staining intensity of MCH immunoreactive perikarya and fibres was observed concurrent with a significant increase in the level of MCH mRNA; Bahjaoui-Bouhaddi et al., Neuropeptides 24:251-258, (1994). Consistent with the ability of MCH to stimulate feeding in rats; Rossi et al., Endocrinology 138:351-355, (1997); is the observation that MCH mRNA levels are upregulated in the hypothalami of obese ob/ob mice; Qu et al., Nature 380:243-247, (1996); and decreased in the hypothalami of rats treated with leptin, whose food intake and body weight gains are also decreased; Sahu, Endocrinology 139:795-798, (1998). MCH appears to act as a functional antagonist of the melanocortin system in its effects on food intake and on hormone secretion within the HPA (hypothalamopituitary/adrenal axis); Ludwig et al., Am. J. Physiol. Endocrinol. Metab. 274: E627-E633, (1998). Together these data suggest a role for endogenous MCH in the regulation of energy balance and response to stress, and provide a rationale for the development of specific compounds acting at MCH receptors for use in the treatment of obesity and stress-related disorders.

Accordingly, a MCH receptor antagonist is desirable for the prophylaxis or treatment of obesity or obesity related disorders. An obesity related disorder is a disorder that has been directly or indirectly associated to obesity, such as, type II diabetes, syndrome X, impaired glucose tolerance, dyslipidaemia, hypertension, coronary heart disease and other cardiovascular disorders including atherosclerosis, insulin resistance associated with obesity and psoriasis, for treating diabetic complications and other diseases such as polycystic ovarian syndrome (PCOS), certain renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal diseases and microalbuminuria as well as certain eating disorders.

In species studied to date, a major portion of the neurons of the MCH cell group occupies a rather constant location in those areas of the lateral hypothalamus and subthalamus where they lie and can be a part of some of the so-called “extrapyramidal” motor circuits. These involve substantial striato- and pallidofugal pathways involving the thalamus and cerebral cortex, hypothalamic areas, and reciprocal connections to subthalamic nucleus, substantia nigra, and mid-brain centers; Bittencourt et al., J. Comp. Neurol. 319:218-245, (1992). In their location, the MCH cell group may offer a bridge or mechanism for expressing hypothalamic visceral activity with appropriate and coordinated motor activity. Clinically it can be of some value to consider the involvement of this MCH system in movement disorders, such as Parkinson's disease and Huntingdon's Chorea in which extrapyramidal circuits are known to be involved.

Human genetic linkage studies have located authentic hMCH loci on chromosome 12 (12q23-24) and the variant hMCH loci on chromosome 5 (5q12-13) (Pedeutour et al., 1994). Locus 12q23-24 coincides with a locus to which autosomal dominant cerebellar ataxia type II (SCA2) has been mapped; Auburger et al., Cytogenet. Cell. Genet. 61:252-256, (1992); Twells et al., Cytogenet. Cell. Genet. 61:262-265, (1992). This disease comprises neurodegenerative disorders, including an olivopontocerebellar atrophy. Furthermore, the gene for Darier's disease, has been mapped to locus 12q23-24; Craddock et al., Hum. Mol. Genet. 2:1941-1943, (1993). Dariers' disease is characterized by abnormalities I keratinocyte adhesion and mental illnesses in some families. In view of the functional and neuroanatomical patterns of the MCH neural system in the rat and human brains, the MCH gene can represent a good candidate for SCA2 or Darier's disease. Interestingly, diseases with high social impact have been mapped to this locus. Indeed, the gene responsible for chronic or acute forms of spinal muscular atrophies has been assigned to chromosome 5q12-13 using genetic linkage analysis; Melki et al., Nature (London) 344:767-768, (1990); Westbrook et al., Cytogenet. Cell. Genet. 61:225-231, (1992). Furthermore, independent lines of evidence support the assignment of a major schizophrenia locus to chromosome 5q11.2-13.3; Sherrington et al., Nature (London) 336:164-167, (1988); Bassett et al., Lancet 1:799-801, (1988); Gilliam et al., Genomics 5:940-944, (1989). The above studies suggest that MCH can play a role in neurodegenerative diseases and disorders of emotion.

Additional therapeutic applications for MCH-related compounds are suggested by the observed effects of MCH in other biological systems. For example, MCH can regulate reproductive functions in male and female rats. MCH transcripts and MCH peptide were found within germ cells in testes of adult rats, suggesting that MCH can participate in stem cell renewal and/or differentiation of early spermatocytes; Hervieu et al., Biology of Reduction 54:1161-1172, (1996). MCH injected directly into the medial preoptic area (MPOA) or ventromedial nucleus (VMN) stimulated sexual activity in female rats; Gonzalez et al., Peptides 17:171-177, (1996). In ovariectomized rats primed with estradiol, MCH stimulated luteinizing hormone (LH) release while anti-MCH antiserum inhibited LH release; Gonzalez et al., Neuroendocrinology 66:254-262, (1997). The zona incerta, which contains a large population of MCH cell bodies, has previously been identified as a regulatory site for the preovulatory LH surge; MacKenzie et al., Neuroendocrinology 39:289-295, (1984). MCH has been reported to influence release of pituitary hormones including ACTH and oxytocin. MCH analogues can also be useful in treating epilepsy. In the PTZ seizure model, injection of MCH prior to seizure induction prevented seizure activity in both rats and guinea pigs, suggesting that MCH-containing neurons can participate in the neural circuitry underlying PTZ-induced seizure; Knigge and Wagner, Peptides 18:1095-1097, (1997). MCH has also been observed to affect behavioral correlates of cognitive functions. MCH treatment hastened extinction of the passive avoidance response in rats; McBride et al., Peptides 15:757-759, (1994); raising the possibility that MCH receptor antagonists can be beneficial for memory storage and/or retention. A possible role for MCH in the modulation or perception of pain is supported by the dense innervation of the periaqueductal grey (PAG) by MCH-positive fibers. Finally, MCH can participate in the regulation of fluid intake. ICV infusion of MCH in conscious sheep produced diuretic, natriuretic, and kaliuretic changes in response to increased plasma volume; Parkes, J. Neuroendocrinol. 8:57-63, (1996). Together with anatomical data reporting the presence of MCH in fluid regulatory areas of the brain, the results indicate that MCH can be an important peptide involved in the central control of fluid homeostasis in mammals.

In a recent citation MCHR1 antagonists surprisingly demonstrated their use as an anti-depressants and/or anti-anxiety agents. MCHR1 antagonists have been reported to show antidepressant and anxiolytic activities in rodent models, such as, social interaction, forced swimming test and ultrasonic vocalization. Therefore, MCHR1 antagonists could be useful to independently treat subjects with depression and/or anxiety. Also, MCHR1 antagonists could be useful to treat subjects that suffer from depression and/or anxiety and obesity.

This invention provides a method of treating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of a mammalian MCH 1 receptor which comprises administering to the subject an amount of a compound which is a mammalian MCH1 receptor antagonist effective to treat the abnormality. In separate embodiments, the abnormality is a regulation of a steroid or pituitary hormone disorder, an epinephrine release disorder, an anxiety disorder, genta gastrointestinal disorder, a cardiovascular disorder, an electrolyte balance disorder, hypertension, diabetes, a respiratory disorder, asthma, a reproductive function disorder, an immune disorder, an endocrine disorder, a musculoskeletal disorder, a neuroendocrine disorder, a cognitive disorder, a memory disorder, a sensory modulation and transmission disorder, a motor coordination disorder, a sensory integration disorder, a motor integration disorder, a dopaminergic function disorder, a sensory transmission disorder, an olfaction disorder, a sympathetic innervation disorder, an affective disorder, a stress-related disorder, a fluid-balance disorder, a seizure disorder, pain, psychotic behavior, morphine tolerance, opiate addiction or migraine.

Compositions of the invention can conveniently be administered in unit dosage form and can be prepared by any of the methods well known in the pharmaceutical art, for example, as described in Remington's Pharmaceutical Sciences (Mack Pub. Co., Easton, Pa., 1980).

The compounds of the invention can be employed as the sole active agent in a pharmaceutical or can be used in combination with other active ingredients which could facilitate the therapeutic effect of the compound.

Compounds of the present invention or a solvate or physiologically functional derivative thereof can be used as active ingredients in pharmaceutical compositions, specifically as a MCH receptor antagonists. By the term “active ingredient” is defined in the context of a “pharmaceutical composition” and shall mean a component of a pharmaceutical composition that provides the primary pharmaceutical benefit, as opposed to an “inactive ingredient” which would generally be recognized as providing no pharmaceutical benefit. The term “pharmaceutical composition” shall mean a composition comprising at one active ingredient and at least one ingredient that is not an active ingredient (for example and not limitation, a filler, dye, or a mechanism for slow release), whereby the composition is amenable to use for a specified, efficacious outcome in a mammal (for example, and not limitation, a human).

Pharmaceutical compositions, including, but not limited to, pharmaceutical compositions, comprising at least one compound of the present invention and/or an acceptable salt or solvate thereof. (e.g., a pharmaceutically acceptable salt or solvate) as an active ingredient combined with at least one carrier or excipient (e.g., pharmaceutical carrier or excipient) can be used in the treatment of clinical conditions for which a MCH receptor antagonist is indicated. At least one compound of the present invention can be combined with the carrier in either solid or liquid form in a unit dose formulation. The pharmaceutical carrier must be compatible with the other ingredients in the composition and must be tolerated by the individual recipient. Other physiologically active ingredients can be incorporated into the pharmaceutical composition of the invention if desired, and if such ingredients are compatible with the other ingredients in the composition. Formulations can be prepared by any suitable method, typically by uniformly mixing the active compound(s) with liquids or finely divided solid carriers, or both, in the required proportions, and then, if necessary, forming the resulting mixture into a desired shape.

Conventional excipients, such as binding agents, fillers, acceptable wetting agents, tabletting lubricants, and disintegrants can be used in tablets and capsules for oral administration. Liquid preparations for oral administration can be in the form of solutions, emulsions, aqueous or oily suspensions, and syrups. Alternatively, the oral preparations can be in the form of dry powder that can be reconstituted with water or another suitable liquid vehicle before use. Additional additives such as suspending or emulsifying agents, non-aqueous vehicles (including edible oils), preservatives, and flavorings and colorants can be added to the liquid preparations. Parenteral dosage forms can be prepared by dissolving the compound of the invention in a suitable liquid vehicle and filter sterilizing the solution before filling and sealing an appropriate vial or ampoule. These are just a few examples of the many appropriate methods well known in the art for preparing dosage forms.

It is noted that when the MCH receptor antagonists are utilized as active ingredients in a pharmaceutical composition, these are not intended for use only in humans, but in other non-human mammals as well. Indeed, recent advances in the area of animal health-care mandate that consideration be given for the use of MCH receptor antagonists for the treatment of obesity in domestic animals (e.g., cats and dogs), and MCH receptor antagonists in other domestic animals where no disease or disorder is evident (e.g., food-oriented animals such as cows, chickens, fish, etc.). Those of ordinary skill in the art are readily credited with understanding the utility of such compounds in such settings.

Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with the appropriate base or acid in water, in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, dioxane, or acetonitrile are preferred. For instance, when the compound (I) possesses an acidic functional group, it can form an inorganic salt such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g. calcium salt, magnesium salt, barium salt, etc.), and an ammonium salt. When the compound (I) possesses a basic functional group, it can form an inorganic salt (e.g., hydrochloride, sulfate, phosphate, hydrobromate, etc.) or an organic salt (e.g., acetate, maleate, fumarate, succinate, methanesulfonate, p-toluenesulfonate, citrate, tartrate, etc.).

Other Utilities

Another object of the present invention relates to radiolabelled compounds of Formula (Ia) that would be useful not only in radio-imaging but also in assays, both in vitro and in vivo, for localizing and quantitating MCH in tissue samples, including human, and for identifying MCH ligands by inhibition binding of a radiolabelled compound. It is a further object of this invention to develop novel MCH assays of which comprise such radiolabelled compounds.

Suitable radionuclides that can be incorporated in compounds of the present invention include but are not limited to ³H (also written as T), ¹¹C, ¹⁴C, ¹⁸F, ¹²⁵I, ⁸²Br, ¹²³I, ¹²⁴I, ¹²⁵I, ¹³¹I, ⁷⁵Br, ⁷⁶Br, ¹⁵O, ¹³N, 35S and ⁷⁷Br. The radionuclide that is incorporated in the instant radiolabelled compounds will depend on the specific application of that radiolabelled compound. Thus, for in vitro MCH labeling and competition assays, compounds that incorporate ³H, ¹⁴C, ¹²⁵I, ¹³¹I, ³⁵S or ⁸²Br will generally be most useful. For radio-imaging applications ¹¹C, ¹⁸F, ¹²⁵I, ¹²³I, ¹²⁴I, ¹³¹I, ⁷⁵Br, ⁷⁶Br or ⁷⁷Br will generally be most useful.

It is understood that a “radio-labelled” or “labelled compound” is a compound of Formula (Ia) that has incorporated at least one radionuclide; in some embodiments the radionuclide is selected from the group consisting of: ³H, ¹⁴C, ¹²⁵I, ³⁵S and ⁸²Br; in some embodiments the radionuclide ³H or ¹⁴C. Moreover, it should be understood that all of the atoms represented in the compounds of the invention can be either the most commonly occurring isotope of such atoms or the more scarce raido-isotope or nonradio-active isotope.

Synthetic methods for incorporating radio-isotopes into organic including those applicable to those compounds of the invention are well known in the art and included incorporating activity levels of tritium into target molecules include: A. Catalytic Reduction with Tritium Gas—This procedure normally yields high specific activity products and requires halogenated or unsaturated precursors. B. Reduction with Sodium Borohydride [³H]—This procedure is rather inexpensive and requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. C. Reduction with Lithium Aluminum Hydride [³H ]—This procedure offers products at almost theoretical specific activities. It also requires precursors containing reducible functional groups such as aldehydes, ketones, lactones, esters, and the like. D. Tritium Gas Exposure Labeling—This procedure involves exposing precursors containing exchangeable protons to tritium gas in the presence of a suitable catalyst. E. N-Methylation using Methyl Iodide [³H]—This procedure is usually employed to prepare O-methyl or N-methyl (³H) products by treating appropriate precursors with high specific activity methyl iodide (³H). This method in general allows for high specific activity, such as about 80-87 Ci/mmol.

Synthetic methods for incorporating activity levels of ¹²⁵I into target molecules include: A. Sandmeyer and like reactions—This procedure transforms an aryl or heteroaryl amine into a diazonium salt, such as a tetrafluoroborate salt, and subsequently to ¹²⁵I labelled compound using Na¹²⁵I. A represented procedure was reported by Zhu, D.-G. and co-workers in J. Org. Chem. 2002, 67, 943-948. B. Ortho ¹²⁵Iodination of phenols—This procedure allows for the incorporation of ¹²⁵I at the ortho position of a phenol as reported by Collier, T. L. and co-workers in J. Labelled Compd Radiopharm. 1999, 42, S264-S266. C. Aryl and heteroaryl bromide exchange with ¹²⁵I—This method is generally a two step process. The first step is the conversion of the aryl heteroaryl bromide to the corresponding tri-alkyltin intermediate using for example, Pd catalyzed reaction [i.e. Pd(Ph₃P)₄] or through an aryl or heteroaryl lithium, in the presence of a tri-alkyltinhalide or hexaalkylditin [e.g., (CH₃)₃SnSn(CH₃)₃]. A represented procedure was reported by Bas, M.-D. and co-workers in J. Labelled Compd Radiopharm. 2001, 44, S280-S282.

A radiolabelled MCH compound of formula (I) can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the “radiolabelled compound of Formula (Ia)” to the MCH receptor. Accordingly, the ability of a test compound to compete with the “radio-labelled compound of Formula (Ia)” for the binding to the MCH receptor directly correlates to its binding affinity.

The labelled compounds of the present invention bind to the MCH receptor. In one embodiment the labelled compound has an IC₅₀ less than about 500 μM, in another embodiment the labelled compound has an IC₅₀ less than about 100 μM, in yet another embodiment the labelled compound has an IC₅₀ less than about 10 μM, in yet another embodiment the labelled compound has an IC₅₀ less than about 1 μM, and in still yet another embodiment the labelled inhibitor has an IC₅₀ less than about 0.1 μM.

Preparation of Compound of Formula (I)—General Synthetic Methods

The novel substituted quinolines, tetrahydroquinazolines, and pyrimidines of the present invention can be readily prepared according to a variety of synthetic manipulations, all of which would be familiar to one skilled in the art. Preferred methods for the preparation of compounds of the present invention include, but are not limited to, those described in Scheme 1-24.

The common intermediate (F) of the novel substituted quinolines can be prepared as shown in Scheme 1. Commercially available 2,4-dihydroxyquinoline (A), wherein T and p is as defined above, is converted to 2,4-dihalo-quinoline (B) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably N,N-diisopropylethylamine, etc.) or an aromatic amine (preferably N,N-dimethylaniline, etc.). Reaction temperature ranges from about 100° C. to 200° C., preferably about 140° C. to 180° C.

The halogen of 4-position of 2,4-dihalo-quinoline (B) is selectively substituted by a primary or secondary amine (HNR_2aR_2b, wherein R_2a and R_2b are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (C). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0° C. to 200° C., preferably about 10° C. to 150° C.

In turn, this is substituted by the mono-protected diamine (D), wherein R₃, R₄, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2,4-disubstituted amino quinoline (E). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 150° C. Also this reaction can be carried out under microwave conditions.

Representative protecting groups suitable for a wide variety of synthetic transformations are disclosed in Greene and Wuts, Protective Groups in Organic Synthesis, second edition, John Wiley & Sons, New York, 1991, the disclosure of which is incorporated herein by reference in its entirety. The deprotection of the protective group leads to the common intermediate (F) of the novel substituted quinolines.

The conversion of the common intermediate (F) to the novel substituted quinolines (G-K) of the present invention is outlined in Scheme 2.

The amine (F) is reacted with a carboxylic acid (R₁CO₂H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (G) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

Alternatively, the novel amide (G) of the present invention can be obtained by amidation reaction using an acid chloride (R₁COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

The novel amide (G) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (H) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about −78° C. to 200° C., preferably about 50° C. to 120° C.

Alternatively, the novel amine (H) of the present invention can be obtained by reductive amination reaction using aldehyde (R₁CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C. Also this reaction can be carried out under microwave conditions.

The novel urea (I) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The amine (F) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (J) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The novel urethane (K) of the present invention can be obtained by urethane reaction using R₁OCOX, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

Compounds of Formula (N) can be prepared as shown in Scheme 3. [4-(Benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (L) is synthesized by the method which is described in WO 01/72710. The deprotection of Boc-group is achieved by an acid to give the amine (M). The coupling of the amine with quinoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (N).

Compounds of Formula (P) can be prepared as shown in Scheme 4. The dicarboxylic acid of commercially available cis-cyclohexane-1,4-dicarboxylic acid is transformed to dibenzyl carbamate by curtius rearrangement. The deprotection of Z-group is achieved by hydrogen reduction to give the diamine. The monoprotection of the diamine can be achieved by the method described in Synthetic communications, 20, 2559-2564 (1990) to give the compound (O). The coupling of the amine with quinoline core (C), which is synthesized as scheme 1, gives 2,4-disubstituted amino quinoline. The deprotection of Boc-group is achieved by an acid to give the amine (P).

The common intermediate (V) of the novel substituted tetrahydroquinazolines can be prepared as shown in Scheme 5. Commercially available ethyl 2-cyclohexanonecarboxylate (Q), wherein T and p is as defined above, is transformed to 2,4-dihydroxytetrahydroquinazoline (R) according to the method described in EP 0604920. 2,4-Dihydroxytetrahydroquinazoline (R) is converted to 2,4-dihalo-tetrahydroquinazoline (S) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably N,N-diisopropylethylamine, etc.) or an aromatic amine (preferably N,N-dimethylaniline, etc.). Reaction temperature ranges from about 100° C. to 200° C., preferably about 140° C. to 180° C.

The halogen of 4-position of 2,4-dihalo-tetrahydroquinazoline (S) is selectively substituted by a primary or secondary amine (HNR_2aR_2b, wherein R_2a and R_2b are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (T). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0° C. to 200° C., preferably about 10° C. to 150° C.

In turn, this is substituted by the mono-protected diamine (D), wherein R₃, R₄, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2,4-disubstituted amino tetrahydroquinazoline (U). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 150° C. Also this reaction can be carried out under microwave conditions.

The deprotection of the protective group leads to the common intermediate (V) of the novel substituted tetrahydroquinazolines.

The conversion of the common intermediate (V) to the novel substituted tetrahydroquinazolines (W-A′) of the present invention is outlined in Scheme 6.

The amine (V) is reacted with a carboxylic acid (R₁CO₂H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (W) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

Alternatively, the novel amide (W) of the present invention can be obtained by amidation reaction using an acid chloride (R₁COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

The novel amide (W) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (X) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about −78° C. to 200° C., preferably about 50° C. to 120° C.

Alternatively, the novel amine (X) of the present invention can be obtained by reductive amination reaction using aldehyde (R₁CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C. Also this reaction can be carried out under microwave conditions.

The novel urea (Y) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The amine (V) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (Z) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The novel urethane (A′) of the present invention can be obtained by urethane reaction using R₁OCOX, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

Compounds of Formula (B′) can be prepared as shown in Scheme 7. The coupling of the amine (M), which is synthesized as scheme 3, with tetrahydroquinazoline core (T), which is synthesized as scheme 5, gives 2,4-disubstituted amino tetrahydroquinazoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (B′).

Compounds of Formula (C′) can be prepared as shown in Scheme 8. The coupling of the amine (O), which is synthesized as scheme 4, with tetrahydroquinazoline core (T), which is synthesized as scheme 5, gives 2,4-disubstituted amino tetrahydroquinazoline. The deprotection of Boc-group is achieved by an acid to give the amine (C′).

The common intermediate (H′) of the novel substituted pyrimidines can be prepared as shown in Scheme 9. Commercially available substituted uracil (D′), wherein T and p is as defined above, is converted to substituted 2,4-dihalo-pyrimidines (E′) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably N,N-diisopropylethylamine, etc.) or an aromatic amine (preferably N,N-dimethylaniline, etc.). Reaction temperature ranges from about 100° C. to 200° C., preferably about 140° C. to 180° C.

The halogen of 4-position of substituted 2,4-dihalo-pyrimidines (E′) is selectively substituted by a primary or secondary amine (HNR_2a R_2b, wherein R_2a and R_2b are as defined above) with or without a base in an inert solvent to provide the corresponding 4-substitued amino adduct (F′). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane, etc.), or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 0° C. to 200° C., preferably about 10° C. to 150° C.

In turn, this is substituted by the mono-protected diamine (D), wherein R₃, R₄, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2,4-disubstituted amino pyrimidines (G′). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 150° C. Also this reaction can be carried out under microwave conditions.

The deprotection of the protective group leads to the common intermediate (H′) of the novel substituted pyrimidines.

The conversion of the common intermediate (H′) to the novel substituted pyrimidines (I′-M′) of the present invention is outlined in Scheme 10.

The amine (H′) is reacted with a carboxylic acid (R₁CO₂H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (I′) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

Alternatively, the novel amide (I′) of the present invention can be obtained by amidation reaction using an acid chloride (R₁COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

The novel amide (I′) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (J′) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about −78° C. to 200° C., preferably about 50° C. to 120° C.

Alternatively, the novel amine (I′) of the present invention can be obtained by reductive amination reaction using aldehyde (R₁CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C. Also this reaction can be carried out under microwave conditions.

The novel urea (K′) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The amine (H′) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (L′) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The novel urethane (M′) of the present invention can be obtained by urethane reaction using R₁OCOCl, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

Compounds of Formula (N′) can be prepared as shown in Scheme 11. The coupling of the amine (M), which is synthesized as scheme 3, with pyrimidine core (F′), which is synthesized as scheme 9, gives 2,4-disubstituted amino pyrimidine. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (N′).

Compounds of Formula (O′) can be prepared as shown in Scheme 12. The coupling of the amine (O), which is synthesized as scheme 4, with pyrimidine core (F′), which is synthesized as scheme 9, gives 2,4-disubstituted amino pyrimidine. The deprotection of Boc-group is achieved by an acid to give the amine (O′).

The common intermediate (S′) of the novel substituted quinolines can be prepared as shown in Scheme 13. Commercially available substituted 2-hydroxy-quinoline (P′), wherein R₂, T, and p is as defined above, is converted to 2-halo-quinolines (Q′) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably N,N-diisopropylethylamine, etc.) or an aromatic amine (preferably N,N-dimethylaniline, etc.). Reaction temperature ranges from about 100° C. to 200° C., preferably about 140° C. to 180° C.

The halide (Q′) is substituted by the mono-protected diamine (D), wherein R₃, R₄, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2-substituted amino quinoline (R′). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 150° C. Also this reaction can be carried out under microwave conditions.

The deprotection of the protective group leads to the common intermediate (S′) of the novel substituted quinolines.

The conversion of the common intermediate (S′) to the novel substituted quinolines (T′-X′) of the present invention is outlined in Scheme 14.

The amine (S′) is reacted with a carboxylic acid (R₁CO₂H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (T′) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

Alternatively, the novel amide (T′) of the present invention can be obtained by amidation reaction using an acid chloride (R₁COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

The novel amide (T′) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amide (U′) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about −78° C. to 200° C., preferably about 50° C. to 120° C.

Alternatively, the novel amine (U′) of the present invention can be obtained by reductive amination reaction using aldehyde (R₁CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C. Also this reaction can be carried out under microwave conditions.

The novel urea (V′) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The amine (S′) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (W′) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The novel urethane (X′) of the present invention can be obtained by urethane reaction using R₁OCOCl, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

Compounds of Formula (Y′) can be prepared as shown in Scheme 15. The coupling of the amine (M), which is synthesized as scheme 3, with quinoline core (Q′), which is synthesized as scheme 13, gives 2-substituted amino quinoline. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (Y′).

Compounds of Formula (Z′) can be prepared as shown in Scheme 16. The coupling of the amine (O), which is synthesized as scheme 4, with quinoline core (Q′), which is synthesized as scheme 13, gives 2-substituted amino quinoline. The deprotection of Boc-group is achieved by an acid to give the amine (Z′).

The common intermediate (D″) of the novel substituted pyrimidines can be prepared as shown in Scheme 17. Commercially available substituted 2-hydroxy-pyrimidines (A″), wherein R₂, T, and p is as defined above, is converted to 2-halo-pyrimidines (B″) by a halogenating agent with or without a base (wherein X is halogen such as chloro, bromo, or iodo). The halogenating agent includes phosphorous oxychloride (POCl₃), phosphorous oxybromide (POBr₃), or phosphorus pentachloride (PCl₅). The base includes a tertiary amine (preferably N,N-diisopropylethylamine, etc.) or an aromatic amine (preferably N,N-dimethylaniline, etc.). Reaction temperature ranges from about 100° C. to 200° C., preferably about 140° C. to 180° C.

The halide (B″) is substituted by the mono-protected diamine (D), wherein R₃, R₄, A, and B are as defined above and P is a protective group, with or without a base in an inert solvent to provide 2-substituted amino pyrimidine (C″). The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 150° C. Also this reaction can be carried out under microwave conditions.

The deprotection of the protective group leads to the common intermediate (D″) of the novel substituted pyrimidines.

The conversion of the common intermediate (D″) to the novel substituted pyrimidines (E″-I″) of the present invention is outlined in Scheme 18.

The amine (D″) is reacted with a carboxylic acid (R₁CO₂H) and a dehydrating condensing agent in an inert solvent with or without a base to provide the novel amide (E″) of the present invention. The dehydrating condensing agent includes dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC.HCl), bromo-tris-pyrrolidino-phosnium hexafluorophosphate (PyBroP), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), or 1-cyclohexyl-3-methylpolystyrene-carbodiimide. The base includes a tertiary amine (preferably N,N-diisopropylethylamine or triethylamine, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), nitrile solvents (preferably acetonitrile, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). In case of need, 1-hydroxybenzotriazole (HOBT), HOBT-6-carboxaamidomethyl polystyrene, or 1-hydroxy-7-azabenzotriazole (HOAT) can be used as a reactant agent. Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

Alternatively, the novel amide (E″) of the present invention can be obtained by amidation reaction using an acid chloride (R₁COCl) and a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, poly−4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), amide solvents (preferably N,N-dimethylformamide, etc.), or aromatic solvents (preferably toluene or pyridine, etc.). Reaction temperature ranges from about −20° C. to 50° C., preferably about 0° C. to 40° C.

The novel amide (E″) of the present invention is reacted with a reducing agent in an inert solvent to provide the novel amine (F″) of the present invention. The reducing agent includes alkali metal aluminum hydrides (preferably lithium aluminum hydride), alkali metal borohydrides (preferably lithium borohydride), alkali metal trialkoxyaluminum hydrides (preferably lithium tri-tert-butoxyaluminum hydride), dialkylaluminum hydrides (preferably di-isobutylaluminum hydride), borane, dialkylboranes (preferably di-isoamyl borane), alkali metal trialkylboron hydrides (preferably lithium triethylboron hydride). The inert solvent includes ethereal solvents (preferably tetrahydrofuran or dioxane) or aromatic solvents (preferably toluene, etc.). Reaction temperature ranges from about −78° C. to 200° C., preferably about 50° C. to 120° C.

Alternatively, the novel amine (F″) of the present invention can be obtained by reductive amination reaction using aldehyde (R₁CHO) and a reducing agent in an inert solvent with or without an acid. The reducing agent includes sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, or boran-pyridine complex, preferably sodium triacetoxyborohydride or sodium cyanoborohydride. The inert solvent includes lower alkyl alcohol solvents (preferably methanol or ethanol, etc.), lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), or aromatic solvents (preferably toluene, etc.). The acid includes an inorganic acid (preferably hydrochloric acid or sulfuric acid) or an organic acid (preferably acetic acid). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C. Also this reaction can be carried out under microwave conditions.

The novel urea (G″) of the present invention can be obtained by urea reaction using an isocyanate (R₁NCO) in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The amine (D″) is reacted with a isothiocyanate (R₁NCS) in an inert solvent with or without a base to provide the novel thiourea (H″) of the present invention. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine or imidazole, etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or amide solvents (preferably N,N-dimethylformamide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

The novel urethane (I″) of the present invention can be obtained by urethane reaction using R₁OCOCl, wherein X is halogen such as chloro, bromo, or iodo, in an inert solvent with or without a base. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydrogencarbonate (preferably sodium hydrogencarbonate or potassium hydrogencarbonate, etc.), an alkali hydroxide (preferably sodium hydroxide or potassium hydroxide, etc.), a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.), or an aromatic amine (preferably pyridine, imidazole, or poly-(4-vinylpyridine), etc.). The inert solvent includes lower halocarbon solvents (preferably dichloromethane, dichloroethane, or chloroform, etc.), ethereal solvents (preferably tetrahydrofuran or dioxane), aromatic solvents (preferably benzene or toluene, etc.), or polar solvents (preferably N,N-dimethylformamide or dimethyl sulfoxide, etc.). Reaction temperature ranges from about −20° C. to 120° C., preferably about 0° C. to 100° C.

Compounds of Formula (J″) can be prepared as shown in Scheme 19. The coupling of the amine (M), which is synthesized as scheme 3, with pyrimidine core (B″), which is synthesized as scheme 17, gives 2-substituted amino pyrimidine. The deprotection of Z-group is achieved by hydrogen reduction to give compounds of Formula (J″).

Compounds of Formula (K″) can be prepared as shown in Scheme 20. The coupling of the amine (O), which is synthesized as scheme 4, with pyrimidine core (B″), which is synthesized as scheme 17, gives 2-substituted amino pyrimidine. The deprotection of Boc-group is achieved by an acid to give the amine (K″).

Alternatively, the novel quinoline (M″), the novel tetrahydroquinazoline (N″), the novel pyrimidine (O″), the novel quinoline (P″), and the novel pyrimidine (Q″) of the present invention are directly synthesized from the quinoline core (C), which is synthesized in Scheme 1, the tetrahydroquinazoline core (T), which is synthesized in Scheme 5, the pyrimidine core (F′), which is synthesized in Scheme 9, the quinoline core (Q′), which is synthesized in Scheme 13, and the pyrimidine core (B″), which is synthesized in Scheme 17, as shown in Scheme 21. This coupling is performed with or without a base in an inert solvent. The base includes an alkali metal carbonate (preferably sodium carbonate or potassium carbonate, etc.), an alkali metal hydroxide (preferably sodium hydroxide, etc.), or a tertiary amine (preferably N,N-diisopropylethylamine, triethylamine, or N-methylmorpholine, etc.). The inert solvent includes lower alkyl alcohol solvents (preferably methanol, ethanol, 2-propanol, or butanol, etc.) or amide solvents (preferably N,N-dimethylformamide or 1-methyl-pyrrolidin-2-one, etc.). Reaction temperature ranges from about 50° C. to 200° C., preferably about 80° C. to 180° C. Also this reaction can be carried out under microwave conditions.

For example, compounds of Formula (T″) can be prepared as shown in Scheme 22. The amine (O), which is synthesized in Scheme 4, is subjected to reductive amination by aldehyde (R₁CHO). The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with pyrimidine core (F′), which is synthesized as scheme 9, gives the novel pyrimidine (T″) of the present invention.

Compounds of Formula (W″) can be prepared as shown in Scheme 23. The amine (O), which is synthesized in Scheme 4, is subjected to amidation by carboxylic acid (R₁CO₂H) or acid chloride (R₁COCl). The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with quinoline core (Q′), which is synthesized as scheme 13, gives the novel quinoline (W″) of the present invention.

Compounds of Formula (Z″) can be prepared as shown in Scheme 24. The amine (O), which is synthesized in Scheme 4, is subjected to amidation by carboxylic acid (R₁CO₂H) or acid chloride (R₁COCl). The deprotection of Boc-group is achieved by an acid to give the amine. The coupling of the amine with pyrimidine core (B″), which is synthesized as scheme 17, gives the novel pyrimidine (Z″) of the present invention.

When a compound of the invention contains optical isomers, stereoisomers, regio isomers, rotational isomers, a single substance and a mixture of them are included as a compound of the invention. For example, when a chemical formula is represented as showing no stereochemnical designation(s), such as Formula VI, then all possible stereoisomer, optical isomers and mixtures thereof are considered within the scope of that formula. Accordingly, Formula VII, specifically designates the cis relationship between the two amino groups on the cyclohexyl ring and therefore this formula is also fully embraced by Formula VI.

Other uses of the disclosed invention will become apparent to those in the art based upon, inter alia, a review of this patent document.

The following examples are given to illustrate the invention and are not intended to be inclusive in any manner:

EXAMPLES

The compounds of the invention and their synthesis are further illustrated by the following examples. The following examples are provided to further define the invention without, however, limiting the invention to the particulas of these examples. “Ambient temperature” as referred to in the following example is meant to indicate a temperature falling between 0° C. and 40° C. The following compounds are named by Beilstein Auto Nom Version 4.0, CS Chem Draw Ultra Version 6.0, CS Chem Draw Ultra Version 6.0.2, CS Chem Draw Ultra Version 7.0.1, or ACD Name Version 7.0.

Abbreviations used in the instant specification, particularly the Schemes and Examples, are as follows:

• ¹H NMR: proton nuclear magnetic resonance spectrum
• AcOH: acetic acid
• APCl: atmospheric pressure chemical ionization
• (Boc)₂O: di-tertiary-butyl dicarbonate
• BuLi: butyl lithium
• BuOH: butanol
• Cbz: carbobenzoxy
• CDCl₃: deuterated chloroform
• CH₂Cl₂: dichloromethane
• CHCl₃: chloroform
• CI: chemical ionization
• mCPBA: meta chloroperbenzoic acid
• DMA: N,N-dimethyl acetamide
• DCM: dichloromethane
• DIEA: diisopropylethylamine
• DMSO: dimethyl sulfoxide
• Dppf: bis-(diphenylphosphino)ferrocene
• EI: electron ionization
• ESI: electrospray ionization
• Et₂O: diethyl ether
• EtOAc: acetic acid ethyl ester
• EtOH: ethanol
• FAB: fast atom bombardment
• HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-Hexafluorophosphate
• H₂SO₄: sulfuric acid
• HCl: hydrogen chloride
• IPA: isopropanol
• K₂CO₃: potassium carbonate
• Me₂NH: dimethylamine
• MeNH₂: methylamine
• MeOH: methanol
• MgSO₄: magnesium sulfate
• MsOH: methanesulfonic acid
• NaBH(OAc)₃: sodium triacetoxyborohydride
• NaBH₃CN: sodium cyanoborohydride
• NaBH₄: sodium borohydride
• NaHCO₃: sodium hydrogencarbonate
• Pd/C: palladium carbon
• POCl₃: phosphoryl chloride
• PVP: poly(4-vinylpyridine)
• SOCl₂: thionyl chloride
• TBME: tert-butyl methyl ether
• TFA: trifluoroacetic acid
• THF: tetrahydrofuran
• ZCl: benzyloxycarbonyl chloride
• s: singlet
• d: doublet
• t: triplet
• q: qualtet
• dd: doublet doublet
• dt: doublet triplet
• ddd: doublet doublet doublet
• brs: broad singlet
• m: multiplet
• J: coupling constant
• Hz: Hertz

Example 1

N²-[cis-4-(4-Bromo-2-triflouromethoxy-benzyl)-amino-cyclohexyl]-N⁴-methyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of 2,4-dichloro-quinoline.

A suspension of quinoline-2,4-diol (150 g, 931 mmol) in POCl₃ (975 mL, 10.4 mol) was stirred at reflux for 6 hr and the reaction mixture was concentrated. The residue was diluted with CHCl₃ (500 mL) and the solution was poured into ice water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 20% EtOAc in hexane) to give 2,4-dichloro-quinoline (177 g, 96%) as a pale brown solid.

EI MS m/e 197, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.50 (s, 1H), 7.65 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 7.79 (ddd, J=8.5, 7.0, 1.3 Hz, 1H), 8.00-8.06 (m, 1H), 8.16-8.21 (m, 1H).

Step B: Synthesis of (2-chloro-quinolin-4-yl)-methyl-amine.

To a solution of 2,4-dichloro-quinoline (29.8 g, 150 mmol) in THF (300 mL) was added 40% MeNH₂ in water (58.4 g, 752 mmol). The mixture was stirred at ambient temperature for 12 days and concentrated. The residue was suspended in CHCl₃ and H₂O. The precipitate was collected by filtration, washed with acetone, and dried at 50° C. under reduced pressure to give (2-chloro-quinolin-4-yl)-methyl -amine (13.2 g, 45%) as a colorless solid.

ESI MS m/e 215, M+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 2.91 (d, J=4.7 Hz, 3H), 6.35 (s, 1H), 7.47 (ddd, J=8.3, 6.6, 1.7 Hz, 1H), 7.62-7.75 (m, 3H), 8.16 (d, J=8.6 Hz, 1H).

Step C: Synthesis of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid-benzyl ester.

To a suspension of cis-cyclohexane-1,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr. Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.

ESI MS m/e 405, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45-1.60 (m, 4H), 1.60-1.80 (m, 4H), 3.52-3.80 (m, 2H), 4.70-5.00 (m, 2H), 5.07 (s, 4H), 7.15-7.40 (m, 10H).

Step D: Synthesis of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester.

To a solution of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtrated through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)₂O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 1.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-antino-cyclohexyl)-carbamic acid tert-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in MeOH (660 mL) was added a solution of (Boc)₂O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 10 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)₂O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 3.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (5.01 g, 10% based on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)₂O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 13 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.53 g, 7% based on the starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtrated, and concentrated to give a recovered diamine (11.1 g) as a colorless oil.

ESI MS m/e 215, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.20-1.80 (m, 8H), 1.44 (s, 9H), 2.78-2.95 (m, 1H), 3.50-3.80 (m, 1H), 430-4.82 (m, 1H).

Step E: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-quinoline-2,4-diamine.

A mixture of (2-chloro-quinolin-4-yl)-methyl-amine (2.00 g, 10.4 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (2.45 g, 11.4 mmol) in butanol (3 mL) was stirred at 130° C. for 2 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give [cis-4-(4-methylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (1.45 g) as a pale yellow oil. To a solution of the above material (1.31 g) in EtOAc (15 mL) was added 4 M hydrogen chloride in EtOAc (30 mL). The reaction mixture was stirred at ambient temperature for 5 hr. The precipitate was collected by filtration and dissolved in saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-quinoline-2,4-diamine (999 mg, 40%) as a pale yellow solid.

EI MS m/e 271 M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.42-1.92 (m, 8H), 2.81 (d, J=4.7 Hz, 3H), 2.89-3.01 (m, 1H), 3.17 (s, 2H), 4.07 (brs, 1H), 5.77 (s, 1H), 6.32 (d, J=6.5 Hz, 1H), 6.69-6.80 (m, 1H), 6.94-7.06 (m, 1H), 7.34 (d, J=3.7 Hz, 2H), 7.85 (d, J=8.2 Hz, 1H).

Step F: Synthesis of 4-bromo-2-trifluoromethoxy-benzaldehyde.

A solution of 4-bromo-1-iodo-2-trifluoromethoxy-benzene (1.00 g, 2.72 mmol) in THF (15 mL) was cooled to −78° C. and 2.66 M BuLi in hexane (2.05 mL, 5.44 mmol) was added dropwise. The reaction mixture was stirred at −78° C. for 1.5 h and N-formylmorpholine (0.57 mL, 5.63 mmol) was added. The reaction mixture was stirred at −78° C. for 15 min and at ambient temperature for 80 min. The reaction was quenched with 0.25 M aqueous citric acid (10 mL) and the resulting mixture was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 2% to 5% EtOAc in hexane) to give 4-bromo-2-trifluoromethoxy-benzaldehyde (560 mg, 77%) as a pale brown solid.

CI MS m/e 269, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.50-7.67 (m, 2H), 7.85 (d, J=8.1 Hz, 1H), 10.33 (s, 1H).

Step G: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴-methyl-quinoline-2,4-diamine dihydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-quinoline-2,4-diamine (370 mg, 1.37 mmol), in methanol (4 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde (368 mg, 1.37 mmol), acetic acid (82 mg, 1.37 mmol), and NaBH₃CN (129 mg, 2.05 mmol). The reaction mixture was stirred at ambient temperature for 20 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silca gel, 20% ETOAc in hexane) and flash chromatography (silica gel, 5% MeOH in CHCl₃) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (12 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴-methyl-quinoline-2,4-diamine dihydrochloride (365 mg, 45%) as a white solid.

ESI MS m/e 523, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.61-2.11 (m, 8H), 296 (d, J=4.4 Hz, 3H), 3.19-3.41 (m, 2H), 4.11-4.34 (m, 2H), 5.92 (brs, 1H), 7.40 (t, J=8.2 Hz, 1H), 7.63-7.79 (m, 3H), 7.93 (d, J=8.4 Hz, 1H), 8.22 (d, J=8.2 Hz, 1H), 8.30-8.48 (m, 2H), 9.59 (brs, 2H).

Example 2

N²-{cis-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-quinoline2,4-diamine dihydrochloride

Step A: Synthesis of (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde.

To a suspension of (methoxymethyl)-triphenylphosphonium chloride (5.29 g, 14.9 mol) in Et₂O (50 mL) was added 1.8 M phenyl lithium in 30% Et₂O in cyclohexane (8.58 mL, 15.5 mmol). The mixture was stirred at ambient temperature for 10 min. To the reaction mixture was added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step F of example 1 (4.00 g, 14.9 mmol) in Et₂O (18 mL). The mixture was stirred at ambient temperature for 4 hr, filtrated and concentrated. To the above residue was added 10% H₂SO₄ in AcOH (40 mL). The mixture was stirred at ambient temperature for 90 min. The solution was poured into H₂O and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was washed with saturated aqueous NaHCO₃ and brine, dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 9% EtOAc in hexane) to give (4-bromo-2-trifluoromethoxy-phenyl)-acetaldehyde (1.25 g, 30%) as a pale brown oil.

ESI MS m/e 284, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 3.75 (d, J=1.5 Hz, 2H), 7.16 (d, J=8.4 Hz, 1H), 7.41-7.51 (m, 2H), 9.74 (t, J=1.5 Hz, 1H).

Step B: Synthesis of N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-quinoline-2,4-diamine dihydrochloride.

using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 537M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.62-2.06 (m, 8H), 2.96 (d, J=4.4 Hz, 3H), 3.04-3.39 (m, 5H), 4.17 (brs, 1H), 5.90 (brs, 1H), 7.40 (t, J=8.2 Hz, 1H), 7.52 (d, J=8.7 Hz, 1H), 7.57-7.85 (m, 3H), 8.20 (d, J=8.2 Hz, 1H), 8.26-8.47 (m, 2H), 9.23 (brs, 2H).

Example 3

N²-{cis-4-[(4-Bromo-2-trifluoromethhxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴-methyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester.

A suspension of cis-4-amino-cyclohexanecarboxylic acid (244 g, 1.70 mol) in MeOH (2.45 L) was cooled to −8° C. Thionyl chloride (45.0 mL, 617 mmol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in CHCl₃(3.00 L) were added triethylamine (261 mL, 1.87 mol) and (Boc)₂O (409 g, 1.87 mol) successively The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHCl₃(three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, CHCl₃ only to 10% MeOH in CHCl₃) to give a colorless oil (531 g). To a suspension cooled at −4° C. of lithium aluminum hydride (78.3 g, 2.06 mol) in Et₂O (7.9 L) was added a solution of the above oil (530.9 g) in Et₂O (5.3 L) below 0° C. The resulting suspension was stirred at ambient temperature for 2 hr. The reaction mixture was cooled on an ice-bath, quenched with cold water, and filtrated through a pad of celite. The filtrate was dried over MgSO₄, filtrated, and concentrated. The precipitate was suspended in hexane (300 mL), filtrated, washed with hexane, and dried under reduced pressure to give (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (301 g, 77%) as a white solid.

ESI MS m/e 252, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.36 (m, 2H), 1.45 (s, 9H), 1.52-1.77 (m, 7H), 3.51 (d, J=6.2 Hz, 2H), 3.75 (brs, 1H), 4.30-4.82 (m, 1H).

Step B: Synthesis of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added triphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of the above solid (27.5 g) in EtOH (275 mL) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. To a solution of the above residue in CHCl₃ (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0° C. and ZCl (14.4 g, 84.4 mmol) was added below 5° C. The reaction mixture was stirred at ambient temperature for 16 hr and poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCl₃) to give [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (25.3 g, 91%) as a colorless oil.

ESI MS m/e 385, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.13-1.31 (m, 2H), 1.44 (s, 9H), 1.48-1.75 (m, 7H), 3.10 (t, J=6.4 Hz, 2H), 3.72 (brs, 1H), 4.42-4.76 (m, 1H), 4.76-4.92 (m, 1H), 5.09 (s, 2H), 7.27-7.38 (m, 5H).

Step C: Synthesis of (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtrated, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (five times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and dried under reduced pressure to give (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

ESI MS m/e 263, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.36-1.98 (m, 9H), 2.96-3.32 (m, 3H), 5.12 (brs, 3H), 7.36 (s, 5H).

Step D: Synthesis of [cis-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-quinolin-4-yl)-methyl-amine obtained in step B of example 1 (2.00 g, 10.4 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (3.27 g, 12.5 mmol) in butanol (3 mL) was stirred at 130° C. for 16 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica, 10% MeOH in CHCl₃) to give [cis-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid-benzyl ester (2.16 g, 49%) as a white solid.

ESI MS m/e 419, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.42-1.99 (m, 9H), 3.05 (d, J=4.7 Hz, 3H), 3.08-3.16 (m, 2H), 3.81 (brs, 1H), 5.07 (s, 2H), 5.18-5.28 (m, 1H), 5.34 (s, 1H), 7.07-7.18 (m, 1H), 7.22-7.45 (m, 6H), 7.56-7.70 (m, 1H), 8.16 (d, J=8.4 Hz, 1H), 8.23 (d, J=7.6 Hz, 1H), 12.76 (brs, 1H).

Step E: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl)-N4-methyl-quinoline-2,4-diamine dihydrochloride.

To a solution of [cis-4-(4-methylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid-benzyl ester (2.02 g, 4.83 mmol) in MeOH (20 mL) was added 10% Pd/C (202 mg). The mixture was stirred at 50° C. under hydrogen atmosphere for 23.5 hr. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue (500 mg) in methanol (5 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step F of example 1 (497 mg, 1.85 mmol), acetic acid (111 mg, 1.85 mmol), and NaBH₃CN (166 mg, 2.64 mmol). The reaction mixture was stirred at ambient temperature for 23 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% EtOAc in hexane) and flash chromatography (silica gel, 2% to 50% MeOH in CHCl₃) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (12 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N₄-methyl -quinoline-2,4-diamine dihydrochloride (147 mg, 14%) as a white solid.

ESI MS m/e 537, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.34-2.15 (m, 9H), 2.63-3.08 (m, 5H), 3.41-3.88 (m, 1H), 4.28 (s, 2H), 7.00-7.62 (m, 6H), 7.65-8.38 (m, 3H), 10.01 (brs, 2H), 11.76 (brs, 1H).

Example 4

N⁴-Methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of N⁴-methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride.

To a solution of N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴-methyl-quinoline-2,4-diamine obtained in step E of example 3 (250 mg, 0.465 mmol) in EtOH (2.5 mL) was added 10% Pd/C (75 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 15 hr. The reaction mixture was filtrated through a pad of celite and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended with Et₂O (10 mL) and stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O and dried under reduced pressure to give N⁴-methyl-N²-{cis-4-[(2-trifluoromethoxy -benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride (114 mg, 46% ) as a white solid.

ESI MS m/e 459, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.46-2.09 (m, 9H), 2.84 (brs, 3H), 2.92 (brs, 2H), 3.60-3.82 (m, 1H), 4.32 (s, 2H), 7.05-7.49 (m, 6H), 7.88 (d, J=7.8 Hz, 1H), 8.11-8.35 (m, 2H), 9.91 (brs, 2H), 11.83 (s, 1H).

Example 5

N²-[cis-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of (2-chloro-quinolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-quinoline (177 g, 894 mmol) in THF (2.1 L) was added 50% aqueous Me₂NH (234 mL, 2.23 mol). The mixture was stirred at ambient temperature for 68 hr. To the mixture was added 50% aqueous Me₂NH (47 mL, 448 mmol) and stirred at ambient temperature for 3 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 1% to 3% EtOAc in hexane) to give (2-chloro-quinolin-4-yl)-dimethyl-amine (75.9 g, 41%) as a pale yellow oil and (4-chloro-quinolin-2-yl)-dimethyl-amine (28.0 g, 15%) as a pale yellow oil.

(2-chloro-quinolin-4-yl)-dimethyl-amine;

ESI MS m/e 207, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.06 (s, 6H), 6.71 (s, 1H), 7.45 (ddd, J=8.4, 7.0, 1.2 Hz, 1H), 7.63 (ddd, J=8.4, 6.9, 1.5 Hz, 1H), 7.91-7.93 (m, 1H), 7.97-8.03 (m, 1H).

(4-chloro-quinolin-2-yl)-dimethyl-amine;

ESI MS m/e 229, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.18 (s, 6H), 6.97 (brs, 1H), 7.18-7.31 (m, 1H), 7.49-7.63 (m, 1H), 7.66-7.72 (m, 1H), 7.95-8.00 (m, 1H).

Step B: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine.

Using the procedure for the step E of example 1, the title compound was obtained.

FAB MS m/e 285, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.12-2.00 (m, 9H), 2.81-2.98 (m, 1H), 2.93 (s, 6H), 4.09 (brs, 1H), 4.75 (d, J=7.9 Hz, 1H), 6.03 (s, 1H), 7.14 (ddd, J=8.2, 6.7, 1.3 Hz, 1H), 7.45 (ddd, J=8.4, 6.8, 15 Hz, 1H), 7.62 (m, 1H), 7.84 (dd, J=8.4, 1.3 Hz, 1H).

Step C: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 537, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-2.36 (m, 10H), 3.05-3.31 (m, 2H), 3.20 (s, 6H), 4.32 (s, 2H), 7.30-7.62 (m, 5H), 7.86 (d, J=8.6 Hz, 1H), 821 (d, J=8.4 Hz, 1H), 8.53-8.64 (m, 1H), 13.04 (brs, 1H).

Example 6

N²-{cis-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 551, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.69-2.40 (m, 10H), 3.11-3.46 (m, 10H), 7.26-7.49 (m, 5H), 7.59 (t, J=7.3 Hz, 1H), 7.86 (d, J=7.5 Hz, 1H), 8.53-8.70 (m , 1H), 9.75-10.14 (m, 2H), 13.05 (brs, 1H).

Example 7

N²-{cis-4-[(4-Bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine obtained in step A of example 5 (23.6 g, 114 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3 (36.0 g, 137 mmol) in butanol (31 mL) was stirred at reflux for 14 days. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 14% to 66% EtOAc in hexane) to give [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 39%) as a pale yellow solid.

ESI MS m/e 433, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.12-1.97 (m, 9H), 2.94 (s, 6H), 3.13 (t, J=6.4 Hz, 2H), 4.06-4.26 (m, 1H), 4.62-4.94 (m, 2H), 5.11 (s, 2H), 6.04 (s, 1H), 7.14 (ddd, J=8.4, 7.0, 1.3 Hz, 1H), 7.29-7.40 (m, 5H), 7.45 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.57-7.64 (m, 1H), 7.84 (dd, J=8.4, 1.3 Hz, 1H).

Step B: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine.

To a solution of [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 44.6 mmol) in MeOH (200 mL) was added 5% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue in methanol (200 mL) was added 10% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 day. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 5% to 14% 7 M NH₃/MeOH in CHCl₃) to give N²-(cis-4-aminomethyl-cyclohexy)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine (12.7 g, 95%) as a pale yellow solid.

FAB MS m/e 299, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.08-1.99 (m, 11H), 2.60 (d, J=6.2 Hz, 2H), 2.94 (s, 6H), 4.04-4.22 (m, 1H), 4.77-4.93 (m, 1H), 6.06 (s, 1H), 7.14 (ddd, J=8.4, 7.0, 1.3 Hz, 1H), 7.45 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.61 (m, 1H), 7.84 (dd, J=8.4, 1.3 Hz, 1H).

Step C: Synthesis of N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 551, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.50-2.20 (m, 9H), 2.89 (s, 2H), 3.20 (s, 6H), 3.75-4.02 (m, 1H), 4.23 (s, 2H), 7.22-7.32 (m, 2H), 7.40-7.46 (m, 1H), 7.49-7.62 (m, 2H), 7.83 (d, J=8.7 Hz, 1H), 8.17 (d, J=8.4 Hz, 1H), 8.53-8.69 (m, 1H), 10.05 (brs, 2H), 13.00 (brs, 1H).

Example 8

N⁴,N⁴-Dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride

Step A: Synthesis of N⁴,N⁴-dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-quinoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 473, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-2.20 (m, 9H), 2.87 (brs, 2H), 3.19 (s, 6H), 3.70-4.03 (m, 1H), 4.28 (brs, 2H), 7.15-7.67 (m, 6H), 7.81 (d, J=8.4 Hz, 1H), 8.17 (d, J=7.3 Hz, 1H), 8.63 (brs, 1H), 9.92 (brs, 1H), 13.13 (s, 1H).

Example 9

N²-[cis-4-(4-Bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of 5,6,7,8-tetrahydro-quinazoline-2,4-diol.

To a solution of 2-oxo-cyclohexanecarboxylic acid ethyl ester (61.5 g, 361 mmol) in EtOH (61.5 mL) was added urea (73.8 g, 1.23 mol). The mixture was stirred at reflux for 10.5 days and stirred at ambient temperature for 30 min. The precipitate was filtrated, washed with acetone, and dried. A suspension of the above solid in H₂O (100 mL) stirred on an ice-bath for 1 hr. The precipitate was filtrated, washed with hexane, and dried under reduced pressure to give 5,6,7,8-tetrahydro-quinazoline-2,4-diol (21.0 g, 35%) as a pale yellow solid.

CI MS m/e 167, M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.48-1.71 (m, 4H), 2.09-2.19 (m, 2H), 2.24-2.34 (m, 2H), 10.41-10.98 (m, 2H).

Step B: Synthesis of 2,4-dichloro-5,6,7,8-tetrahydro-quinazoline.

Using the procedure for the step A of example 1, the title compound was obtained.

ESI MS m/e 203, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-1.94 (m, 4H), 2.67-2.79 (m, 2H), 2.84-2.95 (m, 2H).

Step C: Synthesis of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine.

To a solution of 2,4-dichloro-5,6,7,8-tetrahydro-quinazolin (8.70 g, 42.8 mmol) in THF (87 mL) was added 40% aqueous MeNH₂ (8.32 g, 107 mmol). The mixture was stirred at ambient temperature for 8 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 50% EtOAc in hexane) to give (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine (7.04 g, 83%) as a white solid.

ESI MS m/e 220, M+N⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.74-1.92 (m, 4H), 2.26 (t, J=5.5 Hz, 2H), 2.67 (t, J=5.6 Hz, 2H), 3.05 (d, J=5.0 Hz, 3H), 4.81 (s, 1H).

Step D: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

Using the procedure for the step E of example 1, the title compound was obtained.

ESI MS m/e 276, M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.33-1.76 (m, 12H), 2.11-2.21 (m, 2H), 2.31-2.40 (m, 2H), 2.70-2.77 (m, 2H), 2.78 (d, J=4.5 Hz, 3H), 3.71-3.83 (m, 1H), 5.50-5.63 (m, 1H), 6.10-6.22 (m, 1H).

Step E: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 528, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.24 (m, 12H), 2.41-2.56 (m , 4H), 3.00 (d, J=4.5 Hz, 3H), 3.04 (brs, 1H), 4.03 (brs, 1H), 4.30 (brs, 2H), 7.45-7.48 (m, 1H), 7.52 (dd, J=8.3, 1.8 Hz, 1H), 7.61 (d, J=5.8 Hz, 1H), 7.74 (brs, 1H), 8.14 (d, J=8.2 Hz, 1H), 11.84 (brs, 1H).

Example 10

N²-{cis-4-[2-(4-Bromo-2-trifluorometboxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 542, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.25 (m, 12H), 2.35-2.60 (m, 4H), 2.94-3.28 (m, 6H), 3.32-3.45 (m, 2H), 4.13 (brs, 1H), 7.30-7.51 (m, 4H), 7.72 (d, J=6.2 Hz, 1H), 9.86 (brs, 2H) 11.90 (s, 1H).

Example 11

N²-{cis-4-[(4-Bromo-2-trifluoromethoxy-beny)amino-methyl]-cyclobexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-methylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-methyl-amine obtained in step C of example 9 (2.00 g, 10.1 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3 (3.19 g, 12.2 mmol) in butanol (3 mL) was stirred at 130° C. for 16 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 10% MeOH in CHCl₃) to give [cis-4-(4-methylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (1.38 g, 32%) as a pale yellow oil.

ESI MS m/e 424, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.31-2.02 (m, 13H), 2.22-2.34 (m, 2H), 2.52-2.64 (m, 2H), 3.05 (d, J=4.8 Hz, 3H), 3.11 (t, J=6.1 Hz, 2H), 5.05-5.23 (m, 1H), 5.08 (s, 2H), 6.34-6.47 (m, 1H), 7.23-7.42 (m, 5H), 7.99 (d, J=7.3 Hz, 1H), 12.34 (br, 1H)

Step B: Synthesis of N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step E of example 3, the title compound was obtained.

ESI MS m/e 542, M (free)+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.50-2.19 (m, 13H), 2.58-2.61 (m, 2H), 2.72-2.91 (m, 2H), 2.83-2.97 (m, 2H), 3.24 (s, 6H), 4.15-4.20 (m, 1H), 4.22-4.38 (m, 2H), 7.43-7.50 (m, 1H), 7.56-7.61 (m, 1H), 8.18-8.29 (m, 2H), 10.06 (brs, 2H), 12.30 (brs, 1H).

Example 12

N⁴-Methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of N⁴-methyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 464, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.28-2.04 (m, 15H), 2.14-2.30 (m, 2H), 2.83-2.95 (m, 2H), 2.91 (d, J=4.5 Hz, 3H), 4.13 (brs, 1H), 4.22 (brs, 2H), 7.43-7.62 (m, 3 H), 7.91 (dd, J=7.5, 1.6 Hz, 1H), 8.09 (d, J=6.7 Hz, 2H), 9.37 (brs, 2H), 12.30-12.70 (m, 1H).

Example 13

N²-[cis-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclobexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-5,6,7,8-tetrahydro-quinazolin (7.00 g, 34.5 mmol) in THF (70 mL) was added 50% aqueous MeNH₂ (7.77 g, 86.2 mmol). The mixture was stirred at ambient temperature for 2.25 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (6.08 g, 83%) as a white solid.

ESI MS m/e 234, M+N⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-1.90 (m, 4H), 2.59 (t, J=6.0 Hz, 2H), 2.76 (t, J=6.6 Hz, 2H), 3.06 (s, 6H).

Step B: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

Using the procedure for the step E of example 1, the title compound was obtained.

FAB MS m/e 290, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 0.95-1.94 (m, 14H), 2.49 (t, J=5.9 Hz, 2H), 2.61 (t, J=7.0 Hz, 2H), 2.72-2.94 (m, 1H), 2.94 (s, 6H), 3.89-4.11(m, 1H), 4.73 (d,J=7.5 Hz, 1H).

Step C: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine-dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 542, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.32 (m, 12H), 2.60 (m, 2H), 2.63-2.72 (m, 2H), 3.11-3.24 (m, 7H), 4.12-4.23 (m, 1H), 4.28 (s, 2H), 7.41 (d, J=10.4 Hz, 1H), 7.49 (dd, J=8.2, 1.9 Hz, 1H), 8.19 (d, J=8.4 Hz, 1H), 8.25 (d, J=8.1 Hz, 1H), 10.02 (brs, 1H), 12.43 (brs, 1H).

Example 14

N²-{cis-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine-dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 556, M (free)+H⁺; ¹NMR (300 MHz, CDCl₃) δ 1.57-2.32 (m, 12H), 2.56 (t, J=5.8 Hz, 2H), 2.69 (t, J=6.2 Hz, 2H), 3.14-3.41 (m, 9H), 4.13-4.25 (m, 1H), 7.35-7.44 (m, 2H), 7.49-7.55 (m, 1H), 8.20 (d, J=7.8 Hz, 1H).

Example 15

N²-{cis-4-[(4-Bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

Using the procedure for the step A of example 11, the title compound was obtained.

ESI MS m/e 438, M+H^'; ¹H NMR (300 MHz, CDCl₃) δ 1.18-1.39 (m, 2H), 1.48-1.94 (m, 11H), 2.49 (t, J=5.9 Hz, 2H), 2.60 (t, J=6.6 Hz, 2H), 2.94 (s, 6H), 3.09 (t, J=6.1 Hz, 2H), 4.01-4.13 (m, 1H), 4.70-4.91 (m, 2H), 5.09 (s, 2H), 7.27-7.39 (m, 5H).

Step B: Synthesis of N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step E of example 3, the title compound was obtained.

ESI MS m/e 556, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.46-2.17 (m, 12H), 2.55 (t, J=5.8 Hz, 2H), 2.69 (t, J=6.1 Hz, 2H), 2.79-2.92 (m, 2H), 3.20 (s, 6H), 4.08-4.18 (m, 1H), 4.20-4.31 (m, 2H), 7.43-7.47 (m, 1H), 7.53 (dd, J=8.4, 1.9 Hz, 1H), 8.16 (d, J=7.8 Hz, 1H), 8.22 (d, J=8.4 Hz, 1H), 10.02 (brs, 2H), 12.28 (brs, 1H).

Example 16

N⁴,N⁴-Dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride

Step A: Synthesis of N⁴,N⁴-dimethyl-N²-{cis-4-[(2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydro-quinazoline-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 478, M (free)+H^'; ¹H NMR (300 MHz, CDCl₃) δ 1.48-2.15 (m, 13H), 2.55 (t, J=5.4 Hz, 2H), 2.71 (t, J=6.2 Hz, 2H), 2.77-2.89 (m, 2H), 3.19 (s, 6H), 4.10 (br 1H), 4.26-4.37 (m, 2H), 7.27-7.34 (m, 1H), 7.36-7.47 (m, 2H), 8.15-8.25 (m, 2H), 9.90 (s, 2H), 12.52 (s, 1H).

Example 17

N²-[cis-4-(4-Bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-pyrimidin-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step D of example 1 (6.72 g, 31.4 mmol) in CHCl₃ (67 mL) were added 4-bromo-2-trifluoromethoxy-benzaldehyde obtained in step F of example 1 (8.44 g, 31.4 mmol), acetic acid (1.88 g, 31.3 mmol), and NaBH(OAc)₃ (9.97 g, 47.0 mmol). The reaction mixture was stirred at ambient temperature for 4 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give [cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-carbamic acid tert-butyl ester (10.28 g, 70%) as a pale yellow oil.

ESI MS m/e 467, M+H^'; ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.78 (m, 17H), 2.57-2.70 (m, 1H), 3.62 (brs, 1H), 3.78 (s, 2H), 4.60 (brs, 1H), 7.34-7.54 (m, 3H).

Step B: Synthesis of (2-chloro-pyrimidin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-pyrimidine (15.0 g, 10.15 mmol) in THF (150 mL) was added 50% aqueous MeNH₂ (22.7 g, 25.2 mmol). The mixture was stirred at ambient temperature for 2 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-dimethyl-amine (8.66 g, 55%) as a white solid and (4-chloro-pyrimidin-2-yl)-dimethyl-amine (0.87 g, 6%) as a white solid.

(2-chloro-pyrimidin-4-yl)-dimethyl-amine;

CI MS m/e 158, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 6H), 6.32 (d, J=6.1 Hz, 1H), 8.00 (d, J=6.1 Hz, 1H).

(4-chloro-pyrimidin-2-yl)-dimethyl-amine;

ESI MS m/e 157, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.21 (s, 6H), 6.50 (d, J=5.1 Hz, 1H), 8.18 (d, J=5.1 Hz, 1H).

Step C: Synthesis of N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride.

To a solution of [cis-4-(4-bromo-2-trifluoromethoxy-benzylamino)-cyclohexyl]-carbamic acid tert-butyl ester (3.00 g, 6.42 mmol) in EtOAc (30 mL) was added 4 M hydrogen chloride in EtOAc (60 mL). The reaction mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was alkalized with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. The above material (466 mg, 1.27 mmol) and (2-chloro-pyrimidin-4-yl)-dimethyl-amine (200 mg, 1.27 mmol) in butanol (1 mL) was stirred at 130° C. for 13.5 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above oil in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (12 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to N²-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)-amino-cyclohexyl]-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride (180 mg, 25%) as a white solid.

ESI MS m/e 488, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-1.72 (m, 2H), 2.01-2.29 (m, 6H), 3.02 (brs, 1H), 3.16 (s, 3H), 3.24 (s, 3H), 4.13 (brs, 1H), 4.30 (s, 2H), 6.02 (d, J=7.5 Hz, 1H), 7.40-7.43 (m, 1H), 7.50 (dd, J=8.4, 1.9 Hz, 1H), 7.99 (d, J=7.3 Hz, 1H), 8.26 (d, J=8.4 Hz, 1H), 8.57 (d, J=7.0 Hz, 1H), 10.25 (s, 2H).

Example 18

N²-{cis-4-[2-(4-Bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

A mixture of (2chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step B of example 17 (1.50 g, 9.52 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step D of example 1 (2.24 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130° C. for 22 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane) to give [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (1.34 g, 42%) as a white solid.

ESI MS m/e 358, M+N⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H), 1.48 (s, 8H), 3.03 (s, 6H), 3.61 (brs, 1H), 3.89-4.04 (m, 1H), 4.47-4.63 (m, 1H),4.77-4.89 (m, 1H), 5.80 (d, J=6.1 Hz, 1H), 7.84 (d, J=6.1 Hz, 1H).

Step B: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine.

To a solution of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (1.26 g, 3.76 mmol) in EtOAc (15 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was alkalized with 1 M aqueous NaOH. The aqueous layer was extracted with CHCl₃ (six times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine(923 mg, quant.) as a pale yellow oil.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29-1.51 (m, 2H), 1.61-1.91 (m, 6H), 2.80-2.92 (m, 1H), 3.03 (s, 6H), 3.96-4.04 (m, 1H), 4.85-4.98 (m, 1H), 5.79 (d, J=6.1 Hz, 1H), 7.84 (d, J=6.1 Hz, 1H).

Step C: Synthesis of N²-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 502, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-1.82 (m, 2H), 1.97-2.44 (m, 6H), 3.16 (s, 3H), 3.14-3.31 (m, 1H), 3.25 (s, 3H), 3.34-3.46 (m, 2H), 4.18 (brs, 1H), 6.02 (d, J=6.8 Hz, 1H), 7.34-7.43 (m, 2H), 7.45-7.52 (m, 1H), 7.85-7.97 (m, 1H), 8.49-8.59 (m, 1H), 9.95 (brs, 2H), 12.42 (brs, 1H).

Example 19

N²-{cis-4-[(4-Bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl -pyrimidine-2,4-diamine dihydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step B of example 17 (1.50 g, 9.52 mmol) and cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (2.75 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130° C. for 22 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane to EtOAc) to give [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]carbamic acid benzyl ester (816 mg, 22%) as a pale yellow oil.

ESI MS m/e 406, M+N⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.22-1.92 (m, 9H), 3.03 (s, 6H), 3.11 (t, J=6.2 Hz, 2H), 4.02-4.15 (m, 1H), 4.82-4.93 (m, 2H), 5.10 (s, 2H), 5.79 (d, J=6.1 Hz, 1H), 7.28-7.42 (m, 5H), 7.83 (d, J=6.1 Hz, 1H).

Step B: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine.

Using the procedure for the step B of example 7, the title compound was obtained.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.88 (m, 9H), 2.87 (d, J=5.9 Hz, 2H), 3.03 (s, 6H), 4.11 (brs, 1H), 5.63 (brs, 1H), 5.78 (d, J=6.2 Hz, 1H), 7.08 (brs, 2H), 7.82 (d, J=6.2 Hz, 1H).

Step C: Synthesis of N²-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)-amino-methyl]-cyclohexyl}-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine dihydrochloride.

Using the procedure for the step G of example 1, the title compound was obtained.

ESI MS m/e 502, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.52-2.21 (m, 9H), 2.85 (d, J=5.8 Hz, 2H), 3.16 (s, 3H), 3.24 (s, 3H), 4.15-4.30 (m, 3H), 6.00 (d, J=7.6 Hz, 1H), 7.43-7.47 (m, 1H), 7.53 (dd, J=8.3, 1.9 Hz, 1H), 7.66 (d, J=7.5 Hz, 1H), 8.20 (d, J=8.4 Hz, 1H), 8.53 (d, J=7.5 Hz, 1H), 10.07 (brs, 2H).

Example 20-672

To a solution of poly(4-vinylpyridine) (75 μL) in CH₂Cl₂ (200 μL) were added the amines (30 μmol) as shown below in CH₂Cl₂ (200 μL) and acid chloride (60 μmol) in CH₂Cl₂ (200 μL) at ambient temperature. After stirring at the same temperature for 19 hr, the reaction mixture was filtrated and concentrated by a stream of dry N₂. To the residue were added dry CH₂Cl₂ (700 μL) and PSA (300 μL). After the stirring at ambient temperature for 14 hr, the reaction mixture was purified by silica gel chromatography (NH-silica, 50% EtOAc in hexane to EtOAc only) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 673-1084

To a solution of 1-cyclohexyl-3-methylpolystyrene-carbodiimide (150 μL) in CH₂Cl₂ (400 μL) were added the amines (30 μmol) as shown below in CH₂Cl₂ (200 μL) and carboxylic acid (60 μmol) in CH₂Cl₂ (200 μL) at ambient temperature. After stirring at the same temperature for 20 hr, the reaction mixture was filtrated through NH-silica gel, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl)-N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1085-1446

Method A

To a solution of the amines (36 μmol) as shown below in MeOH (200 μL) were added aromatic aldehyde (30 μmol) in MeOH (200 μL) and AcOH (90 μmol) at ambient temperature. The reaction mixture was stirred at the same temperature for 1 hr. To the mixture was added NaBH₃CN (120 μmol) in MeOH (200 μL). After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N₂. The residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃ (500 μL) and EtOAc (300 μL). The combined organic layers were dried over MgSO₄, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Method B

To a solution of the amines (36 μmol) as shown below in MeOH (200 μL) were added aliphatic aldehyde (30 μmol) in MeOH (200 μL), AcOH (90 μmol), and NaBH₃CN (120 μmol) in MeOH (200 μL) at ambient temperature. After stirring at the same temperature for 20 hr, the reaction mixture was concentrated by a stream of dry N₂. The residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃ (500 μL) and EtOAc (300 μL). The combined organic layers were dried over MgSO₄, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl) -N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1457-1462, 1478-1480, 1491-1497, and 1510-1512

To a solution of the amide product in THF (200 μl) was added 1 M borane-THF complex in THF (300 μl, 300 μmol). The mixture was stirred at 80° C. for 1 hr, and concentrated by a stream of dry N₂. To the residue were added 1 M aqueous HCl (300 μl) and THF (200 μl). The mixture was stirred at 80° C. for 1 hr and concentrated by a stream of dry N₂. To the residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃ (300 μL, twice) and EtOAc (300 μL). The combined organic layers were dried over MgSO₄, concentrated by a stream of dry N₂, and the purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Example 1447-1456, 1463-1477, 1481-1490, 1498-1509, and 1513-1538

To a suspension of Dess-Martin periodinane (63 μmol) in CH₂Cl₂ (200 μL) was added alcohol (35 μmol) in CH₂Cl₂ (200 μL) at ambient temperature, and the reaction mixture was stirred at the same temperature for 18 hr. To the reaction mixture were added amines (36 μmol) as shown below in MeOH (200 μL) and AcOH (90 μL). The mixture was stirred at the same temperature for 1 hr, and then NaBH₃CN (120 μmol) in MeOH (200 μL) was added. After stirring at the same temperature for 17 hr, the reaction mixture was concentrated by a stream of dry N₂. The residue was partitionated between CHCl₃ and 2 M aqueous sodium hydroxide. The aqueous layer was extracted with CHCl₃ (500 mL) and EtOAc (300 μL). The combined organic layers were dried over MgSO₄, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl) -N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1539-1658

To a solution of poly(4-vinylpyridine) (75 μL) in CH₂Cl₂ (200 μL) were added the amines (30 μmol) as shown below in CH₂Cl₂ (200 μL) and chloroformate (60 μmol) in CH₂Cl₂ (200 μL) at ambient temperature. After stirring at the same temperature for 17 hr, the reaction mixture was filtrated and concentrated by a stream of dry N₂. To the residue were added CH₂Cl₂ (700 μL) and PSA (300 μL). After the stirring at ambient temperature for 19 hr, the reaction mixture was filtrated and purified by silica gel chromatography (NH-silica gel, 20% EtOAc in hexane to EtOAc only, and silica gel, 2% to 7% 2 M NH₃/MeOH in CHCl₃) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro -quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl) -N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Example 1659-2496

To a solution of amines (30 μmol) as shown below in DMSO (300 μL) were added isocyanate or isothiocyanate (60 μmol) in DMSO (200 μL) at ambient temperature. The mixture was stirred at the same temperature for 22 hr. To the reaction mixture were added 2 M MeNH₂ in THF (30 μL, 60 μmol) or D-gulcamine (60 μmol) in DMSO (200 μL) at ambient temperature. After stirring at the same temperature for 20 hr, the reaction mixture was filtrated through a SCX, concentrated by a stream of dry N₂, and purified by silica gel chromatography (silica gel, 2% to 10% 2 M NH₃/MeOH in CHCl₃) and silica gel chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give the desired product. The product was determined by ESI-MS or APCI-MS.

Wherein the amines are selected from N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 5, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in step B of example 13, N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine obtained in intermediate of step B of example 15, N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 18, or N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine obtained in step B of example 19.

Ex. No.	compound name	MS	class
20	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	419 (M + H)	2
	methoxybenzamide
21	3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	467 (M + H)	1
	yl]amino}cyclohexyl)benzamide
22	4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	467 (M + H)	2
	yl]amino}cyclohexyl)benzamide
23	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	431 (M + H)	1
	2,1,3-benzoxadiazole-5-carboxamide
24	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	423 (M + H)	1
	yl]amino}cyclohexyl)benzamide
25	4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	423 (M + H)	1
	yl]amino}cyclohexyl)benzamide
26	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)-3-phenylacrylamide
27	4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	468 (M + H)	1
	yl]amino}cyclohexyl)-3-nitrobenzamide
28	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)acetamide
29	3-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-	414 (M + H)	2
	yl]amino}cyclohexyl)benzamide
30	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	2
	yl]amino}cyclohexyl)benzamide
31	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	1
	yl]amino}cyclohexyl)benzamide
32	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	479 (M + H)	2
	2,2-diphenylacetamide
33	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	425 (M + H)	1
	3,4-difluorobenzamide
34	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	425 (M + H)	2
	3,5-difluorobenzamide
35	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-	463 (M + H)	3
	2-yl]amino}cyclohexyl)acetamide
36	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	450 (M + H)	3
	(ethylthio)nicotinamide
37	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	407 (M + H)	1
	fluorobenzamide
38	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	475 (M + H)	2
	fluoro-5-(trifluoromethyl)benzamide
39	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	475 (M + H)	3
	yl]amino}cyclohexyl)-5-fluorobenzamide
40	N-(cis-4-{[4-(dimethylamino)quinolin-2-	383 (M + H)	3
	yl]amino}cyclohexyl)hexanamide
41	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	515 (M + H)	3
	iodobenzamide
42	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	436 (M + H)	3
	(methylthio)nicotinamide
43	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	448 (M + H)	2
	methyl-3-nitrobenzamide
44	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	434 (M + H)	1
	nitrobenzamide
45	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	403 (M + H)	3
	phenlacetamide
46	(2R)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide
47	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	433 (M + H)	3
	1,3-benzodioxole-5-carboxamide
48	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	447 (M + H)	1
	phenoxybutanamide
49	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	433 (M + H)	1
	phenoxypropanamide
50	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	403 (M + H)	1
	methylbenzamide
51	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	403 (M + H)	3
	methylbenzamide
52	N-(cis-4-{[4-(dimethylamino)quinolin-2-	395 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
53	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	409 (M + H)	3
	(2-thienyl)acetamide
54	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	473 (M + H)	2
	(trifluoromethoxy)benzamide
55	benzyl (cis-4-{[4-(dimethylamino)quinolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)carbamate
56	4-nitrobenzyl (cis-4-{[4-(dimethylamino)quinolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)carbamate
57	4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
58	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	515 (M + H)	2
	iodobenzamide
59	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-2-fluorobenzamide
60	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	439 (M + H)	3
	2,3-difluoro-4-methylbenzamide
61	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-4-fluorobenzamide
62	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	459 (M + H)	2
	yl]amino}cyclohexyl)-2,4-difluorobenzamide
63	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	435 (M + H)	3
	(phenylthio)acetamide
64	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	475 (M + H)	3
	fluoro-3-(trifluoromethyl)benzamide
65	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	475 (M + H)	3
	fluoro-5-(trifluoromethyl)benzamide
66	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	431 (M + H)	3
	phenylbutanamide
67	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	433 (M + H)	3
	(3-methoxyphenyl)acetamide
68	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	421 (M + H)	3
	(4-fluorophenyl)acetamide
69	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	433 (M + H)	3
	(4-methoxyphenyl)acetamide
70	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	461 (M + H)	3
	methyl-2-(trifluoromethyl)-3-furamide
71	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	407 (M + H)	1
	2,5-dimethyl-3-furamide
72	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	433 (M + H)	3
	ethoxybenzamide
73	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	441 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
74	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	421 (M + H)	2
	fluoro-4-methylbenzamide
75	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	395 (M + H)	3
	yl]amino}cyclohexyl)acetamide
76	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	3,5-dimethoxybenzamide
77	4-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)benzamide
78	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	525 (M + H)	2
	3,5-bis(trifluoromethyl)benzamide
79	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide
80	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)acetamide
81	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	421 (M + H)	1
	fluoro-3-methylbenzamide
82	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)benzamide
83	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	463 (M + H)	2
	yl]amino}cyclohexyl)thiophene-3-carboxamide
84	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	464 (M + H)	3
	(propylthio)nicotinamide
85	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	525 (M + H)	3
	yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide
86	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)-1-methyl-1H-pyrazole-5-carboxamide
87	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide
88	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)nicotinamide
89	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	453 (M + H)	3
	(1-naphthyl)acetamide
90	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)-5-methyl-1H-pyrazole-3-carboxamide
91	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	445 (M + H)	3
	benzothiophene-3-carboxamide
92	2-[(cis-4-{[4-(dimethylamino)quinolin-2-	461 (M + H)	3
	yl]amino}cyclohexyl)amino]-2-oxo-1-phenylethyl acetate
93	N-(cis-4-{[4-(dimethylamino)quinolin-2-	389 (M + H)	3
	yl]amino}cyclohexyl)benzamide
94	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	445 (M + H)	3
	benzothiophene-2-carboxamide
95	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)acetamide
96	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	453 (M + H)	1
	yl]amino}cyclohexyl)acetamide
97	N-(cis-4-{[4-(dimethylamino)quinolin-2-	395 (M + H)	3
	yl]amino}cyclohexyl)cyclohexanecarboxamide
98	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	504 (M + H)	1
	yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide
99	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	491 (M + H)	2
	yl]amino}cyclohexyl)cyclopentanecarboxamide
100	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-	522 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-
	methylisoxazole-4-carboxamide
101	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-	535 (M + H)	3
	2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)thiophene-
	2-carboxamide
102	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-4-nitrobenzamide
103	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	407 (M + H)	3
	1,3-dimethyl-1H-pyrazole-5-carboxamide
104	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	3,4-dimethoxybenzamide
105	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	407 (M + H)	2
	fluorobenzamide
106	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	475 (M + H)	1
	fluoro-3-(trifluoromethyl)benzamide
107	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	470 (M + H)	2
	methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide
108	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	556 (M + H)	1
	(4-methoxyphenoxy)-5-nitrobenzamide
109	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	439 (M + H)	3
	naphthamide
110	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	439 (M + H)	3
	naphthamide
111	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	424 (M + H)	1
	nitro-2-furamide
112	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	419 (M + H)	1
	phenoxyacetamide
113	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	464 (M + H)	3
	(2-nitrophenoxy)acetamide
114	N-(cis-4-{[4-(dimethylamino)quinolin-2-	441 (M + H)	2
	yl]amino}cyclohexyl)quinoxaline-2-carboxamide
115	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	479 (M + H)	3
	3,4,5-trimethoxybenzamide
116	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	457 (M + H)	3
	(trifluoromethyl)benzamide
117	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	457 (M + H)	3
	(trifluoromethyl)benzamide
118	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	473 (M + H)	3
	(trifluoromethoxy)benzamide
119	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)quinolin-	524 (M + H)	3
	2-yl]amino}cyclohexyl)carbamate
120	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	447 (M + H)	3
	phenoxybutanamide
121	2-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	497 (M + H)	3
	yl]amino}cyclohexyl)-5-methoxybenzamide
122	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	509 (M + H)	3
	(pentafluorophenoxy)acetamide
123	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-	463 (M + H)	3
	2-yl]amino}cyclohexyl)acetamide
124	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	443 (M + H)	3
	2,3,4-trifluorobenzamide
125	N-(cis-4-{[4-(dimethylamino)quinolin-2-	381 (M + H)	3
	yl]amino}cyclohexyl)cyclopentanecarboxamide
126	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	425 (M + H)	3
	2,4-difluorobenzamide
127	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	417 (M + H)	3
	phenylpropanamide
128	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	461 (M + H)	3
	2,3,4,5-tetrafluorobenzamide
129	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	483 (M + H)	3
	ethoxy-1-naphthamide
130	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	479 (M + H)	3
	2,3,4,5,6-pentafluorobenzamide
131	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	489 (M + H)	3
	[(trifluoromethyl)thio]benzamide
132	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	497 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
133	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	453 (M + H)	1
	yl]amino}cyclohexyl)acetamide
134	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	538 (M + H)	1
	yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide
135	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	482 (M + H)	1
	phenoxynicotinamide
136	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	498 (M + H)	3
	(phenylthio)nicotinamide
137	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	496 (M + H)	1
	(4-methylphenoxy)nicotinamide
138	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	552 (M + H)	3
	[(dipropylamino)sulfonyl]benzamide
139	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)-2-methylpropanamide
140	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	557 (M + H)	3
	yl]amino}cyclohexyl)-2-(trifluoromethyl)-3-furamide
141	2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-	514 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-
	1,3-thiazole-4-carboxamide
142	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-	593 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-
	1H-pyrazole-5-carboxamide
143	6-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)-2H-chromene-3-carboxamide
144	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
145	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	501 (M + H)	3
	[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide
146	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	478 (M + H)	1
	(2-thienyl)-1,3-thiazole-4-carboxamide
147	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methoxybenzamide
148	3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
149	4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
150	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	445 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-
	5-carboxamide
151	3-chloro-N-[cis-4-{[4-(dimethylamino)quinolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
152	4-chloro-N-[cis-4-{[4-(dimethylamino)quinolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
153	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-phenylacrylamide
154	4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-nitrobenzamide
155	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
156	3-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
157	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
158	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)methyl}benzamide
159	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	493 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide
160	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide
161	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide
162	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-	477 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]acetamide
163	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide
164	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	421 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
165	N-[(cis-4{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	489 (M + H)	3
	methyl]-3-fluoro-5-(trifluoromethyl)benzamide
166	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	489 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-fluorobenzamide
167	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	397 (M + H)	3
	yl]amino}cyclohexyl)methyl]hexanamide
168	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	529 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-iodobenzamide
169	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide
170	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide
171	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-nitrobenzamide
172	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	417 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylacetamide
173	(2R)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylcyclopropanecarboxamide
174	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide
175	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	461 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide
176	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide
177	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	417 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
178	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	417 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methylbenzamide
179	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	409 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
180	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	423 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide
181	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	487 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide
182	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-	433 (M + H)	3
	carbamic acid benzyl ester
183	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-	478 (M + H)	3
	carbamic acid 4-nitro-benzyl ester
184	4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
185	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	529 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-iodobenzamide
186	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluorobenzamide
187	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide
188	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
189	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	3
	yl]amino}cyclohexyl)methy]-2,4-difluorobenzamide
190	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide
191	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	489 (M + H)	3
	methyl]-2-fluoro-3-(trifluoromethyl)benzamide
192	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	489 (M + H)	3
	methyl]-2-fluoro-5-(trifluoromethyl)benzamide
193	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	445 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylbutanamide
194	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide
195	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide
196	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide
197	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	475 (M + H)	3
	methyl]-5-methyl-2-(trifluoromethyl)-3-furamide
198	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	421 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide
199	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide
200	3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
201	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide
202	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	409 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
203	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide
204	4-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
205	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	539 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide
206	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	474 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide
207	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
208	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide
209	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)quinolin-	485 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]benzamide
210	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-3-carboxamide
211	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	478 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(propylthio)nicotinamide
212	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	539 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1H-pyrazole-5-carboxamide
213	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1-methyl-1H-pyrazole-
	5-carboxamide
214	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-methyl-3-phenylacrylamide
215	5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)methyl]nicotinamide
216	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide
217	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-methyl-1H-pyrazole-
	3-carboxamide
218	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	459 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1-benzothiophene-3-carboxamide
219	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	479 (M + H)	3
	yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide
220	2-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
221	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
222	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	529 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-iodobenzamide
223	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	417 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-methylbenzamide
224	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
225	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-fluorobenzamide
226	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	505 (M + H)	3
	yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide
227	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3,6-trifluorobenzamide
228	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide
229	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide
230	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)	489 (M + H)	3
	methyl]-2-fluoro-6-(trifluoromethyl)benzamide
231	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	445 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide
232	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-6-fluorobenzamide
233	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	505 (M + H)	1
	yl]amino}cyclohexyl)methyl]benzamide
234	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-	463 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]acrylamide
235	6-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluoro-3-methylbenzamide
236	2-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,6-difluorobenzamide
237	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	431 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide
238	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	370 (M + H)	2
	3-methoxybenzamide
239	3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	418 (M + H)	1
	yl]amino}cyclohexyl)benzamide
240	4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	418 (M + H)	3
	yl]amino}cyclohexyl)benzamide
241	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	382 (M + H)	1
	2,1,3-benzoxadiazole-5-carboxamide
242	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	374 (M + H)	1
	yl]amino}cyclohexyl)benzamide
243	4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	374 (M + H)	2
	yl]amino}cyclohexyl)benzamide
244	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	366 (M + H)	3
	yl]amino}cyclohexyl)-3-phenylacrylamide
245	4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	419 (M + H)	1
	yl]amino}cyclohexyl)-3-nitrobenzamide
246	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	388 (M + H)	3
	yl]amino}cyclohexyl)acetamide
247	3-cyano-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	365 (M + H)	3
	yl]amino}cyclohexyl)benzamide
248	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)benzamide
249	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)benzamide
250	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	430 (M + H)	2
	2,2-diphenylacetamide
251	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	376 (M + H)	1
	3,4-difluorobenzamide
252	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	376 (M + H)	2
	3,5-difluorobenzamide
253	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-	414 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
254	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	401 (M + H)	3
	2-(ethylthio)nicotinamide
255	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	358 (M + H)	3
	4-fluorobenzamide
256	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	2
	3-fluoro-5-(trifluoromethyl)benzamide
257	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	426 (M + H)	3
	yl]amino}cyclohexyl)-5-fluorobenzamide
258	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	334 (M + H)	3
	yl]amino)}cyclohexyl)hexanamide
259	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	466 (M + H)	3
	4-iodobenzamide
260	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	387 (M + H)	3
	2-(methylthio)nicotinamide
261	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	2
	4-methyl-3-nitrobenzamide
262	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	385 (M + H)	1
	3-nitrobenzamide
263	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	354 (M + H)	3
	2-phenylacetamide
264	(2R)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	380 (M + H)	3
	yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide
265	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	1,3-benzodioxole-5-carboxamide
266	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	398 (M + H)	2
	2-phenoxybutanamide
267	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	2-phenoxypropanamide
268	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	354 (M + H)	2
	3-methylbenzamide
269	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	354 (M + H)	3
	4-methylbenzamide
270	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	346 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
271	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	360 (M + H)	3
	2-(2-thienyl)acetamide
272	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	424 (M + H)	1
	3-(trifluoromethoxy)benzamide
273	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic	370 (M + H)	3
	acid benzyl ester
274	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic	415 (M + H)	3
	acid 4-nitro-benzyl ester
275	4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
276	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	466 (M + H)	1
	3-iodobenzamide
277	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	392 (M + H)	3
	yl]amino}cyclohexyl)-2-fluorobenzamide
278	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	390 (M + H)	3
	2,3-difluoro-4-methylbenzamide
279	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	392 (M + H)	3
	yl]amino}cyclohexyl)-4-fluorobenzamide
280	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	410 (M + H)	3
	yl]amino}cyclohexyl)-2,4-difluorobenzamide
281	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	386 (M + H)	3
	2-(phenylthio)acetamide
282	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	3
	2-fluoro-3-(trifluoromethyl)benzamide
283	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	3
	2-fluoro-5-(trifluoromethyl)benzamide
284	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	382 (M + H)	3
	2-phenylbutanamide
285	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	2-(3-methoxyphenyl)acetamide
286	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	372 (M + H)	3
	2-(4-fluorophenyl)acetamide
287	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	2-(4-methoxyphenyl)acetamide
288	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	412 (M + H)	3
	5-methyl-2-(trifluoromethyl)-3-furamide
289	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	358 (M + H)	2
	2,5-dimethyl-3-furamide
290	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	2-ethoxybenzamide
291	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	392 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
292	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	372 (M + H)	3
	3-fluoro-4-methylbenzamide
293	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	346 (M + H)	3
	yl]amino}cyclohexyl)acetamide
294	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	400 (M + H)	1
	3,5-dimethoxybenzamide
295	4-cyano-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	365 (M + H)	3
	yl]amino}cyclohexyl)benzamide
296	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	476 (M + H)	1
	3,5-bis(trifluoromethyl)benzamide
297	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide
298	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)acetamide
299	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	372 (M + H)	1
	4-fluoro-3-methylbenzamide
300	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-	422 (M + H)	3
	2-yl]amino}cyclohexyl)benzamide
301	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	414 (M + H)	2
	yl]amino}cyclohexyl)thiophene-3-carboxamide
302	N-(cis-4-{[4-dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	3
	2-(propylthio)nicotinamide
303	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	476 (M + H)	2
	yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide
304	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)-1-methyl-1H-pyrazole-5-carboxamide
305	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	380 (M + H)	3
	yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide
306	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)nicotinamide
307	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	404 (M + H)	2
	2-(1-naphthyl)acetamide
308	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)-5-methyl-1H-pyrazole-3-carboxamide
309	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	396 (M + H)	3
	1-benzothiophene-3-carboxamide
310	2-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	412 (M + H)	3
	yl]amino}cyclohexyl)amino]-2-oxo-1-phenylethyl acetate
311	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	340 (M + H)	3
	yl]amino}cyclohexyl)benzamide
312	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	396 (M + H)	3
	1-benzothiophene-2-carboxamide
313	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)acetamide
314	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	404 (M + H)	1
	yl]amino}cyclohexyl)acetamide
315	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	346 (M + H)	3
	yl]amino}cyclohexyl)cyclohexanecarboxamide
316	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide
317	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	442 (M + H)	2
	yl]amino}cyclohexyl)cyclopentanecarboxamide
318	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-	473 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-
	5-methylisoxazole-4-carboxamide
319	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-	486 (M + H)	3
	2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)thiophene-
	2-carboxamide
320	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)-4-nitrobenzamide
321	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	358 (M + H)	3
	1,3-dimethyl-1H-pyrazole-5-carboxamide
322	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	400 (M + H)	3
	3,4-dimethoxybenzamide
323	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	358 (M + H)	3
	3-fluorobenzamide
324	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	1
	4-fluoro-3-(trifluoromethyl)benzamide
325	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	421 (M + H)	1
	5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide
326	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	507 (M + H)	1
	2-(4-methoxyphenoxy)-5-nitrobenzamide
327	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	390 (M + H)	3
	1-naphthamide
328	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	390 (M + H)	3
	2-naphthamide
329	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	375 (M + H)	3
	5-nitro-2-furamide
330	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	370 (M + H)	2
	2-phenoxyacetamide
331	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	3
	2-(2-nitrophenoxy)acetamide
332	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	392 (M + H)	1
	yl]amino}cyclohexyl)quinoxaline-2-carboxamide
333	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	430 (M + H)	3
	3,4,5-trimethoxybenzamide
334	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	408 (M + H)	2
	3-(trifluoromethyl)benzamide
335	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	408 (M + H)	3
	4-(trifluoromethyl)benzamide
336	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	424 (M + H)	3
	2-(trifluoromethoxy)benzamide
337	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-	475 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate
338	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	398 (M + H)	3
	4-phenoxybutanamide
339	2-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)-5-methoxybenzamide
340	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	460 (M + H)	2
	2-(pentafluorophenoxy)acetamide
341	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-	414 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
342	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	394 (M + H)	3
	2,3,4-trifluorobenzamide
343	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	332 (M + H)	3
	yl]amino}cyclohexyl)cyclopentanecarboxamide
344	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	376 (M + H)	3
	2,4-difluorobenzamide
345	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	368 (M + H)	3
	3-phenylpropanamide
346	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	412 (M + H)	3
	2,3,4,5-tetrafluorobenzamide
347	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	434 (M + H)	3
	2-ethoxy-1-naphthamide
348	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	430 (M + H)	3
	2,3,4,5,6-pentafluorobenzamide
349	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	440 (M + H)	3
	4-[(trifluoromethyl)thio]benzamide
350	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
351	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	404 (M + H)	1
	yl]amino}cyclohexyl)acetamide
352	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	489 (M + H)	1
	yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide
353	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	433 (M + H)	2
	2-phenoxynicotinamide
354	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	2-(phenylthio)nicotinamide
355	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	447 (M + H)	1
	2-(4-methylphenoxy)nicotinamide
356	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	503 (M + H)	1
	4-[(dipropylamino)sulfonyl]benzamide
357	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	2
	yl]amino}cyclohexyl)-2-methylpropanamide
358	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	508 (M + H)	3
	yl]amino}cyclohexyl)-2-(trifluoromethyl)-3-furamide
359	2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-	465 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-
	4-carboxamide
360	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-	544 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-pyrazole-
	5-carboxamide
361	6-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	2
	yl]amino}cyclohexyl)-2H-chromene-3-carboxamide
362	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	458 (M + H)	3
	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
363	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	452 (M + H)	3
	2-[(4-methyl-2-oxo-2H-chromen-8-yl)oxy]acetamide
364	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	429 (M + H)	1
	2-(2-thienyl)-1,3-thiazole-4-carboxamide
365	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methoxybenzamide
366	3-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
367	4-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
368	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	396 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-
	5-carboxamide
369	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	388 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
370	4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	388 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
371	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	380 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-phenylacrylamide
372	4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	433 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-nitrobenzamide
373	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	402 (M + H)	2
	yl]amino}cyclohexyl)methyl]acetamide
374	3-cyano-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	379 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
375	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
376	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
377	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	444 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide
378	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide
379	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide
380	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)-	428 (M + H)	3
	pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide
381	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide
382	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	372 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
383	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	440 (M + H)	3
	methyl]-3-fluoro-5-(trifluoromethyl)benzamide
384	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	440 (M + H)	2
	yl]amino}cyclohexyl)methyl]-5-fluorobenzamide
385	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	348 (M + H)	3
	yl]amino}cyclohexyl)methyl]hexanamide
386	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-iodobenzamide
387	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	401 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide
388	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	413 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide
389	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	399 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-nitrobenzamide
390	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylacetamide
391	(2R)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	394 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylcyclopropanecarboxamide
392	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide
393	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	412 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide
394	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide
395	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
396	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methylbenzamide
397	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	360 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
398	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	374 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide
399	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide
400	benzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
401	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
402	4-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	446 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
403	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-iodobenzamide
404	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluorobenzamide
405	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	404 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide
406	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
407	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	424 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,4-difluorobenzamide
408	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide
409	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	440 (M + H)	3
	methyl]-2-fluoro-3-(trifluoromethyl)benzamide
410	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	440 (M + H)	3
	methyl]-2-fluoro-5-(trifluoromethyl)benzamide
411	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	396 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-phenylbutanamide
412	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	2
	yl}amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide
413	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	386 (M + H)	3
	yl}amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide
414	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide
415	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	3
	methyl]-5-methyl-2-(trifluoromethyl)-3-furamide
416	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	372 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide
417	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide
418	3-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
419	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	386 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide
420	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	360 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
421	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide
422	4-cyano-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	379 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
423	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	490 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide
424	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	425 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide
425	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	446 (M + H)	2
	yl]amino}cyclohexyl)methyl]acetamide
426	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	386 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide
427	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)-	436 (M + H)	3
	pyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide
428	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-3-carboxamide
429	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	429 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2-(propylthio)nicotinamide
430	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	490 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1H-pyrazole-5-carboxamide
431	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1-methyl-1H-pyrazole-
	5-carboxamide
432	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	394 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-methyl-3-phenylacrylamide
433	5-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)methyl]nicotinamide
434	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	418 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide
435	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)pyriniidin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-methyl-1H-pyrazole-
	3-carboxamide
436	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	410 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1-benzothiophene-3-carboxamide
437	N-[cis-4-{[4-(dimethylamino)pyrimidin-2-	430 (M + H)	3
	yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide
438	2-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
439	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
440	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-iodobenzamide
441	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-methylbenzamide
442	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
443	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-fluorobenzamide
444	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	456 (M + H)	2
	yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide
445	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3,6-trifluorobenzamide
446	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide
447	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide
448	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	440 (M + H)	3
	methyl]-2-fluoro-6-(trifluoromethyl)benzamide
449	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	396 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide
450	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]-6-fluorobenzamide
451	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	456 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
452	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin	414 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]acrylamide
453	6-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	420 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluoro-3-methylbenzamide
454	2-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	424 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,6-difluorobenzamide
455	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	382 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide
456	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	424 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
457	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	472 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
458	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	472 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
459	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	436 (M + H)	1
	yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide
460	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	428 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
461	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	428 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
462	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	420 (M + H)	3
	2-yl]amino}cyclohexyl)-3-phenylacrylamide
463	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide
464	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	442 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetainide
465	3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	419 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
466	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	462 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
467	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	462 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
468	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	1
	yl]amino}cyclohexyl)-2,2-diphenylacetamide
469	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	430 (M + H)	1
	yl]amino}cyclohexyl)-3,4-difluorobenzamide
470	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	430 (M + H)	1
	yl]amino}cyclohexyl)-3,5-difluorobenzamide
471	2-(2,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
472	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-2-(ethylthio)nicotinamide
473	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	412 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
474	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide
475	2,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	480 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-fluorobenzamide
476	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	388 (M + H)	2
	yl]amino}cyclohexyl)hexanamide
477	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	520 (M + H)	3
	yl]amino}cyclohexyl)-4-iodobenzamide
478	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-2-(methylthio)nicotinamide
479	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	1
	yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide
480	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	1
	yl]amino}cyclohexyl)-3-nitrobenzamide
481	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	408 (M + H)	3
	yl]amino}cyclohexyl)-2-phenylacetamide
482	(2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	434 (M + H)	2
	2-yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide
483	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide
484	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	1
	yl]amino}cyclohexyl)-2-phenoxybutanamide
485	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	1
	yl]amino}cyclohexyl)-2-phenoxypropanamide
486	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
487	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	408 (M + H)	2
	yl]amino}cyclohexyl)-4-methylbenzamide
488	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
489	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)-2-(2-thienyl)acetamide
490	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	478 (M + H)	2
	yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide
491	[4-(4-{Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	424 (M + H)	3
	cyclohexyl]-carbamic acid benzyl ester
492	[4-(4-{Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	469 (M + H)	3
	cyclohexyl]-carbamic acid 4-nitro-benzyl ester
493	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methylbenzamide
494	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	520 (M + H)	1
	yl]amino}cyclohexyl)-3-iodobenzamide
495	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	446 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-fluorobenzamide
496	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)-2,3-difluoro-4-methylbenzamide
497	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	446 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide
498	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	464 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide
499	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)-2-(phenylthio)acetamide
500	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)-2-fluoro-3-(trifluoromethyl)benzamide
501	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)-2-fluoro-5-(trifluoromethyl)benzamide
502	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)-2-phenylbutanamide
503	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)-2-(3-methoxyphenyl)acetamide
504	N-(cis-4-{[-4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-fluorophenyl)acetamide
505	N-(cis-4-{[-4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)-2-(4-methoxyphenyl)acetamide
506	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	466 (M + H)	2
	yl]amino}cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide
507	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	412 (M + H)	1
	yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide
508	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)-2-ethoxybenzamide
509	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	446 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide
510	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	2
	yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide
511	2-cyclopentyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	400 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
512	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethoxybenzamide
513	4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	419 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
514	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	530 (M + H)	1
	yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide
515	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	465 (M + H)	3
	2-yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide
516	2-(2-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
517	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide
518	2-[(difluoromethyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
519	2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-
	3-carboxamide
520	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-2-(propylthio)nicotinamide
521	1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	530 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-
	carboxamide
522	3-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	454 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1-
	methyl-1H-pyrazole-5-carboxamide
523	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	434 (M + H)	3
	2-yl]amino}cyclohexyl)-2-methyl-3-phenylacrylamide
524	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide
525	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	458 (M + H)	3
	yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide
526	1-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	454 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-
	methyl-1H-pyrazole-3-carboxamide
527	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)-1-benzothiophene-3-carboxamide
528	2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	466 (M + H)	1
	yl]amino}cyclohexyl)amino}-2-oxo-1-phenylethyl acetate
529	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	394 (M + H)	2
	yl]amino}cyclohexyl)benzamide
530	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)-1-benzothiophene-2-carboxamide
531	2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	438 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
532	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	458 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
533	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)cyclohexanecarboxamide
534	3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	509 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-
	4-carboxamide
535	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	496 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	cyclopentanecarboxamide
536	3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-	527 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-
	methylisoxazole-4-carboxamide
537	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	540 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}amino}cyclohexyl)-4-
	(isopropylsulfonyl)thiophene-2-carboxamide
538	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide
539	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	412 (M + H)	2
	yl]amino}cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide
540	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)-3,4-dimethoxybenzamide
541	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	412 (M + H)	1
	yl]amino}cyclohexyl)-3-fluorobenzamide
542	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide
543	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	475 (M + H)	2
	yl]amino}cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-
	carboxamide
544	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	561 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide
545	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)-1-naphthamide
546	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)-2-naphthamide
547	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	429 (M + H)	1
	yl]amino}cyclohexyl)-5-nitro-2-furamide
548	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	424 (M + H)	1
	yl]amino}cyclohexyl)-2-phenoxyacetamide
549	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-2-(2-nitrophenoxy)acetamide
550	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)quinoxaline-2-carboxamide
551	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide
552	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	1
	yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide
553	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide
554	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	478 (M + H)	3
	yl]amino}cyclohexyl)-2-(trifluoromethoxy)benzamide
555	4,5-dimethoxy-2-nitrobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	529 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
556	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)-4-phenoxybutanamide
557	2-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	502 (M + H)	3
	2-yl]amino}cyclohexyl)-5-methoxybenzamide
558	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	514 (M + H)	3
	yl]amino}cyclohexyl)-2-(pentafluorophenoxy)acetamide
559	2-(3,4-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
560	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide
561	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	386 (M + H)	3
	yl]amino}cyclohexyl)cyclopentanecarboxamide
562	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	430 (M + H)	3
	yl]amino}cyclohexyl)-2,4-difluorobenzamide
563	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)-3-phenylpropanamide
564	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	466 (M + H)	3
	yl]amino}cyclohexyl)-2,3,4,5-tetrafluorobenzamide
565	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	488 (M + H)	3
	yl]amino}cyclohexyl)-2-ethoxy-1-naphthamide
566	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-2,3,4,5,6-pentafluorobenzamide
567	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)-4-[(trifluoromethyl)thio]benzamide
568	3,4,5-trichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	502 (M + H)	3
	2-yl]amino}cyclohexyl)thiophene-2-carboxamide
569	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	458 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
570	3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	543 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-5-methylisoxazole-
	4-carboxamide
571	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	487 (M + H)	2
	yl]amino}cyclohexyl)-2-phenoxynicotinamide
572	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	503 (M + H)	3
	yl]amino}cyclohexyl)-2-(phenylthio)nicotinamide
573	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	501 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide
574	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	557 (M + H)	3
	yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide
575	2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-
	methylpropanamide
576	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	562 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)-
	3-furamide
577	3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)	598 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-1H-
	pyrazole-5-carboxamide
578	6-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	482 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2H-chromene-3-
	carboxamide
579	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	512 (M + H)	3
	2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)-
	benzamide
580	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	506 (M + H)	3
	yl]amino}cyclohexyl)-2-[(4-methyl-2-oxo-2H-chromen-8-
	yl)oxy]acetamide
581	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	483 (M + H)	2
	yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide
582	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methoxybenzamide
583	3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
584	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
585	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,1,3-benzoxadiazole-
	5-carboxamide
586	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	442 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
587	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	442 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
588	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	434 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]-3-phenylacrylamide
589	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	487 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-
	nitrobenzamide
590	2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	456 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
591	3-cyano-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	433 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
592	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
593	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
594	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	498 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide
595	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide
596	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide
597	2-(2,5-dimethoxyphenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	482 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
598	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(ethylthio)nicotinamide
599	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
600	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-fluoro-5-
	(trifluoromethyl)benzamide
601	2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	494 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-
	fluorobenzamide
602	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	402 (M + H)	3
	yl]amino}cyclohexyl)methyl]hexanamide
603	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	534 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-iodobenzamide
604	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(methylthio)nicotinamide
605	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methyl-3-nitrobenzamide
606	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-nitrobenzamide
607	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylacetamide
608	(2R)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	448 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]-2-phenylcyclopropane-
	carboxamide
609	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1,3-benzodioxole-5-carboxamide
610	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	466 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide
611	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide
612	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
613	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methylbenzamide
614	N-[(cis-4{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
615	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(2-thienyl)acetamide
616	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	492 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide
617	benzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	438 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]carbamate
618	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	483 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
619	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	500 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3-
	methylbenzamide
620	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	534 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-iodobenzamide
621	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	460 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]-2-
	fluorobenzamide
622	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	458 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluoro-4-methylbenzamide
623	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	460 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-
	fluorobenzamide
624	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	478 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-2,4-
	difluorobenzamide
625	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(phenylthio)acetamide
626	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluoro-3-
	(trifluoromethyl)benzamide
627	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluoro-5-
	(trifluoromethyl)benzamide
628	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-phenylbutanamide
629	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide
630	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(4-fluorophenyl)acetamide
631	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide
632	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	1
	yl]amino}cyclohexyl)methyl]-5-methyl-2-
	(trifluoromethyl)-3-furamide
633	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,5-dimethyl-3-furamide
634	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-ethoxybenzamide
635	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	460 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-4-
	fluorobenzamide
636	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide
637	2-cyclopentyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	414 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
638	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide
639	4-cyano-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	433 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
640	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	544 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide
641	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	479 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide
642	2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	500 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
643	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	440 (M + H)	2
	yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide
644	2-[(difluoromethyl)thio]-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	490 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
645	2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	482 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]thiophene-3-
	carboxamide
646	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	483 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(propylthio)nicotinamide
647	1-benzyl-3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	544 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-1H-
	pyrazole-5-carboxamide
648	3-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-1-methyl-
	1H-pyrazole-5-carboxamide
649	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	448 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]-2-methyl-3-phenylacrylamide
650	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	487 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)-methyl]nicotinamide
651	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	472 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(1-naphthyl)acetamide
652	1-tert-butyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-5-methyl-
	1H-pyrazole-3-carboxamide
653	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1-benzothiophene-3-carboxamide
654	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide
655	2-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	486 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
656	2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
657	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	534 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-iodobenzamide
658	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-methylbenzamide
659	2,3-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
660	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	460 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]-5-fluorobenzamide
661	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	510 (M + H)	3
	yl]amino}cyclohexyl)methyl]-9-oxo-9H-fluorene-4-carboxamide
662	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3,6-trifluorobenzamide
663	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-difluorobenzamide
664	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,6-difluorobenzamide
665	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-fluoro-6-(trifluoromethyl)-
	benzamide
666	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	450 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide
667	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	460 (M + H)	2
	quinazolin-2-yl]amino}cyclohexyl)methyl]-6-
	fluorobenzamide
668	2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	510 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
669	(2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acrylamide
670	6-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	474 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]-2-fluoro-3-
	methylbenzamide
671	2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	478 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)methyl]-3,6-
	difluorobenzamide
672	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-dimethylbenzamide
673	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	2
	yl]amino}cyclohexyl)thiophene-2-carboxamide
674	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	505 (M + H)	3
	(2,3,6-trichlorophenyl)acetamide
675	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-	455 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide
676	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-	534 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide
677	5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	429 (M + H)	2
	yl]amino}cyclohexyl)thiophene-2-carboxamide
678	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	493 (M + H)	3
	2,3-diphenylpropanamide
679	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	433 (M + H)	3
	(2-hydroxyphenyl)propanamide
680	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	505 (M + H)	1
	iodo-2-furamide
681	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	529 (M + H)	2
	(2-iodophenyl)acetamide
682	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	486 (M + H)	2
	(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
683	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	2
	yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide
684	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	443 (M + H)	3
	oxoindane-1-carboxamide
685	2-benzyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	479 (M + H)	3
	yl]amino}cyclohexyl)benzamide
686	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	547 (M + H)	2
	yl]amino}cyclohexyl)acetamide
687	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	514 (M + H)	3
	(4-methyl-2-nitrophenyl)-2-furamide
688	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	440 (M + H)	1
	nitrothiophene-2-carboxamide
689	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	448 (M + H)	1
	methyl-4-nitrobenzamide
690	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	464 (M + H)	1
	methoxy-4-nitrobenzamide
691	1-benzyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	518 (M + H)	3
	yl]amino}cyclohexyl)-1H-indole-3-carboxamide
692	3-acetyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	431 (M + H)	3
	yl]amino}cyclohexyl)benzamide
693	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	499 (M + H)	3
	yl]amino}cyclohexyl)cyclohexanecarboxamide
694	5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
695	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	423 (M + H)	3
	yl]amino}cyclohexyl)propanamide
696	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	451 (M + H)	3
	[(4-methylpyrimidin-2-yl)thio]acetamide
697	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	489 (M + H)	3
	yl]amino}cyclohexyl)-2-furamide
698	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	485 (M + H)	3
	yl]amino}cyclohexyl)propanamide
699	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)acetamide
700	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	479 (M + H)	3
	(4-hydroxy-3,5-dimethoxyphenyl)acetamide
701	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	551 (M + H)	2
	yl]amino}cyclohexyl)thiophene-2-carboxamide
702	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-	463 (M + H)	3
	2-yl]amino}cyclohexyl)acetamide
703	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-	531 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide
704	N˜2˜,N˜6˜-dibenzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	621 (M + H)	3
	yl]amino}cyclohexyl)lysinamide
705	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)benzamide
706	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-	535 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
707	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	463 (M + H)	3
	(4-fluorophenyl)-4-oxobutanamide
708	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	511 (M + H)	3
	(2-fluorobiphenyl-4-yl)propanamide
709	tert-butyl {(1S)-1-[(1-benzyl-1H-imidazol-4-yl)methyl]-2-[(cis-4-	612 (M + H)	3
	{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]-2-
	oxoethyl}carbamate
710	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	548 (M + H)	3
	[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide
711	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	442 (M + H)	1
	(1H-indol-3-yl)acetamide
712	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	500 (M + H)	3
	(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide
713	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	487 (M + H)	3
	(6-methoxy-3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide
714	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	561 (M + H)	3
	{1-[(4-methoxybenzyl)thio]cyclohexyl}acetamide
715	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	501 (M + H)	3
	(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide
716	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	560 (M + H)	2
	(1H-indol-3-yl)-4-oxo-4-phenylbutanamide
717	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	638 (M + H)	3
	yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide
718	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	635 (M + H)	3
	3,5-dimethyl-2-[({[4(trifluoromethoxy)phenyl]amino}-
	carbonyl)amino]benzamide
719	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	600 (M + H)	3
	yl]amino}cyclohexyl)-2-[(3-phenylprop-2-
	ynoyl)amino]benzamide
720	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	644 (M + H)	3
	yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide
721	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	630 (M + H)	3
	yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-
	yl)-4-oxobutanamide
722	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	588 (M + H)	3
	(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide
723	N-(2,4-dichlorophenyl)-2-{2-[(cis-4-{[4-	590 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)amino]-2-
	oxoethyl}benzamide
724	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	595 (M + H)	3
	methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-
	pyrrole-3-carboxamide
725	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	476 (M + H)	3
	(4-nitrophenyl)butanamide
726	(2E)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)-3-(2-nitrophenyl)acrylamide
727	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	495 (M + H)	3
	(3-phenoxyphenyl)acetamide
728	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	495 (M + H)	3
	(4-phenoxyphenyl)acetamide
729	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	518 (M + H)	2
	(2-phenyl-1H-indol-3-yl)acetamide
730	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)quinolin-2-	601 (M + H)	3
	yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide
731	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	481 (M + H)	3
	phenoxybenzamide
732	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	493 (M + H)	3
	(2-phenylethyl)benzamide
733	3-benzoyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)benzamide
734	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	539 (M + H)	3
	(ethylthio)-2,2-diphenylacetamide
735	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2-	522 (M + H)	3
	yl]amino}cyclohexyl)benzamide
736	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-	539 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide
737	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	586 (M + H)	3
	N′-[(1R)-1-(1-naphthyl)ethyl]phthalamide
738	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-	521 (M + H)	3
	2-yl]amino}cyclohexyl)propanamide
739	N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	640 (M + H)	3
	N,N-bis[(1S)-1-phenylethyl]phthalamide
740	(2S)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	511 (M + H)	3
	yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide
741	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-	635 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-
	4-oxobutanamide
742	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)quinolin-2	615 (M + H)	3
	yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide
743	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	623 (M + H)	3
	{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-
	inden-3-yl}acetamide
744	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	527 (M + H)	3
	[4-(2-thienylcarbonyl)phenyl]propanamide
745	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	451 (M + H)	3
	oxo-4-(2-thienyl)butanamide
746	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	437 (M + H)	3
	(2-thienyl)butanamide
747	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	521 (M + H)	2
	(2,4,6-trichlorophenoxy)acetamide
748	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-	548 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide
749	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	543 (M + H)	3
	(1-naphthoyl)benzamide
750	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	525 (M + H)	2
	yl]amino}cyclohexyl)-4-methoxybenzamide
751	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	544 (M + H)	3
	methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide
752	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-	670 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methyl-5-
	phenyl-1H-pyrrole-3-carboxamide
753	N-(cis-4-{[4-(dimethylamino)quinolin-2-	489 (M + H)	3
	yl]amino}cyclohexyl)anthracene-9-carboxamide
754	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	481 (M + H)	2
	phenoxybenzamide
755	N-(cis-4-{[4-(dimethylamino)quinolin-2-	465 (M + H)	3
	yl]amino}cyclohexyl)biphenyl-2-carboxamide
756	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	493 (M + H)	3
	3,3-diphenylpropanamide
757	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	516 (M + H)	2
	phenylquinoline-4-carboxamide
758	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	536 (M + H)	3
	N′-[(1S)-1-phenylethyl]phthalamide
759	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	507 (M + H)	3
	(4-methylbenzoyl)benzamide
760	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	495 (M + H)	3
	(phenoxymethyl)benzamide
761	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-	596 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)acetamide
762	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	532 (M + H)	3
	[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide
763	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	500 (M + H)	1
	(3-nitrophenyl)-2-furamide
764	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-2-
	carboxamide
765	3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	581 (M + H)	3
	yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-
	(methylthio)thiophene-2-carboxamide
766	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	673 (M + H)	3
	iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-
	carboxamide
767	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-	440 (M + H)	1
	nitrothiophene-3-carboxamide
768	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	437 (M + H)	1
	methyl-4-nitro-1H-pyrrole-2-carboxamide
769	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-1-	568 (M + H)	3
	(phenylsulfonyl)-1H-indole-3-carboxamide
770	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	434 (M + H)	1
	nitrobenzamide
771	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	464 (M + H)	2
	methoxy-4-nitrobenzamide
772	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-	475 (M + H)	1
	fluoro-4-(trifluoromethyl)benzamide
773	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	452 (M + H)	3
	fluoro-4-nitrobenzamide
774	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	2
	3,5-dimethyl-4-nitrobenzamide
775	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	459 (M + H)	2
	mesityl-2-oxoacetamide
776	N-(cis-4-{[4-(dimethylamino)quinolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)quinoline-3-carboxamide
777	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-	433 (M + H)	3
	methoxy-2-phenylacetamide
778	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	443 (M + H)	3
	1,2,3,4-tetrahydronaphthalene-2-carboxamide
779	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	1,3-benzothiazole-6-carboxamide
780	5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	2
	yl]amino}cyclohexyl)-2-hydroxybenzamide
781	2-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-5-(methylthio)benzamide
782	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-7-	459 (M + H)	3
	methoxy-1-benzofuran-2-carboxamide
783	2-amino-N-(cis-4-{[4-(dimethylamino)quinolin-2-	418 (M + H)	3
	yl]amino}cyclohexyl)-3-methylbenzamide
784	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-	465 (M + H)	3
	hydroxy-3,5-dimethoxybenzamide
785	N-(cis-4-{[4-(dimethylamino)quinolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)quinoline-4-carboxamide
786	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)quinolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)nicotinamide
787	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)quinolin-2-	517 (M + H)	3
	yl]amino}cyclohexyl)-4-hydroxybenzamide
788	5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	487 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
789	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	519 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide
790	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)-	469 (M + H)	3
	quinolin-2-yl]amino}cyclohexyl)-methyl]acetamide
791	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-	548 (M + H)	3
	quinolin-2-yl]amino}cyclohexyl)methyl]-2-furamide
792	5-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
793	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide
794	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide
795	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	519 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide
796	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	543 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(2-iodophenyl)acetamide
797	(2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	474 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide
798	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide
799	2-benzyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
800	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-	561 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]acetamide
801	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	528 (M + H)	3
	methyl]-5-(4-methyl-2-nitrophenyl)-2-furamide
802	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide
803	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide
804	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	478 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide
805	1-benzyl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	532 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1H-indole-3-carboxamide
806	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	421 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
807	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	675 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-
	oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide
808	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	501 (M + H)	3
	methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide
809	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	537 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-dimethylbenzamide
810	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide
811	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
812	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	424 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
813	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	456 (M + H)	3
	2-(2,3,6-trichlorophenyl)acetamide
814	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-	406 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
815	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-	485 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide
816	5-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	380 (M + H)	3
	yl]amino}cyclohexyl)thiophene-2-carboxamide
817	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	444 (M + H)	3
	2,3-diphenylpropanamide
818	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	3-(2-hydroxyphenyl)propanamide
819	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	456 (M + H)	2
	5-iodo-2-furamide
820	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	480 (M + H)	3
	2-(2-iodophenyl)acetamide
821	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	437 (M + H)	3
	2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
822	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide
823	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	394 (M + H)	3
	3-oxoindane-1-carboxamide
824	2-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	430 (M + H)	3
	yl]amino}cyclohexyl)benzamide
825	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-	498 (M + H)	3
	2-yl]amino}cyclohexyl)acetamide
826	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	465 (M + H)	2
	5-(4-methyl-2-nitrophenyl)-2-furamide
827	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	391 (M + H)	2
	5-nitrothiophene-2-carboxamide
828	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	2
	3-methyl-4-nitrobenzamide
829	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	1
	3-methoxy-4-nitrobenzamide
830	1-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-1H-indole-3-carboxamide
831	3-acetyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	382 (M + H)	2
	yl]amino}cyclohexyl)benzamide
832	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)cyclohexanecarboxamide
833	5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
834	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	374 (M + H)	3
	yl]amino}cyclohexyl)propanamide
835	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	402 (M + H)	3
	2-[(4-methylpyrimidin-2-yl)thio]acetamide
836	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	440 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
837	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)propanamide
838	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)acetamide
839	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	430 (M + H)	3
	2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide
840	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	501 (M + H)	2
	yl]amino}cyclohexyl)thiophene-2-carboxamide
841	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-	414 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
842	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-	482 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
843	N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	572 (M + H)	2
	yl]amino}cyclohexyl)lysinamide
844	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	383 (M + H)	2
	yl]amino}cyclohexyl)benzamide
845	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	486 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
846	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	414 (M + H)	3
	4-(4-fluorophenyl)-4-oxobutanamide
847	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	462 (M + H)	3
	2-(2-fluorobiphenyl-4-yl)propanamide
848	1-benzyl-Nalpha-(tert-butoxycarbonyl)-N-	563 (M + H)	3
	(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-
	L-histidinamide
849	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	499 (M + H)	3
	2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide
850	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	393 (M + H)	2
	2-(1H-indol-3-yl)acetamide
851	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	451 (M + H)	2
	2-(5-methyl-2-phenyl-1,3-thiazol-4-yl)acetamide
852	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	438 (M + H)	3
	2-(6-methoxy-3-oxo-2,3-dihydro-1H-inden-1-yl)acetamide
853	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	512 (M + H)	3
	2-{1-[(4-methoxybenzyl)thio]cyclohexyl}acetamide
854	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	452 (M + H)	3
	2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide
855	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	511 (M + H)	1
	2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide
856	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	589 (M + H)	2
	yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide
857	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	586 (M + H)	3
	3,5-dimethyl-2-[({[4(trifluoromethoxy)phenyl]amino}carbonyl)-
	amino]benzamide
858	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	551 (M + H)	2
	yl]amino}cyclohexyl)-2-[(3-phenylprop-2-
	ynoyl)amino]benzamide
859	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-	655 (M + H)	3
	indol-1-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-
	yl]amino}cyclohexyl)benzamide
860	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	595 (M + H)	3
	yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide
861	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	581 (M + H)	3
	yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-
	oxobutanamide
862	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	539 (M + H)	1
	2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide
863	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	546 (M + H)	2
	2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-
	3-carboxamide
864	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	427 (M + H)	2
	4-(4-nitrophenyl)butanamide
865	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	432 (M + H)	—
	2-[(3-nitropyridin-2-yl)thio]acetamide
866	(2E)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)-3-(2-nitrophenyl)acrylamide
867	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	2-(3-phenoxyphenyl)acetamide
868	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	2-(4-phenoxyphenyl)acetamide
869	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	469 (M + H)	1
	2-(2-phenyl-1H-indol-3-yl)acetamide
870	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)pyrimidin-2-	552 (M + H)	2
	yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide
871	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-	432 (M + H)	2
	3-phenoxybenzamide
872	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	444 (M + H)	3
	2-(2-phenylethyl)benzamide
873	3-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	444 (M + H)	2
	yl]amino}cyclohexyl)benzamide
874	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	490 (M + H)	1
	2-(ethylthio)-2,2-diphenylacetamide
875	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-	473 (M + H)	3
	2-yl]amino}cyclohexyl)benzamide
876	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-	490 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
877	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	537 (M + H)	2
	N′-[(1R)-1-(1-naphthyl)ethyl]phthalamide
878	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-	472 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)propanamide
879	N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	591 (M + H)	1
	N,N-bis[(1S)-1-phenylethyl]phthalamide
880	(2S)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide
881	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-	586 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-
	4-oxobutanamide
882	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)pyrimidin-	566 (M + H)	3
	2-yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide
883	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	574 (M + H)	2
	2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-
	inden-3-yl}acetamide
884	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	478 (M + H)	2
	2-[4-(2-thienylcarbonyl)phenyl]propanamide
885	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	402 (M + H)	3
	4-oxo-4-(2-thienyl)butanamide
886	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	388 (M + H)	3
	4-(2-thienyl)butanamide
887	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-	499 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
888	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	494 (M + H)	3
	2-(1-naphthoyl)benzamide
889	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	476 (M + H)	1
	yl]amino}cyclohexyl)-4-methoxybenzamide
890	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	495 (M + H)	1
	2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide
891	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-	621 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-5-
	phenyl-1H-pyrrole-3-carboxamide
892	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)anthracene-9-carboxamide
893	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	432 (M + H)	2
	2-phenoxybenzamide
894	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	416 (M + H)	3
	yl]amino}cyclohexyl)biphenyl-2-carboxamide
895	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	444 (M + H)	3
	3,3-diphenylpropanamide
896	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	467 (M + H)	2
	2-phenylquinoline-4-carboxamide
897	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	487 (M + H)	3
	N′-[(1S)-1-phenylethyl]phthalamide
898	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	458 (M + H)	3
	2-(4-methylbenzoyl)benzamide
899	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	2-(phenoxymethyl)benzamide
900	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-	547 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide
901	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	483 (M + H)	2
	1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide
902	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	451 (M + H)	2
	5-(3-nitrophenyl)-2-furamide
903	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	458 (M + H)	3
	yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-
	2-carboxamide
904	3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	532 (M + H)	2
	yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-
	(methylthio)thiophene-2-carboxamide
905	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	624 (M + H)	2
	3-iodo-4-(isopropylsulfonyl)-5-(methylthio)thiophene-
	2-carboxamide
906	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	391 (M + H)	1
	5-nitrothiophene-3-carboxamide
907	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	388 (M + H)	1
	1-methyl-4-nitro-1H-pyrrole-2-carboxamide
908	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	519 (M + H)	3
	1-(phenylsulfonyl)-1H-indole-3-carboxamide
909	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	385 (M + H)	2
	4-nitrobenzamide
910	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	3
	2-methoxy-4-nitrobenzamide
911	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	426 (M + H)	3
	3-fluoro-4-(trifluoromethyl)benzamide
912	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	403 (M + H)	3
	2-fluoro-4-nitrobenzamide
913	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	2
	3,5-dimethyl-4-nitrobenzamide
914	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	410 (M + H)	2
	2-mesityl-2-oxoacetamide
915	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	391 (M + H)	3
	yl]amino}cyclohexyl)quinoline-3-carboxamide
916	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	384 (M + H)	3
	2-methoxy-2-phenylacetamide
917	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	394 (M + H)	3
	1,2,3,4-tetrahydronaphthalene-2-carboxamide
918	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M + H)	3
	1,3-benzothiazole-6-carboxamide
919	5-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)-2-hydroxybenzamide
920	2-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	420 (M + H)	3
	yl]amino}cyclohexyl)-5-(methylthio)benzamide
921	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	410 (M + H)	3
	7-methoxy-1-benzofuran-2-carboxamide
922	2-amino-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	369 (M + H)	3
	yl]amino}cyclohexyl)-3-methylbenzamide
923	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	413 (M + H)	3
	yl]amino}cyclohexyl)nicotinamide
924	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-	468 (M + H)	1
	yl]amino}cyclohexyl)-4-hydroxybenzamide
925	5-bromo-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
926	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	470 (M + H)	1
	yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide
927	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)-	420 (M + H)	3
	pyrimidin-2-yl]amino}-cyclohexyl)methyl]acetamide
928	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-	499 (M + H)	3
	pyrimidin-2-yl]amino}-cyclohexyl)methyl]-2-furamide
929	5-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	394 (M + H)	3
	yl]amino}cyclohexyl)methyl]thiophene-2-carboxamide
930	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	458 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide
931	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide
932	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	470 (M + H)	2
	yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide
933	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	451 (M + H)	3
	methyl]-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide
934	(2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	425 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide
935	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide
936	2-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	444 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
937	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-	512 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]acetamide
938	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	479 (M + H)	3
	methyl]-5-(4-methyl-2-nitrophenyl)-2-furamide
939	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	405 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide
940	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	413 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide
941	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	429 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide
942	1-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	483 (M + H)	3
	yl]amino}cyclohexyl)methyl]-1H-indole-3-carboxamide
943	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	372 (M + H)	3
	yl]amino}cyclohexyl)methyl]acetamide
944	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	626 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-
	oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide
945	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	452 (M + H)	1
	cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]-
	acetamide
946	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	488 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,5-dimethylbenzamide
947	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	458 (M + H)	1
	yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide
948	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	424 (M + H)	1
	yl]amino}cyclohexyl)methyl]acetamide
949	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	478 (M + H)	2
	2-yl]amino}cyclohexyl)-thiophene-2-carboxamide
950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	510 (M + H)	2
	yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide
951	2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-	460 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
952	5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	539 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide
953	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	434 (M + H)	1
	2-yl]amino}cyclohexyl)-thiophene-2-carboxamide
954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	498 (M + H)	2
	yl]amino}cyclohexyl)-2,3-diphenylpropanamide
955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)-3-(2-hydroxyphenyl)propanamide
956	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	510 (M + H)	1
	yl]amino}cyclohexyl)-5-iodo-2-furamide
957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	534 (M + H)	2
	yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide
958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	491 (M + H)	2
	yl]amino}cyclohexyl)-2-(5-methoxy-2-methyl-1H-
	indol-3-yl)acetamide
959	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	465 (M + H)	3
	2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide
960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	448 (M + H)	2
	yl]amino}cyclohexyl)-3-oxoindane-1-carboxamide
961	2-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	484 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
962	2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	552 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
963	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	519 (M + H)	2
	yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide
964	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	445 (M + H)	1
	yl]amino}cyclohexyl)-5-nitrothiophene-2-carboxamide
965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	1
	yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide
966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide
967	1-benzyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	523 (M + H)	3
	2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide
968	3-acetyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	436 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
969	(2R)-2-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	504 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	cyclohexanecarboxamide
970	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	462 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide
971	3-cyclohexyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	428 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide
972	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	456 (M + H)	2
	yl]amino}cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide
973	5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	494 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide
974	3-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	490 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide
975	2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	476 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
976	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-hydroxy-3,5-
	dimethoxyphenyl)acetamide
977	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	556 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-
	carboxamide
978	2-(3,5-dimethoxyphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
979	2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-	536 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-
	cyclohexyl)acetamide
980	N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	626 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)lysinamide
981	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	437 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
982	4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	540 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide
983	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	2
	yl]amino}cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide
984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	516 (M + H)	2
	yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide
985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	553 (M + H)	2
	yl]amino}cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-
	yl)pheny]propanamide
986	N-(cis-4-{[4-(diniethylamino)-5,6,7,8-tetrahydroquinazolin-2-	447 (M + H)	1
	yl]amino}cyclohexyl)-2-(1H-indol-3-yl)acetamide
987	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	505 (M + H)	3
	yl]amino}cyclohexyl)-2-(5-methyl-2-phenyl-1,3-
	thiazol-4-yl)acetamide
988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	492 (M + H)	3
	yl]amino}cyclohexyl)-2-(6-methoxy-3-oxo-2,3-dihydro-1H-
	inden-1-yl)acetamide
989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	566 (M + H)	3
	yl]amino}cyclohexyl)-2-{1-[(4-methoxybenzyl)thio]-
	cyclohexyl}acetamide
990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	506 (M + H)	1
	yl]amino}cyclohexyl)-2-(7-methoxy-2-oxo-2H-
	chromen-4-yl)acetamide
991	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	565 (M + H)	2
	yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-4-
	oxo-4-phenylbutanamide
992	4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	643 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1H-indol-3-yl)-
	4-oxobutanamide
993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	640 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethyl-2-[({[4-
	(trifluoromethoxy)phenyl]amino}carbonyl)amino]benzamide
994	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	605 (M + H)	1
	2-yl]amino}cyclohexyl)-2-[(3-phenylprop-2-
	ynoyl)amino}benzamide
995	3-[2-(4-bromophenyl)-6,6-dimethyl-4-oxo-4,5,6,7-tetrahydro-1H-	709 (M + H)	3
	indol-1-yl]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
996	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	649 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(7-ethyl-1H-
	indol-3-yl)-4-oxobutanamide
997	4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	635 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-
	indol-3-yl)-4-oxobutanamide
998	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	593 (M + H)	2
	yl]amino}cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-
	methylphenyl)-4-oxobutanamide
999	N-(2,4-dichlorophenyl)-2-{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	595 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-2-
	oxoethyl}benzamide
1000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	600 (M + H)	1
	yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-
	phenyl-1H-pyrrole-3-carboxamide
1001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	481 (M + H)	1
	yl]amino}cyclohexyl)-4-(4-nitrophenyl)butanamide
1002	(2E)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	465 (M + H)	3
	2-yl]amino}cyclohexyl)-3-(2-nitrophenyl)acrylamide
1003	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	2
	yl]amino}cyclohexyl)-2-(3-phenoxyphenyl)acetamide
1004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	2
	yl]amino}cyclohexyl)-2-(4-phenoxyphenyl)acetamide
1005	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	523 (M + H)	1
	yl]amino}cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide
1006	N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)-5,6,7,8-	606 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N1,N1-
	dipropylglutamamide
1007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	486 (M + H)	1
	yl]amino}cyclohexyl)-3-phenoxybenzamide
1008	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	498 (M + H)	3
	yl]amino}cyclohexyl)-2-(2-phenylethyl)benzamide
1009	3-benzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	498 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
1010	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	544 (M + H)	2
	yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide
1011	2-[(2-cyanophenyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	527 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide
1012	2-[4-(benzyloxy)-3-methoxyphenyl]-N-(cis-4-{[4-	544 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)acetamide
1013	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	591 (M + H)	3
	yl]amino}cyclohexyl)-N′-[(1R)-1-(1-naphthyl)ethyl]phthalamide
1014	(2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	526 (M +H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)propanamide
1015	N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	645 (M + H)	1
	yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide
1016	(2S)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	516 (M + H)	2
	2-yl]amino}cyclohexyl)-2-(2-fluorobiphenyl-4-yl)propanamide
1017	2-[(4-chlorobenzyl)thio]-4-(4-chlorophenyl)-N-(cis-4-{[4-	640 (M + H)	3
	(dimethylamino}-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)-4-oxobutanamide
1018	2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	620 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-(4-
	methylphenyl)-4-oxobutanamide
1019	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	628 (M + H)	1
	yl]amino}cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-
	(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide
1020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	532 (M + H)	2
	yl]amino}cyclohexyl)-2-[4-(2-
	thienylcarbonyl)phenyl]propanamide
1021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	456 (M + H)	3
	yl]amino}cyclohexyl)-4-oxo-4-(2-thienyl)butanamide
1022	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	442 (M + H)	3
	yl]amino}cyclohexyl)-4-(2-thienyl)butanamide
1023	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	526 (M + H)	3
	yl]amino}cyclohexyl)-2-(2,4,6-trichlorophenoxy)acetamide
1024	2-[5-(benzyloxy)-1H-indol-3-yl]-N-(cis-4-{[4-(dimethylamino)-	553 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide
1025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	548 (M + H)	3
	yl]amino}cyclohexyl)-2-(1-naphthoyl)benzamide
1026	3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	530 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-
	methoxybenzamide
1027	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	549 (M + H)	2
	yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl-1H-
	pyrrole-3-carboxamide
1028	1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-	675 (M + H)	2
	(dimethy-lamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-
	cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide
1029	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	494 (M + H)	3
	yl]amino}cyclohexyl)anthracene-9-carboxamide
1030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	486 (M + H)	1
	yl]amino}cyclohexyl)-2-phenoxybenzamide
1031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	470 (M + H)	3
	yl]amino}cyclohexyl)biphenyl-2-carboxamide
1032	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	498 (M + H)	3
	yl]amino}cyclohexyl)-3,3-diphenylpropanamide
1033	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	521 (M + H)	2
	yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide
1034	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	541 (M + H)	3
	yl]amino}cyclohexyl)-N′-[(1S)-1-phenylethyl]phthalamide
1035	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	512 (M + H)	3
	yl]amino}cyclohexyl)-2-(4-methylbenzoyl)benzamide
1036	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	3
	yl]amino}cyclohexyl)-2-(phenoxymethyl)benzamide
1037	2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-	601 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)acetamide
1038	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	537 (M + H)	3
	yl]amino}cyclohexyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-
	3-carboxamide
1039	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	505 (M + H)	2
	yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide
1040	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	512 (M + H)	3
	2-yl]amino}cyclohexyl)-4-(methylsulfonyl)thiophene-
	2-carboxamide
1041	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	586 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-
	(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide
1042	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	678 (M + H)	3
	yl]amino}cyclohexyl)-3-iodo-4-(isopropylsulfonyl)-5-
	(methylthio)thiophene-2-carboxamide
1043	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	445 (M + H)	1
	yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide
1044	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	442 (M + H)	1
	yl]amino}cyclohexyl)-1-methyl-4-nitro-1H-
	pyrrole-2-carboxamide
1045	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	573 (M + H)	3
	yl]amino}cyclohexyl)-1-(phenylsulfonyl)-
	1H-indole-3-carboxamide
1046	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-4-nitrobenzamide
1047	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-2-methoxy-4-nitrobenzamide
1048	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide
1049	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)-2-fluoro-4-nitrobenzamide
1050	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide
1051	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide
1052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)-2-methoxy-2-phenylacetamide
1053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)-1,2,3,4-tetrahydronaphthalene-
	2-carboxamide
1054	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)-1,3-benzothiazole-6-carboxamide
1055	5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	444 (M + H)	1
	2-yl]amino}cyclohexyl)-2-hydroxybenzamide
1056	2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	474 (M + H)	3
	2-yl]amino}cyclohexyl)-5-(methylthio)-benzamide
1057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)-7-methoxy-1-benzofuran-2-carboxamide
1058	2-amino-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	423 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-3-methylbenzamide
1059	2-(allylthio)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	467 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide
1060	3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-	522 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)-4-
	hydroxybenzamide
1061	5-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	492 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]thiophene-2-
	carboxamide
1062	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	524 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide
1063	2-(2-chloro-4-fluorophenyl)-N-[(cis-4-{[4-(dimethylamino)-	474 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-
	acetamide
1064	5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)-	553 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-
	2-furamide
1065	5-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	448 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]thiophene-2-
	carboxamide
1066	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	512 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide
1067	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(2-hydroxyphenyl)propanamide
1068	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	524 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-iodo-2-furamide
1069	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	548 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-(2-iodophenyl)acetamide
1070	(2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	479 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide
1071	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-oxoindane-1-carboxamide
1072	2-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	498 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide
1073	2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	566 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
1074	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	533 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-(4-methyl-2-nitrophenyl)-
	2-furamide
1075	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	459 (M + H)	3
	yl]amino}cyclohexyl)methyl]-5-nitrothiophene-2-carboxamide
1076	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methyl-4-nitrobenzamide
1077	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	483 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide
1078	1-benzyl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	537 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-1H-
	indole-3-carboxamide
1079	2-cyclohex-1-en-1-yl-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	426 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
1080	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	680 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-(4-ethoxyphenyl)-2-(3-methyl-5-
	oxo-1-phenyl-4,5-dihydro-1H-pyrazol-4-yl)-4-oxobutanamide
1081	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	506 (M + H)	3
	yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]-
	acetamide
1082	4-(benzyloxy)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	542 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-3,5-
	dimethylbenzamide
1083	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	512 (M + H)	3
	yl]amino}cyclohexyl)methyl]-9H-xanthene-9-carboxamide
1084	2-(1-benzothien-3-yl)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	478 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]acetamide
1085	N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	435 (M + H)	3
	dimethylquinoline-2,4-diamine
1086	N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-	419 (M + H)	3
	dimethylquinoline-2,4-diamine
1087	N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-	414 (M + H)	3
	dimethylquinoline-2,4-diamine
1088	N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	435 (M + H)	3
	dimethylquinoline-2,4-diamine
1089	N2-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-	455 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1090	N2-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}-	444 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1091	N2-(cis-4-{[(2-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-	455 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1092	4-bromo-2-{[(cis-4-{[4-(dimethylamino)quinolin-2-	499 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol
1093	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-	492 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1094	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	435 (M + H)	3
	dimethylquinoline-2,4-diamine
1095	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-	465 (M + H)	3
	trimethoxybenzyl)amino]cyclohexyl}quinoline-2,4-diamine
1096	4-{[(cis-4-{[4-(dimethylamino)quinolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol
1097	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1098	N4,N4-dimethyl-N2-{cis-4-[({3-[4-(trifluoromethyl)phenyl]-1H-	509 (M + H)	3
	pyrazol-4-yl}methyl)amino]cyclohexyl}quinoline-2,4-diamine
1099	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-	465 (M + H)	3
	trimethoxybenzyl)amino]cyclohexyl}quinoline-2,4-diamine
1100	N4,N4-dimethyl-N2-{cis-4-	445 (M + H)	3
	[(pentamethylbenzyl)amino]cyclohexyl}quinoline-2,4-diamine
1101	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	435 (M + H)	3
	dimethylquinoline-2,4-diamine
1102	4-{[(cis-4-{[4-(dimethylamino)quinolin-2-	547 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol
1103	4-{[(cis-4-{[4-(dimethylamino)quinolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol
1104	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-	405 (M + H)	3
	dimethylquinoline-2,4-diamine
1105	N2-{cis-4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	471 (M + H)	3
	dimethylquinoline-2,4-diamine
1106	N4,N4-dimethyl-N2-{cis-4-[(3-	417 (M + H)	3
	phenylbutyl)amino]cyclohexyl}quinoline-2,4-diamine
1107	3-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	457 (M + H)	3
	amino]methyl}-6-methyl-4H-chromen-4-one
1108	3-{[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	471 (M + H)	3
	amino]methyl}-6,8-dimethyl-4H-chromen-4-one
1109	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-	468 (M + H)	3
	yl)methyl]amino}cyclohexyl)-N4,N4-dimethylquinoline-
	2,4-diamine
1110	N4,N4-dimethyl-N2-{cis-4-[(2-	403 (M + H)	3
	phenylpropyl)amino]cyclohexy}quinoline-2,4-diamine
1111	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-	471 (M + H)	3
	dimethylquinoline-2,4-diamine
1112	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-	431 (M + H)	3
	yl]amino}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1113	6-chloro-3-{[(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-4H-chromen-4-one
1114	N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}amino)-	470 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1115	ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)quinolin-2-	552 (M − H)	1
	yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate
1116	methyl 2-[(5-{[(cis-4-{[4-(dimethylamino)quinolin-2-	587 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}imidazo[2,1-b][1,3]thiazol-
	6-yl)thio]benzoate
1117	N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}amino)-	459 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1118	N4,N4-dimethyl-N2-(cis-4-{[4-	421 (M + H)	3
	(methylthio)benzyl]amino}cyclohexyl)quinoline-2,4-diamine
1119	N4,N4-dimethyl-N2-{cis-4-[(1-	425 (M + H)	3
	naphthylmethyl)amino]cyclohexyl}quinoline-2,4-diamine
1120	4-{[(cis-4-{[4-(dimethylamino)quinolin-2-	421 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol
1121	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	427 (M + H)	3
	dimethylquinoline-2,4-diamine
1122	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	2
	N4,N4-dimethylquinoline-2,4-diamine
1123	N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-	433 (M + H)	2
	dimethylquinoline-2,4-diamine
1124	N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-	428 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1125	N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1126	N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)-	469 (M + H)	2
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1127	N2-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}-	458 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1128	N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)-	469 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1129	4-bromo-2-({[(cis-4-{[4-(dimethylamino)quinolin-2-	513 (M + H)	2
	yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol
1130	N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)-	506 (M + H)	2
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1131	N2-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1132	N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)amino]-	479 (M + H)	3
	methyl}cyclohexyl)-quinoline-2,4-diamine
1133	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	465 (M + H)	3
	methyl]amino}methyl)-2,6-dimethoxyphenol
1134	N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}-	463 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1135	N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-	523 (M + H)	3
	pyrazol-4-yl}methyl)amino]methyl}cyclohexyl)-quinoline-
	2,4-diamine
1136	N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]-	479 (M + H)	3
	methyl}cyclohexyl)-quinoline-2,4-diamine
1137	N4,N4-dimethyl-N2-(cis-4-{[(pentamethylbenzyl)amino]-	459 (M + H)	3
	methyl}cyclohexyl)-quinoline-2,4-diamine
1138	N2-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1139	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	561 (M + H)	3
	methyl]amino}methyl)-2-iodo-6-methoxyphenol
1140	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol
1141	N2-(cis-4-{[(4-methoxybenzyl)amino]methyl}cyclohexyl)-	419 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1142	N2-(cis-4-{[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino]-	447 (M + H)	3
	methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1143	N2-(cis-4-{[(3-bromobenzyl)amino]methyl}cyclohexyl)-N4,N4-	467 (M + H)	3
	dimethylquinoline-2,4-diamine
1144	N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}-	527 (M + H)	2
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1145	N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}-	497 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1146	3-chloro-4-({[(cis-4-{[4-(dimethylamino)quinolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1147	2-({[(cis-4-{[4-(dimethylamino)quinolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1148	N2-(cis-4-{[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	423 (M + H)	?
	dimethylquinoline-2,4-diamine
1149	N2-(cis-4-{[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	423 (M + H)	3
	dimethylquinoline-2,4-diamine
1150	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-	460 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1151	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-	432 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1152	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}methyl)-	506 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1153	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}methyl)-	475 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1154	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-	405 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1155	[5-({[(cis-4-{[4-(dimethylamino)quinolin-2-	409 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol
1156	N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-	447 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1157	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-	423 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1158	N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-	491 (M + H)	1
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1159	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol
1160	N2-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)-	482 (M + H)	3
	methyl]cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine
1161	N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)-	479 (M + H)	2
	amino]methyl}cyclohexyl)quinoline-2,4-diamine
1162	2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)quinolin-2-	517 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1163	3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1164	N2-(cis-4-{[(2-fluoro-5-methoxybenzyl)amino]methyl}-	437 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1165	N4,N4-dimethyl-N2-{cis-4-[({2-[(trifluoromethyl)thio]benzyl}-	489 (M + H)	3
	amino)methyl]cyclohexyl}quinoline-2,4-diamine
1166	N2-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}-	511 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1167	N2-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}-	463 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1168	N4,N4-dimethyl-N2-[cis-4-({[2-(trifluoromethoxy)benzyl]-	473 (M + H)	3
	amino}methyl)cyclohexyl]-quinoline-2,4-diamine
1169	N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-	477 (M + H)	2
	N4,N4-dimethylquinoline-2,4-diamine
1170	N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-	477 (M + H)	2
	N4,N4-dimethylquinoline-2,4-diamine
1171	N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}-	575 (M + H)	2
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1172	N2-[cis-4-({[2-(difluoromethoxy)benzyl]amino}methyl)-	455 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1173	N2-(cis-4-{[(5-fluoro-2-methoxybenzyl)amino]methyl}-	437 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1174	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-	521 (M + H)	2
	triethoxybenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1175	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]-	479 (M + H)	2
	methyl}cyclohexyl)-quinoline-2,4-diamine
1176	N2-(cis-4-{[(2,3-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1177	N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-	445 (M + H)	2
	N4,N4-dimethylquinoline-2,4-diamine
1178	N2-(cis-4-{[(1-benzothien-3-ylmethyl)amino]methyl}-	445 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1179	N4,N4-dimethyl-N2-[cis-4-({[(1-methyl-1H-indol-3-	442 (M + H)	3
	yl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine
1180	N4,N4-dimethyl-N2-[cis-4-({[(5-methyl-2-	409 (M + H)	3
	thienyl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine
1181	N2-(cis-4-{[(mesitylmethyl)amino]methyl}cyclohexyl)-N4,N4-	431 (M + H)	3
	dimethylquinoline-2,4-diamine
1182	N2-(cis-4-{[(1,3-benzodioxol-5-ylmethyl)amino]methyl}-	433 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1183	N4,N4-dimethyl-N2-(cis-4-{[(3-	395 (M + H)	3
	thienylmethyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1184	N4,N4-dimethyl-N2-(cis-4-{[(3-	403 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1185	N4,N4-dimethyl-N2-(cis-4-{[(2-	403 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1186	N4,N4-dimethyl-N2-(cis-4-{[(4-	403 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1187	N2-(cis-4-{[(3,5-dichlorobenzyl)amino]methyl}cyclohexyl)-	457 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1188	N2-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}-	463 (M + H)	2
	methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1189	N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}-	527 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1190	N2-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}-	433 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1191	N2-(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}-	527 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1192	N4,N4-dimethyl-N2-[cis-4-({[(2-methyl-5-phenyl-3-	469 (M + H)	3
	furyl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine
1193	N2-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1194	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-methylphenol
1195	N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}-	447 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1196	2-({[(cis-4-{[4-(dimethylamino)quinolin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol
1197	N2-[cis-4-({[3-chloro-2-fluoro-5-(trifluoromethyl)benzyl]-	509 (M + H)	3
	amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1198	N2-[cis-4-({[3-fluoro-5-(trifluoromethyl)benzyl]amino}-	475 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1199	4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	453 (M + H)	3
	methyl]amino}methyl)-2-fluoro-6-methoxyphenol
1200	N2-(cis-4-{[(2-fluoro-4,5-dimethoxybenzyl)amino]methyl}-	467 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1201	N2-(cis-4-{[(2-ethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-	417 (M + H)	3
	dimethylquinoline-2,4-diamine
1202	3-[[4-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-	471 (M + H)	3
	cyclohexyl)methyl]amino}methyl)phenyl](methyl)amino]-
	propanenitrile
1203	N2-{cis-4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]-	573 (M + H)	3
	cyclohexyl}-N4,N4-dimethylquinoline-2,4-diamine
1204	N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}-	589 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1205	N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	386 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1206	N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-	370 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1207	N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-	365 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1208	N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	386 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1209	N2-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-	406 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1210	N2-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}-	395 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1211	N2-(cis-4-{[(2-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-	406 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1212	4-bromo-2-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	450 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol
1213	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-	443 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1214	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	386 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1215	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-	416 (M + H)	3
	trimethoxybenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1216	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	402 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol
1217	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-	400 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1218	N4,N4-dimethyl-N2-{cis-4-[({3-[4-(trifluoromethyl)phenyl]-1H-	460 (M + H)	3
	pyrazol-4-yl}methyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1219	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-	416 (M + H)	3
	trimethoxybenzyl)amino]cyclohexcyl}pyrimidine-2,4-diamine
1220	N4,N4-dimethyl-N2-{cis-4-	396 (M + H)	3
	[(pentamethylbenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1221	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	386 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1222	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	498 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol]
1223	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	370 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol
1224	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-	356 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1225	N2-{cis4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	422 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1226	N4,N4-dimethyl-N2-{cis-4-[(3-	368 (M + H)	3
	phenylbutyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1227	3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	408 (M + H)	3
	cylohexyl}-amino]methyl}-6-methyl-4H-chromen-4-one
1228	6-chloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	442 (M + H)	3
	cyclohexyl)amino]methyl}-7-methyl-4H-chromen-4-one
1229	3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	422 (M + H)	3
	cyclohexyl)-amino]methyl}-6,8-dimethyl-4H-chromen-4-one
1230	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)methyl]-	419 (M + H)	3
	amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1231	N4,N4-dimethyl-N2-{cis-4-[(2-	354 (M + H)	3
	phenylpropyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1232	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-	422 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1233	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-	382 (M + H)	3
	yl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1234	6-chloro-3-{[(cis4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	3
	yl]amino]cyclohexyl)amino]methyl}-4H-chromen-4-one
1235	N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}-	421 (M + H)	2
	amino)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1236	ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	503 (M − H)	1
	yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate
1237	methyl 2-[(5-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	538 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}imidazo[2,1-b][1,3]thiazol-
	6-yl)thio]benzoate
1238	N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-yl]methyl}-	410 (M + H)	3
	amino)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1239	N4,N4-dimethyl-N2-(cis-4-{[4-	372 (M + H)	3
	(methylthio)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine
1240	N4,N4-dimethyl-N2-{cis-4-[(1-	376 (M + H)	3
	naphthylmethyl)amino]cyclohexyl}pyrimidine-2,4-diamine
1241	4-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	372 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol
1242	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	378 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1243	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1244	N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-	384 (M + H)	2
	dimethylpyrimidine-2,4-diamine
1245	N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-	379 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1246	N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1247	N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)-	420 (M + H)	1
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1248	N2-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}-	407 (M − H)	2
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1249	N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)-	420 (M + H)	1
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1250	4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	462 (M − H)	1
	yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol
1251	N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)-	455 (M − H)	1
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1252	N2-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1253	N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)-	430 (M + H)	1
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1254	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	414 (M + H)	1
	cyclohexyl)methyl]amino}methyl)-2,6-dimethoxyphenol
1255	N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}-	414 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1256	N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H	474 (M + H)	1
	pyrazol-4-yl}methyl)amino]methyl}cyclohexyl)-
	pyrimidine-2,4-diamine
1257	N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxybenzyl)-	430 (M + H)	2
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1258	N4,N4-dimethyl-N2-(cis-4-{[(pentamethylbenzyl)-	410 (M + H)	3
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1259	N2-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1260	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	512 (M + H)	1
	cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol
1261	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	382 (M − H)	1
	yl]amino)cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol
1262	N2-(cis-4-{[(4-methoxybenzyl)amino]methyl}cyclohexyl)-	370 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1263	N2-(cis-4-{[(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)amino]-	398 (M + H)	3
	methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1264	N2-(cis-4-{[(3-bromobenzyl)amino]methyl}cyclohexyl)-N4,N4-	418 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1265	N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}-	478 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1266	N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}-	448 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1267	3-chloro-4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	388 (M − H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1268	2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	365 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1269	N2-(cis-4-{[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	374 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1270	N2-(cis-4-{[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	374 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1271	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-	411 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1272	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-	383 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1273	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}-	457 (M + H)	1
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1274	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}-	426 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1275	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	354 (M − H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1276	[5-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	360 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol
1277	N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-	398 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1278	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-	374 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1279	N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-	442 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1280	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	400 (M + H)	2
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol
1281	N2-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)-	433 (M + H)	2
	methyl]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine
1282	N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)-	430 (M + H)	1
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1283	2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino)methyl)phenol
1284	3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	365 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1285	N2-(cis-4-{[(2-fluoro-5-methoxybenzyl)amino]methyl}-	388 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1286	N4,N4-dimethyl-N2-{cis-4-[({2-[(trifluoromethyl)thio]benzyl}-	440 (M + H)	3
	amino)methyl]cyclohexyl}pyrimidine-2,4-diamine
1287	N2-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}-	462 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1288	N2-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}-	414 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1289	N4,N4-dimethyl-N2-[cis-4-({[2-(trifluoromethoxy)benzyl]-	424 (M + H)	3
	amino}methyl)cyclohexyl]pyrimidine-2,4-diamine
1290	N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-	428 (M + H)	1
	N4,N4-dimethylpyrimidine-2,4-diamine
1291	N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-	428 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1292	N2-(cis-4-({[(3,5-dibromo-2-methoxybenzyl)amino]methyl}-	526 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1293	N2-[cis-4-({[2-(difluoromethoxy)benzyl]amino}methyl)-	406 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1294	N2-(cis-4-{[(5-fluoro-2-methoxybenzyl)amino]methyl}-	388 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1295	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)-	472 (M + H)	1
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1296	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)-	430 (M + H)	2
	amino]methyl}cyclohexyl)-pyrimidine-2,4-diamine
1297	N2-(cis-4-{[(2,3-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1298	N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-	396 (M + H)	1
	N4,N4-dimethylpyrimidine-2,4-diamine
1299	N2-(cis-4-{[(1-benzothien-3-ylmethyl)amino]methyl}-	396 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1300	N4,N4-dimethyl-N2-[cis-4-({[(1-methyl-1H-indol-3-	393 (M + H)	2
	yl)methyl]amino}methyl)cyclohexyl]pyrimidine-2,4-diamine
1301	N4,N4-dimethyl-N2-[cis-4-({[(5-methyl-2-	360 (M + H)	3
	thienyl)methyl]amino}methyl)cyclohexyl]pyrimidine-2,4-diamine
1302	N2-(cis-4-{[(mesitylmethyl)amino]methyl}cyclohexyl)-N4,N4-	382 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1303	N2-(cis-4-{[(1,3-benzodioxol-5-ylmethyl)amino]methyl}-	384 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1304	N4,N4-dimethyl-N2-(cis-4-{[(3-	346 (M + H)	3
	thienylmethyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1305	N4,N4-dimethyl-N2-(cis-4-{[(3-	354 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1306	N4,N4-dimethyl-N2-(cis-4-{[(2-	354 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1307	N4,N4-dimethyl-N2-(cis-4-{[(4-	354 (M + H)	3
	methylbenzyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1308	N2-(cis-4-{[(3,5-dichlorobenzyl)amino]methyl}cyclohexyl)-	408 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1309	N2-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}-	414 (M + H)	1
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1310	N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}-	478 (M + H)	1
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1311	N2-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}-	384 (M + H)	2
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1312	N2-(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}-	478 (M + H)	2
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1313	N4,N4-dimethyl-N2-[cis-4-({[(2-methyl-5-phenyl-3-	420 (M + H)	3
	furyl)methyl]amino}methyl)cyclohexyl]pyrimidine-2,4-diamine
1314	N2-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	400 (M + H)	2
	N4,N4-dimethylpyrimidine-2,4-diamine
1315	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	368 (M − H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-methylphenol
1316	N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}-	398 (M + H)	2
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1317	2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	386 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol
1318	N2-[cis-4-({[3-chloro-2-fluoro-5-(trifluoromethyl)benzyl]amino}-	460 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1319	N2-[cis-4-({[3-fluoro-5-(trifluoromethyl)benzyl]amino}-	426 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1320	4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	402 (M − H)	3
	cyclohexyl)methyl]amino}methyl)-2-fluoro-6-methoxyphenol
1321	N2-(cis-4-{[(2-fluoro-4,5-dimethoxybenzyl)amino]methyl}-	418 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1322	N2-(cis-4-{[(2-ethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-	368 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1323	3-[[4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-	422 (M + H)	2
	cyclohexyl)-methyl]amino}methyl)phenyl](methyl)amino]-
	propanenitrile
1324	N2-{cis-4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]-	524 (M + H)	2
	cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine
1325	N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}-	540 (M + H)	2
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1326	N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	440 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1327	N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-	424 (M + H)	3
	5,6,7,8-tetrahydroquinazoline-2,4-diamine
1328	N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-	419 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1329	N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	440 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1330	N2-(cis-4-{[(4-methoxy-1-naphthyl)methyl]amino}cyclohexyl)-	460 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1331	N2-(cis-4-{[(5-methoxy-1H-indol-3-yl)methyl]amino}-	449 (M + H)	1
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1332	N2-(cis-4-{[(2-methoxy-1-naphthyl)methyl]amino)cyclohexyl)-	460 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1333	4-bromo-2-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	504 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]methyl}-6-
	methoxyphenol
1334	N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-	497 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1335	N2-{cis-4-[(2,4-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	440 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1336	N4,N4-dimethyl-N2-{cis-4-[(2,3,4-trimethoxybenzyl)amino]-	470 (M + H)	3
	cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1337	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	456 (M + H)	2
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethoxyphenol
1338	N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-	454 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1339	N4,N4-dimethyl-N2-{cis-4-[({3-[4-(trifluoromethyl)phenyl]-1H-	514 (M + H)	3
	pyrazol-4-yl}methyl)amino]cyclohexyl}-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1340	N4,N4-dimethyl-N2-{cis-4-[(3,4,5-trimethoxybenzyl)amino]-	470 (M + H)	3
	cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1341	N4,N4-dimethyl-N2-{cis-4-[(pentamethylbenzyl)amino]-	450 (M + H)	2
	cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1342	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-	440 (M + H)	2
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1343	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	552 (M + H)	2
	yl]amino}cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol
1344	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	424 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2,6-dimethylphenol
1345	N2-{cis-4-[(3-methoxybenzyl)amino]cyclohexyl}-N4,N4-	410 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1346	N2-{cis-4-[(3-bromo-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	476 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1347	N4,N4-dimethyl-N2-{cis-4-[(3-phenylbutyl)amino]cyclohexyl{-	422 (M + H)	3
	5,6,7,8-tetrahydroquinazoline-2,4-diamine
1348	3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-6-methyl-
	4H-chromen-4-one
1349	6-chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-	496 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-
	7-methyl-4H-chromen-4-one
1350	3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	476 (M + H)	2
	yl]amino}cyclohexyl)amino}methyl}-6,8-dimethyl-
	4H-chromen-4-one
1351	N2-(cis-4-{[(2,5-dimethyl-1-phenyl-1H-pyrrol-3-	473 (M + H)	3
	yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1352	N4,N4-dimethyl-N2-{cis-4-[(2-phenylpropyl)amino]cyclohexyl}-	408 (M + H)	3
	5,6,7,8-tetrahydroquinazoline-2,4-diamine
1353	N2-(cis-4-{[(2E)-2-benzylideneheptyl]amino}cyclohexyl)-N4,N4-	476 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1354	N2-(cis-4-{[(2E)-3-(2-methoxyphenyl)prop-2-en-1-	436 (M + H)	3
	yl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1355	6-chloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-	482 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-4H-
	chromen-4-one
1356	N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}-	475 (M + H)	3
	amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1357	ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-	559 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]methyl}-1H-
	indole-2-carboxylate
1358	methyl 2-[(5-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-	592 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-
	methyl}imidazo-[2,1-b][1,3]thiazol-6-yl)thio]benzoate
1359	N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol-4-	464 (M + H)	1
	yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1360	N4,N4-dimethyl-N2-(cis-4-{[4-(methylthio)benzyl]amino}-	426 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1361	N4,N4-dimethyl-N2-{cis-4-[(1-naphthylmethyl)amino]-	430 (M + H)	3
	cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1362	4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	3
	yl]amino}cyclohexyl)amino]methyl}-2-methoxyphenol
1363	N2-{cis-4-[(3-chloro-4-fluorobenzyl)amino]cyclohexyl}-N4,N4-	432 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1364	N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	1
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1365	N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-	438 (M + H)	2
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1366	N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-	433 (M + H)	2
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1367	N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	2
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1368	N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)-	474 (M + H)	2
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1369	N2-[cis-4-({[(5-methoxy-1H-indol-3-yl)methyl]amino}-	463 (M + H)	1
	methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1370	N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)-	474 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1371	4-bromo-2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-	518 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl
	amino}methyl)-6-methoxyphenol
1372	N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)-	511 (M + H)	1
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1373	N2-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1374	N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)-	484 (M + H)	3
	amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1375	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	470 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-
	2,6-dimethoxyphenol
1376	N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}-	468 (M + H)	1
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1377	N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl}-1H-	528 (M + H)	2
	pyrazol-4-yl}methyl)amino]methyl}cyclohexyl)-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1378	N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-	484 (M + H)	2
	trimethoxybenzyl)amino]methyl}cyclohexyl)-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1379	N4,N4-dimethyl-N2-(cis-4-{[(pentamethylbenzyl)amino]-	464 (M + H)	3
	methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1380	N2-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	2
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1381	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	566 (M + H)	1
	yl]amino}cyclohexyl)methyl]amino}methyl)-
	2-iodo-6-methoxyphenol
1382	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol
1383	N2-(cis-4-{[(4-methoxybenzyl)amino]methyl}cyclohexyl)-	424 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1384	N2-(cis-4-{[(2,3-dihydro-1,4-benzodioxin-6-	452 (M + H)	3
	ylmethyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1385	N2-(cis-4-{[(3-bromobenzyl)amino]methyl}cyclohexyl)-N4,N4-	472 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1386	N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}-	532 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1387	N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}-	502 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1388	3-chloro-4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-	444 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]amino}-
	methyl)phenol
1389	2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1390	N2-(cis-4-{[(3-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	428 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1391	N2-(cis-4-{[(4-chlorobenzyl)amino]methyl}cyclohexyl)-N4,N4-	428 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1392	N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-	465 (M + H)	2
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1393	N2-[cis-4-({[4-(dimethylamino)benzyl]amino}methyl)-	437 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1394	N2-[cis-4-({[(9-ethyl-9H-carbazol-3-yl)methyl]amino}-	511 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1395	N2-[cis-4-({[2-fluoro-5-(trifluoromethyl)benzyl]amino}-	480 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1396	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	410 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)phenol
1397	[5-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-furyl]methanol
1398	N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-	452 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1399	N2-[cis-4-({[(5-ethyl-2-thienyl)methyl]amino}methyl)-	428 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1400	N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}-	496 (M + H)	1
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1401	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	2
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol
1402	N2-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)-	487 (M + H)	2
	methyl]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1403	N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)-	484 (M + H)	1
	amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1404	2-bromo-4-chloro-6-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-	522 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-
	amino}methyl)phenol
1405	3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)benzonitrile
1406	N2-(cis-4-{[(2-fluoro-5-methoxybenzyl)amino]methyl}-	442 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1407	N4,N4-dimethyl-N2-{cis-4-[({2-[(trifluoromethyl)thio]-	494 (M + H)	3
	benzyl}amino)methyl]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1408	N2-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}-	516 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1409	N2-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}-	468 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1410	N4,N4-dimethyl-N2-[cis-4-({[2-(trifluoromethoxy)benzyl]-	478 (M + H)	3
	amino}methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1411	N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-	482 (M + H)	1
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1412	N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-	482 (M + H)	1
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1413	N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}-	580 (M + H)	1
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1414	N2-[cis-4-({[2-(difluoromethoxy)benzyl]amino}methyl)-	460 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1415	N2-(cis-4-{[(5-fluoro-2-methoxybenzyl)amino]methyl}-	442 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1416	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]-	526 (M + H)	1
	methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1417	N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]-	484 (M + H)	1
	methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1418	N2-(cis-4-{[(2,3-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1419	N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-	450 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1420	N2-(cis-4-{[(1-benzothien-3-ylmethyl)amino]methyl}-	450 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1421	N4,N4-dimethyl-N2-[cis-4-({[(1-methyl-1H-indol-3-	447 (M + H)	3
	yl)methyl]amino}methyl)cyclohexyl]-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1422	N4,N4-dimethyl-N2-[cis-4-({[(5-methyl-2-thienyl)methyl]-	414 (M + H)	3
	amino}methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1423	N2-(cis-4-{[(mesitylmethyl)amino]methyl}cyclohexyl)-N4,N4-	436 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1424	N2-(cis-4-{[(1,3-benzodioxol-5-ylmethyl)amino]methyl}-	438 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1425	N4,N4-dimethyl-N2-(cis-4-{[(3-thienylmethyl)amino]methyl}-	400 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1426	N4,N4-dimethyl-N2-(cis-4-{[(3-methylbenzyl)amino]methyl}-	408 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1427	N4,N4-dimethyl-N2-(cis-4-{[(2-methylbenzyl)amino]methyl}-	408 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1428	N4,N4-dimethyl-N2-(cis-4-{[(4-methylbenzyl)amino]methyl}-	408 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1429	N2-(cis-4-{[(3,5-dichlorobenzyl)amino]methyl}cyclohexyl)-	462 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1430	N2-[cis-4-({[(7-methoxy-1,3-benzodioxol-5-yl)methyl]amino}-	468 (M + H)	2
	methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1431	N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}-	532 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1432	N2-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}-	438 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1433	N2-(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}-	532 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1434	N4,N4-dimethyl-N2-[cis-4-({[(2-methyl-5-phenyl-3-	474 (M + H)	3
	furyl)methyl]amino}methyl)cyclohexyl]-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1435	N2-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-	454 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1436	4-({[(cis-4-}[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	424 (M + H)	2
	yl]amino}cyclohexyl)methyl]amino}methyl)-2-methylphenol
1437	N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}-	452 (M + H)	2
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1438	2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol
1439	N2-[cis-4-({[3-chloro-2-fluoro-5-(trifluoromethyl)benzyl]-	514 (M + H)	3
	amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1440	N2-[cis-4-({[3-fluoro-5-(trifluoromethyl)benzyl]amino}-	480 (M + H)	3
	methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1441	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	458 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-fluoro-
	6-methoxyphenol
1442	N2-(cis-4-{[(2-fluoro-4,5-dimethoxybenzyl)amino]methyl}-	472 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1443	N2-(cis-4-{[(2-ethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-	422 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1444	3-[[4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	476 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]amino}methyl)phenyl](Methyl)-
	amino]propanenitrile
1445	N2-{cis4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]-	578 (M + H)	3
	cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1446	N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}-	594 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1447	N2-(cis-4-{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-	467 (M + H)	3
	dimethylquinoline-2,4-diamine
1448	N2-(cis-4-{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-	423 (M + H)	—
	dimethylquinoline-2,4-diamine
1449	N2-(cis-4-{[2-(2-chlorophenoxy)ethyl]amino}cyclohexyl)-	439 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1450	N2-{cis-4-[(2-methoxy-2-phenylethyl)amino]cyclohexyl}-N4,N4-	419 (M + H)	3
	dimethylquinoline-2,4-diamine
1451	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-	445 (M + H)	3
	cyclohexyl]-quinoline-2,4-diamine
1452	N2-{cis-4-[(3-ethoxybenzyl)amino]cyclohexyl}-N4,N4-	419 (M + H)	3
	dimethylquinoline-2,4-diamine
1453	N2-(cis-4-{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-	539 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1454	N2-(cis-4-{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-	455 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1455	3-[{2-[(cis-4-{[4-(dimethylamino)quinolin-2-	457 (M + H)	2
	yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]propanenitrile
1456	N-{(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)quinolin-2-	572 (M + H)	3
	yl]amino}cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide
1457	(2-{[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylamino]-	487 (M + H)	3
	methyl}-cyclohexyl)-phenyl-methanol
1458	N2-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino}cyclohexyl)-	449 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1459	N4,N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indol-3-	504 (M + H)	2
	yl)ethyl]amino}cyclohexyl)quinoline-2,4-diamine
1460	N2-(cis-4-{[2,2-bis(4-chlorophenyl)ethyl]amino}cyclohexyl)-	533 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1461	(3-{(1S)-2-[(cis-4-{[4-(dimethylamino)quinolin-2-	509 (M + H)	3
	yl]amino}cyclohexyl)amino]-1-methylethyl}phenyl)-
	(phenyl)methanol
1462	N2-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)-	520 (M + H)	1
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1463	N2-[cis-4-({[2-(4-bromophenyl)ethyl]amino}methyl)cyclohexyl]-	481 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1464	N2-[cis-4-({[4-(4-methoxyphenyl)butyl]amino}methyl)-	461 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1465	N4,N4-dimethyl-N2-(cis-4-{[(6-	459 (M + H)	3
	phenylhexyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1466	N2-(cis-4-{[(2-mesitylethyl)amino]methyl}cyclohexyl)-N4,N4-	445 (M + H)	3
	dimethylquinoline-2,4-diamine
1467	N4,N4-dimethyl-N2-(cis-4-{[(8-	487 (M + H)	3
	phenyloctyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1468	N2-[cis-4-({[2-(4-tert-butylphenyl)ethyl]amino}methyl)-	459 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1469	N4,N4-dimethyl-N2-(cis-4-{[(5-phenylpent-4-yn-1-	441 (M + H)	3
	yl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1470	N2-[cis-4-({[2-(2-methoxyphenyl)ethyl]amino}methyl)-	433 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1471	N4,N4-dimethyl-N2-(cis-4-{[(3-	433 (M + H)	3
	phenoxypropyl)amino]methyl}cyclohexyl)quinoline-2,4-diamine
1472	N4,N4-dimethyl-N2-(cis-4-{[(2,3,5,6-tetrafluorobenzyl)-	461 (M + H)	3
	amino]methyl}cyclohexyl)quinoline-2,4-diamine
1473	N2-(cis-4-{[(2,5-dichlorobenzyl)amino]methyl]cyclohexyl)-	457 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1474	N2-(cis-4-{[(5-chloro-2-methoxybenzyl)amino]methyl}-	453 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1475	N2-(cis-4-{[(4-chloro-2-methoxybenzyl)amino]methyl}-	453 (M + H)	3
	cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine
1476	N2-(cis-4-{[(3-iodo-4-methylbenzyl)amino]methyl}cyclohexyl)-	529 (M + H)	3
	N4,N4-dimethylquinoline-2,4-diamine
1477	N2-[cis-4-({[(2S)-2-(dibenzylamino)propyl]amino}methyl)-	536 (M + H)	3
	cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine
1478	N4,N4-dimethyl-N2-[cis-4-({[(1-phenyl-5-propyl-1H-pyrazol-4-	497 (M + H)	1
	yl)methyl]amino}methyl)cyclohexyl]quinoline-2,4-diamine
1479	N2-{cis-4-[({[1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-	531 (M + H)	1
	yl]methyl}amino)methyl]cyclohexyl}-N4,N4-dimethylquinoline-
	2,4-diamine
1480	N4,N4-dimethyl-N2-[cis-4-({[4-(4-nitrophenyl)butyl]-	476 (M + H)	3
	amino}methyl)cyclohexyl]quinoline-2,4-diamine
1481	N2-(cis-4-{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-	472 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1482	N2-(cis-4-{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-	428 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1483	N2-{cis-4-[(2-methoxy-2-phenylethyl)amino]cyclohexyl)}-N4,N4-	424 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1484	N2-[4-(2-Methoxy-2-phenyl-ethylamino)-cyclohexyl]-N4,N4-	424 (M + H)	3
	dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
1485	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-	450 (M + H)	2
	cyclohexyl]-5,6,7,8-tetrahydro-quinazoline-2,4-diamine
1486	N2-{cis-4-[(3-ethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-	424 (M + H)	3
	5,6,7,8-tetrahydroquinazoline-2,4-diamine
1487	N2-(cis-4-{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-	544 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1488	N2-(cis-4-{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-	460 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1489	3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	476 (M + H)	2
	2-yl]amino}cyclohexyl)amino]ethyl}(3-methylphenyl)-
	amino]propanenitrile
1490	3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	462 (M + H)	1
	2-yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]-
	propanenitrile
1491	N-{(1S)-1-benzyl-2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	577 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]ethyl}-4-
	methylbenzenesulfonamide
1492	(2-{[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-	490 (M + H)	3
	2-ylamino)-cyclohexylamino]-methyl}-cyclohexyl)-
	phenyl-methanol
1493	N2-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino}cyclohexyl)-	454 (M + H)	2
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1494	N4,N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indol-3-	509 (M + H)	3
	yl)ethyl]amino}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1495	N2-(cis-4-{[2,2-bis(4-chlorophenyl)ethyl]amino}cyclohexyl)-	538 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1496	(3-{(1S)-2-[(cis-4-([4-(dimethylamino)-5,6,7,8-	512 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]-1-
	methylethyl}phenyl)(phenyl)methanol
1497	N2-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)-	525 (M + H)	1
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1498	N2-[cis-4-({[2-(4-bromophenyl)ethyl]amino}methyl)cyclohexyl]-	486 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1499	N2-[cis-4-({[4-(4-methoxyphenyl)butyl]amino}methyl)-	466 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1500	N4,N4-dimethyl-N2-(cis-4-{[(6-phenylhexyl)amino]methyl}-	464 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1501	N2-(cis-4-{[(2-mesitylethyl)amino]methyl}cyclohexyl)-N4,N4-	450 (M + H)	3
	dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1502	N4,N4-dimethyl-N2-(cis-4-{[(8-phenyloctyl)amino]methyl}-	492 (M + H)	3
	cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1503	N2-[cis-4-({[2-(4-tert-butylphenyl)ethyl]amino}methyl)-	464 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1504	N2-[cis-4-({[2-(2-methoxyphenyl)ethyl]amino}methyl)-	438 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1505	N4,N4-dimethyl-N2-(cis-4-{[(3-phenoxypropyl)amino]-	438 (M + H)	3
	methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1506	N2-(cis-4-{[(5-chloro-2-methoxybenzyl)amino]methyl}-	458 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1507	N2-(cis-4-{[(4-chloro-2-methoxybenzyl)amino]methyl}-	458 (M + H)	3
	cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1508	N2-(cis-4-{[(3-iodo-4-methylbenzyl)amino]methyl}cyclohexyl)-	534 (M + H)	3
	N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1509	N2-[cis-4-({[(2S)-2-(dibenzylamino)propyl]amino}methyl)-	541 (M + H)	3
	cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-
	2,4-diamine
1510	N4,N4-dimethyl-N2-[cis-4-({[(1-phenyl-5-propyl-1H-pyrazol-4-	502 (M + H)	1
	yl)methyl]amino)methyl)cyclohexyl]-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1511	N2-{cis-4-[({[1-(4-chlorophenyl)-5-propyl-1H-pyrazol-4-	536 (M + H)	1
	yl]methyl}amino)methyl]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-
	tetrahydroquinazoline-2,4-diamine
1512	N4,N4-dimethyl-N2-[cis-4-({[4-(4-nitrophenyl)butyl]amino}-	481 (M + H)	3
	methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine
1513	N2-(cis-4-{[2-(4-bromophenyl)ethyl]amino}cyclohexyl)-N4,N4-	418 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1514	N2-(cis-4-{[2-(3-chlorophenyl)ethyl]amino}cyclohexyl)-N4,N4-	374 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1515	N2-(cis-4-{[2-(2-chlorophenoxy)ethyl]amino}cyclohexyl)-	390 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1516	N2-{cis-4-[(2-methoxy-2-phenylethyl)amino]cyclohexyl}-N4,N4-	370 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1517	N2-[4-(2-Methoxy-2-phenyl-ethylamino)-cyclohexyl]-N4,N4-	370 (M + H)	3
	dimethyl-pyrimidine-2,4-diamine
1518	N2-(cis-4-{[2-(4-bromophenoxy)ethyl]amino}cyclohexyl)	434 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1519	N4,N4-Dimethyl-N2-[4-(pentamethylphenylmethyl-amino)-	396 (M + H)	3
	cyclohexyl]-pyrimidine-2,4-diamine
1520	N2-{cis-4-[(3-ethoxybenzyl)amino]cyclohexyl}-N4,N4-	370 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1521	N2-(cis-4-{[(2S)-2,3-bis(benzyloxy)propyl]amino}cyclohexyl)-	490 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1522	N2-(cis-4-{[(3-methoxy-2-naphthyl)methyl]amino}cyclohexyl)-	406 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1523	3-[{2-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)amino]ethyl}(3-methylphenyl)-
	amino]propanenitrile
1524	3-[{2-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	408 (M + H)	3
	yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]propanenitrile
1525	N2-[cis-4-({[4-(4-methoxyphenyl)butyl]amino}methyl)-	412 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1526	N4,N4-dimethyl-N2-(cis-4-{[(6-	410 (M + H)	3
	phenylhexyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1527	N2-(cis-4-{[(2-mesitylethyl)amino]methyl}cyclohexyl)-N4,N4-	396 (M + H)	3
	dimethylpyrimidine-2,4-diamine
1528	N4,N4-dimethyl-N2-(cis-4-{[(8-	438 (M + H)	3
	phenyloctyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1529	N2-[cis-4-({[2-(4-tert-butylphenyl)ethyl]amino}methyl)-	410 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1530	N4,N4-dimethyl-N2-(cis-4-{[(5-phenylpent-4-yn-1-	392 (M + H)	3
	yl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine
1531	N2-[cis-4-({[2-(2-methoxyphenyl)ethyl]amino}methyl)-	384 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1532	N4,N4-dimethyl-N2-(cis-4-{[(3-phenoxypropyl)amino]-	384 (M + H)	3
	methyl}cyclohexyl)pyrimidine-2,4-diamine
1533	N4,N4-dimethyl-N2-(cis-4-{[(2,3,5,6-tetrafluorobenzyl)amino]-	412 (M + H)	3
	methyl}cyclohexyl)pyrimidine-2,4-diamine
1534	N2-(cis-4-{[(2,5-dichlorobenzyl)amino]methyl}cyclohexyl)-	408 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1535	N2-(cis-4-{[(5-chloro-2-methoxybenzyl)amino]methyl}-	404 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1536	N2-(cis-4-{[(4-chloro-2-methoxybenzyl)amino]methyl}-	404 (M + H)	3
	cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine
1537	N2-(cis-4-{[(3-iodo-4-methylbenzyl)amino]methyl}cyclohexyl)-	480 (M + H)	3
	N4,N4-dimethylpyrimidine-2,4-diamine
1538	N2-[cis-4-({[(2S)-2-(dibenzylamino)propyl]amino}methyl)-	487 (M + H)	3
	cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine
1539	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)quinolin-2-	463 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1540	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)quinolin-2-	399 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1541	“[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic	524 (M + H)	2
	acid 4,5-dimethoxy-2-nitro-benzyl ester
1542	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1543	4-bromophenyl (cis-4-{[4-(dimethylamino)quinolin-2-	483 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1544	2-methoxyphenyl (cis-4-{[4-(dimethylamino)quinolin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1545	2-methoxyethyl (cis-4-{[4-(dimethylamino)quinolin-2-	387 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1546	octyl (cis-4-{[4-(dimethylamino)quinolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1547	ethyl (cis-4-{[4-(dimethylamino)quinolin-2-	357 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1548	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic	464 (M + H)	3
	acid 4-nitro-benzyl ester
1549	2-naphthyl (cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1550	allyl (cis-4-{[4-(dimethylamino)quinolin-2-	369 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1551	[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-carbamic	419 (M + H)	3
	acid benzyl ester
1552	phenyl (cis-4-{[4-(dimethylamino)quinolin-2-	405 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1553	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-	467 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)carbamate
1554	4-methylphenyl (cis-4-{[4-(dimethylamino)quinolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1555	methyl (cis-4-{[4-(dimethylamino)quinolin-2-	343 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1556	2-chlorobenzyl (cis-4-{[4-(dimethylamino)quinolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1557	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)quinolin-2-	507 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1558	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)quinolin-2-	459 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1559	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1560	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)quinolin-2-	413 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1561	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)-	538 (M + H)	3
	quinolin-2-yl]amino}cyclohexyl)methyl]carbamate
1562	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)quinolin-2-	487 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1563	4-bromophenyl [(cis-4-{[4-(dimethylamino)quinolin-2-	497 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1564	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)quinolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1565	2-methoxyethyl [(cis-4-{[4-(dimethylamino)quinolin-2-	401 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1566	octyl [(cis-4-{[4-(dimethylamino)quinolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1567	ethyl [(cis-4-{[4-(dimethylamino)quinolin-2-	371 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1568	4-nitrobenzyl [(cis-4-{[4-(dimethylamino)quinolin-2-	478 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1569	2-naphthyl [(cis-4-{[4-(dimethylamino)quinolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1570	allyl [(cis-4-{[4-(dimethylamino)quinolin-2-	383 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1571	benzyl [(cis-4-{[4-(dimethylamino)quinolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1572	phenyl [(cis-4-{[4-(dimethylamino)quinolin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1573	(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-	481 (M + H)	3
	{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-
	carbamate
1574	4-methylphenyl [(cis-4-{[4-(dimethylamino)quinolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1575	methyl [(cis-4-{[4-(dimethylamino)quinolin-2-	357 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1576	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)quinolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1577	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)quinolin-2-	521 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1578	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)quinolin-2-	473 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1579	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	468 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1580	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	404 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1581	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	529 (M + H)	2
	cyclohexy]-carbamic acid 4,5-dimethoxy-2-nitro-benzyl ester
1582	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	478 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1583	4-bromophenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	488 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1584	2-methoxyphenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	440 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1585	2-methoxyethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	392 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1586	octyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	446 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1587	ethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	362 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1588	4-nitrobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1589	2-naphthyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	460 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1590	allyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	374 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1591	benzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	424 (M + H)	3
	2-yl]amino}cyclohexyl)carbamate
1592	phenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	410 (M + H)	3
	2-yl]amino}cyclohexyl)carbamate
1593	(2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-	472 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)carbamate
1594	4-methylphenyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	424 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1595	methyl (cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	348 (M + H)	3
	2-yl]amino}cyclohexyl)carbamate
1596	2-chlorobenzyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	458 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1597	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	512 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1598	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)-5,6,7,8-	464 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)carbamate
1599	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	482 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1600	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	418 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1601	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	543 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1602	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	492 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1603	4-bromophenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	502 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1604	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	454 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1605	2-methoxyethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	406 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1606	octyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1607	ethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	376 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1608	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	483 (M + H)	3
	cyclohexylmethyl]-carbamic acid 4-nitro-benzyl ester
1609	2-naphthyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	474 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1610	allyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	388 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1611	[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	438 (M + H)	3
	cyclohexylmethyl]-carbamic acid benzyl ester
1612	phenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	424 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]carbamate
1613	(2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-	486 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)methyl]carbamate
1614	4-methylphenyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	438 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1615	methyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	362 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]carbamate
1616	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	472 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1617	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	526 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1618	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)-5,6,7,8-	478 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]carbamate
1619	2-(benzyloxy)ethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	414 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1620	2,2-dimethylpropyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	350 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1621	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamid	475 (M + H)	3
	acid 4,5-dimethoxy-2-nitro-benzyl ester
1622	3-(trifluoromethyl)phenyl (cis-4-{[4-(dimethylamino)pyrimidin-	424 (M + H)	3
	2-yl]amino}cyclohexyl)carbamate
1623	4-bromophenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	434 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1624	2-methoxyphenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	386 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1625	2-methoxyethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	338 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1626	octyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	392 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1627	ethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	308 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1628	4-nitrobenzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1629	2-naphthyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1630	allyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	320 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1631	benzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	370 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1632	phenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	356 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1633	(2S,5R)-2-isopropyl-5-methylcyclohexyl (cis-4-{[4-	418 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)carbamate
1634	4-methylphenyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	370 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1635	methyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	294 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1636	2-chlorobenzyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	404 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1637	9H-fluoren-9-ylmethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	458 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1638	2,2,2-trichloroethyl (cis-4-{[4-(dimethylamino)pyrimidin-2-	410 (M + H)	3
	yl]amino}cyclohexyl)carbamate
1639	2-(benzyloxy)ethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1640	2,2-dimethylpropyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	364 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1641	4,5-dimethoxy-2-nitrobenzyl [(cis-4-{[4-(dimethylamino)-	489 (M + H)	3
	pyrimidin-2-yl]amino}cyclohexyl)methyl]carbamate
1642	3-(trifluoromethyl)phenyl [(cis-4-{[4-(dimethylamino)pyrimidin-	438 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]carbamate
1643	4-bromophenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1644	2-methoxyphenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1645	2-methoxyethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	352 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1646	octyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1647	ethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	322 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1648	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-	429 (M + H)	3
	carbamic acid 4-nitro-benzyl ester
1649	2-naphthyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	420 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1650	allyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	334 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1651	[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-	384 (M + H)	3
	carbamic acid benzyl ester
1652	phenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	370 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1653	(2S,5R)-2-isopropyl-5-methylcyclohexyl [(cis-4-{[4-	432 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-
	carbamate
1654	4-methylphenyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1655	methyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	308 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1656	2-chlorobenzyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	418 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1657	9H-fluoren-9-ylmethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	472 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1658	2,2,2-trichloroethyl [(cis-4-{[4-(dimethylamino)pyrimidin-2-	424 (M + H)	3
	yl]amino}cyclohexyl)methyl]carbamate
1659	N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	443 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1660	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,6-dimethylphenyl)urea
1661	N-(2,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1662	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	1
	yl]amino}cyclohexyl)-N′-(2-ethyl-6-methylphenyl)urea
1663	ethyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	475 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}leucinate
1664	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	427 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea
1665	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(methylthio)phenyl]urea
1666	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	477 (M + H)	3
	yl]amino{cyclohexyl)-N′-[2-(trifluoromethyl)phenyl]urea
1667	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	1
	yl]amino}cyclohexyl)-N′-mesitylurea
1668	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	423 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methylphenyl)urea
1669	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	511 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea
1670	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	642 (M + H)	1
	yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)urea
1671	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	583 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1672	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	465 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1673	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	511 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1674	N-(2-chloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1675	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	457 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1676	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	479 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)urea
1677	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-ethylphenyl)urea
1678	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	535 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-iodophenyl)urea
1679	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	465 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-isopropyl-6-methylphenyl)urea
1680	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-isopropylphenyl)urea
1681	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methyl-3-nitrophenyl)urea
1682	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-propylphenyl)urea
1683	N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	479 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1684	N-(2-tert-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	465 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1685	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1686	N-(4-bromo-2,6-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	523 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1687	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	511 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1688	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	434 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1689	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	499 (M + H)	1
	yl]amino}cyclohexyl)-N′-(diphenylmethyl)urea
1690	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	515 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1691	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	490 (M + H)	1
	yl]amino}cyclohexyl)-N′-(3-methyl-5-phenylisoxazol-4-yl)urea
1692	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)-N′-[5-methyl-2-(trifluoromethyl)-3-furyl]-
	urea
1693	N-(2-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	487 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1694	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1695	N-butyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	389 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1696	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3-dimethylphenyl)urea
1697	ethyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	481 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1698	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	491 (M + H)	3
	yl]amino}cyclohexyl)-N′-[1-(3-isopropenylphenyl)-1-methyl-
	ethyl]-urea
1699	methyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	479 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}methioninate
1700	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	459 (M + H)	2
	yl]amino}cyclohexyl)-N′-1-naphthylurea
1701	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)-N′-[(2S)-2-phenylcyclopropyl]urea
1702	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	501 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-phenoxyphenyl)urea
1703	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	403 (M + H)	3
	yl]amino}cyclohexyl)-N′-pentylurea
1704	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	487 (M + H)	1
	yl]amino}cyclohexyl)-N′-[1-(1-naphthyl)ethyl]urea
1705	methyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	495 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}-
	phenylalaninate
1706	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(1-phenylethyl)urea
1707	1-[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	437 (M + H)	3
	cyclohexyl]-3-(1-phenyl-ethyl)-urea
1708	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	545 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3,5,6-tetrachlorophenyl)urea
1709	N-(2,4-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	565 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1710	N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	491 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1711	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1712	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-ethoxyphenyl)urea
1713	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-fluorobenzyl)urea
1714	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methyl-4-nitrophenyl)urea
1715	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methyl-5-nitrophenyl)urea
1716	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methylbenzyl)urea
1717	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-nitrophenyl)urea
1718	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	453 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1719	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	499 (M + H)	1
	yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea
1720	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1721	N-(3-chloro-4-methoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1722	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	555 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1723	N-(4-bromobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	501 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1724	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1725	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	2
	yl]amino}cyclohexyl-N′-(4-fluorobenzyl)urea
1726	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-methoxy-2-methylphenyl)urea
1727	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	503 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1728	N-[1-(4-bromophenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-	515 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1729	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	501 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1730	ethyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	509 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}-
	phenylalaninate
1731	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-(dimethylamino)-	467 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1732	N-(2,6-dibromo-4-isopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	607 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1733	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N′-(cis-4-{[4-	523 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)urea
1734	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N′-(cis-4-{[4-	481 (M + H)	3
	(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)urea
1735	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	479 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1736	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	490 (M + H)	1
	yl]amino}cyclohexyl)-N′-(5-methyl-3-phenylisoxazol-4-yl)urea
1737	N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	503 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1738	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	450 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1739	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1740	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1741	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,6-dimethylphenyl)thiourea
1742	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino)}cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)thiourea
1743	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxyphenyl)thiourea
1744	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	475 (M + H)	3
	yl]amino}cyclohexyl)-N′-1-naphthylthiourea
1745	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	515 (M + H)	1
	yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea
1746	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1747	N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)-	518 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1748	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-ethylphenyl)thiourea
1749	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxy-4-nitrophenyl)thiourea
1750	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-methoxy-5-methylphenyl)thiourea
1751	N-(4-bromo-2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	537 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1752	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	551 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-iodophenyl)thiourea
1753	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	658 (M + H)	1
	yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)thiourea
1754	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	527 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)thiourea
1755	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	1
	yl]amino}cyclohexyl)-N′-mesitylthiourea
1756	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2,4-dimethylphenyl)thiourea
1757	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	481 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1758	N-(2-bromo-4-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	517 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1759	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1760	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-ethyl-6-methylphenyl)thiourea
1761	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-isopropylphenyl)thiourea
1762	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	483 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	benzoate
1763	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	531 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1764	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	517 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1765	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	571 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1766	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1767	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	489 (M + H)	3
	yl]amino}cyclohexyl)-N′-(1-naphthylmethyl)thiourea
1768	N-(2,3-dimethoxybenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	499 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1769	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,4,5-trimethylphenyl)thiourea
1770	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	501 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1771	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	482 (M − H)	3
	yl]amino}cyclohexyl)-N′-(2-methyl-4-nitrophenyl)thiourea
1772	N-(3-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1773	ethyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-
	2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-	497 (M + H)	3
	benzoate
1774	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-	527 (M + H)	2
	thiourea
1775	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	457 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-fluoro-2-methylphenyl)thiourea
1776	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-methoxy-2-methylphenyl)thiourea
1777	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	519 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1778	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-[(1R)-1-phenylethyl]thiourea
1779	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3-dimethylphenyl)thiourea
1780	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	599 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1781	N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	507 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1782	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-ethoxyphenyl)thiourea
1783	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-isopropyl-6-methylphenyl)thiourea
1784	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-(dimethylamino)-	483 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1785	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1786	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1787	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N′-(cis-4-{[4-	587 (M + H)	2
	(dimethyl-amino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-
	cyclohexyl)-thiourea
1788	N-(4-chloro-2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	519 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1789	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	506 (M + H)	3
	yl]amino}cyclohexyl)-N′-(5-methyl-3-phenylisoxazol-4-yl)-
	thiourea
1790	1-Bicyclo[2.2.1]hept-2-yl-3-[4-(4-dimethylamino-5,6,7,8-	443 (M + H)	3
	tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-thiourea
1791	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	503 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	4-methylthiophene-2-carboxylate
1792	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	489 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	thiophene-2-carboxylate
1793	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	495 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1794	N-(3,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1795	N-(2,3-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1796	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	423 (M + H)	2
	yl]amino}cyclohexyl)-N′-(4-methylphenyl)urea
1797	N-(2,6-diisopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1798	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3-dimethyl-6-nitrophenyl)urea
1799	N-(2,6-dibromo-4-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	583 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1800	N-(2,6-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1801	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxy-5-methylphenyl)urea
1802	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methyl-6-nitrophenyl)urea
1803	N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1804	N-(3,5-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1805	N-(3-chloro-4-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	461 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1806	N-(3-acetylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	451 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1807	N-1-adamantyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	467 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1808	N-(4-acetylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	451 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1809	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}benzamide
1810	N-(tert-butyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	389 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1811	N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	545 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1812	N-benzyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	423 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1813	N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	487 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1814	N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	443 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1815	N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	443 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1816	N-cyclohexyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	415 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1817	N-(3-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	434 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1818	N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1819	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1820	N-(2,6-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1821	N-(2,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	477 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1822	ethyl N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	419 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}glycinate
1823	ethyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	481 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1824	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-ethylphenyl)urea
1825	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	361 (M + H)	3
	yl]amino}cyclohexyl)-N′-ethylurea
1826	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	472 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-fluoro-3-nitrophenyl)urea
1827	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	427 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-fluorophenyl)urea
1828	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	427 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-fluorophenyl)urea
1829	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-isopropylphenyl)urea
1830	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	375 (M + H)	3
	yl]amino}cyclohexyl)-N′-isopropylurea
1831	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxyphenyl)urea
1832	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methyl-2-nitrophenyl)urea
1833	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxyphenyl)urea
1834	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)urea
1835	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxybenzyl)urea
1836	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methylbenzyl)urea
1837	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	375 (M + H)	3
	yl]amino}cyclohexyl)-N′-propylurea
1838	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-(trifluoromethyl)phenyl]urea
1839	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	537 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-(triethoxysilyl)propyl]urea
1840	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	423 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methylphenyl)urea
1841	N-(3-chloro-4-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1842	1-[4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-	487 (M + H)	3
	cyclohexyl]-3-(1-naphthalen-1-yl-ethyl)-urea
1843	N-[2-(difluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	475 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1844	methyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	467 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1845	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(methylthio)phenyl]urea
1846	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	511 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2,4,5-trichlorophenyl)urea
1847	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,4-dimethylphenyl)urea
1848	N-(2,5-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1849	N-(2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1850	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,5-dimethylphenyl)urea
1851	N-(2-benzylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	499 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1852	N-(2-bromo-4,6-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	523 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1853	N-[2-chloro-4-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	511 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	urea
1854	N-(2-chloro-4-nitrophenyl)-N′-(cis-4-{[4-(dimethylamino)-	488 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1855	N-[2-chloro-5-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	511 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	urea
1856	N-(2-chloro-5-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1857	ethyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	481 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1858	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-fluoro-3-(trifluoromethyl)phenyl]-
	urea
1859	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-fluoro-5-(trifluoromethyl)phenyl]-
	urea
1860	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-fluoro-5-methylphenyl)urea
1861	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxy-4-nitrophenyl)urea
1862	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxy-5-nitrophenyl)urea
1863	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	459 (M + H)	3
	yl]amino}cyclohexyl)-N′-2-naphthylurea
1864	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	501 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-phenoxyphenyl)urea
1865	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-(methylthio)phenyl]urea
1866	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	509 (M + H)	3
	yl]amino}cyclohexyl)-N′-{3-[(trifluoromethyl)thio]phenyl}urea
1867	N-(3,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	491 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1868	N-(3,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	469 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1869	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3,5-dimethylphenyl)urea
1870	methyl 3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	467 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1871	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-ethylphenyl)urea
1872	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-fluoro-5-(trifluoromethyl)phenyl]-
	urea
1873	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-fluorobenzyl)urea
1874	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-nitrophenyl)urea
1875	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	501 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-phenoxyphenyl)urea
1876	N-[4-(difluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	475 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1877	butyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	509 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1878	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(trifluoromethyl)phenyl]urea
1879	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	509 (M + H)	3
	yl]amino}cyclohexyl)-N′-{4-[(trifluoromethyl)thio]phenyl}urea
1880	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4,5-dimethyl-2-nitrophenyl)urea
1881	N-[4-(benzyloxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	515 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1882	N-(4-benzylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	499 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1883	N-(4-bromo-2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	521 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1884	N-(4-bromo-2-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	505 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1885	N-(4-bromo-3-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	501 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1886	N-(4-chloro-2-nitrophenyl)-N′-(cis-4-{[4-(dimethylamino)-	488 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1887	N-4[4-chloro-3-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	511 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1888	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-ethoxyphenyl)urea
1889	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	472 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-fluoro-2-nitrophenyl)urea
1890	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-fluoro-3-(trifluoromethyl)phenyl]-
	urea
1891	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	523 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(heptyloxy)phenyl]urea
1892	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	535 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-iodophenyl)urea
1893	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxy-2-nitrophenyl)urea
1894	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methyl-3-nitrophenyl)urea
1895	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methylbenzyl)urea
1896	N-(4-butoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	481 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1897	N-(4-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	465 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1898	N-biphenyl-4-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1899	N-(5-chloro-2-methoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1900	N-(5-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1901	N-(5-chloro-2-nitrophenyl)-N′-(cis-4-{[4-(dimethylamino)-	488 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1902	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)-N′-(5-fluoro-2-methylphenyl)urea
1903	N-(2,3-dihydro-1H-inden-5-yl)-N′-(cis-4-{[4-(dimethylamino)-	449 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1904	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	497 (M + H)	3
	yl]amino}cyclohexyl)-N′-9H-fluoren-2-ylurea
1905	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	497 (M + H)	3
	yl]amino}cyclohexyl)-N′-9H-fluoren-9-ylurea
1906	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-phenylethyl)urea
1907	N-cyclopentyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	401 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1908	methyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	467 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1909	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	2
	yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea
1910	butyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	509 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	benzoate
1911	dimethyl 5-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	525 (M + H)	3
	2-yl]amino{cyclohexyl)amino]carbonyl}amino)-
	isophthalate
1912	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(trifluoromethoxy)phenyl]urea
1913	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	539 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,2,4,4-tetrafluoro-4H-1,3-
	benzodioxin-6-yl)urea
1914	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(2-thienyl)ethyl]urea
1915	N-(2-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	434 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1916	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)-N′-2-thienylurea
1917	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)-N′-3-thienylurea
1918	N-(4-tert-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	465 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1919	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	491 (M + H)	3
	yl]amino}cyclohexyl)-N′-(5-phenyl-2-thienyl)urea
1920	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	485 (M + H)	3
	yl]amino}cyclohexyl)-N′-(6-fluoro-4H-1,3-benzodioxin-8-yl)urea
1921	benzyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	550 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonyl}amino)-
	piperidine-1-carboxylate
1922	N-[4-(dimethylamino)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	452 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1923	N-(2,6-dichloropyridin-4-yl)-N′-(cis-4-{[4-(dimethylamino)-	478 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea
1924	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	428 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3,5-dimethylisoxazol-4-yl)urea
1925	N-(3-acetylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	467 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1926	N-(4-acetylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	465 (M − H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1927	N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethyl-	561 (M + H)	3
	amino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1928	N-benzyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	439 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1929	N-(3-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	503 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1930	N-butyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	405 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1931	N-cyclohexyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	431 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1932	N-cyclopentyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	417 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1933	N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1934	N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1935	N-(2,5-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	461 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1936	N-(2,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1937	N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino{cyclohexyl)thiourea
1938	N-(2,6-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1939	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-ethoxyphenyl)thiourea
1940	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-furylmethyl)thiourea
1941	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-fluorophenyl)thiourea
1942	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)-N′-hexylthiourea
1943	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	549 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(trans-4-propylcyclohexyl)phenyl]-
	thiourea
1944	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	405 (M + H)	3
	yl]amino}cyclohexyl)-N′-isobutylthiourea
1945	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	531 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxybiphenyl-3-yl)thiourea
1946	N-(1,3-benzodioxol-5-ylmethyl)-N′-(cis-4-{[4-(dimethylamino)-	483 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1947	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methylphenyl)thiourea
1948	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(methylthio)phenyl]thiourea
1949	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M − H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxyphenyl)thiourea
1950	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	403 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methylprop-2-en-1-yl)thiourea
1951	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	363 (M + H)	3
	yl]amino}cyclohexyl)-N′-methylthiourea
1952	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	470 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-nitrophenyl)thiourea
1953	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	470 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-nitrophenyl)thiourea
1954	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	461 (M + H)	3
	yl]amino}cyclohexyl)-N′-(1,1,3,3-tetramethylbutyl)thiourea
1955	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	425 (M + H)	3
	yl]amino}cyclohexyl)-N′-phenylthiourea
1956	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	391 (M + H)	3
	yl]amino}cyclohexyl)-N′-propylthiourea
1957	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-(trifluoromethyl)phenyl]thiourea
1958	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)-N′-(tetrahydrofuran-2-ylmethyl)thiourea
1959	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methylphenyl)thiourea
1960	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	439 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methylphenyl)thiourea
1961	N-(tert-butyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	405 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1962	N-1-adamantyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	483 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1963	N-(2-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	503 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1964	N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1965	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-phenylethyl)thiourea
1966	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-ethylphenyl)thiourea
1967	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(methylthio)phenyl]thiourea
1968	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	509 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]thiourea
1969	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(trifluoromethyl)phenyl]thiourea
1970	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	479 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3,4-trifluorophenyl)thiourea
1971	N-(2,3-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1972	N-(2,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	461 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1973	N-(2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1974	N-(2,6-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	461 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1975	N-(2-chloro-4-nitrophenyl)-N′-(cis-4-{[4-(dimethylamino)-	504 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1976	N-[2-(difluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	491 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1977	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	511 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-fluoro-5-(trifluoromethyl)phenyl]-
	thiourea
1978	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-fluorophenyl)thiourea
1979	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	551 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-iodophenyl)thiourea
1980	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	525 (M + H)	3
	yl]amino}cyclohexyl)-N′-{3-[(trifluoromethyl)thio]phenyl}-
	thiourea
1981	N-(3,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	493 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1982	N-(3,5-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	461 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1983	N-(3-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	450 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1984	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-fluorophenyl)thiourea
1985	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	551 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-iodophenyl)thiourea
1986	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)thiourea
1987	N-[4-(difluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	491 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1988	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	509 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(trifluoromethoxy)phenyl]thiourea
1989	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(trifluoromethyl)phenyl]thiourea
1990	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	525 (M + H)	3
	yl]amino}cyclohexyl)-N′-{4-[(trifluoromethyl)thio]phenyl}-
	thiourea
1991	N-(4-bromo-2-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	520 (M)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1992	N-[4-chloro-3-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethyl-	527 (M + H)	3
	amino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
1993	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	511 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-fluoro-3-(trifluoromethyl)phenyl]-
	thiourea
1994	N-(5-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1995	N-bicyclo[2.2.1]hept-2-yl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	443 (M + H)	3
	tetrahydroquinazolin-2-ylπamino}cyclohexyl)thiourea
1996	tert-butyl [4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	540 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl)amino)-
	phenyl]carbamate
1997	N-[2-(3,4-dimethoxyphenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-	513 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1998	N-[2-(4-chlorophenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-	487 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
1999	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	561 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,3,4,5-tetrachlorophenyl)thiourea
2000	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	527 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,4,5-trichlorophenyl)thiourea
2001	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	479 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,4,6-trifluorophenyl)thiourea
2002	N-(2,6-diisopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	509 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2003	N-[2-chloro-5-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethyl-	527 (M + H)	3
	amino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	thiourea
2004	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)-N′-[3-(methylthio)phenyl]thiourea
2005	N-(3,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	507 (M + H)	3
	tetrahydroquinazolin-2-yl]amino{cyclohexyl)thiourea
2006	N-(3,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	485 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2007	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3,5-dimethylphenyl)thiourea
2008	N-[3-(benzyloxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	531 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2009	3-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoic acid
2010	N-(3-chloro-4-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	473 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2011	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-phenylpropyl)thiourea
2012	N-[4-(diethylamino)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	496 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2013	ethyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	497 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	benzoate
2014	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	471 (M + H)	3
	yl]amino}cyclohexyl)-N′-[1-(4-fluorophenyl)ethyl]thiourea
2015	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-fluorobenzyl)thiourea
2016	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	466 (M)	3
	yl]amino}cyclohexyl)-N′-(4-isopropylphenyl)thiourea
2017	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxy-2-nitrophenyl)thiourea
2018	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methoxybenzyl)thiourea
2019	methyl 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro-	483 (M + H)	3
	quinazolin-2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	benzoate
2020	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methyl-2-nitrophenyl)thiourea
2021	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-methylbenzyl)thiourea
2022	N-(4-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	481 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2023	N-(5-chloro-2-methoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-	489 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2024	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(1-phenylethyl)thiourea
2025	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	515 (M + H)	3
	yl]amino}cyclohexyl)-N′-(diphenylmethyl)thiourea
2026	N-cyclododecyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	515 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2027	N-(cyclohexylmethyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2028	N-cyclopropyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2029	N-cyclopropyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	389 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2030	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	529 (M)	2
	yl]amino}cyclohexyl)-N′-(2,2-diphenylethyl)thiourea
2031	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	561 (M + H)	3
	yl]amino}cyelohexyl)-N′-(2,3,5,6-tetrachlorophenyl)thiourea
2032	N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	507 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2033	N-(2,5-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	581 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2034	N-[2-(2,5-dimethoxyphenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-	513 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2035	N-(2-chloro-5-nitrophenyl)-N′-(cis-4-{[4-(dimethylamino)-	504 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2036	N-(2-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	450 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2037	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-fluorobenzyl)thiourea
2038	N-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}-2-furamide
2039	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	500 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxy-5-nitrophenyl)thiourea
2040	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methylbenzyl)thiourea
2041	N-(3,4-dimethoxybenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	499 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2042	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-ethylphenyl)thiourea
2043	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	457 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-fluorobenzyl)thiourea
2044	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methoxybenzyl)thiourea
2045	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl)amino}cyclohexyl)-N′-(3-methylbenzyl)thiourea
2046	N-(4-bromo-3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	537 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2047	N-(4-bromo-3-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	517 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2048	N-(4-decylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	565 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2049	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	562 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(4-nitrophenoxy)phenyl]thiourea
2050	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	578 (M + H)	3
	yl]amino}cyclohexyl)-N′-{4-[(4-nitrophenyl)thio]phenyl}thiourea
2051	4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	502 (M − H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	benzenesulfonamide
2052	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)-N′-[2-(4-methylphenyl)ethyl]thiourea
2053	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	517 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-phenoxyphenyl)thiourea
2054	N-(2,3-dihydro-1H-inden-5-yl)-N′-(cis-4-{[4-(dimethylamino)-	465 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2055	N-cycloheptyl-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	445 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2056	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	387 (M + H)	3
	yl]amino}cyclohexyl)-N′-prop-2-yn-1-ylthiourea
2057	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	572 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(piperidin-1-ylsulfonyl)phenyl]-
	thiourea
2058	N-(2-cyclohex-1-en-1-ylethyl)-N′-(cis-4-{[4-(dimethylamino)-	457 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2059	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2,5-dimethylphenyl)thiourea
2060	N-(2-bromo-4-isopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-	545 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2061	N-(2-bromo-5-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	521 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2062	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-methoxybenzyl)thiourea
2063	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	453 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3,4-dimethylphenyl)thiourea
2064	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	481 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-phenylbutyl)thiourea
2065	N-(4-tert-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	481 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2066	N-(5-chloro-2-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	477 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2067	N-bicyclo[2.2.1]hept-5-en-2-yl-N′-(cis-4-{[4-(dimethylamino)-	441 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2068	N-(cyclopropylmethyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	403 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2069	ethyl 2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-	557 (M + H)	3
	2-yl]amino}cyclohexyl)amino]carbonothioyl}amino)-
	4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
2070	N-(2-bromo-4-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	521 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2071	N-(3-chloro-4-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-	477 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2072	N-[4-(dimethylamino)phenyl]-N′-(cis-4-{[4-(dimethylamino)-	468 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2073	N-[3-(diethylamino)propyl]-N′-(cis-4-{[4-(dimethylamino)-	462 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2074	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	462 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-morpholin-4-ylethyl)thiourea
2075	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	642 (M + H)	3
	yl]amino}cyclohexyl)-N′-(4-phenanthro[9,10-d][1,3]oxazol-2-
	ylphenyl)thiourea
2076	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	426 (M + H)	3
	yl]amino}cyclohexyl)-N′-pyridin-3-ylthiourea
2077	N-(4-{(E)-[4-(dimethylamino)phenyl]diazenyl}phenyl)-N′-(cis-4-	572 (M + H)	3
	{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-
	yl]amino}cyclohexyl)thiourea
2078	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	476 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-morpholin-4-ylpropyl)thiourea
2079	N-(4-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-	473 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2080	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	529 (M + H)	3
	yl]amino}cyclohexyl)-N′-{4-[(E)-phenyldiazenyl]phenyl}thiourea
2081	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)-N′-(2-piperidin-1-ylethyl)thiourea
2082	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	491 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(1H-pyrazol-1-yl)phenyl]thiourea
2083	N-2,1,3-benzothiadiazol-4-yl-N′-(cis-4-{[4-(dimethylamino)-	483 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2084	N-2,1,3-benzothiadiazol-5-yl-N′-(cis-4-{[4-(dimethylamino)-	483 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea
2085	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3,5-dimethylisoxazol-4-yl)thiourea
2086	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	492 (M + H)	3
	yl]amino}cyclohexyl)-N′-[4-(1,3-oxazol-5-yl)phenyl]thiourea
2087	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	511 (M + H)	3
	yl]amino}cyclohexyl)-N′-(6-morpholin-4-ylpyridin-3-yl)thiourea
2088	N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	518 (M + H)	3
	yl]amino}cyclohexyl)-N′-(6-phenoxypyridin-3-yl)thiourea
2089	N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	438 (M + H)	2
	yl]amino}cyclohexyl)urea
2090	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	432 (M + H)	3
	N′-(2,6-dimethylphenyl)urea
2091	N-(2,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)urea
2092	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	446 (M + H)	2
	N′-(2-ethyl-6-methylphenyl)urea
2093	ethyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-	470 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}leucinate
2094	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	422 (M + H)	3
	N′-(4-fluorophenyl)urea
2095	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	450 (M + H)	3
	N′-[4-(methylthio)phenyl]urea
2096	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	472 (M + H)	3
	N′-[2-(trifluoromethyl)phenyl]urea
2097	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	446 (M + H)	1
	N′-mesitylurea
2098	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	418 (M + H)	3
	N′-(2-methylphenyl)urea
2099	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	506 (M + H)	2
	N′-(2,4,6-trichlorophenyl)urea
2100	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	637 (M + H)	1
	N′-(2,4,6-tribromophenyl)urea
2101	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-	578 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2102	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	1
	yl]amino}cyclohexyl)urea
2103	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	506 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2104	N-(2-chloro-6-methylphenyl)-N′-(cis-4-{[4-	452 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2105	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	452 (M + H)	2
	yl]amino}cyclohexyl)urea
2106	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	474 (M + H)	2
	N′-(2-ethyl-6-isopropylphenyl)urea
2107	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	432 (M + H)	3
	N′-(2-ethylphenyl)urea
2108	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	530 (M + H)	3
	N′-(2-iodophenyl)urea
2109	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	460 (M + H)	2
	N′-(2-isopropyl-6-methylphenyl)urea
2110	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	N′-(2-isopropylphenyl)urea
2111	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	463 (M + H)	3
	N′-(2-methyl-3-nitrophenyl)urea
2112	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	N′-(2-propylphenyl)urea
2113	N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-	474 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2114	N-(2-tert-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)urea
2115	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-	452 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2116	N-(4-bromo-2,6-difluorophenyl)-N′-(cis-4-{[4-	518 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2117	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	506 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2118	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)urea
2119	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	494 (M + H)	2
	N′-(diphenylmethyl)urea
2120	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-	510 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2121	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	485 (M + H)	2
	N′-(3-methyl-5-phenylisoxazol-4-yl)urea
2122	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	476 (M + H)	3
	N′-[5-methyl-2-(trifluoromethyl)-3-furyl]urea
2123	N-(2-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)urea
2124	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	480 (M + H)	3
	yl]amino}cyclohexyl)urea
2125	N-butyl-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)urea
2126	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	432 (M + H)	3
	N′-(2,3-dimethylphenyl)urea
2127	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	476 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate
2128	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	486 (M + H)	3
	N′-[1-(3-isopropenylphenyl)-1-methylethyl]urea
2129	methyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-	474 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}methioninate
2130	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	454 (M + H)	1
	N′-1-naphthylurea
2131	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	444 (M + H)	3
	N′-[(2S)-2-phenylcyclopropyl]urea
2132	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	496 (M + H)	3
	N′-(4-phenoxyphenyl)urea
2133	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	398 (M + H)	3
	N′-pentylurea
2134	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	482 (M + H)	1
	N′-[1-(1-naphthyl)ethyl]urea
2135	methyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-	490 (M + H)	2
	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate
2136	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	432 (M + H)	3
	N′-(1-phenylethyl)urea
2137	1-[4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-3-(1-	432 (M + H)	3
	phenyl-ethyl)-urea
2138	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	540 (M + H)	3
	N′-(2,3,5,6-tetrachlorophenyl)urea
2139	N-(2,4-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	560 (M + H)	3
	yl]amino}cyclohexyl)urea
2140	N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	486 (M + H)	3
	yl]amino}cyclohexyl)urea
2141	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-	464 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2142	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(2-ethoxyphenyl)urea
2143	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	436 (M + H)	3
	N′-(2-fluorobenzyl)urea
2144	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	463 (M + H)	3
	N′-(2-methyl-4-nitrophenyl)urea
2145	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	463 (M + H)	3
	N′-(2-methyl-5-nitrophenyl)urea
2146	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	432 (M + H)	3
	N′-(2-methylbenzyl)urea
2147	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	449 (M + H)	3
	N′-(2-nitrophenyl)urea
2148	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	448 (M + H)	3
	yl]amino}cyclohexyl)urea
2149	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	494 (M + H)	1
	N′-(3,4,5-trimethoxyphenyl)urea
2150	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-	464 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2151	N-(3-chloro-4-methoxyphenyl)-N′-(cis-4-{[4-	468 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2152	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	550 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2153	N-(4-bromobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	496 (M + H)	3
	yl]amino}cyclohexyl)urea
2154	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-	452 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2155	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	436 (M + H)	3
	N′-(4-fluorobenzyl)urea
2156	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(4-methoxy-2-methylphenyl)urea
2157	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	498 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2158	N-[1-(4-bromophenyl)ethyl]-N′-(cis-4-{[4-	510 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2159	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-	496 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2160	ethyl N-{[(cis-4-{[4-(dimethylamino)quinolin-2-	504 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate
2161	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-	462 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2162	N-(2,6-dibromo-4-isopropylphenyl)-N′-(cis-4-{[4-	602 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2163	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N′-(cis-4-{[4-	518 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2164	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N′-(cis-4-{[4-	476 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2165	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-	474 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea
2166	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	485 (M + H)	3
	N′-(5-methyl-3-phenylisoxazol-4-yl)urea
2167	N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	498 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2168	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	445 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2169	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	488 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2170	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-	480 (M + H)	2
	2-yl]amino}cyclohexyl)thiourea
2171	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(2,6-dimethylphenyl)thiourea
2172	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	490 (M + H)	3
	N′-(2-ethyl-6-isopropylphenyl)thiourea
2173	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	450 (M + H)	3
	N′-(2-methoxyphenyl)thiourea
2174	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	470 (M + H)	3
	N′-1-naphthylthiourea
2175	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	510 (M + H)	1
	N′-(3,4,5-trimethoxyphenyl)thiourea
2176	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-	480 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea
2177	N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-	513 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2178	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(2-ethylphenyl)thiourea
2179	N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	389 (M + H)	3
	yl]amino}cyclohexyl)urea
2180	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N′-(2,6-dimethylphenyl)urea
2181	N-(2,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	391 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2182	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M + H)	3
	N′-(2-ethyl-6-methylphenyl)urea
2183	ethyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	421 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}leucinate
2184	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	373 (M + H)	3
	N′-(4-fluorophenyl)urea
2185	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	401 (M + H)	3
	N′-[4-(methylthio)phenyl]urea
2186	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	445 (M + Na)	3
	N′-[2-(trifluoromethyl)phenyl]urea
2187	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M + H)	2
	N′-mesitylurea
2188	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	369 (M + H)	3
	N′-(2-methylphenyl)urea
2189	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	457 (M + H)	1
	N′-(2,4,6-trichlorophenyl)urea
2190	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	588 (M + H)	1
	N′-(2,4,6-tribromophenyl)urea
2191	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-	529 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2192	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)urea
2193	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	457 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2194	N-(2-chloro-6-methylphenyl)-N′-(cis-4-{[4-	403 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2195	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	403 (M + H)	3
	yl]amino}cyclohexyl)urea
2196	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	447 (M + Na)	3
	N′-(2-ethyl-6-isopropylphenyl)urea
2197	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N′-(2-ethylphenyl)urea
2198	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	481 (M + H)	3
	N′-(2-iodophenyl)urea
2199	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	411 (M + H)	3
	N′-(2-isopropyl-6-methylphenyl)urea
2200	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M + H)	3
	N′-(2-isopropylphenyl)urea
2201	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	414 (M + H)	3
	N′-(2-methyl-3-nitrophenyl)urea
2202	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M + H)	3
	N′-(2-propylphenyl)urea
2203	N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-	425 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2204	N-(2-tert-butylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)urea
2205	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-	403 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2206	N-(4-bromo-2,6-difluorophenyl)-N′-(cis-4-{[4-	469 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2207	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	457 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2208	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	380 (M + H)	3
	yl]amino}cyclohexyl)urea
2209	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	445 (M + H)	1
	N′-(diphenylmethyl)urea
2210	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-	461 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2211	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	436 (M + H)	3
	N′-(3-methyl-5-phenylisoxazol-4-yl)urea
2212	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	427 (M + H)	3
	N′-[5-methyl-2-(trifluoromethyl)-3-furyl]urea
2213	N-(2-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	433 (M + H)	3
	yl]amino}cyclohexyl)urea
2214	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	431 (M + H)	3
	yl]amino}cyclohexyl)urea
2215	N-butyl-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	335 (M + H)	3
	yl]amino}cyclohexyl)urea
2216	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N′-(2,3-dimethylphenyl)urea
2217	ethyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	427 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}amino)benzoate
2218	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	437 (M + H)	3
	N′-[1-(3-isopropenylphenyl)-1-methylethyl]urea
2219	methyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	425 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}methioninate
2220	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	405 (M + H)	3
	N′-1-naphthylurea
2221	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	395 (M + H)	3
	N′-[(2S)-2-phenylcyclopropyl]urea
2222	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	447 (M + H)	3
	N′-(4-phenoxyphenyl)urea
2223	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	349 (M + H)	3
	N′-pentylurea
2224	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	433 (M + H)	1
	N′-[1-(1-naphthyl)ethyl]urea
2225	methyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	441 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate
2226	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N′-(1-phenylethyl)urea
2227	1-[4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-(1-	383 (M + H)	3
	phenyl-ethyl)-urea
2228	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	491 (M + H)	3
	N′-(2,3,5,6-tetrachlorophenyl)urea
2229	N-(2,4-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	511 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2230	N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	437 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2231	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	415 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2232	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(2-ethoxyphenyl)urea
2233	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	387 (M + H)	3
	N′-(2-fluorobenzyl)urea
2234	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	414 (M + H)	3
	N′-(2-methyl-4-nitrophenyl)urea
2235	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	414 (M + H)	3
	N′-(2-methyl-5-nitrophenyl)urea
2236	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	383 (M + H)	3
	N′-(2-methylbenzyl)urea
2237	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	400 (M + H)	3
	N′-(2-nitrophenyl)urea
2238	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	399 (M + H)	3
	2-yl]amino}cyclohexyl)urea
2239	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	445 (M + H)	1
	N′-(3,4,5-trimethoxyphenyl)urea
2240	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-	415 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2241	N-(3-chloro-4-methoxyphenyl)-N′-(cis-4-{[4-	419 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2242	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	501 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2243	N-(4-bromobenzyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)urea
2244	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-	403 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2245	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	387 (M + H)	3
	N′-(4-fluorobenzyl)urea
2246	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(4-methoxy-2-methylphenyl)urea
2247	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	449 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2248	N-[1-(4-bromophenyl)ethyl]-N′-(cis-4-{[4-	461 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2249	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-	447 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2250	ethyl N-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-	455 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonyl}phenylalaninate
2251	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-	413 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2252	N-(2,6-dibromo-4-isopropylphenyl)-N′-(cis-4-{[4-	553 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2253	N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N′-(cis-4-{[4-	469 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2254	N-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-N′-(cis-4-{[4-	427 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2255	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-	425 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea
2256	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	436 (M + H)	3
	N′-(5-methyl-3-phenylisoxazol-4-yl)urea
2257	N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2258	N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	396 (M + H)	2
	yl]amino}cyclohexyl)thiourea
2259	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	439 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea
2260	N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	431 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2261	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(2,6-dimethylphenyl)thiourea
2262	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	441 (M + H)	3
	N′-(2-ethyl-6-isopropylphenyl)thiourea
2263	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	401 (M + H)	3
	N′-(2-methoxyphenyl)thiourea
2264	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	421 (M + H)	3
	N′-1-naphthylthiourea
2265	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	461 (M + H)	1
	N′-(3,4,5-trimethoxyphenyl)thiourea
2266	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-	431 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2267	N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-	464 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2268	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(2-ethylphenyl)thiourea
2269	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	495 (M + H)	3
	N′-(2-methoxy-4-nitrophenyl)thiourea
2270	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	464 (M + H)	3
	N′-(2-methoxy-5-methylphenyl)thiourea
2271	N-(4-bromo-2-chlorophenyl)-N′-(cis-4-{[4-	532 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2272	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	546 (M + H)	3
	N′-(4-iodophenyl)thiourea
2273	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	653 (M + H)	1
	N′-(2,4,6-tribromophenyl)thiourea
2274	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	522 (M + H)	2
	N′-(2,4,6-trichlorophenyl)thiourea
2275	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	1
	N′-mesitylthiourea
2276	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(2,4-dimethylphenyl)thiourea
2277	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	476 (M + H)	1
	yl]amino}cyclohexyl)thiourea
2278	N-(2-bromo-4-methylphenyl)-N′-(cis-4-{[4-	512 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2279	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2280	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	3
	N′-(2-ethyl-6-methylphenyl)thiourea
2281	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	3
	N′-(2-isopropylphenyl)thiourea
2282	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	478 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate
2283	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-	526 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2284	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-	512 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2285	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	566 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2286	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-	468 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2287	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	484 (M + H)	3
	N′-(1-naphthylmethyl)thiourea
2288	N-(2,3-dimethoxybenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-	494 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea
2289	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	3
	N′-(2,4,5-trimethylphenyl)thiourea
2290	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	496 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2291	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	479 (M + H)	3
	N′-(2-methyl-4-nitrophenyl)thiourea
2292	N-(3-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	468 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2293	ethyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	492 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate
2294	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	522 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2295	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	452 (M + H)	3
	N′-(4-fluoro-2-methylphenyl)thiourea
2296	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	464 (M + H)	3
	N′-(4-methoxy-2-methylphenyl)thiourea
2297	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	514 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2298	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-[(1R)-1-phenylethyl]thiourea
2299	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	448 (M + H)	3
	N′-(2,3-dimethylphenyl)thiourea
2300	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-	594 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2301	N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-	502 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2302	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	464 (M + H)	3
	N′-(2-ethoxyphenyl)thiourea
2303	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	476 (M + H)	3
	N′-(2-isopropyl-6-methylphenyl)thiourea
2304	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-	478 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2305	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)quinolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2306	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-	468 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2307	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N′-(cis-4-{[4-	582 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2308	N-(4-chloro-2,5-dimethoxyphenyl)-N′-(cis-4-{[4-	514 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2309	N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	501 (M + H)	3
	N′-(5-methyl-3-phenylisoxazol-4-yl)thiourea
2310	N-bicyclo[2.2.1]hept-2-yl-N′-(cis-4-{[4-(dimethylamino)quinolin-	438 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea
2311	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	498 (M + H)	2
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4-
	methylthiophene-2-carboxylate
2312	methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)thiophene-2-
	carboxylate
2313	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-	490 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea
2314	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	446 (M + H)	3
	N′-(2-methoxy-4-nitrophenyl)thiourea
2315	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M − H)	3
	N′-(2-methoxy-5-methylphenyl)thiourea
2316	N-(4-bromo-2-chlorophenyl)-N′-(cis-4-{[4-	483 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2317	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	497 (M + H)	3
	N′-(4-iodophenyl)thiourea
2318	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	604 (M + H)	1
	N′-(2,4,6-tribromophenyl)thiourea
2319	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	473 (M + H)	3
	N′-(2,4,6-trichlorophenyl)thiourea
2320	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	1
	N′-mesitylthiourea
2321	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(2,4-dimethylphenyl)thiourea
2322	N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	427 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2323	N-(2-bromo-4-methylphenyl)-N′-(cis-4-{[4-	463 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2324	N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2325	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	3
	N′-(2-ethyl-6-methylphenyl)thiourea
2326	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	3
	N′-(2-isopropylphenyl)thiourea
2327	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	429 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate
2328	N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-	477 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2329	N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-	463 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2330	N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	517 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2331	N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-	419 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2332	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	435 (M + H)	3
	N′-(1-naphthylmethyl)thiourea
2333	N-(2,3-dimethoxybenzyl)-N′-(cis-4-{[4-	443 (M − H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2334	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	3
	N′-(2,4,5-trimethylphenyl)thiourea
2335	N-biphenyl-2-yl-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	447 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2336	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	428 (M − H)	3
	N′-(2-methyl-4-nitrophenyl)thiourea
2337	N-(3-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-	419 (M + H)	3
	yl]amino}cyclohexyl)thiourea
2338	ethyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	441 (M − H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)benzoate
2339	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	473 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2340	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	403 (M + H)	3
	N′-(4-fluoro-2-methylphenyl)thiourea
2341	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	3
	N′-(4-methoxy-2-methylphenyl)thiourea
2342	N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-	465 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2343	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	397 (M − H)	3
	N′-[(1R)-1-phenylethyl]thiourea
2344	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	399 (M + H)	3
	N′-(2,3-dimethylphenyl)thiourea
2345	N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-	545 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2346	N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-	453 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2347	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	415 (M + H)	3
	N′-(2-ethoxyphenyl)thiourea
2348	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	427 (M + H)	3
	N′-(2-isopropyl-6-methylphenyl)thiourea
2349	N-(2,3-dihydro-1,4-benzodioxin-6-yl)-N′-(cis-4-{[4-	429 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2350	N-1,3-benzodioxol-5-yl-N′-(cis-4-{[4-(dimethylamino)pyrimidin-	415 (M + H)	3
	2-yl]amino}cyclohexyl)thiourea
2351	N-(3-chloro-2-methylphenyl)-N′-(cis-4-{[4-	419 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2352	N-[4-bromo-2-(trifluoromethoxy)phenyl]-N′-(cis-4-{[4-	533 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2353	N-(4-chloro-2,5-dimethoxyphenyl)-N′-(cis-4-{[4-	465 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2354	N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	452 (M + H)	3
	N′-(5-methyl-3-phenylisoxazol-4-yl)thiourea
2355	N-bicyclo[2.2.1]hept-2-yl-N′-(cis-4-{[4-	387 (M − H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2356	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	449 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)-4-
	methylthiophene-2-carboxylate
2357	methyl 3-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)amino]carbonothioyl}amino)thiophene-2-
	carboxylate
2358	N-(4-butyl-2-methylphenyl)-N′-(cis-4-{[4-	441 (M + H)	3
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea
2359	N-(2-chlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2360	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	446 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea
2361	N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2362	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea
2363	ethyl N-({[(cis-4-{[4-(dimethylamino)quinolin-2-	484 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}carbonyl)leucinate
2364	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(4-fluorophenyl)urea
2365	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	464 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[4-(methylthio)phenyl]urea
2366	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	486 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[2-(trifluoromethyl)phenyl]urea
2367	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-mesitylurea
2368	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methylphenyl)urea
2369	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	520 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea
2370	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	651 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea
2371	N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-	592 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2372	N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	474 (M + H)	2
	yl]amino}cyclohexyl)methyl]urea
2373	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-	520 (M + H)	2
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2374	N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-	466 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2375	N-(2-chlorobenzyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	466 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2376	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	488 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea
2377	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	446 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-ethylphenyl)urea
2378	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	544 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-iodophenyl)urea
2379	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	474 (M + H)	2
	methyl]-N′-(2-isopropyl-6-methylphenyl)urea
2380	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-isopropylphenyl)urea
2381	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea
2382	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	460 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-propylphenyl)urea
2383	N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-	488 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2384	N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	474 (M + H)	1
	yl]amino}cyclohexyl)methyl]urea
2385	N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-	466 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2386	N-(4-bromo-2,6-difluorophenyl)-N′-[(cis-4-{[4-	532 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2387	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-	520 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2388	N-(4-cyanophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	443 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2389	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	508 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea
2390	N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-	524 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2391	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	499 (M + H)	3
	methyl]-N′-(3-methyl-5-phenylisoxazol-4-yl)urea
2392	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	490 (M + H)	3
	methyl]-N′-[5-methyl-2-(trifluoromethyl)-3-furyl]urea
2393	N-(3,5-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-	486 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]urea
2394	N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-	486 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]urea
2395	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(4-methylphenyl)urea
2396	N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-	502 (M + H)	1
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2397	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	491 (M + H)	3
	methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea
2398	N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-	592 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2399	N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-	486 (M + H)	3
	2-yl]amino}cyclohexyl)methyl]urea
2400	N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-	462 (M + H)	3
	methyl]-N′-(2-methoxy-5-methylphenyl)urea
2401	N-[(cis-4-{[4-(dimethylamino)quinolin-2-	477 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-6-nitrophenyl)urea
2402	N-(3,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2403	N-(3,5-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-	454 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2404	N-(3-chloro-4-fluorophenyl)-N′-[(cis-4-{[4-	470 (M + H)	3
	(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea
2405	N-(2-chlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	403 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2406	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	397 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea
2407	N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	405 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]urea
2408	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea
2409	ethyl N-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-	435 (M + H)	3
	yl]amino}cyclohexyl)methyl]amino}carbonyl)leucinate
2410	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	387 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(4-fluorophenyl)urea
2411	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	415 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[4-(methylthio)phenyl]urea
2412	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	435 (M − H)	3
	yl]amino}cyclohexyl)methyl]-N′-[2-(trifluoromethyl)phenyl]urea
2413	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-mesitylurea
2414	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	383 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methylphenyl)urea
2415	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	471 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea
2416	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	602 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea
2417	N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-	543 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2418	N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	425 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2419	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-	471 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2420	N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-	417 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2421	N-(2-chlorobenzyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	417 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2422	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	437 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea
2423	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	397 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-ethylphenyl)urea
2424	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-iodophenyl)urea
2425	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	425 (M + H)	1
	methyl]-N′-(2-isopropyl-6-methylphenyl)urea
2426	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-isopropylphenyl)urea
2427	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea
2428	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	411 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2-propylphenyl)urea
2429	N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-	439 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2430	N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	425 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2431	N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-	417 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2432	N-(4-bromo-2,6-difluorophenyl)-N′-[(cis-4-{[4-	483 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl}urea
2433	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-	471 (M + H)	2
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2434	N-(4-cyanophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	394 (M + H)	3
	yl]amino}cyclohexyl)methyl]urea
2435	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	459 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea
2436	N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-	475 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2437	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	450 (M + H)	1
	methyl]-N′-(3-methyl-5-phenylisoxazol-4-yl)urea
2438	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	441 (M + H)	3
	methyl]-N′-[5-methyl-2-(trifluoromethyl)-3-furyl]urea
2439	N-(3,5-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	437 (M + H)	2
	2-yl]amino}cyclohexyl)methyl]urea
2440	N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	437 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2441	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	383 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(4-methylphenyl)urea
2442	N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-	453 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2443	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	442 (M + H)	1
	methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea
2444	N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-	543 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2445	N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	437 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2446	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-	413 (M + H)	2
	methyl]-N′-(2-methoxy-5-methylphenyl)urea
2447	N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-	428 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-6-nitrophenyl)urea
2448	N-(3,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	405 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2449	N-(3,5-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-	405 (M + H)	1
	2-yl]amino}cyclohexyl)methyl]urea
2450	N-(3-chloro-4-fluorophenyl)-N′-[(cis-4-{[4-	421 (M + H)	1
	(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea
2451	N-(2-chlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	457 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2452	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea
2453	N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2454	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	465 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea
2455	ethyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydro	489 (M + H)	2
	quinazolin-2-yl]amino}cyclohexyl)methyl]amino}carbonyl)-
	leucinate
2456	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	441 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(4-fluorophenyl)urea
2457	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	469 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[4-(methylthio)phenyl]urea
2458	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	491 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[2-(trifluoromethyl)phenyl]urea
2459	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	465 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-mesitylurea
2460	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methylphenyl)urea
2461	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	525 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea
2462	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	657 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea
2463	N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-	597 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2464	N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	479 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2465	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethyl-	525 (M + H)	1
	amino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	methyl]urea
2466	N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-	471 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2467	N-(2-chlorobenzyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	471 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2468	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	493 (M + H)	1
	yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea
2469	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	451 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-ethylphenyl)urea
2470	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	549 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-iodophenyl)urea
2471	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	479 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)-
	urea
2472	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	465 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-isopropylphenyl)urea
2473	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea
2474	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	465 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-propylphenyl)urea
2475	N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-	493 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2476	N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	479 (M + H)	2
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2477	N-(3-chloro-2-methylphenyl)-N′-[(cis-4{[4-(dimethylamino)-	471 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2478	N-(4-bromo-2,6-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-	537 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2479	N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-	525 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-
	methyl]urea
2480	N-(4-cyanophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	448 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2481	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	513 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea
2482	N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-	529 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2483	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	504 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(3-methyl-5-phenylisoxazol-
	4-yl)urea
2484	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	495 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-[5-methyl-2-(trifluoromethyl)-3-
	furyl]urea
2485	N-(3,5-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	491 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2486	N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	491 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2487	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	437 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(4-methylphenyl)urea
2488	N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-	507 (M + H)	2
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2489	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	496 (M + H)	2
	yl]amino}cyclohexyl)methyl]-N′-(2,3-dimethyl-6-nitrophenyl)-
	urea
2490	N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-	597 (M + H)	1
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2491	N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	491 (M + H)	1
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2492	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	467 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methoxy-5-methylphenyl)-
	urea
2493	N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-	482 (M + H)	3
	yl]amino}cyclohexyl)methyl]-N′-(2-methyl-6-nitrophenyl)urea
2494	N-(3,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2495	N-(3,5-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-	459 (M + H)	3
	tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea
2496	N-(3-chloro-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-	475 (M + H)	3
	5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea

Example 2497

2,3,4-Trifluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate

Step A: Synthesis of cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (4 g, 0.019 mol) in 50 mL CH₂Cl₂ was added DIEA (4.9 mL, 0.028 mol). The solution was cooled on an ice bath and CbzCl (2.9 mL, 0.020 mol) was added slowly. The solution was removed from the ice bath and stirring continued for an additional hour. The solvent was evaporated and the material was subjected to chromatography (0-40% ethyl acetate in hexanes) to yield cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (6.2 g, 0.018 mol, 95%) as a white solid.

ESI MS m/e 349.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.34-7.28 (m, 5H), 7.12 (d, J=5.6 Hz, 1H), 6.62 (brs, 1H), 4.98 (s, 2H), 3.39-3.37 (m, 2H), 1.60-1.45 (m, 8H), 1.37 (s, 9H).

Step B: Synthesis of cis-(4-amino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of cis-(4-tert-butoxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (6.2 g, 0.018 mol) in 40 mL CH₂Cl₂ was added TFA (2.7 mL, 0.36 mol). The solution was stirred at room temperature for 4 hours. The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq)/NaHCO₃ (aq) solution. The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated to yield cis-(4-amino-cyclohexyl)-carbamic acid benzyl ester (4.3 g, 97%) as a colorless oil. The oil was carried forward without further purification.

ESI MS m/e 249.2 M+H⁺.

Step C: Synthesis of cis-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid benzyl ester (0.5 g, 0.0020 mol) in 1 mL 2-propanol was added 2-chloro-4-methyl-quinoline (0.43 g, 0.0024 mol) and IEA (526 uL, 0.0030 mol). The mixture was heated in a microwave synthesizer at 170° C. for 5 hours. The reaction was repeated 7 more times (4 g total material) and the reaction mixtures were pooled. The solvent was evaporated and the material subjected to chromatography (2-4% 2M NH₃ in MeOH/CH₂Cl₂) to yield cis-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester (3.3 g, 53%) as a colorless oil.

ESI MS m/e 390.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (d, J=8 Hz, 1H), 7.46-7.39 (m, 2H), 7.37-7.19 (m, 7H), 6.68 (m, 2H), 5.01 (s, 2H), 4.07 (m, 1H), 3.46 (m, 1H), 2.44 (s, 3H), 1.79-1.71 (m, 2H), 1.70-1.59 (m, 6H).

Step D: Synthesis of cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine.

To a solution of cis-[4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-carbamic acid benzyl ester (3.3 g, 0.0085 mol) in 200 mL EtOH was added 10% Pd/C (330 mg). The reaction mixture was stirred at room temperature under H₂(g) atmosphere for 3 hours. The H₂(g) atmosphere was removed and the mixture was through a pad of celite and washed with ethyl acetate. The solvent was concentrated and the material was subjected to chromatography (2-4% 2M NH₃ in MeOH/CH₂Cl₂) to yield cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (2.0 g, 92%) as a light brown solid.

ESI MS m/e 256.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.71 (d, J=8 Hz, 1H), 7.46-7.39 (m, 2H), 7.14-7.10 (m, 1H), 6.69-6.68 (m, 2H), 4.07-4.05 (m, 1H), 2.81-2.77 (m, 1H), 2.44 (s, 3H), 1.78-1.71 (m, 2H), 1.62-1.40 (m, 6H).

Step E: Synthesis of 2,3,4-trifluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

To a solution of cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (23 mg, 0.090 mmol) in 0.5 mL DMF was added pyridine (12 uL, 0.15 mmol) and 2,3,4-trifluorobenzoyl chloride (12.8 uL, 0.10 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield 2,3,4-trifluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate (10.1 mg, 21%) as a white solid.

ESI MS m/e 414.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.44 (brs, 1H), 9.27 (brs, 1H), 8.45 (d, J=6.4 Hz, 1H), 7.98-7.93 (m, 2H), 7.80 (t, J=7.6 Hz, 1H), 7.53 (t, J=8.0 Hz, 1H), 7.43-7.37 (m, 2H), 7.01 (s, 1H), 4.05 (m, 1H), 3.97 (m, 1H), 2.69 (s, 3H), 1.86-1.74 (m, 8H).

Example 2498

3,4-Difluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3,4-difluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate

Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 396.18 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.40 (brs, 1H), 9.25 (brs, 1H), 8.33 (d, J=6.0 Hz, 1H), 7.98-7.90 (m, 3H), 7.80-7.76 (m, 2H), 7.58-7.50 (m, 2H), 7.02 (brs, 1H), 4.09 (m, 1H), 3.94 (m, 1H), 2.61 (s, 3H), 1.84-1.74 (m, 8H).

Example 2499

4-Cyano-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 4-cyano-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate.

Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 385.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (brs, 1H), 9.27 (brs, 1H), 8.51 (d, J=6.0 Hz, 1H), 8.01-7.95 (m, 6H), 7.80 (t, J=7.2 Hz, 1H), 7.54 (t, J=8.0 Hz, 1H), 7.02 (brs, 1H), 4.09 (m, 1H), 3.96 (m, 1H), 2.66 (s, 3H), 1.85-1.75 (m, 8H).

Example 2500

3-Fluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3-fluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate.

Using the procedure of step E of example 2497, the title compound was obtained.

ESI m/e 378 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.38 (brs, 1H), 9.25 (brs, 1H), 8.33 (d, J=6.0 Hz, 1H), 7.98-7.91 (m, 2H), 7.80 (t, J=7.6 Hz, 1H), 7.71-7.64 (m, 2H), 7.55-7.49 (m, 2H), 7.41-7.36 (m, 1H), 4.12 (m, 1H), 4.08 (m, 1H), 2.77 (s, 3H), 1.85-1.74 (m, 8H).

Example 2501

3,5-Difluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3,5-difluoro-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

Using the procedure of step E of example 2497, the title compound was obtained.

ESI MS m/e 396 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.40 (brs, 1H), 9.25 (brs, 1H), 8.40 (d, J=6.0 Hz, 1H), 7.98-7.96 (m, 2H), 7.80 (t, J=7.2 Hz, 1H), 7.59-7.44 (m, 4H), 7.02 (brs, 1H), 4.09 (m, 1H), 3.94 (m, 1H), 2.68 (s, 3H), 1.85-1.74 (m, 8H).

Example 2502

N-{cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl}-2-[4-(trifluoromethoxy)phenoxy]-acetamide trifluoroacetate

Step A: Synthesis of N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-[4-(trifluoromethoxy)phenoxy]-acetamide trifluoroacetate.

To a solution of cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (25.5 mg, 0.1 mmol) in 0.5 mL DMF was added 4-(trifluoromethoxy)phenoxyacetic acid (23.6 mg, 0.1 mmol), DIEA (0.026 mL, 0.15 mmol), and HATU (45.6 mg, 0.12 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-[4-(trifluoromethoxy)phenoxy]-acetamide trifluoroacetate (22.3 mg, 38%) as a white solid.

ESI MS m/e 474.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.47 (s, 1H), 9.25 (s, 1H), 8.00-7.92 (m, 3H), 7.80 (t, J=7.2 Hz, 1H), 7.53 (t, J=8.0 Hz, 1H), 7.31 (d, J=8.8 Hz, 2H), 7.04-7.01 (m, 3H), 4.55 (s, 2H), 4.06 (m, 1H), 3.84 (m, 1H), 2.69 (s, 3H), 1.78-1.68 (m, 8H).

Example 2503

2-(3,4-Difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate

Step A: Synthesis of 2-(3,4-difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 410 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.42 (brs, 1H), 9.26 (brs, 1H), 8.09 (d, J=6.4 Hz, 1H), 7.98-7.92 (m, 2H), 7.80 (t, J=7.6 Hz, 1H), 7.54 (t, J=8.8 Hz, 1H), 7.38-7.27 (m, 2H), 7.10-7.07 (m, 1H), 7.01 (brs, 1H), 4.02 (m, 1H), 3.94 (m, 1H), 2.61 (s, 3H), 1.79-1.69 (m, 8H).

Example 2504

2-(2-Bromo-4,5-dimethoxyphenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide trifluoroacetate

Step A: Synthesis of 2-(2-bromo-4,5-dimethoxyphenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 512.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.45 (brs, 1H), 9.25 (brs, 1H), 8.00-7.92 (m, 3H), 7.80 (t, J=7.6 Hz, 1H), 7.53 (t, J=7.6 Hz, 1H), 7.09 (s, 1H), 7.01 (brs, 1H), 6.95 (s, 1H), 4.10 (m, 1H), 3.78 (m, 1H), 3.74 (s, 3H), 3.72 (s, 3H), 3.53 (s, 2H), 2.69 (s, 3H), 1.78-1.67 (m, 8H).

Example 2505

4-(Benzyloxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 4-(benzyloxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-benzamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 466.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.39 (brs, 1H), 9.25 (brs, 1H), 8.06 (d, J=6.0 Hz, 1H), 7.98-7.96 (m, 2H), 7.84-7.76 (m, 3H), 7.54 (t, J=8.0 Hz, 1H), 7.46 (d, J=7.2 Hz, 2H), 7.41 (t, J=7.2 Hz, 2H), 7.35-7.31 (m, 1H), 7.08 (d, J=8.8 Hz, 2H), 7.02 (brs, 1H), 5.17 (s, 2H), 4.09 (m, 1H), 3.93 (m, 1H), 2.66 (s, 3H), 1.84-1.72 (m, 8H).

Example 2506

2-(2-Methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate

Step A: Synthesis of 2-(2-methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 420.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.50 (brs, 1H), 9.25 (brs, 1H), 7.98-7.93 (m, 2H), 7.80-7.76 (m, 2H), 7.53 (t, J=5.6 Hz, 1H), 7.02-6.85 (m, 5H), 4.50 (s, 2H), 4.07 (m, 1H), 3.85 (m, 1H), 3.79 (s, 3H), 2.61 (s, 3H), 1.84-1.69 (m, 8H).

Example 2507

2-(4-Fluorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate

Step A: Synthesis of 2-(4-fluorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 471.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.29 (dd, J=7.6, 2.0 Hz, 1H), 8.19 (dd, J=4.8, 2.0 Hz, 1H), 8.01 (d, J=8.0 Hz, 1H), 7.88 (brs, 1H), 7.80 (t, J=8.4 Hz, 1H), 7.57 (t, J=8.0 Hz, 1H), 7.25-7.15 (m, 5H), 6.90 (brs, 1H), 4.20 (brs, 1H), 4.07 (brs, 1H), 2.67 (s, 3H), 2.02-1.81 (m, 8H).

Example 2508

2-(4-Chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate

Step A: Synthesis of 2-(4-Chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 487.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 13.0 (brs, 1H), 9.50 (d, J=6.8 Hz, 1H), 8.35 (m, 1H), 8.19 (m, 1H), 8.07 (d, J=6.8 Hz, 1H), 7.93 (d, J=7.6 Hz, 1H), 7.75 (t, J=7.2 Hz, 1H), 7.50 (m, 3H), 7.30 (m, 3H), 7.10 (brs, 1H), 4.38 (brs, 1H), 4.01 (brs, 1H), 2.57 (s, 3H), 1.83 (m, 8H).

Example 2509

2,6-Dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate

Step A: Synthesis of 2,6-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide trifluoroacetate.

Using the procedure of step A of example 2502, the title compound was obtained.

ESI MS m/e 421.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 13.1 (brs, 1H), 9.74 (d, J=8.0 Hz, 1H), 8.30 (d, J=8.4 Hz, 1H), 8.17 (d, J=8.4 Hz, 1H), 7.98 (m, 2H), 7.60 (m, 1H), 7.50 (t, J=7.6 Hz, 1H), 7.19 (brs, 1H), 4.43 (brs, 1H), 3.94 (brs, 7H), 2.58 (s, 3H), 1.90 (m, 8H).

Example 2510

cis-N-[4-Bromo-2-(trifluoromethoxy)benzyl]-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of cis-N-[4-bromo-2-(trifluoromethoxy)benzyl]-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

To a solution of cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (25.5 mg, 0.1 mmol) in 0.5 mL MeOH was added 4-bromo-2-trifluoromethoxybenzaldehyde (26.9 mg, 0.1 mmol). The reaction mixture was stirred for a half hour and then sodium triacetoxyborohydride (84.8 mg, 0.4 mmol) was added to the reaction. The mixture was stirred overnight and then 0.5 mL of DMSO was added. The compound was then subjected to purification by prep LCMS to yield cis-N-[4-bromo-2-trifluoromethoxy)benzyl]-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate (9.6 mg, 13%) as a white solid.

ESI MS m/e 508.0 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.04 (d, J=8.0 Hz, 1H), 7.84 (brs, 1H), 7.81 (t, J=7.2 Hz, 1H), 7.69-7.63 (m, 3H), 7.58 (t, J=8.0 Hz, 1H), 7.16 (brs, 1H), 4.36 (s, 2H), 4.26 (m, 1H), 3.32-3.30 (m, 1H), 2.71 (s, 2H), 2.66 (s, 3H), 2.16-1.93 (m, 8H).

Example 2511

cis-N-[(5-Bromo-1H-indol-3-yl)methyl]-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of cis-N-[(5-bromo-1H-indol-3-yl)methyl]-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 463.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.03 (d, J=8.0 Hz, 1H), 7.92 (s, 1H), 7.87 (brs, 1H), 7.80-7.76 (t, J=7.2 Hz, 1H), 7.57-7.53 (m, 2H), 7.38 (d, J=8.8 Hz, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.14 (brs, 1H), 4.47 (s, 2H), 4.23 (m, 1H), 3.37 (m, 1H), 2.71 (brs, 2H), 2.65 (s, 3H), 2.15-1.91 (m, 8H).

Example 2512

cis-N-(3,5-Dimethoxybenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of cis-N-(3,5-dimethoxybenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 406.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.03 (d, J=8.0 Hz, 1H), 7.88 (brs, 1H), 7.80 (t, J=7.2 Hz, 1H), 7.57 (t, J=8.4 Hz, 1H), 7.17 (brs, 1H), 6.71 (s, 2H), 6.55 (s, 1H), 4.24 (m, 1H), 4.21 (s, 2H), 3.81 (s, 6H), 3.35 (m, 1H), 2.70 (brs, 2H), 2.66 (s, 3H), 2.14-1.90 (m, 8H).

Example 2513

cis-N-(3,5-Dichlorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of cis-N-(3,5-dichlorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 414.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.04 (d, J=8.4 Hz, 1H), 7.86 (brs, 1H), 7.81 (t, J=7.2 Hz, 1H), 7.58-7.54 (m, 4H), 7.16 (brs, 1H), 4.30 (s, 2H), 4.25 (m, 1H), 3.41 (m, 1H), 2.76 (brs, 2H), 2.66 (s, 3H), 2.12-1.92 (m, 8H).

Example 2514

cis-N-(3,4-Difluorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate

Step A: Synthesis of cis-N-(3,4-difluorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine bis-trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 382.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.03 (d, J=8.0 Hz, 1H), 7.86 (brs, 1H), 7.80 (t, J=7.2 Hz, 1H), 7.57-7.51 (m, 2H), 7.39-7.37 (m, 2H), 7.16 (brs, 1H), 4.29 (s, 2H), 4.25 (m, 1H), 3.37 (m, 1H), 2.71 (brs, 2H), 2.66 (s, 3H), 2.11-1.95 (m, 8H).

Example 2515

N-(3,5-Difluorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of N-(3,5-difluorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

To a solution of cis-N-(4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (20 mg, 0.078 mmol) in 0.5 mL of DMSO was added 3,5-difluorophenyl isocyanate (9.3 uL, 0.078 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield N-(3,5-difluorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate (12 mg, 29%) as a white solid. ESI MS m/e 411.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.02 (d, J=8.0 Hz, 1H), 7.87 (brs, 1H), 7.80 (t, J=7.6 Hz, 1H), 7.56 (t, J=7.6 Hz, 1H), 7.07 (s, 1H), 7.03 (s, 1H), 6.97 (brs, 1H), 6.50 (t, J=9.2 Hz, 1H), 4.02 (m, 1H), 3.89 (m, 1H), 2.68 (brs, 3H), 2.66 (s, 3H), 1.99-1.78 (m, 8H).

Example 2516

N-[3,5-Bis(trifluoromethyl)phenyl]-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of N-[3,5-bis(trifluoromethyl)phenyl]-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 511.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.02 (s, 2H), 8.00 (s, 1H), 7.87 (brs, 1H), 7.80 (t, J=7.2 Hz, 1H), 7.57 (t, J=8.0 Hz, 1H), 7.49 (s, 1H), 6.98 (brs, 1H), 4.04 (m, 1H), 3.91 (m, 1H), 2.69 (brs, 3H), 2.66 (s, 3H), 2.01-1.80 (m, 8H).

Example 2517

N-(3-Chlorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of N-(3-chlorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 409.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, J=8.4 Hz, 1H), 7.87 (brs, 1H), 7.79 (t, J=7.6 Hz, 1H), 7.59 (s, 1H), 7.56 (t, J=7.6 Hz, 1H), 7.21-7.15 (m, 2H), 6.96 (brs, 1H), 6.93-6.91 (m, 1H), 4.01 (m, 1H), 3.89 (t, 1H), 2.66 (brs, 6H), 1.99-1.78 (m, 8H).

Example 2518

N-(3,4-Dichlorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of N-(3,4-dichlorophenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 443.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, J=7.6 Hz, 1H), 7.87 (brs, 1H), 7.79-7.74 (m, 2H), 7.56 (t, J=7.6 Hz, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.20 (d, J=8.4 Hz, 1H), 6.97 (brs, 1H), 4.02 (m, 1H), 3.88 (m, 1H), 2.66 (brs, 6H), 1.98-1.78 (m, 8H).

Example 2519

N-(3-Methoxyphenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate

Step A: Synthesis of N-(3-methoxyphenyl)-N′-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}urea trifluoroacetate.

Using the procedure of step A of example 2515, the title compound was obtained.

ESI MS m/e 405.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.00 (d, J=8.0 Hz, 1H), 7.87 (brs, 1H), 7.79 (t, J=7.6 Hz, 1H), 7.56 (t, J=8.0 Hz, 1H), 7.14-7.10 (m, 2H), 6.96 (brs, 1H), 6.84 (d, J=8.0 Hz, 1H), 6.53 (d, J=8.4 Hz, 1H), 4.01 (m, 1H), 3.89 (m, 1H), 3.75 (s, 3H), 2.71 (brs, 6H), 1.99-1.78 (m, 8H).

Example 2520

3-Methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate

Step A: Synthesis of cis-[4-(3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (2.8 g, 0.013 mol) in 40 mL CH₂Cl₂ stirring on ice was added DIEA (3.41 mL, 0.020 mol). The solution was cooled on an ice bath and m-anisoyl chloride (1.84 mL, 0.013 mol) was added slowly. The solution was removed from the ice bath and stirring continued for an additional hour. The solvent was evaporated and the material was subjected to chromatography (0-40% ethyl acetate in hexanes) to yield cis-[4-(3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid tert-butyl ester (4.3 g, 94%) as a white solid.

ESI MS m/e 349.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (d, J=6.8 Hz, 1H), 7.42-7.32 (m, 3H), 7.07 (dd, J=8.4, 2.4 Hz, 1H), 6.62 (brs, 1H), 3.79 (s, 3H), 3.77 (m, 1H), 3.41 (m, 1H), 1.71-1.70 (m, 4H), 1.52-1.46 (m, 4H), 1.38 (s, 9H).

Step B: Synthesis of cis-N-(4-amino-cyclohexyl)-3-methoxy-benzamide.

To a solution of cis-[4-3-methoxy-benzoylamino)-cyclohexyl]-carbamic acid tert-butyl ester (4.3 g, 0.012 mol) in 50 mL CH₂Cl₂ was added TFA (1.84 mL, 0.024 mol). The solution was stirred for 4 hours and the solvent evaporated. The resulting oil was re-dissolved in 50 mL CH₂Cl₂. The organic layer was extracted with 50 mL of a dilute NaOH (aq)/NaHCO₃ (aq) solution. The aqueous layer was extracted twice more with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated. The resulting precipitate was crystallized in ether and hexanes to yield cis-N-(4-amino-cyclohexyl)-3-methoxy-benzamide (2.4 g, 78%) as a white solid.

ESI MS m/e 249.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.10 (d, J=7.2 Hz, 1H), 7.42-7.32 (m, 3H), 7.07 (dd, J=8.0, 2.4 Hz, 1H), 3.79 (brs, 4H), 2.91 (m, 1H), 1.80-1.74 (m, 2H), 1.52-1.46 (m, 6H), 1.31 (brs, 2H).

Step C: Synthesis of 3-methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate.

To a solution of cis-N-(4-amino-cyclohexyl)-3-methoxy-benzamide (28.4 mg, 0.1 mmol) in 0.5 mL 2-propanol was added 2-chloroquinoline (32.7 mg, 0.2 mmol) and DIEA (34.8 uL, 0.2 mmol). The reaction mixture was heated in a microwave synthesizer at 170° C. for 10 hours. The solvent was removed and the resulting oil dissolved in 1 mL of DMSO. The compound was then subject to purification by prep LCMS to yield 3-methoxy-N-[cis-4-(quinolin-2-ylamino)cyclohexyl]benzamide trifluoroacetate (26 mg, 53%) as a colorless oil.

ESI MS m/e 376.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.85 (d, J=9.2 Hz, 1H), 7.62 (t, J=8.8 Hz, 2H), 7.50 (t, J=7.2 Hz, 1H), 7.39-7.36 (m, 3H), 7.19 (t, J=7.2 Hz, 1H), 7.10-7.07 (m, 1H), 6.82 (d, J=9.2 Hz, 1H), 4.18 (m, 1H), 4.02 (m, 1H), 3.84 (s, 3H), 1.95-1.22 (m, 1H).

Example 2521

3-methoxy-N-(cis-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-trifluoromethyl-quinoline.

To a solution of 4-trifluoromethyl-quinolin-2-ol (1.01 g, 0.0047 mol) in 10 mL POCl₃ was added N, N-dimethylaniline (661 uL, 0.0052 mol). The mixture was heated to reflux (125° C.) and stirred for 4 hours until the starting material completely dissolved and the solution turned dark purple in color. The solution was then cooled and poured slowly on ice (30 g; caution highly exothermic) to quench the reaction. The aqueous layer was then extracted three times with CH₂Cl₂ (25 mL). The organic layer was dried with MgSO₄, concentrated, and subjected to purification by chromatography (100% CH₂Cl₂) to yield 2-chloro-4-trifluoromethyl-quinoline (823 mg, 75%) as a slightly yellow solid.

ESI MS m/e 232.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.15-8.09 (m, 2H), 8.06 (s, 1H), 8.01-7.97 (m, 1H), 7.88-7.85 (m, 1H).

Step B: Synthesis of 3-methoxy-N-(cis-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

To a solution of cis-N-(4-amino-cyclohexyl)-3-methoxy-benzamide (50 mg, 0.20 mmol) in 0.5 mL 2-propanol was added 2-chloro-4-trifluoromethyl-quinoline (56 mg, 0.24 mmol), and DIEA (52.6 uL, 0.30 mmol). The reaction mixture was heated in a microwave synthesizer at 170° C. for 5 hours. The solvent was removed and the resulting oil dissolved in 1 mL of DMSO. The compound was then subjected to purification by prep LCMS to yield 3-methoxy-N-(cis-4-{[4-(trifluoromethyl)quinolin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate (71.8 mg, 64%) as a white solid.

ESI MS m/e 444.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.22 (d, J=6.4 Hz, 1H), 7.79-7.77 (m, 2H), 7.69 (m, 1H), 7.50 (s, 1H), 7.44-7.34 (m, 4H), 7.09 (dd, J=8.0, 2.4 Hz, 1H), 4.14 (m, 1H), 3.87 (m, 1H), 3.80 (s, 3H), 1.94-1.92 (m, 2H), 1.82-1.72 (m, 6H).

Example 2522

3-Methoxy-N-{cis-4-[(quinolin-2-ylmethyl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 3-methoxy-N-{cis-4-[(quinolin-2-ylmethyl)amino]cyclohexyl}benzamide trifluoroacetate.

Using the procedure of step A of example 2510, the title compound was obtained.

ESI MS m/e 390.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.41 (d, J=8.8 Hz, 1H), 8.14 (d, J=8.4 Hz, 1H), 7.99 (d, J=8.0 Hz, 1H), 7.84 (t, J=7.2 Hz, 1H), 7.67 (t, J=7.2 Hz, 1H), 7.55 (d, J=8.4 Hz, 1H), 7.43-7.36 (m, 3H), 7.12-7.10 (m, 1H), 4.66 (s, 2H), 4.13 (m, 1H), 3.85 (s, 3H), 3.46 (m, 1H), 2.16-2.05 (m, 4H), 2.05-1.96 (m, 2H), 1.85-1.78 (m, 2H).

Example 2523

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-dimethylamino-5-methylpyrimidine.

In 8 mL tetrahydrofuran was dissolved 2,4-dichloro-5-methylpyrimidine (0.5 g, 3.07 mmol) at 0° C. To the reaction mixture was added dimethylamine (2M in methanol, 3.4 mL, 6.8 mmol) dropwise. The reaction mixture was stirred at 10° C. for 1.5 hour: do not increase the reaction temperature. The solution was concentrated and purified by flash chromatography (silica gel, 20% ethyl acetate and 5% methanol in hexanes) to give 2-chloro-4-dimethylamino-5-methylpyrimidine (307 mg, 58%) as a white solid.

ESI MS m/e 172 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.8 (s, 1H), 3.18 (s, 6H), 2.23 (s, 3H).

Step B: Synthesis of cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

To a suspension of 2-chloro-4-dimethylamino-5-methylpyrimidine (250 mg, 1.46 mmol) in 2-propanol (2.5 mL) was added cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (340 mg, 1.60 mmol) and DIEA (507 μL, 2.91 mmol). The reaction was performed in the Smith synthesizer for 4.5 hours at 175° C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (219 mg, 43%) as a pale yellow solid.

ESI MS m/e 350.4 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1H), 4.6 (brs, 1H), 3.94 (brs, 1H), 3.60 (brs, 1H), 3.02 (s, 6H), 2.18 (s, 3H), 1.85-1.70 (m, 8H), 1.41 (s, 9H).

Step C: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-amino-cyclohexane.

To a suspension of cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (219 mg, 0.627 mmol) in DCM (3 mL) was added trifluoroacetic acid (2 mL). The reaction stirred at room temperature for 2 hours and concentrated. A few drops NaHCO₃ was added, followed by 1M NaOH until the solution was basic. The product was extracted with H₂O and CH₂Cl₂ three times. The organic layers were combined, dried over MgSO₄, filtered and concentrated to give cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (115.9 mg, 74%) as yellow oil.

ESI MS m/e 250.2 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, 1H), 4.95 (brs, 1H), 3.90 (brs, 1H), 2.98 (s, 6H), 2.80 (brs, 1H), 2.48 (brs, 2H), 2.04 (s, 3H), 1.78 (m, 2H), 1.62 (m, 4H), 1.4 (m, 2H).

Step D: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-4-methylbenzamide trifluoroacetate.

To a suspension of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (30 mg, 0.12 mmol) was added 4-methyl-benzoyl chloride (15.8 μL, 0.12 mmol) and DIEA (5 drops). The reaction was stirred overnight at room temperature under argon gas. The solution was concentrated and the product purified using prep HPLC to give N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide trifluoroacetate (29.1 mg, 50.4%) as a white solid.

ESI MS m/e 368 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1H), 7.68 (d, J=8.0 Hz, 2H), 7.24 (d, J=8.0 Hz, 2H), 6.72 (s, 1H), 4.25 (s, 1H), 3.23 (s, 6H), 2.71 (s, 1H), 2.34 (s, 3H), 2.27 (s, 3H), 1.7-1.88 (m, 8H).

Example 2524

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

To a suspension of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-4-aminocyclohaexane (70 mg, 0.28 mmol) in DCM (5 mL) was added 3,4-difluorobenzoyl chloride (50 mg, 0.28 mmol) and DIEA (45 μL, 0.28 mmol). The reaction was stirred overnight and the product was purified by column chromatography (silica gel, DCM/MeOH=100:0 to 90:10). The purified product was dissolved in DCM (3 mL), and 2M-HCl in ethyl ether (0.3 mL) was added. After stirring 20 min, removal of the volatile solvent gave N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride (26 mg, 23%) as a white solid.

ESI MS m/e 390 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.8 (brs, 1H), 8.23 (brs, 1H), 7.80 (m, 2H), 7.63 (m, 1H), 7.51 (s, 1H), 7.40 (d, J=8.8 Hz, 1H), 3.74 (brs, 2H), 3.14 (s, 6H), 2.11 (s, 3H), 1.73-1.58 (m, 8H).

Example 2525

3-Chloro-N-(cis-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using procedure of step A of example 2524, the title compound was obtained.

ESI MS m/e 388 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.7 (brs, 1H), 8.22 (brs, 1H), 7.72 (m, 2H), 7.62 (d, J=8.0 Hz, 1H), 7.45 (s, 1H), 7.42 (d, J=8.0 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 3.70 (brs, 2H), 3.10 (s, 6H), 2.06 (s, 3H), 1.68-1.54 (m, 8H).

Example 2526

N-(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-dimethylamino-6-methylpyrimidine.

In 100 mL tetrahydrofuran was dissolved 2,4-dichloro-6-methylpyrimidine (10 g, 61.3 mmol) at 0° C. To the reaction mixture was added dimethylamine (2M in methanol, 67.4 mL, 134.8 mmol) dropwise. The reaction mixture was stirred at 10° C. for 2.5 hours. The solution was concentrated and purified by flash chromatography (silica gel, 20% ethyl acetate and 5% methanol in hexanes) to give 2-chloro-4-dimethylamino-6-methylpyrimidine (4.18 g, 40%) as a pale yellow solid.

ESI MS m/e 172 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 6.25 (s, 1H), 3.2 (s, 6H), 2.64 (s, 3H).

Step B: Synthesis of cis-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester.

To a suspension of 2-chloro-4-dimethylamino-6-methylpyrimidine (15 mg, 0.0874 mmol) in 2-propanol (1.7 mL) was added cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (20.6 mg, 0.096 mmol) and DIEA (30.3 μL, 0.175 mmol). The reaction was performed in the Smith synthesizer for 4.5 hours at 175° C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give cis-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (18.9 mg, 62%) as a pale yellow solid.

ESI MS m/e 350.4 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 5.65 (s, 1H), 4.75 (brs, 1H), 4.0 (brs, 1H), 3.60 (brs, 1H), 3.05 (s, 6H), 2.22 (s, 3H), 1.78 (m, 6H), 1.59 (m, 2H), 1.44 (s, 9H).

Step C: Synthesis of cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane.

To a suspension of cis-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (617 mg, 1.77 mmol) in DCM (3 mL) was added trifluoroacetic acid (2 mL). The reaction stirred at room temperature for 2 hours and concentrated. A few drops NaHCO₃ was added, followed by 1M NaOH until the solution was basic. The product was extracted with H₂O and CH₂Cl₂ three times. The organic layers were combined, dried over MgSO₄, filtered and concentrated to give cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-4-aminocyclohexane (318 mg, 72%) as yellow oil.

ESI MS m/e 250 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 5.52 (s, 1H), 5.10 (brs, 1H), 3.88 (brs, 1H), 3.20 (brs, 2H), 2.88 (s, 6H), 2.75 (s, 1H), 2.04 (s, 3H), 1.70 (m, 2H), 1.58 (m, 4H), 1.38 (m, 2H).

Step D: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide trifluoroacetate.

Using the procedure of step D of example 2523, the title compound was obtained.

ESI MS m/e 368.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) 9.0 (s, 1H), 7.6 (m, 2H), 7.22 (s, 1H), 6.72 (s, 1H), 5.68 (s, 1H), 4.2 (s, 1H), 4.12 (s, 1H), 3.18 (s, 3H), 3.08 (s, 3H), 2.35 (s, 3H), 2.29 (s, 3H), 1.85-1.62 (m, 8H).

Example 2527

cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide

Step A: Synthesis of cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester.

To a suspension of 2-chloro-4-dimethylamino-6-methylpyrimidine (250 mg, 1.46 mmol) in 2-propanol (1.5 mL) was added cis-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride (330 mg, 1.59 mmol) and DIEA (0.60 mL, 3.44 mmol). The reaction was performed in the Smith synthesizer for 1 hour at 155° C. The solution was concentrated and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester (378.9 mg, 84.7%) as a pale yellow solid.

ESI MS m/e 307 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (brs, 1H), 6.21 (s, 1H), 4.04 (q, J=6.4 Hz, 2H), 3.98 (brs, 1H), 3.15 (s, 6H), 2.20 (s, 3H), 1.58-1.80 (m, 8H), 1.20 (t, J=6.0 Hz, 3H).

Step B: Synthesis of cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid.

To a suspension of cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester (597.6 mg, 1.95 mmol) in H₂O (10 mL) and ethanol (0.3 mL) was added KOH (547 mg, 9.75 mmol). The reaction was stirred at 70° C. for 2.5 hours until reaction was homogenous. The reaction was cooled in an ice bath and acidified with concentrated HCl. The product was purified using flash chromatography (silica gel, 0-10% MeOH in CH₂Cl₂) to give cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid (302 mg, 55%) as a white solid.

ESI MS m/e 279.2 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.50 (brs, 1H), 5.79 (s, 1H), 4.02 (brs, 1H), 3.19 (brs, 6H), 2.49 (brs, 1H), 2.29 (s, 3H), 2.05 (m, 2H), 1.81 (m, 2H), 1.64 (m, 4H).

Step C: Synthesis of cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide.

To a suspension of 3-trifluoromethylbenzylamine (14 μL, 0.0987 mmol) and cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid (25 mg, 0.0898 mmol) in DCM (5 mL) was added HATU (37.5 mg, 0.0987 mmol). The reaction stirred at room temperature under argon for 30 seconds and triethylamine (5 drops) was added. The reaction stirred under argon at room temperature for 16 hours. The reaction was quenched by diluting with 5 mL DCM, followed by washing twice with saturated NaHCO₃ (5 mL), twice with 1M HCl (5 mL) and once with H₂O (5 mL). The product was purified by filtering through silica gel with 0-10% MeOH in CH₂Cl₂ to give cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]-cyclohexanecarboxamide (17.6 mg, 45%) as a white solid.

ESI MS m/e 436 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.01 (brs, 1H), 7.59 (brs, 1H), 7.53 (m, 2H), 7.40 (m, 2H), 5.76 (s, 1H), 4.50 (d, J=6.4 Hz, 2H), 4.28 (brs, 1H), 3.19 (s, 6H), 2.39 (m, 1H), 2.30 (s, 3H), 2.0 (m, 2H), 1.87 (m, 4H), 1.60 (m, 2H).

Example 2528

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[3-(propionylamino)benzyl]-cyclohexanecarboxamide

Step A: Synthesis of cis-[4-(3-nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester.

cis-4-(tert-Butoxycarbonylamino)-cyclohexanecarboxylic acid (2.0 g, 8.2 mmol) and 3-nitrobenzyl amine hydrochloride (1.54 g, 8.2 mmol) in DCM (30 mL) was reacted in the presence of HATU (3.5 g, 9.02 mmol) and Et₃N (4 mL). The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. From column chromatography (silica gel, DCM/MeOH=100:0 to 95 to 5), 2.7 g (90%) of cis-[4-(3-nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester was isolated.

ESI MS m/e 378 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (brs, 1H), 8.09 (s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.48 (t, J=7.6 Hz, 1H), 6.17 (brs, 1H), 4.72 (brs, 1H), 4.53 (d, J=6.0 Hz, 2H), 3.74 (brs, 1H), 2.27 (m, 1H), 1.80-1.71 (m, 6H), 1.65-1.59 (m, 2H), 1.45 (s, 9H).

Step B: Synthesis of cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride.

cis-[4-(3-Nitrobenzylcarbamoyl)-cyclohexyl]-carbamic acid tert-butyl ester (2.5 g, 6.6 mmol) was reacted in TFA/DCM (1:2=23 mL) for 2 hr at room temperature. After removal of the solvents, the residue was dissolved in DCM (15 mL), and added 2M-HCl in ethyl ether (2 eq.). After stirring for 20 min at room temperature, the volatile solvent was removed to give cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzamide hydrochloride (2.0 g, 95%) as a yellowish white solid.

ESI MS m/e 278 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.53 (t, J=6.0 Hz, 1H), 8.07 (d, J=7.6 Hz, 1H), 8.06 (s, 1H), 7.84 (brs, 2H), 7.68 (d, J=7.6 Hz, 1H), 7.59 (t, J=7.6 Hz, 1H), 4.37 (d, J=6.4 Hz, 2H), 3.13 (m, 1H), 2.40 (m, 1H), 1.89 (m, 2H), 1.68 (m, 4H), 1.57 (m, 2H).

Step C: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzylamide.

2-Chloro-4-dimethylamino-5-methylpyrimidine (0.31 g, 1.8 mmol) and cis-4-amino-cyclohexanecarboxylic acid 3-nitro-benzylamide hydrochloride (0.52 g, 1 eq.) in IPA (2.5 mL) and DIEA (0.7 mL) was reacted in a Smith synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. The crude compound was purified from column chromatography (silica gel, DCM/MeOH=100:0 to 90:10) to give 0.23 g (31%) of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-nitro-benzylamide.

ESI MS m/e 413 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.11 (brs, 1H), 8.03 (d, J=8.0 Hz, 1H), 7.95 (brs, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.43 (t, J=7.6 Hz, 1H), 7.28 (s, 1H), 4.51 (d, J=5.6 Hz, 2H), 4.33 (m, 1H), 3.23 (s, 6H), 2.39 (m, 1H), 2.22 (s, 3H), 2.02 (m, 2H), 1.86 (m, 4H), 1.60 (m, 2H).

Step D: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide.

A solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexane carboxylic acid 3-amino-benzylamide (0.21 g, 0.5 mmol) and 10% Pd/C (50 mg) in EtOH (10 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH=100:0 to 80:20) to give 0.18 g (95%) of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide as the desired product.

ESI MS m/e 383 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.29 (s, 1H), 7.03 (t, J=7.6 Hz, 1H), 6.64 (m, 2H), 6.51 (d, J=8.0 Hz, 1H), 4.33 (d, J=5.6 Hz, 2H), 4.25 (brs, 1H), 3.19 (s, 6H), 2.32 (m, 1H), 2.19 (s, 3H), 1.97-1.78 (m, 6H), 1.62 (m, 2H).

Step E: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[3-(propionylamino)benzyl]cyclohexanecarboxamide.

cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid 3-amino-benzylamide (30 mg, 0.075 mmol) and propionyl chloride (7 mg, 0.075 mmol) was reacted in the presence of catalytic Et₃N (7 drops). The product was purified from column chromatography (silica gel, DCM/MeOH=100:0 to 90:10) to give cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[3-(propionylamino)benzyl]cyclohexanecarboxamide (11 mg, 32%).

ESI MS m/e 439 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (brs, 1H), 7.92 (brs, 1H), 7.35 (s, 1H), 7.28 (s, 1H), 7.21 (t, J=7.6 Hz, 1H), 6.92 (d, J=7.6 Hz, 1H), 6.46 (brs, 1H), 4.42 (d, J=6.0 Hz, 2H), 4.23 (m, 1H), 3.22 (s, 6H), 2.47 (d, J=7.6 Hz, 2H), 2.33 (m, 1H), 2.22 (s, 3H), 1.95-1.90 (m, 6H), 1.63 (m, 2H), 1.22 (t, J=7.6 Hz, 3H).

Example 2529

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[3-(isobutyrylamino)benzyl]-cyclohexanecarboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[3-(isobutyrylamino)benzyl]cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 453 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.80 (brs, 1H), 8.10 (brs, 1H), 7.93 (brs, 1H), 7.39 (s, 1H), 7.23 (s, 1H), 7.18 (t, J=7.6 Hz, 1H), 6.91 (d, J=7.6 Hz, 1H), 6.69 (brs, 1H), 4.40 (d, J=5.6 Hz, 2H), 4.22 (m, 1H), 3.23 (s, 6H), 2.74 (m, 1H), 2.33 (m, 1H), 2.20 (s, 3H), 1.96-1.87 (m, 6H), 1.60 (m, 2H), 1.22 (d, J=6.4 Hz, 6H).

Example 2530

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{3-[(3-methylbutanoyl)amino]-benzyl}cyclohexanecarboxamide.

Step A: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{3-[(3-methylbutanoyl)amino]benzyl}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 467 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.62 (brs, 1H), 8.04 (brs, 1H), 7.91 (d, J=7.2 Hz, 1H), 7.35 (s, 1H), 7.26 (s, 1H), 7.20 (t, J=7.6 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.59 (brs, 1H), 4.42 (d, J=5.2 Hz, 2H), 4.22 (m, 1H), 3.23 (s, 6H), 2.33 (m, 1H), 2.31 (d, J=7.2 Hz, 2H), 2.23 (m, 1H), 2.21 (s, 3H), 1.96-1.87 (m, 6H), 1.62 (m, 2H), 1.00 (d, J=6.0 Hz, 6H).

Example 2531

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{3-[(2,2-dimethylpropanoyl)amino]benzyl}cyclohexanecarboxamide

Step A: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{3-[(2,2-dimethylpropanoyl)amino]benzyl}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 467 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.84 (brs, 1H), 7.78 (d, J=7.6 Hz, 1H), 7.40 (s, 1H), 7.25 (s, 1H), 7.22 (t, J=7.6 Hz, 1H), 7.00 (d, J=7.6 Hz, 1H), 6.85 (brs, 1H), 4.41 (d, J=5.6 Hz, 2H), 4.23 (m, 1H), 3.23 (s, 6H), 2.34 (m, 1H), 2.22 (s, 3H), 1.99-1.84 (m, 6H), 1.60 (m, 2H), 1.33 (s, 9H).

Example 2532

cis-N-{3-[(Cyclobutylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclobutylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 465 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.50 (brs, 1H), 8.23 (brs, 1H), 7.93 (d, J=6.4 Hz, 1H), 7.33 (s, 1H), 7.24 (s, 1H), 7.20 (t, J=8.0 Hz, 1H), 6.92 (d, J=8.0 Hz, 1H), 6.76 (brs, 1H), 4.41 (d, J=5.6 Hz, 2H), 4.23 (m, 1H), 3.33 (m, 1H), 3.24 (s, 6H), 2.35 (m, 4H), 2.21 (s, 3H), 2.18 (m, 1H), 2.00-1.87 (m, 8H), 1.60 (m, 2H).

Example 2533

cis-N-{3-[(Cyclopentylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclopentylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 479 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.47 (brs, 1H), 8.10 (brs, 1H), 7.91 (d, J=6.4 Hz, 1H), 7.35 (s, 1H), 7.26 (s, 1H), 7.20 (t, J=8.0 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.61 (brs, 1H), 4.42 (d, J=5.6 Hz, 2H), 4.22 (m, 1H), 3.22 (s, 6H), 2.85 (m, 1H), 2.33 (m, 1H), 2.21 (s, 3H), 2.00-1.88 (m, 10H), 1.75 (m, 2H), 1.60 (m, 4H).

Example 2534

cis-N-{3-[(Cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

Step A: Synthesis of cis-N-{3-[(cyclohexylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 493 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.30 (brs, 1H), 8.01 (brs, 1H), 7.86 (d, J=7.6 Hz, 1H), 7.36 (s, 1H), 7.26 (s, 1H), 7.20 (t, J=8.0 Hz, 1H), 6.94 (d, J=7.6 Hz, 1H), 6.65 (brs, 1H), 4.41 (d, J=5.2 Hz, 2H), 4.22 (m, 1H), 3.22 (s, 6H), 2.35 (m, 2H), 2.21 (s, 3H), 1.96-1.28 (m, 18H).

Example 2535

cis-N-{3-[(Cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide

Step A: Synthesis of cis-N-{3-[(cyclopropylcarbonyl)amino]benzyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide.

Using the procedure of step E of example 2528, the title compound was obtained.

ESI MS m/e 451 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.10 (brs, 1H), 7.93 (m, 1H), 7.36 (s, 1H), 7.25 (s, 1H), 7.19 (t, J=8.0 Hz, 1H), 6.90 (d, J=7.2 Hz, 1H), 6.50 (brs, 1H), 4.43 (d, J=6.0 Hz, 2H), 4.23 (m, 1H), 3.23 (s, 6H), 2.33 (m, 1H), 2.21 (s, 3H), 1.96-1.88 (m, 7H), 1.63 (m, 2H), 1.03 (m, 2H), 0.79 (m, 2H).

Example 2536

N-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide.

Step A: Synthesis of {cis-4-[(3-nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester.

A mixture of cis-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (1.55 g, 6.8 mmol) and 3-nitrobenzoyl chloride (1.25 g, 6.8 mmol) was stirred overnight at room temperature, diluted with DCM, washed with 1N-HCl and water, and concentrated. The crude product was preliminary purified by a short pad of silica gel with DCM/MeOH (100:0 to 90:10) to give 1.5 g (75%) of {cis-4-[(3-nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester.

ESI MS m/e 378 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.54 (t, J=2.0 Hz, 1H), 8.33 (d, J=8.0 Hz, 1H), 8.14 (d, J=8.0 Hz, 1H), 7.63 (t, J=7.6 Hz, 1H), 6.31 (brs, 1H), 4.62 (brs, 1H), 3.73 (brs, 1H), 3.41 (t, J=6.4 Hz, 2H), 1.72-1.57 (m, 7H), 1.44 (s, 9H), 1.32 (m, 2H).

Step B: Synthesis of cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride.

{cis-4-[(3-Nitro-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (1.4 g, 3.7 mmol) in DCM/TFA (1:1=13 mL) was stirred for 2 h at room temperature. After removal of the volatile solvent, the residue was dissolved in DCM (10 mL), and 2M-HCl in ether (4 mL) was added. After stirring for 20 min at room temperature, removal of the volatile solvent gave 1.2 g (82%) of cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride as the desired product.

ESI MS m/e 278 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.91 (t, J=5.6 Hz, 1H), 8.65 (m, 1H), 8.36 (d, J=2.0 Hz, 1H), 8.29 (d, J=8.0 Hz, 1H), 7.97 (brs, 2H), 7.74 (t, J=8.0 Hz, 1H), 3.25 (t, J=6.8 Hz, 2H), 3.13 (brs, 1H), 1.77 (m, 1H), 1.65-1.61 (m, 4H), 1.51 (m, 4H).

Step C: Synthesis of cis-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3-nitrobenzamide.

A solution of 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25 g, 1.46 mmol) and cis-N-(4-amino-cyclohexylmethyl)-3-nitro-benzamide hydrochloride (0.46 g) in IPA (2 mL) and DIEA (0.46 mL) was reacted for 1 hr 10 min. at 155° C. in a Smith synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, dried over MgSO₄, and concentrated. The crude compound was purified from column chromatography (silica gel, DCM/MeOH=100:0 to 90:10) to give 0.23 g (38%) of cis-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3-nitro-benzamide.

ESI MS m/e 413.2 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.73 (t, J=2.0 Hz, 1H), 8.34 (d, J=7.6 Hz, 1H), 8.28 (d, J=8.0 Hz, 1H), 8.20 (brs, 1H), 7.60 (t, J=7.6 Hz, 1H), 7.35 (brs, 1H), 7.25 (s, 1H), 4.18 (m, 1H), 3.48 (t, J=4.8 Hz, 2H), 3.24 (s, 6H), 2.21 (s, 3H), 1.89-1.57 (m, 9H).

Step D: Synthesis of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide.

A solution of cis-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3-nitro-benzamide (0.22 g, 0.53 mmol) and 10% Pd/C (30 mg) in EtOH (15 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite. After removal of the volatile solvent, the residue was purified from a short pad of silica gel (DCM/MeOH=100:0 to 80:20) to give 0.19 g (95%) as yellowish oil. 17 mg (0.04 mmol) of this oil was reacted with isovaleryl chlorides (5 mg, 0.04 mmol) using the procedure of step E of example 2528 to give N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-[(3-methylbutanoyl)amino]benzamide (9 mg, 47%).

ESI MS m/e 467.6 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.11 (brs, 1H), 8.22 (d, J=7.2 Hz, 1H), 8.04 (s, 1H), 7.55 (d, J=7.6 Hz, 1H), 7.34 (t, J=7.6 Hz, 1H), 7.30 (s, 1H), 6.42 (m, 1H), 4.14 (m, 1H), 3.43 (t, J=4.8 Hz, 2H), 3.19 (s, 6H), 2.33 (d, J=6.8 Hz, 2H), 2.25 (m, 1H), 2.20 (s, 3H), 1.94 (m, 2H), 1.72-1.59 (m, 7H), 1.02 (d, J=6.4 Hz, 6H).

Example 2537

N-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(propionylamino)benzamide

Step A: Synthesis of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-(propionylamino)benzamide.

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 439 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.10 (brs, 1H), 8.23 (d, J=7.2 Hz, 1H), 8.02 (s, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.35 (t, J=7.6 Hz, 1H), 7.29 (s, 1H), 6.36 (m, 1H), 4.16 (brs, 1H), 3.47 (m, 2H), 3.21 (s, 6H), 2.50 (q, J=7.6 Hz, 2H), 2.21 (s, 3H), 1.95 (m, 2H), 1.72-1.61 (m, 7H), 1.25 (t, J=7.2 Hz, 3H).

Example 2538

N-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(isobtityrylamino)benzamide

Step A: Synthesis of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3-(isobutyrylamino)benzamide

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 453 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.09 (brs, 1H), 8.23 (d, J=6.8 Hz, 1H), 8.07 (s, 1H), 7.55 (d, J=7.6 Hz, 1H), 7.34 (t, J=7.6 Hz, 1H), 7.29 (s, 1H), 6.38 (m, 1H), 4.16 (brs, 1H), 3.45 (m, 2H), 3.21 (s, 6H), 2.73 (m, 1H), 2.20 (s, 3H), 1.95 (m, 2H), 1.72-1.61 (m, 7H), 1.26 (d, J=6.8 Hz, 6H).

Example 2539

3-[(Cyclopropylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Step A: Synthesis of 3-[(cyclopropylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 451 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.60 (brs, 1H), 8.22 (d, J=6.8 Hz, 1H), 8.03 (s, 1H), 7.56 (brs, 1H), 7.55 (d, J=7.6 Hz, 1H), 7.32 (t, J=7.6 Hz, 1H), 7.28 (s, 1H), 6.41 (m, 1H), 4.15 (brs, 1H), 3.45 (m, 2H), 3.21 (s, 6H), 2.20 (s, 3H), 1.95 (m, 2H), 1.89 (m, 1H), 1.72˜1.61 (m, 7H), 1.05 (m, 2H), 0.82 (m, 2H).

Example 2540

3-[(Cyclobutylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Step A: Synthesis of 3-[(cyclobutylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 465 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.90 (brs, 1H), 8.21 (d, J=6.8 Hz, 1H), 8.04 (s, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.34 (t, J=7.6 Hz, 1H), 7.31 (s, 1H), 6.41 (m, 1H), 4.14 (brs, 1H), 3.43 (t, J=5.2 Hz, 2H), 3.34 (m, 1H), 3.19 (s, 6H), 2.41 (m, 2H), 2.23 (m, 1H), 2.20 (s, 3H), 2.02-1.88 (m, 4H), 1.72-1.55 (m, 8H).

Example 2541

3-[(Cyclopentylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

Step A: Synthesis of 3-[(cyclopentylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 479 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.14 (brs, 1H), 8.22 (d, J=7.2 Hz, 1H), 8.07 (s, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 7.29 (s, 1H), 6.43 (m, 1H), 4.14 (brs, 1H), 3.44 (t, J=5.2 Hz, 2H), 3.19 (s, 6H), 2.91 (m,l H), 2.20 (s, 3H), 1.98-1.59 (m, 17H).

Example 2542

3-[(Cyclohexylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide

Step A: Synthesis of 3-[(cyclohexylcarbonyl)amino]-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide.

Using the procedure of step D of example 2536, the title compound was obtained.

ESI MS m/e 479 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.94 (brs, 1H), 8.17 (d, J=7.2 Hz, 1H), 8.05 (s, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.33 (t, J=8.0 Hz, 1H), 7.30 (s, 1H), 6.44 (m, 1H), 4.13 (brs, 1H), 3.42 (t, J=5.2 Hz, 2H), 3.19 (s, 6H), 2.42 (m, 1H), 2.20 (s, 3H), 1.98-1.52 (m, 15H), 1.29 (m, 4H).

Examples 2543-2553

Compounds 2543 to 2553 were prepared in a similar manner as described in Example 2497 using the appropriate acid chloride and amine intermediate from Step D.

Examples 2554-2557

Compounds 2554 to 2557 were prepared in a similar manner as described in Example 2502 using the appropriate carboxylic acid and amine intermediate from Example 2497 Step D.

Examples 2558-2561

Compounds 2558 to 2561 were prepared in a similar manner as described in Example 2515 using the appropriate isocyanate and amine intermediate from Example 2497 Step D.

Examples 2562 and 2563

Compounds 2562 and 2563 were prepared in a similar manner as described in Example 2523 using the appropriate acid chloride and amine intermediate from Step C.

Examples 2564-2570

Compounds 2564 to 2570 were prepared in a similar manner as described in Example 2526 using the appropriate acid chloride and amine intermediate from Step C.

Examples 2571-2587

Compounds 2571 to 2587 were prepared in a similar manner as described in Example 2527 using the appropriate benzyl amine and carboxylic acid intermediate from Step B.

Ex. No.	compound name	MS	class
2543	3-methyl-N-{cis-4-[(4-methylquinolin-2-	374.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2544	4-methyl-N-{cis-4-[(4-methylquinolin-2-	374.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2545	4-fluoro-N-{cis-4-[(4-methylquinolin-2-	378.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2546	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3-	428 (M + H)	3
	(trifluoromethyl)benzamide
2547	3-chloro-N-{cis-4-[(4-methylquinolin-2-	394.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2548	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3,5-	496.2 (M + H)	1
	bis(trifluoromethyl)benzamide
2549	3-methoxy-N-{cis-4-[(4-methylquinolin-2-	390.4 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2550	3-cyano-N-{cis-4-[(4-methylquinolin-2-	385.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2551	2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-	424.2 (M + H)	1
	yl)amino]cyclohexyl}acetamide
2552	3,4,5-trimethoxy-N-{cis-4-[(4-methylquinolin-2-	450.4 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2553	3,5-dimethoxy-N-{cis-4-[(4-methylquinolin-2-	420.2 (M + H)	1
	yl)amino]cyclohexyl}benzamide
2554	2-(3-methoxyphenoxy)-N-{cis-4-[(4-methylquinolin-2-	420.2 (M + H)	1
	yl)amino]cyclohexyl}acetamide
2555	(2R)-2-(3-chlorophenyl)-2-hydroxy-N-{cis-4-[(4-methylquinolin-	424.2 (M + H)	1
	2-yl)amino]cyclohexyl}acetamide
2556	2-(3-methylphenoxy)-N-{cis-4-[(4-methylquinolin-2-	404.2 (M + H)	1
	yl)amino]cyclohexyl}acetamide
2557	5-bromo-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-2-	428 (M + H)	1
	furamide
2558	N-[4-(benzyloxy)phenyl]-N′-{cis-4-[(4-methylquinolin-2-	481.2 (M + H)	2
	yl)amino]cyclohexyl}urea
2559	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N′-(4-	467.4 (M + H)	1
	phenoxyphenyl)urea
2560	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N′-(3-	467.4 (M + H)	2
	phenoxyphenyl)urea
2561	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-N′-(2-	467.4 (M + H)	1
	phenoxyphenyl)urea
2562	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	368.2 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2563	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	384.2 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
2564	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	384.2 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
2565	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	368.2 (M + H)	1
	yl]amino}cyclohexyl)-4-methylbenzamide
2566	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	388.2 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2567	3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	388.4 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2568	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	390.2 (M + H)	1
	yl]amino}cyclohexyl)-3,4-difluorobenzamide
2569	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	438.2 (M + H)	3
	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
2570	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	372.2 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
2571	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	494.2 (M + H)	1
	iodobenzyl)cyclohexanecarboxamide
2572	cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2573	cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2574	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-	382.2 (M + H)	1
	methylbenzyl)cyclohexanecarboxamide
2575	cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2576	cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-	428.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2577	cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-	402.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2578	cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-	504.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2579	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	398.2 (M + H)	1
	methoxybenzyl)cyclohexanecarboxamide
2580	cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-	402.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2581	cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2582	cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2583	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2584	cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2585	cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-	464.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2586	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	382.4 (M + H)	1
	methylbenzyl)cyclohexanecarboxamide
2587	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-	452.2 (M + H)	1
	(trifluoromethoxy)benzyl]cyclohexanecarboxamide

Example 2588

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (2.18 g, 10 mmol) in anhydrous benzene (25 mL) was slowly added 3,5-bistrifluoromethyl benzoyl chloride (2.8 g, 1 eq.) and followed by Et₃N (˜3 mL) at room temperature under N₂ atmosphere: formation of solid salts makes stirring difficult. The reaction was stirred vigorously for an additional 2 h at room temperature, washed with sat.-NaHCO₃ (3×) and water (1×), dried with MgSO₄, and concentrated to give [cis-4-[(3,5-bistrifluoromethyl-benzoylamino)-cyclohexyl]-carbamic acid tert-butyl ester (4.5 g, 99%), which was used for the next reaction without further purification. ESI MS m/e 455 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (s, 2H), 7.98 (s, 1H), 6.12 (bs, 1H), 4.58 (bs, 1H), 4.11 (m, 1H), 3.69 (bs, 1H), 1.95˜1.65 (m, 8H), 1.44 (s, 9H).

[cis-4-[(3,5-Bistrifluoromethyl-benzoylamino)-cyclohexyl]-carbamic acid tert-butyl ester (4.5 g, 10 mmol) was dissolved in DCM (20 mL), and TFA (10 mL) was added to the reaction. After 1.5 h stirring at room temperature, removal of the volatile solvent gave the crude N-(cis-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate as a sticky oil. With addition of water (˜50 mL) to the crude product, shaking for 5 to 10 min provided formation of precipitates. The precipitates were filtered, washed with water, and dried. 3.98 (82%) of N-(cis-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate was isolated as a white powder. ESI MS m/e 355 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.62 (bd, 1H, J=4.8 Hz), 8.47 (s, 2H), 8.29 (s, 1H), 7.84 (bs, 3H), 3.91 (bs, 1H), 3.16 (bs, 1H), 1.94 (m, 2H), 1.75˜1.66 (m, 6H).

Step B: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-5-methylpyrimidine (0.25 g, 1.45 mmol), N-(cis-4-amino-cyclohexyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate (0.68 g, 1 eq.), DIEA (0.5 mL, 2 eq.), and tert-BuOH (2.5 mL) was reacted for 2 h at 180° C. in a Smith microwave synthesizer: over 95% conversion was observed by LC-MS. The reaction was diluted with DCM, washed with diluted-HCl and water, dried, and concentrated. 0.35 g (48%) of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-bistrifluoromethyl-benzamide was isolated by column chromatography (silica gel; DCM:MeOH=100:0 to 95:5).

To a solution of this neutral compound in DCM (10 mL) was added 4M-HCl in dioxane (0.4 mL, 2 eq.). After 30 min stirring at room temperature, removal of the volatile solvent provided N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride as a white powder. ESI MS m/e 490 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.1 (bs, 1H), 8.78 (bd, 1H, J=5.6 Hz), 8.48 (s, 2H), 8.28 (s, 1H), 8.05 (bd, 1H, J=6.4 Hz), 7.62 (s, 1H), 3.91 (bs, 2H), 3.26 (s, 6H), 2.23 (s, 3H), 1.87 (m, 2H), 1.73 (bs, 6H).

Example 2589

N-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of cis-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (1.1 g, 4.8 mmol) in dry benzene (15 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (1.33 g, 1 eq.) and followed by Et₃N (2 mL) at room temperature under N₂. The reaction was stirred for an additional 2 h at room temperature, washed with sat.-NaHCO₃ (3×) and water (1×), dried with MgSO₄, and concentrated. The crude {cis-4-[(3,5-bistrifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester was used for the next reaction without further purification.

To a solution of {cis-4-[(3,5-bistrifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (2.1 g, 4.5 mmol) in DCM (10 mL) was added TFA (5 mL) at room temperature. After 1.5 h stirring at ambient temperature, removal of the volatile solvent gave the crude N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate as a sticky oil. After addition of water (˜40 mL) to the crude product, 5˜10 min shaking provided formation of precipitates. The ppts were filtered, washed with water, and dried. 1.40 (61%) of N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 369 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (bs, 1H), 8.47 (s, 2H), 8.29 (s, 1H), 7.78 (bs, 3H), 3.29 (t, 2H, J=6.8 Hz), 3.15 (bs, 1H), 1.78 (bs, 1H), 1.66 (m, 4H), 1.52 (m, 4H).

Step B: Synthesis of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-5-methylpyrimidine (0.21 g, 1.2 mmol), N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate (0.6 g, 1 eq.), DIEA (0.45 mL, 2 eq.), and tert-BuOH (2.5 mL) was reacted for 1.6 h at 185° C. in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with diluted HCl and water, dried, and concentrated. The crude product was purified by column chromatography (silica gel; DCM:MeOH=100:0 to 95:5). 0.3 g (50%) of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,5-bistrifluoromethyl-benzamide was isolated.

To a solution of neutral compound in DCM (10 mL) was added 4M-HCl in dioxane (0.3 mL, 2 eq.). After 30 min stirring at ambient temperature, removal of the volatile solvent provided N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride as a white powder. ESI MS m/e 504 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.5 (bs, 1H), 8.79 (d, 1H, J=8.0 Hz), 8.43 (s, 2H), 7.93 (s, 1H), 7.50 (bs, 1H), 7.15 (d, 1H, J=4.4 Hz), 4.23 (bs, 1H), 3.51 (bs, 2H), 3.27 (s, 6H), 2.23 (s, 3H), 1.89˜1.82 (m, 5H), 1.66˜1.60 (m, 4H).

Example 2590

N-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-5-methyl pyrimidine (0.4 g, 2.3 mmol), cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (0.61 g, 1 eq.), DIEA (0.8 mL, 2 eq.), and t-BuOH (2.5 mL), were reacted in a Smith microwave synthesizer for 6500 sec at 185° C. Completion of the reaction was confirmed by LC-MS. The combined reaction was diluted with DCM, washed with 1N-HCl (2×) and water (1×), and dried with anhydrous MgSO₄. The organic was concentrated and purified by column chromatography (silica gel; hexane:DCM:MeOH=1:5:0 to 0:95:5). Removal of the solvent gave 3.2 g (58%) of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

ESI MS m/z 398 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.00 (bs, 1H), 7.36 (m, 6H), 5.10 (s, 3H, NH-was overlapped), 4.12 (bs, 1H), 3.24 (s, 6H), 3.14 (t, 2H, J=6.4 Hz), 2.22 (s, 3H), 1.88˜1.50 (m, 9H).

Step B: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine.

The heterogenous mixture of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (3.0 g, 7.5 mmol) and 10% Pd/C (0.12 g) in EtOH (20 mL) was stirred overnight under H₂ atmosphere at room temperature. Cbz of all starting material was cleaved, which was confirmed by ESI MS. The reaction was filtered through a pad of celite, and the organic was concentrated and purified by column chromatography (silica gel, DCM:MeOH=100:0 to 80:20). 1.5 g (75%) of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine was isolated as a yellowish powder.

ESI MS m/z 264 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d6) (7.70 (bs, 2H), 7.60 (s, 1H), 6.05 (d, 1H, J=6.4 Hz), 3.89 (bs, 1H), 2.96 (s, 6H), 2.71 (d, 2H, J=6.8 Hz), 2.08 (s, 3H), 1.70˜1.45 (m, 9H).

Step C: Synthesis of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate.

To a solution of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine (25 mg, 0.01 mmol) in DCM (1.0 mL) was added 4-trifluoromethoxybenzoyl chloride (21 mg, 1 eq.), and followed by Et3N (30 (L). The reaction was stirred for 4 h at room temperature, concentrated, and purified by prep-HPLC. 20 mg (38%) of N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/z 452 (M+H)+; 1H NMR (400 MHz, CDCl₃) (13.9 (bs, 1H), 8.36 (bd, 1H, J=6.4 Hz), 7.88 (d, 2H, J=8.4 Hz), 7.27 (s, 1H), 7.23 (d, 2H, J=8.4 Hz), 7.08 (bs, 1H), 4.17 (bs, 1H), 3.42 (t, 2H, J=5.6 Hz), 3.28 (s, 6H), 2.23 (s, 3H), 1.91˜1.78 (m, 3H), 1.65˜1.55 (m, 6H).

Example 2591

3,5-Dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-methyl)cyclohexyl]benzamide trifluoroacetate

Step A: Synthesis of N-cis-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-5-methyl pyrimidine (0.4 g, 2.3 mmol), cis-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (0.53 g, 1 eq.), DIEA (0.7 mL, 2 eq.), and t-BuOH (2 mL), were reacted in a Smith microwave synthesizer for 7000 sec at 185° C. ESI MS confirmed that all starting material was consumed. The reactions were combined, diluted with DCM and washed with 1N-HCl (2×) and water (1×). The organic was concentrated and carried to the next step without a further purification.

The crude N-{cis-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester was dissolved in DCM (15 mL), and TFA (10 mL) was added. After 1.5 h stirring, removal of the volatile solvent gave N-cis-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine trifluoroacetate as a sticky oil. The sticky oil was treated with sat. NaOH (15 mL), and the basic aqueous layer was extracted with DCM (2×) to remove nonpolar organic impurity, and the aqueous was concentrated to give a solid residue. The solid residue was extracted several times with DCM/MeOH (3/1), and removal of the solvent provided neutral N-cis-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (1.5 g, 41%) as a yellowish powder.

ESI MS 264 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, 1H), 5.05 (bs, 1H), 3.29 (t, 2H, J=6.4 Hz), 3.03 (s, 7H, CH—NH2 was overlapped), 2.54 (bs, 2H), 2.13 (s, 3H), 1.72 (bm, 1H), 1.59˜1.45 (m, 8H).

Step B: Synthesis of 3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide trifluoroacetate.

To a solution of N-cis-4-[(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (28 mg, 0.01 mmol) in benzene/DCM (2/1, 1.5 mL) was added 3,5-dichlorobenzoyl chloride (22 mg, 1 eq.), and followed by Et₃N (30 μL). The reaction was stirred for 3 h at room temperature, concentrated, and purified by prep-HPLC. 30 mg (51%) of 3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 436 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.7 (bs, 1H), 8.71 (bs, 1H), 7.61 (d, 2H, J=1.6 Hz), 7.44 (t, 1H, J=1.6 Hz), 7.29 (s, 1H), 6.59 (d, 1H, J=6.4 Hz), 4.23 (bm, 1H), 3.36 (t, 2H, J=6.0 Hz), 3.29 (s, 6H), 2.24 (s, 3H), 1.81 (m, 3H), 1.68 (m, 4H), 1.45 (m, 2H).

Example 2592

N-[cis-4-({[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of N-cis-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-6-methyl pyrimidine (0.4 g, 2.3 mmol), cis-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (0.53 g, 1 eq.), DIEA (0.7 mL, 2 eq.), and t-BuOH (2 mL), were reacted in a Smith microwave synthesizer for 6500 sec at 185° C. The reaction was monitored by LC-MS. The combined reaction was diluted with DCM and washed with 1N-HCl (2×) and water (1×). The organic was concentrated and performed deprotection without a further purification.

To a solution of N-{cis-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester in DCM (15 mL) was added TFA (10 mL). The reaction was stirred for 1.5 h at room temperature, and removal of the volatile solvent gave N-cis-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine trifluoroacetate as a sticky oil. The sticky oil was treated with sat. NaOH (15 mL), and the basic aqueous layer was extracted with DCM (2×), and the aqueous was concentrated to give a solid residue. The solid residue was extracted several times with DCM/MeOH (3/1), and removal of the solvent provided neutral N-cis-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (2.1 g, 57%) as a yellowish powder.

ESI MS m/e 264 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 5.91 (bs, 1H), 5.65 (s, 1H), 3.33 (t, 2H, J=6.4 Hz), 3.06 (s, 6H), 2.97 (m, 1H), 2.27 (bs, 2H), 2.11 (s, 3H), 1.70 (m, 1H), 1.59˜1.45 (m, 8H).

Step B: Synthesis of N-[cis-4-({[(dimethylamino)-6-methylpyrimidin-2-yl]amino}-methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

To a solution of N-cis-4-[(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-methyl]-cyclohexylamine (20 mg, 0.008 mmol) in benzene/DCM (2/1, 1.5 mL) was added 3,5-bistrifluoromethylbenzoyl chloride (21 mg, 1 eq.), and followed by Et₃N (30 μL). The reaction was stirred for 3 h at room temperature, concentrated, and purified by prep-HPLC. 25 mg (53%) of N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 504 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.9 (bs, 1H), 8.86 (bs, 1H), 8.25 (s, 2H), 7.96 (s, 1H), 7.30 (d, 1H, J=6.4 Hz), 5.74 (s, 1H), 4.40 (bm, 1H), 3.42 (t, 2H, J=6.0 Hz), 3.26 (s, 3H), 3.13 (s, 3H), 2.33 (s, 3H), 1.91˜1.60 (m, 9H).

Example 2593

4-Chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide trifluoroacetate

Step A: Synthesis of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]carbamic acid benzyl ester.

Six sealed tubes, each containing 2-chloro-4-dimethylamino-6-methyl pyrimidine (0.4 g, 2.3 mmol), cis-(4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (0.61 g, 1 eq.), DIEA (0.8 mL, 2 eq.), and t-BuOH (2.5 mL), were reacted in a Smith microwave synthesizer for 6500 sec at 180° C. The combined reaction was diluted with DCM, washed with 1N-HCl (2×) and water (1×), dried with MgSO4, and concentrated. Purification by column chromatography (silica gel; hexane:DCM:MeOH=1:5:0 to 0:95:5) gave 4.8 g (86%) of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

ESI MS m/z 398 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.40 (bs, 1H), 7.38 (m, 5H), 5.70 (s, 1H), 5.10 (s, 3H, NH-was overlapped), 4.17 (bs, 1H), 3.14 (bs, 6H), 3.12 (t, 2H, J=6.0 Hz), 2.32 (s, 3H), 1.90˜1.50 (m, 9H).

Step B: Synthesis of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine.

The heterogenous solution of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (4.5 g, 11.3 mmol) and 10% Pd/C (0.20 g) in EtOH (25 mL) was stirred overnight under H₂ atmosphere at room temperature. The reaction was filtered through a pad of celite, and the organic was concentrated and purified by column chromatography (silica gel, DCM:MEOH=100:0 to 80:20). 2.2 g (76%) of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine was isolated as a yellowish powder.

ESI MS m/e 264 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.82 (bs, 1H), 5.72 (s, 1H), 4.40 (bs, 2H), 4.15 (bm, 1H), 3.16 (s, 6H), 2.84 (d, 2H, J=6.8 Hz), 2.32 (s, 3H), 1.80 (m, 2H), 1.70˜1.45 (m, 7H).

Step C: Synthesis of 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide trifluoroacetate.

To a solution of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]amine (25 mg, 0.01 mmol) in DCM/benzene (3/1, 1.0 mL) was added 4-chlorobenzoyl chloride (17 mg, 1 eq.), and followed by Et₃N (30 μL). The reaction was stirred for 4 h at room temperature, concentrated, and purified by prep-HPLC. 25 mg (51%) of 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 402 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1H), 8.60 (bd, 1H, J=6.4 Hz), 7.78 (d, 2H, J=8.4 Hz), 7.35 (d, 2H, J=8.4 Hz), 7.03 (bm, 1H), 5.71 (s, 1H), 4.20 (bs, 1H), 3.42 (t, 2H, J=6.0 Hz), 3.22 (s, 3H), 3.10 (s, 3H), 2.31 (s, 3H), 1.91˜1.78 (m, 3H), 1.65˜1.55 (m, 6H).

Example 2594

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide hydrochloride

Step A: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid ethyl ester.

A sealed tube containing a suspension of 2-chloro-4-dimethylamino-5-methylpyrimidine (0.28 g, 1.6 mmol), cis-4-amino-cyclohexanecarboxylic acid ethyl ester hydrochloride (0.33 g, 1 eq.), DIEA (0.65 mL, 2 eq.) in IPA (2 mL) was reacted in a Smith microwave synthesizer for 1 hour at 155° C. The solution was diluted with DCM, washed with 1N-HCl and water, concentrated, and purified by flash chromatography (silica gel, 1% MeOH in CH₂Cl₂) to give cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester (0.3 g, 60%) as a pale yellow solid.

ESI MS m/e 307 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (s, 1H), 4.72 (bd, 1H, J=6.8 Hz), 4.13 (q, 2H, J=6.8 Hz), 3.96 (bs, 1H), 3.01 (s, 6H), 2.44 (m, 1H), 2.13 (s, 3H), 1.89 (m, 2H), 1.72 (m, 6H), 1.25 (t, 3H, J=6.8 Hz).

Step B: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid.

A suspension of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid ethyl ester (0.25 g, 0.8 mmol) in 4N-HCl (10 mL) was stirred for 4 h at 85° C. Progress of the reaction was monitored by LC-MS. The reaction was cooled to room temperature and completely removed the volatile solvent under a vacuum to give cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid (0.2 g, 90%) as a white powder.

ESI MS m/e 279 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.95 (bs, 1H), 7.43 (s, 1H), 3.94 (bs, 1H), 3.28 (bs, 6H), 2.49 (bs, 1H), 2.25 (s, 3H), 2.04 (m, 2H), 1.82 (m, 2H), 1.73 (m, 4H), COOH was not observed.

Step C: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide hydrochloride.

To a suspension of (S)-1-(4-methylphenyl)-ethylamine (12 mg, 1 eq.) and cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexanecarboxylic acid (24 mg, 0.09 mmol) in DCM (2 mL) was added HATU (36 mg, 1.1 eq.). The reaction stirred for 30 seconds at room temperature under argon, and triethylamine (5 drops) was added. The reaction stirred overnight at room temperature. The reaction was diluted with DCM, washed with saturated NaHCO₃ (2×) and H₂O (1×), and concentrated. Purification by column chromatography (silica gel; DCM:MeOH=100:0 to 94:6) gave cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid (S)-(1-p-tolyl-ethyl)-amide (15 mg, 43%). To a solution of the amide in DCM (1 mL) was added 4M-HCl in dioxane (50 μL). The reaction was stirred for 30 min at room temperature, and removal of the volatile solvent gave cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide hydrochloride as a white powder.

ESI MS m/e 396 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.0 (bs, 1H), 8.14 (d, 1H, J=8.4 Hz), 7.68 (bs, 1H), 7.54 (s, 1H), 7.14 (d, 2H, J=8.0 Hz), 7.07 (d, 2H, J=8.0 Hz), 4.84 (m, 1H), 4.01 (bs, 1H), 3.24 (s, 6H), 2.27 (m, 1H), 2.25 (s, 3H), 2.22 (s, 3H), 1.80˜1.54 (m, 8H), 1.29 (d, 3H, J=6.8 Hz).

Example 2595

2,2-Difluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate

Step A: Synthesis of 2,2-difluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate.

2-(3,5-Dimethoxy-4-formyl)phenoxy ethyl polystyrene resin (1.0 gram; 0.94 mmol/gram) and methylamine (0.0122 mol) in 15 mL of CH₂Cl₂ was suspended in a fritted synthesis flask. To this suspension was added a solution of NaBH(OAc)₃ (0.0122 mol) in CH₂Cl₂ (15 mL). After shaking the mixture overnight in a rotary shaker, the solution was removed by filtration. The resulting resin bound N-methylamine was washed sequentially with CH₂Cl₂, DMF, and MeOH. The washing sequence was repeated four times. The resin bound N-methylamine was dried under vacuum for 20 minutes.

The resin bound N-methylamine was suspended in DMF (10 mL). To the resin suspension was added 2,4-dichloro-5-methyl-pyrimidine (1.41 mmol) followed by triethylamine (0.393 mL, 2.82 mmol). The reaction mixture was shaken at 40° C. overnight. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂ and MeOH. The wash sequence was repeated four times. The resulting resin bound intermediate was dried under vacuum for 20 minutes

The resin bound intermediate was divided up into three portions and each portion was transferred into a 5 ml Smith synthesizer reaction vessel. The resins (0.282 mmol) were separately suspended in a 1:1 solution of IPA/H₂O (3 mL). To each suspension was added cis-1,4-diamino-cyclohexane (0.85 mmol) and DIEA (0.295 ml; 1.69 mmol). The reactions were heated in a microwave synthesizer at 180° C. for 4.5 hours. The resins were pooled together; and the solution removed by filtration. The resin was sequentially washed with IPA, H₂O, MeOH, CH₂Cl₂, and MeOH. The washing sequence was repeated three times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

The resin bound intermediate was suspended in DMF (10 ml). To the resin suspension was added the 2,2-diflouro-benzo[1,3]dioxole 5-carbonyl chloride (0.94 mmol) and triethylamine (0.256 mL; 1.88 mol). The reaction was shaken in a rotary mixer at room temperature for 45 minutes. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂, MeOH. The wash sequence repeated three times.

After drying under vacuum for 20 minutes, the resin was treated with 15 mL of TFA solution (TFA/CH₂Cl₂/H₂O 20:20:1 v/v). The reaction was shaken for 2 hours and the TFA solution was collected after filtration. The TFA was removed by rotary evaporation and the compound subjected to purification by preparative HPLC to give 2,2-difluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate (8.6 mg, 5%) as a white solid.

ESI MS m/e 420.5 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.21 (d, J=4 Hz, 1H), 7.75-7.67 (m, 2H), 7.41 (s, 1H), 7.28 (d, J=8 Hz, 1H), 3.99 (m, 2H), 3.05 (s, 3H), 1.99 (s, 3H), 1.95-1.71 (m, 8H).

Example 2596

5-Bromo-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide trifluoroacetate

Step A: Synthesis of 5-bromo-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 408.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.41 (s, 1H), 7.10 (s, 1H), 6.60 (s, 1H), 4.08-3.97 (m, 2H), 3.05 (s, 3H), 1.99 (s, 31H), 1.95-1.71 (m, 8H).

Example 2597

3,5-Dibromo-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide trifluoroacetate

Step A: Synthesis of 3,5-dibromo-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 496.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.37 (m, J=4 Hz, 1H), 8.02-7.91 (m, 3H) 7.41 (s, 1H), 4.12-3.97 (m, 2H), 3.05 (s, 3H), 1.99 (s, 3H), 1.95-1.71 (m, 8H).

Example 2598

3-Fluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 3-fluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(trifluoromethyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 426.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.02 (m, 1H), 7.98 (d, J=4 Hz, 1H) 7.68 (d, J=4 Hz 1H), 7.43-7.41 (s, 1H) 4.31-3.81 (m, 2H), 3.05 (s, 3H), 1.87 (s, 3H), 1.87-1.73 (m, 8H).

Example 2599

N-(cis-4-{[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 424.3 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.34 (d, J=4 Hz, 1H), 7.85 (d, J=8 Hz, 1H) 7.72-7.55 (s, 1H), 7.47-7.31 (m, 3H), 4.31-3.82 (m, 2H), 3.05 (s, 3H), 1.98 (s, 3H), 1.96-1.72 (m, 8H).

Example 2600

N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride.

To a solution of (2-chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (200 mg, 1.27 mmol) in 1 mL 2-propanol was added cis-N-(4-amino-cyclohexyl)-3,5-bis-trifluoromethyl-benzamide (676 mg, 1.91 mmol) and DIEA (2.54 mmol). The mixture was heated in a microwave synthesizer at 180° C. for 2 hours. The solvent was evaporated and the material subjected to chromatography (70˜95% ethyl acetate/hexanes). The combined compound in CH₂Cl₂ was added 2 M HCl in diethyl ether (1.5 ml, 0.38 mmol). The solvents were removed in vacuo to yield N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride (385.5 mg, 0.75 mmol, 59%) as a white solid.

ESI MS 476.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d6) δ 11.7 (s, 1H), 8.64 (s, 1H), 8.35 (s, 2H), 8.14 (s, 1H), 8.09 (bs, 1H), 8.00 (bs, 1H), 7.45 (s, 1H), 3.83 (bs, 1H), 3.75 (bs, 1H), 3.20 (s, 3H), 2.77-2.76 (d, J=4 Hz, 3H), 1.76 (m, 2H), 1.58 (m, 6H).

Example 2601

N-(cis-4-{[4-(Ethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(ethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 390.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.22 (d, J=4 Hz, 1H), 7.78 (m, 1H), 7.68 (m, 1H), 7.42 (s, 1H), 7.38 (m, 1H), 4.22-3.99 (m, 2H), 3.63-3.56 (quartet, J=4 Hz, 2H), 1.99 (s, 3H), 1.93-1.81 (m, 8H), 1.29-1.19 (t, J=8 Hz, 3H).

Example 2602

3,4-Difluoro-N-(cis-4-{[4-(isopropylamino)-5-methylpyrimidin-2yl]amino}cyclohexyl)-benzamide trifluoroacetate

Step A: Synthesis of 3,4-difluoro-N-(cis-4-{[4-(isopropylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 404.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.10 (m, 1H), 7.80-7.75 (m, 1H), 7.68 (m, 1H), 7.42 (s, 1H), 7.39-7.34 (m, 1H), 4.28-4.07 (m, 3H), 2.03 (s, 3H), 1.99-1.79 (m, 8H), 1.31-1.26 (d, J=12 Hz, 6H).

Example 2603

N-(cis-4-{[4-(cyclopropylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(cyclopropylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 402.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.78-7.73 (m, 1H), 7.69-7.66 (m, 1H), 7.42 (s, 1H), 7.40-7.33 (m, 1H), 4.26-3.88 (m, 2H), 3.02-2.96 (m, 1H), 1.97-1.81 (m, 11H), 0.90-0.85 (m, 2H), 0.72-0.68 (m, 2H).

Example 2604

3,4-Difluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide trifluoroacetate

Step A: Synthesis of 3,4-difluoro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 376.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.80-7.75 (m, 1H), 7.68 (m, 1H), 7.43-7.35 (m, 2H), 4.31-4.06 (m, 2H), 3.05 (s, 3H), 2.04 (s, 3H), 1.99-1.75 (m, 8H).

Example 2605

2-(3,4-Dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-(3,4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 438.3 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.45-7.40 (m, 2H), 7.20 (s, 1H), 6.97-6.94 (m, 1H), 4.55 (s, 2H), 3.92-3.34 (s, 2H) 3.04 (s, 3H), 1.98 (s, 3H), 1.53-1.71 (m, 8H).

Example 2606

2-(2,3-Dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate.

Using the procedure of Example 2595, the title compound was obtained.

ESI MS m/e 438.3 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.42 (s, 1H), 7.31-6.92 (m, 3H), 4.65 (s, 2H), 4.07-3.95 (m, 2H), 3.05 (s, 3H), 1.98 (s, 3H), 1.93-1.69 (m, 8H).

Example 2607

N-(cis-4-{[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate

Step A: Synthesis of 2,4-dichloro-5,6-dimethyl-pyrimidine.

To a suspension of 2,4-dihydroxy-5,6-dimethylpyrimidine (6.2 g, 0.044 mol) in POCl₃ (25 mL) was slowly added N,N-dimethylaniline (6.18 mL, 0.049 mol). The mixture was then refluxed at 125° C. for 3 hours. After this time, the starting material completely dissolved indicating that the reaction was completed. The reaction mixture was cooled and then poured slowly onto ice to quench the POCl₃ (caution exothermic!). A precipitate formed, which was filtered and washed with ice-cold water. The precipitate was dried under high vacuum overnight to yield 2,4-dichloro-5,6-dimethyl-pyrimidine (7.2 g, 0.041 mol, 92%) as a yellow solid.

¹H NMR (400 MHz, CDCl₃) δ 2.56 (s, 3H), 2.36 (s, 3H).

Step B: Synthesis of (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-5,6-dimethyl-pyrimidine (0.2 g, 0.0011 mol) in 1 mL 2-propanol was added DIEA (268 uL, 0.0017 mol) and dimethylamine (514 uL, 0.0010 mol). The mixture was then heated in a microwave at 170° C. for 10 minutes. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (0-50% ethyl acetate in hexanes) to yield (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine (75 mg, 0.40 mmol, 40%) as a white solid.

ESI MS 186.0 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 3.03 (s, 6H), 2.37 (s, 3H), 2.15 (s, 3H).

Step C: Synthesis of cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (2-chloro-5,6-dimethyl-pyrimidin-4-yl)-dimethyl-amine (0.5 g, 0.0027 mol) in 2 mL 2-propanol was added DIEA (514 uL, 0.0040 mol) and cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (635 mg, 0.0030 mol). The mixture was then heated in a microwave at 170° C. for 1 hour. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (0-100% ethyl acetate in hexanes) to yield cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (875 mg, 2.4 mmol, 89%) as a white solid.

ESI MS 364.6 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 3.97 (m, 1H), 3.53 (m, 1H), 2.95 (s, 6H), 2.23 (s, 3H), 2.09 (s, 3H), 1.78-1.55 (m, 8H), 1.48 (s, 9H).

Step D: Synthesis of cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane.

To a solution of cis-[4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (3.4 g, 0.0094 mol) in 40 mL CH₂Cl₂ was added TFA (1.4 mL, 0.019 mol). The solution was stirred at room temperature for 4 hours (or until the reaction was complete as judged by TLC). The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq)/NaHCO₃ (aq) solution (the aqueous layer was confirmed to remain basic during the extraction using pH paper indicator). The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated to yield cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (2.2 g, 0.0084 mol, 90%) as a white solid.

ESI MS 264.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 3.99 (m, 1H), 2.95 (s, 6H), 2.80 (m, 1H), 2.23 (s, 3H), 2.09 (s, 3H), 1.84-1.67 (m, 6H), 1.52-1.49 (m, 2H).

Step E: Synthesis of N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}-cyclohexyl)benzamide trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (30 mg, 0.11 mmol) in 0.5 mL DMF was added pyridine (13.8 uL, 0.17 mmol) and benzoyl chloride (12.6 uL, 0.11 mmol). The reaction mixture was stirred overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subject to purification by prep LCMS to yield N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidin-2-yl]amino}cyclohexyl)benzamide trifluoroacetate (27 mg, 0.056 mmol, 52%) as a white solid TFA salt.

ESI MS m/e 368.2 M+H⁺; ¹H NMR (400 MHz, CD3OD) δ 7.85-7.83 (m, 2H), 7.58-7.54 (m, 1H), 7.51-7.47 (m, 2H), 4.15 (m, 1H), 4.03 (m, 1H), 3.28 (s, 6H), 2.34 (s, 3H), 2.19 (s, 3H), 2.00-1.80 (m, 8H).

Example 2608

N-(cis-4-{[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}-cyclohexyl)-3-(trifluoromethyl)benzamide trifluoroacetate.

Using the procedure of Example 2607, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 436.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.16 (s, 1H), 8.12 (d, 1H, J=7.6 Hz), 7.89 (d, 1H, J=8.0 Hz), 7.71 (t, 1H, J=8.0 Hz), 4.16 (m, 1H), 4.05 (m, 1H), 3.28 (s, 6H), 2.34 (s, 3H), 2.20 (s, 3H), 2.00-1.82 (m, 8H).

Example 2609

N-(cis-4-{[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxynicotinamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}-cyclohexyl)-2-hydroxynicotinamide trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (30 mg, 0.11 mmol) in 0.5 mL DMF was added 2-hydroxynicotinic acid (15 mg, 0.11 mmol), DIEA (29.8 uL, 0.17 mmol), and HATU (52 mg, 0.14 mmol). The reaction mixture was stirred overnight and then 0.5 mL DMSO was added to the mixture. The compound was then subject to purification by prep LCMS to yield N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy nicotinamide trifluoroacetate (17 mg, 0.034 mmol, 31%) as a white solid.

ESI MS m/e 385.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.53 (dd, 1H, J₁=7.2 Hz, J₂=2.0 Hz), 7.70 (dd, 1H, J₁=6.4 Hz, J₂=2.0 Hz), 6.61 (t, 1H, J=6.8 Hz), 4.17 (m, 1H), 4.01 (m, 1H), 3.28 (s, 6H), 2.33 (s, 3H), 2.19 (s, 3H), 1.98-1.72 (m, 8H).

Example 2610

5-Bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide trifluoroacetate

Step A: Synthesis of 5-Bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide trifluoroacetate.

Using a similar procedure of Example 2609, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 436.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.15 (d, 1H, J=3.6 Hz), 6.63 (d, 1H, J=3.2 Hz), 4.16 (m, 1H), 3.99 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.19 (s, 3H), 1.98-1.95 (m, 2H), 1.89-1.76 (m, 6H).

Example 2611

N²-{cis-4-[(3,5-Dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate

Step A: Synthesis of N²-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (26.3 mg, 0.1 mmol) in 0.5 mL MeOH was added 3,5-dimethoxybenzaldehyde (15.0 mg, 0.09 mmol). The mixture was stirred at room temperature for a half an hour and then sodium triacetoxyborohydride (84.8 mg, 0.4 mmol) was added. The mixture was stirred at room temperature overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subjected to purification by prep LCMS to yield N²-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate (24 mg, 0.037 mmol, 42%) as a white solid TFA salt.

ESI MS m/e 414.6 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 6.71 (d, 2H, J=2.0 Hz), 6.59 (t, 1H, J=2.0 Hz), 4.28 (m, 1H), 4.21 (s, 2H), 3.84 (s, 6H), 3.28 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.19 (s, 3H), 2.10-2.08 (m, 4H), 1.85-1.83 (m, 4H).

Example 2612

N²-{cis-4-[(3-Bromobenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate

Step A: Synthesis of N²-{cis-4-[(3-bromobenzyl)amino]cyclohexyl}-N⁴,N⁴,5,6-tetramethylpyrimidine-2,4-diamine bis-trifluoroacetate.

Using the procedure of Example 2611, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 432.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.78 (s, 1H), 7.68 (d, 1H, J=8.0 Hz), 7.54 (d, 1H, J=7.6 Hz), 7.45 (t, 1H, J=4 Hz), 4.29 (m, 3H), 3.28 (m, 1H), 3.27 (s, 6H), 2.34 (s, 3H), 2.20 (s, 3H), 2.11-2.09 (m, 4H), 1.87-1.82 (m, 4H).

Example 2613

N-(cis-4-{[4-(Dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)urea trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2yl]amino}-cyclohexyl)-N′-(3-methoxyphenyl)urea trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5,6-dimethyl-pyrimidin-2-ylamino)-1-aminocyclohexane (26.3 mg, 0.1 mmol) in 0.5 mL DMSO was added 3-methoxyphenyl isocyanate (13.1 uL, 0.1 mmol). The mixture was stirred at room temperature overnight and then 0.5 mL of DMSO was added to the mixture. The compound was then subject to purification by prep LC MS to yield N-(cis-4-{[4-(dimethylamino)-5,6-dimethyl pyrimidin-2-yl]amino}cyclohexyl)-N′-(3′-methoxyphenyl)urea trifluoroacetate (28 mg, 0.053 mmol, 53%) as a white solid.

ESI MS m/e 413.6 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.18 (m, 2H), 6.86 (dd, 1H, J₁=8.0 Hz, J₂=2.0 Hz), 6.58 (dd, 1H, J₁=8.4 Hz, J₂=2.4 Hz), 4.03 (m, 1H), 3.82 (m, 1H), 3.79 (s, 3H), 3.27 (s, 6H), 2.33 (s, 3H), 2.19 (s, 3H), 1.92-1.73 (m, 8H).

Example 2614

N-(3,5-Difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate

Step A: Synthesis of N-(3,5-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate.

Using the procedure of Example 2613, the title compound was obtained as a white solid TFA salt.

ESI MS m/e 419.3 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 7.08-7.03 (m, 2H), 6.55-6.49 (m, 1H), 4.04 (m, 1H), 3.81 (m, 1H), 3.28 (s, 6H), 2.33 (s, 3H), 2.20 (s, 3H), 1.93-1.73 (m, 8H).

Example 2615

1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (35 mg, 0.14 mmol), 1-(4-chlorophenyl)-cyclobutanecarboxylic acid (30 mg, 1 eq.) in DCM (2 mL) was added HATU (58 mg, 1.1 eq.) and followed by Et₃N (40 μL, 2 eq.). The reaction was stirred at room temperature for 4 h, and completion of the reaction was confirmed by LCMS. After removal of the volatile solvent, the residue was purified by prep-HPLC to give 32 mg (41%) of 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate as a white solid.

ESI MS m/e 442 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.6 (bs, 1H), 8.38 (d, 1H, J=7.2 Hz), 7.32-7.22 (m, 5H), 5.76 (d, 1H, J=8.8 Hz), 4.09 (bs, 1H), 3.81 (m, 1H), 3.26 (s, 6H), 2.77 (m, 2H), 2.44 (m, 2H), 2.22 (s, 3H), 2.02 (m, 1H), 1.86 (m, 1H), 1.65˜1.50 (m, 8H).

Example 2616

2-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate

Step A: Synthesis of 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 430 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.3 (bs, 1H), 8.21 (d, 1H, J=7.6 Hz), 7.28 (bs, 4H), 7.22 (m, 1H), 5.67 (d, 1H, J=8.4 Hz), 4.09 (bs, 1H), 3.85 (m, 1H), 3.26 (s, 6H), 2.22 (s, 3H), 1.71˜1.61 (m, 6H), 1.54 (s, 6H), 1.50 (m, 2H).

Example 2617

2-[3,5-bis(Trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 532 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.9 (bs, 1H), 8.68 (d, 1H, J=7.6 Hz), 7.78 (s, 2H), 7.72 (s, 1H), 7.21 (d, 1H, J=4.4 Hz), 6.14 (d, 1H, J=8.4 Hz), 4.20 (bs, 1H), 3.93 (m, 1H), 3.26 (s, 6H), 2.22 (s, 3H), 1.77˜1.56 (m, 8H), 1.61 (s, 6H).

Example 2618

2-[3,5-bis(Trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide trifluoroacetate.

Using the procedure of Example 2615, the title compound was obtained.

ESI MS m/e 504 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1H), 8.51 (d, 1H, J=7.8 Hz), 7.78 (s, 2H), 7.73 (s, 1H), 7.22 (m, 1H), 5.87 (d, 1H, J=8.0 Hz), 4.15 (bs, 1H), 3.96 (m, 1H), 3.62 (s, 2H), 3.28 (s, 6H), 2.24 (s, 3H), 1.80˜1.65 (m, 8H).

Example 2619

1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (36 mg, 0.14 mmol), 1-(4-chlorophenyl)-cyclopropanecarboxylic acid (31 mg, 1 eq.) in DCM (2 mL) was added HATU (60 mg, 1.1 eq.) and followed by Et₃N (40 μL, 2 eq.). The reaction was stirred at room temperature for 4 h, and completion of the reaction was confirmed by ESI MS. After removal of the volatile solvent, the residue was purified by prep-HPLC to give 45 mg (72%) of 1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropane carboxamide trifluoroacetate as a white solid.

ESI MS m/e 428 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.4 (bs, 1H), 8.61 (d, 1H, J=7.2 Hz), 7.32 (m, 4H), 5.70 (s, 1H), 5.46 (d, 1H, J=8.0 Hz), 4.04 (bs, 1H), 3.79 (m, 1H), 3.21 (s, 3H), 3.10 (s, 3H), 2.31 (s, 3H), 1.68˜1.47 (m, 9H), 1.22 (m, 1H), 1.00 (m, 2H).

Example 2620

1-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide trifluoroacetate.

Using the procedure of Example 2619, the title compound was obtained.

ESI MS m/e 442 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.1 (bs, 1H), 8.41 (d, 1H, J=7.6 Hz), 7.28 (s, 4H), 5.95 (d, 1H, J=8.8 Hz), 5.72 (s, 1H), 4.14 (bs, 1H), 3.82 (m, 1H), 3.21 (s, 3H), 3.11 (s, 3H), 2.77 (m, 2H), 2.44 (m, 2H), 2.31 (s, 3H), 2.01 (m, 1H), 1.83 (m, 1H), 1.70˜1.50 (m, 8H).

Example 2621

1-(2,4-Dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate.

Using the procedure of Example 2619, the title compound was obtained.

ESI MS m/e 462 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.4 (bs, 1H), 8.54 (bs, 1H), 7.43 (s, 1H), 7.28 (d, 1H, J=8.4 Hz), 7.26 (d, 1H, J=8.0 Hz), 5.70 (s, 1H), 5.39 (d, 1H, J=8.0 Hz), 4.06 (bs, 1H), 3.84 (m, 1H), 3.20 (s, 3H), 3.10 (s, 3H), 2.30 (s, 3H), 1.69˜1.62 (m, 8H), 1.50 (m, 2H), 1.01 (m, 2H).

Example 2622

2-[3,5-bis(Trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate

Step A: Synthesis of 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide trifluoroacetate.

Using the procedure of Example 2619, the title compound was obtained.

ESI MS m/e 532 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1H), 8.80 (d, 1H, J=8.4 Hz), 7.79 (s, 2H), 7.72 (s, 1H), 6.20 (d, 1H, J=8.4 Hz), 5.70 (s, 1H), 4.24 (bs, 1H), 3.94 (bm, 1H), 3.22 (s, 3H), 3.10 (s, 3H), 2.30 (s, 3H), 1.79˜1.60 (m, 8H), 1.61 (s, 6H).

Example 2623

2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide hydrochloride

Step A: 2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide hydrochloride.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (43 mg, 0.17 mmol), 3,4-difluoro mandelic acid (34 mg, 1 eq.) in DCM (2 mL) was added HATU (68 mg, 1.1 eq.) and followed by Et₃N (50 μL, 2 eq.). The reaction was stirred at room temperature for 4 h and quenched. After removal of the volatile solvent, the residue was purified by column chromatography (DCM:MeOH=100:0 to 94:6). 28 mg (39%) of the product was isolated and converted into HCl salt.

ESI MS m/e 420 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (d, 1H, J=8.0 Hz), 7.39˜7.20 (m, 3H), 7.04 (m, 1H), 5.05 (s, 1H), 4.08 (bs, 1H), 3.89 (bs, 1H), 3.26 (s, 6H), 2.22 (s, 3H), 1.78˜1.60 (m, 8H), two exchangeable protons (—NH— and —OH) were not detected.

Example 2624

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 452 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.83 (bs, 1H), 7.22 (s, 1H), 7.65 (d, 1H, J=8.0 Hz), 7.51 (d, 1H, J=8.0 Hz), 7.42 (t, 1H, J=8.0 Hz), 7.22 (s, 1H), 7.00 (d, 1H, J=8.0 Hz), 5.10 (s, 1H), 4.04 (bs, 1H), 3.89 (bs, 1H), 3.20 (s, 6H), 2.18 (s, 3H), 1.78˜1.64 (m, 8H), one exchangeable proton (—OH) was not detected.

Example 2625

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 414 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.72 (d, 1H, J=6.8 Hz), 7.31 (d, 2H, J=8.4 Hz), 7.22 (s, 1H), 6.83 (d, 2H, J=8.4 Hz), 6.78 (d, 1H, J=7.6 Hz), 4.98 (s, 1H), 4.06 (bs, 1H), 3.90 (bs, 1H), 3.76 (s, 3H), 3.25 (s, 6H), 2.20 (s, 3H), 1.78˜1.64 (m, 8H.

Example 2626

2-(3-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide

Step A: Synthesis of 2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 418 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.63 (bs, 1H), 7.44 (s, 1H), 7.33 (m, 1H), 7.21 (m, 2H), 7.12 (bs, 1H), 5.03 (s, 1H), 4.08 (bs, 1H), 3.88 (bs, 1H), 3.24 (s, 6H), 2.19 (s, 3H), 1.78˜1.63 (m, 8H).

Example 2627

2-(2,3-Difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide

Step A: Synthesis of 2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide.

Using the procedure of Example 2623, the title compound was obtained.

ESI MS m/e 420 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.26 (s, 1H), 7.14 (m, 1H), 7.06 (m, 2H), 6.73 (d, 1H, J=8.0 Hz), 5.32 (s, 1H), 4.06 (bs, 1H), 3.93 (bs, 1H), 3.22 (s, 6H), 2.20 (s, 3H), 1.78˜1.64 (m, 8H).

Example 2628

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-(trifluoromethyl)benzenesulfonamide hydrochloride.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (45 mg, 0.18 mmol) in IPA (2 mL) was added 2-trifluoromethyl benzenesulfonyl chloride (44 mg, 1 eq.) and followed by DIEA (50 μL, 2 eq.). The reaction was stirred at room temperature for 1.5 h under an inert atmosphere, and the progress of the reaction was monitored by ESI MS. The reaction was diluted with DCM (7 mL), washed with saturated NaHCO₃ (1×5 mL) and water (1×5 mL), and concentrated. The crude product was purified by column chromatography (DCM:MeOH=100:0 to 95:5). 31 mg (38%) of the product was isolated and converted into HCl salt.

ESI MS m/e 458 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (bs, 1H), 8.13 (m, 2H), 8.06 (d, 1H, J=6.0 Hz), 7.93 (d, 1H, J=8.0 Hz), 7.87 (t, 1H, J=7.6 Hz), 7.79 (t, 1H, J=7.6 Hz), 7.62 (bs, 1H), 3.78 (bs, 1H), 3.22 (s, 6H), 3.21 (bs, 1H), 2.20 (s, 3H), 1.78˜1.54 (m, 8H).

Example 2629

4-Chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzenesulfonamide hydrochloride

Step A: Synthesis of 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzenesulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 424 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (bs, 1H), 7.92 (bs, 1H), 7.83 (s, 1H, overlapped with the doublet of 7.81 ppm), 7.81 (d, 2H, J=8.4 Hz), 7.64 (d, 2H, J=8.4 Hz), 7.58 (bs, 1H), 3.74 (bs, 1H), 3.21 (s, 6H), 3.08 (bs, 1H), 2.20 (s, 3H), 1.70˜1.44 (m, 8H).

Example 2630

2-Bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-benzenesulfonamide hydrochloride

Step A: Synthesis of 2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzenesulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 468 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (bs, 1H), 8.00 (d, 1H, J=7.2 Hz), 7.92 (bs, 1H), 7.82 (d, 2H, J=7.6 Hz), 7.59˜7.48 (m, 3H), 3.73 (bs, 1H), 3.21 (s, 6H), 3.20 (bs, 1H), 2.20 (s, 3H), 1.72 (m, 2H), 1.58 (m, 6H).

Example 2631

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)thiophene-2-sulfonamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)thiophene-2-sulfonamide hydrochloride.

Using the procedure of Example 2628, the title compound was obtained.

ESI MS m/e 396 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.1 (bs, 1H), 7.99 (bs, 1H), 7.92 (bs, 1H), 7.88 (d, 1H, J=4.8 Hz), 7.60 (bs, 1H), 7.57 (d, 1H, J=2.8 Hz), 7.14 (t, 1H, J=4.8 Hz), 3.75 (bs, 1H), 3.22 (s, 6H), 3.17 (bs, 1H), 2.20 (s, 3H), 1.70˜1.51 (m, 8H).

Example 2632

N⁴,N⁴,5-Trimethyl-N²-(cis-4-{[3-(trifluoromethyl)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate

Step A: Synthesis of N⁴,N⁴,5-trimethyl-N²-(cis-4-{[3-(trifluoromethyl)benzyl]amino}-cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate.

A solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (31 mg, 0.12 mmol) and 3-trifluoromethyl benzaldehyde (22 mg, 1 eq.) in MeOH (1.5 mL) was stirred at room temperature for 4 h. NaBH(OAc)₃ (85 mg, ˜4 eq.) was added into the reaction, and the reaction was stirred overnight. The reaction was quenched with water, extracted with DCM, concentrated, and purified by prep-HPLC. 35 mg (54%) of N⁴,N⁴,5-trimethyl-N²-(cis-4-{[3-trifluoromethyl)benzyl]amino}cyclohexyl)pyrimidine-2,4-diamine bistrifluoroacetate was isolated as a white powder.

ESI MS m/e 408 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.7 (bs, 1H), 9.70 (bs, 2H), 8.60 (d, 1H, J=8.8 Hz), 7.70 (m, 2H), 7.59 (d, 1H, J=8.0 Hz), 7.48 (t, 1H, J=8.4 Hz), 4.31 (m, 1H), 4.23 (s, 2H), 3.30 (m, 1H), 3.29 (s, 6H), 2.25 (s, 3H), 2.05 (m, 2H), 1.93 (m, 4H), 1.64 (m, 2H).

Example 2633

N²-(cis-4-{[4-(Difluoromethoxy)benzyl]amino}cyclohexyl)-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine bistrifluoroacetate

Step A: Synthesis of N²-(cis-4-{[4-(difluoromethoxy)benzyl]amino}cyclohexyl)-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine bistrifluoroacetate.

Using the procedure of Example 2632, the title compound was obtained.

ESI MS m/e 406 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1H), 9.60 (bs, 1H), 8.60 (d, 1H, J=8.8 Hz), 7.46 (d, 2H, J=8.8 Hz), 7.24 (s, 1H), 7.07 (d, 2H, J=8.8 Hz), 6.48 (t, 1H, J_F-H=73.6 Hz), 4.31 (m, 1H), 4.15 (s, 2H), 3.40 (bs, 1H), 3.29 (s, 6H), 2.24 (s, 3H), 2.05 (m, 2H), 1.90 (m, 4H), 1.63 (m, 2H).

Example 2634

N²-{cis-4-[(3-Bromo-4-methoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine bistrifluoroacetate

Step A: Synthesis of N²-{cis-4-[(3-bromo-4-methoxybenzyl)amino]cyclohexyl}-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine bistrifluoroacetate.

Using the procedure of Example 2632, the title compound was obtained.

ESI MS m/e 448 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.8 (bs, 1H), 9.44 (bs, 1H), 8.57 (d, 1H, J=8.0 Hz), 7.58 (d, 1H, J=2.4 Hz), 7.41 (dd, 1H, J=8.8 and 2.0 Hz), 7.24 (s, 1H), 6.86 (d, 1H, J=8.0 Hz), 4.29 (m, 1H), 4.07 (s, 2H), 3.86 (s, 3H), 3.28 (s, 6H), 3.25 (bs, 1H), 2.24 (s, 3H), 2.05˜1.85 (m, 6H), 1.64 (m, 2H).

Example 2635

N²-(3,4-Dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methylglycinamide bistrifluoroacetate

Step A: Synthesis of 2-bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide.

cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (3.5 g, 14.0 mmol) was dissolved in 20 mL of methylene chloride, and cooled to 0° C. in an ice bath. Bromo-acetyl bromide (1.26 mL, 14.0 mmol) was added dropwise into the stirring solution over the ice bath. The reaction mixture was stirred at room temperature for 10 minutes. Methylene chloride was evaporated off to yield 2-bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide as a pinkish crude solid. (6.1 g, 95%).

ESI MS m/z 370.1 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 12.20 (s, 1H), 8.21 (d, J=7.2 Hz, 1H), 6.85 (d, J=6.8 Hz, 1H), 4.15 (s, 1H), 3.97-3.89 (m, 3H), 3.31 (s, 6H), 2.27 (s, 3H), 1.93-1.72 (m, 8H).

Step B: Synthesis of N²-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methylglycinamide bistrifluoroacetate.

2-Bromo-N-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide (50 mg, 0.135 mmol) and (3,4-dichloro-phenyl)-methyl-amine (48 mg, 0.270 mmol) were dissolved in 0.8 mL of DMF. The reaction mixture was heated via Smith Synthesizer at 180° C. for 50 minutes. The crude was purified by HPLC to give N²-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N²-methylglycinamide bistrifluoroacetate as a white solid. (12.8 mg, 18%)

ESI MS m/z 465.3 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, J=6.0 Hz, 1H), 6.80 (d, J=2.8 Hz, 1H), 6.67-6.65 (m, 1H), 6.57 (dd, J=9.0, 3.0 Hz, 1H), 4.13 (s, 1H), 3.98 (s, 1H), 3.86 (s, 2H), 3.29 (s, 6H), 3.06 (s, 3H), 2.25 (s, 3H), 1.73-1.62 (m, 8H).

Example 2636

N-[((1R,3S)-3-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate

Step A: Synthesis of (3-{[(2-Chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid tert-butyl ester.

(3-Aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester (0.050 g, 0.23 mmol), 2-chloronicotinoyl chloride (0.041 g, 0.23 mmol), and diisopropylethylamine (0.061 mL, 0.34 mmol) were combined in dichloromethane (2.00 mL) at ambient temperature and stirred 18 hrs. The mixture was concentrated and purified by flash silica chromatography (5% methanol in ethyl acetate) to give (3-{[(2-chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid tert-butyl ester (0.035 g, 43%) as a solid.

ESI MS m/e 354, M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.47 (dd, Jaa=1.5 Hz, Jab=4.7 Hz, 1H), 8.11 (dd, Jaa=1.5 Hz, Jab=7.6 Hz, 1H), 7.35 (dq, Jaa=1.2 Hz, Jab=4.8 Hz, Jac=7.6 Hz, 1H), 6.56 (bs, 1H), 4.59 (bs, 1H), 3.97 (m, 1H), 3.48 (m, 2H), 2.27 (m, 2H), 1.94 (m, 2H), 1.49 (m, 1H), 1.44 (s, 9H), 1.25 (m, 2H).

Step B: Synthesis of N-(3-Amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide.

(3-{[(2-Chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid tert-butyl ester (0.23 mmol), 4-fluorophenol (0.026 g, 0.23 mmol), cesium carbonate (0.152 g, 0.46 mmol), and dioxane (2.00 mL) were combined and heated to 180° C. for 1 hr. utilizing a SmithSynthesizer microwave apparatus. Trifluoroacetic acid (3.00 mL) was added and the mixture stirred 18 hrs. Then it was concentrated, neutralized with saturated aqueous NaHCO₃, extracted with dichloromethane, and concentrated to give N-(3-amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide as the crude product.

ESI MS m/e 330, M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (dd, Jaa=1.0 Hz, Jab=7.6 Hz, 1H), 8.19 (dd, Jaa=1.9 Hz, Jab=3.9 Hz, 1H), 8.06 (t, J=5.8 Hz, 1 Hz), 6.91 (t, J=8.2 Hz, 1H), 6.77 (dd, Jaa=3.6 Hz, Jab=3.2 Hz, 1H), 3.62 (m, 2H), 2.26 (m, 2H), 2.05 (m, 1H), 1.81 (m, 2H), 1.62 (m, 1H), 1.48 (m, 2H).

Step C: Synthesis of N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]-amino}cyclopentyl)methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate.

5-Methyl-4-dimethylamino-2-chloropyrimidine (0.040 g, 0.23 mmol), N-(3-amino-cyclopentylmethyl)-2-(4-fluoro-phenoxy)-nicotinamide (0.23 mmol), diisopropyl-ethylamine (0.061 mL, 0.34 mmol), and isopropanol (2.00 mL) were combined and heated to 180° C. for 2 hrs. utilizing a SmithSynthesizer microwave apparatus. The mixture was then purified by prep LCMS (gradient: 15-95% acetonitrile-water with 0.05% TFA) to give N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-2-(4-fluorophenoxy)nicotinamide trifluoroacetate as a white solid (0.018 g, 13.5% over two steps).

ESI MS m/e 465, M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.63 (bs, 1H), 8.44 (t, J=5.7 Hz, 1H), 8.16 (dd, Jaa=1.9 Hz, Jab=4.8 Hz, 1H), 8.04 (dd, Jaa=1.8 Hz, Jab=7.4 Hz, 1H), 7.98 (bs, 1H), 7.53 (s, 1H), 7.25-7.19 (m, 2H), 4.08 (bs, 1H), 3.22 (s, 6H), 2.53 (s, 3H), 2.19 (m, 2H), 1.95 (m, 1H), 1.71 (m, 1H), 1.54 (m, 2H), 1.46 (m, 2H), 1.22 (m, 2H).

Example 2637

N-[((1R,3S)-3-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate

Step A: Synthesis of (3-{[(6-Chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid tert-butyl ester.

(3-Aminomethyl-cyclopentyl)-carbamic acid tert-butyl ester (0.050 g, 0.23 mmol), 6-chloronicotinoyl chloride (0.041 g, 0.23 mmol), and diisopropylethylamine (0.061 mL, 0.34 mmol) were combined in dichloromethane (2.00 mL) at ambient temperature and stirred 18 hrs. The mixture was concentrated and purified by flash silica chromatography (5% methanol in ethyl acetate) to give an orange gel.

ESI MS m/e 354, M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, J=2.1 Hz, 1H), 8.09 (dd, Jaa=1.8 Hz, Jab=8.3 Hz, 1H), 7.41 (d, J=8.3 Hz, 1H), 6.48 (bs, 1H), 4.65 (d, J=8 Hz, 1H), 3.92 (m, 1H), 3.46 (m, 2H), 2.25 (m, 2H), 1.98 (m, 2H), 1.81 (m, 1H), 1.47 (s, 9H), 1.18 (m, 2H).

Step B: Synthesis of N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate.

(3-{[(6-Chloro-pyridine-3-carbonyl)-amino]-methyl}-cyclopentyl)-carbamic acid tert-butyl ester (0.23 mmol), 2-methoxyphenol (0.029 g, 0.23 mmol), cesium carbonate (0.152 g, 0.46 mmol), and dioxane (2.00 mL) were combined and heated to 180° C. for 1 hr. utilizing a SmithSynthesizer microwave apparatus. Trifluoroacetic acid (3.00 mL) was added and the mixture stirred 18 hrs. Then it was concentrated, neutralized with saturated aqueous NaHCO₃, extracted with dichloromethane, and concentrated to give a foam. 5-Methyl-4-dimethylamino-2-chloropyrimidine (0.040 g, 0.23 mmol), diisopropylethylamine (0.061 mL, 0.34 mmol), and isopropanol (2.00 mL) were added and the combined mixture was heated to 180° C. for 2 hrs utilizing a Smith synthesizer microwave apparatus. The mixture was then purified by prep-LCMS (gradient: 15-95% acetonitrile-water with 0.05% TFA) to give N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)nicotinamide trifluoroacetate as a white solid (0.011 g, 8.1% over four steps).

ESI MS m/e 477, M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 9.05 (bs, 1H), 8.63 (s, 1H), 8.16 (dd, Jaa=2.2 Hz, Jab=8.6 Hz, 1H), 7.58 (bs, 1H), 7.23 (s, 1H), 7.19 (d, J=6.2 Hz, 1H), 7.16 (dd, Jaa=1.5 Hz, Jab=7.7 Hz, 1H), 7.00 (t, J=8.8 Hz, 1H), 6.91 (d, J=12 Hz, 1H), 4.25 (bs, 1H), 3.75 (s, 3H), 3.66 (m, 1H), 3.29 (s, 6H), 3.11 (m, 2H), 2.52 (m, 2H), 2.23 (s, 3H), 2.10 (m, 2H), 1.78 (m, 1H), 1.62 (m, 2H).

Example 2638

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-bromoacetamide.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (150 mg, 0.6 mmol) in DCM (10 mL) was added dropwise bromacetylbromide (120 mg, 1 eq.) at 0° C. under an inert atmosphere. After 5 min stirring, DIEA (0.1 mL, 1 eq.) was added into the reaction. The reaction was stirred for an additional 3 h at below 15° C., quenched, and purified by column chromatography.

0.12 g (55%) of the product was isolated.

Step B: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-(3-fluorophenoxy)acetamide.

A sealed tube containing a heterogenous solution of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-bromoacetamide (30 mg, 0.08 mmol), 3-fluorophenol (27 mg, 3 eq.), and Cs₂CO₃ (30 mg, 1.1 eq.) in dioxane (˜0.7 mL) was reacted in a Smith microwave synthesizer for 3000 sec at 180° C. The reaction was diluted with DCM, washed with sat.-NaHCO₃ (2×) and water (1×), concentrated, and purified by column chromatography to give 11 mg (34%) of the product.

ESI MS m/e 402 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.58 (s, 1H), 7.26 (m, 1H), 6.74˜6.63 (m, 3H), 6.51 (d, 1H, J=8.0 Hz), 5.15 (bs, 1H), 4.45 (s, 2H), 4.01 (m, 1H), 3.97 (bs, 1H), 3.05 (s, 6H), 2.15 (s, 3H), 1.82˜1.61 (m, 8H).

Example 2639

2-[(5-Chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide

Step A: Synthesis of 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide.

Using the procedure of Example 2638, the title compound was obtained.

ESI MS m/e 419 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (m, 2H), 7.53 (s, 1H), 7.27 (t, 1H, J=2.4 Hz), 6.56 (d, 1H, J=7.6 Hz), 5.57 (bs, 1H), 4.50 (s, 2H), 4.01 (bs, 2H), 3.08 (s, 6H), 2.16 (s, 3H), 1.83˜1.64 (m, 8H).

Example 2640

N-(cis-4-{[4-(Dimethylamino)-5-ethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide

Step A: Synthesis of 2,4-dichloro-5-ethylpyrimidine.

To a suspension of 5-ethyluracil (1 g, 7.1 mmol) in POCl₃ (4.5 mL) was slowly added N,N-dimethylaniline (1 mL). The reaction was heated at reflux (˜120° C.) for 5 h until the starting material was completely dissolved and the entire solution turned a purple color. The mixture was allowed to cool and poured very slowly into ice (˜40 g). The resulting ppt was filtered and washed with ice water. The ppt was dissolved with a minimal amount of DCM and poured onto a short column of silica gel, and the product (1.2 g, ˜100%) was obtained by column chromatography with DCM.

¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 2.75 (q, 2H, J=7.6 Hz), 1.29 (t, 3H, J=7.6 Hz).

Step B: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-ethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide.

A solution of 2,4-dichloro-5-ethylpyrimidine (1.2 g, 6.8 mmol), in THF (15 mL) was cooled to 5° C. in an ice bath, and 2M-dimethylamine (7 mL, 2 eq.) was slowly added. The reaction was stirred for 2 h at around 10° C., and the volatile solvent was removed. The residue was purified by column chromatography (hexane:DCM=50:50 to 10:90) to give 0.89 g (70%) of 2-chloro-4-dimethylamino-5-ethylpyrimidine:

ESI MS m/e=186 M+H⁺.

A sealed tube containing 2-chloro-4-dimethylamino-5-ethylpyrimidine (35 mg, 0.019 mmol), cis-(4-amino-cyclohexyl)-3,4-difluoro-benzamide (48 mg, 1 eq.), DIEA (50 mg, 2 eq.), and IPA (1 mL) was reacted in a Smith microwave synthesizer for 2 h at 180° C. The reaction was diluted with DCM, washed with 1-N HCl and water, concentrated, and purified from column chromatography (DCM:MeOH=100:0 to 95:5) to give 11 mg (14%) of the product.

ESI MS m/e 404 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.68 (s, 1H), 7.61 (m, 1H), 7.48 (m, 1H), 7.19 (m, 1H), 5.99 (d, 1H, J=7.2 Hz), 4.38 (d, 1H, J=6.0 Hz), 4.20 (m, 1H), 4.12 (m, 1H), 3.10 (s, 6H), 2.29 (q, 2H, J=7.2 Hz), 1.96˜1.64 (m, 8H), 1.18 (t, 3H, J=7.6 Hz).

Example 2641

N-[cis-4-({4-[Ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide hydrochloride

Step A: Synthesis of N-[cis-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide hydrochloride.

A solution of 2,4-dichloro-5-methylpyrimidine (2.6 g, 16 mmol) and ethyl methylamine (2.7 mL, 2 eq.) in THF (20 mL) was stirred at <10° C. for 4 h. After removal of the volatile solvent, the residue was purified by column chromatography. 1.3 g (45%) of 2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine was isolated.

ESI MS m/e 186 M+H⁺.

A sealed tube containing 2-chloro-4-(ethyl-methyl-amino)-5-methylpyrimidine (80 mg, 0.019 mmol), cis-(4-amino-cyclohexyl)-3,4-difluoro-benzamide (100 mg, 1 eq.), DIEA (0.14 mL, 2 eq.), and IPA (1 mL) was reacted in a Smith microwave synthesizer for 2 h at 180° C. The reaction was diluted with DCM, washed with 1-N HCl and water, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 95:5) to give 35 mg (20%) of the product, which was converted to HCl salt.

ESI MS m/e 404 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (bs, 1H), 8.36 (bs, 1H), 7.97 (d, 1H, J=6.0 Hz), 7.90 (m, 1H), 7.73 (m, 1H), 7.63 (s, 1H), 7.51 (m, 1H), 3.85 (bm, 2H), 3.65 (q, 2H, J=7.2 Hz), 3.25 (s, 3H), 2.22 (s, 3H), 1.84 (m, 2H), 1.69 (m, 6H), 1.18 (t, 3H, J=7.2 Hz).

Example 2642

N-(cis-4-{[4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine.

To a solution of 2,4-dichloro-5-trifluoromethylpyrimidine (1 g, 4.6 mmol) in THF (15 mL) was added 2M-dimethylamine (4.6 mL, 2 eq.) at 0° C. The reaction was stirred for an additional 1.5 h at <5° C., concentrated, and purified by column chromatography (DCM:hexane:MeOH=90:10:0 to 95:0:5). 0.49 g (47%) of 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine was isolated.

ESI MS m/e 226 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.36 (s, 1H), 3.21 (s, 6H).

Step B: Synthesis of cis-[4-(4-Dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

A sealed tube containing 2-chloro-4-dimethylamino-5-trifluoromethylpyrimidine (0.49 g, 2.0 mmol), cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.47 g, 1 eq.), DIEA (0.7 mL, 2 eq.) in IPA (2.5 mL) was reacted in a Smith microwave synthesizer for 2 h at 175° C. The solution was concentrated and purified by column chromatography (DCM:MeOH=100:0 to 96:4). 0.57 g (65%) of cis-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester was isolated.

ESI MS m/e 404 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.15 (s, 1H), 5.10 (bs, 1H), 4.53 (bs, 1H), 3.94 (bs, 1H), 3.61 (bs, 1H), 3.09 (s, 6H), 1.78˜1.49 (m, 8H), 1.44 (s, 9H).

Step C: Synthesis of cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine.

To a solution of cis-[4-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (0.55 g, 1.3 mmol) in DCM (10 mL) was added TFA (7 mL). The reaction was stirred at room temperature for 2 h and concentrated. The residue was neutralized with sat-NaOH, and the aqueous layer was extracted with DCM (3×). The combined organic layers were washed with water, dried, and concentrated to give 0.25 g (65%) of cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine.

ESI MS m/e 304 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.16 (s, 1H), 5.42 (bs, 1H), 3.98 (bs, 1H), 3.09 (s, 6H), 2.87 (bs, 1H), 1.81 (m, 2H), 1.73˜1.65 (m, 4H), 1.43 (m, 4H).

Step D: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

To a solution of cis-N-(4-dimethylamino-5-trifluoromethyl-pyrimidin-2-yl)-cyclohexane-1,4-diamine (30 mg, 0.01 mmol) in dry benzene (2 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (27 mg, 1 eq.) and followed by Et₃N (20 μL, 2.5 eq). The reaction was stirred overnight, concentrated, and purified by prep-HPLC. 32 mg (49%) of N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 544 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.35 (d, 1H, J=8.0 Hz), 8.47 (s, 1H), 8.32 (s, 2H), 8.07 (s, 1H), 7.61 (d, 1H, J=8.4 Hz), 4.31 (bs, 1H), 4.20 (bs, 1H), 3.33 (s, 6H), 1.93˜1.79 (m, 8H.

Example 2643

N-(cis-4-{[4-(Dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide trifluoroacetate.

Using the procedure of Example 2642, the title compound was obtained.

ESI MS m/e 492 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 9.45 (d, 1H, J=8.0 Hz), 8.05 (s, 1H), 7.88 (d, 2H, J=8.8 Hz), 7.24 (m, 2H, overlapped with solvent), 7.04 (d, 1H, J=8.4 Hz), 4.27 (bs, 1H), 4.18 (bs, 1H), 3.31 (s, 6H), 1.89˜1.77 (m, 8H).

Example 2644

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide hydrochloride

Step A: Synthesis of (3-trifluoromethyl-phenylsulfanyl)-acetic acid ethyl ester.

A solution of ethyl bromoacetate (0.65 g, 3.2 mmol), 3-trifluoromethyl thiophenol (0.88 g, 1.5 eq.), and Et₃N (1.5 mL) in THF (15 mL) was stirred for 2 h at 62° C. The mixture was diluted with DCM, washed with sat.-NaHCO₃ (3×) and water, dried with MgSO₄, and concentrated. The crude product (0.73 g, 85%) was used to next reaction without a further purification.

¹H NMR (400 MHz, CDCl₃) δ 7.62 (s, 1H), 7.55 (d, 1H, J=8.0 Hz), 7.46˜7.37 (m, 2H), 4.16 (q, 2H, J=7.2 Hz), 3.66 (s, 2H), 1.22 (t, 3H, J=7.2 Hz).

Step B: Synthesis of (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester.

To a solution of (3-trifluoromethyl-phenylsulfanyl)-acetic acid ethyl ester (0.5 g, 1.9 mmol) in DCM (10 mL) was added 77%-MCPBA (0.42 g, 1 eq.) under Ar atmosphere at 0° C. The reaction was stirred for an additional 3 h, diluted with DCM, washed with sat-NaHCO₃ and water, and concentrated. (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester (0.34 g, 64%) and (3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester (0.15 g, 27%) were isolated by column chromatography (hexane:EtOAc=95:5 to 80:20).

(3-Trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester:

¹H NMR (400 MHz, CDCl₃) δ 7.95 (s, 1H), 7.87 (d, 1H, J=8.0 Hz), 7.78 (d, 1H, J=8.0 Hz), 7.67 (t, 1H, J=8.0 Hz), 4.15 (q, 2H, J=7.2 Hz), 3.86 (d, 1H, J=14.0 Hz), 3.70 (d, 1H, J=14.0 Hz), 1.22 (t, 3H, J=7.2 Hz).

(3-Trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester:

¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 8.14 (d, 1H, J=7.6 Hz), 7.94 (d, 1H, J=7.6 Hz), 7.74 (t, 1H, J=7.6 Hz), 4.15 (s, 2H), 4.14 (q, 2H, J=7.6 Hz), 1.20 (t, 3H, J=7.2 Hz).

Step C: Synthesis of (3-trifluoromethyl-phenylsulfinyl)-acetic acid.

To a heterogenous solution of (3-trifluoromethyl-phenylsulfinyl)-acetic acid ethyl ester (0.2 g, 0.7 mmol) in H₂O (5 mL)/EtOH (0.5 mL) was added KOH (120 mg, 3 eq.). The reaction was stirred for 2 h at 85° C., concentrated to about half of the reaction volume, and acidified with conc-HCl at an ice bath. (3-Trifluoromethyl-phenylsulfinyl)-acetic acid (100 mg, 56%) was filtered and dried.

¹H NMR (400 MHz, DMSO-d₆) δ 8.05 (s, 1H), 8.01 (d, 1H, J=8.0 Hz), 7.92 (d, 1H, J=8.0 Hz), 7.81 (t, 1H, J=8.0 Hz), 4.16 (d, 1H, J=14.4 Hz), 3.87 (d, 1H, J=14.4 Hz).

Step D: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide hydrochloride.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (60 mg, 0.024 mmol) in DCM (5 mL) was added (3-trifluoromethyl-phenylsulfinyl)-acetic acid (60 mg, 1 eq.), followed by HATU (85 mg, 1.1 eq.), and Et₃N (30 μL). The reaction was stirred for 16 h at room temperature and concentrated. The residue was purified by column chromatography to give N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide (52 mg, 45%), which was converted to HCl salt with 4M-HCl in dioxane.

ESI MS m/e 484 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.7 (bs, 1H), 8.08 (d, 1H, J=6.4 Hz), 7.99 (m, 2H), 7.92 (d, 1H, J=8.0 Hz), 7.90 (bs, 1H), 7.82 (t, 1H, J=8.0 Hz), 7.59 (s, 1H), 3.94 (d, 1H, J=12.8 Hz), 3.86 (d, 1H, J=12.8 Hz), 3.80 (bs, 1H), 3.68 (bs, 1H), 3.25 (s, 6H), 2.23 (s, 3H), 1.70˜1.50 (m, 8H).

Example 2645

2-[(3,4-Dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide hydrochloride

Step A: Synthesis of 2-[(3,4-dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethyl amino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide hydrochloride.

Using the procedure of Example 2644, the title compound was obtained.

ESI MS m/e 484 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (bs, 1H), 8.13 (d, 1H, J=6.8 Hz), 7.98 (bs, 1H), 7.87 (s, 1H), 7.86 (d, 1H, J=8.8 Hz), 7.65 (d, 1H, J=8.8 Hz), 7.61 (bs, 1H), 3.93 (d, 1H, J=12.8 Hz), 3.87 (d, 1H, J=12.8 Hz), 3.81 (bs, 1H), 3.64 (bs, 1H), 3.25 (s, 6H), 2.23 (s, 3H), 1.70˜1.50 (m, 8H).

Example 2646

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide hydrochloride.

(3-trifluoromethyl-phenylsulfonyl)-acetic acid ethyl ester was obtained from step B in Example 2644. The ester was hydrolyzed to (3-trifluoromethyl-phenylsulfonyl)-acetic acid using the procedure of step C in Example 2644.

¹H NMR (400 MHz, DMSO-d₆) δ 8.22 (d, 1H, J=8.0 Hz), 8.21 (s, 1H), 8.14 (d, 1H, J=8.0 Hz), 7.90 (t, 1H, J=8.0 Hz), 4.69 (s, 2H).

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (56 mg, 0.023 mmol) in DCM (5 mL) was added (3-trifluoromethyl-phenylsulfonyl)-acetic acid (60 mg, 1 eq.), followed by HATU (85 mg, 1.1 eq.), and Et₃N (30 μL). The reaction was stirred for 16 h at room temperature and concentrated. The residue was purified by column chromatography to give N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide (50 mg, 45%), which was converted to HCl salt with 4M HCl in dioxane.

ESI MS m/e 500 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.6 (bs, 1H), 8.22 (d, 1H, J=6.4 Hz), 8.17˜8.12 (m, 3H), 7.90 (t, 1H, J=7.6 Hz), 7.87 (bs, 1H), 7.57 (s, 1H), 4.45 (s, 2H), 3.79 (bs, 1H), 3.61 (bs, 1H), 3.25 (s, 6H), 2.23 (s, 3H), 1.70˜1.47 (m, 8H).

Example 2647

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride

Step A: Synthesis of 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (0.6 g, 2.4 mmol) in DCM (20 mL) was added 2-chloronicotinoyl chloride (0.44 g, 1.01 eq.) and followed by DIEA (0.4 mL, ˜1.1 eq.). The reaction was stirred overnight at room temperature, washed with sat-NaHCO₃ (2×) and water (1×), dried with MgSO₄, and concentrated. The crude residue was purified by column chromatography to give 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (0.57 g, 65%).

ESI MS m/e 389 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.72 (bs, 1H), 8.47 (d, 1H, J=5.0 Hz), 7.98 (d, 1H, J=7.0 Hz), 7.32 (dd, 1H, J=8.0 and 5.0 Hz), 7.28 (s, 1H), 6.88 (d, 1H, J=8.0 Hz), 4.18 (m, 2H), 3.27 (s, 6H), 2.23 (s, 3H), 1.90˜1.80 (m, 8H).

Step B: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride.

A sealed tube containing 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (0.35 g, 0.9 mmol), 4-fluorophenol (0.25 g, 2.5 eq.), Cs₂CO₃ (0.33 g, 1.1 eq.), and dioxane (3 mL) was reacted in a Smith microwave synthesizer for 1 h at 180° C. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3×) and water (1×), dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH=100:0 to 95:5) to give N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide (0.33 g, 80%). The neutral compound was dissolved in DCM (5 mL), and 4M-HCl (0.45 mL, 2.5 eq.) in dioxane was added. After 20 min stirring, removal of the volatile solvent gave N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide hydrochloride.

ESI MS m/e 465 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.1 (bs, 1H), 8.34 (d, 1H, J=7.2 Hz), 8.15 (dd, 1H, J=5.2 and 2.0 Hz), 8.06 (d, 1H, J=6.8 Hz), 8.01 (d, 1H, J=7.6 Hz), 7.63 (s, 1H), 7.26˜7.18 (m, 5H), 3.94 (bs, 1H), 3.88 (bs, 1H), 3.25 (s, 6H), 2.21 (s, 3H), 1.72 (bs, 8H).

Example 2648

2-(2-Bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 525 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.8 (bs, 1H), 8.20 (d, 1H, J=7.6 Hz), 8.16˜8.11 (m, 2H), 7.96 (bs, 1H), 7.70 (dd, 1H, J=8.0 and 1.6 Hz), 7.60 (s, 1H), 7.47˜7.38 (m, 2H), 7.25˜7.19 (m, 2H), 3.97 (bs, 1H), 3.89 (bs, 1H), 3.24 (s, 6H), 2.22 (s, 3H), 1.74 (bs, 8H).

Example 2649

2-(4-Bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 525 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.9 (bs, 1H), 8.28 (d, 1H, J=7.0 Hz), 8.12 (dd, 1H, J=4.4 and 1.6 Hz), 7.97 (d, 1H, J=7.6 Hz), 7.91 (bs, 1H), 7.56 (bs, 1H), 7.54 (d, 2H, J=8.8 Hz), 7.17 (m, 1H), 7.14 (d, 2H, J=8.8 Hz), 3.87 (bs, 1H), 3.81 (bs, 1H), 3.19 (s, 6H), 2.16 (s, 3H), 1.65 (bs, 8H).

Example 2650

2-(4Chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 481 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.8 (bs, 1H), 8.27 (d, 1H, J=6.6 Hz), 8.12 (dd, 1H, J=4.8 and 1.6 Hz), 7.97 (dd, 1H, J=7.0 and 1.6 Hz), 7.86 (bs, 1H), 7.55 (s, 1H), 7.41 (d, 2H, J=8.8 Hz), 7.20 (d, 2H, J=8.8 Hz), 7.17 (m, 1H), 3.88 (bs, 1H), 3.81 (bs, 1H), 3.19 (s, 6H), 2.16 (s, 3H), 1.65 (bs, 8H).

Example 2651

2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of Example 2647, the title compound was obtained.

ESI MS m/e 482 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.6 (bs, 1H), 8.46 (s, 1H), 8.31 (d, 1H, J=1.6 Hz), 8.01 (bm, 1H), 7.83 (t, 1H, J=2.0 Hz), 7.56 (d, 1H, J=5.2 Hz), 7.49 (bm, 1H), 7.25 (bs, 1H), 6.07 (bs, 1H), 5.74 (s, 1H), 4.51 (bs, 1H), 4.00 (bs, 1H), 3.23 (s, 6H), 2.19 (s, 3H), 1.90 (m, 2H), 1.75 (m, 4H), 1.39 (m, 2H).

Example 2652

2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

A sealed tube containing 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (70 mg, 0.018 mmol), 2-methyl-2-propanethiol (80 mg, 5 eq.), Cs₂CO₃ (60 mg, 1.1 eq) in dioxane (0.8 mL) was reacted in a Smith microwave synthesizer for 1.5 h at 180° C. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3×) and water (1×), dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH=100:0 to 95:5) to give 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide (50 mg, 62%), which was converted to HCl salt.

ESI MS m/e 443 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (bs, 1H), 8.47 (dd, 1H, J=4.8 and 1.6 Hz), 8.40 (d, 1H, J=6.0 Hz), 8.00 (bm, 1H), 7.62 (s, 1H), 7.56 (dd, 1H, J=7.6 and 1.6 Hz), 7.15 (m, 1H), 3.90 (bs, 2H), 3.25 (s, 6H), 2.21 (s, 3H), 1.80˜1.65 (m, 8H), 1.49 (s, 9H).

Example 2653

N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide hydrochloride.

Using the procedure of Example 2652, the title compound was obtained.

ESI MS m/e 429 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.4 (bs, 1H), 8.44 (m, 2H), 8.04 (d, 1H, J=6.8 Hz), 7.63 (d, 2H, J=6.4 Hz), 7.12 (m, 1H), 3.85 (bs, 2H), 3.24 (s, 6H), 3.06 (t, 2H, J=6.8 Hz), 2.21 (s, 3H), 1.83˜1.65 (m, 8H), 1.62 (m, 2H), 0.95 (t, 3H, J=7.2 Hz).

Example 2654

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-2-(isopropylthio)nicotinamide hydrochloride.

Using the procedure of Example 2652, the title compound was obtained.

ESI MS m/e 429 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (bs, 1H), 8.46 (dd, 1H, J=4.8 and 1.6 Hz), 8.42 (bs, 1H), 8.02 (d, 1H, J=6.4 Hz), 7.62 (m, 2H), 7.12 (m, 1H), 3.95 (sept, 1H, J=6.4 Hz), 3.83 (bs, 2H), 3.25 (s, 6H), 2.21 (s, 3H), 1.82˜1.65 (m, 8H), 1.30 (d, 6H, J=6.8 Hz).

Example 2655

2-(tert-Butylsulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide

Step A: Synthesis of 2-(tert-butylsulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide.

To a solution of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-tert-butyl sulfanyl-nicotinamide (30 mg, 0.07 mmol) in DCM (5 mL) was added MCPBA (16 mg, 1.1 eq) at 0° C. The reaction was stirred for an additional 2 h at <10° C. with monitoring the progress by ESI MS. The reaction was diluted with DCM, washed with sat.-NaHCO₃ (2×) and water (1×), dried, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 94:6). 26 mg (85%) of 2-(tert-butylsulfinyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide was isolated.

ESI MS m/e 459 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.71 (dd, 1H, J=4.8 and 1.6 Hz), 8.54 (d, 1H, J=6.8 Hz), 8.20 (d, 1H, J=8.0 Hz), 7.61 (s, 1H), 7.43 (dd, 1H, J=8.0 and 4.0 Hz), 5.03 (d, 1H, J=6.0 Hz), 4.12 (bs, 1H), 3.98 (bs, 1H), 2.99 (s, 6H), 2.12 (s, 3H), 1.87˜1.75 (m, 8H), 1.23 (s, 9H).

Example 2656

2-[(3,4-Difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(3,4-difluorophenyl)-sulfanyl-nicotinamide.

A sealed tube containing 2-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (100 mg, 0.025 mmol), 3,4-difluorothiophenol (90 mg, 2.5 eq.), Cs₂CO₃ (150 mg, 2 eq), and dioxane (2 mL) was reacted in a Smith microwave synthesizer for 1.0 h at 180° C. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3×) and water (1×), dried, and concentrated. The residue was purified by column chromatography (DCM:MeOH=100:0 to 95:5) to give N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(3,4-difluorophenyl)-sulfanyl-nicotinamide (70 mg, 55%).

ESI MS m/e 499 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.34 (dd, 1H, J=4.8 and 1.6 Hz), 7.79 (dd, 1H, J=7.2 and 2.0 Hz), 7.62 (s, 1H), 7.35 (m, 1H), 7.25 (m, 1H), 7.16 (m, 1H), 7.08 (dd, 1H, J=7.6 and 4.8 Hz), 6.28 (d, 1H, J=7.2 Hz), 4.71 (d, 1H, J=7.2 Hz), 4.18 (m, 1H), 3.97 (m, 1H), 3.02 (s, 6H), 2.13 (s, 3H), 1.92˜1.85 (m, 4H), 1.80˜1.74 (m, 4H).

Step B: Synthesis of 2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

To a solution of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(3,4-difluorophenyl)-sulfanyl-nicotinamide (45 mg, 0.09 mmol) in DCM (6 mL) was added MCPBA (77%, 31 mg, 2 eq.) at 0° C. under Ar atmosphere. The reaction was stirred overnight, washed with sat.-NaHCO₃ (2×) and water, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 94:6). 25 mg (53%) of 2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide was isolated and converted to its HCl salt.

ESI MS m/e 531 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.8 (bs, 1H), 8.70 (m, 2H), 8.04 (m, 1H), 7.95 (dd, 1H, J=7.6 and 1.6 Hz), 7.89 (m, 1H), 7.78˜7.70 (m, 2H), 7.60 (s, 1H), 3.95 (bs, 1H), 3.87 (bs, 1H), 3.25 (s, 6H), 2.22 (s, 3H), 1.76 (bs, 8H).

Example 2657

N-(3,4-Difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate

Step A: Synthesis of ethyl 3,4-difluorophenylcarbamate.

3,4-Difluoroaniline (2.8 mL, 28 mmol) and N,N′-diisopropylethylamine (5.4 mL, 31 mmol) were dissolved in 10 mL of anhydrous THF, and cooled to 0° C. in an ice bath. Ethyl chloroformate (5.4 mL, 31 mmol) was added slowly into the stirring solution over the ice bath. The solution was allowed to warm up to room temperature and stir for 30 minutes. The solvent was removed via vacuo and the crude solid was purified by column chromatography using ethyl acetate and hexane mixture (3:97) to yield ethyl 3,4-difluorophenylcarbamate as an off-white solid. (5.59 g, 99%)

ESI MS m/z 202.1 (M+H⁺); ¹H NMR (400 MHz, DMSO-d₆) δ 9.79 (s, 1H), 7.55-7.50 (m, 1H), 7.29-7.22 (m, 1H), 7.16-7.15 (m, 1H), 4.10 (q, J=7.2 Hz, 2H), 1.22 (t, J=7.2 Hz, 3H).

Step B: Synthesis of (3,4-difluorophenyl)-methyl-amine.

Lithium aluminum hydride (2.2 g, 56 mmol) was placed in a 500 mL round bottom flask. THF (100 mL) was syringed into the flask under argon. The solution was cooled to 0° C. in an ice bath. To the ice-old solution, 3,4-difluorophenylcarbamate (5.59 g, 28 mmol) was added slowly into the flask. The solution was refluxed for 3 hours. After cooling the reaction mixture to 0° C., H₂O (3 mL), 1 N NaOH (3 mL), and then more H₂O (15 mL) were added for quenching. The precipitate was filtered off and THF was evaporated from the filtrate. The crude was dissolved in 150 mL of ethyl acetate, washed with water, and dried over Na₂SO₄. The organic solvent was removed via vacuo to yield (3,4-difluoro-phenyl)-methyl-amine as a light brown oil. (2.86 g, 71%)

ESI MS m/z 144.2 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 7.04-6.97 (m, 1H), 6.45-6.39 (m, 1H), 6.32-6.28 (m, 1H), 3.69 (b, 1H), 2.86 (s, 3H).

Step C: Synthesis of N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methyl-pyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate.

cis-[4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (100 mg, 0.402 mmol) and 1,1-carbonyldiimidazole (78.1 mg, 0.482 mmol) were dissolved in 1 mL of methylene chloride and allowed to stir at room temperature overnight. To the vial, (3,4-difluoro-phenyl)-methyl-amine (88 mg, 0.603 mmol) was added. The solution was heated via Smith Synthesizer at 130° C. for 15 minutes. The solvent was evaporated, and 1 mL of methanol was added to the crude. The crude was purified by HPLC to yield N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate as a white solid. (47.8 mg, 22%)

ESI MS m/z 419.3 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 14.0 (s, 1H), 8.62 (d, J=6.4 Hz, 1H), 7.29-7.21 (m, 2H), 7.13-7.01 (m, 2H), 4.61 (bs, 1H), 4.10 (m, 1H), 3.78 (m, 1H), 3.46-3.29 (b, 3H), 3.24 (s, 6H), 2.24 (s, 3H), 1.77-1.56 (m, 8H).

Example 2658

N-[(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate.

To a solution of cis-(4-aminomethyl-cyclohexyl)-carbamic acid tert-butyl ester (1.1 g, 4.8 mmol) in dry benzene (15 mL) was added 3,5-bistrifluoromethyl benzoyl chloride (1.33 g, 1 eq.) and followed by Et₃N (˜2 mL) at room temperature under N₂. The reaction was stirred for an additional 2 h at room temperature, washed with sat.-NaHCO₃ (3×) and water (1×), dried with MgSO₄, and concentrated. The crude {cis-{4-[(3,5-Bis-trifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester was pure enough to use for the next deprotection without a further purification.

{cis-{4-[(3,5-Bis-trifluoromethyl-benzoylamino)-methyl]-cyclohexyl}-carbamic acid tert-butyl ester (2.1 g, 4.5 mmol) was dissolved in DCM (10 mL), and TFA (5 mL) was added to the reaction. After 1.5 h stirring at room temperature, removal of the volatile solvent gave crude N-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide trifluoroacetate as a sticky oil. Addition of water (˜40 mL) to the crude product and shaking well for 5˜10 min provided formation of precipitates, and the ppts were filtered, washed with water, and dried; 1.40 (61%) of N-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide trifluoroacetate was isolated as a white powder.

ESI MS m/e 369 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.97 (bs, 1H), 8.47 (s, 2H), 8.29 (s, 1H), 7.78 (bs, 3H), 3.29 (t, 2H, J=6.8 Hz), 3.15 (bs, 1H), 1.78 (bs, 1H), 1.66 (m, 4H), 1.52 (m, 4H).

Step B: Synthesis of N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide hydrochloride.

A sealed tube containing 2-chloro-4-dimethylamino-6-methylpyrimidine (0.21 g, 1.2 mmol), N-(cis-4-amino-cyclohexylmethyl)-3,5-bistrifluoromethyl-benzamide trifluoroacetate (0.6 g, 1 eq.), DIEA (0.45 mL, 2 eq.), and tert-BuOH (2.5 mL) was reacted for 1.6 h at 185° C. in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with diluted-HCl and water, dried, and concentrated. The crude product was purified by column chromatography (silica gel; DCM:MeOH=100:0 to 95:5). 0.3 g (50%) of N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide was isolated and converted to HCl-salt.

ESI MS m/e 504 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.8 (bs, 1H), 8.72 (d, 1H, J=8.0 Hz), 8.39 (s, 2H), 7.93 (s, 1H), 7.43 (bs, 1H), 5.70 (s, 1H), 4.24 (bm, 1H), 3.49 (t, 2H, J=4.4 Hz), 3.22 (s, 3H), 3.11 (s, 3H), 2.31 (s, 3H), 1.91˜1.79 (m, 5H), 1.64˜1.56 (m, 4H).

Example 2659

N²-[cis-4-({6-[(3,4-Difluorophenyl)sulfinyl]pyrazin-2-yl}amino)cyclohexyl]-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine

Step A: Synthesis of cis-[1-(6-chloro-pyrazin-2-ylamino)-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)]-cyclohexane.

A sealed tube containing cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane hydrochloride (0.2 g, 0.7 mmol), 2,6-dichloropyrazine (0.1 g, 1 eq.), DIEA (0.3 mL, 2 eq.), and IPA (2 mL) was reacted for 1.5 h at 170° C. in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and water, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 96:4). 0.15 g (61%) of cis-[1-(6-chloro-pyrazin-2-ylamino)-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)]-cyclohexane was isolated.

ESI MS m/e 362 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.70 (bs, 1H), 7.76 (s, 1H), 7.71 (s, 1H), 7.29 (s, 1H), 5.32 (bs, 1H), 4.11 (bs, 1H), 4.00 (bs, 1H), 3.27 (s, 6H), 2.23 (s, 3H), 1.80 (m, 8H).

Step B: Synthesis of cis-{1-[6-(3,4-difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)}-cyclohexane.

A sealed tube containing cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-(6-chloro-pyrazin-2-ylamino)-cyclohexane (0.1 g, 0.27 mmol), 3,4-difluorothiophenol (0.1 g, 2.5 eq.), Cs₂CO₃ (0.15 g, 2 eq.), and dioxane (2 mL) was reacted for 1 h at 180° C. in a Smith microwave synthesizer. The reaction was diluted with DCM, washed with sat-NaHCO₃ (3×) and water, concentrated, and purified by column chromatography to give 85 mg (65%) of cis-{1-[6-(3,4-difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)}-cyclohexane.

ESI MS m/e 472 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.60 (s, 1H), 7.48 (s, 1H), 7.42 (m, 2H), 7.29 (m, 1H), 7.15 (m, 1H), 6.70 (bs, 1H), 5.15 (d, 1H, J=7.6 Hz), 4.03 (bs, 1H), 3.67 (bm, 1H), 3.16 (s, 6H), 2.19 (s, 3H), 1.81˜1.61 (m, 8H).

Step C: Synthesis of N²-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino)-cyclohexyl]-N⁴,N⁴,5-trimethylpyrimidine-2,4-diamine.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-[6-(3,4-difluoro-phenylsulfanyl)-pyrazin-2-ylamino]-cyclohexane (35 mg, 0.07 mmol) in DCM (5 mL) was added MCPBA (33 mg, 2 eq.) at room temperature under an Ar atmosphere. The reaction was stirred overnight, washed with sat-NaHCO₃ (2×) and water, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 95:5). 12 mg (33%) of N²-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin-2-yl}amino)cyclohexyl]-N⁴N⁴,5-trimethylpyrimidine-2,4-diamine was isolated.

ESI MS m/e 488 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.25 (s, 1H), 7.87 (s, 1H), 7.63 (m, 1H), 7.57 (s, 1H), 7.53 (m, 1H), 7.26 (m, 1H), 5.36 (bs, 1H), 5.14 (d, 1H, J=6.8 Hz), 4.01 (bs, 1H), 3.82 (bm, 1H), 3.06 (s, 6H), 2.15 (s, 3H), 1.87˜1.60 (m, 8H).

Example 2660

cis-N-[1-(4-Bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide hydrochloride

Step A: Synthesis of cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide hydrochloride.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid obtained from step B of Example 2594 (24 mg, 0.08 mmol) in DCM (3 mL) was added 1-(4-bromophenyl)-ethylamine (18 mg, 1 eq.), and followed by HATU (36 mg, 1.1 eq.) and Et₃N (20 μL). The reaction was stirred overnight, concentrated, and purified by column chromatography (DCM:MeOH=100:0 to 95:5). 16 mg (41%) of cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide was isolated and converted to HCl salt.

ESI MS m/e 460 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.0 (bs, 1H), 8.20 (d, 1H, J=7.6 Hz), 7.66 (bs, 1H), 7.50 (s, 1H), 7.43 (d, 2H, J=8.4 Hz), 7.18 (d, 2H, J=8.4 Hz), 4.79 (m, 1H), 3.95 (bs, 1H), 3.19 (s, 6H), 2.23 (bs, 1H), 2.16 (s, 3H), 1.70˜1.50 (m, 8H), 1.24 (d, 3H, J=7.2 Hz).

Example 2661

N-[(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamidehydrochloride

Step A: Synthesis of (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine.

2,4-Dichloro-5-methylpyrimidine (3.8 g, 23.4 mmol) in 20 ml in CH₂Cl₂ was added 2.0 M methylamine in methyl alcohol (14.05 ml, 28.1 mmol) at 0° C. The reaction mixture was stirred overnight and then the excess solvent was evaporated off and the material subjected to chromatography (50% hexanes in ethyl acetate) to yield (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (968.7 mg, 6.17 mmol, 26%) as a white solid.

ESI MS 158.0 M+H⁺; ¹H NMR (400 MHz, DMSOd₆) δ 7.86 (s, 1H), 7.39 (s, 1H), 2.93-2.92 (d, J=4 Hz, 3H), 2.04 (s, 3H).

Step B: Synthesis of N-[(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamidehydrochloride.

To a solution of (2-Chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (200 mg, 1.27 mmol) in 1 mL 2-propanol was added cis-N-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide in TFA salt (736 mg, 1.52 mmol) and DIEA (2.54 mmol). The mixture was heated in a microwave synthesizer at 180° C. for 2 hours. The solvent was evaporated and the material subjected to chromatography (70˜95% ethyl acetate/hexanes). The combined compound was dissolved in CH₂Cl₂ and was added 2 M HCl in diethyl ether (5.6 ml, 1.42 mmol) to yield N-[(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamidehydrochloride (443 mg, 0.84 mmol, 66%) as a white solid.

ESI MS 490.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.5 (s, 1H), 8.86-8.83 (t, J=4 Hz, 8 Hz, 1H), 8.32 (s, 2H), 8.11 (s, 1H), 8.03 (bs, 1H), 7.97 (bs, 1H), 7.40 (s, 1H), 3.90 (bs, 1H), 3.24 (s, 3H), 3.06-3.04 (d, J=8 Hz, 2H), 2.72-2.71 (d, J=4 Hz, 3H), 1.54 (bs, 4H), 1.42 (m, 4H), 1.20 (2H).

Example 2662

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide hydrochloride

Step A: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide hydrochloride.

Using the procedure of Example 2660, the title compound was obtained.

ESI MS m/e 412 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 10.9 (bs, 1H), 7.98 (d, 1H, J=8.0 Hz), 7.53 (bs, 1H), 6.98 (t, 1H, J=8.0 Hz), 6.63 (d, 1H, J=7.4 Hz), 6.62 (s, 1H), 6.54 (d, 2H, J=8.0 Hz), 4.64 (m, 1H), 3.79 (bs, 1H), 3.50 (s, 3H), 3.03 (s, 6H), 2.08 (bs, 1H), 1.97 (s, 3H), 1.60˜1.30 (m, 8H), 1.10 (d, 3H, J=6.8 Hz).

Example 2663

cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide hydrochloride

Step A: Synthesis of cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide hydrochloride.

Using the procedure of Example 2660, the title compound was obtained.

ESI MS m/e 432 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.1 (bs, 1H), 8.39 (d, 1H, J=8.0 Hz), 8.09 (d, 1H, J=8.0 Hz), 7.94 (m, 1H), 7.82 (d, 1H, J=8.0 Hz), 7.73 (bs, 1H), 7.56˜7.49 (m, 5H), 5.69 (m, 1H), 4.01 (bs, 1H), 3.25 (s, 6H), 2.33 (bs, 1H), 2.23 (s, 3H), 1.85˜1.55 (m, 8H), 1.49 (d, 3H, J=6.8 Hz).

Example 2664

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-3-methylbenzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 368 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (bs, 1H), 8.28 (bs, 1H), 7.98 (bd, 1H, J=6.0 Hz), 7.64 (m, 3H), 7.31 (s, 1H), 7.30 (s, 1H), 3.91 (bs, 1H), 3.85 (bs, 1H), 3.25 (s, 6H), 2.35 (s, 3H), 2.22 (s, 3H), 1.85 (bs, 2H), 1.70 (bs, 6H).

Example 2665

N-{cis-4-[(4-Methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of cis-N-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide.

To a solution of cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.2 g, 0.015 mol) in CH₂Cl₂ (50 mL) was added DIEA (3.9 mL, 0.022 mol). The mixture was cooled on an ice bath and 3,5-bis(trifluoromethyl)benzoyl chloride (2.9 mL, 0.015 mol) was slowly added. The mixture was brought to room temperature and stirred for 1 hour. After this time, the solvent and excess DIEA was evaporated in vacuo. The resulting oil was re-dissolved in CH₂Cl₂ (30 mL) and extracted with H₂O (30 mL), 1M NaOH (30 mL), and brine (30 mL). The brine layer was twice back extracted with CH₂Cl₂ and the organic layers were combined, dried over MgSO₄, and concentrated. The resulting precipitate was re-dissolved in CH₂Cl₂ (50 mL) and TFA (4.6 mL, 0.060 mol) was added. The solution was stirred at room temperature for 4 hours (or until the reaction was complete as judged by TLC). The excess solvent was evaporated off and the resulting oil was dissolved in 30 mL CH₂Cl₂. The organic layer was extracted with 30 mL of a dilute NaOH (aq)/NaHCO₃ (aq) solution (the aqueous layer was confirmed to remain basic during the extraction using pH paper indicator). The aqueous layer was back extracted twice with CH₂Cl₂ and the organic layers combined, dried over MgSO₄, and concentrated. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield cis-N-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (4.0 g, 0.011 mol, 77%) as a white solid.

ESI MS 355.0 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 2H), 8.18 (s, 1H), 4.04 (m, 1H), 3.00 (m, 1H), 1.89-1.84 (m, 2H), 1.79-1.74 (m, 4H), 1.74-1.64 (m, 2H).

Step B Synthesis of N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride.

To a solution of 2-chloro-4-methyl-quinoline (326 mg, 1.84 mmol) in 2 mL t-BuOH was added DIEA (369 uL, 2.12 mmol) and cis-N-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (500 mg, 1.41 mmol). The mixture was then heated in a microwave at 180° C. for 12 hours. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (<5% MeOH in CH₂Cl₂). The organic solvents were evaporated and the resulting oil was re-dissolved into 4 mL CH₂Cl₂ and HCl (1.4 mL, 2.82 mol) was added. The reaction was stirred for 30 minutes and the solvent was removed. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride (620 mg, 1.17 mmol, 83%).

ESI MS 496.4 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ 8.47 (s, 2H), 8.21 (s, 1H), 8.05 (d, 1H, J=8.0 Hz), 7.93 (bs, 1H), 7.82 (t, 1H, J=7.8 Hz), 7.59 (t, 1H, J=8.2 Hz), 7.09 (bs, 1H), 4.17 (m, 1H), 4.15 (m, 1H), 2.73 (s, 3H), 2.08-1.95 (m, 8H).

Example 2666

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 438 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.9 (bs, 1H), 8.59 (bd, 1H, J=6.8 Hz), 7.69 (s, 1H), 7.68 (d, 1H, J=8.4 Hz), 7.43 (t, 1H, J=8.0 Hz), 7.30 (d, 1H, J=7.6 Hz), 7.20 (d, 1H, J=5.2 Hz), 6.55 (d, 1H, J=8.0 Hz), 4.17 (bs, 1H), 4.10 (bs, 1H), 3.29 (s, 6H), 2.24 (s, 3H), 1.98˜1.83 (m, 6H), 1.73 (m, 2H).

Example 2667

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 438 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.3 (bs, 1H), 8.54 (bd, 1H, J=6.8 Hz), 7.86 (d, 2H, J=8.8 Hz), 7.22 (d, 2H, J=8.8 Hz), 7.21 (s, 1H), 6.68 (d, 1H, J=8.0 Hz), 4.17 (bs, 1H), 4.10 (bs, 1H), 3.28 (s, 6H), 2.24 (s, 3H), 1.95˜1.85 (m, 6H), 1.72 (m, 2H).

Example 2668

3-Chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 472 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.5 (bs, 1H), 8.37 (bd, 1H, J=7.2 Hz), 8.06 (s, 1H), 7.86 (d, 1H, J=8.4 Hz), 7.51 (d, 1H, J=8.4 Hz), 7.30 (d, 1H, J=8.0 Hz), 7.24 (s, 1H), 4.17 (bs, 1H), 4.08 (bm, 1H), 3.28 (s, 6H), 2.23 (s, 3H), 1.92˜1.85 (m, 6H), 1.71 (m, 2H).

Example 2669

4-Chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 456 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.8 (bs, 1H), 8.58 (bd, 1H, J=6.8 Hz), 8.19 (s, 1H), 7.90 (d, 1H, J=8.4 Hz), 7.54 (d, 1H, J=8.4 Hz), 7.19 (bd, 1H, J=5.2 Hz), 6.76 (d, 1H, J=8.4 Hz), 4.19 (bs, 1H), 4.10 (bm, 1H), 3.29 (s, 6H), 2.24 (s, 3H), 1.94˜1.83 (m, 6H), 1.72 (m, 2H).

Example 2670

3,5-Dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3,5-dichloro-N-(cis-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.1 (bs, 1H), 8.50 (bs, 1H), 8.02 (bd, 1H, J=5.2 Hz), 7.86 (d, 2H, J=1.6 Hz), 7.77 (t, 1H, J=1.6 Hz), 7.63 (s, 1H), 3.90 (bs, 1H), 3.85 (bs, 1H), 3.25 (s, 6H), 2.22 (s, 3H), 1.85 (bs, 2H), 1.70 (bs, 6H).

Example 2671

3,4-Dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2yl]amino}cyclohexyl)-benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (bs, 1H), 8.47 (bs, 1H), 8.09 (d, 1H, J=2.0 Hz), 8.05 (d, 1H, J=6.4 Hz), 7.82 (dd, 1H, J=8.0 and 1.6 Hz), 7.71 (d, 1H, J=8.4 Hz), 7.63 (s, 1H), 3.90 (bs, 1H), 3.85 (bs, 1H), 3.25 (s, 6H), 2.22 (s, 3H), 1.85 (bs, 2H), 1.70 (bs, 6H).

Example 2672

5-Bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide

Step A: Synthesis of 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 422 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.64 (s, 1H), 7.02 (d, 1H, J=3.6 Hz), 6.41 (d, 1H, J=3.6 Hz), 6.23 (bs, 1H), 4.77 (bs, 1H), 4.08 (bs, 1H), 3.96 (bs, 1H), 3.02 (s, 6H), 2.14 (s, 3H), 1.88˜1.60 (m, 8H).

Example 2673

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(methylsulfonyl)benzamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(methylsulfonyl)benzamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, 1H, J=7.6 Hz), 7.69 (t, 1H, J=8.0 Hz), 7.59 (t, 2H, J=7.6 Hz), 6.39 (d, 1H, J=8.0 Hz), 6.34 (bs, 1H), 4.10 (bs, 2H), 3.33 (s, 3H), 3.25 (s, 6H), 2.25 (s, 3H), 1.93˜1.71 (m, 8H).

Example 2674

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)benzamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)benzamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 8.18 (d, 1H, J=7.6 Hz), 8.08 (d, 1H, J=7.6 Hz), 7.67 (t, 1H, J=7.6 Hz), 7.34 (s, 1H), 6.99 (d, 1H, J=8.0 Hz), 6.57 (bd, 1H, J=6.4 Hz), 4.17 (bm, 2H), 3.32 (s, 6H), 3.16 (s, 3H), 2.27 (s, 3H), 1.90˜1.71 (m, 8H).

Example 2675

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(methylsulfonyl)benzamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-4-(methylsulfonyl)benzamide.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 432 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, 2H, J=8.4 Hz), 7.98 (d, 2H, J=8.4 Hz), 7.28 (s, 1H), 6.86 (d, 1H, J=8.4 Hz), 6.41 (d, 1H, J=7.6 Hz), 4.14 (bm, 2H), 3.32 (s, 6H), 3.07 (s, 3H), 2.27 (s, 3H), 1.90˜1.71 (m, 8H).

Example 2676

Methyl 2-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoate

Step A: Synthesis of methyl 2-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}benzoate.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 428 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.10 (bs, 1H), 7.87 (d, 1H, J=7.6 Hz), 7.52 (t, 1H, J=7.6 Hz), 7.46 (m, 2H), 7.30 (s, 1H), 6.56 (d, 1H, J=8.0 Hz), 4.13 (bm, 2H), 3.87 (s, 3H), 3.24 (s, 6H), 2.22 (s, 3H), 1.93˜1.75 (m, 8H).

Example 2677

Methyl 3-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoate

Step A: Synthesis of methyl 3-{[(cis-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexylamino]carbonyl}benzoate.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 428 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.48 (s, 1H), 8.17 (bs, 1H), 8.14 (d, 1H, J=7.6 Hz), 8.08 (d, 1H, J=7.6 Hz), 7.51 (t, 1H, J=8.0 Hz), 7.31 (s, 1H), 7.16 (d, 1H, J=7.6 Hz), 4.14 (bm, 2H), 3.94 (s, 3H), 3.26 (s, 6H), 2.23 (s, 3H), 1.93˜1.73 (m, 8H).

Example 2678

2-{[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoic acid hydrochloride

Step A: Synthesis of 2-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}benzoic acid hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 398 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.5 (bs, 2H), 8.32 (bs, 1H), 8.04 (d, 1H, J=6.4 Hz), 7.80 (d, 1H, J=7.6 Hz), 7.68 (s, 1H), 7.58 (m, 1H), 7.51 (t, 1H, J=7.6 Hz), 7.39 (d, 1H, J=7.6 Hz), 3.89 (bs, 2H), 3.28 (s, 6H), 2.25 (s, 3H), 1.85˜1.70 (m, 8H).

Example 2679

3-{[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-amino]carbonyl}benzoic acid hydrochloride

Step A: Synthesis of 3-{[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]carbonyl}benzoic acid hydrochloride.

Using the procedure of example 2523, the title compound was obtained.

ESI MS m/e 398 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 13.2 (bs, 1H), 12.3 (bs, 1H), 8.59 (bs, 1H), 8.47 (m, 1H), 8.16˜8.11 (m, 3H), 7.72 (s, 1H), 7.64 (t, 1H, J=8.0 Hz), 3.95 (bs, 2H), 3.32 (s, 6H), 2.29 (s, 3H), 1.93 (bs, 2H), 1.78 (bs, 6H).

Example 2680

N-(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 390 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.7 (bs, 1H), 8.37 (bs, 1H), 7.93˜7.88 (m, 2H), 7.73 (m, 1H), 7.51 (dd, 1H, J=18.8 and 8.4 Hz), 6.26 (s, 1H), 3.96 (bs, 1H), 3.84 (bs, 1H), 3.17 (s, 3H), 3.13 (s, 3H), 2.25 (s, 3H), 1.85 (bm, 2H), 1.70 (bs, 6H).

Example 2681

N-(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid.

To a solution of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (242 mg, 1.41 mmol) in 2 mL t-BuOH was added DIEA (369 uL, 2.12 mmol) and cis-N-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (500 mg, 1.41 mmol). The mixture was then heated in a microwave at 180° C. for 1.7 hours. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (<5% MeOH in CH₂Cl₂). The organic solvents were evaporated and the resulting oil was re-dissolved into 4 mL CH₂Cl₂ and HCl (1.4 mL, 2.82 mol) was added. The reaction was stirred for 30 minutes and the solvent was removed. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide hydrochloric acid (653 mg, 1.24 mmol, 88%).

ESI MS 490.4 M+H⁺; ¹H NMR (400 MHz, CD3OD) δ 12.58 (bs, 1H), 8.81 (d, 1H, J=6.4 Hz), 8.50 (s, 2H), 8.30 (s, 1H), 7.89 (bs, 1H), 6.28 (s, 1H), 4.00 (m, 1H), 3.90 (m, 1H), 3.18 (s, 3H), 3.12 (s, 3H), 2.25 (s, 3H), 1.87-1.71 (m, 8H).

Example 2682

N-(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 438 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.0 (bs, 1H), 8.52 (bd, 1H, J=7.6 Hz), 7.87 (d, 2H, J=8.8 Hz), 7.23 (d, 2H, J=8.8 Hz), 6.84 (d, 1H, J=8.0 Hz), 5.72 (s, 1H), 4.22 (bm, 1H), 4.11 (bm, 1H), 3.24 (s, 3H), 3.12 (s, 3H), 2.34 (s, 3H), 1.95˜1.85 (m, 6H), 1.72 (m, 2H).

Example 2683

3-Chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 472 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 12.9 (bs, 1H), 8.52 (d, 1H, J=7.6 Hz), 7.96 (d, 1H, J=2.4 Hz), 7.73 (dd, 1H, J=8.8 and 2.0 Hz), 7.34 (d, 1H, J=8.4 Hz), 6.59 (d, 1H, J=8.0 Hz), 5.72 (s, 1H), 4.22 (bm, 1H), 4.10 (bm, 1H), 3.24 (s, 3H), 3.12 (s, 3H), 2.34 (s, 3H), 1.95˜1.83 (m, 6H), 1.72 (m, 2H).

Example 2684

4-Chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-benzamide hydrochloride

Step A: Synthesis of 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 388 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.1 (bs, 1H), 8.57 (bd, 1H, J=8.0 Hz), 7.73 (d, 2H, J=8.4 Hz), 7.37 (d, 2H, J=8.4 Hz), 6.46 (d, 1H, J=6.0 Hz), 5.71 (s, 1H), 4.20 (bs, 1H), 4.10 (bs, 1H), 3.24 (s, 3H), 3.12 (s, 3H), 2.34 (s, 3H), 1.94˜1.82 (m, 6H), 1.73 (m, 2H).

Example 2685

3,4-Dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2yl]amino}cyclohexyl)-benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 422 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.0 (bs, 1H), 8.51 (d, 1H, J=7.6 Hz), 7.94 (d, 1H, J=2.0 Hz), 7.64 (dd, 1H, J=8.4 and 2.0 Hz), 7.47 (d, 1H, J=8.4 Hz), 6.88 (d, 1H, J=8.8 Hz), 5.72 (s, 1H), 4.22 (bm, 1H), 4.09 (bm, 1H), 3.24 (s, 3H), 3.13 (s, 3H), 2.34 (s, 3H), 1.94˜1.82 (m, 6H), 1.72 (m, 2H).

Example 2686

N-(cis-4-{[4-(Dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide.

Using the procedure of example 2526, the title compound was obtained.

ESI MS m/e 414 M+H⁺; ¹H NMR (400 MHz, CDCl₃) 66.88 (d, 2H, J=2.0 Hz), 6.57 (t, 1H, J=2.0 Hz), 6.15 (d, 1H, J=7.6 Hz), 5.69 (s, 1H), 5.10 (bs, 1H), 4.06 (bm, 2H), 3.82 (s, 6H), 3.04 (s, 6H), 2.21 (s, 3H), 1.90˜1.81 (m, 6H), 1.67 (m, 2H).

Example 2687

5-Bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-nicotinamide hydrochloride

Step A: Synthesis of 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 433.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.2 (s, 1H), 8.85 (d, J=4 Hz, 1H), 8.73 (d, J=4 Hz, 1H), 8.51 (bs, 1H), 8.34-8.33 (m, 1H), 7.55 (bs, 1H), 3.76 (bs, 2H), 3.14 (bs, 6H), 2.10 (s, 3H), 1.74-1.59 (m, 8H).

Example 2688

N-(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride

Step A: Synthesis of N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 520.4 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (s, 1H), 8.84 (s, 1H), 8.36 (bs, 1H), 7.91 (bs, 1H), 7.88 (d, J=8 Hz, 2H), 7.73-7.71 (d, J=8 Hz, 2H), 7.60 (s, 1H), 3.85 (bs, 2H), 3.23 (s, 6H), 2.20 (s, 3H), 1.82 (m, 2H), 1.68 (m, 6H).

Example 2689

3-Bromo-4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride

Step A: Synthesis of 3-bromo-4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide hydrochloride.

Using the procedure of example 2526, the title compound was obtained.

ESI MS 466.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 12.0 (s, 1H), 8.32-8.31 (d, J=4 Hz, 1H), 8.08-8.07 (d, J=2 Hz, 1H), 7.88-7.86 (d, J=8 Hz, 1H), 7.73-7.70 (dd, J₁=4 Hz, J₂=4 Hz, 1H), 7.57-7.55 (d, J=8 Hz, 1H), 7.49 (s, 1H), 3.76-3.69 (m, 2H), 3.16 (s, 6H), 2.07 (s, 3H), 1.70 (bs, 2H), 1.55 (bs, 6H).

Examples 2690-2711

Compounds 2690 to 2711 were prepared in a similar manner as described in Example 2590 using the appropriate acid chloride and amine intermediate from Step B.

Examples 2712-2731

Compounds 2712 to 2731 were prepared in a similar manner as described in Example 2591 using the appropriate acid chloride and amine intermediate from Step A.

Examples 2732-2750

Compounds 2732 to 2750 were prepared in a similar manner as described in Example 2592 using the appropriate acid chloride and amine intermediate from Step A.

Examples 2751-2770

Compounds 2751 to 2770 were prepared in a similar manner as described in Example 2593 using the appropriate acid chloride and amine intermediate from Step B.

Examples 2771-2794

Compounds 2771 to 2794 were prepared in a similar manner as described in Example 2594 using the appropriate amine and the carboxylic acid intermediate from Step B.

Examples 2795-2823

Compounds 2795 to 2823 were prepared in a similar manner as described in Example 2527 using the appropriate amine and the carboxylic acid intermediate from Step B.

Examples 2824-2864

Compounds 2824 to 2864 were prepared in a similar manner as described in Example 2607 using the appropriate acid chloride and the amine intermediate from Step D.

Examples 2865-2866

Compounds 2865 and 2866 were prepared in a similar manner as described in Example 2611 using the appropriate benzaldehyde and the amine from Step A.

Examples 2867-2869

Compounds 2867 to 2869 were prepared in a similar manner as described in Example 2613 using the appropriate isocyanate and the amine from Step A.

Examples 2870-2875

Compounds 2870 to 2875 were prepared in a similar manner as described in Example 2615 using the appropriate carboxylic acid and the amine from Step A.

Example 2876

Compound 2876 was prepared in a similar manner as described in Example 2623 using the appropriate 4-chloro mandelic acid and the amine of Step A.

Examples 2877-2879

Compounds 2877 to 2879 were prepared in a similar manner as described in Example 2638 using the appropriate phenol and the bromoacetamide intermediate of Step B.

Examples 2880-2884

Compounds 2880 to 2884 were prepared in a similar manner as described in Example 2644 using the appropriate thiophenol.

Examples 2885-2895

Compounds 2885 to 2895 were prepared in a similar manner as described in Example 2647 using the appropriate phenol and the chloropyridyl intermediate of Step A.

Examples 2896-2940

Compounds 2896 to 2940 were prepared in a similar manner as described in Example 2523 using the appropriate acid chloride and the amine of Step C.

Examples 2941-2948

Compounds 2941 to 2948 were prepared in a similar manner as described in Example 2635 using the appropriate N-methylaniline and the bromoacetamide intermediate from step A.

Examples 2949-2950

Compounds 2949 and 2950 were prepared in a similar manner as described in Example 2619 using the appropriate carboxylic acid and the amine of Step A.

Examples 2951-2994

Compounds 2951 to 2994 were prepared in a similar manner as described in Example 2526 using the appropriate acid chloride and the amine of Step C.

Example 2995

Compound 2995 was prepared in a similar manner as described in Example 2628 using phenylsulfonyl chloride and the amine of Step A.

Examples 2996-3004

Compounds 2996 to 3004 were prepared in a similar manner as described in Example 2632 using the appropriate benzaldehyde and the amine of Step A.

Example 3005

Compound 3005 was prepared in a similar manner as described in Example 2632 using 3-trifluoromethoxy benzaldehyde and the amine from step C of Example 2526.

Example 3006

Compound 3006 was prepared in a similar manner as described in Example 2642 using 3,4-difluorobenzoyl chloride and the amine from Step C.

Examples 3007-3011

Compounds 3007 to 3011 were prepared in a similar manner as described in Example 2637 using the appropriate phenol and the chloropyridyl intermediate from Step A.

Examples 3012-3020

Compounds 3012 to 3020 were prepared in a similar manner as described in Example 2636 using the appropriate phenol and the chloropyridyl intermediate of Step A.

Examples 3021-3029

Compounds 3021 to 3029 were prepared in a similar manner as described in Example 2657 using the appropriate N-methylaniline and the intermediate prepared in Step C.

Example 3030

Compound 3030 was prepared in a similar manner as described in Example 2595 using 3,4-dichlorobenzoyl chloride and the amine of Step A.

Specific compounds as shown in the Examples and in the Tables herein are represented as a mono or di-salt, for example, trifluoroacetate, hydrochloride, and the like; or as a free base. It is understood that these specific representations of the compounds in no way limit the scope of the invention to the respective salt or free base. For example, a trifluoroacetate salt can be readily converted to the corresponding free amine by treatment with a sufficient amount of base and if desired converted to another salt, for example, a pharmaceutically acceptable salt as described herein.

It is understood that the present invention embraces compounds, as disclosed herein, as free bases, inorganic salts, and organic salts; and as solvates, and hydrates thereof.

Compounds in the subsequent table are listed specifically as the free base and may have been specifically isolated as a trifluoroacetate, hydrochloride, or like salt as dictated by the specific synthetic procedure.

Ex. No.	compound name	MS	class
2690	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
2691	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	382 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methylbenzamide
2692	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	404 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide
2693	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methoxybenzamide
2694	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	428 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide
2695	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	400 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide
2696	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	400 (M + H)	2
	yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide
2697	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide
2698	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-(trifluoromethyl)benzamide
2699	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide
2700	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	2
	yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide
2701	4-cyano-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	393 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
2702	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)methyl]benzamide
2703	4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	460 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
2704	3-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	420 (M + H)	1
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
2705	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	454 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-
	(trifluoromethyl)benzamide
2706	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	1
	yl]amino}cyclohexyl)methyl]benzamide
2707	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	1
	yl]amino}cyclohexyl)methyl]benzamide
2708	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	448 (M + H)	2
	yl]amino}cyclohexyl)methyl]-2,2-difluoro-1,3-benzodioxole-5-
	carboxamide
2709	N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide
2710	4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	402 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
2711	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	428 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide
2712	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	368 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2713	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	382 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-methylbenzamide
2714	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	404 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide
2715	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	398 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-methoxybenzamide
2716	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	428 (M + H)	2
	yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide
2717	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	400 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-fluoro-4-methylbenzamide
2718	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	400 (M + H)	2
	yl]amino}methyl)cyclohexyl]-4-fluoro-3-methylbenzamide
2719	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-(trifluoromethyl)benzamide
2720	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-(trifluoromethyl)benzamide
2721	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-(trifluoromethoxy)benzamide
2722	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-(trifluoromethoxy)benzamide
2723	4-cyano-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	393 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2724	4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	446 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2725	4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	460 (M + H)	2
	yl]amino}methyl)cyclohexyl]-3-methylbenzamide
2726	3-chloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	420 (M + H)	2
	yl]amino}methyl)cyclohexyl]-4-fluorobenzamide
2727	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	454 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-fluoro-4-(trifluoromethyl)-
	benzamide
2728	3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-	436 (M + H)	2
	2-yl]amino}methyl)cyclohexyl]benzamide
2729	3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2730	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	448 (M + H)	3
	yl]amino}methyl)cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-
	carboxamide
2731	N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-	504 (M + H)	2
	yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide
2732	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	368 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2733	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	382 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-methylbenzamide
2734	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	404 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide
2735	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	398 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-methoxybenzamide
2736	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	428 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide
2737	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	400 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-fluoro-4-methylbenzamide
2738	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	400 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-fluoro-3-methylbenzamide
2739	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-(trifluoromethyl)benzamide
2740	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-(trifluoromethyl)benzamide
2741	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-(trifluoromethoxy)benzamide
2742	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-(trifluoromethoxy)benzamide
2743	4-cyano-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	393 (M + H)	3
	yl]amino}methyl)cyclohexyl]benzamide
2744	4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	446 (M + H)	2
	yl]amino}methyl)cyclohexyl]benzamide
2745	4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	460 (M + H)	2
	yl]amino}methyl)cyclohexyl]-3-methylbenzamide
2746	3-chloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	420 (M + H)	3
	yl]amino}methyl)cyclohexyl]-4-fluorobenzamide
2747	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	454 (M + H)	3
	yl]amino}methyl)cyclohexyl]-3-fluoro-4-(trifluoromethyl)-
	benzamide
2748	3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	2
	yl]amino}methyl)cyclohexyl]benzamide
2749	3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	2
	yl]amino}methyl)cyclohexyl]benzamide
2750	N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-	448 (M + H)	3
	yl]amino}methyl)cyclohexyl]-2,2-difluoro-1,3-benzodioxole-5-
	carboxamide
2751	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
2752	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	382 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methylbenzamide
2753	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	404 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide
2754	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-methoxybenzamide
2755	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	400 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-methylbenzamide
2756	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	400 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-fluoro-3-methylbenzamide
2757	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide
2758	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	2
	yl]amino}cyclohexyl)methyl]-4-(trifluoromethyl)benzamide
2759	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide
2760	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	452 (M + H)	3
	yl]amino}cyclohexyl)methyl]-4-(trifluoromethoxy)benzamide
2761	4-cyano-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	393 (M + H)	3
	yl]amino}cyclohexyl)methyl]benzamide
2762	4-bromo-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)methyl]benzamide
2763	4-bromo-N-[(cis-4-{[4-dimethylamino)-6-methylpyrimidin-2-	460 (M + H)	1
	yl]amino}cyclohexyl)methyl]-3-methylbenzamide
2764	3-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	420 (M + H)	1
	yl]amino}cyclohexyl)methyl]-4-fluorobenzamide
2765	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	454 (M + H)	2
	yl]amino}cyclohexyl)methyl]-3-fluoro-4-(trifluoromethyl)-
	benzamide
2766	3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
2767	3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	436 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
2768	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	448 (M + H)
	yl]amino}cyclohexyl)methyl]-2,2-difluoro-1,3-benzodioxole-5-
	carboxamide
2769	N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	444 (M + H)
	yl]amino}cyclohexyl)methyl]biphenyl-4-carboxamide
2770	4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	402 (M + H)	2
	yl]amino}cyclohexyl)methyl]benzamide
2771	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	382 (M + H)	2
	[(1R)-1-phenylethyl]cyclohexanecarboxamide
2772	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	396 (M + H)	1
	[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide
2773	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	400 (M + H)	1
	[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide
2774	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	400 (M + H)	2
	[(1S)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide
2775	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	1
	[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide
2776	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	1
	[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide
2777	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	1
	[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide
2778	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-	416 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2779	cis-N-[1-(4-bromophenyl)ethyl]-4-{[-4-(dimethylamino)-5-	460 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2780	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	427 (M + H)	1
	[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide
2781	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	427 (M + H)	2
	[(1S)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide
2782	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	432 (M + H)	1
	[(1R)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide
2783	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]ainino}-N-	432 (M + H)	1
	[(1S)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide
2784	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-	372 (M + H)	2
	fluorophenyl)cyclohexanecarboxamide
2785	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(4-	396 (M + H)	2
	propylphenyl)cyclohexanecarboxamide
2786	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(4-	384 (M + H	3
	methoxyphenyl)cyclohexanecarboxamide
2787	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-	384 (M + H)	1
	methoxyphenyl)cyclohexanecarboxamide
2788	cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-	388 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2789	cis-N-(2-bromophenyl)-4-{[4-(dimethylamino)-5-	432 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2790	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	394 (M + H)	1
	[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide
2791	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-	422 (M + H)	1
	(trifluoromethyl)phenyl]cyclohexanecarboxamide
2792	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[2-	400 (M + H)	2
	(methylthio)phenyl]cyclohexanecarboxamide
2793	N2-[cis-4-(3,4-dihydroisoquinolin-2(1H)-ylcarbonyl)cyclohexyl]-	394 (M + H)	3
	N4,N4,5-trimethylpyrimidine-2,4-diamine
2794	cis-N-(4-chlorophenyl)-4-{[4-(dimethylamino)-5-	402 (M + H)
	methylpyrimidin-2-yl]amino}-N-methylcyclohexanecarboxamide
2795	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-	396 (M + H)	1
	[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide
2796	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	2
	[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide
2797	cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-	416 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2798	cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	368 (M + H)	2
	yl]amino}cyclohexanecarboxamide
2799	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-	386 (M + H)	2
	fluorobenzyl)cyclohexanecarboxamide
2800	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(2-	386 (M + H)	2
	fluorobenzyl)cyclohexanecarboxamide
2801	cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2802	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	1
	[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide
2803	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-	412 (M + H)	2
	[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide
2804	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-	400 (M + H)	2
	[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide
2805	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-	416 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2806	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	494 (M + H)	1
	iodobenzyl)cyclohexanecarboxamide
2807	cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2808	cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2809	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-	382 (M + H)	1
	methylbenzyl)cyclohexanecarboxamide
2810	cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2811	cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-	428 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2812	cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-	402 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2813	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-	436 (M + H)	2
	(trifluoromethyl)benzyl]cyclohexanecarboxamide
2814	cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-	504 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2815	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	398 (M + H)	1
	methoxybenzyl)cyclohexanecarboxamide
2816	cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-	402 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2817	cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-	436 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2818	cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2819	cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2820	cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-	404 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2821	cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-	464 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
2822	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-	382 (M + H)	1
	methylbenzyl)cyclohexanecarboxamide
2823	cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-	452 (M + H)	1
	(trifluoromethoxy)benzyl]cyclohexanecarboxamide
2824	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	398 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
2825	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	401 (M + H)	3
	yl]amino}cyclohexyl)-2,6-dihydroxyisonicotinamide
2826	N-(cis-4-{[dimethylamino)-5,6-dimethylpyrimidin-2-	370 (M + H)	3
	yl]amino}cyclohexyl)pyrazine-2-carboxamide
2827	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	385 (M + H)	3
	yl]amino}cyclohexyl)-6-hydroxynicotinamide
2828	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	373 (M + H)	2
	yl]amino}cyclohexyl)-5-methylisoxazole-3-carboxamide
2829	2-(3,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-	434 (M + H)	2
	dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide
2830	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	373 (M + H)	2
	yl]amino}cyclohexyl)-2-methyl-1,3-oxazole-4-carboxamide
2831	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	383 (M + H)	3
	yl]amino}cyclohexyl)-2-methylnicotinamide
2832	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	429 (M + H)	1
	yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide
2833	3-amino-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	385 (M + H)	2
	yl]amino}cyclohexyl)pyrazine-2-carboxamide
2834	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	413 (M + H)	3
	yl]amino}cyclohexyl)-2-ethoxynicotinamide
2835	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	369 (M + H)	3
	yl]amino}cyclohexyl)pyridine-2-carboxamide
2836	3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	393 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2837	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	382 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2838	3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	402 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2839	3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2840	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	428 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethoxybenzamide
2841	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	504 (M + H)	1
	yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide
2842	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-	436 (M + H)	1
	dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide
2843	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	452 (M + H)	2
	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
2844	4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	393 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2845	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	382 (M + H)	1
	yl]amino}cyclohexyl)-4-methylbenzamide
2846	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	386 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
2847	4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	402 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2848	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	398 (M + H)	2
	yl]amino}cyclohexyl)-2-methoxybenzamide
2849	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2850	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	436 (M + H)	1
	yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide
2851	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	412 (M + H)	3
	yl]amino}cyclohexyl)-4-ethoxybenzamide
2852	4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	460 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2853	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	400 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide
2854	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	400 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide
2855	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	396 (M + H)	2
	yl]amino}cyclohexyl)-3-ethylbenzamide
2856	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	452 (M + H)	1
	yl]amino{cyclohexyl)-3-(trifluoromethoxy)benzamide
2857	5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	447 (M + H)	1
	yl]amino}cyclohexyl)nicotinamide
2858	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	388 (M + H)	1
	yl]amino{cyclohexyl)-5-methylthiophene-2-carboxamide
2859	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	437 (M + H)	2
	yl]amino{cyclohexyl)-6-(trifluoromethyl)nicotinamide
2860	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	456 (M + H)	1
	yl]amino{cyclohexyl)-3,5-diethoxybenzamide
2861	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	412 (M + H)	1
	yl]amino{cyclohexyl)-3-ethoxybenzamide
2862	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	426 (M + H)	1
	yl]amino{cyclohexyl)-3-isopropoxybenzamide
2863	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	385 (M + H)	3
	yl]amino{cyclohexyl)-6-hydroxypyridine-2-carboxamide
2864	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	404 (M + H)	1
	yl]amino{cyclohexyl)-3,4-difluorobenzamide
2865	N4,N4,5,6-tetramethyl-N2-(cis-4-{[3-	438 (M + H)	3
	(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-
	2,4-diamine
2866	N2-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N4,N4,5,6-	390 (M + H)	2
	tetramethylpyrimidine-2,4-diamine
2867	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-	433 (M + H)	1
	dimethylpyrimidin-2-yl]amino}cyclohexyl)urea
2868	N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-	427 (M + H)	1
	yl]amino}cyclohexyl)-N′-(2-ethoxyphenyl)urea
2869	N-[4-(benzyloxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6-	489 (M + H)	3
	dimethylpyrimidin-2-yl]amino}cyclohexyl)urea
2870	1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	428 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
2871	1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	462 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
2872	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	402 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2873	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	408 (M + H)	1
	yl]amino]cyclohexyl)-1-(4-methylphenyl)-
	cyclopropanecarboxamide
2874	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	416 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)propanamide
2875	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	424 (M + H)	1
	yl]amino}cyclohexyl)-1-(4-methoxyphenyl)-
	cyclopropanecarboxamide
2876	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	418 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide
2877	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	414 (M + H)	1
	yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide
2878	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	1
	yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide
2879	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-	418 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2880	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	484 (M + H)	1
	yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]-
	sulfinyl}acetamide
2881	2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-	450 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2882	2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-	494 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2883	2-[(3,4-difluorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-	452 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2884	2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	468 (M + H)
	methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2885	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	461 (M + H)	1
	yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide
2886	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)	1
	yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide
2887	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)	1
	yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide
2888	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide
2889	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	573 (M + H)	1
	yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide
2890	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)	1
	yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide
2891	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)	1
	yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide
2892	2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-	481 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
2893	2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-	481 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
2894	2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-	525 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
2895	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	515 (M + H)	1
	yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]-
	nicotinamide
2896	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide
2897	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	372 (M + H)	1
	yl]amino}cyclohexyl)-3-fluorobenzamide
2898	3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	432 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2899	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	372 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
2900	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	414 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethoxybenzamide
2901	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	390 (M + H)	1
	yl]amino}cyclohexyl)-2,4-difluorobenzamide
2902	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	390 (M + H)	1
	yl]amino}cyclohexyl)-2,5-difluorobenzamide
2903	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	408 (M + H)	1
	yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide
2904	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	354 (M + H)	2
	yl]amino}cyclohexyl)benzamide
2905	4-tert-butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	410 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2906	4-butyl-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	410 (M + H)
	yl]amino}cyclohexyl)benzamide
2907	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	388 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2908	3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	379 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2909	4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	379 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2910	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)-2-methoxybenzamide
2911	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	432 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2912	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide
2913	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)-4-methoxybenzamide
2914	2-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	432 (M + H)	3
	yl]amino}cyclohexyl)benzamide
2915	2-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	388 (M + H)	3
	yl]amino}cyclohexyl)benzamide
2916	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	372 (M + H)	3
	yl]amino}cyclohexyl)-2-fluorobenzamide
2917	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	368 (M + H)	3
	yl]amino}cyclohexyl)-2-methylbenzamide
2918	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	422 (M + H)	3
	yl]amino}cyclohexyl)-2-(trifluoromethyl)benzamide
2919	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	440 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide
2920	4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2921	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	398 (M + H)	2
	yl]amino}cyclohexyl)-4-ethoxybenzamide
2922	3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5-	397 (M + H)
	methylpyrimidin-2-yl]amino}cyclohexyl)benzamide
2923	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	386 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide
2924	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	386 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide
2925	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	382 (M + H)	1
	yl]amino}cyclohexyl)-3-ethylbenzamide
2926	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	434 (M + H)	1
	yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-
	carboxamide
2927	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	398 (M + H)	2
	yl]amino}cyclohexyl)-3-ethoxybenzamide
2928	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	412 (M + H)	2
	yl]amino}cyclohexyl)-3-isopropoxybenzamide
2929	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	442 (M + H)	1
	yl]amino}cyclohexyl)-3,5-diethoxybenzamide
2930	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	440 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide
2931	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	440 (M + H)	3
	yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide
2932	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	406 (M + H)	3
	yl]amino}cyclohexyl)-4-fluorobenzamide
2933	3,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	510 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2934	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	382 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethylbenzamide
2935	4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	402 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2936	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	452 (M + H)	1
	yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide
2937	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	368 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2938	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	384 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
2939	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	368 (M + H)	1
	yl]amino}cyclohexyl)-4-methylbenzamide
2940	3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	388 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2941	N˜2˜-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	431 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide
2942	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	411 (M + H)	1
	yl]amino}cyclohexyl)-N2-methyl-N2-(3-methylphenyl)-
	glycinamide
2943	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	415 (M + H)	1
	yl]amino}cyclohexyl)-N2-(3-fluorophenyl)-N2-
	methylglycinamide
2944	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	415 (M + H)	1
	yl]amino}cyclohexyl)-N2-(4-fluorophenyl)-N2-
	methylglycinamide
2945	N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	431 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide
2946	N2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	433 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide
2947	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	427 (M + H)	1
	yl]amino}cyclohexyl)-N2-(3-methoxyphenyl)-N2-
	methylglycinamide
2948	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	427 (M + H)	2
	yl]amino}cyclohexyl)-N2-(4-methoxyphenyl)-N2-
	methylglycinamide
2949	2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-	430 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide
2950	2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-	504 (M + H)	2
	6-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide
2951	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	354 (M + H)	3
	yl]amino}cyclohexyl)benzamide
2952	4-butyl-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	410 (M + H)	3
	yl]amino}cyclohexyl)benzamide
2953	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	372 (M + H)	2
	yl]amino}cyclohexyl)-3-fluorobenzamide
2954	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide
2955	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)-2-methoxybenzamide
2956	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	384 (M + H)	3
	yl]amino}cyclohexyl)-4-methoxybenzamide
2957	3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	379 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2958	4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	379 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2959	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	414 (M + H)	1
	yl]amino}cyclohexyl)-3,5-dimethoxybenzamide
2960	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	440 (M + H)	2
	yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide
2961	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	440 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide
2962	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	440 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide
2963	3-chloro-N-(cis4-{[4-(dimethylamino)-6-methylpyrimidin-2-	406 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
2964	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	386 (M + H)	1
	yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide
2965	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	386 (M + H)	1
	yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide
2966	3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2967	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	438 (M + H)	1
	yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide
2968	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	390 (M + H)	1
	yl]amino}cyclohexyl)-3,5-difluorobenzamide
2969	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	446 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2970	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	382 (M + H)	3
	yl]amino}cyclohexyl)-3-ethylbenzamide
2971	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	398 (M + H)	3
	yl]amino}cyclohexyl)-4-ethoxybenzamide
2972	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	422 (M + H)	2
	yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide
2973	4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	432 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2974	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	382 (M + H)	2
	yl]amino}cyclohexyl)-4-ethylbenzamide
2975	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	442 (M + H)	1
	yl]amino}cyclohexyl)-3,5-diethoxybenzamide
2976	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	398 (M + H)	2
	yl]amino}cyclohexyl)-3-ethoxybenzamide
2977	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	412 (M + H	1
	yl]amino}cyclohexyl)-3-isopropoxybenzamide
2978	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	433 (M + H)	1
	yl]amino}cyclohexyl)nicotinamide
2979	5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
2980	5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	378 (M + H)	1
	yl]amino}cyclohexyl)-2-furamide
2981	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	452 (M + H)	2
	yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide
2982	4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	456 (M + H)	1
	yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide
2983	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	368 (M + H)	1
	yl]amino}cyclohexyl)-3-methylbenzamide
2984	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	384 (M + H)	1
	yl]amino}cyclohexyl)-3-methoxybenzamide
2985	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	368 (M + H)	1
	yl]amino}cyclohexyl)-4-methylbenzamide
2986	4-chloro-N-(cis4-{[4-(dimethylamino)-6-methylpyrimidin-2-	388 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2987	3-chloro-N-(cis4-{[4-(dimethylamino)-6-methylpyrimidin-2-	388 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2988	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	390 (M + H)	1
	yl]amino}cyclohexyl)-3,4-difluorobenzamide
2989	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	438 (M + H)	3
	yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide
2990	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	372 (M + H)	1
	yl]amino}cyclohexyl)-4-fluorobenzamide
2991	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	444 (M + H)	1
	yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide
2992	N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-	399 (M + H)	1
	yl]amino}cyclohexyl)-3-nitrobenzamide
2993	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	444 (M + H)	1
	yl]amino}cyclohexyl)-2,2-diphenylacetamide
2994	3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	422 (M + H)	1
	yl]amino}cyclohexyl)benzamide
2995	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	390 (M + H)	3
	yl]amino}cyclohexyl)benzenesulfonamide
2996	N4,N4,5-trimethyl-N2-{cis-4-[(4-	354 (M + H)	3
	methylbenzyl)amino]cyclohexyl}pyrimidine-2,4-diamine
2997	N2-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N4,N4,5-	376 (M + H)	3
	trimethylpyrimidine-2,4-diamine
2998	N2-{cis-4-[(3-chlorobenzyl)amino]cyclohexyl}-N4,N4,5-	374 (M + H)	3
	trimethylpyrimidine-2,4-diamine
2999	N2-{cis-4-[(3-bromobenzyl)amino]cyclohexyl}-N4,N4,5-	418 (M + H)	3
	trimethylpyrimidine-2,4-diamine
3000	N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4,5-	400 (M + H)	2
	trimethylpyrimidine-2,4-diamine
3001	N2-{cis-4-[(3,5-dichlorobenzyl)amino]cyclohexyl}-N4,N4,5-	408 (M + H)	3
	trimethylpyrimidine-2,4-diamine
3002	N2-{cis-4-[(3,4-dichlorobenzyl)amino]cyclohexyl}-N4,N4,5-	408 (M + H)	3
	trimethylpyrimidine-2,4-diamine
3003	N2-{cis-4-[(4-methoxy-3-methylbenzyl)amino]cyclohexyl}-	384 (M + H)	3
	N4,N4,5-trimethylpyrimidine-2,4-diamine
3004	N4,N4,5-trimethyl-N2-(cis-4-{[3-	424 (M + H)	3
	(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-
	2,4-diamine
3005	N4,N4,6-trimethyl-N2-(cis-4-{[3-	424 (M + H)	3
	(trifluoromethoxy)benzyl]amino}cyclohexyl)pyrimidine-
	2,4-diamine
3006	N-(cis-4-{[4-(dimethylamino)-5-(trifluoromethyl)pyrimidin-2-	444 (M + H)	3
	yl]amino}cyclohexyl)-3,4-difluorobenzamide
3007	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)
	yl]amino}cyclopentyl)methyl]-6-(3-fluorophenoxy)nicotinamide
3008	6-(3-chlorophenoxy)-N-[((1R,3S)-3-{[4-(dimethylamino)-5-	481 (M + H)
	methylpyrimidin-2-yl]amino}cyclopentyl)methyl]nicotinamide
3009	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)
	yl]amino}cyclopentyl)methyl]-6-(3-methoxyphenoxy)-
	nicotinamide
3010	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)
	yl]amino}cyclopentyl)methyl]-6-(2-methoxyphenoxy)-
	nicotinamide
3011	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)
	yl]amino}cyclopentyl)methyl]-6-(2-fluorophenoxy)nicotinamide
3012	2-(4-bromophenoxy)-N-[((1R,3S)-3-{[4-(dimethylamino)-5-	525 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclopentyl)methyl]nicotinamide
3013	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)	1
	yl]amino}cyclopentyl)methyl]-2-(2-methoxyphenoxy)-
	nicotinamide
3014	2-(2-bromophenoxy)-N-[((1R,3S)-3-{[4-(dimethylamino)-5-	525 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclopentyl)methyl]nicotinamide
3015	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)	1
	yl]amino}cyclopentyl)methyl]-2-(2-fluorophenoxy)nicotinamide
3016	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	477 (M + H)
	yl]amino}cyclopentyl)methyl]-2-(4-methoxyphenoxy)-
	nicotinamide
3017	N-[((1R,3S)-3-{[4-(dimethylamino)-5-methylpyrimidin-2-	465 (M + H)	3
	yl]amino}cyclopentyl)methyl]-2-(3-fluorophenoxy)nicotinamide
3018	2-(3-chlorophenoxy)-N-[((1R,3S)-3-{[4-(dimethylamino)-5-	481 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclopentyl)methyl]nicotinamide
3019	2-(3-chloro-4-fluorophenoxy)-N-[((1R,3S)-3-{[4-	499 (M + H)	2
	(dimethylamino)-5-methylpyrimidin-2-
	yl]amino}cyclopentyl)methyl]-nicotinamide
3020	2-(4-chloro-3-fluorophenoxy)-N-[((1R,3S)-3-{[4-	499 (M + H)	3
	(dimethylamino)-5-methylpyrimidin-2-
	yl]amino}cyclopentyl)methyl]-nicotinamide
3021	N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	417 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea
3022	N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	451 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea
3023	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	397 (M + H)	1
	yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea
3024	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	397 (M + H)	1
	yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea
3025	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	401 (M + H)	1
	yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea
3026	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	401 (M + H)	1
	yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea
3027	N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	417 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea
3028	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	413 (M + H)	1
	yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea
3029	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	413 (M + H)	1
	yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea
3030	3,4-dichloro-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-	408 (M + H)	3
	yl]amino}cyclohexyl)benzamide

Example 3031

3,4-Difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester.

To a suspension of cis-cyclohexane-1,4-dicarboxylic acid (25.0 g, 145 mmol) in benzene (125 mL) were added phosphorazidic acid diphenyl ester (81.9 g, 298 mmol) and triethylamine (30.1 g, 297 mmol). The reaction mixture was stirred at reflux for 2.5 hr. Benzyl alcohol (32.2 g, 298 mmol) was added and the mixture was stirred at reflux for 24 hr. The reaction mixture was concentrated and the residue was dissolved in EtOAc and H₂O. The organic layer was separated and the aqueous layer was extracted with EtOAc (twice). The combined organic layer was washed with 1 M aqueous KHSO₄, saturated aqueous NaHCO₃, and brine, dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (52.0 g, 94%) as a colorless oil.

ESI MS m/e 405, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.15-7.40 (m, 10H), 5.07 (s, 4H), 4.70-5.00 (m, 2H), 3.52-3.80 (m, 2H), 1.60-1.80 (m, 4H), 1.45-1.60 (m, 4H).

Step B: Synthesis of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester.

To a solution of (cis-4-benzyloxycarbonylamino-cyclohexyl)-carbamic acid benzyl ester (91.7 g, 240 mmol) in MeOH (460 mL) was added 5% Pd/C (9.17 g). The reaction mixture was stirred at ambient temperature under hydrogen atmosphere for 2.5 days, filtered through a pad of celite, and concentrated to give a diamine as a colorless oil. To a solution of the diamine in MeOH (550 mL) was added a solution of (Boc)₂O (6.59 g, 30.2 mmol) in MeOH (80 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 1.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (7.78 g, 15%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (32.9 g) as a colorless oil. To a solution of the recovered diamine (32.9 g, 288 mmol) in MeOH (660 mL) was added a solution of (Boc)₂O (6.29 g, 28.8 mmol) in MeOH (80 mL) dropwise over 5 hr. The reaction mixture was stirred at ambient temperature for 10 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (8.16 g, 16%, crude) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (23.1 g) as a colorless oil. To a solution of the recovered diamine (23.1 g, 202 mmol) in MeOH (462 mL) was added a solution of (Boc)₂O (4.42 g, 20.3 mmol) in MeOH (56 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 3.5 days and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (5.01 g, 10% based on starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (16.0 g) as a colorless oil. To a solution of the recovered diamine (16.0 g, 140 mmol) in MeOH (320 mL) was added a solution of (Boc)₂O (3.06 g, 14.0 mmol) in MeOH (40 mL) dropwise over 4 hr. The reaction mixture was stirred at ambient temperature for 13 hr and concentrated. After dissolution with H₂O, the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (3.53 g, 7% based on the starting material) as a colorless oil. The aqueous layer was concentrated and the residue was dissolved in MeOH, dried over MgSO₄, filtered, and concentrated to give a recovered diamine (11.1 g) as a colorless oil.

ESI MS m/e 215, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.30-4.82 (m, 1H), 3.50-3.80 (m, 1H), 2.78-2.95 (m, 1H), 1.44 (s, 9H), 1.20-1.80 (m, 8H).

Step C: Synthesis of (cis-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-carbamic acid tert-butyl ester.

To a solution of 3,4-difluoro-benzoic acid (4.10 g, 25.9 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (5.05 g, 23.6 mmol) in DMF (50 mL) were added Et₃N (90 mL, 56.7 mmol), HOBt-H₂O (541 g, 35.3 mmol), and EDC-HCl (4.97 g, 25.9 mmol). The reaction mixture was stirred at ambient temperature for 17 hr. To the reaction mixture was added water (200 mL) and the suspension was stirred at ambient temperature for 10 min. The precipitated was collected by filtration, washed with H₂O and EtOH, and dried at 80° C. under reduced pressure to give (cis-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-carbamic acid tert-butyl ester (5.20 g, 62.3%) as a white solid.

ESI MS m/e 377, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H), 1.53-1.95 (m, 8H), 3.60-3.74 (m, 1H), 4.00-4.16 (m, 1H), 4.50-4.68 (m, 1H), 5.95-6.09 (m, 1H), 7.15-7.28 (m, 1H), 7.43-7.68 (m, 2H).

Step D: Synthesis of N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide.

A solution of (cis-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexyl)-carbamic acid tert-butyl ester (5.20 g, 14.7 mmol) in EtOAc (52 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (104 mL) was added. The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and dried at 60° C. under reduced pressure to give N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide (3.00 g, 80%) as a white solid.

ESI MS m/e 255, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.15-1.52 (m, 3H), 1.59-1.89 (m, 5H), 2.94-3.06 (m, 1H), 4.06-4.20 (m, 1H), 6.01-6.18 (m, 1H), 7.13-7.26 (m, 1H), 7.43-7.50 (m, 1H), 7.57-7.67 (m, 1H).

Step E: Synthesis of 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

A mixture of 2-chloro-quinoline (200 mg, 1.22 mmol) and N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide (342 mg, 1.34 mmol) in butanol (1 mL) was stirred at 130° C. for 60 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et₂O, and dried at 80° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (189 mg, 37%) as a white solid.

ESI MS m/e 382, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.09 (m, 8H), 3.96-4.24 (m, 2H), 6.90-7.03 (m, 2H), 7.14-7.25 (m, 1H), 7.41-7.48 (m, 1H), 7.57-7.64 (m, 1H), 7.69-7.79 (m, 4H), 8.18 (d, J=9.6 Hz, 1H), 9.73-9.76 (m, 1H).

Example 3032

2-Phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of N-(cis-4-amino-cyclohexyl)-2-phenoxy-nicotinamide.

To a solution of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (6.00 g, 27.8 mmol) in CHCl₃ (60 mL) was added i-Pr₂NEt (9.67 mL, 55.6 mmol). The mixture was cooled on an ice-bath and 2-phenoxy-nicotinoyl chloride (6.50 g, 27.8 mmol) was added. The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. To a solution of the above material in EtOAc (100 mL) and CHCl₃ (40 mL) was added 4 M hydrogen chloride in EtOAc (100 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 0.2% to 1% MeOH in CHCl₃) to give N-(cis-4-amino-cyclohexyl)-2-phenoxy-nicotinamide (3.51 g, 41%) as a pale yellow oil.

ESI MS m/e 312, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.39 (m, 3H), 1.65-1.94 (m, 5H), 2.80-2.91 (m, 1H), 4.18-4.30 (m, 1H), 7.13-7.22 (m, 3H), 7.25-7.33 (m, 1H), 7.41-7.51 (m, 2H), 8.04-8.14 (m, 1H), 8.22 (dd, J=4.7, 2.1 Hz, 1H), 8.62 (dd, J=7.6, 2.0 Hz, 1H).

Step B: Synthesis of 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

A mixture of 2-chloro-quinoline (200 mg, 1.22 mmol) and cis-N-(4-amino-cyclohexyl)-2-phenoxy-nicotinamide (418 mg, 1.34 mmol) in butanol (1 mL) was stirred at 130° C. for 6 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% to 16% EtOAc in hexane). To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride (138 mg, 37%) as a white solid.

ESI MS m/e 461, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.87-2.10 (m, 8H), 3.83-3.97 (m, 1H) 4.12-4.24 (m, 1H), 6.90 (d, J=9.5 Hz, 1H), 7.12 (dd, J=7.6, 4.5 Hz, 1H), 7.20-7.32 (m, 3H), 7.37-7.50 (m, 3H), 7.66-7.80 (m, 3H), 7.95 (d, J=7.0 Hz, 1H) 8.13 (d, J=9.6 Hz, 1H), 8.21 (dd, J=4.6, 2.2 Hz, 1H), 8.53 (dd, J=7.6, 1.9 Hz, 1H), 9.77-9.92 (m, 1H).

Example 3033

3-Methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of cis-N-quinolin-2-yl-cyclohexane-1,4-diamine.

A mixture of 2-chloro-quinoline (16.0 g, 97.8 mol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (23.0 g, 107.5 mol) in butanol (16 mL) was stirred at 130° C. for 3 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (160 mL) was added 4 M hydrogen chloride in EtOAc (80 mL). The mixture was stirred at ambient temperature for 12 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 5% MeOH in CHCl₃) to give cis-N-quinolin-2-yl-cyclohexane-1,4-diamine (6.30 g, 27%) as pale yellow solid.

ESI MS m/e 242, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.53 (m, 4H), 1.65-1.93 (m, 6H), 2.84-2.98 (m, 1H), 4.04-4.16 (m, 1H), 4.78-4.91 (m, 1H), 6.61 (d, J=9.0 Hz, 1H), 7.17 (ddd, J=8.0, 6.9, 1.2 Hz, 1H), 7.46-7.58 (m, 2H), 7.61-7.66 (m, 1H), 7.79 (d, J=8.9 Hz, 1H).

Step B: Synthesis of 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of cis-N-quinolin-2-yl-cyclohexane-1,4-diamine (300 mg, 1.24 mmol) in CHCl₃ (2 mL) were added i-Pr₂NEt (0.45 mL, 2.60 mmol) and 3-methyl-benzoyl chloride (210 mg, 1.36 mmol) in CHCl₃ (1 mL). The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (294 mg, 60%) as a white solid.

ESI MS m/e 382, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.07 (m, 8H), 2.40 (s, 3H), 3.93-4.04 (m, 1H), 4.08-4.26 (m, 1H), 6.49-6.58 (m, 1H), 6.94 (d, J=9.5 Hz, 1H), 7.25-7.32 (m, 2H), 7.40-7.48 (m, 1H), 7.56-7.66 (m, 2H), 7.67-7.81 (m, 3H) 8.17 (d, J=9.5 Hz, 1H), 9.74-9.87 (m, 1H).

Example 3034

3-Methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 398, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.09 (m, 8H), 3.86 (s, 3H), 3.94-4.06 (m, 1H), 4.08-4.25 (m, 1H), 6.63 (d, J=8.6 Hz, 1H), 6.91-7.05 (m, 2H), 7.28-7.48 (m, 4H), 7.68-7.80 (m, 3H), 8.17 (d, J=9.3 Hz, 1H), 9.75-9.84 (m, 1H).

Example 3035

3-Chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 402, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.10 (m, 8H), 3.96-4.07 (m, 1H), 4.09-4.26 (m, 1H), 6.75 (d, J=7.8 Hz, 1H), 6.96 (d, J=9.3 Hz, 1H), 7.33-7.49 (m, 3H), 7.66-7.79 (m, 4H), 7.83-7.88 (m, 1H), 8.19 (d, J=9.3 Hz, 1H), 9.80 (d, J=8.5 Hz, 1H).

Example 3036

5-Nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

To a solution of 5-nitro-thiophene-3-carboxylic acid (516 mg, 2.98 mmol) and cis-N-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (600 mg, 2.48 mmol) in DMF (6 mL) were added Et₃N (0.83 mL, 5.95 mmol), HOBt-H₂O (570 mg, 3.72 mmol), and EDC-HCl (571 g, 2.98 mmol). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% to 50% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride (329 mg, 60%) as a yellow solid.

ESI MS m/e 419, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.18 (m, 8H), 3.96-4.25 (m, 2H), 6.97 (d, J=9.3 Hz, 1H), 7.39-7.53 (m, 2H), 7.67-7.80 (m, 3H), 8.20 (d, J=9.4 Hz, 1H), 8.26-8.30 (m, 1H), 8.39-8.42 (m, 1H), 9.59 (d, J=8.6 Hz, 1H).

Example 3037

2-Chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 403, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl) δ 1.84-2.17 (m, 8H), 3.93-4.05 (m, 1H), 4.13-4.30 (m, 1H), 6.89-7.02 (m, 2H), 7.30-7.50 (m, 2H), 7.67-7.81 (m, 3H), 7.96 (d, J=7.5 Hz, 1H), 8.19 (d, J=9.6 Hz, 1H), 8.44-8.50 (m, 1H), 9.73-9.87 (m, 1H).

Example 3038

3-Chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 420, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.08 (m, 8H), 3.95-4.06 (m, 1H), 4.07-4.23 (m, 1H), 6.68-6.78 (m, 1H), 6.95 (d, J=9.6 Hz, 1H), 7.18 (t, J=8.6 Hz, 1H), 7.41-7.48 (m, 1H), 7.68-7.79 (m, 4H), 7.95 (dd, J=7.0, 2.2 Hz, 1H), 8.18 (d, J=9.6 Hz, 1H), 9.79 (d, J=8.4 Hz, 1H).

Example 3039

3,5-Dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,5-dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 428, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.14 (m, 8H), 3.85 (s, 6H), 3.95-4.26 (m, 2H), 6.53-6.66 (m, 2H), 6.89-7.01 (m, 3H), 7.40-7.51 (m, 1H), 7.68-7.82 (m, 3H), 8.18 (d, J=9.6 Hz, 1H), 9.76-9.85 (m, 1H).

Example 3040

3,4-Dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 436, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.15 (m, 8H), 3.98-4.25 (m, 2H), 6.87-7.00 (m, 2H), 7.42-7.52 (m, 2H), 7.65-7.80 (m, 4H), 7.98 (d, J=2.0 Hz, 1H), 8.19 (d, J=9.5 Hz, 1H), 9.87 (d, J=8.6 Hz, 1H).

Example 3041

Benzo[2,1,3]oxadiazole-5-carboxylic acid-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step B of example 3033, the title compound was obtained.

ESI MS m/e 388, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.23 (m, 8H), 3.98-4.31 (m, 2H), 6.97 (d, J=9.5 Hz, 1H), 7.38-7.50 (m, 2H), 7.70-7.78 (m, 3H), 7.88 (ddd, J=14.3, 9.3, 1.2 Hz, 2H), 8.20 (d, J=9.5 Hz, 1H), 8.41 (t, J=1.2 Hz, 1H), 9.75 (d, J=8.1 Hz, 1H).

Example 3042

1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 394, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.14 (m, 8H), 3.91-4.15 (m, 5H), 6.96 (d, J=9.4 Hz, 1H), 7.09 (d, J=9.0 Hz, 1H), 7.28-7.31 (m, 1H), 7.41-7.54 (m, 2H), 7.67-7.79 (m, 3H), 8.19 (d, J=9.6 Hz, 1H), 9.66 (m, 1H).

Example 3043

9H-Xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 9H-Xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 472, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-1.89 (m, 8H), 3.76-3.94 (m, 2H), 5.99-6.09 (m, 1H), 6.87 (d, J=10.1 Hz, 1H), 7.05-7.18 (m, 4H), 7.24-7.47 (m, 5H), 7.65-7.79 (m, 3H) 8.13 (d, J=9.6 Hz, 1H), 9.62 (d, J=7.6 Hz, 1H).

Example 3044

5-(4-Chloro-phenyl)-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-(4-chloro-phenyl)-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 468, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.13 (m, 8H), 3.93-4.07 (m, 1H), 4.10-4.28 (m, 1H), 6.65-7.03 (m, 3H), 7.12-7.23 (m, 1H), 7.32-7.52 (m, 3H), 7.63-7.85 (m, 5H), 8.12-8.26 (m, 1H), 9.74-9.94 (m, 1H).

Example 3045

3-Nitro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-nitro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 413, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.30 (m, 8H), 3.99-4.10 (m, 1H), 4.13-4.31 (m, 1H), 6.97 (d, J=9.5 Hz, 1H), 7.24-7.33 (m, 1H), 7.42-7.51 (m, 1H), 7.63 (t, J=7.9 Hz, 1H), 7.70-7.79 (m, 3H), 8.17-8.24 (m, 2H), 8.30-8.35 (m, 1H), 8.75-8.77 (m, 1H), 9.76 (d, J=7.3 Hz, 1H).

Example 3046

4-Fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of cis-N-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (250 mg, 1.04 mmol) in CHCl₃ (5 mL) were added Et₃N (0.3 mL, 2.15 mmol) and 4-fluoro-3-methyl-benzoyl chloride (197 mg, 1.14 mmol). The mixture was stirred at ambient temperature for 12 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 6 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (363 mg, 85%) as a white solid.

ESI MS m/e 400, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.10 (m, 8H), 2.32 (d, J=1.9 Hz, 3H), 3.96-4.07 (m, 1H), 4.09-4.27 (m, 1H), 6.62-6.72 (m, 1H), 6.96 (d, J=9.5 Hz, 1H), 7.04 (t, J=8.9 Hz, 1H), 7.40-7.51 (m, 1H), 7.61-7.83 (m, 5H) 8.19 (d, J=9.6 Hz, 1H), 9.71-9.85 (m, 1H).

Example 3047

3-Bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 446, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8H), 3.96-4.08 (m, 1H), 4.09-4.27 (m, 1H), 6.84 (d, J=7.8 Hz, 1H), 6.96 (d, J=9.6 Hz, 1H), 7.30 (t, J=7.9 Hz, 1H), 7.41-7.50 (m, 1H), 7.57-7.64 (m, 1H), 7.69-7.80 (m, 4H), 8.01 (t, J=1.6 Hz, 1H), 8.19 (d, J=9.3 Hz, 1H), 9.71 (m, 1H).

Example 3048

2-(2-Bromophenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

To a solution of 2-bromo-phenol (453 mg, 2.62 mmol) in DMA (4 mL) was added 60% NaH in oil (210 mg, 5.24 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide obtained in step A of example 3037 (1.00 g, 2.62 mmol) in DMA (2 mL). The mixture was stirred at 120° C. for 3 hr and the reaction was quenched with water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 1% to 2% MeOH in CHCl₃) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride (262 mg, 18%) as a white solid.

ESI MS m/e 517, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.89-2.17 (m, 8H), 3.81-3.98 (m, 1H), 4.14-4.30 (m, 1H), 6.92 (d, J=9.5 Hz, 1H), 7.11-7.20 (m, 2H), 7.34-7.47 (m, 3H), 7.63-7.80 (m, 4H), 7.92-8.00 (m, 1H), 8.10-8.20 (m, 2H), 8.54 (dd, J=7.5, 2.0 Hz, 1H), 9.71-9.88 (m, 1H).

Example 3049

3-Cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 393, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.17 (m, 8H), 3.98-4.30 (m, 2H), 6.97 (d, J=9.3 Hz, 1H), 7.07-7.18 (m, 1H), 7.42-7.50 (m, 1H) 7.56 (t, J=7.8 Hz, 1H), 7.70-7.80 (m, 4H), 8.08 (d, J=7.9 Hz, 1H), 8.17-8.25 (m, 2H), 9.69-9.84 (m, 1H).

Example 3050

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 436, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.13 (m, 8H), 3.97-4.09 (m, 1H), 4.12-4.33 (m, 1H), 6.92-7.05 (m, 2H), 7.41-7.50 (m, 1H), 7.57 (t, J=7.7 Hz, 1H), 7.69-7.79 (m, 4H), 8.02 (d, J=8.1 Hz, 1H), 8.13-8.26 (m, 2H), 9.72-9.85 (m, 1H).

Example 3051

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide hydrochloride

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide hydrochloride.

To a solution of m-tolyloxy-acetic acid (189 mg, 1.14 mmol) and cis-N-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3036 (250 mg, 1.04 mmol) in DMF (15 mL) were added Et₃N (0.35 mL, 2.50 mmol), HOBt-H₂O (238 mg, 1.56 mmol), and EDC-HCl (219 g, 1.14 mmol). The reaction mixture was stirred at ambient temperature for 13 hr. To the reaction mixture was added water (30 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 1% to 5% MeOH in CHCl₃) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide hydrochloride (140 mg, 32%) as a white solid.

ESI MS m/e 412, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.06 (m, 8H), 2.33 (s, 3H), 3.88-4.12 (m, 2H), 4.44 (s, 2H), 6.72-6.96 (m, 5H), 7.18 (t, J=8.0 Hz, 1H), 7.39-7.47 (m, 1H), 7.68-7.81 (m, 3H), 8.17 (d, J=9.3 Hz, 1H), 9.72-9.89 (m, 1H).

Example 3052

2,2-Diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2,2-diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 458, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-1.97 (m, 8H), 3.84-4.10 (m, 2H), 4.87 (s, 1H), 6.16-6.25 (m, 1H), 6.90 (d, J=9.5 Hz, 1H), 7.20-7.36 (m, 10H), 7.39-7.48 (m, 1H), 7.67-7.79 (m, 3H), 8.15 (d, J=9.2 Hz, 1H), 9.63-9.77 (m, 1H).

Example 3053

5-Bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 436, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.84-2.09 (m, 8H), 3.92-4.18 (m, 2H), 6.42 (d, J=3.5 Hz, 1H), 6.61 (d, J=8.6 Hz, 1H), 6.95 (d, J=8.2 Hz, 1H), 7.05 (d, J=3.5 Hz, 1H), 7.42-7.48 (m, 1H), 7.69-7.83 (m, 3H), 8.19 (d, J=9.5 Hz, 1H), 9.85 (d, J=8.6 Hz, 1H).

Example 3054

2-(4-Fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester.

To a solution of 2-fluoro-phenol (3.02 g, 26.9 mmol) in DMA (20 mL) was added 60% NaH in oil (1.08 mg, 26.9 mmol). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added 2-chloro-nicotinic acid ethyl ester (5.00 g, 26.9 mmol) in DMA (5 mL). The mixture was stirred at 120° C. for 2 hr and the reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 10% Et₂O in hexane (50 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with hexane, and dried at 70° C. under reduced pressure to give 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester (3.08 g, 44%) as a white solid.

ESI MS m/e 284, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.40 (td, J=7.1, 1.6 Hz, 3H), 4.41 (qd, J=7.1, 1.6 Hz, 2H), 6.99-7.21 (m, 5H), 8.23-8.29 (m, 2H).

Step B: Synthesis of 2-(4-fluoro-phenoxy)-nicotinic acid.

To a solution of 2-(4-fluoro-phenoxy)-nicotinic acid ethyl ester (3.00 g, 11.5 mmol) in EtOH (90 mL) was added 2 M aqueous NaOH (6 mL). The mixture was stirred at ambient temperature for 4 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 10% Et₂O in hexane (80 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with hexane, and dried at 70° C. under reduced pressure to give 2-(4-fluoro-phenoxy)-nicotinic acid (2.39 g, 89%) as a white solid.

ESI MS m/e 233, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.05-7.25 (m, 5H), 8.32 (dd, J=4.8, 2.0 Hz, 1H), 8.49 (dd, J=7.6, 2.0 Hz, 1H).

Step C: Synthesis of 2-(4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 479, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.14 (m, 8H), 3.88-4.01 (m, 1H), 4.13-4.30 (m, 1H), 6.93 (d, J=9.3 Hz, 1H), 7.11-7.20 (m, 3H), 7.25-7.31 (m, 2H), 7.43 (t, J=7.9 Hz, 1H), 7.67-7.81 (m, 3H), 7.93 (d, J=7.2 Hz, 1H), 8.16 (d, J=9.2 Hz, 1H), 8.21 (dd, J=4.8, 2.0 Hz, 1H), 8.54 (dd, J=7.6, 2.0 Hz, 1H), 9.81-9.94 (m, 1H).

Example 3055

2-(3,4-Difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenoxy)-nicotinic acid.

To a solution of 3,4-difluoro-phenol (3.77 g, 28.9 mmol) in DMA (20 mL) was added 60% NaH in oil (1.16 mg, 28.9 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-nicotinic acid ethyl ester (5.36 g, 28.9 mmol) in DMA (5 mL). The mixture was stirred at 120° C. for 2.5 hr and the reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 10% Et₂O in hexane (150 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitate was filtered, washed with hexane, and dried at 70° C. under reduced pressure to give a white solid. To a solution of the above material in EtOH (150 mL) was added 2 M aqueous NaOH (15.2 mL). The mixture was stirred at ambient temperature for 12 hr. To the mixture was added 1 M aqueous HCl (46 mL, pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated. The residue was suspended in 10% Et₂O in hexane (150 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with hexane, and dried at 70° C. under reduced pressure to give 2-(3,4-difluoro-phenoxy)-nicotinic acid (4.85 g, 67) as a white solid.

ESI MS m/e 251, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 6.90-7.30 (m, 4H), 8.30-8.35 (m, 1H), 8.46-8.52 (m, 1H).

Step B: Synthesis of 2-(3,4-difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 475, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.13 (m, 8H), 3.91-4.03 (m, 1H), 4.13-4.29 (m, 1H), 6.94 (d, J=9.6 Hz, 1H), 7.11-7.34 (m, 4H), 7.40-7.47 (m, 1H), 7.67-7.85 (m, 4H), 8.17 (d, J=9.5 Hz, 1H), 8.22 (dd, J=4.8, 2.0 Hz, 1H), 8.53 (dd, J=7.6, 2.0 Hz, 1H), 9.84-9.98 (m, 1H).

Example 3056

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide hydrochloride

Step A: Synthesis of 2-p-tolyloxy-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 229, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.40 (s, 3H) 7.05-7.31 (m, 5H), 8.30-8.35 (m, 1H), 8.52-8.57 (m, 1H).

Step B: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 475, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.86-2.13 (m, 8H), 2.36 (s, 3H), 3.86-3.98 (m, 1H), 4.11-4.29 (m, 1H), 6.86-7.00 (m, 1H), 7.07-7.31 (m, 5H), 7.43 (t, J=7.6 Hz, 1H), 7.64-7.82 (m, 3H), 7.92-8.28 (m, 3H), 8.53 (d, J=7.0 Hz, 1H), 9.74-9.87 (m, 1H).

Example 3057

2-(4-Chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-chloro-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.10-7.21 (m, 3H), 7.36-7.45 (m, 2H), 8.30-8.36 (m, 1H), 8.45-8.51 (m, 1H).

Step B: Synthesis of 2-(4-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 473, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.13 (m, 8H), 3.87-4.04 (m, 1H), 4.10-4.33 (m, 1H), 6.87-7.01 (m, 1H), 7.10-7.35 (m, 3H), 7.38-7.50 (m, 3H), 7.65-7.93 (m, 4H), 8.10-8.26 (m, 2H), 8.53 (d, J=6.4 Hz, 1H), 9.78-9.97 (m, 1H).

Example 3058

2-(4-Bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: 2-(4-bromo-phenoxy)-nicotinic acid

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 294, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.05-7.12 (m, 2H), 7.18 (dd, J=7.6, 4.8 Hz, 1H), 7.52-7.62 (m, 2H), 8.31-8.35 (m, 1H), 8.48 (dd, J=7.6, 2.0 Hz, 1H).

Step B: Synthesis of 2-(4-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 517, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.11 (m, 8H), 3.87-4.02 (m, 1H), 4.12-4.30 (m, 1H), 6.86-7.01 (m, 1H), 7.09-7.29 (m, 3H), 7.38-7.48 (m, 1H), 7.51-7.62 (m, 2H), 7.64-7.93 (m, 4H), 8.11-8.25 (m, 2H), 8.53 (d, J=7.6 Hz, 1H), 9.78-9.96 (m, 1H).

Example 3059

2-(4-Methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-methoxy-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 245, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 6.94-7.01 (m, 2H), 7.09-7.20 (m, 3H), 8.31-8.35 (m, 1H), 8.50-8.55 (m, 1H).

Step B: Synthesis of 2-(4-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 491, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.12 (m, 8H), 3.81 (brs, 3H), 3.86-3.99 (m, 1H), 4.12-4.30 (m, 1H), 6.84-7.29 (m, 6H), 7.37-7.49 (m, 1H), 7.64-7.82 (m, 3H), 7.96-8.28 (m, 3H), 8.48-8.60 (m, 1H), 9.71-9.86 (m, 1H).

Example 3060

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-nicotinic acid.

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 268, M+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 7.03-7.32 (m, 4H), 8.29-8.37 (m, 1H), 8.44-8.53 (m, 1H).

Step B: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 491, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.10 (m, 8H), 3.88-4.04 (m, 1H), 4.11-4.27 (m, 1H), 6.92 (d, J=9.6 Hz, 1H) 7.16 (dd, J=7.6, 4.8 Hz, 1H), 7.21-7.46 (m, 4H), 7.67-7.81 (m, 4H), 8.15 (d, J=9.5 Hz, 1H), 8.20 (dd, J=4.8, 2.0 Hz, 1H), 8.52 (dd, J=7.6, 2.0 Hz, 1H), 9.83-9.95 (m, 1H).

Example 3061

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide hydrochloride

Step A: Synthesis of 2-m-tolyloxy-nicotinic acid

Using the procedure for the step A of example 3055, the title compound was obtained.

ESI MS m/e 229, M⁺; ¹H NMR (200 MHz, CDCl₃) δ 2.40 (s, 3H), 6.95-7.41 (m, 5H), 8.33 (dd, J=4.8, 1.8 Hz, 1H), 8.54 (dd, J=7.7, 1.9 Hz, 1H).

Step B: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 475, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.87-2.07 (m, 8H), 2.40 (s, 3H), 3.85-3.98 (m, 1H), 4.10-4.25 (m, 1H), 6.88-6.99 (m, 1H), 7.01-7.18 (m, 4H), 7.33 (t, J=7.8 Hz, 1H), 7.42 (t, J=7.5 Hz, 1H), 7.66-7.81 (m, 3H), 7.93-8.03 (m, 1H), 8.12-8.20 (m, 1H), 8.23 (dd, J=4.7, 1.9 Hz, 1H), 8.52 (dd, J=7.5, 1.9 Hz, 1H), 9.71-9.83 (m, 1H).

Example 3062

2-(3-Methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of (3-methoxy-phenoxy)-acetic acid ethyl ester.

To a solution of 3-methoxy-phenol (3.54 g, 28.5 mmol) in DMA (20 mL) was added 60% NaH in oil (1.14 g, 28.5 mmol). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added bromo-acetic acid ethyl ester (4.53 g, 28.5 mmol) in DMA (10 mL). The mixture was stirred at ambient temperature for 1.5 hr and the reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (3-methoxy-phenoxy)-acetic acid ethyl ester (5.19 g, 91%) as a colorless oil.

ESI MS m/e 233, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J=7.1 Hz, 3H), 3.79 (s, 3H), 4.27 (q, J=7.1 Hz, 2H), 4.60 (s, 2H), 6.44-6.61 (m, 3H), 7.15-7.23 (m, 1H).

Step B: Synthesis of (3-methoxy-phenoxy)-acetic acid.

To a solution of (3-methoxy-phenoxy)-acetic acid ethyl ester (5.06 g, 24.1 mmol) in EtOH (100 mL) was added 1 M aqueous NaOH (25.3 mL). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated to give (3-methoxy-phenoxy)-acetic acid (4.05 g, 92%) as a white solid.

ESI MS m/e 182, M⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 3.73 (s, 3H), 4.65 (s, 2H), 6.45-6.57 (m, 3H), 7.13-7.23 (m, 1H), 12.97 (brs, 1H).

Step C: Synthesis of 2-(3-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.05 (m, 8H), 3.82 (s, 3H), 3.90-4.11 (m, 2H), 4.46 (s, 2H), 6.52-6.61 (m, 3H), 6.80-6.87 (m, 1H), 6.93 (d, J=9.5 Hz, 1H), 7.16-7.24 (m, 1H), 7.41-7.48 (m, 1H), 7.69-7.82 (m, 3H), 8.17 (d, J=9.5 Hz, 1H) 9.78-9.88 (m, 1H).

Example 3063

2-(3-Chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of (3-chloro-phenoxy)-acetic acid ethyl ester.

Using the procedure for the step A of example 3062, the title compound was obtained.

ESI MS m/e 237, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J=7.2 Hz, 3H), 4.28 (q, J=7.2 Hz, 2H), 4.60 (s, 2H), 6.73-7.02 (m, 3H), 7.14-7.30 (m, 1H).

Step B: Synthesis of (3-chloro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

ESI MS m/e 187, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.73 (d, J=1.2 Hz, 2H), 6.87-6.94 (m, 1H), 6.98-7.05 (m, 2H), 7.27-7.35 (m, 1H), 13.07 (s, 1H).

Step C: Synthesis of 2-(3-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 410, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.07 (m, 8H), 3.90-4.14 (m, 2H), 4.45 (s, 2H) 6.74-6.84 (m, 1H), 6.86-7.03 (m, 4H), 7.20-7.29 (m, 1H), 7.40-7.49 (m, 1H), 7.69-7.82 (m, 3H), 8.18 (d, J=9.3 Hz, 1H), 9.79-9.93 (m, 1H).

Example 3064

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of (3-chloro-4-fluoro-phenoxy)-acetic acid ethyl ester.

Using the procedure for the step A of example 3062, the title compound was obtained.

ESI MS m/e 233, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J=7.1 Hz, 3H), 4.28 (q, J=7.1 Hz, 2H), 4.58 (s, 2H), 6.75-6.82 (m, 1H), 6.95 (dd, J=5.9, 3.1 Hz, 1H), 7.01-7.11 (m, 1H).

Step B: Synthesis of (3-chloro-4-fluoro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

ESI MS m/e 205, M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 4.72 (s, 2H), 6.92-6.97 (m, 1H), 7.17 (dd, J=6.1, 3.1 Hz, 1H), 7.34 (t, J=9.1 Hz, 1H), 13.08 (brs, 1H).

Step C: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 450, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.76-2.08 (m, 8H), 3.91-4.13 (m, 2H), 4.42 (s, 2H), 6.73-6.97 (m, 3H), 7.00-7.14 (m, 2H), 7.41-7.49 (m, 1H), 7.70-7.80 (m, 3H), 8.18 (d, J=9.5 Hz, 1H), 9.79-9.90 (m, 1H).

Example 3065

2-(3,4-Dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of (3,4-dichloro-phenoxy)-acetic acid ethyl ester.

Using the procedure for the step A of example 3062, the title compound was obtained.

CI MS m/e 249, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.30 (t, J=7.1 Hz, 3H), 4.28 (q, J=7.1 Hz, 2H), 4.59 (s, 2H), 6.78 (dd, J=9.0, 2.9 Hz, 1H), 7.01 (d, J=2.8 Hz, 1H), 7.34 (d, J=9.1 Hz, 1H).

Step B: Synthesis of (3,4-dichloro-phenoxy)-acetic acid.

Using the procedure for the step B of example 3062, the title compound was obtained.

ESI MS m/e 221, M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 4.76 (s, 2H), 6.96 (dd, J=8.9, 2.9 Hz, 1H), 7.24 (d, J=2.9 Hz, 1H), 7.53 (d, J=8.9 Hz, 1H), 13.12 (brs, 1H).

Step C: Synthesis of 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 466, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.07 (m, 8H), 3.92-4.13 (m, 2H), 4.44 (s, 2H), 6.78 (d, J=8.1 Hz, 1H), 6.86-6.97 (m, 2H), 7.10 (d, J=2.9 Hz, 1H), 7.37 (d, J=8.9 Hz, 1H), 7.41-7.49 (m, 1H), 7.67-7.82 (m, 3H), 8.18 (d, J=9.5 Hz, 1H), 9.80-9.90 (m, 1H).

Example 3066

C-(Methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of (methyl-phenyl-amino)-acetic acid ethyl ester.

To a solution of bromo-acetic acid ethyl ester (5.00 g, 29.9 mmol) in IPA (10 mL) were added i-Pr₂NEt (4.06 g, 31.4 mmol) and methyl-phenyl-amine (3.37 g, 31.4 mmol). The mixture was stirred at reflux for 2.5 hr and the reaction was quenched with saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (methyl-phenyl-amino)-acetic acid ethyl ester (5.61 g, 97%) as a yellow oil.

ESI MS m/e 216, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.24 (t, J=7.1 Hz, 3H), 3.07 (s, 3H), 4.05 (s, 2H), 4.17 (q, J=7.1 Hz, 2H), 6.63-6.79 (m, 3H), 7.18-7.29 (m, 2H).

Step B: Synthesis of (methyl-phenyl-amino)-acetic acid.

To a solution of (methyl-phenyl-amino)-acetic acid ethyl ester (5.48 g, 28.4 mmol) in EtOH (100 mL) was added 1 M aqueous NaOH (29.8 mL). The mixture was stirred at ambient temperature for 1.5 hr. To the mixture was added 1 M aqueous HCl (pH=3) and concentrated. The residue was dissolved in water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give (methyl-phenyl-amino)-acetic acid (1.73 g, 37%) as a yellow oil.

ESI MS m/e 165, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 3H), 4.07 (s, 2H), 6.65-6.85 (m, 3H), 7.18-7.30 (m, 2H), 8.62 (brs, 1H).

Step C: Synthesis of C-(methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 411, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-1.99 (m, 8H), 3.05-3.16 (m, 3H), 3.79-4.02 (m, 4H), 6.82-7.00 (m, 4H), 7.06-7.49 (m, 5H), 7.65-7.80 (m, 3H), 8.15 (d, J=9.9 Hz, 1H), 9.57-9.68 (m, 1H).

Example 3067

2-(3,4-Dichloro-phenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of (3,4-dichloro-phenylamino)-acetic acid ethyl ester.

Using the procedure for the step A of example 3066, the title compound was obtained.

CI MS m/e 248, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.31 (t, J=7.1 Hz, 3H), 3.85 (d, J=5.4 Hz, 2H), 4.26 (q, J=7.1 Hz, 2H), 4.33-4.42 (m, 1H), 6.45 (dd, J=8.7, 2.8 Hz, 1H), 6.66 (d, J=2.8 Hz, 1H), 7.21 (d, J=8.7 Hz, 1H).

Step B: Synthesis of (3,4-dichloro-phenylamino)-acetic acid.

Using the procedure for the step B of example 3054, the title compound was obtained.

ESI MS m/e 220, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.84 (s, 2H), 6.37 (brs, 1H), 6.57 (dd, J=8.8, 2.7 Hz, 1H), 6.76 (d, J=2.6 Hz, 1H), 7.26 (d, J=8.8 Hz, 1H), 12.67 (brs, 1H).

Step C: Synthesis of 2-(3,4-dichlorophenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 465, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.72-2.05 (m, 8H), 3.80 (s, 2H), 3.87-4.10 (m, 2H), 6.48-6.57 (m, 1H), 6.73 (brs, 1H), 6.86-7.05 (m, 2H), 7.18 (d, J=8.7 Hz, 1H), 7.39-7.50 (m, 1H), 7.66-7.80 (m, 3H), 8.11-8.24 (m, 1H), 9.55-9.68 (m, 1H).

Example 3068

3,4-Difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride

Step A: Synthesis of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester.

A suspension of cis-4-amino-cyclohexanecarboxylic acid (244 g, 1.70 mol) in MeOH (2.45 L) was cooled to −8° C. Thionyl chloride (45.0 mL, 617 mmol) was added dropwise. The resulting solution was stirred at ambient temperature for 4.5 hr and concentrated to give a white solid. To a suspension of the above solid in CHCl₃ (3.00 L) were added triethylamine (261 mL, 1.87 mol) and (Boc)₂O (409 g, 1.87 mol) successively. The reaction mixture was stirred at ambient temperature for 5 hr and poured into water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, CHCl₃ only to 10% MeOH in CHCl₃) to give a colorless oil (531 g). To a suspension cooled at −4° C. of lithium aluminum hydride (78.3 g, 2.06 mol) in Et₂O (7.9 L) was added a solution of the above oil (530.9 g) in Et₂O (5.3 L) below 0° C. The resulting suspension was stirred at ambient temperature for 2 hr. The reaction mixture was cooled on an ice-bath, quenched with cold water, and filtrated through a pad of celite. The filtrate was dried over MgSO₄, filtrated, and concentrated. The precipitate was suspended in hexane (300 mL), filtrated, washed with hexane, and dried under reduced pressure to give (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (301 g, 77%) as a white solid.

ESI MS m/e 252, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.36 (m, 2H), 1.45 (s, 9H), 1.52-1.77 (m, 7H), 3.51 (d, J=6.2 Hz, 2H), 3.75 (brs, 1H), 4.30-4.82 (m, 1H).

Step B: Synthesis of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester.

To a solution of (cis-4-hydroxymethyl-cyclohexyl)-carbamic acid tert-butyl ester (17.7 g, 77.2 mmol) in THF (245 mL) were added triphenylphosphine (20.2 g, 77.0 mmol) and phthalimide (11.4 g, 77.5 mmol) successively. The resulting suspension was cooled on an ice-bath and 40% diethyl azodicarboxylate (DEAD) in toluene (33.6 mL, 74.1 mmol) was added over 1 hr. The reaction mixture was stirred at ambient temperature for 2.5 days, concentrated, and purified by flash chromatography (silica gel, 33% EtOAc in hexane) to give a white solid. To a suspension of the above solid (27.5 g) in EtOH (275 mL) was added hydrazine hydrate (5.76 g, 115 mmol). The mixture was stirred at reflux for 2.25 hr, cooled, and concentrated. The precipitate was dissolved in 10% aqueous sodium hydroxide (350 mL). The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. To a solution of the above residue in CHCl₃ (275 mL) was added triethylamine (8.54 g, 84.4 mmol). The resulting solution was cooled to 0° C. and ZCl (14.4 g, 84.4 mmol) was added below 5° C. The reaction mixture was stirred at ambient temperature for 16 hr and poured into saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 2% MeOH in CHCl₃) to give [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (25.3 g, 91%) as a colorless oil.

ESI MS m/e 385, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.13-1.31 (m, 2H), 1.44 (s, 9H), 1.48-1.75 (m, 7H), 3.10 (t, J=6.4 Hz, 2H), 3.72 (brs, 1H), 4.42-4.76 (m, 1H), 4.76-4.92 (m, 1H), 5.09 (s, 2H), 7.27-7.38 (m, 5H).

Step C: Synthesis of (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester.

To a solution of [cis-4-(benzyloxycarbonylamino-methyl)-cyclohexyl]-carbamic acid tert-butyl ester (12.9 g, 35.6 mmol) in EtOAc (129 mL) was added 4 M hydrogen chloride in EtOAc (129 mL). The reaction mixture was stirred at ambient temperature for 3 hr, filtrated, washed with EtOAc, and dried under reduced pressure. The solid was dissolved in saturated aqueous NaHCO₃. The aqueous layer was extracted with CHCl₃ (five times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and dried under reduced pressure to give (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (8.88 g, 95%) as a colorless oil.

ESI MS m/e 263, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.36-1.98 (m, 9H), 2.96-3.32 (m, 3H), 5.12 (brs, 3H), 7.36 (s, 5H).

Step D: Synthesis of (cis-4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine.

A mixture of 2-chloro-quinoline (10.0 g, 61.1 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester (17.6 g, 67.2 mmol) in butanol (10 mL) was stirred at reflux for 2 days. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (100 mL) was added 10% Pd/C (1.00 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% MeOH in CHCl₃) to give (cis-4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine (6.20 g, 40%) as a pale yellow solid.

ESI MS m/e 256, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.51 (m, 4H), 1.59-1.93 (m, 5H), 2.60 (d, J=6.2 Hz, 2H), 4.08-4.20 (m, 1H), 4.94 (d, J=7.4 Hz, 1H), 6.65 (d, J=9.0 Hz, 1H), 7.18 (ddd, J=7.9, 6.8, 1.1 Hz, 1H) 7.47-7.59 (m, 2H), 7.61-7.67 (m, 1H) 7.81 (d, J=8.9 Hz, 1H).

Step E: Synthesis of 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride.

To a solution of cis-(4-aminomethyl-cyclohexyl)-quinolin-2-yl-amine (300 mg, 1.17 mmol) and 3,4-difluoro-benzoic acid (223 mg, 1.41 mmol) in DMF (3 mL) were added Et₃N (0.40 mL, 2.87 mmol), HOBt-H₂O (270 mg, 1.76 mmol), and EDC-HCl (270 mg, 1.41 mmol). The reaction mixture was stirred at ambient temperature for 16 hr. To the reaction mixture was added water (20 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 2 hr, filtered, washed with Et₂O, and dried at 80° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride (390 mg, 77%) as a white solid.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.08 (m, 9H), 3.48-3.56 (m, 2H), 3.98-4.09 (m, 1H), 6.92-7.07 (m, 2H), 7.18-7.29 (m, 1H), 7.39-7.47 (m, 1H), 7.67-7.76 (m, 3H), 7.81-7.93 (m, 2H), 8.15 (d, J=9.6 Hz, 1H), 9.86-9.95 (m, 1H).

Example 3069

2-Phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-pbenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide hydrochloride.

Using the procedure for the step E of example 3068, the title compound was obtained.

ESI MS m/e 475, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-2.02 (m, 9H), 3.42-3.52 (m, 2H), 3.91-4.05 (m, 1H), 6.91 (d, J=9.5 Hz, 1H), 7.10-7.20 (m, 3H), 7.23-7.31 (m, 1H), 7.38-7.50 (m, 3H), 7.65-7.82 (m, 3H), 8.06-8.17 (m, 2H), 8.20 (dd, J=4.7, 2.0 Hz, 1H) 8.60 (dd, J=7.7, 1.9 Hz, 1H), 9.65-9.78 (m, 1H).

Example 3070

N-[cis-4-(4-Methylquinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine.

A mixture of 2-Chloro-4-methyl-quinoline (10.0 g, 56.3 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (13.3 g, 62.1 mmol) in IPA (10 mL) was stirred at reflux for 7 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (150 mL) was added 4 M hydrogen chloride in EtOAc (150 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (3.41 g, 24%) as pale yellow solid.

ESI MS m/e 256, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.19-1.55 (m, 4H), 1.67-1.94 (m, 4H), 2.56 (s, 3H), 2.85-2.98 (m, 1H), 4.03-4.15 (m, 1H), 4.77 (d, J=6.8 Hz, 1H), 6.49 (s, 1H), 7.17-7.25 (m, 1H), 7.47-7.55 (m, 1H), 7.62-7.68 (m, 1H), 7.72-7.77 (m, 1H).

Step B: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine (300 mg, 1.17 mmol) in CHCl₃ (2 mL) were added Et₃N (0.45 mL, 2.60 mmol) and 2-phenoxy-nicotinoyl chloride (411 mg, 1.76 mmol) in CHCl₃ (1 mL). The mixture was stirred at ambient temperature for 14 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (85 mg, 15%) as a white solid.

ESI MS m/e 453, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.12 (m, 8H), 2.70 (s, 3H), 3.83-4.00 (m, 1H), 4.11-4.28 (m, 1H), 6.74 (s, 1H), 7.08-7.18 (m, 1H), 7.19-7.34 (m, 3H), 7.38-7.53 (m, 3H), 7.63-7.85 (m, 3H), 7.91-7.99 (m, 1H), 8.20-8.24 (m, 1H), 8.54 (d, J=7.4 Hz, 1H).

Example 3071

3,4-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of 3,4-difluoro-benzoic acid (222 mg, 1.40 mmol) and N-(cis-4-methyl-quinolin-2-yl)cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in DMF (3 mL) were added Et₃N (0.39 mL, 2.80 mmol), HOBt-H₂O (268 mg, 1.76 mmol), and EDC-HCl (268 g, 1.40 mmol). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give a yellow oil. To a solution of the above material in EtOAc (8 mL) was added 4 M hydrogen chloride in EtOAc (0.5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (377 mg, 75%) as a white solid.

ESI MS m/e 396, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.17 (m, 8H), 2.73 (s, 3H), 3.95-4.26 (m, 2H), 6.71 (d, J=7.1 Hz, 1H), 6.79 (s, 1H), 7.14-7.28 (m, 1H), 7.41-7.51 (m, 1H), 7.54-7.64 (m, 1H), 7.66-7.79 (m, 3H), 7.85 (d, J=8.2 Hz, 1H), 9.57-9.67 (m, 1H).

Example 3072

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride.

To a solution of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (242 mg, 1.29 mmol). The mixture was stirred at ambient temperature for 5 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane) and flash chromatography (silica gel, 2% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea hydrochloride (421 mg, 68%) as a white solid.

ESI MS m/e 465, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.76-2.17 (m, 8H), 2.70 (s, 3H), 3.69-4.08 (m, 2H), 6.65-6.83 (m, 2H), 6.95-7.17 (m, 2H), 7.41 (t, J=8.1 Hz, 1H), 7.54-7.89 (m, 4H), 8.05-8.17 (m, 1H), 9.13-9.27 (m, 1H).

Example 3073

3-Chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (300 mg, 1.17 mmol) in CHCl₃ (3 mL) were added Et₃N (0.35 mL, 2.51 mmol) and 3-chloro-benzoyl chloride (226 mg, 1.29 mmol). The mixture was stirred at ambient temperature for 1.5 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give 3-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (441 mg, 87%) as a white solid.

ESI MS m/e 416, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.11 (m, 8H), 2.72 (s, 3H), 3.92-4.29 (m, 2H), 6.78 (s, 1H), 6.94 (d, J=9.0 Hz, 1H), 7.33-7.50 (m, 3H), 7.68-7.76 (m, 3H), 7.83-7.88 (m, 2H), 9.58 (d, J=9.0 Hz, 1H).

Example 3074

5-Nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 411, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.14 (m, 8H), 2.73 (s, 3H), 3.97-4.26 (m, 2H), 6.79 (s, 1H), 7.41-7.57 (m, 2H), 7.68-7.76 (m, 2H), 7.85 (d, J=8.2 Hz, 1H), 8.26 (d, J=1.4 Hz, 1H), 8.38 (d, J=1.4 Hz, 1H), 9.41 (d, J=9.0 Hz, 1H).

Example 3075

3-Methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 374, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.10 (m, 8H), 2.41 (s, 3H), 2.72 (d, J=0.8 Hz, 3H), 3.94-4.05 (m, 1H), 4.08-4.25 (m, 1H), 6.62 (d, J=8.1 Hz, 1H), 6.78 (s, 1H), 7.28-7.36 (m, 2H), 7.42-7.49 (m, 1H), 7.58-7.66 (m, 2H), 7.67-7.79 (m, 2H), 7.84 (d, J=8.1 Hz, 1H), 9.62 (d, J=8.1 Hz, 1H).

Example 3076

3-Methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 390, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.10 (m, 8H), 2.72 (s, 3H), 3.87 (s, 3H), 3.94-4.26 (m, 2H), 6.69-6.81 (m, 2H), 6.99-7.07 (m, 1H), 7.28-7.51 (m, 4H), 7.66-7.79 (m, 2H), 7.84 (d, J=7.9 Hz, 1H), 9.55-9.68 (m, 1H).

Example 3077

4-Cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 385, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.16 (m, 8H), 2.73 (d, J=0.9 Hz, 3H), 3.99-4.29 (m, 2H), 6.79 (s, 1H), 7.20-7.28 (m, 1H), 7.42-7.51 (m, 1H), 7.69-7.76 (m, 4H), 7.86 (d, J=8.2 Hz, 1H), 7.95-8.02 (m, 2H), 9.54 (d, J=8.9 Hz, 1H).

Example 3078

3,4-Dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 428, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.14 (m, 8H), 2.73 (d, J=0.6 Hz, 3H), 3.95-4.24 (m, 2H), 6.75-6.87 (m, 2H), 7.42-7.52 (m, 2H), 7.64-7.76 (m, 3H), 7.85 (d, J=8.2 Hz, 1H), 7.98 (d, J=1.9 Hz, 1H), 9.60 (d, J=7.9 Hz, 1H).

Example 3079

3-Chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 412, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.14 (m, 8H), 2.73 (d, J=0.8 Hz, 3H), 3.96-4.26 (m, 2H), 6.70-6.82 (m, 2H), 7.18 (t, J=8.6 Hz, 1H), 7.42-7.51 (m, 1H), 7.68-7.78 (m, 3H), 7.85 (d, J=8.2 Hz, 1H), 7.96 (dd, J=7.0, 2.2 Hz, 1H), 9.61 (d, J=8.4 Hz, 1H).

Example 3080

4-Fluoro-3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 414, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-2.10 (m, 8H), 2.33 (d, J=1.9 Hz, 3H), 2.72 (s, 3H), 3.95-4.25 (m, 2H), 6.45-6.54 (m, 1H), 6.78 (s, 1H), 7.00-7.08 (m, 1H), 7.42-7.50 (m, 1H), 7.60-7.80 (m, 4H), 7.84 (d, J=8.6 Hz, 1H), 9.58-9.70 (m, 1H).

Example 3081

1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 408, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.11 (m, 8H), 2.72 (s, 3H), 3.94-4.14 (m, 5H), 6.77 (s, 1H), 7.09-7.16 (m, 1H), 7.26-7.29 (m, 1H), 7.41-7.55 (m, 2H), 7.67-7.78 (m, 2H), 7.84 (d, J=8.2 Hz, 1H), 9.51-9.63 (m, 1H).

Example 3082

9H-Xanthene-9-carboxylic acid-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 486, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-1.91 (m, 8H), 2.68 (s, 3H), 3.75-3.97 (m, 2H), 4.88 (s, 1H), 6.14-6.27 (m, 1H), 6.69 (brs, 1H), 7.03-7.18 (m, 4H), 7.23-7.49 (m, 5H), 7.62-7.86 (m, 3H), 9.34-9.47 (m, 1H).

Example 3083

5-Bromo-furan-2-carboxylic acid-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-bromo-furan-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 428, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.08 (m, 8H), 2.72 (s, 3H), 3.90-4.19 (m, 2H), 6.42 (d, J=3.6 Hz, 1H), 6.67-6.80 (m, 2H), 7.05 (d, J=3.6 Hz, 1H), 7.41-7.51 (m, 1H), 7.67-7.81 (m, 2H), 7.85 (d, J=8.4 Hz, 1H), 9.59-9.72 (m, 1H).

Example 3084

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 426, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.07 (m, 8H), 2.34 (s, 3H), 2.72 (s, 3H), 3.86-4.14 (m, 2H), 4.46 (s, 2H), 6.70-6.95 (m, 5H), 7.15-7.24 (m, 1H), 7.41-7.50 (m, 1H), 7.67-7.88 (m, 3H), 9.58-9.69 (m, 1H).

Example 3085

Benzo[2,1,3]oxadiazole-5-carboxylic acid-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS m/e 402, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.28 (m, 8H), 2.73 (s, 3H), 3.98-4.11 (m, 1H), 4.12-4.32 (m, 1H), 6.79 (s, 1H), 7.37-7.50 (m, 2H), 7.71 (s, 1H), 7.72 (s, 1H), 7.81-7.96 (m, 3H), 8.40 (s, 1H), 9.56 (d, J=8.7 Hz, 1H).

Example 3086

3-Bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS m/e 438, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8H), 2.72 (s, 3H), 3.96-4.06 (m, 1H), 4.08-4.26 (m, 1H), 6.75-6.85 (m, 2H), 7.26-7.34 (m, 1H), 7.42-7.50 (m, 1H), 7.57-7.64 (m, 1H), 7.66-7.79 (m, 3H), 7.85 (d, J=8.2 Hz, 1H), 8.01 (s, 1H), 9.55-9.66 (m, 1H).

Example 3087

3-Cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS m/e 385, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.18 (m, 8H), 2.73 (s, 3H), 3.98-4.29 (m, 2H), 680 (s, 1H), 7.13-7.22 (m, 1H), 7.43-7.60 (m, 2H), 7.68-7.79 (m, 3H), 7.85 (d, J=8.1 Hz, 1H), 808 (d, J=72 Hz, 1H), 8.22 (s, 1H), 9.49-9.62 (m, 1H).

Example 3088

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS m/e 428, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.14 (m, 8H), 2.73 (s, 3H), 3.95-4.09 (m, 1H), 4.12-4.31 (m, 1H), 6.79 (s, 1H), 6.85-6.99 (m, 1H), 7.43-7.50 (m, 1H), 7.57 (t, J=7.8 Hz, 1H), 7.64-7.79 (m, 3H), 7.85 (d, J=8.2 Hz, 1H), 8.01 (d, J=7.8 Hz, 1H), 8.15 (s, 1H), 9.56-9.68 (m, 1H).

Example 3089

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide hydrochloride.

Using the procedure for the step A of example 3073, the title compound was obtained.

ESI MS m/e 472, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.56-2.10 (m, 8H), 2.51-2.87 (m, 3H), 3.81-4.16 (m, 2H), 4.94 (s, 1H), 6.40-6.88 (m, 2H), 7.17-7.51 (m, 11H), 7.63-7.89 (m, 3H), 9.44 (brs, 1H).

Example 3090

2-(4-Fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 493, M (free)+Na⁺; ¹H NMR (300 MHz, CDIC₃) δ 1.85-2.12 (m, 8H), 2.71 (s, 3H), 3.87-4.00 (m, 1H), 4.11-4.30 (m, 1H), 6.76 (brs, 1H), 7.09-7.21 (m, 3H), 7.24-7.35 (m, 2H), 7.44 (t, J=7.1 Hz, 1H), 7.65-7.99 (m, 4H), 8.19-8.25 (m, 1H), 8.54 (d, J=6.2 Hz, 1H), 9.60-9.73 (m, 1H).

Example 3091

2-(3,4-Difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 511, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.13 (m, 8H), 2.71 (s, 3H), 3.90-4.03 (m, 1H), 4.13-4.30 (m, 1H), 6.76 (s, 1H), 7.10-7.51 (m, 5H), 7.65-7.88 (m, 4H), 8.18-8.27 (m, 1H), 8.50-8.58 (m, 1H), 9.67-9.81 (m, 1H).

Example 3092

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 489, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.83-2.15 (m, 8H), 2.36 (s, 3H), 2.71 (s, 3H), 3.78-4.03 (m, 1H), 4.10-4.32 (m, 1H), 6.67-6.84 (m, 1H), 7.06-7.51 (m, 6H), 7.62-7.90 (m, 3H), 7.95-8.08 (m, 1H), 8.19-8.30 (m, 1H), 8.48-8.61 (m, 1H), 9.62 (brs, 1H).

Example 3093

2-(4-Chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 487, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.58-2.13 (m, 8H), 2.71 (s, 3H), 3.87-4.02 (m, 1H), 4.10-4.31 (m, 1H), 6.75 (brs, 1H), 7.15 (dd, J=7.5, 4.8 Hz, 1H), 7.22-7.33 (m, 2H), 7.37-7.49 (m, 3H), 7.64-7.92 (m, 4H), 8.21 (dd, J=4.8, 2.0 Hz, 1H), 8.53 (dd, J=7.6, 2.0 Hz, 1H), 9.63-9.78 (m, 1H).

Example 3094

2-(4-Bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 531, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.20 (m, 8H), 2.72 (s, 3H), 3.83-4.31 (m, 2H), 6.66-6.85 (m, 1H), 7.03-7.93 (m, 10H), 8.16-8.28 (m, 1H), 8.46-8.61 (m, 1H), 9.55-9.61 (m, 1H)

Example 3095

2-(4-Methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 483, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.84-2.19 (m, 8H), 2.71 (s, 3H), 3.74-4.00 (m, 4H), 4.12-4.28 (m, 1H), 6.68-6.82 (m, 1H), 6.91-7.30 (m, 5H), 7.38-7.50 (m, 1H), 7.63-7.88 (m, 3H), 7.96-8.09 (m, 1H), 8.17-8.33 (m, 1H), 8.48-8.61 (m, 1H), 9.50-9.70 (m, 1H).

Example 3096

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 505, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.13 (m, 8H), 2.71 (s, 3H), 3.89-4.02 (m, 1H), 4.13-4.29 (m, 1H), 6.76 (brs, 1H), 7.17 (dd, J=7.6, 4.8 Hz, 1H), 7.22-7.49 (m, 4H), 7.65-7.87 (m, 4H), 8.21 (dd, J=4.8, 2.0 Hz, 1H), 8.52 (dd, J=7.6, 2.0 Hz, 1H), 9.65-9.77 (m, 1H).

Example 3097

N-[cis-4-(4-Methylquinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 467, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.85-2.10 (m, 8H), 2.40 (s, 3H), 2.70 (s, 3H), 3.84-3.98 (m, 1H), 4.10-4.24 (m, 1H), 6.76 (brs, 1H), 7.00-7.21 (m, 4H), 7.28-7.48 (m, 2H), 7.62-7.87 (m, 3H), 7.94-8.06 (m, 1H), 8.21-8.29 (m, 1H), 8.53 (d, J=6.4 Hz, 1H), 9.51-9.64 (m, 1H).

Example 3098

2-(3-Methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 442, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-2.06 (m, 8H), 2.72 (s, 3H), 3.82 (s, 3H), 3.89-4.11 (m, 2H), 4.46 (s, 3H), 6.52-6.61 (m, 3H), 6.75 (s, 1H) 6.84-6.92 (m, 1H), 7.16-7.24 (m, 1H), 7.41-7.49 (m, 1H), 7.67-7.80 (m, 1H), 7.84 (d, J=8.2 Hz, 1H), 9.57-9.70 (m, 1H).

Example 3099

2-(3-Chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 446, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.06 (m, 8H), 2.72 (s, 3H), 3.91-4.13 (m, 2H), 4.45 (s, 2H), 6.73-7.03 (m, 5H), 7.19-7.28 (m, 1H), 7.41-7.50 (m, 1H), 7.67-7.87 (m, 3H), 9.58-9.72 (m, 1H).

Example 3100

2-(3-Chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 464, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.70-2.07 (m, 8H), 2.72 (s, 3H), 3.91-4.14 (m, 2H), 4.42 (s, 2H), 6.76 (s, 1H), 6.83-6.95 (m, 2H), 6.99-7.16 (m, 2H), 7.42-7.50 (m, 1H), 7.67-7.80 (m, 2H), 7.84 (d, J=7.9 Hz, 1H), 9.59-9.70 (m, 1H).

Example 3101

2-(3,4-Dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 480, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.13 (m, 8H), 2.72 (s, 3H), 3.91-4.14 (m, 2H), 4.44 (s, 2H), 6.76 (brs, 1H), 6.84-6.93 (m, 2H), 7.09 (d, J=2.8 Hz, 1H), 7.37 (d, J=8.9 Hz, 1H), 7.42-7.49 (m, 1H), 7.67-7.80 (m, 2H), 7.84 (d, J=8.1 Hz, 1H), 9.54-9.72 (m, 1H).

Example 3102

C-(Methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 403, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-1.99 (m, 8H), 2.70 (s, 3H), 3.11 (s, 3H), 3.76-4.06 (m, 4H), 6.63-7.01 (m, 4H), 7.08-7.50 (m, 4H), 7.60-7.92 (m, 3H), 9.34-9.51 (m, 1H).

Example 3103

2-(3,4-Dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of 2-(3,4-dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 479, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.02 (m, 8H), 2.71 (s, 3H), 3.74-4.08 (m, 4H), 6.45-6.56 (m, 1H), 6.67-6.78 (m, 2H), 7.04-7.19 (m, 2H), 7.39-7.50 (m, 1H), 7.62-7.87 (m, 3H), 9.31-9.46 (m, 1H).

Example 3104

3,4-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride

Step A: Synthesis of (cis-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine.

A mixture of 2-chloro-4-methyl-quinoline (10.0 g, 56.3 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (17.7 g, 67.6 mmol) in butanol (10 mL) was stirred at reflux for 5 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% to 20% EtOAc in hexane and silica gel, 2% to 10% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above oil in MeOH (140 mL) was added 10% Pd/C (1.40 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 10% MeOH in CHCl₃) to give (cis-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine (5.74 g, 38%) as a pale yellow solid.

ESI MS m/e 470, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.14-1.51 (m, 4H), 1.60-1.94 (m, 5H), 2.56 (s, 3H), 2.60 (d, J=6.4 Hz, 2H), 4.08-4.22 (m, 1H), 4.82-4.92 (m, 1H), 6.52 (s, 1H), 7.17-7.24 (m, 1H), 7.47-7.54 (m, 1H), 7.62-7.67 (m, 1H), 7.72-7.77 (m, 1H).

Step B: Synthesis of 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride.

To a solution of (cis-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine (300 mg, 0.90 mmol) in CHCl₃ (2 mL) were added i-Pr₂NEt (0.33 mL, 1.89 mmol) and 3,4-difluoro-benzoyl chloride (175 mg, 0.99 mmol) in CHCl₃ (1 mL). The mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 25% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide hydrochloride (289 mg, 72%) as a white solid.

ESI MS m/e 432, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.56-2.05 (m, 9H), 2.70 (s, 3H), 3.49-3.54 (m, 2H), 3.97-4.09 (m, 1H), 6.75 (s, 1H), 6.89-6.98 (m, 1H), 7.19-7.30 (m, 1H), 7.40-7.47 (m, 1H), 7.66-7.75 (m, 2H), 7.79-7.93 (m, 3H), 9.72-9.85 (m, 1H).

Example 3105

N-[cis-4-(4-Methylquinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step C of example 3104, the title compound was obtained.

ESI MS m/e 467, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.14 (m, 9H), 2.69 (s, 3H), 3.42-3.50 (m, 2H), 3.92-4.04 (m, 1H), 6.73 (brs, 1H), 7.10-7.32 (m, 4H), 7.38-7.49 (m, 3H), 7.64-7.84 (m, 3H), 8.06-8.15 (m, 1H), 8.19-8.24 (m, 1H), 8.57-8.63 (m, 1H), 9.49-9.62 (m, 1H).

Example 3106

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of (cis-4-aminomethyl-cyclohexyl)-(4-methyl-quinolin-2-yl)-amine obtained in step B of example 3014 (300 mg, 1.11 mmol) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (230 mg, 1.22 mmol). The mixture was stirred at ambient temperature for 21 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (247 mg, 45%) as a white solid.

ESI MS m/e 479, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.51-2.18 (m, 9H), 2.71 (d, J=0.8 Hz, 3H), 3.37-3.44 (m, 2H), 4.04-4.14 (m, 1H), 6.78 (s, 1H), 6.89-7.13 (m, 3H), 7.42-7.50 (m, 1H), 7.70-7.76 (m, 2H), 7.84 (d, J=8.1 Hz, 1H), 8.13-8.22 (m, 2H), 9.38 (d, J=9.2 Hz, 1H), 13.95 (brs, 1H).

Example 3107

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of 5,6,7,8-tetrahydro-quinazoline-2,4-diol.

To a solution of 2-oxocyclohexanecarboxylic acid ethyl ester (61.5 g, 361 mmol) in EtOH (61.5 mL) was added urea (73.8 g, 1.23 mol). The mixture was stirred at reflux for 10.5 days and stirred at ambient temperature for 30 min. The precipitate was filtrated, washed with acetone, and dried. A suspension of the above solid in H₂O (100 mL) stirred on an ice-bath for 1 hr. The precipitate was filtrated, washed with hexane, and dried under reduced pressure to give 5,6,7,8-tetrahydro-quinazoline-2,4-diol (21.0 g, 35%) as a pale yellow solid.

CI MS m/e 167, M+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.48-1.71 (m, 4H), 2.09-2.19 (m, 2H), 2.24-2.34 (m, 2H), 10.41-10.98 (m, 2H).

Step B: Synthesis of (2-chloro-5,6,7,8-tetrahydroquinazolin-4-yl)-dimethyl-amine.

A suspension of 5,6,7,8-tetrahydro-quinazoline-2,4-diol (20.9 g, 100 mmol) in POCl₃ (105 mL) was stirred at reflux for 2 hr and the reaction mixture was concentrated. The residue was poured into ice water. The aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated. To the solution of residue (7.00 g) in THF (70 mL) was added 50% aqueous Me₂NH (7.77 g, 86.2 mmol) and the mixture stirred at ambient temperature for 2 hr. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (silica gel, 20% EtOAc in hexane) to give (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (6.08 g, 64%) as a white solid.

ESI MS m/e 234, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-1.90 (m, 4H), 2.59 (t, J=6.0 Hz, 2H), 2.76 (t, J=6.6 Hz, 2H), 3.06 (s, 6H).

Step C: Synthesis of (cis-4-amino-cyclohexyl)-carbamic acid benzyl ester.

To a solution of (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (75.0 g, 350 mmol) in CHCl₃ (750 mL) were added Et₃N (53.7 mL, 385 mmol) and benzyl chloroformate (55 mL, 385 mmol). The mixture was stirred at ambient temperature for 20 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, purified by flash chromatography (silica gel, 0.4% to 5% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the residue in EtOAc (200 mL) was added 4 M hydrogen chloride in EtOAc (200 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (silica gel, 25% to 50% EtOAc in hexane) to give (cis-4-amino-cyclohexyl)-carbamic acid benzyl ester (37.6 g, 43%) as a pale brown oil.

ESI MS m/e 249, M⁺+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.13-1.83 (m, 8H), 2.77-2.97 (m, 1H), 3.63-3.83 (m, 1H), 4.92-5.20 (m, 3H), 7.25-7.47 (m, 5H).

Step D: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

A mixture of (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine (16.0 g, 75.7 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid benzyl ester (18.8 g, 75.7 mmol) in butanol (21 mL) was stirred at reflux for 6 days. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (270 mL) was added 10% Pd/C (2.70 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine (15.8 g, 72%) as a pale yellow solid.

FAB MS m/e 290, M⁺+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.00-1.90 (m, 14H), 2.49 (t, J=5.9 Hz, 2H), 2.61 (t, J=6.6 Hz, 2H), 2.71-3.00 (m, 7H), 3.93-4.07 (m, 1H), 4.67-4.80 (m, 1H).

Step E: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine (300 mg, 1.04 mmol) in CHCl₃ (3 mL) were added Et₃N (0.31 mL, 2.22 mmol) and 2-phenoxy-nicotinoyl chloride (266 mg, 1.14 mmol). The mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (159 mg, 29%) as a white solid.

ESI MS m/e 487, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-1.98 (m, 12H), 2.54 (t, J=5.9 Hz, 2H), 2.74 (t, J=6.5 Hz, 2H), 3.20 (s, 6H), 4.02-4.20 (m, 2H), 7.12 (dd, J=7.5, 4.8 Hz, 1H), 7.21-7.30 (m, 3H), 7.42-7.50 (m, 2H), 7.87-7.93 (m, 1H), 8.21 (dd, J=4.8,2.2 Hz, 1H), 8.25-8.32 (m, 1H), 8.52 (dd, J=7.6, 2.0 Hz, 1H), 13.18 (s, 1H).

Example 3108

3-Chloro-N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS m/e 468, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.00 (m, 12H), 2.51-2.61 (m, 2H), 2.68-2.81 (m, 2H), 3.23 (s, 6H), 4.02-4.26 (m, 2H), 6.73-6.90 (m, 1H), 7.13-7.23 (m, 1H), 7.65-7.82 (m, 1H), 7.96 (d, J=6.8 Hz, 1H), 8.22-8.44 (m, 1H), 12.63-12.89 (m, 1H).

Example 3109

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-4-fluoro-3-methyl-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS m/e 448, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.60-2.04 (m, 12H), 2.27-2.36 (m, 3H), 2.50-2.61 (m, 2H), 2.65-2.84 (m, 2H), 3.23 (s, 6H), 4.03-4.27 (m, 2H), 6.42-6.58 (m, 1H), 6.96-7.11 (m, 1H), 7.56-7.75 (m, 2H), 8.25-8.47 (m, 1H).

Example 3110

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,5-dimethoxy-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS m/e 476, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.04 (m, 12H), 2.51-2.62 (m, 2H), 2.66-2.86 (m, 2H), 3.23 (s, 6H), 3.85 (s, 6H), 4.04-4.27 (m, 2H), 6.50-6.70 (m, 2H), 6.95 (brs, 2H), 8.19-8.47 (m, 1H).

Example 3111

Benzo[2,1,3]oxadiazole-5-carboxylic acid-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of benzo[2,1,3]oxadiazole-5-carboxylic acid-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydroquinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS m/e 458, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.01 (m, 12H), 2.56 (t, J=5.8 Hz, 2H), 2.71 (t, J=6.5 Hz, 2H), 3.23 (s, 6H), 4.04-4.27 (m, 2H), 7.71 (d, J=8.2 Hz, 1H), 7.85 (dd, J=9.5, 1.1 Hz, 1H), 7.91-7.96 (m, 1H), 8.27 (d, J=8.1 Hz, 1H), 8.42 (t, J=1.2 Hz, 1H).

Example 3112

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3-nitro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3-nitro-benzamide hydrochloride.

Using the procedure for the step E of example 3107, the title compound was obtained.

ESI MS m/e 461, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.04 (m, 12H), 2.50-2.85 (m, 4H), 3.24 (s, 6H), 4.11-4.29 (m, 2H), 7.04-7.20 (m, 1H), 7.56-7.68 (m, 1H), 8.13-8.38 (m, 3H), 8.72-8.79 (m, 1H).

Example 3113

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine.

A mixture of (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (3.10 g, 11.8 mmol) and (2-chloro-5,6,7,8-tetrahydro-quinazolin-4-yl)-dimethyl-amine obtained in step B of example 3107 (2.00 g, 9.44 mmol) in butanol (3 mL) was stirred at reflux for 19 hr. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil (2.48 g) in MeOH (25 mL) was added 10% Pd/C (248 mg). The mixture was stirred at 50° C. under hydrogen atmosphere for 8 hr. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine (1.70 g, 59%) as a pale yellow solid.

FAB MS m/e 304, M (free)+H⁺.

Step B: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 501, M (free)+H⁺.

Example 3114

N-[cis-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of 2,4-dichloro-quinoline.

A suspension of quinoline-2,4-diol (150 g, 931 mmol) in POCl₃ (975 mL, 10.4 mol) was stirred at reflux for 6 hr and the reaction mixture was concentrated. The residue was diluted with CHCl₃ (500 mL) and the solution was poured into ice water. The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (silica gel, 20% EtOAc in hexane) to give 2,4-dichloro-quinoline (177 g, 96%) as a pale brown solid.

EI MS m/e 197, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 7.50 (s, 1H), 7.65 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 7.79 (ddd, J=8.5, 7.0, 1.3 Hz, 1H), 8.00-8.06 (m, 1H), 8.16-8.21 (m, 1H).

Step B: Synthesis of (2-chloro-quinolin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-quinoline (177 g, 894 mmol) in THF (2.1 L) was added 50% aqueous Me₂NH (234 mL, 2.23 mol). The mixture was stirred at ambient temperature for 68 hr. To the mixture was added 50% aqueous Me₂NH (47 mL, 448 mmol) and stirred at ambient temperature for 3 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 1% to 3% EtOAc in hexane) to give (2-chloro-quinolin-4-yl)-dimethyl-amine (75.9 g, 41%) as a pale yellow oil and (4-chloro-quinolin-2-yl)-dimethyl-amine (28.0 g, 15%) as a pale yellow oil.

(2-chloro-quinolin-4-yl)-dimethyl-amine;

ESI MS m/e 207, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.06 (s, 6H), 6.71 (s, 1H), 7.45 (ddd, J=8.4, 7.0, 1.2 Hz, 1H), 7.63 (ddd, J=8.4, 6.9, 1.5 Hz, 1H), 7.91-7.93 (m, 1H), 7.97-8.03 (m, 1H).

(4-chloro-quinolin-2-yl)dimethyl-amine;

ESI MS m/e 207, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.18 (s, 6H), 6.97 (brs, 1H), 7.18-7.31 (m, 1H), 7.49-7.63 (m, 1H), 7.66-7.72 (m, 1H), 7.95-8.00 (m, 1H).

Step C: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine.

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine (15.6 g, 75.7 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid benzyl ester obtained in step C of example 3107 (18.8 g, 75.7 mmol) in butanol (20 mL) was stirred at reflux for 6 days. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (170 mL) was added 10% Pd/C (1.70 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 1% to 5% MeOH in CHCl₃) to give N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine (11.7 g, 55%) as a pale yellow solid.

FAB MS m/e 285, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.19-1.96 (m, 10H), 2.81-3.03 (m, 7H), 4.02-4.17 (m, 1H), 4.66-4.83 (m, 1H), 6.03 (s, 1H), 7.06-7.21 (m, 1H), 7.39-7.52 (m, 1H), 7.55-7.67 (m, 1H), 7.80-7.90 (m, 1H).

Step D: Synthesis of N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine (300 mg, 1.05 mmol) in CHCl₃ (3 mL) were added Et₃N (0.31 mL, 2.22 mmol) and 2-phenoxy-nicotinoyl chloride (271 mg, 1.16 mmol). The mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (160 mg, 29%) as a white solid.

ESI MS m/e 482, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.15 (m, 8H), 3.21 (s, 6H), 3.73-3.88 (m, 1H), 4.06-4.27 (m, 1H), 5.79 (s, 1H), 7.12 (dd, J=7.6, 4.8 Hz, 1H), 7.19-7.33 (m, 4H), 7.41-7.71 (m, 4H), 7.81-7.97 (m, 2H), 8.21 (dd, J=4.8, 2.0 Hz, 1H), 8.52 (dd, J=7.6, 2.0 Hz, 1H), 8.94-9.08 (m, 1H), 13.81 (brs, 1H).

Example 3115

N-[cis-4-(4-Chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

A mixture of 2,4-dichloroquinoline obtained in step A of example 3114 (1.5 g, 7.57 mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 2 (2.3 g, 7.57 mmol) in butanol (2 mL) was stirred at 130° C. for 3 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (295 mg, 8%) as a white solid and N-[cis-4-(2-chloro-quinolin-4-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (283 mg, 7%) as a white solid.

N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride;

ESI MS m/e 495, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.86-2.10 (m, 8H), 3.82-3.96 (m, 1H), 4.13-4.28 (m, 1H), 7.04 (s, 1H), 7.10-7.34 (m, 4H), 7.41-7.55 (m, 3H), 7.71-7.84 (m, 2H), 7.92-8.11 (m, 2H), 8.20-8.26 (m, 1H), 8.50-8.59 (m, 1H), 9.83 (brs, 1H).

N-[cis-4-(2-chloro-quinolin-4-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride;

ESI MS m/e 495, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.72-2.37 (m, 8H), 3.64-3.84 (m, 1H), 4.36 (brs, 1H), 6.33 (brs, 1H), 7.05-7.60 (m, 8H), 8.06-8.66 (m, 6H).

Example 3116

3,4-Difluoro-N-[cis-4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2-chloro-quinolin-4-ol.

A mixture of 2,4-dichloro-quinoline obtained in step A of example 3114 (3.00 g, 15.1 mmol) and MeOH (485 mg, 15.1 mmol) in butanol (3 mL) was stirred at reflux for 3 hr. The reaction mixture was suspended in CHCl₃ (15 mL) and stirred at ambient temperature for 30 min. The precipitate was collected by filtration, washed with CHCl₃, and dried at 50° C. under reduced pressure to give 2-chloro-quinolin-4-ol (1.47 g, 54%) as a pale yellow solid.

ESI MS m/e 179, M⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 6.83 (s, 1H), 7.27-7.43 (m, 2H), 7.60-7.67 (m, 1H), 7.86 (d, J=7.9 Hz, 1H), 12.05 (brs, 1H).

Step B: Synthesis of 2-chloro-4-methoxyquinoline.

To a solution of 2-chloroquinolin-4-ol (500 mg, 2.78 mmol) in DMF (5 mL) were added K₂CO₃ (462 mg, 3.37 mmol) and MeI (210 μL, 3.37 mmol). The mixture was stirred at 50° C. for 3 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 10% EtOAc in hexane) to give 2-chloro-4-methoxy-quinoline (440 mg, 82%) as a white solid.

ESI MS m/e 194, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.71 (s, 3H), 6.89 (s, 1H), 7.27-7.43 (m, 2H), 7.60-7.69 (m, 1H), 8.01 (d, J=8.1 Hz, 1H).

Step C: Synthesis of 3,4-difluoro-N-[cis-4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

A mixture of 2-chloro-4-methoxy-quinoline (250 mg, 1.29 mmol) and N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (361 mg, 1.42 mmol) in butanol (1 mL) was stirred at 130° C. for 5 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et₂O, and dried at 80° C. under reduced pressure to give cis-3,4-difluoro-N-[4-(4-methoxy-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (79 mg, 14%) as a white solid.

ESI MS m/e 434, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.58-2.09 (m, 8H), 3.55-3.72 (m, 4H), 3.88-4.06 (m, 1H), 5.93 (s, 1H), 7.03-8.09 (m, 7H), 8.25-8.45 (m, 2H).

Example 3117

N-[cis-4-(4-Chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3115, the title compound was obtained.

N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride;

ESI MS m/e 416, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.82-2.22 (m, 8H), 3.93-4.28 (m, 2H), 6.65-6.77 (m, 1H), 7.08 (s, 1H), 7.14-7.29 (m, 1H), 7.48-7.64 (m, 2H), 7.68-7.88 (m, 3H), 8.09 (d, J=8.1 Hz, 1H), 9.82-9.90 (m, 1H).

N-[cis-4-(2-chloroquinolin-4-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride;

ESI MS m/e 438, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.72-2.37 (m, 8H), 3.76-3.95 (m, 1H), 4.49-4.65 (m, 1H), 6.37 (brs, 1H), 6.94-7.12 (m, 1H), 7.18-7.33 (m, 1H), 7.39-7.55 (m, 1H), 7.60-7.76 (m, 1H), 7.85-7.95 (m, 1H), 8.06-8.20 (m, 2H), 8.46-8.58 (m, 1H), 8.70-8.87 (m, 1H).

Example 3118

N-[cis-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-quinolin-4-yl)-dimethyl-amine obtained in step B of example 3114 (23.6 g, 114 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (36.0 g, 137 mmol) in butanol (31 mL) was stirred at reflux for 14 days. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 14% to 66% EtOAc in hexane) to give [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 39%) as a pale yellow solid.

ESI MS m/e 433, M (free)+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.12-1.97 (m, 9H), 2.94 (s, 6H), 3.13 (t, J=6.4 Hz, 2H), 4.06-4.26 (m, 1H), 4.62-4.94 (m, 2H), 5.11 (s, 2H), 6.04 (s, 1H), 7.14 (ddd, J=8.4, 7.0, 1.3 Hz, 1H), 7.29-7.40 (m, 5H), 7.45 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.57-7.64 (m, 1H), 7.84 (dd, J=8.4, 1.3 Hz, 1H).

Step B: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine.

To a solution of [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (19.3 g, 44.6 mmol) in MeOH (200 mL) was added 5% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 6 days. The reaction mixture was filtrated through a pad of celite and concentrated. To a solution of the residue in methanol (200 mL) was 10% Pd/C (1.93 g). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1 day. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by flash chromatography (silica gel, 5% to 14% 7 M NH₃/MeOH in CHCl₃) to give N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine (12.7 g, 95%) as a pale yellow solid.

FAB MS m/e 299, M⁺+H⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.08-1.99 (m, 11H), 2.60 (d, J=6.2 Hz, 2H), 2.94 (s, 6H), 4.04-4.22 (m, 1H), 4.77-4.93 (m, 1H), 6.06 (s, 1H), 7.14 (ddd, J=8.4, 7.0, 1.3 Hz, 1H), 7.45 (ddd, J=8.4, 6.8, 1.5 Hz, 1H), 7.61 (s, 1H), 7.84 (dd, J=8.4, 1.3 Hz, 1H).

Step C: Synthesis of N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of 2-Phenoxy-nicotinic acid (190 mg, 1.20 mmol) and N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine (300 mg, 1.00 mmol) in DMF (3 mL) were added Et₃N (0.33 mL, 2.40 mmol), HOBt-H₂O (230 mg, 1.50 mmol), and EDC-HCl (230 g, 1.20 mmol). The reaction mixture was stirred at ambient temperature for 20 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride (164 mg, 31%) as a white solid.

ESI MS m/e 496, M (free)+H⁺.

Example 3119

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of 2-chloro-4-dimethylamino-5-methylpyrimidine.

To the solution of 2,4-dichloro-5-methylpyrimidine (20.0 g, 123 mmol) in THF (200 mL) was added 50% aqueous Me₂NH (13.3 g, 143 mol) and the mixture was stirred at ambient temperature for 5 days. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (NH-silica gel, 2% EtOAc in hexane) to give 2-chloro-4-dimethylamino-5-methylpyrimidine (19.9 g, 94%) as a white solid and 4-chloro-2-dimethylamino-5-methylpyrimidine (1.53 g, 7%) as a white solid.

2-chloro-4-dimethylamino-5-methylpyrimidine;

ESI MS m/e 172, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.27 (s, 3H), 3.15 (s, 6H), 7.82 (s, 1H).

4-chloro-2-dimethylamino-5-methylpyrimidine;

ESI MS m/e 194, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.14 (s, 3H), 3.15 (s, 6H), 8.06 (s, 1H).

Step B: Synthesis of [cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

A mixture of 2-chloro-4-dimethylamino-5-methylpyrimidine (7.00 g, 40.8 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (9.61 g, 44.8 mmol) in butanol (7 mL) was stirred at 130° C. for 26 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 3% to 50% EtOAc in hexane) to give [cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (5.90 g, 42%) as a colorless oil.

ESI MS m/e 350, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.84 (m, 17H), 2.14 (d, J=0.8 Hz, 3H), 3.02 (s, 6H), 3.53-3.71 (m, 1H), 3.85-3.99 (m, 1H), 4.51-4.64 (m, 1H), 4.68-4.78 (m, 1H), 7.66 (s, 1H).

Step C: Synthesis of N²-(cis-4-amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine.

A solution of [cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)cyclohexyl]-carbamic acid tert-butyl ester (5.71 g, 16.3 mmol) in EtOAc (60 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (120 mL) was added. The mixture was stirred at ambient temperature for 1.5 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and dried under reduced pressure to give N²-(cis-4-amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (3.99 g, 98%) as a pale yellow oil.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.39-1.91 (m, 8H), 2.12 (s, 3H), 2.79-2.97 (m, 1H), 3.00 (s, 6H), 3.86-4.05 (m, 1H), 4.71-4.92 (m, 1H), 7.66 (s, 1H).

Step D: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (200 mg, 0.80 mmol) in CHCl₃ (4 mL) were added Et₃N (0.25 mL, 1.79 mmol) and 1,3-difluoro-benzoyl chloride (156 mg, 0.88 mmol). The mixture was stirred at ambient temperature for 22 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 3% MeOH in CHCl₃). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr, and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (56 mg, 16%) as a white solid.

ESI MS m/e 412, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-1.99 (m, 8H), 2.26 (s, 3H), 3.30 (s, 6H), 4.02-4.25 (m, 2H), 6.65-6.74 (m, 1H), 7.13-7.26 (m, 2H), 7.53-7.62 (m, 1H), 7.67-7.79 (m, 1H), 8.55-8.65 (m, 1H).

Example 3120

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step D of example 3119, the tide compound was obtained.

ESI MS m/e 447, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-1.97 (m, 8H), 2.23 (s, 3H), 3.28 (s, 6H), 4.01-4.21 (m, 2H), 7.13 (dd, J=7.6, 4.8 Hz, 1H), 7.19-7.32 (m, 4H), 7.42-7.52 (m, 2H), 7.86-7.95 (m, 1H), 8.21 (dd, J=4.8, 2.0 Hz, 1H), 8.39-8.48 (m, 1H), 8.53 (dd, J=7.6, 2.0 Hz, 1H).

Example 3121

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methyl-benzamide hydrochloride.

Using the procedure for the step D of example 3119, the title compound was obtained.

ESI MS m/e 390, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.01 (m, 8H), 2.25 (s, 3H), 2.41 (s, 3H), 3.30 (s, 6H), 4.04-4.22 (m, 2H), 6.41-6.52 (m, 1H), 7.19-7.34 (m, 3H), 7.56-7.66 (m, 2H), 8.53-8.63 (m, 1H), 13.04 (s, 1H).

Example 3122

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methoxy-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-methoxy-benzamide hydrochloride.

Using the procedure for the step D of example 3119, the title compound was obtained.

ESI MS m/e 406, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-1.99 (m, 8H), 2.25 (s, 3H), 3.30 (s, 6H), 3.86 (s, 3H), 4.06-4.23 (m, 2H), 6.72-6.81 (m, 1H), 6.98-7.05 (m, 1H), 7.20-7.43 (m, 4H), 8.47-8.57 (m, 1H).

Example 3123

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride.

To a solution of 4-fluoro-phenol (317 mg, 2.83 mmol) in DMA (4 mL) was added 60% NaH in oil (226 mg, 5.56 mmol). The mixture was stirred at ambient temperature for 1 hr. To the mixture was added 2-chloro-N-[cis-4-(dimethylamino-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (1.10 g, 2.83 mmol) in DMA (3 mL). The mixture was stirred at 120° C. for 2 hr and the reaction was quenched with water (60 mL). The aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% to 50% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride (154 mg, 11%) as a white solid.

ESI MS m/e 487, M (free)+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.61-2.02 (m, 8H), 2.24 (s, 3H), 3.28 (s, 6H), 4.03-4.25 (m, 2H), 7.06-7.33 (m, 6H), 7.79-7.91 (m, 1H), 8.16-8:23 (m, 1H), 8.46-8.59 (m, 2H).

Example 3124

2-(2-Bromo-phenoxy)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-(2-bromo-phenoxy)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3123, the title compound was obtained.

ESI MS m/e 547, M (free)+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.72-2.02 (m, 8H), 2.23 (s, 3H), 3.28 (s, 6H), 3.97-4.27 (m, 2H), 7.09-7.48 (m, 5H), 7.66 (dd, J=7.9, 1.3 Hz, 1H), 7.84-7.95 (m, 1H), 8.13-8.19 (m, 1H), 8.31-8.43 (m, 1H), 8.53 (dd, J=7.4, 2.2 Hz, 1H), 13.32 (s, 1H).

Example 3125

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-5,N⁴N⁴-trimethyl-pyrimidine-2,4-diamine.

A mixture of 2-chloro-4-dimethylamino-5-methylpyrimidine obtained in step A of example 3119 (3.00 g, 17.4 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (5.48 g, 20.9 mmol) in butanol (3 mL) was stirred at reflux for 70 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 33% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above oil in MeOH (30 mL) was added 10% Pd/C (600 mg). The mixture was stirred at ambient temperature under hydrogen atmosphere for 1.5 days. The reaction mixture was filtrated through a pad of celite, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% MeOH in CHCl₃) to give N²-(cis-4-aminomethyl-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (1.03 g, 22%) as a pale yellow solid.

ESI MS m/e 264, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.15-1.89 (m, 11H), 2.13 (s, 3H), 2.59 (d, J=6.4 Hz, 2H), 3.02 (s, 6H), 4.03-4.13 (m, 1H), 4.77-4.85 (m, 1H), 7.67 (s, 1H).

Step B: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (300 mg, 1.14 mmol) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (236 mg, 1.25 mmol). The mixture was stirred at ambient temperature for 16 hr and poured into water (20 mL). The precipitate was collected by filtration, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 3% MeOH in CHCl₃) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. A suspension of the residue in Et₂O (20 mL) was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (326 mg, 59%) as a white solid.

ESI MS m/e 473, M (free)+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.45-1.99 (m, 9H), 2.24 (s, 3H), 3.30 (s, 6H), 3.32-3.43 (m, 2H), 4.22-4.38 (m, 2H), 6.85-7.15 (m, 3H), 7.22 (brs, 1H), 8.14-8.26 (m, 2H), 8.49-8.62 (m, 1H), 12.14 (s, 1H).

Example 3126

N-[cis-4-(4-Dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of (2-chloro-6-methylpyrimidin-4-yl)-dimethyl-amine.

To the solution of 2,4-dichloro-6-methylpyrimidine (20.0 g, 123 mmol) in THF (200 mL) was added 50% aqueous Me₂NH (13.3 g, 147 mmol) and the mixture was stirred at ambient temperature for 24 hr. To the reaction was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified flash chromatography (NH-silica gel, 5% to 16% EtOAc in hexane) to give (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (14.4 g, 68%) as a pale yellow solid and (4-chloro-6-methyl-pyrimidin-2-yl)-dimethyl-amine (6.57 g, 31%) as a pale yellow solid.

(2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine;

ESI MS m/e 194, M⁺+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.34 (s, 3H), 3.10 (s, 6H), 6.16 (s, 1H).

(4-chloro-6-methyl-pyrimidin-2-yl)-dimethyl-amine;

CI MS m/e 172, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.29 (s, 3H), 3.16 (s, 6H), 6.34 (s, 1H).

Step B: Synthesis of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

A mixture of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (300 mg, 1.75 mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 3032 (598 mg, 1.92 mmol) in butanol (1 mL) was stirred at 130° C. for 40 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was filtered, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (549 mg, 65%) as a white solid.

ESI MS m/e 447, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.05 (m, 8H), 2.34 (s, 3H), 3.12 (s, 3H), 3.23 (s, 3H), 4.03-4.22 (m, 2H), 5.71 (s, 1H), 7.13 (dd, J=7.5, 4.8 Hz, 1H), 7.21-7.32 (m, 3H), 7.41-7.51 (m, 2H), 7.84-7.95 (m, 1H), 8.21 (dd, J=4.7,2.1 Hz, 1H), 8.45-8.57 (m, 2H), 13.43 (brs, 1H).

Example 3127

N-[cis-4-(4-dimethylamino-C-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N²-(cis-4-amino-cyclohexyl)-6,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine.

A mixture of (2-chloro-6-methyl-pyrimidin-4-yl)-dimethyl-amine (6.00 g, 35.0 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (8.30 g, 38.5 mmol) in butanol (6 mL) was stirred at 130° C. for 48 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 16% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (60 mL) was added 4 M hydrogen chloride in EtOAc (60 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 2% to 10% MeOH in CHCl₃) to give N²-(cis-4-amino-cyclohexyl)-6,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (2.29 g, 26%) as a pale yellow oil.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.18-1.50 (m, 4H), 1.58-1.93 (m, 6H), 2.19 (s, 3H), 2.76-2.87 (m, 1H), 3.03 (s, 6H), 3.96-4.06 (m, 1H), 4.78-4.89 (m, 1H), 5.67 (s, 1H).

Step B: Synthesis of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

To a solution of N²-(cis-4-amino-cyclohexyl)-6,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (300 mg, 1.20 mmol) in CHCl₃ (2 mL) were added i-Pr₂NEt (0.44 mL, 2.52 mmol) and 3,4-difluoro-benzoyl chloride (233 mg, 1.32 mmol) in CHCl₃ (1 mL). The mixture was stirred at ambient temperature for 15 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (359 mg, 70%) as a white solid.

ESI MS m/e 390, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.00 (m, 8H), 2.35 (d, J=0.6 Hz, 3H), 3.14 (s, 3H), 3.26 (s, 3H), 4.03-4.29 (m, 2H), 5.74 (d, J=0.7 Hz, 1H), 6.61-6.72 (m, 1H), 7.14-7.26 (m, 1H), 7.53-7.62 (m, 1H), 7.67-7.78 (m, 1H), 8.59 (d, J=7.8 Hz, 1H).

Example 3128

3-Chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3127, the title compound was obtained.

ESI MS m/e 410, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.00 (m, 8H), 2.35 (s, 3H), 3.13 (s, 3H), 3.25 (s, 3H), 4.04-4.26 (m, 2H), 5.75 (s, 1H), 6.53 (d, J=8.6 Hz, 1H), 7.32-7.48 (m, 2H), 7.64-7.70 (m, 1H), 7.83 (t, J=1.9 Hz, 1H), 8.60 (d, J=7.9 Hz, 1H), 13.11 (brs, 1H).

Example 3129

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of (2-chloro-pyrimidin-4-yl)-dimethyl-amine.

To a solution of 2,4-dichloro-pyrimidine (15.0 g, 10.15 mmol) in THF (150 mL) was added 50% aqueous MeNH₂ (22.7 g, 25.2 mmol). The mixture was stirred at ambient temperature for 2 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-dimethyl-amine (8.66 g, 55%) as a white solid and (4-chloro-pyrimidin-2-yl)-dimethyl-amine (0.87 g, 6%) as a white solid.

(2-chloro-pyrimidin-4-yl)-dimethyl-amine;

CI MS m/e 158, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.12 (s, 6H), 6.32 (d, J=6.1 Hz, 1H), 8.00 (d, J=6.1 Hz, 1H).

(4-chloro-pyrimidin-2-yl)-dimethyl-amine;

ESI MS m/e 157, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.21 (s, 6H), 6.50 (d, J=5.1 Hz, 1H), 8.18 (d, J=5.1 Hz, 1H).

Step B: Synthesis of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine (1.50 g, 9.52 mmol) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 3031 (2.24 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130° C. for 22 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane) to give [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (1.34 g, 42%) as a white solid.

ESI MS m/e 358, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.45 (s, 9H), 1.48 (s, 8H), 3.03 (s, 6H), 3.61 (brs, 1H), 3.89-4.04 (m, 1H), 4.47-4.63 (m, 1H), 4.77-4.89 (m, 1H), 5.80 (d, J=6.1 Hz, 1H), 7.84 (d, J=6.1 Hz, 1H).

Step C: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine.

To a solution of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (1.26 g, 3.76 mmol) in EtOAc (15 mL) was added 4 M hydrogen chloride in EtOAc (15 mL). The reaction mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was alkalized with 1 M aqueous NaOH. The aqueous layer was extracted with CHCl₃ (six times). The combined organic layer was dried over MgSO₄, filtrated, and concentrated to give N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine (923 mg, quant.) as a pale yellow oil.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29-1.51 (m, 2H), 1.61-1.91 (m, 6H), 2.80-2.92 (m, 1H), 3.03 (s, 6H), 3.96-4.04 (m, 1H), 4.85-4.98 (m, 1H), 5.79 (d, J=6.1 Hz, 1H), 7.84 (d, J=6.1 Hz, 1H).

Step D: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine (300 mg, 1.20 mmol) in CHCl₃ (3 mL) were added Et₃N (0.35 mL, 2.51 mmol) and 2-phenoxy-nicotinoyl chloride (309 mg, 132 mmol). The mixture was stirred at ambient temperature for 22 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane and silica gel, 3% MeOH in CHCl₃). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride (150 mg, 26%) as a white solid.

ESI MS m/e 433, M (free)+H⁺.

Example 3130

3,4-Difluoro-N-[cis-4-(4-trifluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(4-trifluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride.

A mixture of 2-chloro-4-trifluoromethyl-pyrimidine (200 mg, 1.09 mmol) and N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (306 mg, 1.20 mmol) in butanol (1 mL) was stirred at 130° C. for 12 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(4-fluoromethyl-pyrimidin-2-yl)amino-cyclohexyl]-benzamide hydrochloride (123 mg, 26%) as a white solid.

ESI MS m/e 423, M⁺ (free)+Na⁺.

Example 3131

3,4-Difluoro-N-[cis-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 385, M (free)+Na⁺.

Example 3132

N-[cis-4-(4,6-Dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4,6-dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 415, M (free)+Na⁺.

Example 3133

2-Phenoxy-N-[cis-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-phenoxy-N-[cis-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide hydrochloride.

A mixture of 2-chloro-4-trifluoromethyl-pyrimidine (200 mg, 1.10 mmol) and N-(cis-4-amino-cyclohexyl)-2-phenoxy-nicotinamide obtained in step A of example 3032 (375 mg, 1.20 mmol) in butanol (1 mL) was stirred at 130° C. for 3 days in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give 2-phenoxy-N-[cis-4-(4-trifluoromethyl-pyrimidin-2-yl)-amino-cyclohexyl]-nicotinamide hydrochloride (111 mg, 21%) as a white solid.

ESI MS m/e 480, M (free)+Na⁺.

Example 3134

N-[cis-4-(4-Methoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 442, M (free)+Na⁺.

Example 3135

N-[cis-4-(4,6-Dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4,6-dimethoxy-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 472, M (free)+Na⁺.

Example 3136

N-[cis-4-(4-Dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of (5-bromo-2-chloro-pyrimidin-4-yl)-dimethyl-amine.

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS m/e 236, M+H⁺.

Step B: Synthesis of (2-chloro-5-phenyl-pyrimidin-4-yl)-dimethyl-amine.

To a solution of (5-bromo-2-chloro-pyrimidin-4-yl)-dimethyl-amine (2.00 g, 8.46 mmol) in toluene (30 mL) were added 2 M aqueous K₂CO₃ (15 mL), phenylboronic acid (1.03 g, 8.45 mmol), and tetrakis-(triphenylphosphine)-palladium (977 mg, 0.845 mmol). The reaction mixture was stirred at reflux for 8 hr. The mixture was poured into water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 3% EtOAc in hexane) to give (2-chloro-5-phenyl-pyrimidin-4-yl)-dimethyl-amine (1.44 g, 73%).

ESI MS m/e 256, M+Na⁺.

Step C: Synthesis of N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the-title compound was obtained.

ESI MS m/e 531, M (free)+Na⁺.

Example 3137

N-[cis-4-(5-Chloro-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of (2,5-dichloro-pyrimidin-4-yl)-dimethyl-amine.

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS m/e 191, M⁺.

Step B: Synthesis of N-[cis-4-(5-chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 467, M (free)+H⁺.

Example 3138

N-[cis-4-(4-Dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-phenyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 474, M (free)+Na⁺.

Example 3139

N-[cis-4-(5-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(5-chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 432, M (free)+Na⁺.

Example 3140

N-[cis-4-(4-Dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of (2-chloro-5-fluoro-pyrimidin-4-yl)-dimethyl-amine.

Using the procedure for the step A of example 3129, the title compound was obtained.

ESI MS m/e 176, M+H⁺.

Step B: Synthesis of N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 451, M (free)+H⁺.

Example 3141

N-[cis-4-(5-Bromo-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(5-bromo-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 533, M (free)+Na⁺.

Example 3142

N-[cis-4-(4,6-Dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 383, M (free)+Na⁺.

Example 3143

N-[cis-4-(4,6-Dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4,6-dimethyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step A of example 3133, the title compound was obtained.

ESI MS m/e 440, M (free)+Na⁺.

Example 3144

3,4-Difluoro-N-[cis-4-(pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3130, the title compound was obtained.

ESI MS m/e 355, M (free)+Na⁺.

Example 3145

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-dimethyl-amine obtained in step A of example 3129 (1.50 g, 9.52 mmol) and (cis-4-amino-cyclohexylmethyl)-carbamic acid benzyl ester obtained in step C of example 3068 (2.75 g, 10.5 mmol) in IPA (1.5 mL) was stirred at 130° C. for 22 hr in a sealed tube. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by medium-pressure liquid chromatography (NH-silica, 10% EtOAc in hexane to EtOAc) to give [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-carbamic acid benzyl ester (816 mg, 22%) as a pale yellow oil.

ESI MS m/e 406, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.22-1.92 (m, 9H), 3.03 (s, 6H), 3.11 (t, J=6.2 Hz, 2H), 4.02-4.15 (m, 1H), 4.82-4.93 (m, 2H), 5.10 (s, 2H), 5.79 (d, J=6.1 Hz, 1H), 7.28-7.42 (m, 5H), 7.83 (d, J=6.1 Hz, 1H).

Step B: Synthesis of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine.

Using the procedure for the step B of example 3118, the title compound was obtained.

ESI MS m/e 250, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.40-1.88 (m, 9H), 2.87 (d, J=5.9 Hz, 2H), 3.03 (s, 6H), 4.11 (brs, 1H), 5.63 (brs, 1H), 5.78 (d, J=6.2 Hz, 1H), 7.08 (brs, 2H), 7.82 (d, J=6.2 Hz, 1H).

Step C: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N^4,N4-dimethyl-pyrimidine-2,4-diamine (400 mg, 1.60 mmol) in CHCl₃ (2 mL) were added i-Pr₂NEt (0.56 mL, 3.36 mmol) and 2-phenoxy-nicotinoyl chloride (523 mg, 2.24 mmol) in CHCl₃ (2 mL). The mixture was stirred at ambient temperature for 5 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give a colorless oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 60° C. under reduced pressure to give N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide hydrochloride (199 mg, 26%) as a white solid.

ESI MS m/e 469, M (free)+Na⁺.

Example 3146

3-Hydroxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-hydroxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 362, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.60-2.09 (m, 8H), 3.83-4.02 (m, 1H), 4.22-4.49 (m, 1H), 6.79-7.02 (m, 1H), 7.12-7.59 (m, 5H), 7.67-8.45 (m, 5H), 9.40-9.78 (m, 2H), 12.91-13.17 (m, 1H).

Example 3147

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 404, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.54-2.12 (m, 8H), 3.89-4.31 (m, 5H), 6.89-7.05 (m, 2H), 7.41-7.58 (m, 2H), 7.68-7.82 (m, 3H), 8.00-8.22 (m, 3H), 8.46-8.51 (m, 1H), 9.66-9.85 (m, 1H).

Example 3148

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 482, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.75-2.27 (m, 8H), 4.00-4.32 (m, 2H), 6.97 (d, J=9.4 Hz, 1H), 7.42-7.65 (m, 2H), 7.69-7.80 (m, 3H), 7.96-8.02 (m, 1H), 8.20 (d, J=9.3 Hz, 1H), 8.35-8.42 (m, 2H), 9.69-9.79 (m, 1H).

Example 3149

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 430, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.33 (m, 8H), 3.96-4.29 (m, 2H), 6.88-7.03 (m, 2H), 7.29-7.51 (m, 3H), 7.69-7.82 (m, 5H), 8.19 (d, J=9.5 Hz, 1H), 9.73-9.86 (m, 1H).

Example 3150

N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester.

To a solution of isophthalic acid monomethyl ester (435 mg) and cis-N-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (500 mg) in DMF (5 mL) were added Et₃N (0.96 mL), HOBt-H₂O (476 mg), and EDC-HCl (437 mg). The reaction mixture was stirred at ambient temperature for 18 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% EtOAc in hexane) to give N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (740 mg) as a white solid.

ESI MS m/e 404, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-2.05 (m, 8H), 3.96 (s, 3H), 4.10-4.28 (m, 2H), 4.80-4.90 (m, 1H), 6.16-6.26 (m, 1H), 6.66 (d, J=8.8 Hz, 1H), 7.18-7.20 (m, 1H), 7.49-7.68 (m, 4H), 7.84 (d, J=8-3 Hz, 1H), 8.03-8.10 (m, 1H), 8.15-8.22 (m, 1H), 8.35-8.38 (m, 1H).

Step B: Synthesis of N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid.

To a solution of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (400 mg) in EtOH (12 mL) was added 2 M aqueous NaOH (0.52 mL). The reaction mixture was stirred at ambient temperature for 11 hr. To the reaction mixture was added 1 M aqueous HCl (0.6 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (silica gel, 1% to 5% MeOH in CHCl₃) to give a white solid. The suspension of above solid in Et₂O (20 mL) was stirred at ambient temperature for 1 hr and filtered to to give N-[cis-4-(Quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid (183 mg) as a white solid.

ESI MS m/e 412, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.63-2.09 (m, 8H), 3.84-4.18 (m, 2H), 6.83-6.91 (m, 2H), 7.07-7.17 (m, 1H), 7.39-7.64 (m, 4H), 7.83 (d, J=9.0 Hz, 1H), 8.03-8.13 (m, 2H), 8.39-8.53 (m, 2H).

Example 3151

C-(Ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-(ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 403, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.18-1.36 (m, 3H), 1.54-2.15 (m, 8H), 3.39-3.65 (m, 3H), 3.68-4.11 (m, 3H), 6.80-7.20 (m, 3H), 7.29-7.86 (m, 8H), 8.07-8.23 (m, 1H), 9.48-9.68 (m, 1H).

Example 3152

3,5-Difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,5-Difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3046, the title compound was obtained.

ESI MS m/e 404, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.71-2.02 (m, 8H), 3.87-4.13 (m, 1H), 4.24-4.53 (m, 1H), 7.21-8.01 (m, 7H), 8.18-8.60 (m, 3H), 9.48-9.81 (m, 1H), 13.09-13.28 (m, 1H).

Example 3153

4-Chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide-hydrochloride

Step A: Synthesis of 4-chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 398, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80-2.10 (m, 8H), 3.97-4.27 (m, 2H), 6.88-7.03 (m, 2H), 7.39-7.50 (m, 2H), 7.54-7.62 (m, 1H), 7.66-7.83 (m, 4H), 8.19 (d, J=9.4 Hz, 1H), 9.65-9.82 (m, 1H).

Example 3154

C-[(4-Chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3036, the title compound was obtained.

ESI MS m/e 459, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 0.99-1.19 (m, 3H), 1.42-1.96 (m, 8H), 3.30-3.55 (m, 2H), 3.71-3.87 (m, 1H), 3.94 (s, 2H), 4.29-4.51 (m, 1H), 6.57-6.77 (m, 2H), 7.02-7.58 (m, 4H), 7.65-8.04 (m, 3H), 8.15-8.44 (m, 2H), 9.61-9.85 (m, 1H), 13.17-13.42 (m, 1H).

Example 3155

N-[cis-4-(Quinolin-2-ylamino)cyclohexyl]-isophthalamide hydrochloride

Step A: Synthesis of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride.

To a solution of N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid obtained in step B of example 3150 (160 mg) in DMF (2 mL) were added 28% aqueous NH₃ (30 mg), Et₃N (0.14 mL), HOBt-H₂O (94 mg), and EDC-HCl (95 mg). The reaction mixture was stirred at ambient temperature for 16 hr. To the reaction mixture was added water (20 mL) and the aqueous layer extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). The solution of above purified material in EtOH (3 mL) was added 4 M hydrogen chloride in EtOAc (0.3 mL). The mixture was stirred at ambient temperature for 2 hr, filtered, and dried under reduced pressure to give N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride (9 mg) as a white solid.

ESI MS m/e 411, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.70-2.06 (m, 8H), 3.89-4.08 (m, 1H), 4.19-4.39 (m, 1H), 7.17-7.60 (m, 4H), 7.71-8.46 (m, 8H), 12.84-12.97 (m, 1H).

Example 3156

3,4-Difluoro-N-{cis-4-[(quinolin-2-ylmethyl)-amino]-cyclohexyl}-benzamide dihydrochloride

Step A: Synthesis of 3,4-difluoro-N-{cis-4-[(quinolin-2-ylmethyl)-amino]-cyclohexyl}-benzamide dihydrochloride.

To a solution of N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (250 mg) in CHCl₃ (5 mL) were added quinoline-2-carbaldehyde (185 mg), acetic acid (71 mg), and NaBH(OAc)₃ (316 mg). The reaction mixture was stirred at ambient temperature for 16 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give a colorless oil. To a solution of the above oil in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (12 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 3,4-difluoro-N-(cis-4-[(quinolin-2-ylmethyl)-amino]-cyclohexyl)-benzamide dihydrochloride (100 mg) as a white solid.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.50-1.68 (m, 2H), 1.90-2.15 (m, 6H), 3.20-3.37 (m, 1H), 3.91-4.01 (m, 1H), 4.53-4.66 (m, 2H), 7.46-8.29 (m, 9H), 8.52 (d, J=8.5 Hz, 1H), 9.44-9.62 (m, 2H).

Example 3157

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3,5-bis-trifluoromethyl-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 496, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.19 (m, 8H), 2.74 (s, 3H), 3.98-4.31 (m, 2H), 6.78-6.81 (m, 1H), 7.40-7.52 (m, 1H), 7.58-7.78 (m, 3H), 7.85 (d, J=9.2 Hz, 1H), 7.96-8.01 (m, 1H), 8.36-8.41 (m, 2H), 9.49-9.64 (m, 1H).

Example 3158

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 444, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.68-2.20 (m, 8H), 2.71-2.75 (m, 3H), 3.96-4.30 (m, 2H), 6.76-6.87 (m, 2H), 7.30-7.39 (m, 1H), 7.42-7.52 (m, 2H), 7.67-7.89 (m, 5H), 9.50-9.72 (m, 1H).

Example 3159

C-(Ethyl-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-(ethyl-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 417, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.10-1.38 (m, 3H), 1.59-2.05 (m, 8H), 2.45-2.84 (m, 3H), 3.35-4.15 (m, 6H), 6.57-6.81 (m, 1H), 6.85-7.52 (m, 7H), 7.57-7.89 (m, 4H), 9.20-9.50 (m, 1H).

Example 3160

3-Hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 398, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.67-2.02 (m, 8H), 2.53-2.70 (m, 3H), 3.86-3.99 (m, 1H), 4.24-4.40 (m, 1H), 6.88-6.96 (m, 1H), 7.06-7.31 (m, 4H), 7.46-7.57 (m, 1H), 7.73-7.83 (m, 1H), 7.92-8.28 (m, 3H), 9.66 (s, 1H), 12.83-12.94 (m, 1H).

Example 3161

2-Amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride

Step A: Synthesis of 2-amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 376, M (free)+H⁺; ¹H NMR (300 MHz, DMSOd₆) δ 1.63-2.06 (m, 8H), 2.53-2.70 (m, 3H), 3.87-4.04 (m, 1H), 4.36-4.59 (m, 1H), 6.92-7.06 (m, 1H), 7.15-7.27 (m, 1H), 7.45-7.58 (m, 1H), 7.69-7.84 (m, 1H), 7.89-8.01 (m, 1H), 8.14-8.58 (m, 4H), 8.69-8.86 (m, 1H), 9.54-9.72 (m, 1H).

Example 3162

2,3-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2,3-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.56-2.17 (m, 8H), 2.72 (s, 3H), 3.88-4.04 (m, 1H), 4.09-4.30 (m, 1H), 6.67-6.92 (m, 2H), 7.10-7.35 (m, 2H), 7.41-7.52 (m, 1H), 7.60-7.93 (m, 4H), 9.53-9.75 (m, 1H).

Example 3163

2,4-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.22 (m, 8H), 2.73 (s, 3H), 3.87-4.06 (m, 1H), 4.11-4.31 (m, 1H), 6.69-7.06 (m, 4H), 7.40-7.56 (m, 1H), 7.65-7.88 (m, 3H), 7.98-8.14 (m, 1H), 9.51-9.83 (m, 1H).

Example 3164

2,5-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.46-2.14 (m, 8H), 2.72 (s, 3H), 3.84-4.04 (m, 1H), 4.09-4.32 (m, 1H), 6.77 (s, 1H), 6.82-7.21 (m, 3H), 7.37-7.54 (m, 1H), 7.63-7.89 (m, 4H), 9.54-9.72 (m, 1H).

Example 3165

2,6-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2,6-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.72-2.08 (m, 8H), 2.72 (s, 3H), 3.91-4.03 (m, 1H), 4.13-4.33 (m, 1H), 6.42-6.54 (m, 1H), 6.77 (s, 1H), 6.88-6.99 (m, 2H), 7.27-7.50 (m, 2H), 7.66-7.78 (m, 2H), 7.84 (d, J=8.2 Hz, 1H), 9.53-9.70 (m, 1H).

Example 3166

3,5-Difluoro-N-[cis-4-(4-methylquinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 418, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.16 (m, 8H), 2.72 (s, 3H), 3.96-4.26 (m, 2H), 6.78 (s, 1H), 6.86-7.02 (m, 2H), 7.33-7.52 (m, 3H), 7.67-7.78 (m, 2H), 7.85 (d, J=8.2 Hz, 1H), 9.48-9.71 (m, 1H).

Example 3167

C-[(4-Chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 451, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.14-1.26 (m, 3H), 1.69-2.00 (m, 8H), 2.60 (s, 3H), 3.39-3.61 (m, 2H), 3.75-4.03 (m, 4H), 6.63-7.06 (m, 4H), 7.14-7.32 (m, 2H), 7.39-7.51 (m, 1H), 7.64-7.89 (m, 3H), 9.44-9.59 (m, 1H).

Example 3168

4-Chloro-3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 412, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.13 (m, 8H), 2.70-2.76 (m, 3H), 3.95-4.28 (m, 2H), 6.65-6.81 (m, 2H), 7.41-7.50 (m, 2H), 7.53-7.59 (m, 1H), 7.65-7.77 (m, 3H), 7.82-7.88 (m, 1H), 9.57-9.71 (m, 1H).

Example 3169

4-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 378, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.81-2.10 (m, 8H), 2.72 (s, 3H), 3.95-4.29 (m, 2H), 6.65-6.81 (m, 2H), 7.10 (t, J=8.6 Hz, 2H), 7.42-7.51 (m, 1H), 7.67-7.91 (m, 5H), 9.55-9.67 (m, 1H).

Example 3170

3-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 378, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.77-2.09 (m, 8H), 2.71-2.76 (m, 3H), 3.94-4.25 (m, 2H), 6.54-6.65 (m, 1H), 6.76-6.81 (m, 1H), 7.13-7.23 (m, 1H), 7.35-7.61 (m, 4H), 7.67-7.88 (m, 3H), 9.58-9.73 (m, 1H).

Example 3171

2-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 2-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 378, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.84-2.15 (m, 8H), 2.72 (s, 3H), 3.87-4.01 (m, 1H), 4.13-4.29 (m, 1H), 6.73-6.89 (m, 2H), 7.07-7.28 (m, 2H), 7.40-7.51 (m, 2H), 7.66-7.87 (m, 3H), 7.96-8.05 (m, 1H), 9.62-9.72 (m, 1H).

Example 3172

4-Chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 4-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3070, the title compound was obtained.

ESI MS m/e 394, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.64-2.04 (m, 8H), 2.55-2.70 (m, 3H), 3.87-4.04 (m, 1H), 4.27-4.52 (m, 1H), 7.07-7.18 (m, 1H), 7.46-7.58 (m, 3H), 7.73-8.02 (m, 4H), 8.23-8.38 (m, 2H), 9.39-9.52 (m, 1H), 12.96-13.10 (m, 1H).

Example 3173

2-Hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 2-Hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 399, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.46-1.99 (m, 8H), 2.53-2.72 (m, 3H), 4.02-4.15 (m, 1H), 4.20-4.45 (m, 1H), 6.46-6.56 (m, 1H), 6.95-7.08 (m, 1H), 7.45-7.57 (m, 1H), 7.69-7.83 (m, 2H), 7.90-8.47 (m, 3H), 10.08-10.27 (m, 1H), 12.48-12.63 (m, 1H).

Example 3174

N-[cis-4-(4-Methylquinolin-2-ylamino)-cyclohexyl]-isophthalamic acid-methyl ester hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 440, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.78-2.21 (m, 8H), 2.73 (d, J=1.1 Hz, 3H), 3.92-4.07 (m, 4H), 4.13-4.29 (m, 1H), 6.78 (s, 1H), 6.99-7.10 (m, 1H), 7.40-7.57 (m, 2H), 7.67-7.79 (m, 2H), 7.82-7.89 (m, 1H), 8.02-8.19 (m, 2H), 8.46-8.52 (m, 1H), 9.46-9.65 (m, 1H).

Example 3175

6-Chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 417, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.67-2.03 (m, 8H), 2.54-2.72 (m, 3H), 3.91-4.06 (m, 1H), 4.26-4.42 (m, 1H), 7.05-7.18 (m, 1H), 7.45-7.57 (m, 1H), 7.63-7.69 (m, 1H), 7.73-7.83 (m, 1H), 7.91-8.04 (m, 1H), 8.17-8.31 (m, 2H), 8.51-8.62 (m, 1H), 8.83-8.89 (m, 1H), 9.33-9.51 (m, 1H), 12.86-13.03 (m, 1H).

Example 3176

6-Dimethylamino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride

Step A: Synthesis of 6-dimethylamino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride.

To a solution of 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide obtained in step A of example 3175 (250 mg) in EPA (1 mL) were added 50% aqueous Me₂NH (63 mg) and iPr₂NEt (172 mg). The mixture was stirred at reflux for 5 hr, added 50% aqueous Me₂NH (120 mg), and stirred at reflux for 5 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, EtOAc). To a solution of the above material in EtOH (3 mL) was added 4 M hydrogen chloride in EtOAc (0.47 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (3 mL) was stirred at ambient tempareture for 4 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 6-dimethylamino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride (200 mg) as a white solid.

ESI MS m/e 426, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.73-2.13 (m, 8H), 2.63-2.80 (m, 3H), 3.34-3.61 (m, 6H), 3.91-4.28 (m, 2H), 6.70-7.07 (m, 2H), 7.35-8.10 (m, 5H), 8.29-8.46 (m, 1H), 8.82-8.98 (m, 1H), 9.36-9.51 (m, 1H).

Example 3177

3-Hydroxymethyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-hydroxymethyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a suspension of LiAlH (18 mg) in Et₂O (5 mL) was added N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester obtained in step A of example 3174 (200 mg) in Et₂O (2 mL). The mixture was stirred at ambient temperature for 3 hr. The reaction was quenched with water and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure and purified by medium-pressure liquid chromatography (silica gel, 3% to 10% MeOH in CHCl₃). To a solution of the above material in EtOH (2 mL) was added 4 M hydrogen chloride in EtOAc (0.24 mL). The mixture was stirred at ambient temperature for 2 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (3 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 70° C. under reduced pressure to give 3-hydroxymethyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (93 mg) as a white solid.

ESI MS m/e 390, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.66-2.02 (m, 8H), 2.61 (s, 3H), 3.87 (brs, 1H), 4.22-4.42 (m, 1H), 4.55 (s, 2H), 7.03-7.17 (m, 1H), 7.35-7.59 (m, 3H), 7.67-7.87 (m, 3H), 7.91-8.04 (m, 1H), 8.11-8.31 (m, 2H), 12.75-12.96 (m, 1H).

Example 3178

N-[cis-4-(4-Methylquinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester.

To a solution of isophthalic acid monomethyl ester (400 mg) and N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine in step A of example 3070 (400 mg) in DMF (4 mL) were added Et₃N (0.52 mL), HOBt-H₂O (358 mg), and EDC-HCl (330 mg). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (silica gel, 9% MeOH in CHCl₃) to give N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (740 mg) as a white solid.

ESI MS m/e 440, M+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.59-2.09 (m, 8H), 2.58 (s, 3H), 3.96 (s, 3H), 4.02-4.29 (m, 2H), 4.72-4.87 (m, 1H), 6.12-6.27 (m, 1H), 6.48-6.59 (m, 1H), 7.17-7.30 (m, 1H), 7.45-7.82 (m, 4H), 8.00-8.22 (m, 2H), 8.32-8.39 (m, 1H).

Step B: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride.

To a solution of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester (150 mg) in EtOH (4.5 mL) was added 2 M aqueous NaOH (0.27 mL). The reaction mixture was stirred at ambient temperature for 13 hr. To the reaction mixture was added 1 M aqueous HCl (0.3 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (silica gel, 1% to 5% MeOH in CHCl₃) to give a white solid. To a solution of the above solid in DMF (2 mL) was added 28% aqueous NH₃ (21 mg), Et₃N (0.1 mL), HOBt-H₂O (67 mg), and EDC-HCl (67 mg). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (NH-silica gel, 3% to 9% MeOH in CHCl₃). The solution of above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (12 mL) was stirred at ambient tempareture for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and under reduced pressure to give N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamide hydrochloride

ESI MS m/e 403, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.69-2.04 (m, 8H), 2.56-2.63 (m, 3H), 3.92-4.06 (m, 1H), 4.28-4.48 (m, 1H), 7.06-7.17 (m, 1H), 7.41-7.58 (m, 3H), 7.70-8.04 (m, 3H), 8.06-8.43 (m, 3H), 9.35-9.54 (m, 1H), 12.87-13.07 (m, 1H).

Example 3179

3-Chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 412, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.79-2.12 (m, 8H), 2.73 (d, J=0.9 Hz, 3H), 3.96-4.22 (m, 2H), 6.75-6.90 (m, 2H), 7.17-7.25 (m, 1H), 7.42-7.51 (m, 2H), 7.59-7.89 (m, 4H), 9.51-9.72 (m, 1H).

Example 3180

3,4,5-Trifluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4,5-trifluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 414, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.76-2.16 (m, 8H), 2.73 (d, J=1.1 Hz, 3H), 3.97-4.24 (m, 2H), 6.78 (s, 1H), 6.92-7.04 (m, 1H), 7.41-7.60 (m, 3H), 7.68-7.77 (m, 2H), 7.82-7.89 (m, 1H), 9.50-9.64 (m, 1H).

Example 3181

Pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 383, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.63-2.07 (m, 8H), 2.54-2.71 (m, 3H), 4.00-4.13 (m, 1H), 4.49-4.62 (m, 1H), 7.10-7.20 (m, 1H), 7.46-7.56 (m, 1H), 7.61-8.12 (m, 5H), 8.33-8.42 (m, 2H), 8.65-8.72 (m, 1H), 9.46-9.60 (m, 1H), 13.23-13.38 (m, 1H).

Example 3182

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 383, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.76-2.05 (m, 8H), 2.54-2.73 (m, 3H), 3.93-4.07 (m, 1H), 4.29-4.48 (m, 1H), 7.10-7.19 (m, 1H), 7.47-7.57 (m, 1H), 7.72-7.85 (m, 2H), 7.92-8.04 (m, 1H), 8.21-8.33 (m, 1H), 8.48-8.57 (m, 1H), 8.65-8.73 (m, 1H), 8.82-8.89 (m, 1H), 9.14-9.20 (m, 1H), 9.42-9.58 (m, 1H), 12.93-13.08 (m, 1H).

Example 3183

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-isonicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isonicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 383, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.68-2.08 (m, 8H), 2.53-2.71 (m, 3H), 3.92-4.08 (m, 1H), 4.33-4.54 (m, 1H), 7.11-7.22 (m, 1H), 7.43-7.60 (m, 1H), 7.69-7.86 (m, 1H), 7.89-8.41 (m, 4H), 8.81-9.07 (m, 3H), 9.48-9.67 (m, 1H), 13.03-13.24 (m, 1H).

Example 3184

4-Chloro-pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 4-Chloro-pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 417, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.62-2.05 (m, 8H), 2.53-2.72 (m, 3H), 3.99-4.51 (m, 2H), 7.04-7.15 (m, 1H), 7.46-7.57 (m, 1H), 7.72-7.85 (m, 2H), 7.92-8.10 (m, 2H), 8.16-8.29 (m, 1H), 8.39 (d, J=8-1 Hz, 1H), 8.66 (d, J=5.3 Hz, 1H), 9.32-9.51 (m, 1H), 12.93-13.08 (m, 1H).

Example 3185

5-Bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride

Step A: Synthesis of 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 439, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.71-2.02 (m, 8H), 2.54-2.71 (m, 3H), 3.88-4.08 (m, 1H), 4.25-4.50 (m, 1H), 7.06-7.18 (m, 1H), 7.47-7.56 (m, 1H), 7.70-7.83 (m, 1H), 7.91-8.04 (m, 1H), 8.19-8.33 (m, 1H), 8.43-8.64 (m, 2H), 8.86-8.88 (m, 1H), 8.97-8.99 (m, 1H), 9.35-9.50 (m, 1H), 12.89-13.08 (m, 1H).

Example 3186

N-[cis-4-(4-Methyl-quinolin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide hydrochloride.

Using the procedure for the step A of example 3071, the title compound was obtained.

ESI MS m/e 451, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.58-2.04 (m, 8H), 2.53-2.75 (m, 3H), 3.91-4.09 (m, 1H), 4.22-4.44 (m, 1H), 7.03-7.22 (m, 1H), 7.45-7.59 (m, 1H), 7.71-7.85 (m, 1H), 7.91-8.10 (m, 2H), 8.15-8.30 (m, 1H), 8.42-8.54 (m, 1H), 8.64-8.81 (m, 1H), 9.12-9.21 (m, 1H), 9.33-9.54 (m, 1H), 12.88-13.00 (m, 1H).

Example 3187

6-Imidazol-1-yl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride

Step A: Synthesis of 6-imidazol-1-yl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride.

To a solution of 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide obtained in step A of example 3175 (250 mg) in BuOH (1 mL) were added imidazole (47 mg) and iPr₂NEt (172 mg). The mixture was heated in a microwave synthesizer at 220° C. for 10 min and 230° C. for 20 min. To the mixture was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 50% in EtOAc in nexane). To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (12 mL) was stirred at ambient tempareture for 4 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 6-imidazol-1-yl-N-[cis-4-(4-methyl-quinolin-2-ylamino)cyclohexyl]-nicotinamide dihydrochloride (83 mg) as a white solid.

ESI MS m/e 427, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.35-2.39 (m, 8H), 2.60-2.81 (m, 3H), 3.92-4.28 (m, 2H), 6.63-6.92 (m, 1H), 7.09-8.23 (m, 8H), 8.53-8.82 (m, 1H), 8.95-9.41 (m, 2H), 9.96-10.17 (m, 1H), 13.97-14.19 (m, 1H).

Example 3188

N-[cis-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluorobenzamide hydrochloride.

To a solution of 3,4-difluoro-benzoic acid (199 mg) and N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-quinoline-2,4-diamine obtained in step E of example 1 (300 mg) in DMF (3 mL) were added Et₃N (0.35 mL), HOBt-H₂O (241 mg), and EDC-HCl (242 mg). The reaction mixture was stirred at ambient temperature for 15 hr. To the mixture was added water (4.8 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (4 mL) was added 4 M hydrogen chloride in EtOAc (0.5 mL). The mixture was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (263 mg) as a white solid.

ESI MS m/e 425, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.69-2.20 (m, 8H), 3.24 (s, 6H), 3.81-4.30 (m, 2H), 5.82 (s, 1H), 6.74-6.88 (m, 1H), 7.10-7.40 (m, 2H), 7.51-7.98 (m, 5H), 8.86-8.99 (m, 1H), 13.44-13.63 (m, 1H).

Example 3189

5-Nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitrothiophene-3-carboxylic acid [cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3188, the title compound was obtained.

ESI MS m/e 462, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.17 (m, 8H), 3.25 (s, 6H), 3.82-4.00 (m, 1H), 4.00-4.23 (m, 1H), 5.82 (s, 1H), 7.25-7.40 (m, 1H), 7.58-7.97 (m, 4H) 8.28-8.42 (m, 2H), 8.56-8.73 (m, 1H), 13.02-13.30 (m, 1H).

Example 3190

N-[cis-4-(4-Dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7 (300 mg) in CHCl₃ (3 mL) were added iPr₂NEt (0.36 mL) and 3,4-difluoro-benzoyl chloride (194 mg). The mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 9% to 20% EtOAc in hexane and 2% to 9% MeOH in CHCl₃) to give N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride (272 mg) as white solid.

ESI MS m/e 439, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.53-2.08 (m, 9H), 3.21 (s, 6H), 3.47-3.56 (m, 2H), 3.86-3.98 (m, 1H), 5.81 (s, 1H), 6.95-7.09 (m, 1H), 7.16-7.34 (m, 2H), 7.53-7.68 (m, 2H), 7.80-7.95 (m, 3H), 9.08-9.22 (m, 1H), 13.40-13.51 (m, 1H).

Example 3191

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-quinoline-2,4-diamine obtained in step B of example 7 (300 mg) in DMSO (3 mL) was added 1,2-dichloro-4-isocyanato-benzene (207 mg). The mixture was stirred at ambient temperature for 12 hr and poured into water. The precipitate was filtrated, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (170 mg) as a white solid.

ESI MS m/e 486, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.51-2.18 (m, 9H), 3.23 (s, 6H), 3.36-3.44 (m, 2H), 3.91-4.02 (m, 1H), 5.78-5.88 (m, 1H), 6.97-7.12 (m, 3H), 7.26-7.35 (m, 1H), 7.58-7.66 (m, 1H), 7.86 (m, J=9.0 Hz, 2H), 8.16 (dd, J=8.2, 1.7 Hz, 1H), 8.20-8.31 (m, 1H), 8.65-8.76 (m, 1H), 12.98-13.21 (m, 1H).

Example 3192

N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of 3,4-difluoro-benzoic acid (199 mg) and N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine in step D of example 3107 (304 mg) in DMF (4 mL) were added Et₃N (0.35 mL), HOBt-H₂O (241 mg), and EDC-HCl (242 mg). The reaction mixture was stirred at ambient temperature for 7 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane). To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (252 mg) as a white solid.

ESI MS m/e 430, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.56-2.22 (m, 12H), 2.48-2.84 (m, 4H), 3.23 (s, 6H), 3.92-4.33 (m, 2H), 6.51-6.77 (m, 1H), 7.01-7.30 (m, 1H), 7.43-7.86 (m, 2H), 8.28-8.57 (m, 1H), 12.56 (m, 1H).

Example 3193

5-Nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3192, the title compound was obtained.

ESI MS m/e 467, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.51-2.24 (m, 12H), 2.51-2.62 (m, 2H), 2.67-2.81 (m, 2H), 3.23 (s, 6H), 3.98-4.29 (m, 2H), 7.42-7.48 (m, 1H), 8.22-8.29 (m, 2H), 8.37 (s, 1H).

Example 3194

1-Methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexyl]-amide hydrochloride

Using the procedure for the step A of example 3192, the title compound was obtained.

ESI MS m/e 442, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-2.13 (m, 12H), 2.49-2.61 (m, 2H), 2.68-2.81 (m, 2H), 3.22 (s, 6H), 3.93-4.04 (m, 4H), 4.14-4.24 (m, 1H), 7.04-7.12 (m, 1H), 7.23-7.27 (m, 1H), 7.49-7.54 (m, 1H), 8.30-8.41 (m, 1H), 12.66-12.92 (m, 1H).

Example 3195

N-[cis-4-(4-Dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine in step A of example 3113 (300 mg) in CHCl₃ (3 mL) were added iPr₂NEt (0.36 mL) and 3,4-difluoro-benzoyl chloride (194 mg). The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride (263 mg) as a white solid.

ESI MS m/e 466, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.50-1.96 (m, 13H), 2.49-2.59 (m, 2H), 2.66-2.77 (m, 2H), 3.21 (s, 6H), 3.42-3.51 (m, 2H), 4.16-4.28 (m, 1H), 6.91-7.01 (m, 1H), 7.17-7.26 (m, 1H), 7.80-7.92 (m, 2H), 8.55 (d, J=8.2 Hz, 1H), 12.61-12.77 (m, 1H).

Example 3196

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of N²-(cis-4-aminomethylcyclohexyl)-N⁴,N⁴-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine in step A of example 3113 (300 mg) in DMSO (3 mL) was added 1,2-dichloro-4-isocyanato-benzene (207 mg). The mixture was stirred at ambient temperature for 12 hr and poured into water. The precipitate was filtrated, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (113 mg) as a white solid.

ESI MS m/e 491, M⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.42-2.04 (m, 13H), 2.46-2.80 (m, 4H), 3.21 (s, 6H), 3.29-3.44 (m, 2H), 4.18-4.38 (m, 1H), 6.80-7.22 (m, 3H), 8.06-8.45 (m, 3H), 12.04-12.29 (m, 1H).

Example 3197

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step D of example 3129, the title compound was obtained.

ESI MS m/e 376, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.01 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 3.98-4.32 (m, 2H), 5.98 (d, J=7.3 Hz, 1H), 6.45-6.63 (m, 1H), 7.11-7.30 (m, 1H), 7.41-7.79 (m, 3H), 8.67-8.94 (m, 1H), 12.89-13.06 (m, 1H).

Example 3198

5-Nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2-ylamino)-cyclohexyl]-amide hydrochloride.

To a solution of 5-nitro-thiophene-3-carboxylic acid (265 mg) and cis-N²-(4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine in step C of example 3129 (300 mg) in DMF (3 mL) were added Et₃N (0.43 mL), HOBt-H₂O (293 mg), and EDC-HCl (293 mg). The reaction mixture was stirred at ambient temperature for 12 hr. To the reaction mixture was added water (20 mL) and the suspension was stirred at ambient temperature for 1 hr. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (2 mL). The mixture was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-dimethylamino-pyrimidine-2-ylamino)-cyclohexyl]-amide hydrochloride (71 mg) as a white solid.

ESI MS m/e 413, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.02 (m, 8H), 3.18 (s, 3H), 3.27 (s, 3H), 3.99-4.29 (m, 2H) 5.99 (d, J=7.5 Hz, 1H), 7.48-7.64 (m, 2H), 8.34 (d, J=1.8 Hz, 1H), 8.48 (d, J=1.8 Hz, 1H), 8.50-8.67 (m, 1H), 12.58-12.76 (m, 1H).

Example 3199

5-(4-Chloro-phenyl)-furan-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 5-(4-Chloro-phenyl)-furan-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 462, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.07 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.01-4.27 (m, 2H), 5.97 (d, J=6.9 Hz, 1H), 6.71 (d, J=3.5 Hz, 1H), 6.76-6.87 (m, 1H), 7.17 (d, J=3.5 Hz, 1H), 7.36-7.55 (m, 3H), 7.69-7.79 (m, 2H), 8.65-8.86 (m, 1H), 13.08-13.30 (m, 1H).

Example 3200

4′-Fluoro-biphenyl-4-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 4′-fluoro-biphenyl-4-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 456, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.06 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.06-4.32 (m, 2H), 5.97 (d, J=7.3 Hz, 1H), 6.50-6.60 (m, 1H), 7.09-7.20 (m, 2H), 7.43-7.64 (m, 5H), 7.85-7.91 (m, 2H), 8.74-8.86 (m, 1H), 12.98-13.23 (m, 1H).

Example 3201

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 473, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.05 (m, 8H), 3.16 (s, 3H), 3.26 (s, 3H), 4.07-4.24 (m, 2H), 5.94 (d, J=7.3 Hz, 1H), 7.09-7.20 (m, 3H), 7.23-7.32 (m, 2H), 7.42-7.52 (m, 1H), 7.81-7.94 (m, 1H), 8.20 (dd, J=4.8, 2.0 Hz, 1H), 8.54 (dd, J=7.5, 2.1 Hz, 1H), 8.70-8.80 (m, 1H), 13.23-13.38 (m, 1H).

Example 3202

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide dihydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide dihydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 419, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.14-1.35 (m, 3H), 1.55-1.92 (m, 8H), 3.15 (s, 3H), 3.24 (s, 3H), 3.45-3.64 (m, 2H), 3.75-4.06 (m, 4H), 5.91-6.03 (m, 1H), 7.00-7.64 (m, 7H), 8.32-8.48 (m, 1H), 13.12-13.34 (m, 1H).

Example 3203

C-[cis-(4-Chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride

Step A: Synthesis of C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide dihydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 431, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.12-1.24 (m, 3H), 1.51-1.96 (m, 8H), 3.15 (s, 3H), 3.25 (s, 3H), 3.43-3.55 (m, 2H), 3.74-3.98 (m, 3H), 4.01-4.18 (m, 1H), 5.88-6.02 (m, 1H), 6.68-6.87 (m, 3H), 7.15-7.24 (m, 2H), 7.43-7.52 (m, 1H), 8.49-8.62 (m, 1H), 13.11-13.28 (m, 1H).

Example 3204

2-(3,4-Difluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 390, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.46-1.87 (m, 8H), 3.15 (s, 3H), 3.18 (s, 3H), 3.46 (s, 2H), 3.58-3.75 (m, 1H), 3.86-4.04 (m, 1H), 6.36 (d, J=7.4 Hz, 1H), 7.05-7.13 (m, 1H), 7.27-7.40 (m, 2H), 7.84-7.94 (m, 1H), 8.10-8.19 (m, 1H), 8.27-8.38 (m, 1H), 12.14-12.23 (m, 1H).

Example 3205

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide hydrochloride.

Using the procedure for the step D of example 3129, the title compound was obtained.

ESI MS m/e 376, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.02 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.01-4.31 (m, 2H), 5.97 (d, J=7.4 Hz, 1H), 6.46-6.57 (m, 1H), 6.87-6.98 (m, 1H), 7.30-7.40 (m, 2H), 7.49 (d, J=7.4 Hz, 1H), 8.77-8.93 (m, 1H).

Example 3206

3-Chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-Chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 392, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.00 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.03-4.30 (m, 2H), 5.97 (d, J=7.5 Hz, 1H), 6.43-6.53 (m, 1H), 7.19 (t, J=8.5 Hz, 1H), 7.43-7.54 (m, 1H), 7.65-7.75 (m, 1H), 7.90-7.97 (m, 1H), 8.76-8.94 (m, 1H), 12.95-13.14 (m, 1H).

Example 3207

4-Chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide hydrochloride

Step A: Synthesis of 4-Chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 392, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.56-1.98 (m, 8H), 3.05-3.27 (m, 6H), 3.76-4.10 (m, 2H), 6.37 (d, J=7.6 Hz, 1H), 7.65-7.80 (m, 2H), 7.84-7.97 (m, 2H), 8.21-8.34 (m, 1H), 8.39-8.56 (m, 1H), 12.09-12.27 (m, 1H).

Example 3208

Pyridine-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of pyridine-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 341, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.72-2.07 (m, 8H), 3.17 (s, 3H), 3.27 (s, 3H), 4.02-4.22 (m, 2H), 5.97 (d, J=7.4 Hz, 1H), 7.36-7.55 (m, 2H), 7.76-7.88 (m, 1H), 8.10-8.29 (m, 2H), 8.52-8.70 (m, 2H).

Example 3209

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide dihydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 341, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.62-2.03 (m, 8H), 3.15 (s, 3H), 3.20 (s, 3H), 3.83-4.08 (m, 2H), 6.37 (d, J=7.4 Hz, 1H), 7.81-7.98 (m, 2H), 8.34-8.48 (m, 1H), 8.58-8.66 (m, 1H), 8.76-8.93 (m, 2H), 9.17-9.23 (m, 1H), 12.30-12.48 (m, 1H).

Example 3210

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-isonicotinamide dihydrochloride

Step A: Synthesis of N-(cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-isonicotinamide dihydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 341, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.67-1.99 (m, 8H), 3.16 (s, 3H), 3.20 (s, 3H), 3.84-4.07 (m, 2H), 6.37 (d, J=7.4 Hz, 1H), 7.86-8.02 (m, 1H), 8.25 (d, J=6.5 Hz, 2H), 8.48-8.57 (m, 1H), 8.95-9.13 (m, 3H), 12.53-12.69 (m, 1H).

Example 3211

5-Bromo-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride

Step A: Synthesis of 5-Bromo-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 419, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.07 (m, 8H), 3.18 (s, 3H), 3.28 (s, 3H), 4.04-4.31 (m, 2H), 5.95-6.04 (m, 1H), 7.37-7.65 (m, 2H), 8.42 (brs, 1H), 8.63-8.74 (m, 1H), 8.79 (brs, 1H), 9.12 (brs, 1H), 12.72-12.97 (m, 1H).

Example 3212

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 409, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.06 (m, 8H), 3.18 (s, 3H), 3.27 (s, 3H), 4.07-4.34 (m, 2H), 5.98 (d, J=7.4 Hz, 1H), 7.47-7.62 (m, 2H), 7.72 (d, J=8.0 Hz, 1H), 8.35-8.45 (m, 1H), 8.57-8.74 (m, 1H), 9.24-9.31 (m, 1H).

Example 3213

4-Chloro-pyridine-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride

Step A: Synthesis of 4-chloro-pyridine-2-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-amide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 375, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.71-2.09 (m, 8H), 3.18 (s, 3H), 3.28 (s, 3H), 4.01-4.24 (m, 2H), 5.88-6.08 (m, 1H), 7.39-7.59 (m, 2H), 8.05-8.35 (m, 2H), 8.43-8.72 (m, 2H), 13.20-13.45 (m, 1H).

Example 3214

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step D of example 3129, the title compound was obtained.

ESI MS m/e 380, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.24 (m, 8H), 3.17 (s, 3H), 3.27 (s, 3H), 4.01-4.32 (m, 2H), 5.97 (d, J=7.3 Hz, 1H), 6.38-6.57 (m, 1H), 7.01-7.17 (m, 2H), 7.41-7.54 (m, 1H), 7.77-7.91 (m, 2H), 8.76-8.84 (m, 1H), 12.86-13.14 (m, 1H).

Example 3215

3-Chloro-N-cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-Chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 414, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.03 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.02-4.31 (m, 2H), 5.97 (d, J=7.4 Hz, 1H), 6.53-6.67 (m, 1H), 7.16-7.23 (m, 1H), 7.41-7.51 (m, 2H), 7.58-7.64 (m, 1H), 8.76-8.91 (m, 1H).

Example 3216

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 416, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66-2.03 (m, 8H), 3.18 (s, 3H), 3.28 (s, 3H), 4.01-4.34 (m, 2H), 5.98 (d, J=7.4 Hz, 1H), 6.70-6.79 (m, 1H), 7.42-7.63 (m, 3H), 8.73-8.86 (m, 1H).

Example 3217

3,5-Di-tert-butyl-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-hydroxy-benzamide hydrochloride

Step A: Synthesis of 3,5-di-tert-butyl-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-hydroxy-benzamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 490, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.47 (s, 18H), 1.63-2.13 (m, 8H), 3.17 (s, 3H), 3.28 (s, 3H), 4.05-4.27 (m, 2H), 5.52 (s, 1H), 5.90-6.02 (m, 1H), 6.57-6.73 (m, 1H), 7.41-7.55 (m, 1H), 7.63 (s, 2H), 8.60-8.77 (m, 1H), 13.00-13.24 (m, 1H).

Example 3218

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-urea hydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine in step C of example 3129 (300 mg) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (264 mg). The mixture was stirred at ambient temperature for 12 hr and poured into water. The precipitate was filtrated, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-urea hydrochloride (421 mg) as a white solid.

ESI MS m/e 445, M (free)+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.63-2.19 (m, 8H), 3.15 (s, 3H), 3.25 (s, 3H), 3.80-4.22 (m, 2H), 5.94 (d, J=7.4 Hz, 1H), 7.00-7.19 (m, 2H), 7.43-7.64 (m, 2H), 8.16 (dd, J=8.3, 1.7 Hz, 1H), 8.37-8.52 (m, 1H), 12.70-13.00 (m, 1H).

Example 3219

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine in step B of example 3145 (300 mg) in CHCl₃ (3 mL) were added iPr₂NEt (0.59 mL) and 3,4-difluoro-benzoyl chloride (233 mg). The mixture was stirred at ambient temperature for 17 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide hydrochloride (155 mg) as a white solid.

ESI MS m/e 412, M (free)+Na⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.26-2.03 (m, 9H), 3.16 (s, 3H), 3.26 (s, 3H), 3.37-3.61 (m, 2H), 4.18-4.35 (m, 1H), 5.94 (d, J=7.4 Hz, 1H), 6.82-7.33 (m, 2H), 7.46 (d, J=7.4 Hz, 1H), 7.74-8.07 (m, 2H), 8.83-9.12 (m, 1H).

Example 3220

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-(2,3,6-trichloro-phenyl)-acetamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-2-(2,3,6-trichloro-phenyl)-acetamide hydrochloride.

Using the procedure for the step C of example 3118, the title compound was obtained.

ESI MS m/e 492, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-1.98 (m, 9H), 3.16 (s, 3H), 3.21-3.33 (m, 4H), 4.16 (s, 2H), 4.20-4.34 (m, 1H), 5.95-5.99 (m, 1H), 6.51-6.64 (m, 1H), 7.23-7.51 (m, 3H), 8.75-8.83 (m, 1H), 12.80-12.95 (m, 1H).

Example 3221

9H-Xanthene-9-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-amide hydrochloride

Step A: Synthesis of 9H-xanthene-9-carboxylic acid [cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-amide hydrochloride.

Using the procedure for the step C of example 3118, the title compound was obtained.

ESI MS m/e 480, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.27-1.94 (m, 9H), 3.05-3.19 (m, 5H), 3.24 (s, 3H), 4.14-4.28 (m, 1H), 5.10 (s, 1H), 5.91 (d, J=7.4 Hz, 1H), 6.19-6.33 (m, 1H), 6.98-7.18 (m, 3H), 7.20-7.31 (m, 2H), 7.37-7.54 (m, 3H), 8.62-8.82 (m, 1H), 12.88-13.08 (m, 1H).

Example 3222

1-(2,3-Dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride

Step A: Synthesis of 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride.

To a solution of N²-(cis-4-aminomethyl-cyclohexyl)-N⁴,N⁴-dimethyl-pyrimidine-2,4-diamine in step B of example 3145 (300 mg) in DMSO (3 mL) was added 1,2-dichloro-3-isocyanato-benzene (249 mg). The mixture was stirred at ambient temperature for 15 hr and poured into water (20 mL). The precipitate was filtrated, washed with water, and purified by medium-pressure liquid chromatography (NH-silica gel, 25% to 50% EtOAc in hexane). To a solution of the above material in EtOAc (2 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the residue in Et₂O (20 mL) was stirred at ambient tempareture for 1 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea hydrochloride (260 mg) as a white solid.

ESI MS m/e 437, M⁺; ¹H NMR (200 MHz, CDCl₃) δ 1.35-2.10 (m, 9H), 3.16 (s, 3H), 3.26 (s, 3H), 3.32-3.47 (m, 2H), 4.27-4.47 (m, 1H), 5.96 (d, J=7.5 Hz, 1H), 6.80-7.20 (m, 3H), 7.47 (d, J=7.5 Hz, 1H), 8.08-8.37 (m, 2H), 8.63-8.93 (m, 1H).

Example 3223

3,4-Difluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide-hydrochloride

Step A: Synthesis of (2-chloro-pyrimidin-4-yl)-methyl-amine.

To a solution of 2,4-dichloro-pyrimidine (15.0 g) in THF (150 mL) was added 40% aqueous MeNH₂ (19.5 g). The mixture was stirred at ambient temperature for 1.5 hr. The solution was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated, and purified by flash chromatography (NH-silica, 20% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-methyl-amine (10.0 g) as a white solid and (4-chloro-pyrimidin-2-yl)-methyl-amine (0.87 g, 6%) as a white solid.

(2-chloro-pyrimidin-4-yl)-methyl-amine;

ESI MS m/e 143, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.01 (d, J=5.0 Hz, 3H), 5.58-5.96 (m, 1H), 6.55 (d, J=5.1 Hz, 1H), 8.09-8.23 (m, 1H).

(4-chloro-pyrimidin-2-yl)-methyl-amine;

ESI MS m/e 143, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.98 (d, J=5.0 Hz, 3H), 6.27 (d, J=6.1 Hz, 1H), 7.93-8.20 (m, 1H).

Step B: Synthesis of [cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester.

A mixture of (2-chloro-pyrimidin-4-yl)-methyl-amine (2.50 g) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester obtained in step B of example 1 (4.10 g) in BuOH (2.50 mL) was stirred at reflux for 24 hr. The reaction mixture was poured into saturated aqueous NaHCO₃, and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica, 25% to 66% EtOAc in hexane) to give [cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]carbamic acid tert-butyl ester (2.63 g) as a white solid.

ESI MS m/e 344, M+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.36-1.88 (m, 17H), 2.89 (d, J=5.1 Hz, 3H), 3.53-3.69 (m, 1H), 3.84-4.04 (m, 1H), 4.44-4.70 (m, 2H), 4.76-4.86 (m, 1H), 5.69-5.72 (m, =1H), 7.80-7.91 (m, 1H).

Step C: Synthesis of N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-pyrimidine-2,4-diamine.

A solution of [cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-carbamic acid tert-butyl ester (4.76 g) in EtOAc (48 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (24 mL) was added. The mixture was stirred at ambient temperature for 4 hr and concentrated under reduced pressure. The residue was dissolved in 1 M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (five times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and dried under reduced pressure to give N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-pyrimidine-2,4-diamine (3.00 g, 80%) as a white solid.

ESI MS m/e 222, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 0.95-1.92 (m, 10H), 2.78-2.99 (m, 4H), 3.92-4.08 (m, 1H), 4.56-4.75 (m, 1H), 4.84-4.97 (m, 1H), 5.68 (d, J=5.9 Hz, 1H), 7.85 (d, J=5.7 Hz, 1H).

Step D: Synthesis of 3,4-difluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

To a solution of 3,4-difluoro-benzoic acid (196 mg) and N²-(cis-4-amino-cyclohexyl)-N⁴-methyl-pyrimidine-2,4-diamine (250 mg) in DMF (4 mL) were added Et₃N (0.38 mL), HOBt-H₂O (259 mg), and EDC-HCl (238 mg). The reaction mixture was stirred at ambient temperature for 12 hr. To the mixture was added water (20 mL) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 33% to 75% EtOAc in hexane). To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr. The precipitate was collected by filtration, washed with EtOAc, and dried under reduced pressure to give 3,4-difluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride (317 mg) as a white solid.

ESI MS m/e 362, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.59-1.90 (m, 8H), 2.89 (d, J=4.6 Hz, 3H), 3.80-4.11 (m, 2H), 6.03-6.13 (m, 1H), 7.47-8.03 (m, 4H), 8.27-8.49 (m, 2H), 8.82-9.06 (m, 1H), 11.92-12.11 (m, 1H).

Example 3224

3-Chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step C of example 3223, the title compound was obtained.

ESI MS m/e 378, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.59-1.90 (m, 8H), 2.89 (d, J=4.6 Hz, 3H), 3.77-4.10 (m, 2H), 6.00-6.12 (m, 1H), 7.49-7.60 (m, 1H), 7.67-7.76 (m, 1H), 7.85-7.94 (m, 1H), 8.11 (dd, J=7.1, 2.2 Hz, 1H), 8.24-8.51 (m, 2H), 8.82-8.94 (m, 1H), 11.80-11.98 (m, 1H).

Example 3225

N-[cis-4-(4-Ethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of (2-chloro-pyrimidin-4-yl)-ethyl-amine.

To the solution of 2,4-dichloro-pyrimidine (5.00 g) in THF (50 mL) was added 70% aqueous EtNH₂ (5.40 g). The mixture was stirred at ambient temperature for 1 hr. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (two times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified flash chromatography (silica gel, 17% to 50% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-ethyl-amine (3.69 g) as a white solid and (4-chloro-pyrimidin-2-yl)-ethyl-amine (1.28 g) as a white solid.

(2-chloro-pyrimidin-4-yl)-ethyl-amine;

ESI MS m/e 157, M⁺; ¹H NMR (500 MHz, CDCl₃) δ 1.26 (t, J=7.3 Hz, 3H), 3.16-3.62 (m, 2H), 4.80-5.95 (m, 1H), 6.23 (d, J=5.8 Hz, 1H), 8.02-8.22 (m, 1H).

(4-chloro-pyrimidin-2-yl)-ethyl-amine;

CI MS m/e 158, M+H⁺; ¹H NMR (500 MHz, CDCl₃) δ 1.23 (t, J=7.5 Hz, 3H), 3.42-3.49 (m, 2H), 5.30-5.62 (m, 1H), 6.54 (d, J=5.2 Hz, 1H), 8.02-8.22 (m, 1H).

Step B: Synthesis of N-[cis-4-(4-ethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

To a solution of N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step D of example 3031 (300 mg) in BuOH (1 mL) was added (2-chloro-pyrimidin-4-yl)-ethyl-amine (532 mg). The mixture was heated in a microwave synthesizer at 200° C. for 30 min. To the mixture was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% in EtOAc in nexane). To a solution of the above material in EtOAc (10.0 mL) was added 4 M hydrogen chloride in EtOAc (5.00 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (20 mL) was stirred at ambient tempareture for 4 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give N-[cis-4-(4-ethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride (398 mg) as a white solid.

ESI MS m/e 398, M (free)+Na⁺; ¹H NMR (500 MHz, CDCl₃) δ 1.19-1.42 (m, 3H), 1.61-2.05 (m, 8H), 3.46-3.65 (m, 2H), 4.00-4.34 (m, 2H), 5.85-6.00 (m, 1H), 6.42-6.72 (m, 2H), 7.11-7.37 (m, 2H), 7.52-7.82 (m, 2H), 8.68-8.90 (m, 1H).

Example 3226

N-{cis-4-[4-(Ethyl-methyl-amino)-pyrimidin-2-ylamino]-cyclohexyl}-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of (2-chloro-pyrimidin-4-yl)-ethyl-methyl-amine.

To the solution of 2,4-dichloro-pyrimidine (5.00 g) in THF (50 mL) was added ethyl-methyl-amine (2.08 g). The mixture was stirred at ambient temperature for 1 hr. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (two times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified flash chromatography (silica gel, 17% to 50% EtOAc in hexane) to give (2-chloro-pyrimidin-4-yl)-ethyl-methyl-amine (4.49 g) as a white solid and (4-chloro-pyrimidin-2-yl)-ethyl-methyl-amine (0.91 g) as a colorless oil.

(2-chloro-pyrimidin-4-yl)-ethyl-methyl-amine;

CI MS m/e 172, M (free)+H⁺; ¹H NMR (500 MHz, CDCl₃) δ 1.18 (t, J=3.0 Hz, 3H), 3.06 (br, 3H), 3.35-3.70 (m, 2H), 6.29 (d, J=4.8 Hz, 1H), 7.99(d, J=6.1 Hz, 1H).

(4-chloro-pyrimidin-2-yl)-ethyl-methyl-amine;

CI MS m/e 172, M+H⁺; ¹H NMR (500 MHz, CDCl₃) δ 1.17 (t, J=3.0 Hz, 3H), 3.10 (s, 3H), 3.66 (q, J=7.0 Hz, 2H), 6.45 (d, J=5.0 Hz, 1H), 8.14 (d, J=5.0 Hz, 1H).

Step B: Synthesis of N-{cis-4-[4-(ethyl-methyl-amino)-pyrimidin-2-ylamino]-cyclohexyl)-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 412, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ1.18-1.33 (m, 3H), 1.64-2.03 (m, 8H), 3.13-3.32 (m, 3H), 3.44-3.56 (m, 1H), 3.67-3.82 (m, 1H), 4.04-4.31 (m, 2H), 5.90-600 (m, 1H), 6.59-6.72 (m, 1H), 7.14-7.27 (m, 1H), 7.43-7.62 (m, 2H), 7.68-7.79 (m, 1H), 8.71-8.83 (m, 1H).

Example 3227

3,4-Difluoro-N-(cis-4-{4-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-2-ylamino}-cyclohexyl)-benzamide hydrochloride

Step A: Synthesis of [(2-chloro-pyrimidin-4-yl)-methyl-amino]-ethanol.

To the solution of 2,4-dichloro-pyrimidine (5.00 g) in THF (50 mL) was added 2-methylamino-ethanol (2.65 g). The mixture was stirred at ambient temperature for 1 hr. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (two times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified flash chromatography (silica gel, 17% to 50% EtOAc in hexane) to give [(2-chloro-pyrimidin-4-yl)-methyl-amino]-ethanol (3.50 g) as a white solid and [(4-chloro-pyrimidin-2-yl)-methyl-amino]-ethanol (827 mg) as a white solid.

[(2-chloro-pyrimidin-4-yl)-methyl-amino]-ethanol;

ESI MS m/e 188, M (free)+H⁺; ¹H NMR (500 MHz, CDCl₃) δ 2.91 (brs, 3H), 3.13 (s, 3H), 3.64-3.92 (m, 4H), 6.46-6.49 (m, 1H), 7.99 (d, J=6.1 Hz, 1H).

[(4-chloro-pyrimidin-2-yl)-methyl-amino]-ethanol

ESI MS m/e 210, M+Na⁺; ¹H NMR (500 MHz, CDCl₃) δ 3.23 (s, 3H), 3.76-3.92 (m, 4H), 6.52 (d, J=5.2 Hz, 1H), 8.12 (d, J=4.6 Hz, 1H).

Step B: Synthesis of 3,4-difluoro-N-(cis-4-{4-[(2-hydroxy-ethyl)-methyl-amino]-pyrimidin-2-ylamino}-cyclohexyl)-benzamide hydrochloride.

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 428, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.61-1.98 (m, 8H), 3.13-3.25 (m, 3H), 3.54-4.31 (m, 5H), 4.76-5.02 (m, 1H), 6.26-6.52 (m, 1H), 7.48-7.62 (m, 1H), 7.68-8.17 (m, 4H), 8.28-8.47 (m, 1H), 11.74-11.95 (m, 1H).

Example 3228

3-Chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide.

To a solution of 3-chloro-4-fluoro-benzoic acid (26.9 g) and (cis-4-amino-cyclohexyl)-carbamic acid tert-butyl ester (30.0 g) in DMF (300 mL) were added Et₃N (46.8 mL), HOBt-H₂O (32.2 g), and EDC-HCl (29.5 g). The reaction mixture was stirred at ambient temperature for 20 hr. To the mixture was added water (1.20 L) and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. A solution of the above material in EtOAc (650 mL) was cooled on an ice-bath and 4 M hydrogen chloride in EtOAc (325 mL) was added. The mixture was stirred at ambient temperature for 16 hr and concentrated under reduced pressure. The residue was dissolved in 1 M aqueous NaOH (300 mL) and the aqueous layer was extracted with CHCl₃ (three time). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and dried under reduced pressure to give N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide (44.4 g) as a brown solid.

ESI MS m/e 271, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.37-1.92 (m, 8H), 2.94-3.08 (m, 1H), 4.06-4.22 (m, 1H), 6.13-6.31 (m, 1H), 7.19 (t, J=8.5 Hz, 1H), 7.61-7.70 (m, 1H), 7.79-7.87 (m, 1H).

Step B: Synthesis of 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

To a solution of N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide (432 mg) in BuOH (1 mL) was added 2-chloro-4-dimethylamino-5-methylpyrimidine obtained in step A of example 3119 (250 mg). The mixture was heated in a microwave synthesizer at 200° C. for 10 min. To the mixture was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give a pale yellow oil. To a solution of the above material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.2 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated under reduced pressure. A suspension of the above material in Et₂O (20 mL) was stirred at ambient tempareture for 4 hr. The precipitate was collected by filtration, washed with Et₂O, and dried under reduced pressure to give 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride (174 mg) as a white solid.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.02 (m, 8H), 2.25 (s, 3H), 3.30 (s, 6H), 4.02-4.26 (m, 2H), 6.81-6.93 (m, 1H), 7.13-7.27 (m, 2H), 7.70-7.78 (m, 1H), 7.93-8.00 (m, 1H), 8.50-8.63 (m, 1H), 12.68-12.85 (m, 1H).

Example 3229

3-Chloro-N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(4-dimethylamino-5-fluoro-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3228, the title compound was obtained.

ESI MS m/e 410, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.03 (m, 8H), 3.36 (s, 6H), 4.00-4.23 (m, 2H), 6.73-6.84 (m, 1H), 7.18 (t, J=8.6 Hz, 1H), 7.45 (d, J=7.6 Hz, 1H), 7.67-7.76 (m, 1H), 7.95 (dd, J=7.0, 2.2 Hz, 1H), 8.64-8.78 (m, 1H).

Example 3230

3-Chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3228, the title compound was obtained.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.04 (m, 8H), 2.36 (s, 3H), 3.15 (s, 3H), 3.27 (s, 3H), 4.01-4.31 (m, 2H), 5.76 (s, 1H), 6.73-6.84 (m, 1H), 7.19 (t, J=8.6 Hz, 1H), 7.68-7.79 (m, 1H), 7.97 (dd, J=6.9, 2.2 Hz, 1H), 8.50-8.63 (m, 1H), 12.94-13.16 (m, 1H).

Example 3231

N-[cis-4-(4-Dimethylamino-6-ethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of (2,6-Dichloro-pyrimidin-4-yl)-dimethyl-amine.

To the solution of 2,4,6-trichloro-pyrimidine (10.0 g) in THF (50 mL) were added 50% aqueous Me₂NH (4.92 g) and iPr₂NEt (8.46 g). The mixture was stirred at ambient temperature for 1.5 hr and concentrated under reduced pressure. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified flash chromatography (NH-silica gel, 3% EtOAc in hexane) to give (2,6-dichloro-pyrimidin-4-yl)-dimethyl-amine (6.03 g) as white solid.

ESI MS m/e 192, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.77-3.46 (m, 6H), 6.34 (s, 1H).

Step B: Synthesis of (2-chloro-6-ethyl-pyrimidin-4-yl)-dimethyl-amine.

A solution of ZnBr₂ (3.87 g) in THF (60 mL) was cooled to −60° C. and 1 M EtMgBr in THF (17.2 mL) was added. The mixture was stirred at −60° C. for 1 hr and warmed to ambient temperature. To the mixture was added (2,6-dichloro-pyrimidin-4-yl)-dimethyl-amine in THF (60 mL) and stirred at reflux for 5 days. To the mixture was added saturated aqueous NH₄Cl and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (silica gel, 17% to 33% EtOAc in hexane) to give (2-chloro-6-ethyl-pyrimidin-4-yl)-dimethyl-amine (352 mg) as pale yellow solid and (6-chloro-2-ethyl-pyrimidin-4-yl)-dimethyl-amine (622 mg) as pale yellow solid.

(2-chloro-6-ethyl-pyrimidin-4-yl)-dimethyl-amine;

ESI MS m/e 208, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.25 (t, J=7.6 Hz, 3H), 2.54-2.66 (m, 2H), 3.11 (s, 6H), 6.15 (s, 1H).

(6-chloro-2-ethyl-pyrimidin-4-yl)-dimethyl-amine;

ESI MS m/e 186, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29 (t, J=7.6 Hz, 3H), 2.74 (q, J=7.7 Hz, 2H), 3.10 (s, 6H), 6.24 (s, 1H).

Step C: Synthesis of N-[cis-4-(4-dimethylamino-6-ethyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 426, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29-1.44 (m, 3H), 1.58-2.19 (m, 8H), 2.54-2.77 (m, 2H), 3.15 (s, 3H), 3.26 (s, 3H), 3.98 4.34 (m, 2H), 2H), 5.74 (s, 1H), 6.41-6.63 (m, 1H), 7.08-7.32 (m, 1H), 7.46-7.81 (m, 2H), 8.58 8.81 (m, 1H), 12.83 13.09 (m, 1H).

Example 3232

N-[cis-4-(4,6-Bis-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of 2-chloro-N,N,N′,N′-tetramethyl-pyrimidine-4,6-diamine.

To the solution of (2,6-dichloro-pyrimidin-4-yl)-dimethyl-amine obtained in step A of example 3231 (1.60 g) in THF (2 mL) was added 50% aqueous Me₂NH (789 mg). The mixture was stirred at reflux for 3.5 hr in a sealed tube. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (silica gel, 20% EtOAc in hexane) to give 2-chloro-N,N,N′,N′-tetramethyl-pyrimidine-4,6-diamine (203 mg) as a pale brown solid and 6-chloro-N,N,N′,N′-tetramethyl-pyrimidine-2,4-diamine (1.43 g) as a pale yellow solid.

2-chloro-N,N,N′,N′-tetramethyl-pyrimidine-4,6-diamine;

ESI MS m/e 201, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.05 (s, 12H), 5.15 (s, 1H).

6-chloro-N,N,N′,N′-tetramethyl-pyrimidine-2,4-diamine;

ESI MS m/e 201, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 3.04 (s, 6H), 3.13 (s, 6H), 5.76 (s, 1H).

Step B: Synthesis of N-[cis−4-(4,6-bis-dimethylamino-pyrimidin2-ylamino)-cyclohexyl]3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 441, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.09 (m, 8H), 2.96-3.38 (m, 12H), 4.00−4.31 (m, 2H), 4.73 (s, 1H), 6.65 6.82 (m, 1H), 7.13 7.25 (m, 1H), 7.55-7.63 (m, 1H), 7.68-7.78 (m, 1H), 8.70-8.82 (m, 1H), 11.79-11.99 (m, 1H).

Example 3233

N-[cis-4-(6-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride

Step A: Synthesis of N-[cis-4-(6-chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide hydrochloride.

Using the procedure for the step B of example 3032, the title compound was obtained.

ESI MS m/e 489, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.52-2.10 (m, 8H), 2.96-3.38 (m, 6H), 4.02 4.29 (m, 2H), 5.82 6.03 (m, 1H), 7.04 7.55 (m, 6H), 7.80 8.01 (m, 1H), 8.15-8.28 (m, 1H), 8.47-8.61 (m, 1H).

Example 3234

N-[cis-4-(6-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

N-[cis-4-(6-Chloro-4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 432, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.05 (m, 8H), 3.04-3.37 (m, 6H), 4.02 4.37 (m, 2H), 5.88 6.03 (m, 1H), 6.56 6.86 (m, 1H), 7.14 7.27 (m, 1H), 7.51-7.63 (m, 1H), 7.66-7.82 (m, 1H), 8.85-9.02 (m, 1H).

Example 3235

N-[cis-4-(4-Amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride

Step A: Synthesis of 2-chloro-quinolin-4-ylamine.

To the solution of 2,4-dichloro-quinoline obtained in step A of example 1 (4.00 g) in IPA (40 mL) was added 28% aqueous NH₃ (40.0 mL). The mixture was stirred at reflux for 10 days in a sealed tube. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (silica gel, 9% to 17% EtOAc in hexane) to give 2-chloro-quinolin-4-ylamine (1.39 g) as a white solid and 4-chloro-quinolin2-ylamine (1.17 g) as a white solid.

2-chloro-quinolin-4-ylamine;

ESI MS m/e 178, M⁺; ¹H NMR (200 MHz, CDCl₃) δ 4.69-4.97 (m, 2H), 6.61 (s, 1H), 7.37-7.78 (m, 3H), 7.84-8.02 (m, 1H).

4-chloro-quinolin-2-ylamine

ESI MS m/e 178, M⁺; ¹H NMR (300 MHz, CDCl₃) δ 4.58-4.96 (m, 2H), 6.85 (s, 1H), 7.23-7.41 (m, 1H), 7.53-7.72 (m, 2H), 7.98-8.09 (m, 1H).

Step B: Synthesis of N-[cis-4-(4-amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 397, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.29-2.15 (m, 8H), 3.75-3.90 (m, 1H) 4.05,4.26 (m, 1H), 5.44-5.59 (m, 2H), 5.89 (s, 1H), 6.99 7.43 (m, 3H), 7.55-7.84 (m, 5H), 8.81-8.98 (m, 1H).

Example 3236

2-(cis-4-{[1-(3,4-Difluoro-phenyl)-methanoyl]-amino}-cyclohexylamino)-quinoline-4-carboxylic acid amide

Step A: Synthesis of 2-chloro-quinoline-4-carboxylic acid amide.

To a solution of 2-chloro-quinoline-4-carboxylic acid (3.00 g) in DMF (30 mL) were added 28% aqueous NH₃ (1.05 g), Et₃N (5.04 mL), HOBt-H₂O (3.32 g), and EDC-HCl (3.32 g). The reaction mixture was stirred at ambient temperature for 16 hr. To the reaction mixture was added water (20 mL) and the aqueous layer extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give 2-chloro-quinoline-4-carboxylic acid amide (1.77 g) as a white solid.

ESI MS m/e 207, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 7.65 (s, 1H), 7.68-7.77 (m, 1H), 7.83-7.93 (m, 1H), 7.98 8.09 (m, 2H), 8.18 8.25 (m, 1H), 8.30 8.40 (m, 1H),

Step B: Synthesis of 2-(cis-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino)-cyclohexylamino)-quinoline-4-carboxylic acid amide.

A mixture of 2-chloro-quinoline-4-carboxylic acid amide (300 mg) and N-(cis-4-amino-cyclohexyl)-3,4-difluoro-benzamide obtained in step A of example 3031 (406 mg) in butanol (1 mL) and DMSO (1 mL) was stirred at reflux for 24 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, purified by medium-pressure liquid chromatography (NH-silica gel, EtOAc), and concentrated under reduced pressure. The above material was washed with and dried under reduced pressure to give 2-(cis-4-{[1-(3,4-difluoro-phenyl)-methanoyl]-amino}-cyclohexylamino)quinoline-4-carboxylic acid amide (136 mg) as a white solid.

ESI MS m/e 447, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.61-2.03 (m, 8H), 3.78-3.93 (m, 1H), 4.05-4.20 (m, 1H), 6.89 (s, 1H), 6.99 7.07 (m, 1H), 7.11 7.21 (m, 1H), 7.42-7.61 (m, 3H), 7.65-7.82 (m, 3H), 7.88 7.99 (m, 1H), 8.02 8.10 (m, 1H), 8.28 8.36 (m, 1H).

Example 3237

3,4-Difluoro-N-[cis-4-(4-trifluoromethyl-quinolin-2-yl)-amino-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(4-trifluoromethyl-quinolin-2-yl)-amino-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3225, the title compound was obtained.

ESI MS m/e 472, M (free)+Na⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.80 2.10 (m, 8H), 3.99-4.28 (m, 2H), 6.46-6.63 (m, 1H), 7.12-7.34 (m, 2H), 7.48-7.63 (m, 2H), 7.66 7.90 (m, 3H), 7.94-8.05 (m, 1H), 10.14-10.35 (m, 1H).

Example 3238

3,4-Difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid

Step A: Synthesis of 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid.

To a solution of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (3.00 g) in CHCl₃ (30 mL) were added Et₃N (3.40 mL) and 3,4-difluoro-benzoyl chloride (2.28 g). The mixture was stirred at ambient temperature for 6 hr. To the mixture was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane and silica gel, 2% to 5% MeOH in CHCl₃) to give 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide (3.52 g) as colorless solid. To a solution of 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide (700 mg) in EtOH (7 mL) was added MsOH (179 mg). The mixture was stirred at ambient temperature for 3 hr. The precipitate was collected by filtration, washed with EtOH, and dried at 70° C. under reduced pressure to give 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid (769 mg) as a white solid.

ESI MS m/e 396, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.69-2.01 (m, 8H), 2.42 (s, 3H). 2.62 (brs, 3H), 3.90-4.21 (m, 2H), 7.02-7.13 (m, 1H), 7.47 7.61 (m, 2H), 7.75-8.04 (m, 5H), 8.35, (d, J=6.4 Hz, 1H), 9.15-9.42 (m, 1H), 12.27-12.51 (m, 1H).

Example 3239

3-Chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid

Step A: Synthesis of 3-chloro-4-fluoro-N-[cis−4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid.

To a solution of 3-chloro-4-fluoro-benzoic acid (2.26 g) and N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (3.00 g) in DMF (30 mL) were added Et₃N (3.93 mL), HOBt-H₂O (2.70 g), and EDC-HCl (2.47 g). The reaction mixture was stirred at ambient temperature for 6 hr. To the reaction mixture was added water (200 mL) and the suspension was stirred at ambient temperature for 30 min. The precipitated was collected by filtration, washed with H₂O, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 33% EtOAc in hexane) to give 3-chloro-4-fluoro-N-[cis−4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-benzamide (4.40 g) as a colorless solid. To a solution of 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]benzamide (800 mg) in EtOH (8 mL) was added MsOH (196 mg). The mixture was stirred at ambient temperature for 4 hr. The precipitate was collected by filtration, washed with EtOH, and dried at 80° C. under reduced pressure to give 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid (845 mg) as a white solid.

ESI MS m/e 434, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.66-1.99 (m, 8H), 2.38 (s, 3H), 2.56-2.73 (m, 3H), 3.87+34.21 (m, 2H), 6.99 7.14 (m, 1H) 7.48-7.58 (m, 2H), 7.74-7.84 (m, 1H), 7.87-8.05 (m, 3H), 8.12 (dd, J=7.2, 2.2 Hz, 1H), 8.36−8.41 (m, 1H), 9.14 9.39 (m, 1H), 12.28-12.55 (m, 1H).

Example 3240

3-Methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid

Step A: Synthesis of 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid.

To a solution of cis-N-quinolin-2-yl-cyclohexane-1,4-diamine obtained in step A of example 3033 (4.00 g) in CHCl₃ (40 mL) were added Et₃N (4.85 mL) and 3-methoxy-benzoyl chloride (3.10 g). The mixture was stirred at ambient temperature for 6 hr. The reaction was quenched with saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% EtOAc in hexane) to give 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide (5.42 g) as colorless solid. To a solution of 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide (700 mg) in EtOH (7 mL) was added MsOH (188 mg). The mixture was stirred at ambient temperature for 24 hr. The precipitate was collected by filtration, washed with EtOH, and dried at 80° C. under reduced pressure to give 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide methanesulfonic acid (741 mg) as a white solid.

ESI MS m/e 398, M (free)+Na⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.70-1.99 (m, 8H), 2.35 (s, 3H), 3.81 (s, 3H) 3.90-4.04 (m, 1H), 4.08-4.22 (m, 1H), 7.06 7.26 (m, 2H), 7.32-7.56 (m, 4H), 7.73-8.02 (m, 3H), 8.17-8.38 (m, 2H), 12.41-12.58 (m, 1H).

Example 3241

N-{cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl}3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of 2-chloro-5-methyl-pyrimidin-4-ylamine.

A solution of 2,4-dichloro-5-methyl-pyrimidine (4.1 g, 0.025 mol) was dissolved in THF (30 mL) and cooled with stirring on an ice bath. To the mixture was added 7 N NH₃ in MeOH (14.4 mL, 0.10 mol) and stirring was continued overnight (in which time the ice melted and the reaction warned to room temperature). The excess solvent was removed in vacuo and the precipitate was suspended in CH₂Cl₂ (20 mL). The organic layer was extracted with a NaHCO₃ (aq) solution (20 mL) and both layers of the extraction were filtered to collect the resulting insoluble precipitate. This precipitate was washed with cold H₂O and dried to yield 2-chloro-5-methyl-pyrimidin-4-ylamine (1.0 g, 0.0070 mol, 27%) as a white solid.

ESI-MS m/e 144.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.80 (s, 1H), 7.22 (bs, 2H), 1.93 (s, 3H).

Step B: Synthesis of N-{cis-4-[(4-amino-5-methylpyrimidin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride.

To a solution of 2-chloro-5-methyl-pyrimidin-4-ylamine (292 mg, 2.03 mmol) in 2 mL 2-propanol was added DIEA (531 μL, 3.05 mmol) and cis-N-(4-amino-cyclohexyl)-3,5-bis(trifluoromethyl)-benzamide (720 mg, 2.03 mmol). The mixture was then heated in a microwave at 170° C. for 1 hour. The reaction mixture was cooled and concentrated and the resulting oil was purified by column (0-5% MeOH in CH₂Cl₂). The organic solvents were evaporated and the resulting oil was re-dissolved into 4 mL CH₂Cl₂ and 2M HCl in Et₂O (2.0 mL, 4.0 mmol) was added. The reaction was stirred for 30 minutes and the solvent was removed. A precipitate formed that was subsequently filtered and washed with a cold 50% ether in hexanes solution to yield N-{cis4-[(4-amino5-methylpyrimidin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide hydrochloride (500 mg, 1.00 mmol, 49%) as a HCl salt.

ESI-MS m/e 462.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.86 (s, 1H), 8.79 (s, 1H), 8.51 (s, 1H), 8.39 (s, 1H), 8.31 (s, 1H), 8.01 (s, 1H), 7.85 (s, 1H), 7.66 (s, 1H), 3.90 (bs, 2H), 1.90 (s, 3H), 1.89-1.61 (m, 8H).

Example 3242

2-[(cis-4-{[4-(Dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]1-[4-(trifluoromethoxy)phenyl]ethanone trifluoroacetate

Step A: Synthesis of 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cycolhexyl)amino]-1-[4-(trifluoromethoxy)phenyl]ethanone trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-cyclohexylamine (37 mg, 0.14 mmol) and 4-trifluoromethoxy bromoacetophenone (42 mg, 0.14 mmol) in THF (2 mL) was added DIEA (20 μL). The reaction was stirred for 2 h at 65° C., concentrated, dissolved in DMSO (1 mL), and purified by prep-HPLC to give 2-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)amino]-1-[4-(trifluoromethoxy)phenyl]ethanone trifluoroacetate 24 mg (30%) as a white powder.

ESI-MS m/e 452 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.28 (bs, 2H), 8.09 (d, 2H, J=8.8 Hz), 7.29 (m, 2H), 7.20 (m, 1H), 4.13 (bs, 1H), 3.45 (bs, 1H), 3.33 (s, 6H), 3.27 (bm, 2H), 2.28 (s, 3H), 2.02-1.71 (m, 8H).

Example 3243

N-{1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate

Step A: Synthesis of N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate.

To a solution of 2-(3,5-bistrifluoromethyl-phenyl)-2-methyl propionic acid (0.4 g, 1.3 mmol) and Et₃N (0.17 mL, 1-3 mmol) in dry benzene (4 mL) was added diphenylphosphoryl azide (0.36 g, 1.3 mmol). During the reaction being refluxed for about 3 h, 3,5-bistrifluoromethyl-4-(isocyanato-1-methyl-ethyl)-benzene was formed as the reaction intermediate, which was directly used to prepare urea derivatives.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (40 mg, 0.16 mmol) in EtOH (1 mL) was added 3,5-bistrifluoromethyl-4-(isocyanato1-methyl-ethyl)-benzene (48 mg, 0.16 mmol) from the above reaction. The reaction mixture was stirred at 60° C. for 1 h, and completed consumption of the starting material was observed by LC-MS. After removal of the volatile solvent, the residue was dissolved in DMSO (1.5 mL) and purified by prep-HPLC to give 35 mg (35%) of N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate.

ESI-MS m/e 547 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 13.4 (bs, 1H), 8.37 (bd, 1H, J=6.4 Hz), 7.84 (s, 3H), 7.71 (s, 1H), 5,56 (bs, 1H), 4.01 (bs, 1H), 3.75 (m, 1H), 3.29 (s, 6H), 2.25 (s, 3H), 1.75-1.60 (m, 14H).

Example 3244

N-{1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate

Step A: Synthesis of N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate.

3,5-Bistrifluoromethyl-4-(isocyanato-1-methyl-ethyl)-benzene (36 mg, 0.12 mmol) was added to a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-1-aminocyclohexane (30 mg, 0.12 mmol) and CH₃I (0.17 g, 1.2 mmol) in anhydrous benzene (1 mL) under an inert atmosphere. The reaction mixture was stirred at 50° C. for 2 h, and formation of the methylated and protonated products were observed by LC-MS. After removal of the volatile solvent, the residue was dissolved in DMSO (1.5 mL) and purified by prep-HPLC. 20 mg (25%) of N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea trifluoroacetate was isolated as a white powder.

ESI-MS m/e 561 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 14.5 (bs, 1H), 9.19 (bd, 1H, J=6.0 Hz), 7.84 (s, 2H), 7.79 (s, 1H), 7.70 (s, 1H), 4.87 (s, 1H), 4.23 (bs, 1H), 4.14 (m, 1H), 3.26 (s, 6H), 2.98 (s, 3H), 2.23 (s, 3H), 1.75-1.65 (m, 14H).

Example 3245

cis-N-{1-[3,5-Bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of 1-(3,5-bistrifluoromethyl-phenyl)-1-methyl-ethylamine.

3,5-Bistrifluoromethyl-4-(isocyanato-1-methyl-ethyl)-benzene (0.1 g, 0.33 mmol) was treated with 8-N HCl (4 mL). The acidic aqueous solution was heated for 1 h at 60° C. After cooling the reaction, NaOH pellets were added to make the aqueous mixture alkaline. The solid precipitates were filtered off, and the basic aqueous was extracted with DCM (2×). The combined organic was washed with H₂O, dried, and concentrated to give 1-(3,5-bistrifluoromethyl-phenyl)-1-methyl-ethylamine: 1-(3,5-bistrifluoromethyl-phenyl)-1-methyl-ethylamine appeared to be unstable in neat. The product was kept in DCM solution.

ESI-MS m/e 272 (M+H)⁺.

Step B: Synthesis of cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate.

To a solution of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid (15 mg, 0.05 mmol) and 1-(3,5-bistrifluoromethyl-phenyl)-1-methyl-ethylamine (15 mg, 0.05 mmol) in DCM (1.5 mL) was added HATU (25 mg, 0.06 mmol) and followed by Et₃N (10 mg, 0.1 mmol). After 4 h stirring at room temperature, the reaction was concentrated, dissolved in DMSO (1.5 mL), and purified by prep-HPLC to give 11 mg (30%) of cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate.

ESI-MS m/e 532 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 14.6 (bs, 1H), 8.64 (bd, 1H, J=6.0 Hz), 7.78 (s, 2H), 7.69 (s, 1H), 7.30 (d, 1H, J=7.2 Hz), 7.16 (s, 1H), 4.40 (bs, 1H), 3.30 (s, 6H), 2.26 (s, 3H), 2.18 (m, 1H), 2.07-1.80 (m, 8H), 1.70 (s, 6H).

Example 3246

3,4-Difluoro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4-methoxy-5-methyl pyrimidine.

2,4-dichloro-5-methyl pyrimidine (0.8 g, 5 mmol) was dissolved in MeOH (10 mL), and 0.5 M-NaOCH₃ in MeOH (10 mL, 5 mmol) was slowly added into the solution. The reaction was stirred for 40 min at room temperature, diluted with H₂O, and extracted with DCM (3×). The combined organic was washed with H₂O (2×) and saline (1×), dried, and concentrated. 0.8 g (99%) of 2-chloro-4-methoxy-5-methyl pyrimidine was isolated, which was directly used for the next reaction without a further purification.

¹H NMR (400 MHz, CDCl₃) δ 8.10 (s, 1H), 4.03 (s, 3H), 2.12 (s, 3H).

Step B: Synthesis of N-[cis-4-(4-methoxy-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]carbamic acid tert-butyl ester.

A sealed tube containing 2-chloro-4-methoxy-5-methyl pyrimidine (0.35 g, 2.2 mmol), cis-(4-amino-cyclohexyl)-carbamic acid tert-butyl ester (0.56 g, 2.4 mmol), DIEA (0.8 mL, 4.5 mmol), and IPA (2 mL) was reacted for 4000 sec at 175° C. in a Personal Microwave Synthesizer. The reaction was diluted with DCM, washed with 1N-HCl and H₂O, dried, and concentrated. The crude product was purified by column chromatography [silica gel, DCM:MeOH (100:0 to 97:3)]. 0.25 g (34%) of N-[cis-4-(4-methoxy-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]carbamic acid tert-butyl ester was isolated.

ESI-MS m/e 337 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.80 (s, 1H), 4.86 (bd, 1H, J=6.0 Hz), 4.55 (bs, 1H), 3.93 (bm, 1H), 3.89 (s, 3H), 3.62 (bs, 1H), 1.97 (s, 3H), 1.83-1.55 (m, 8H), 1.45 (s, 9H).

Step C: Synthesis of cis-4-(4-methoxy-5-methyl-pyrimidin-2-ylamino)-aminocyclohexane.

To a solution of N-[cis-4-(4-methoxy-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]carbamic acid tert-butyl ester (0.24 g, 0.7 mmol) in DCM (10 mL) was added TFA (5 mL). The reaction was stirred for 1.5 h at room temperature. After removal of the volatile solvent, the residue was treated with 4N-NaOH (3 mL). The basic aqueous was extracted with DCM (3×), and combined organic was washed with H₂O (2×) and brine (1×), and concentrated. 0.13 g (82%) of cis-4-(4-methoxy5-methyl-pyrimidin-2-ylamino)-aminocyclohexane was isolated as a yellowish solid.

ESI-MS m/e 237 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (s, 1H), 5.05 (bd, 1H, J=6.4 Hz), 3.99 (bs, 1H), 3.89 (s, 3H), 2.92 (bm, 1H), 2.45 (bs, 2H), 1.96 (s, 3H), 1.83-1.45 (m, 8H).

Step D: Synthesis of 3,4-difluoro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate.

To a solution of cis-4-(4-methoxy-5-methyl-pyrimidin-2-ylamino)-aminocyclohexane (20 mg, 0.08 mmol) in DCM (1 mL) was added 3,4-difluorobenzoyl chloride (14 mg, 0.08 mmol), and followed by Et₃N (25 μL). The reaction was stirred for 2 h at room temperature, and MeOH (0.2 mL) was added to quench the reaction. After removal of the volatile solvent, the residue was dissolved in DMSO (1.5 mL) and purified by prep-HPLC to give 12 mg (40%) of 3,4-difluoro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-yl)amino]cyclohexyl}benzamide trifluoroacetate as a white powder.

ESI-MS m/e 377 (M+H)⁺; ¹H NMR (400 MHz, CDCl₃) δ 15.7 (bs, 1H), 9.55 (d, 1H, J=7.2 Hz), 7.73 (m, 1H), 7.59 (m, 1H), 7.57 (s, 1H), 7.20 (m, 1H), 6.80 (d, 1H, J=8.0 Hz), 4.37 (bs, 1H), 4.18 (bm, 1H), 4.09 (s, 3H), 2.04 (s, 3H), 1.89-1.75 (m, 8H).

Example 3247

N-(cis-4-{[4-Methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride

Step A: Synthesis of (2-chloro-6-methyl-pyrimidin-4-yl)-methyl-amine.

2,4-Dichloro-6-methylpyrimidine (10 g, 61.34 mmol) in 50 mL in CH₂Cl₂ was added 2 M methylamine in methyl alcohol (46.01 ml, 92.02 mmol) at 0° C. The reaction mixture was stirred overnight and then the excess solvent was evaporated off and the material subjected to chromatography (50% hexanes in ethyl acetate) to yield (2-chloro-6-methyl-pyrimidin-4yl)-methyl-amine (5.835 g, 37.17 mmol, 60.59%) as a white solid.

ESI-MS 158.0 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.62 (s, 1H), 6.18 (s, 1H), 2.70 (bs, 3H), 2.10 (bs, 3H).

Step B: Synthesis N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride.

To a solution of (2-chloro-6-methyl-pyrimidin-4yl)-methyl-amine (500 mg, 3.18 mmol) in 3 mL 2-propanol was added cis-N-(4-amino-cyclohexyl)-4-trifluoromethoxy-benzamide (1.25 g, 4.14 mmol) and DIEA (1.108 mL, 6.36 mmol). The mixture was heated in a microwave synthesizer at 180° C. for 2 hours. The solvent was evaporated and obtained compound was dissolved in CH₂Cl₂ and was added 2 M HCl in diethyl ether (6.2 mL) to give N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide hydrochloride (1.3014 g, 2.83 mmol, 89%) as a yellowish solid.

ESI-MS 424.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.72 (s, 1H), 8.44 (s, 1H), 7.99-7.96 (d, J=8 Hz, 2H), 7.86 (s, 1H), 7.47-7.45 (d, J=8 Hz, 2H, 4.03 (s, 1H), 3.87 (s, 1H), 2.89-2.88 (d, J=4 Hz, 3H), 2.20 (s, 3H), 1.85 (bs, 2H), 1.72 (bs, 6H).

Example 3248

N-({cis-4-[(4-Amino-5-methylpyrimidin-2-yl)amino]cyclohexyl}methyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride

Step A: Synthesis of N-({cis-4-[(4-amino-5-methylpyrimidin-2-yl)amino]cyclohexyl}methyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride.

To a solution of 2-chloro-5-methyl-pyrimidin-4-ylamine (269 mg, 1.87 mmol) in 1 mL 2-propanol was added cis-N-(4-amino-cyclohexylmethyl)-3,5-bis-trifluoromethyl-benzamide (689.8 mg, 1.87 mmol) and DIEA (489.5.4 μl, 2.81 mmol). The mixture was heated in a microwave synthesizer at 180° C. for 2 hours. The solvent was evaporated and the material subjected to chromatography (1-2% methanol/CH₂Cl₂) The obtained compound was dissolved in CH₂Cl₂ and was added 2 M HCl in diethyl ether (2.2 mL) to give N-({cis-4-[(4-amino5-methylpyrimidin-2-yl)amino]cyclohexyl}methyl)-3,5-bis(trifluoromethyl)benzamide hydrochloride (667.1 mg, 1.30 mmol, 70%) as a white solid.

ESI-MS 476.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 9.16-9.13 (t, J=4 Hz, J=8 Hz, 1H), 8.55 (s, 2H), 8.36-8.31 (bs, 2H), 7.86 (bs, 1H), 7.71 (bs, 1H), 4.07 (bs, 1H), 3.27-3.24 (t, J=8 Hz, J=4 Hz, 2H), 1.91 (bs, 3H), 1.73-1.42 (m, 8H).

Example 3249

2-[(2-Chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide trifluoroacetate

Step A: Synthesis of cis-2-chloro-N-4-(4-dimethylamino-6-methyl-pyrimidin-2ylamino)-cyclohexyl]-nicotinamide.

cis-N²-(4-Amino-cyclohexyl)-6,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine (2.86 g, 11.5 mmol) in 20 mL CH₂Cl₂ was added 2-chloronicotinoyl chloride (2.02 g, 11.5 mmol), and DIEA (3.9 mL, 23 mmol). The reaction mixture was stirred for an hour. The solvent was evaporated off and the compound was crystallized (2% hexanes in ether) to yield cis-2-chloro-N-[4-(4-dimethylamino-6-methyl-pyrimidin-2ylamino)-cyclohexyl]-nicotinamide (4.2 g, 10.8 mmol, 94%).

ESI-MS 389.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 13.1 (bs, 1H), 8.72-8.70 (d, J=8 Hz, 1H), 8.49-8.46 (dt, J=8 Hz, J=4 Hz, 1H), 8.04 (s, 1H), 7.89-7.87 (dd, J=4 Hz, J=4 Hz, 1H), 7.52-7.47 (q, J=8 Hz, J=4 Hz, 1H), 6.27 (s, 1H), 3.95 (bs, 2H), 3.27 (bs, 6H), 2.31 (s, 3H), 1.82-1.74 (m, 8H).

Step B: Synthesis of 2-[(2-chlorophenyl)sulfonyl]-N-(cis4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide trifluoroacetate.

To a solution of cis2-chloro-N-[4-(4-dimethylamino6-methyl-pyrimidin-2ylamino)-cyclohexyl]-nicotinamide (50 mg, 0.128 mmol) in 1 mL dioxane was added 2-chlorobenzenethiol (37.1 mg, 0.256 mmol), and Cs₂CO₃ (83.4 mg, 0.256 mmol). The mixture was heated in a microwave synthesizer at 180° C. for 1 hour. After the solvent was evaporated, the compound was then subjected to purification by prep HPLC to give cis-2-(2-chloro-phenylsulfanyl)-N-[4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide trifluoroacetate (23.2 mg, 30%) as a white solid.

ESI-MS m/e 497.4 M+H⁺;

To a solution of cis-2-(2-chloro-phenylsulfanyl)-N-[4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide trifluoroacetate (23.2 mg, 0.038 mmol) in 1 mL CH₂Cl₂ was added 3-chloroperoxybenzoic acid (31.5 mg 0.14 mmol). The reaction mixture was stirred for 15 h and quenching with NaHCO₃. The solvent was evaporated and compound was then subjected to purification by prep HPLC to give 2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide trifluoroacetate (8.9 mg, 0.014 mmol, 36%) as a white solid.

ESI-MS m/e 529.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 11.98 (s, 1H), 8.61-8.59 (m, 2H), 8.24-8.21 (dd, J=4 Hz, 4 Hz, 1H), 8.08-8.06 (d, J=8 Hz, 1H), 7.79-7.74 (m, 2H), 7.71-7.69 (t, J=4 Hz, 1H), 7.64-7.62 (d, J=8 Hz, 1H), 7.58 (bs, 1H), 6.32 (s, 1H), 3.94 (bs, 2H), 3.21(s, 3H), 3.15 (s, 3H), 2.28 (s, 3H), 1.84-1.78 (m, 8H).

Example 3250

N-(cis-4-{[(4-Methylquinolin-2-yl)methyl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 4-methyl-2-vinyl-quinoline.

To 50 mL toluene in a 150 mL rounded-bottom flask, was added 2-chlorolepidine (1 g, 63 mmol), tetrakis (triphenylphonsine) palladium (0) (65 mg, 0.63 mmol), triphenyl phosphine (0.495 g, 1.89 mmol) and vinyltributyl tin (2.2 g,6.76 mmol). The mixture was refluxed at 116° C. under N₂ for 2 hours. The reaction mixture was concentrated and purified by silica gel with 0-10% EtOAc/Hexane to yield 4-methyl-2-vinyl-quinoline (720 mg, 4.26 mmol, 76%).

ESI MS m/e: 170.0 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.96 (d, J=8 Hz, 1H), 7.85 (d, J=8 Hz, 1H), 7.58 (dd, J₁=J₂=8 Hz, 1H), 7.43 (dd, J₁=J₂=8 Hz, 1H), (7.15 (s, 1H), 6.89 (dd, J₁=16 Hz, J₂=12 Hz, 1H), 6.15 (d, J=16 Hz, 1H), 5.54 (d, J=8 Hz, 1H), 2.60 (s, 3H).

Step B: Synthesis of 4-methyl-quinoline-2-carbaldehyde.

To a 500 mL rounded bottom flask filled with 40 mL 90% THF/H₂O was added 4-methyl-2-vinyl-quinoline (1.2 g, 7.1 mmol) NMO (1.29 g, 10.65 mmol), and OsO₄ (1.3 mL, 0.21 mmol) under N₂. The mixture was stirred at room temperature overnight under N₂. The reaction mixture was quenched with saturated solution of Na₂S₂O₃, and the organic phase was then extracted EtOAc (100 mL×4. The organic layer was combined and washed with brine, and concentrated. The crude product, 1-(4-methyl-quinolin-2-yl)-ethane-1,2-diol (1.5 g), was directly used to next Step without further purification.

To 60 mL 90% THF/H₂O, was added 1.5 g of the crude 1-(4-methyl-quinolin-2-yl)-ethane1,2-diol and NaIO₄ (1.4 g, 8.86 mmol). The mixture was stirred at room temperature under N₂ for 6 hours. The organic phase was extracted with EtOAc (100 mL×4, combined, and dried by anhydrous MgSO₄. It was concentrated to purify by silica gel column using 0-5% EtOAc/Hexane to yield 4-methyl-quinoline-2-carbaldehyde (600 mg, 3.5 mL, 49.4%).

ESI MS m/e: 172.0 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 10.2 (s, 1H), 8.25 (d, J=8 Hz, 1H), 8.07 (d, J=8 Hz, 1H), 7.88 (s, 1H), 7.82 (dd,J₁=J₂=8 Hz, 1H), 7.71 (dd,J₁=J₂=8 Hz, 1H), 2.79 (s, 3H).

Step C: Synthesis of resin bound cis-(4-amino cyclohexyl) carbamic acid fluorenylmethyl ester.

In a 30 mL manual synthesis vessel, 2-(3,5-dimethoxy-4-formyl) phenoxy ethyl polystyrene resin (0.5 gram; 0.90 mmol/gram) and cis-(4-amino cyclohexyl) carbamic acid fluorenylmethyl ester 2 (453 mg, 1.35 mmol) were suspended in 4 mL of DMF. To this suspension was added a solution of NaBH(OAc)₃ (299 mg, 1.35 mmol) in 1% acetic acid/DMF solution (4 ml). After shaking the mixture overnight in a rotary shaker, the solution was removed by filtration and the resin washed sequentially with DMF, 10% DIEA/DMF, DMF, DCM and MeOH. The washing sequence was repeated four times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step D: Synthesis of resin bound-cis-[4-(4-methyl-quinolin-2-methyl-amino)-cyclohexyl]-carbamic acid flourenylmethyl ester.

To the resin bound intermediate (0.315 mmol) was added 4-methyl-quinoline-2-carbaldehyde (96 mg, 0.564 mmol) in dimethyl acetamide (5 mL) and 1% acetic acid (0.050 mL). The resin suspension was mixed in a rotary shaker for 1 hour at room temperature. Sodium cyanoborohydride (195 mg, 3.15 mmol) was added to the resin suspension and the reaction was mixed overnight at room temperature. At the completion of the reaction, the solution was filtered and the resin washed sequentially with DMF, 10% DIEA/DMF, DMF, DCM and MeOH. The washing sequence was repeated four times. The resulting resin bound intermediate 5 was dried under vacuum for 20 minutes

Step E: Synthesis of N-(cis4-{[(4-methylquinolin2-yl)methyl]amino}cyclohexyl)-3,5-bis(trifluoromethyl) benzamide trifluoroacetate.

The resin bound intermediate (0.171 mmol) was treated with 20% piperidine in DMF (3 mL) for 30 minutes at room temperature. After 30 minutes, the solution was filtered and the resin washed with DMF, DCM and MeOH. The washing sequence was repeated four times.

The deprotected resin bound intermediate was suspended in DMF (1.0 mL). 3,5 bis-trifluoromethylbenzoyl chloride (47 mg, 0.171 mmol) was added to the resin suspension followed by triethylamine (0.0519 mL, 0.513 mmol). The reaction was mixed for 30 minutes at room temperature. The solution was then filtered and the resin washed sequentially with DMF, DCM and MeOH. The washing sequence was repeated four times.

After drying under vacuum for 20 minutes, the resin bound intermediate was treated with 5 mL of TFA solution (TFA/CH₂Cl₂/H₂O 20:20:1 v/v). The reaction was shaken for 2 hours and the TFA solution was collected after filtration. The TFA was removed by rotary evaporation and the compound subjected to purification by preparative HPLC to give N-(cis-4-{[(4-methyl quinolin-2-yl)methyl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide trifluoroacetate (3.8 mg; 8%) as a white solid.

ESI MS m/e 510.2 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.56 (m, 1H), 8.42 (s, 2H), 8.19 (m, 3H), 7.82 (m, 1H), 7.69 (m, 1H), 7.39 (s, 1H), 4.6 (s, 2H), 4.14 (m, 1H), 3.40 (m, 1H), 2.78 (s, 3H), 2.22-1.81 (m, 8H).

Example 3251

cis-N-[(1S)-1-(4-Chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid.

A mixture of (2-chloro-5-methyl-pyrimidin-4-yl)-dimethyl-amine (28.9 g, 0.186 mol) and 4-amino-cyclohexanecarboxylic acid (20 g, 0.140 mol) in 100 mL of toluene was stirred at room temperature for 5 minutes to form a slurry under N₂. To the slurry, was added Pd(OAc)₂ (0.34 g, 1.5×10⁻³ mol), 2-(di-t-butylphosphine) biphenyl (0.24, 0.8 mmol) and NaOtBu (33.64 g, 0.35 mol). The mixture was heated and refluxed at 118° C. under N₂ for 2 hours. The reaction mixture was concentrated to give a brown solid. The above brown solid was dissolved with 100 mL MeOH and 5 mL H₂O, neutralized with acetic acid. The precipitate was filtered and washed with cold water (5 mL×2) and toluene (100 mL×2) to yield cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic acid (36.7 g, 0.132 mol, 94%) as a white solid.

ESI MS m/e 279 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.46 (s, 1H), 4.20 (s, 1H), 3.3 (s, 6H), 3.2 (s, 1H), 2.48 (m, 1H), 2.27 (s, 3H), 2.15-1.63 (m, 8H).

Step B: Synthesis of cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate.

To a solution of (S)-1-(4-chloro-phenyl)-ethylamine (61.5 mg, 0.395 mmol) in 10 mL DCM was added cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexanecarboxylic (100 mg, 0.395 mmol), HATU (150 mg, 0.395 mmol), and 5 drops of Et₃N. The reaction mixture was stirred at room temperature under N₂ overnight. The solvent was evaporated and the material subjected to prep-HPLC to give cis-N-[(1S)-1-(4-chlorophenyl)ethyl]4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide trifluoroacetate (20 mg, 0.048 mmol, 13.4%) as a white solid.

ESI MS m/e 416.3 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 8.24-8.12 (d, 1H), 7.55 (s, 1H), 7.32-7.10 (m, 4H), 4.87 (m, 1H), 2.47 (s, 6H), 2.28 (bs, 1H), 2.18 (s, 3H), 1.81-1.39 (m, 8H), 1.31(d, 3H).

Example 3252

cis-N-[(1R)-1-(4-Bromophenyl)ethyl]-4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide trifluoroacetate

Step A: Synthesis of cis-4-(4-methylquinolin-2-ylamino}cyclohexanecarboxylic acid.

A mixture of 2-chloro-4-methyl-quinoline (6.67, 0.0375 mol) and 4-amino-cyclohexanecarboxylic acid (4.48 g, 0.0312 mol) was dissolved in 100 mL of toluene and stirred at room temperature for 5 minutes to form a slurry under N₂. To the slurry, was added Pd(OAc)₂ (0.077 g, 3.43×10⁻⁴ mol), 2-(di-t-butylphosphine) biphenyl (0.093, 3.12×10⁻⁴ mol) and NaOtBu (7.5 g, 0.078 mol). The above material was heated and refluxed at 118° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give a brown solid. The above brown solid was dissolved with 100 mL MeOH and 5 mL H₂O, neutralized with acetic acid. The precipitates were filtered and washed with cold water (5 mL×2) and toluene (100 mL×2) to yield cis-4-(4-methylquinolin-2-ylamino)cyclohexanecarboxylic acid (7.45 g, 0.026 mol, 84%) as a white solid.

ESI MS m/e 285.1 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.78 (d, 1H), 7.49 (m, 1H), 7.21 (m, 1H), 6.85 (d, 1H), 6.72 (s, 1H), 4.19 (s, 1H), 2,54-2.53 (m, 2H), 2.46 (s, 3H).

Step B: Synthesis of cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide trifluoroacetate.

To a solution of (R)-1-(4-bromo-phenyl)-ethylamine (77.4 mg, 0.39 mmol) in 10 mL DCM was added cis-4-(4-methylquinolin-2-ylamino}cyclohexanecarboxylic acid (100 mg, 0.35 mmol), HATU (148 mg, 0.39 mmol), and 5 drops of Et₃N. The reaction mixture was stirred at room temperature under N₂ overnight. The solvent was evaporated and the material subjected to prep HPLC to give cis-N-[(1R)-1-(4-bromophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide trifluoroacetate (24 mg, 0.052 mmol, 14.7%) as white solid.

ESI MS m/e 468.2 M+H⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 9.18-9.07 (s, 1H), 7.94-7.84 (t, 1H), 7.74-7.68 (t, 1H), 7.46 7.42 (m, 2H), 7.22 7.17 (m, 2H), 7.00 6.94 (s, 1H), 4.86 (m, 1H), 4.11 (s,1H), 2.58 (s, 3H), 2.40-2.23 (m, 2H), 1.88-1.49 (m, 8H), 1.33-1.19 (d, 3H).

Example 3253

trans-2-(4-Chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate

Step A: Synthesis of trans-3-(4-chlorophenyl)-N-methoxy-N-methylacrylamide.

A solution of 4-chlorobenzalehyde (3 g, 21.34 mmol) and N-methoxy-N-methyl-2-(triphenylphosphoranylidene)acetamide (8.5 g, 23.47 mmol) in CH₂Cl₂ was stirred at room temperature for 16 h. The solvent was removed in vacuo, and the crude product was purified by column chromatography on silica gel (0-20% EtOAc/Hex) to afford trans3-(4-chlorophenyl)-N-methoxy-N-methylacrylamide (4.78 g, 99%) as colorless crystals.

ESI MS m/e 226.1 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J=5.6 Hz, 1H), 7.45 (d, J=8.4 Hz, 2H), 7.33 (d, J=8.4 Hz, 2H), 6.99 d, J=5.6 Hz, 1H), 3.75 (s, 3H), 3.29 (s, 3H).

Step B: Synthesis of N-methoxy-N-methyl trans-2-(4-chlorophenyl) cyclo-propanecarbxoamide.

To a solution of trimethylsulfoxonium iodide (9.3 g, 42.4 mmol) in DMSO (40 mL) was added sodium hydride (1.7 g, 42.4 mmol) at room temperature in portions. After 1 h, a solution of trans-3-(4-chlorophenyl)-N-methoxy-N-methylacrylamide (4.78 g, 21.2 mmol) in DMSO (20 mL) was added via cannula at r.t. The mixture was stirred for another 6 h, and then it was quenched with saturated aqueous NH₄Cl solution, extracted with CH₂Cl₂, washed with brine and dried over anhydrous MgSO₄. The crude product was purified by column chromatography (0-50% EtOAc/Hex)to afford N-methoxy-N-methyl-trans-2-4-chlorophenyl)cyclopropanecarboxamide as colorless oil (4.76 g, 88.5%).

ESI MS m/e 239.9 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 7.24 (d, J=8 Hz, 2H), 7.06 (d, J=8 Hz, 2H), 3.69 (s, 3H), 3.23 (s, 3H), 2.47 (m, 1H), 2.37 (bs, 1H), 1.63 (m, 1H), 1.27 (m, 1H).

Step C: Synthesis of trans-2-(4-chloro-phenyl)cyclopropanecarboxylic acid.

A suspension of afford N-methoxy-N-methyl-trans-2-(4-chlorophenyl)cyclopropanecarboxamide (4.76 g, 18.76 mmol) and potassium tert-butoxide (4.76 g, 18.76 mmol) in the TBME (130 mL) and water (0.68 mL, 37.5 mmol) was stirred at room temperature for 16 h. The mixture was acidified by slowly adding concentrated HCl, and the aqueous mixture was extracted with CH₂Cl₂ (3×60 mL). The combined organic layers were washed with brine and dried over anhydrous MgSO₄. The solvent was removed in vacuo and the product was obtained as white solid (3.447 g, 93.5%)

ESI MS m/e 197.0 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 11.4 (bs, 1H), 7.28 (d, J=8.4 Hz, 2H), 7.06 (d, J=8.4 Hz, 2H), 2.60 (ddd, J₁=9.5 Hz, J₂=6.6 Hz, J₃=4.1 Hz, 1H), 1.89 (ddd, J₁=9.5 Hz, J₂=5.2 Hz, J₃=4.2 Hz, 1H), 1.69 (dt, J₁=9.5 Hz, J₂=5.1 Hz, 1H), 1.40 (ddd, J₁=8.4 Hz, J₂=5.2 Hz, J₃=4.3 Hz, 1H).

Step D: Synthesis of trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate.

To a mixture of trans-2-(4-chloro-phenyl)cyclopropanecarboxylic acid (22.1 mg, 0.112 mmol) and 2-chloro-4-dimethylamino-5-methylpyrimidine (28 mg, 0.112 mmol) in CH₂Cl₂ (5 mL) was added HATU (42.6 mg, 0.112 mmol)at r.t. After 30 sec Et₃N (5 drops) was added dropwise. The mixture was stirred overnight. trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide trifluoroacetate (20 mg, 37%) was obtained from prep-HPLC.

ESI MS m/e: 428.4 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (bs, 1H), 7.23 (d, J=8 Hz, 2H), 7.02(d, J=8 Hz, 2H), 6.28 (d, J=8 Hz, 1H), 4.11 (m, 1H), 3.99 (m, 1H), 3.29 (s, 6H), 2.45 (ddd, J₁=12 Hz, J₂=8 Hz, J₃=4 Hz, 1H), 2.25 (s, 3H), 1.85-1.65 (m, 1H), 1.58 (dt, J₁=8 Hz, J₂=4 Hz, 1H), 1.18 (dt, J₁=8 Hz, J₂=4 Hz, 1H).

Example 3254

N-{cis-4-[(4,5-Dimethylpyrimidin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide trifluoroacetate

Step A: Synthesis of 2-chloro-4,5-dimethylpyrimidine.

A mixture of 2,4-dichloro-5-methylpyrimidine (0.3 g, 1.84 mmol), AlMe₃ (0.3 mL, 2.0M) and Pd(PPh₃)₄ (85 mg, 4% mol) in dry THF (5 mL) was heated in a microwave synthesizer at 150° C. for 20 min. The solvent was removed in vacuo and the crude product subjected to chromatography (0-40% EtOAC/Hex) to yield 2-chloro-4,5-dimethylpyrimidine (0.13 g, 50%) as yellow solid.

ESI MS m/e: 143.1 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.24 (s, 1H), 2.45 (s, 3H), 2.22 (s, 3H).

Step B: Synthesis of N-{cis-4-[(4,5-dimethylpyrimidin-2-yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide trifluoroacetate.

A mixture of 2-chloro-4,5-dimethylpyrimidine (30 mg, 0.21 mmol), N-(cis-4-aminocyclohexyl)-3,5-bis(trifluoromethyl)benzamide (74.6 mg, 0.21 mmol), Pd(OAc)₂ (0.47 mg, 0.01 equiv.), dppf (1.16 mg, 0.01 equiv.) and KOtBu (59 mg, 0.53 mmol) in toluene (3 mL) was heated in a microwave synthesizer at 150° C. for 20 min. The solvent was removed in vacuo and the crude product subjected to purification by HPLC to give N-{cis4-[(4,5-dimethyl pyrimidin-2-yl)amino]cyclohexyl}3,5-bis(trifluoromethyl)benzamide trifluoroacetate (25 mg, 21%) as yellow solid.

ESI MS m/e 461.2 M+H⁺; ¹H NMR (400 MHz, CDCl₃) δ 8.36 (s, 3H), 7.99 (s, 1H), 4.47 (d, 1H), 4.23 (bs, 1H), 2.52 (s, 3H), 2.13 (s, 3H), 1.95-1.65 (m, 8H).

Example 3255

N-(3,4-Difluorophenyl)-N′-(cis-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate

Step A: Synthesis of N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate.

cis-N²-(4-Amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine2,4-diamine (30 mg, 0.12 mmol) was dissolved in 1 mL of DMSO. 1,2-Difluoro-4-isocyanato-benzene was added to the solution, and the solution was stirred overnight. The crude was purified by HPLC to give N-(3,4-difluoro phenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea trifluoroacetate as a white solid. (32.2 mg, 54.0%).

ESI MS m/e 405.3 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 13.45 (s, 1H), 8.35 (d, J=8.0 Hz, 1H), 7.67 (s, 1H), 7.52-7.47 (m, 1H), 7.28 7.26 (m, 1H), 7.07 6.99 (m, 2H), 4.00 (m, 1H), 3.96 (m, 1H), 3.32 (s, 6H), 2.27 (s, 3H), 1.78-1.67 (m, 8H).

Example 3256

2-[(3,4-Difluorophenyl)amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide

Step A: Synthesis of 2-[(3,4-difluorophenyl)amino]-N-(cis4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide.

3,4-Difluoro-aniline (20.6 uL, 0.204 mmol) was dissolved in 1.0 mL of DMF. NaH (8.2 mg, 0.204 mmol) was added to the solution and allowed to stir for 10 minutes. 2-Chloro-N-[4-(4-dimethylamino-5-methyl}-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide (40 mg, 0.102 mmol) was added and the mixture was stirred for another 5 minutes. The reaction was heated via Smith Synthesizer at 200° C. for 1 hour. The crude was purified by silica column chromatography. The column was flushed with 200 mL mixture methanol and methylene (1:9) and 100 mL of methanol to give 2-[(3,4-difluorophenyl)amino]-N-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide as a white solid. (30.0 mg, 61.2%)

ESI-MS m/z 482.5 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 8.32 (dd, J=4.8, 1.6 Hz, 1H), 7.92-7.86 (m, 1H), 7.71 (dd, J=7.6, J=1.6Hz, 1H), 7.64 (s, 1H), 7.19-7.03 (m, 2H), 6.76-6.73 (m, 1H), 6.34 (d, J=6.8 Hz, 1H), 4.95 (s, 1H), 4.11-4.03 (m, 2H), 2.96 (s, 6H), 2.15 (s, 3H), 1.90-1.68 (m, 8H).

Example 3257

N-(4-Chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea trifluoroacetate

Step A: Synthesis of N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea trifluoroacetate.

cis-N²-(4-Amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine2,4-diamine (75 mg, 0.30 mmol) and 1,1-carbonyldiimidazole (58 mg, 0.36 mmol) were dissolved in 1 mL of methylene chloride in a Smith Synthesizer vial and allowed to stir at room temperature overnight. To the vial, (4-chloro-phenyl)-ethyl-amine (94 mg, 0.60 mmol) was added. The solution was heated via Smith Synthesizer at 130° C. for 30 minutes. The solvent was evaporated, and 1 mL of methanol was added to the crude to redissolve it. The crude was then purified by HPLC to give N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea trifluoroacetate as a white solid. (25.0 mg, 15%)

ESI MS m/e 431.3 (M+H⁺); ¹H NMR (400 MHz, CDCl₃) δ 14.0 (s, 1H), 8.65 (d, J=6.4 Hz, 1H), 7.53 (dd, J=9.2, J=2.4 Hz, 2H), 7.43 (b, 1H), 7.28 (dd, J=9.2, J=2.4 Hz, 2H), 4.48 (bs, 1H), 4.16 (bs, 1H), 3.99 (m, 2H), 3.39 (s, 6H), 2.34 (s, 3H), 1.84-1.60 (m, 8H), 1.21 (t, J=7.0 Hz, 3H).

Example 3258

N-(cis-4-{[5-Methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}acetamide trifluoroacetate

Step A: Synthesis of resin bound N-methylamine.

2-(3,5-Dimethoxy-4-formyl)phenoxy ethyl polystyrene resin (1.0 gram; 0.90 mmol/gram) and methylamine 2 M in methanol (5.85 mL, 11.7 mmol) in 15 mL of CH₂Cl₂ was suspended in a fritted synthesis flask. To this suspension was added a solution of NaBH(OAc)₃ (0.0117 mol) in CH₂Cl₂ (15 mL). After shaking the mixture overnight in a rotary shaker, the solution was removed by filtration. The resulting resin bound N-methylamine was washed sequentially with CH₂Cl₂, DMF, and MeOH. The washing sequence was repeated four times. The resin bound N-methylamine was dried under vacuum for 20 minutes.

Step B: Synthesis of resin bound-4-(N-methyl-5-methyl-2-chloro)-pyrimidine.

The resin bound N-methylamine was suspended in DMF (10 mL). To the resin suspension was added 2,4-dichloro-5-methyl-pyrimidine (1.35 mmol) followed by triethylamine (0.273 mL, 2.70 mmol). The reaction mixture was shaken overnight at room temperature. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂ and MeOH. The wash sequence was repeated four times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step C: Synthesis of resin bound cis-N-(4-N-methyl-5-methyl-pyrimidyl-2yl)cyclohexane-1,4-diamine.

The resin bound intermediate was divided up into three portions and each portion was transferred into a 5 mL Smith synthesizer reaction vessel. The resins (0.272 mmol) were separately suspended in anhydrous dioxane (3 mL). To each suspension was added cis 1,4-diamino cyclohexane (0.405 mmol), tris(dibenzylidineacetone)dipalladium(O) (0.027 mol), 2,2 bisdiphenylphosphino-1,1 binapthyl (BINAP) (0.081 mmol) and sodium tert-butoxide (1.35 mmol). The reactions were heated in a microwave synthesizer at 140° C. for 20 minutes. At the completion of the reaction, the resin suspension was transferred to 8 mL fritted tubes. The solutions were removed by filtration. The resins were sequentially washed with MeOH, H₂O, MeOH, CH₂Cl₂, and MeOH. The washing sequence was repeated three times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step D: Synthesis of cis-N-[4-(4-N-methyl-5-methyl-pyrimidyl-2yl-amino)-cyclohexyl]-bromoacetamide.

The resin bound intermediate (0.27 mmol) was suspended in DCM (3 mL). To the resin suspension was added bromoacetyl bromide (0.27 mmol) and DIEA (0.094 mL; 0.54 mmol). The reaction was mixed in a rotary shaker for 45 minutes at room temperature. At the completion of the reaction, the solution was removed by filtration. The resin was sequentially washed with DCM, DMF, DCM, and MeOH. The washing sequence was repeated three times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step E: Synthesis of N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}acetamide trifluoroacetate.

The resin bound intermediate from Step D (0.27 mmol) was transferred into a 5 mL microwave synthesizer vial. The resin was suspended in anhydrous DMF (2 mL). To the resin suspension was added 4 hydroxy-2-trifluoromethyl pyrimidine (0.54 mmol) and potassium carbonate (0.54 mmol) The reaction was heated in a microwave oven at 140° C. for 30 minutes. At the completion of the reaction, the resin suspension was transferred to an 8 mL fritted tube. The solution was removed by filtration and the resin washed sequentially with DMF, DCM, MeOH. The wash sequence repeated three times.

After drying under vacuum for 20 minutes, the resin bound intermediate was treated with 5 mL of TFA solution (TFA/CH₂Cl₂/H₂O 20:20:1 v/v). The reaction was shaken for 2 hours and the TFA solution was collected after filtration. The TFA was removed by rotary evaporation and the compound subjected to purification by preparative HPLC to give N-(cis4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}acetamide trifluoroacetate 5%) as a white solid.

ESI MS m/e 440.3 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.69 (m, 1H), 7.45 (m, 1H), 7.21-7.17 (m, 1H), 4.95 (m, 2H), 4.03 (bs, 1H), 3.82 (bs, 1H), 3.04 (s, 3H), 1.98 (s, 3H), 1.93-1.61 (m, 8H).

Example 3259

2,2-Difluoro-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate

Step A: Synthesis of resin bound N-methylamine.

2-(3,5-Dimethoxy-4-formyl)phenoxy ethyl polystyrene resin (1.0 gram; 0.94 mmol/gram) and methylamine (0.0122 mol) in 15 mL of CH₂Cl₂ was suspended in a fritted synthesis flask. To this suspension was added a solution of NaBH(OAC)₃ (0.0122 mol) in CH₂Cl₂ (15 mL). After shaking the mixture overnight in a rotary shaker, the solution was removed by filtration. The resulting resin bound N-methylamine was washed sequentially with CH₂Cl₂, DMF, and MeOH. The washing sequence was repeated four times. The resin bound N-methylamine was dried under vacuum for 20 minutes.

Step B: Synthesis of resin bound-4-(N-methyl-6-methyl-2-chloro)-pyrimidine.

The resin bound N-methylamine was suspended in DMF (10 mL). To the resin suspension was added 2,4-dichloro-6-methyl-pyrimidine (1.41 mmol) followed by triethylamine (0.393 mL, 2.82 mmol). The reaction mixture was shaken at 40° C. overnight. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂ and MeOH. The wash sequence was repeated four times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step C: Synthesis of resin bound cis-N-(4-N-methyl-6-methyl-pyrimidyl-2yl)cyclohexane-1,4-diamine.

The resin bound intermediate was divided up into three portions and each portion was transferred into a 5 mL Smith synthesizer reaction vessel. The resins (0.282 mmol) were separately suspended in a 1:1 solution of IPA/H20 (3 mL). To each suspension was added cis 1,4-diamino cyclohexane (0.85 mmol) and DIEA (0.295 ml; 1.69 mmol). The reactions were heated in a microwave synthesizer at 180° C. for 4.5 hours. The resins were pooled together; and the solution removed by filtration. The resin was sequentially washed with IPA, H₂O, MeOH, CH₂Cl₂, and MeOH. The washing sequence was repeated three times. The resulting resin bound intermediate was dried under vacuum for 20 minutes.

Step D: Synthesis of 2,2-difluoro-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate.

The resin bound intermediate was suspended in DMF (8 mL). To the resin suspension was added the 2,2-diflouro 1,3 benzodioxole 5-carbonyl chloride (0.846 mmol) and triethylamine (0.256 mL; 1.69 mmol). The reaction was shaken in a rotary mixer at room temperature for 45 minutes. The solution was removed by filtration and the resin washed sequentially with DMF, CH₂Cl₂, MeOH. The wash sequence repeated three times.

After drying under vacuum for 20 minutes, the resin bound intermediate was treated with 15 mL of TFA solution (TFA/CH₂Cl₂/H₂O 20:20:1 v/v). The reaction was shaken for 2 hours and the TFA solution was collected after filtration. The TFA was removed by rotary evaporation and the compound subjected to purification by preparative HPLC to give 2,2-difluoro-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide trifluoroacetate (2.0 mg. 2%) as a white solid.

ESI MS m/e 420.5 M+H⁺; ¹H NMR (400 MHz, CD₃OD) δ (ppm): 8.24 (m, 1H), 7.72-7.68 (m, 2H), 7.31 7.29 (m, 1H), 5.86 (s, 1H), 4.18 3.99 (m, 2H), 2.99 (s, 3H), 2.25 (s, 3H), 1.93-1.80 (m, 8H).

Examples 3260-3262

Compounds 3260 to 3262 were prepared in a similar manner as described in Example 3242 using the appropriate bromoacetophemone and amine intermediate from Step A.

Examples 3263-3267

Compounds 3263 to 3267 were prepared in a similar manner as described in Example 3243 using the appropriate acid and amine intermediate from Step A.

Examples 3268-3272

Compounds 3268 to 3272 were prepared in a similar manner as described in Example 3244 using the appropriate isocyanate and amine intermediate from Step A.

Examples 3273-3275

Compounds 3723 to 3275 were prepared in a similar manner as described in Example 3245 using the appropriate amine and carboxylic intermediate from Step A.

Examples 3276-3280

Compounds 3276 to 3280 were prepared in a similar manner as described in Example 3246 using the appropriate acid chloride and amine intermediate from Step D.

Examples 3281-3291

Compounds 3281 to 3291 were prepared in a similar manner as described in Example 2656 using the appropriate thioderivative and amine intermediate from Step A.

Examples 3292-3303

Compounds 3292 to 3303 were prepared in a similar manner as described in Example 3251 using the appropriate amine and carboxylic intermediate from Step B.

Examples 3304-3307

Compounds 3304 to 3307 were prepared in a similar manner as described in Example 3252 using the appropriate amine and carboxylic intermediate from Step B.

Examples 3308

Compounds 3308 were prepared in a similar manner as described in Example 3251 using the appropriate amine and carboxylic intermediate from Step B.

Examples 3309-3315

Compounds 3309 to 3315 were prepared in a similar manner as described in Example 3252 using the appropriate amine and carboxylic intermediate from Step B.

Examples 3316-3320

Compounds 3316 to 3320 were prepared in a similar manner as described in Example 3253 using the appropriate aldehyde and amine intermediate from Step D.

Examples 3321-3345

Compounds 3321 to 3345 were prepared in a similar manner as described in Example 3255 using the appropriate isocyate and amine intermediate from Step A.

Examples 3346-3355

Compounds 3346 to 3355 were prepared in a similar manner as described in Example 3257 using the appropriate aniline and amine intermediate from Step A.

Examples 3356-3357

Compounds 3356 to 3357 were prepared in a similar manner as described in Example 2638 using the appropriate hydroxyaryl derivative and bromide intermediate from Step B.

Examples 3358-3359

Compounds 3358 to 3359 were prepared in a similar manner as described in Example 3259 using the appropriate acid chloride and amine intermediate from Step D.

Examples 3360-3365

Compounds 3360 to 3365 were prepared in a similar manner as described in Example 3259 using the appropriate hydroxyaryl derivative and bromide intermediate from Step E.

Examples 3366-3367

Compounds 3366 to 3367 were prepared in a similar manner as described in Example 3250 using the appropriate acid chloride derivative and amine intermediate from Step E.

Examples 3368-3381

Compounds 3368 to 3381 were prepared in a similar manner as described in Example 3249 using the appropriate thiophenol and nicotinamide intermediate from Step A.

Example 3382

Compound 3382 was prepared in a similar manner as described in Example 2497 using 4-trifluoromethoxy-benzoyl chloride and the amine intermediate from Step E.

Ex. No.	Compound name	MS	class
3260	1-(4-chlorophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-	402.4 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)amino]ethanone
3261	1-(3,4-difluorophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-	404.4 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)amino]ethanone
3262	1-(4-bromophenyl)-2-[(cis-4-{[4-(dimethylamino)-5-	446.3 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)amino]ethanone
3263	N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-	547.6 (M + H)	2
	{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-
	cyclohexyl)urea
3264	N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-	445.3 (M + H)	1
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3265	N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-	445.2 (M + H)	2
	(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3266	N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-	443.3 (M + H)	1
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3267	N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-	443.4 (M + H)	1
	(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3268	N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-	561.4 (M + H)	3
	{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-
	N-methylurea
3269	N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-	459.6 (M + H)	1
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-
	methylurea
3270	N-[1-(4-chiorophenyl)-1-methylethyl]-N′-(cis-4-{[4-	459.5 (M + H)	2
	(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-N-
	methylurea
3271	N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-	457.5 (M + H)	2
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-
	methylurea
3272	N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-	457.2 (M + H)	3
	(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-N-
	methylurea
3273	cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-	430.3 (M + H)	2
	5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3274	cis-N-[1-(4-chlorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-	430.4 (M + H)	3
	6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3275	cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-	532.3 (M + H)	3
	(dimethylamino)-6-methylpyrimidin-2-
	yl]amino}cyclohexanecarboxamide
3276	4-chloro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-	375.1 (M + H)	3
	yl)amino]cyclohexyl}benzamide
3277	N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-	425.1 (M + H)	3
	yl)amino]cyclohexyl}-4-(trifluoromethoxy)benzamide
3278	3,4-dichloro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-	408.9 (M + H)	2
	yl)amino]cyclohexyl}benzamide
3279	3,5-dichloro-N-{cis-4-[(4-methoxy-5-methylpyrimidin-2-	409.1 (M + H)	3
	yl)amino]cyclohexyl}benzamide
3280	N-{cis-4-[(4-methoxy-5-methylpyrimidin-2	477.2 (M + H)	3
	yl)amino]cyclohexyl}-3,5-bis(trifluoromethyl)benzamide
3281	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	513.4 (M + H)	1
	yl]amino}cyclohexyl)-2-[(4-fluorophenyl)sulfonyl]nicotinamide
3282	2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	529.4 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3283	2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	529.4 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3284	2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	529.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3285	2-[(3-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	573.6 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3286	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	525.4 (M + H)	3
	yl]amino}cyclohexyl)-2-[(4-methoxyphenyl)sulfonyl]-
	nicotinamide
3287	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	563.5 (M + H)	2
	yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}-
	nicotinamide
3288	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	509.6 (M + H)	2
	yl]amino}cyclohexyl)-2-[(4-methylphenyl)sulfonyl]nicotinamide
3289	2-[(4-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-	573.5 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3290	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	499.4 (M + H)	3
	yl]amino}cyclohexyl)-2-[(2-methyl-3-furyl)sulfonyl]nicotinamide
3291	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	563.5 (M + H)	2
	yl]amino}cyclohexyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}-
	nicotinamide
3292	cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-	416.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3293	cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-	518.4 (M + H)	3
	(dimethylamino)-5-methylpyrimidin-2-
	yl]amino}cyclohexanecarboxamide
3294	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]aminol}-N-	400.3 (M + H)	3
	[(1R)-1-(2-fluorophenyl)ethyl]cyclohexanecarboxamide
3295	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-	400.3 (M + H)	3
	[(1S)-1-(2-fluorophenyl)ethyl]cyclohexanecarboxamide
3296	cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-	460.3 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3297	cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-	460.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3298	4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-	450.2 (M + H)	1
	1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3299	4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1R)-	450.3 (M + H)	1
	1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3300	4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-	450.4 (M + H)	1
	1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3301	4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1R)-	450 (M + H)	3
	1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3302	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-	466.4 (M + H)	1
	N-{(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}-
	cyclohexanecarboxamide
3303	cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-	466.4 (M + H)	2
	N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}-
	cyclohexanecarboxamide
3304	cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin-2-	466.4 (M + H)	3
	yl)amino]cyclohexanecarboxamide
3305	cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-[(4-methylquinolin-2-	422.3 (M + H)	2
	yl)amino]cyclohexanecarboxamide
3306	cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-[(4-methylquinolin-2-	422.4 (M + H)	2
	yl)amino]cyclohexanecarboxamide
3307	cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1R)-1-[3-	456.3 (M + H)	1
	(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3308	cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-	460 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexanecarboxamide
3309	cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-[(4-	524.2 (M + H)	2
	methylquinolin-2-yl)amino]cyclohexanecarboxamide
3310	cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1R)-1-[4-	472.4 (M + H)	3
	(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide
3311	cis-N-[(1R)-1-(2-fluorophenyl)ethyl]-4-[(4-methylquinolin-2-	406.2 (M + H)	3
	yl)amino]cyclohexanecarboxamide
3312	cis-N-[(1S)-1-(2-fluorophenyl)ethyl]-4-[(4-methylquinolin-2-	406.3 (M + H)	1
	yl)amino]cyclohexanecarboxamide
3313	cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1R)-1-[2-	456.2 (M + H)	2
	(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3314	cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[2-	456.3 (M + H)	1
	(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3315	cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[3-	456 (M + H)	1
	(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide
3316	trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	428.4 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
3317	trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	428 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
3318	trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	430.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
3319	trans-2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-	462.3 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
3320	trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-	530.2 (M + H)	1
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-
	cyclopropanecarboxamide
3321	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	399.3 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-methoxyphenyl)urea
3322	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	399.3 (M + H)	3
	yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)urea
3323	N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	429.4 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3324	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	387.5 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-fluorophenyl)urea
3325	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	387.4 (M + H)	2
	yl]amino}cyclohexyl)-N′-(3-fluorophenyl)urea
3326	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	387.4 (M + H)	1
	yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea
3327	N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	405.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3328	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	437.3 (M + H)
	yl]amino}cyclohexyl)-N′-[3-(trifluoromethyl)phenyl]urea
3329	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	437.2 (M + H)
	yl]amino}cyclohexyl)-N′-[4-(trifluoromethyl)phenyl]urea
3330	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	453.1 (M + H)	1
	yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea
3331	N-(3-chloro-4-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	421.1 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3332	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	455.3 (M + H)
	yl]amino}cyclohexyl)-N′-[4-fluoro-3-(trifluoromethyl)-
	phenyl]urea
3333	N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	403.2 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3334	N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	505.3 (M + H)	2
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3335	N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	447.1 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3336	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	383.2 (M + H)	2
	yl]amino}cyclohexyl)-N′-(2-methylphenyl)urea
3337	N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	437.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3338	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	437.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3339	N-(3,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	437.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3340	N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	403.4 (M + H)
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3341	N-benzyl-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	383.5 (M + H)	2
	yl]amino}cyclohexyl)urea
3342	N-(2,5-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	437.3 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3343	N-(2,3-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	437.3 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)urea
3344	N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	471.3 (M + H)	3
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea
3345	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	471.3 (M + H)	1
	yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea
3346	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	401.2 (M + H)	3
	yl]amino}cyclohexyl)-N-(2-fluorophenyl)-N-methylurea
3347	N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	417.1 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea
3348	N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	451.2 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea
3349	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	481.3 (M + H)	2
	yl]amino}cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy)-
	phenyl]urea
3350	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	397.1 (M + H)	1
	yl]amino}cyclohexyl)-N-ethyl-N-phenylurea
3351	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	481.1 (M + H)	1
	yl]amino}cyclohexyl)-N-ethyl-N-[4-(trifluoromethoxy)-
	phenyl]urea
3352	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	467.2 (M + H)	1
	yl]amino}cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)-
	phenyl]urea
3353	N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-	431.3 (M + H)	1
	methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea
3354	N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-	533.1 (M + H)	1
	(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-
	ethylurea
3355	N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	411.3 (M + H)	1
	yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea
3356	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	456.4 (M + H)	1
	yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-
	pyrazol-5-yl]oxy}acetamide
3357	N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-	454.2 (M + H)	3
	yl]amino}cyclohexyl)-2-{[6-(trifluoromethyl)pyrimidin-4-
	yl]oxy}acetamide
3358	2,2-difluoro-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-	420.5 (M + H)
	yl]amino}cyclohexyl)-1,3-benzodioxole-5-carboxamide
3359	4-chloro-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-	442.1 (M + H)
	yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide
3360	2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-	438.3 (M + H)	1
	(methylamino)pyrimidin-2-yl]amino}cycohexyl)acetamide
3361	N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-	440.3 (M + H)
	cyclohexyl)-2-{[2-(trifluoromethyl)pyrimidin-4-yl]oxy}-
	acetamide
3362	N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-	442.5 (M + H)	3
	cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-
	yl]oxy}acetamide
3363	N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-	440.3 (M + H)	3
	cyclohexyl)-2-{[6-(trifluoromethyl)pyrimidin-4-yl]oxy}acetamide
3364	N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-	442.4 (M + H)	3
	cyclohexyl)-2-{[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-
	yl]oxy}acetamide
3365	N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}-	428.2 (M + H)
	cyclohexyl)-2-{[3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}-
	acetamide
3366	3,4-difluoro-N-(cis-4-{[(4-methylquinolin-2-	410.3 (M + H)	3
	yl)methyl]amino}cyclohexyl)benzamide
3367	3-chloro-N-(cis-4-{[(4-methylquinolin-2-	408.3 (M + H)
	yl)methyl]amino}cyclohexyl)benzamide
3368	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	513.5 (M + H)	2
	yl]amino}cyclohexyl)-2-[(4-fluorophenyl)sulfonyl]nicotinamide
3369	2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	513.5 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3370	2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	529.1 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3371	2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	529.1 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3372	2-[(2-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	573.3 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3373	2-[(3-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	575.4 (M + H)	2
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3374	2-[(4-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-	573.2 (M + H)	3
	methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide
3375	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	509.5 (M + H)	2
	yl]amino}cyclohexyl)-2-[(2-methylphenyl)sulfonyl]nicotinamide
3376	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	509.5 (M + H)	3
	yl]amino}cyclohexyl)-2-[(3-methylphenyl)sulfonyl]nicotinamide
3377	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	509.5 (M + H)	2
	yl]amino}cyclohexyl)-2-[(4-methylphenyl)sulfonyl]nicotinamide
3378	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	525.3 (M + H)	3
	yl]amino}cyclohexyl)-2-[(2-methoxyphenyl)sulfonyl]-
	nicotinamide
3379	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	525.3 (M + H)	3
	yl]amino}cyclohexyl)-2-[(3-methoxyphenyl)sulfonyl]-
	nicotinamide
3380	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	525.3 (M + H)	3
	yl]amino}cyclohexyl)-2-[(4-methoxyphenyl)sulfonyl]-
	nicotinamide
3381	N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-	563.4 (M + H)	3
	yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]-
	sulfonyl}nicotinamide
3382	N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-4-	444.4 (M + H)	1
	(trifluoromethoxy)benzamide

Example 3383

4-Chloro-N-[cis-4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride

Step A: Synthesis of 4-chloro-N-[cis4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride.

To a solution of N²-(cis-4-amino-cyclohexyl)-6,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine obtained in step A of example 3127 (300 mg) in DMF (3 mL) were added 4-chloro-3-fluoro-benzoic acid (252 mg), Et₃N (0.42 mL), HOBt-H₂O (276 mg), and EDC-HCl (277 mg). The reaction mixture was stirred at ambient temperature for 1 day. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 15% to 60% EtOAc in hexane). The solution of the above purified material in EtOAc (5 mL) was added 4 M hydrogen chloride in EtOAc (10 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (20 mL) and the suspension was stirred at ambient temperature for 2 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride (335 mg) as a white solid.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.01 (m, 8H), 2.35 (s, 3H), 3.14 (s, 3H), 3.26 (s, 3H), 4.02 4.31 (m, 2H), 5.74 (s, 1H), 6.84 6.96 (m, 1H), 7.40-7.49 (m, 1H), 7.53-7.60 (m, 1H), 7.69 (dd, J=9.7, 1.9 Hz, 1H), 8.48-8.65 (m, 1H), 12.93 13.08 (m, 1H).

Example 3384

3-Chloro-N-[cis-4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]5-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]5-fluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3383, the title compound was obtained.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.05 (m, 8H), 2.36 (s, 3H), 3.15 (s, 3H), 3.26 (s, 3H), 4.01 4.30 (m, 2H), 5.75 (s, 1H), 6.45 6.54 (m, 1H), 7.17-7.23 (m, 1H), 7.40-7.47 (m, 1H), 7.57 7.61 (m, 1H), 8.60 8.71 (m, 1H), 13.07 13.19 (m, 1H).

Example 3385

N-[cis-4-(4-Dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3383, the title compound was obtained.

ESI MS m/e 408, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.62-2.01 (m, 8H), 2.36 (s, 3H), 3.14 (s, 3H), 3.26 (s, 3H), 4.00 4.32 (m, 2H), 5.75 (s, 1H), 6.70 6.81 (m, 1H), 7.47-7.59 (m, 2H), 8.54-8.66 (m, 1H), 12.92-13.08 (m, 1H).

Example 3386

3-Chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride

Step A: Synthesis of (2-chloro-5-methyl-pyrimidin-4-yl)-methyl-amine.

To the solution of 2,4-dichloro-5-methylpyrimidine (5.00 g) in THF (50 mL) were added iPr₂NEt (6.4 mL) and 40% aqueous MeNH₂ (4.78 mL). The mixture was stirred at ambient temperature for 12 hr and concentrated under reduced pressure. To the residue was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 9% to 20% EtOAc in hexane) to give (2-chloro-5-methyl-pyrimidin-4-yl)-methyl-amine (3.55 g) as a white solid.

ESI MS m/e 408, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 2.01 (d, J=0.8 Hz, 3H), 3.07 (d, J=5.0 Hz, 3H), 4.89-5.06 (m, 1H), 7.79 (s, 1H).

Step B: Synthesis of 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide hydrochloride.

Using the procedure for the step B of example 3228, the title compound was obtained.

ESI MS m/e 392, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.64-1.98 (m, 11H), 2.94 (d, J=4.5 Hz, 3H), 3.80-4.08 (m, 2H), 7.48 7.67 (m, 2H), 7.87 7.95 (m, 1H), 8.08 8.51 (m, 4H), 11.95-12.03 (m, 1H).

Example 3387

4-Chloro-N-[cis-4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride

Step A: Synthesis of 4-chloro-N-[cis4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride

To a solution of N²-(cis-4-amino-cyclohexyl)-5,N⁴,N⁴-trimethyl-pyrimidine-2,4-diamine obtained in step C of example 3119 (250 mg) in DMF (4 mL) were added 4-chloro-3-fluoro-benzoic acid (209 mg), Et₃N (0.36 mL), HOBt-H₂O (230 mg), and EDC-HCl (230 mg). The reaction mixture was stirred at ambient temperature for 16 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 40% EtOAc in hexane). The solution of the above purified material in EtOAc (10 mL) was added 4 M hydrogen chloride in EtOAc (0.5 mL). The mixture was stirred at ambient temperature for 1 hr and concentrated. The residue was suspended in Et₂O (10 mL) and the suspension was stirred at ambient temperature for 4 hr. The precipitate was collected by filtration, washed with Et₂O, and dried at 80° C. under reduced pressure to give 4-chloro-N-[cis4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide hydrochloride (208 mg) as a white solid.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65 2.00 (m, 8H), 2.26 (s, 3H), 3.31 (s, 6H), 3.98-4.27 (m, 2H), 6.53 6.72 (m, 1H), 7.20 7.27 (m, 1H), 7.41 7.59 (m, 2H), 7.64-7.73 (m, 1H), 8.53-8.73 (m, 1H), 12.76-12.95 (m, 1H).

Example 3388

3-Chloro-N-[cis-4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]5-fluoro-benzamide hydrochloride

Step A: Synthesis of 3-chloro-N-[cis4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]5-fluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3387, the title compound was obtained.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.64-2.01 (m, 8H), 2.26 (s, 3H), 3.30 (s, 6H), 4.02-4.25 (m, 2H), 7.02 7.28 (m, 3H), 7.46 7.53 (m, 1H), 7.63 7.68 (m, 1H), 8.48-8.60 (m, 1H), 12.70-12.84 (m, 1H).

Example 3389

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide hydrochloride.

Using the procedure for the step A of example 3387, the title compound was obtained.

ESI MS m/e 408, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.60-2.02 (m, 8H), 2.26 (s, 3H), 3.31 (s, 6H), 4.01-4.26 (m, 2H), 6.65 6.76 (m, 1H), 7.21 7.29 (m, 1H), 7.48 7.60 (m, 2H), 8.57-8.69 (m, 1H), 12.73-12.91 (m, 1H).

Example 3390

N-[cis-4-(4-Dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide hydrochloride.

Using the procedure for the step D of example 3119, the title compound was obtained.

ESI MS m/e 390, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.61-2.06 (m, 8H), 2.26 (s, 3H), 3.31 (s, 6H), 4.01-4.29 (m, 2H), 6.55 6.70 (m, 1H), 6.84 7.01 (m, 1H), 7.18 7.43 (m, 3H), 8.54-8.71 (m, 1H), 12.77-12.97 (m, 1H).

Example 3391

2-(3,4-Difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3387, the title compound was obtained.

ESI MS m/e 404, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.57-1.94 (m, 8H), 2.24 (s, 3H), 3.29 (s, 6H), 3.47 (s, 2H), 3.80 3.97 (m, 1H), 4.05 4.18 (m, 1H), 6.01 6.15 (m, 1H), 6.95-7.28 (m, 4H), 8.46-8.86 (m, 1H), 12.81-13.01 (m, 1H).

Example 3392

N-[cis-4-(4-Amino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-chloro-4-fluoro-benzamide hydrochloride

Step A: Synthesis of 2-chloro-5-methyl-pyrimidin-4-ylamine.

To the solution of 2,4-dichloro-5-methylpyrimidine (1.00 g) in IPA (2 mL) was added 28% aqueous NH₃ (2 mL). The mixture was heated in a microwave synthesizer at 120° C. for 20 min. To the mixture was added saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 50% EtOAc in hexane) to give 2-chloro-5-methyl-pyrimidin-4-ylamine (151 mg) as a white solid.

ESI MS m/e 143, M⁺; ¹H NMR (300 MHz, DMSOd₆) δ 1.94 (s, 3H), 7.81 (s, 1H).

Step B: Synthesis of N-[cis-4-(4-amino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-chloro-4-fluoro-benzamide hydrochloride.

Using the procedure for the step B of example 3228, the title compound was obtained.

ESI MS m/e 378, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.63 1.94 (m, 8H), 1.91 (m, 3H), 3.79-4.00 (m, 2H), 7.52 (t, J=8.9 Hz, 1H), 7.63 7.70 (m, 1H), 7.78 7.99 (m, 2H), 8.07-8.13 (m, 1H), 8.28-8.48 (m, 1H), 11.86-11.96 (m, 1H).

Example 3393

2-(3,4-Dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride

Step A: Synthesis of 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 438, M (free)⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.59-2.03 (m, 8H), 3.17 (s, 3H), 3.27 (s, 3H), 3.88-4.08 (m, 1H), 4.11-4.25 (m, 1H), 4.43 (s, 2H), 5.96 (d, J=7.5 Hz, 1H), 6.66-6.79 (m, 1H), 6.88 (dd, J=8.9, 3.0 Hz, 1H), 7.10 (d, J=3.0 Hz, 1H), 7.37 (d, J=8.9 Hz, 1H), 7.43-7.53 (m, 1H), 8.69-8.83 (m, 1H), 13.21 (brs, 1H).

Example 3394

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide hydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide hydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 400, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.63-2.03 (m, 8H), 3.16 (s, 3H), 3.27 (s, 3H), 3.82 (s, 3H), 3.92-4.08 (m, 1H), 4.09-4.23 (m, 1H), 4.45 (s, 2H), 5.96 (d, J=7.3 Hz, 1H), 6.47 6.64 (m, 3H), 6.75 6.90 (m, 1H), 7.14 7.25 (m, 1H), 7.40 7.56 (m, 1H), 8.62-8.79 (m, 1H), 13.29 (brs, 1H).

Example 3395

N-[cis-4-(4-Dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide dihydrochloride

Step A: Synthesis of N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide dihydrochloride.

Using the procedure for the step A of example 3198, the title compound was obtained.

ESI MS m/e 397, M (free)+H⁺; ¹H NMR (300 MHz, DMSO-d₆) δ 1.09 (t, J=7.0 Hz, 3H), 1.41-1.87 (m, 8H), 3.14 (s, 3H), 3.18 (s, 3H), 3.43 (q, J=7.0Hz, 2H), 3.60-3.80 (m, 1H), 3.82-4.01 (m, 3H), 6.36 (d, J=7.5 Hz, 1H), 6.57-6.80 (m, 3H), 7.06 7.28 (m, 2H), 7.72-8.05 (m, 2H), 8.20-8.42 (m, 1H), 12.19 (brs, 1H).

Example 3396

5-Chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide

Step A: Synthesis of 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide.

To a solution of N-(cis-4-methyl-quinolin-2-yl)-cyclohexane-1,4-diamine obtained in step A of example 3070 (5.00 g) in DMF (50 mL) were added 5-bromo-nicotinic acid (4.74 g), Et₃N (6.55 mL), HOBt-H₂O (4.50 g), and EDC-HCl (4.51 g). The reaction mixture was stirred at ambient temperature for 16 hr. The reaction mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 20% to 40% EtOAc in hexane) to give 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide (9.81 g) as a white solid.

ESI MS m/e 439, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.84 (m, 8H), 2.58 (s, 3H), 4.07-4.24 (m, 2H), 4.72-183 4.83 (m, 1H), 6.11-6.20 (m, 1H), 6.52 (s, 1H), 7.20 7.28 (m, 1H), 7.49-7.81 (m, 3H), 8.23-8.29 (m, 1H), 8.79 (d, J=2.3 Hz, 1H), 8.86 (d, J=1.9 Hz, 1H).

Step B: Synthesis of 5-amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide.

To the solution of 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide (6.00 g) in EtOH (40 mL) were added copper (2.17 g), cuprous chloride (3.37 g), and 28% aqueous NH₃ (40.0 mL). The mixture was stirred at 180° C. for 4 hr in a sealed tube. The mixture was filtrated through a pad of celite and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (silica gel, 25% to 50% EtOAc in hexane) to give 5-amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide (3.92 g) as a white solid.

ESI MS m/e 376, M+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.66 2.04 (m, 8H), 2.58 (s, 3H), 3.88-4.24 (m, 4H), 4.75 4.90 (m, 1H), 6.18 6.31 (m, 1H), 6.52 (s, 1H), 7.19 7.29 (m, 1H), 7.39-7.44 (m, 1H), 7.48 7.58 (m, 1H), 7.62 7.70 (m, 1H), 7.73 7.80 (m, 1H), 8.19 (d, J=2.8 1H), 8.29 (d, J=1.6 Hz, 1H).

Step C: Synthesis of 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide.

A mixture of conc. HCl (1.33 mL) and NaNO₂ (137.8 mg) was stirred at 70° C. for 10 min and cooled to ambient temperature. To the reaction mixture was added a solution of 5-amino-N-[cis-4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-nicotinamide (500 mg) in AcOH (45 mL) and the mixture was stirred at ambient temperature for 30 min. To the reaction mixture was added a solution of CuCl (460.8 mg) in conc. HCl (3.0 mL) and the mixture was stirred at 80° C. for 6 hr. The reaction mixture was alkalized with 1M aqueous NaOH and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 20% EtOAc in hexane and silica gel, 2% MeOH in CHCl₃) to give 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide (52.3 mg) as a yellow solid.

ESI MS m/e 395, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.65-2.03 (m, 8H), 2.57 (s, 3H), 4.03-4.29 (m, 2H), 5.05 (brs, 1H), 6.33 6.44 (m, 1H), 6.53 (s, 1H), 7.19 7.28 (m, 1H), 7.48-7.56 (m, 1H), 7.61-7.67 (m, 1H), 7.73-7.79 (m, 1H), 8.08 8.13 (m, 1H), 8.66 (d, J=2.3 Hz, 1H), 8.83 (d, J=1.9 Hz, 1H).

Example 3397

5-Fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide

Step A: Synthesis of 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide.

To a solution of 5-amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide obtained in step B of example 3396 (500 mg) in 48% aqueous HBF₄ (3.95 mL) and EtOH (4.00 mL) was added CuF₂ (132.0 mg) at ambient temperature. To the reaction mixture was added a solution of NaNO₂ (183.5 mg) in H₂O (3.95 mL) and the mixture was stirred at ambient temperature for 1 hr. Then the mixture was stirred at 50° C. for 2 hr and 80° C. for 2 hr. The reaction mixture was alkalized with 1M aqueous NaOH and the aqueous layer was extracted with EtOAc (three times). The combined organic layer was dried over MgSO₄, filtered, concentrated, and purified by flash chromatography (NH-silica gel, 50% EtOAc in hexane) to give 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide (20.9 mg) as a yellow amorphous.

ESI MS m/e 379, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.67-2.05 (m, 8H), 2.57 (s, 3H), 4.08-4.25 (m, 2H), 4.72 (brs, 1H), 6.17 6.29 (m, 1H), 6.52 (s, 1H), 7.19 7.28 (m, 1H), 7.48-7.57 (m, 1H), 7.62-7.69 (m, 1H), 7.73-7.80 (m, 1H), 7.82 7.91 (m, 1H), 8.60 (d, J=2.8 Hz, 1H), 8.76 (t, J=1.5 Hz, 1H).

Example 3398

3-chloro-N-[cis-4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]4-fluoro-benzamide methanesulfonic acid

Step A: Synthesis of 3-chloro-N-[cis4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]4-fluoro-benzamide methanesulfonic acid.

To a solution of N-(cis-4-amino-cyclohexyl)-3-chloro-4-fluoro-benzamide obtained in step A of example 3228 (1.76 g) in BuOH (2.5 mL) was added 2-chloro-4-dimethylamino-5-methylpyrimidine obtained in step A of example 3119 (1.00 g). The mixture was heated in a microwave synthesizer at 200° C. for 15 min. The reaction was repeated 3 more times and the reaction mixtures were pooled. The mixture was poured into saturated aqueous NaHCO₃ and the aqueous layer was extracted with CHCl₃ (three times). The combined organic layer was dried over MgSO₄, filtrated, concentrated under reduced pressure, and purified by medium-pressure liquid chromatography (NH-silica gel, 15% to 80% EtOAc in nexane) to give a colorless solid. To a solution of the above solid (1.85 g) in EtOH (18 mL) was added MsOH (460 mg). The mixture was stirred at ambient temperature for 30 min and stirred on an ice-bath for 4 hr. The precipitate was collected by filtration, washed with EtOH, and dried at 80° C. under reduced pressure to give 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide methanesulfonic acid (1.41 g) as a white solid.

ESI MS m/e 406, M (free)+H⁺; ¹H NMR (300 MHz, CDCl₃) δ 1.60-2.03 (m, 8H), 2.25 (s, 3H), 2.89 (s, 3H), 3.30 (s, 6H), 4.07 4.30 (m, 2H), 7.13 7.29 (m, 2H), 7.38 7.49 (m, 1H), 7.81-7.89 (m, 1H), 7.96-8.05 (m, 1H), 8.07 (dd, J=7.1, 2.3 Hz, 1H), 12.07-12.23 (m, 1H).

Assay Procedures

Example 3399

Assay for Determination of Constitutive Activity of GPCRs

A. Intracellular IP₃ Accumulation Assay

On day 1, cells to be tranfected can be plated onto 24 well plates, usually 1×10⁵ cells/well (although his umber can be optimized. On day 2 cells can be transfected by firstly mixing 0.25 ug DNA (e.g., pCMV vector or pCMV vector comprising polynucleotide enocoding receptor) in 50 ul serum free DMEM/well and 2 ul lipofectamine in 50 μl serum-free DMEM/well. The solutions are gently mixed and incubated for 15-30 min at room temperature. Cells are washed with 0.5 ml PBS and 400 μl of serum free media is mixed with the transfection media and added to the cells. The cells are then incubated for 3-4 hrs at 37° C./5% CO₂ and then the transfection media is removed and replaced with 1 ml/well of regular growth media. On day 3 the cells are labeled with ³H-myo-inositol. Briefly, the media is removed and the cells are washed with 0.5 ml PBS. Then 0.5 ml inositol-free/serum free media (GIBCO BRL) is added/well with 0.25 μCi of ³H-myo-inositol/well and the cells are incubated for 16-18 hrs o/n at 37° C./5% CO₂ On Day 4 the cells are washed with 0.5 ml PBS and 0.45 ml of assay medium is added containing inositol-free/serum free media 10 μM pargyline 10 mM lithium chloride or 0.4 ml of assay medium and 50 ul of 10×ketanserin (ket) to final concentration of 10 μM. The cells are then incubated for 30 min at 37° C. The cells are then washed with 0.5 ml PBS and 200 ul of fresh/ice cold stop solution (1M KOH; 18 mM Na-borate; 3.8 mM EDTA) is added/well. The solution is kept on ice for 5-10 min or until cells were lysed and then neutralized by 200 μl of fresh/ice cold neutralization sol. (7.5% HCL). The lysate is then transferred into 1.5 ml eppendorf tubes and 1 ml of chloroform/methanol (1:2) is added/tube. The solution is vortexed for 15 sec and the upper phase is applied to a Biorad AG 1-X8™ anion exchange resin (100-200 mesh). Firstly, the resin is washed with water at 1:1.25 W/V and 0.9 ml of upper phase is loaded onto the column. The column is washed with 10 mls of 5 mM myo-inositol and 10 ml of 5 mM Na-borate/60 mM Na-formate. The inositol tris phosphates are eluted into scintillation vials containing 10 ml of scintillation cocktail with 2 ml of 0.1 M formic acid/1 M ammonium formate. The columns are regenerated by washing with 10 ml of 0.1 M formic acid/3M ammonium formate and rinsed twice with H₂O and stored at 4° C. in water.

Example 3400

High Throughput Functional Screening: FLIPR™

Subsequently, a functional based assay was used to confirm the lead hits, referred to as FLIPR™ (the Fluorometric Imaging Plate Reader) and FDSS6000™ (Functional Drug Screening System). This assay utilized a non-endogenous, constitutively active version of the MCH receptor.

The FLIPR and FDSS assays are able to detect intracellular Ca²⁺ concentration in cells, which can be utilized to assess receptor activation and determine whether a candidate compound is an, for example, antagonist, inverse agonist or agonist to a Gq-coupled receptor. The concentration of free Ca²⁺ in the cytosol of any cell is extremely low, whereas its concentration in the extracellular fluid and endoplasmic reticulum (ER) is very high. Thus, there is a large gradient tending to drive Ca²⁺ into the cytosol across both the plasma membrane and ER. The FLIPR™ and FDSS6000™ systems (Molecular Devices Corporation, HAMAMATSU Photonics K.K.) are designed to perform functional cell-based assays, such as the measurement of intracellular calcium for high-throughput screening. The measurement of fluorescent is associated with calcium release upon activation of the Gq-coupled receptors. Gi or Go coupled receptors are not as easily monitored through the FLIPR™ and FDSS6000™ systems because these G proteins do not couple with calcium signal pathways.

Fluorometric Imaging Plate Reader system was used to allow for rapid, kinetic measurements of intracellular fluorescence in 96 well microplates (or 384 well microplates). Simultaneous measurements of fluorescence in all wells can be made by FLIPR or FDSS6000™ every second with high sensitivity and precision. These systems are ideal for measuring cell-based functional assays such as monitoring the intracellular calcium fluxes that occur within seconds after activation of the Gq coupled receptor.

Briefly, the cells are seeded into 96 well at 5.5×10⁴ cells/well with complete culture media (Dulbecco's Modified Eagle Medium with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate and 0.5 mg/ml G418, pH 7.4) for the assay next day. On the day of assay, the media is removed and the cells are incubated with 100 μl of loading buffer (4 μM Fluo4-AM in complete culture media containing 2.5 mM Probenicid, 0.5 mg/ml and 0.2% bovine serum albumin) in 5% CO₂ incubator at 37° C. for 1 hr. The loading buffer is removed, and the cells are washed with wash buffer (Hank's Balanced Salt Solution containing 2.5 mM Probenicid, 20 mM HEPES, 0.5 mg/ml and 0.2% bovine serum albumin, pH 7.4)). One hundred fifty μl of wash buffer containing various concentrations of test compound is added to the cells, and the cells are incubated in 5% CO₂ incubator at 37° C. for 30 min. Fifty pi of wash buffer containing various concentration of MCH are added to each well, and transient changes in [Ca²⁺]i evoked by MCH are monitored using the FLIPR or FDSS in 96 well plates at Ex. 488 nm and Em. 530 nm for 290 second. When antagonist activity of compound is tested, 50 nM of MCH is used.

Use of FLIPR™ and FDSS6000™ can be accomplished by following manufacturer's instruction (Molecular Device Corporation and HAMAMATSU Photonics K.K.).

Representative examples are shown below.

Compound No. IC50 (nM)
Example 7    11
Example 15   19
Example 19   21
Example 2524 2.1
Example 2526 7.6

The results were shown on the tables in the Examples section and the table in the next page in accordance with the classification as defined below.

• • Class 1: The value of percent of control at 10⁻⁷ M was less than 40% or the value of IC₅₀ was less than 50 nM.
  • Class 2: The value of percent of control at 10⁻⁷ M was from 40% to 60% or the value of IC′₅₀ was from 50 nM to 200 nM.

Class 3 The value of percent of control at 10⁻⁷ M was more than 60% or the value of IC₅₀ was more than 200 nM.

The compounds in Examples 2497 to 2542, 2588 to 2689, and 3241 to 3259 were tested and they showed IC₅₀ activities less than about 50 μM.

Ex. No. class
1       2
2       2
3       1
4       1
5       2
6       2
7       1
8       1
9       3
10      2
11      1
12      2
13      3
14      1
15      1
16      1
17      2
18      1
19      1
3031    1
3032    1
3033    1
3034    1
3035    1
3036    1
3037    3
3038    1
3039    1
3040    1
3041    1
3042    1
3043    1
3044    2
3045    1
3046    1
3047    1
3048    1
3049    1
3050    1
3051    1
3052    1
3053    1
3054    1
3055    1
3056    1
3057    1
3058    1
3059    1
3060    2
3061    1
3062    1
3063    1
3064    1
3065    1
3066    1
3067    2
3068    2
3069    2
3070    1
3071    1
3072    1
3073    1
3074    1
3075    1
3076    1
3077    1
3078    1
3079    1
3080    1
3081    1
3082    1
3083    1
3084    1
3085    1
3086    1
3087    1
3088    1
3089    1
3090    1
3091    1
3092    1
3093    1
3094    1
3095    1
3096    1
3097    1
3098    1
3099    1
3100    1
3101    1
3102    1
3103    2
3104    2
3105    2
3106    1
3107    1
3108    1
3109    1
3110    1
3111    1
3112    1
3113    3
3114    1
3115    1
3116    3
3117    1
3118    3
3119    1
3120    1
3121    1
3122    1
3123    1
3124    1
3125    1
3126    1
3127    1
3128    1
3129    2
3130    3
3131    3
3132    3
3133    3
3134    3
3135    3
3136    3
3137    2
3138    2
3139    2
3140    2
3141    2
3142    3
3143    3
3144    3
3145    3
3146    1
3147    2
3148    3
3149    2
3150    3
3151    1
3152    1
3153    1
3154    1
3155    3
3156    3
3157    2
3158    1
3159    1
3160    1
3161    2
3162    2
3163    1
3164    2
3165    2
3166    1
3167    1
3168    1
3169    1
3170    1
3171    2
3172    1
3173    3
3174    1
3175    1
3176    2
3177    2
3178    2
3179    1
3180    1
3181    2
3182    3
3183    3
3184    2
3185    1
3186    2
3187    3
3188    1
3189    1
3190    2
3191    2
3192    1
3193    1
3194    1
3195    2
3196    2
3197    2
3198    1
3199    1
3200    3
3201    1
3202    1
3203    1
3204    2
3205    2
3206    1
3207    1
3208    3
3209    3
3210    3
3211    1
3212    3
3213    3
3214    2
3215    2
3216    1
3217    1
3218    3
3219    2
3220    1
3221    1
3222    1
3223    3
3224    2
3225    3
3226    3
3227    3
3228    1
3229    1
3230    1
3231    2
3232    2
3233    3
3234    3
3235    1
3236    3
3237    3
3238    1
3239    1
3240    1
3383    1
3384    1
3385    1
3386    1
3387    1
3388    1
3389    1
3390    1
3391    1
3392    3
3393    1
3394    1
3395    1
3396    1
3397    1
3398    1

Example 3401

Receptor Binding Assay

In addition to the methods described herein, another means for evaluating a test compound is by determining binding affinities to the MCH receptor. This type of assay generally requires a radiolabelled ligand to the MCH receptor. Absent the use of known ligands for the MCH receptor and radiolabels thereof, compounds of Formula (I) can be labelled with a radioisotope and used in an assay for evaluating the affinity of a test compound to the MCH receptor.

A radiolabelled MCH compound of Formula (I) can be used in a screening assay to identify/evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the “radiolabelled compound of Formula (I)” to the MCH receptor. Accordingly, the ability to compete with the “radio-labelled compound of Formula (1)” or Radiolabelled MCH Ligand for the binding to the MCH receptor directly correlates to its binding affinity of the test compound to the MCH receptor.

Assay Protocol for Determining Receptor Binding for MCH:

A. MCH Receptor Preparation

293 cells (human kidney, ATCC), transiently transfected with 10 ug human MCH receptor and 60 ul Lipofectamine (per 15-cm dish), are grown in the dish for 24 hours (75% confluency) with a media change and removed with 10 ml/dish of Hepes-EDTA buffer (20 mM Hepes+10 mM EDTA, pH 7.4). The cells are then centrifuged in a Beckman Coulter centrifuge for 20 minutes, 17,000 rpm (JA-25.50 rotor). Subsequently, the pellet is resuspended in 20 mM Hepes+1 mM EDTA, pH 7.4 and homogenized with a 50-ml Dounce homogenizer and again centrifuged. After removing the supernatant, the pellets can be stored at -80° C., until used in binding assay. When used in the assay, membranes are thawed on ice for 20 minutes and then 10 mL of incubation buffer (20 mM Hepes, 1 mM MgCl₂, 100 mM NaCl, pH 7.4) added. The membranes are then vortexed to resuspend the crude membrane pellet and homogenized with a Brinkmann PT-3100 Polytron homogenizer for 15 seconds at setting 6. The concentration of membrane protein is determined using the BRL Bradford protein assay.

B. Binding Assay

For total binding, a total volume of 50 ul of appropriately diluted membranes (diluted in assay buffer containing 50 mM Tris HCl (pH 7.4), 10 mM MgCl₂, and 1 mM EDTA; 5-50 ug protein) is added to 96-well polyproylene microtiter plates followed by addition of 100 ul of assay buffer and 50 ul of Radiolabelled MCH Ligand. For nonspecific binding, 50 ul of assay buffer is added instead of 100 ul and an additional 50 ul of 10 uM cold MCH is added before 50 ul of Radiolabelled MCH Ligand is added. Plates are then incubated at room temperature for 60-120 minutes. The binding reaction is terminated by filtering assay plates through a Microplate Devices GF/C Unifilter filtration plate with a Brandell 96-well plate harvestor followed by washing with cold 50 mM Tris HCl, pH 7.4 containing 0.9% NaCl. Then, the bottom of the filtration plate are sealed, 50 μl of Optiphase Supermix is added to each well, the top of the plates are sealed, and plates are counted in a Trilux MicroBeta scintillation counter. For compound competition studies, instead of adding 100 μl of assay buffer, 100 μl of appropriately diluted test compound is added to appropriate wells followed by addition of 50 μl of Radiolabelled MCH Ligand.

C. Calculations

The test compounds are initially assayed at 1 and 0.1 μM and then at a range of concentrations chosen such that the middle dose would cause about 50% inhibition of a Radiolabelled MCH Ligand binding (i.e., IC₅₀). Specific binding in the absence of test compound (B_O) is the difference of total binding (B_T) minus non-specific binding (NSB) and similarly specific binding (in the presence of test compound) (B) is the difference of displacement binding (B_D) minus non-specific binding (NSB). IC₅₀ is determined from an inhibition response curve, logit-log plot of % B/B_O vs concentration of test compound.

K_i is calculated by the Cheng and Prustoff transformation:K_i=IC₅₀/(1+[L]/K_D) wherein [L] is the concentration of a Radiolabelled MCH Ligand used in the assay and K_D is the dissociation constant of a Radiolabelled MCH Ligand determined independently under the same binding conditions.

It is intended that each of the patents, applications, printed publications, and other published documents mentioned or referred to in this specification be herein incorporated by reference in their entirety.

Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

Claims

1. A compound of Formula (I):

2. The compound according to claim 1 wherein R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, mono-C1-5 alkylamino substituted by carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by carbocyclic aryl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, mono-carbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino, di-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by C1-5 alkyl, C1-5 alkoxycarbonylamino, carbocyclic arylcarbonylamino, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted C1-5 alkyl, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by halogen, and carbocyclic aryl substituted by C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by nitro, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C2-5 alkenyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-carbocyclic arylaminocarbonyl, mono-carbocyclic arylaminocarbonyl substituted by halogen, di-carbocyclic arylaminocarbonyl, di-carbocyclic arylaminocarbonyl substituted by halogen, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (iii) C2-5 alkynyl, and C2-5 alkynyl substituted by carbocyclic aryl, (iv) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by oxo, C1-5 alkyl substituted by carbocyclic aryl, and carbocyclic aryl, (v) carbocyclyl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, carboxy, carbamoyl, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-7 alkoxy, C1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and halogenated carbocyclic aryl, C2-5 alkenyloxy, C3-6 cycloalkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by nitro, carbocyclic aryloxy substituted by C1-5 alkoxy, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, C1-5 alkoxycarbonylamino, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, carbocyclic aryl azo, carbocyclic aryl azo substituted by mono-C1-5 alkylamino, carbocyclic aryl azo substituted by di-C1-5 alkylamino, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by nitro, carbocyclic arylthio substituted by cyano, aminosulfonyl, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, heterocyclylsulfonyl, C3-6 cycloalkyl, C3-6 cycloalkyl substituted by C1-5 alkyl, carbocyclic aryl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and halogenated carbocyclic aryl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, amino, hydroxy, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, C1-5 alkoxycarbonyl substituted by carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, and C1-5 alkyl substituted by halogen, heterocyclyl; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantly, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, indanyl, indenyl, or menthyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, tetrahydrofuryl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

3. The compound according to claim 2 wherein Q is Formula (II); R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by nitro, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, mono-C1-5 alkylamino substituted by carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by carbocyclic aryl, mono-carbocyclic arylamino, di-carbocyclic arylamino, C1-5 alkoxycarbonylamino, carbocyclic arylcarbonylamino, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted C1-5 alkyl, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by halogen, and carbocyclic aryl substituted by C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C2-5 alkenyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-carbocyclic arylaminocarbonyl, mono-carbocyclic arylaminocarbonyl substituted by halogen, di-carbocyclic arylaminocarbonyl, di-carbocyclic arylaminocarbonyl substituted by halogen, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (iii) C2-5 alkynyl, and C2-5 alkynyl substituted by carbocyclic aryl, (iv) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by oxo, C1-5 alkyl substituted by carbocyclic aryl, and carbocyclic aryl, (v) carbocyclyl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and halogenated carbocyclic aryl, C2-5 alkenyloxy, C3-6 cycloalkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by cyano, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, and carbocyclic aryl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, and C1-5 alkyl substituted by halogen, heterocyclyl; R2 is methylamino or dimethylamino when Y is a single bond or —CH2—; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, bicyclo[2.2.1]heptyl, indenyl, or menthyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

4. The compound according to claim 3 wherein R1 is selected from the group consisting of: (i) C1-7 alkyl, and C1-7 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, mono-carbocyclic arylamino, di-carbocyclic arylamino, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, heterocyclyl, heterocyclyl substituted by carbocyclic aryl, and heterocyclyl substituted by halogen, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkoxy, (iii) C2-5 alkynyl, and C2-5 alkynyl substituted by carbocyclic aryl, (iv) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, and C1-5 alkyl substituted by carbocyclic aryl, (v) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryl substituted by halogen, C2-5 alkenyloxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C1-5 alkylthio, and C1-5 alkylthio substituted by halogen, (vi) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, and carbocyclic aryl, C1-5 alkoxy, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, L is Formula (VII); Y is a single bond or —CH2—; R2 is methylamino or dimethylamino; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, azetidinyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

5. The compound according to claim 4 wherein p is 0; R3 and R4 are hydrogen; A is a single bond or —CH2—; and B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

6. The compound according to claim 5 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, mono-carbocyclic arylamino, di-carbocyclic arylamino, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, heterocyclyl, and heterocyclyl substituted by carbocyclic aryl, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, and C2-5 alkenyloxy, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, and C1-5 alkoxycarbonyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, azetidinyl, or benzo[1,3]dioxolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

7. The compound according to claim 1 selected from the group consisting of: ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)amino]methyl}-1H-indole-2-carboxylate; 3-[{2-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]ethyl}(phenyl)amino]propanenitrile; N4,N4-dimethyl-N2-(cis-4-{[2-(2-phenyl-1H-indol-3-yl)ethyl]amino}-cyclohexyl)quinoline-2,4-diamine; N2-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline2,4-diamine; N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine; 4-bromo-2-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-6-methoxyphenol; N2-[cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine; N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylquinoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine; N4,N4-dimethyl]-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)quinoline-2,4-diamine; N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine; N2-[cis-4-({[(7-methoxy1,3-benzodioxol5-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylquinoline-2,4-diamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4,N4-dimethyl-quinoline-2,4-diamine; N2-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N4,N4-dimethyl-quinoline-2,4-diamine; N2-[cis-4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N4-methyl-quinoline-2,4-diamine; N2-{4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4-methyl-quinoline-2,4-diamine; N4-methyl-N2-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine; N2-{cis-4-[(4-bromo2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4-methyl-quinoline-2,4-diamine; N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4,N4-dimethyl-quinoline-2,4-diamine; N4,N4-dimethyl-N2-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-quinoline-2,4-diamine; cis-N-(3,5-dimethoxybenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine; and cis-N-(3,5-dichlorobenzyl)-N′-(4-methylquinolin-2-yl)cyclohexane-1,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

8. The compound according to claim 3 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by halogen, carbocyclic arylcarbonylamino, C1-5 alkoxycarbonylamino, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-carbocyclic arylaminocarbonyl, mono-carbocyclic arylaminocarbonyl substituted by halogen, di-carbocyclic arylaminocarbonyl, di-carbocyclic arylaminocarbonyl substituted by halogen, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from group consisting of: C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and nitro, (iii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and carbocyclic aryl, and carbocyclic aryl, (iv) carbocyclyl, (v) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, carboxy, carbamoyl, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by cyano, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, and carbocyclic aryl, (vi) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, hydroxy, amino, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkyl, heterocyclyl; L is Formula (VII); Y is —C(O)—; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

9. The compound according to claim 8 wherein R2 is hydrogen, halogen, methyl, trifluoromethyl, methoxy, carbamoyl, amino, methylamino, or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

10. The compound according to claim 9 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by halogen, C3-6 cycloalkyl, carbocyclic aryl, carbocyclic aryl by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkoxy, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy, and carbocyclic aryl, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and nitro, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, carbamoyl, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkyl substituted by hydroxy, C1-5 alkoxycarbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, and carbocyclic aryloxy substituted by C1-5 alkoxy, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, amino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, carbocyclic aryl, carbocyclic aryl substituted by halogen, carbocyclic aryl substituted by nitro, and heterocyclyl; wherein carbocyclic aryl is phenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, pyridyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

11. The compound according to claim 10 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by halogen, carbocyclic aryl, carbocyclic aryl by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkoxy, and heterocyclyl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, hydroxy, cyano, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxycarbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, carbocyclic aryloxy, and carbocyclic aryloxy substituted by C1-5 alkoxy, (iii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryloxy substituted by C1-5 alkoxy, carbocyclic aryl, carbocyclic aryl substituted by halogen, carbocyclic aryl substituted by nitro, and heterocyclyl; wherein carbocyclic aryl is phenyl; heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, pyridyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

12. The compound according to claim 1 selected from the group consisting of: N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxypropanamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-iodobenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; (2E)-N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-3-(4-nitrophenyl)acrylamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)thiophene3-carboxamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)acetamide; 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)cyclopentanecarboxamide; 3-(2-chloro-6-fluorophenyl)-N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-5-methyl-2-phenyl2H1,2,3-triazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)quinolin-2-carboxamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide; N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide; 5-bromo-N-(cis-4-{[4-dimethylamino)quinolin-2-yl]amino}cyclohexyl)-thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide; 5-(4-chloro-2-nitrophenyl)-N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)-2-furamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-thiophene2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-iodophenyl)acetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(5-methoxy2-methyl-1H-indol-3-yl)acetamide; (2E)-N-(cis-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-(3-nitrophenyl)acrylamide; 2,2-bis-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)thiophene2-carboxamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)acetamide; N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)-4-oxo4-phenylbutanamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2-phenyl1H-indol3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-2-(2,4,6-trichlorophenoxy)acetamide; 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenylquinoline4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene3-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-1-methyl-4-nitro1H-pyrrole2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-methoxy4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-hydroxybenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methoxybenzamide; 3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 4-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 4-chloro-N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-methyl]3-nitrobenzamide; 3-cyano-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-difluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-fluoro-5-(trifluoromethyl)benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]4-methyl-3-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-(trifluoromethoxy)benzamide; 4-bromo-N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-methyl]3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-iodobenzamide; 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-2,4-difluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]2,5-dimethyl-3-furamide; 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-4-fluorobenzamide; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-fluoro-4-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide; (2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]4-fluoro-3-methylbenzamide; 2,5-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)methyl]thiophene3-carboxamide; 2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide; 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; (2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acrylamide; 5-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]thiophene-2-carboxamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide; 5-(4-chloro-2-nitrophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-furamide; 5-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]thiophene-2-carboxamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-iodo2-furamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]2-(2-iodophenyl)acetamide; (2E)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide; 2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]acetamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene2-carboxamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-methyl-4-nitrobenzamide; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-methoxy4-nitrobenzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-chloro-N-[cis-4-(4-methylquinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 3-chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,5-dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4-dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis4-(quinolin2-ylamino)-cyclohexyl]-amide; 9H-xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 5-(4-chloro-phenyl)-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 3-nitro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-trifluoromethyl-benzamide; N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide; 3,4-dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 1-methyl-4-nitro1H-pyrrole2-carboxylic acid [cis4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-amide; 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 5-bromo-furan-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide; 2,2-diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 5-bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-amide; 3-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide; 2-(4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3,4-difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide; 2-(4-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-nicotinamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide; 2-(3-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenylamino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenylamino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 3-hydroxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-bis-trifluoromethyl-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide; N-[cis-4-(4-amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide; C-(ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 3-hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-amino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2,3-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2,6-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester; 3,5-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 6-dimethylamino-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-hydroxymethyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamide; 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4,5-trifluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 4-chloro-pyridine-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-6-trifluoromethyl-nicotinamide; 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-2-phenoxy-nicotinamide; N-[cis-4-(4-dimethylamino-quinolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide; 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-benzamide; 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexylmethyl]-nicotinamide; 4-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide; 2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide; 3,4,5-trimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide; 2-(3,4-difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}acetamide; 2-(2-bromo-4,5-dimethoxyphenyl)-N-{cis-4-[(4-methylquinolin2-yl)amino]cyclohexyl}acetamide; 2,6-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide; N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-4-(trifluoromethoxy)benzamide; 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; and 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

13. The compound according to claim 12 selected from the group consisting of: 3-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxypropanamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)acetamide; 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide; 3-(2-chloro-6-fluorophenyl)-N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitro-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide; N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-furamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-5-nitrothiophene3-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-1-methyl-4-nitro1H-pyrrole2-carboxamide; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide; 3-bromo-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; N-[(cis-4-{[4-dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]benzamide; 4-chloro-N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-methyl]3-nitrobenzamide; 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-4-fluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-phenoxypropanamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide; 4-bromo-N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-methyl]3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]2,5-dimethyl-3-furamide; 3-chloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-methyl]-4-fluorobenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]4-fluoro-3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide; 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-iodo2-furamide; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-5-nitrothiophene2-carboxamide; N-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-methyl-4-nitrobenzamide; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]3-methoxy4-nitrobenzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; 3,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-phenoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-methoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-chloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 5-nitro-thiophene-3-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 5-nitro-thiophene-3-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 3-chloro-4-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,5-dimethoxy-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4-dichloro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-methoxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 1-methyl-4-nitro-1H-pyrrole-2-carboxylic acid [cis4-(quinolin2-ylamino)-cyclohexyl]-amide; 9H-xanthene-9-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; 3-nitro-N-[cis-4-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-3-methyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-bromo-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 2-(2-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-cyano-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-trifluoromethyl-benzamide; N-[cis-4-(4-chloro-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide; 3,4-dichloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-chloro-4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-3-methyl-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 1-methyl-4-nitro1H-pyrrole2-carboxylic acid [cis4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-amide; 9H-xanthene-9-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; 5-bromo-furan-2-carboxylic acid [cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-amide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-acetamide; 2,2-diphenyl-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 5-bromo-furan-2-carboxylic acid [cis-4-(quinolin-2-ylamino)-cyclohexyl]-amide; benzo[2,3,1]oxadiazole-5-carboxylic acid [cis-4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-amide; 3-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-cyano-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethyl-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2,2-diphenyl-acetamide; 2-(4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3,4-difluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3,4-difluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-p-tolyloxy-nicotinamide; 2-(4-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-bromo-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-bromo-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(4-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin2-ylamino)-cyclohexyl]-nicotinamide; N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-2-m-tolyloxy-nicotinamide; 2-(3-methoxy-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(methyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-methoxy-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3-chloro-4-fluoro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(methyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-3-trifluoromethoxy-benzamide; N-[cis-4-(4-amino-quinolin-2-ylamino)-cyclohexyl]-3,4-difluoro-benzamide; C-(ethyl-phenyl-amino)-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; C-(ethyl-phenyl-amino)-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 3-hydroxy-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 2,4-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,5-difluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-acetamide; 4-chloro-3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-isophthalamic acid methyl ester; 3,5-difluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-3-fluoro-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-benzamide; C-[(4-chloro-phenyl)-ethyl-amino]-N-[cis-4-(quinolin-2-ylamino)-cyclohexyl]-acetamide; 6-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 3-chloro-5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 3,4,5-trifluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-benzamide; 5-bromo-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; 4-methyl-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide; 2-(4-chlorophenoxy)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide; 3,4,5-trimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}benzamide; 2-(3,4-difluorophenyl)-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-acetamide; 2-(2-bromo-4,5-dimethoxyphenyl)-N-{cis4-[(4-methylquinolin2-yl)amino]-cyclohexyl}acetamide; 2,6-dimethoxy-N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}nicotinamide; N-{cis-4-[(4-methylquinolin-2-yl)amino]cyclohexyl}-4-(trifluoromethoxy)-benzamide; 5-chloro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; and 5-fluoro-N-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-nicotinamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

14. The compound according to claim 3 wherein R1 is selected from the group consisting of: C-1-16 alkyl, and C-1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, L is Formula (XV); Y is —C(O)NR5—; wherein carbocyclic aryl is phenyl; and halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

15. The compound according to claim 14 wherein R1 is selected from the group consisting of: C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, wherein carbocyclic aryl is phenyl; and halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

16. The compound according to claim 14 or 15 wherein R2 is methyl; p is 0; R3 and R4 are both hydrogen; A and B are both single bonds; and R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

17. The compound according to claim 1 selected from the group consisting of: cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-N-[(1R)-1-(2-fluorophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-N-[(1S)-1-(2-fluorophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; and cis-N-[(1S)-1-(4-chlorophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

18. The compound according to claim 1 selected from the group consisting of: cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-N-[(1S)-1-(2-fluorophenyl)ethyl]4-[(4-methylquinolin2-yl)amino]cyclohexanecarboxamide; cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; and cis-4-[(4-methylquinolin-2-yl)amino]-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

19. The compound according to claim 3 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxycarbonyl, C1-5 alkylthio, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C2-5 alkenyl, (ii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxycarbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C3-6 cycloalkoxy, carbocyclic aryloxy, C1-5 alkylthio, and carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by halogen, and carbocyclic aryl; L is Formula (VI); Y is —C(O)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

20. The compound according to claim 19 wherein R2 is hydrogen, methyl, methylamino, or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

21. The compound according to claim 20 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxycarbonyl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, (iii) heterocyclyl, heterocyclyl substituted by C1-5 alkyl, and heterocyclyl substituted by carbocyclic aryl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is isoxazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

22. The compound according to claim 1 selected from the group consisting of: N-(2-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2-ethyl-6-methylphenyl)urea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-mesitylurea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)urea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)urea; N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea; N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)urea; N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-N′-(2-isopropyl6-methylphenyl)urea; N-(2-tert-butyl-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(diphenylmethyl)urea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)urea; N-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-N′-(3-methyl-5-phenylisoxazol4-yl)urea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-1-naphthylurea; N-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-N′-[1-(1-naphthyl)ethyl]urea; methyl N-{[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)-amino]carbonyl}phenylalaninate; N-(cis-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)urea; N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-mesitylurea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea; N-[(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea; N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea; N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin2-yl]amino}-cyclohexyl)methyl]urea; N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis4-{[4-(dimethylamino)-quinolin2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea; N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea; N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin2-yl]-amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea; N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)methyl]urea; N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin2-yl]-amino}cyclohexyl)methyl]urea; N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)quinolin2-yl]-amino}cyclohexyl)methyl]urea; 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexyl]-urea; and 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-methyl-quinolin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

23. The compound according to claim 3 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, (ii) carbocyclyl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy carbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, mono-C1-5 alkylamino, di-C1-5 alkylamino, and carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy carbonyl, and carbocyclic aryl; L is Formula (VII); Y is —C(S)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is bicyclo[2.2.1]heptyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

24. The compound according to claim 23 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

25. The compound according to claim 24 wherein R1 is selected from the group consisting of: (i) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, mono-C1-5 alkylamino, and di-C1-5 alkylamino, (ii) heterocyclyl, and heterocyclyl substituted by C1-5 alkyl, and heterocyclyl substituted by C1-5 alkoxy carbonyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

26. The compound according to claim 1 selected from the group consisting of: N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]-amino}cyclohexyl)thiourea; N(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea; N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-N′-mesitylthiourea; N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}-cyclohexyl)thiourea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea; N-(4-bromo-2-methylphenyl)-N′-(cis4-{[4-(dimethylamino)quinolin2-yl]amino}cyclohexyl)thiourea; N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-quinolin2-yl]amino}cyclohexyl)thiourea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea; N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)thiourea; and methyl 3-({[(cis-4-{[4-(dimethylamino)quinolin-2-yl]amino}cyclohexyl)-amino]carbonothioyl}amino)-4-methylthiophene-2-carboxylate; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

27. The compound according to claim 3 wherein R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (ii) C2-5 alkenyl, (iii) carbocyclyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy; L is Formula (VII); Y is —C(O)O—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 9H-fluorenyl or menthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

28. The compound according to claim 27 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

29. The compound according to claim 2 wherein Q is Formula (III); R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by nitro, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, mono-C1-5 alkylamino substituted by carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by carbocyclic aryl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino, di-carbocyclic arylamino substituted by C1-5 alkyl, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted C1-5 alkyl, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by halogen, and carbocyclic aryl substituted by C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C2-5 alkenyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-carbocyclic arylaminocarbonyl, mono-carbocyclic arylaminocarbonyl substituted by halogen, di-carbocyclic arylaminocarbonyl, di-carbocyclic arylaminocarbonyl substituted by halogen, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (iii) C2-5 alkynyl, (iv) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by oxo, C1-5 alkyl substituted by carbocyclic aryl, and carbocyclic aryl, (v) carbocyclyl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-7 alkoxy, C1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and halogenated carbocyclic aryl, C2-5 alkenyloxy, C3-6 cycloalkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by nitro, carbocyclic aryloxy substituted by C1-5 alkoxy, carboxy, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, C1-5 alkoxycarbonylamino, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, carbocyclic aryl azo, carbocyclic aryl azo substituted by mono-C1-5 alkylamino, carbocyclic aryl azo substituted by di-C1-5 alkylamino, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by nitro, carbocyclic arylthio substituted by cyano, aminosulfonyl, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, heterocyclylsulfonyl, C3-6 cycloalkyl, C3-6 cycloalkyl substituted by C1-5 alkyl, carbocyclic aryl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and halogenated carbocyclic aryl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, C1-5 alkoxycarbonyl substituted by carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, and C1-5 alkyl substituted by halogen, heterocyclyl; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9H-fluorenyl, 9-oxo-9H-fluorenyl, adamantly, bicyclo[2.2.1]heptenyl, bicyclo[2.2.1]heptyl, indanyl, indenyl, or menthyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, 4H-benzo[1,3]dioxinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, azetidinyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazo[2,1-b]thiazolyl, isoxazolyl, morpholino, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, tetrahydrofuryl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

30. The compound according to claim 29 wherein R1 is selected from the group consisting of: (i) C1-7 alkyl, and C1-7 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino substituted by C1-5 alkyl, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and carbocyclic aryl, C1-5 alkoxy, heterocyclyl, and heterocyclyl substituted by carbocyclic aryl, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkoxy, (iii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, and C1-5 alkyl substituted by carbocyclic aryl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryl substituted by halogen, C2-5 alkenyloxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C1-5 alkylthio, and C1-5 alkylthio substituted by halogen, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, and carbocyclic aryl, C1-5 alkoxy, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen; L is Formula (VII); Y is a single bond or —CH2—; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, azetidinyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

31. The compound according to claim 30 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

32. The compound according to claim 31 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino substituted by C1-5 alkyl, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by C1-5 alkyl, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkoxy, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, mono-C1-5 alkylamino, and di-C1-5 alkylamino, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 4-oxo-benzopyranyl, azetidinyl, benzo[1,3]dioxolyl, or pyrazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

33. The compound according to claim 32 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, mono-carbocyclic arylamino, di-carbocyclic arylamino, carbocyclic arylsulfonylamino, carbocyclic arylsulfonylamino substituted by C1-5 alkyl, and carbocyclic aryl, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxycarbonyl, carbocyclic aryl, and carbocyclic aryl substituted by halogen; wherein carbocyclic aryl is phenyl; heterocyclyl is 1H-indolyl, azetidinyl, or pyrazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

34. The compound according to claim 1 selected from the group consisting of: N2-{cis-4-[(2,6-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[(2-ethoxybenzyl)amino]cyclohexyl-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline2,4-diamine; N2-{cis-4-[(1H-indol-3-ylmethyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[(2,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(4-methoxy1-naphthyl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(5-methoxy-1H-indol3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-bromo-2-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)amino]methyl}-6-methoxyphenol; N2-(cis-4-{[(5-bromo-1H-indol3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]methyl}-2,6-dimethoxyphenol; N2-{cis-4-[(3-ethoxy-4-methoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-{cis-4-[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol4-yl}methyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-{cis-4-[(3,4,5-trimethoxybenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-{cis-4-[(pentamethylbenzyl)amino]cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]methyl}-2-iodo-6-methoxyphenol; 4-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]methyl}-2,6-dimethylphenol; 3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]methyl}-6,8-dimethyl-4H-4H-chromen-4-one; ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate; N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol4-yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-[4-(pentamethylphenylmethyl-amino}-cyclohexyl]-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]ethyl}(3-methylphenyl)amino]propanenitrile; 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]propanenitrile; N-{(1S)-1-benzyl-2-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide; N2-(cis-4-{[2-(3,5-dimethoxyphenyl)ethyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(1H-indol-3-ylmethyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-({[(4-methoxy1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-({[(5-methoxy-1H-indol3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-bromo-2-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-6-methoxyphenol; N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis4-{[(3-ethoxy4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol4-yl}methyl)amino]methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]-methyl}cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(3,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2,6-dimethylphenol; 3-chloro-4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol; N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(3,3-diphenylprop2-en1-yl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-ethoxyphenol; N2-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)methyl]-cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 2-bromo-4-chloro-6-({[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)phenol; N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-({[(7-methoxy1,3-benzodioxol5-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-methylphenol; N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-fluoro-6-methoxyphenol; N4,N4-dimethyl-N2-[cis-4-({[(1-phenyl5-propyl1H-pyrazol4-yl)methyl]amino}methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis4-[({[1-(4-chlorophenyl)-5-propyl1H-pyrazol4-yl]methyl}-amino)methyl]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N4,N4-dimethyl-N2-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; and N4-methyl-N2-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

35. The compound according to claim 34 selected from the group consisting of: N2-(cis-4-{[(5-methoxy-1H-indol3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)amino]methyl}-1H-indole-2-carboxylate; N2-[cis-4-({[3-(4-fluorophenyl)-1H-pyrazol4-yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 3-[{2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)amino]ethyl}(phenyl)amino]propanenitrile; N-{(1S)-1-benzyl-2-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)amino]ethyl}-4-methylbenzenesulfonamide; N2-[cis-4-({[1-(diphenylmethyl)azetidin-3-yl]methyl}amino)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-({[(5-methoxy-1H-indol3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-[cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]amino}methyl)-2-iodo-6-methoxyphenol; N2-(cis-4-{[(3,3-diphenylprop2-en1-yl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl}amino]methyl}-cyclohexyl)-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N4,N4-dimethyl-N2-[cis-4-({[(1-phenyl5-propyl1H-pyrazol4-yl)methyl]amino}methyl)cyclohexyl]-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[({[1-(4-chlorophenyl)-5-propyl1H-pyrazol4-yl]methyl}-amino)methyl]cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydroquinazoline-2,4-diamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4-methyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4,N4-dimethyl-5,6,7,8-tetrahydro-quinazoline-2,4-diamine; and N4,N4-dimethyl-N2-{cis-4-[(2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-5,6,7,8-tetrahydroquinazoline-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

36. The compound according to claim 29 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by nitro, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, carbocyclic arylcarbonylamino, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, mono-carbocyclic arylaminocarbonyl, mono-carbocyclic arylaminocarbonyl substituted by halogen, di-carbocyclic arylaminocarbonyl, di-carbocyclic arylaminocarbonyl substituted by halogen, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and nitro, (iii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and carbocyclic aryl, carbocyclic aryl, (iv) carbocyclyl, (v) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by cyano, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, carbocyclic aryl, heterocyclyl, heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and halogenated carbocyclic aryl, (vi) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkyl, heterocyclyl; L is Formula (VII); Y is —C(O)—; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

37. The compound according to claim 36 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

38. The compound according to claim 37 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, carbocyclic arylcarbonylamino, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by halogen, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy, and carbocyclic aryl, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by nitro, (iii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by carbocyclic aryl, (iv) carbocyclyl, (v) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, and carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, mono-C1-5 alkylamino, di-C1-5 alkylamino, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, and (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, (vi) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, and heterocyclyl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkyl, heterocyclyl; wherein carbocyclic aryl is phenyl; carbocyclyl is 1-oxo-indanyl or indenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2-oxo-benzopyranyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

39. The compound according to claim 38 wherein R, is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, carbocyclic arylcarbonylamino, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, and C1-5 alkoxy, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy, and carbocyclic aryl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, and oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, and (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, (iii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkyl substituted by heterocyclyl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, carbocyclic aryl, carbocyclic aryl substituted by halogen, and carbocyclic aryl substituted by nitro; wherein carbocyclic aryl is phenyl; carbocyclyl is indenyl; heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2-oxo-benzopyranyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, furyl, isoxazolyl, morpholino, pyridyl, quinoxalyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

40. The compound according to claim 1 selected from the group consisting of: N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxybenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 4-chloro-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-3-nitrobenzamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,2-diphenylacetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)hexanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-methyl-3-nitrobenzamide; N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-nitrobenzamide; (2R)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-phenylcyclopropanecarboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxypropanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethoxy)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-iodobenzamide; 2-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(3-methoxyphenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-methyl-2-(trifluoromethyl)-3-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2,5-dimethyl-3-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-fluoro-3-methylbenzamide; 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(propylthio)nicotinamide; 1-benzyl-3-tert-butyl-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide; 2-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]2-oxo-1-phenylethyl acetate; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)benzamide; 2-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)acetamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 3-(2-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)cyclopentanecarboxamide; 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-1,3-dimethyl-1H-pyrazole-5-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-methyl-2-phenyl-2H-1,2,3-triazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-nitro2-furamide; N-(cis-4-{[4-diethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxyacetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)quinolin2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethyl)benzamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxynicotinamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methylphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-(2,3,6-trichlorophenyl)acetamide; 2-(2-chloro-4-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,3-diphenylpropanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(2-hydroxyphenyl)propanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-iodo2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-iodophenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(5-methoxy-2-methyl-1H-indol-3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-oxoindane1-carboxamide; 2-benzyl-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-methyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-methoxy4-nitrobenzamide; 3-acetyl-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-[(4-methylpyrimidin-2-yl)thio]acetamide; 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; 2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide; N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)lysinamide; 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-fluorophenyl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-fluorophenyl-4-yl)propanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-[4-(1-oxo-1,3-dihydro-2H-isoindol-2-yl)phenyl]propanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H-indol-3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H-indol-3-yl)-4-oxo-4-phenylbutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy)phenyl]amino}carbonyl)amino]-benzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide; 4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1-methyl-1H-indol-3-yl)-4-(4-methylphenyl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-nitrophenyl)butanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(3-phenoxyphenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-phenoxyphenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide; N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-phenoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide; N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide; (2S)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-(2-fluorophenyl-4-yl)propanamide; 2-[(4-chlorobenzyl)thio]-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-(4-methylphenyl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide; 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-methyl-1,5-diphenyl-1H-pyrrole-3-carboxamide; 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazoin-2-yl]amino}-cyclohexyl)-2-phenoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenylquinoline-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-(3-nitrophenyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-methoxy4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-methoxy2-phenylacetamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-hydroxybenzamide; 3-bromo-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(ethylthio)nicotinamide; N-[(cis-4-{[4-dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(4-methoxyphenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]5-methyl-2-(trifluoromethyl)-3-furamide; (2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]-3-(4-nitrophenyl)acrylamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]4-fluoro-3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(propylthio)nicotinamide; 2,6-dichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2,4,6-trimethylbenzamide; 2-chloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]-6-fluorobenzamide; 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide; N-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(2,3,6-trichlorophenyl)acetamide; (2E)-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]-3-(3-nitrophenyl)acrylamide; and N-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

41. The compound according to claim 40 selected from the group consisting of: N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methoxybenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 4-chloro-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-3-nitrobenzamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2,2-diphenylacetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-fluorobenzamide; N-(cis-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-methyl-3-nitrobenzamide; N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxypropanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-iodobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-fluorophenyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2,5-dimethyl-3-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-fluoro-3-methylbenzamide; 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-3-carboxamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)nicotinamide; 2-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)amino]2-oxo-1-phenylethyl acetate; 3-(2-chloro-6-fluorophenyl)-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-nitro2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxyacetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)quinolin2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-(trifluoromethyl)benzamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-methylphenoxy)nicotinamide; 2-(2-chloro-4-fluorophenyl)-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; 5-(4-chloro-2-nitrophenyl)-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-5-iodo2-furamide; 2,2-bis(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-methyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3-methoxy4-nitrobenzamide; 3-acetyl-N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; 5-4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; 2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(4-hydroxy-3,5-dimethoxyphenyl)acetamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(1H-indol-3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-3,5-dimethyl-2-[({[4-(trifluoromethoxy)phenyl]amino}carbonyl)amino]-benzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide; 4-(4-tert-butylphenyl)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-(7-ethyl-1H-indol-3-yl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-methyl-1-(3-morpholin-4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-4-(4-nitrophenyl)butanamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-(2-phenyl-1H-indol-3-yl)acetamide; N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N1,N1-dipropylglutamamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-3-phenoxybenzamide; N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide; 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-4-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-2-phenoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-5-nitrothiophene-3-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-1-methyl-4-nitro-1H-pyrrole-2-carboxamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)-2-hydroxybenzamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-ethylthio)nicotinamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(4-methoxyphenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]5-methyl-2-(trifluoromethyl)-3-furamide; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]2-(propylthio)nicotinamide; and 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]benzamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

42. The compound according to claim 29 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, C1-5 alkoxy carbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C2-5 alkenyl, and C1-5 alkoxy, C1-5 alkylthio, and heterocyclyl, (ii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, and carbocyclic aryl, C1-5 alkoxy carbonyl, C1-7 alkoxy, C1-7 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, C3-6 cycloalkoxy, carbocyclic aryloxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, and carbocyclic aryl, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy carbonyl C1-5 alkoxy carbonyl substituted by carbocyclic aryl, and carbocyclic aryl; L is Formula (VII); Y is —C(O)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is indanyl, adamantly, or 9H-fluorenyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, 4H-benzo[1,3]dioxinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, piperidyl, pyridyl, or thienyl; halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

43. The compound according to claim 42 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—: R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

44. The compound according to claim 43 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxy carbonyl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, (iii) heterocyclyl, and heterocyclyl substituted by C1-5 alkyl, and heterocyclyl substituted by carbocyclic aryl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is isoxazolyl; halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

45. The compound according to claim 1 selected from the group consisting of: N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2-ethyl-6-methylphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-fluorophenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-mesitylurea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2,4,6-tribromophenyl)urea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(2-chlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethyl-6-isopropylphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethylphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-isopropyl-6-methylphenyl)urea; N-(2-tert-butyl-6-methylphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(diphenylmethyl)urea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(3-methyl-5-phenylisoxazol-4-yl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-1-naphthylurea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-[1-(1-naphthyl)ethyl]urea; N-(2,4-dibromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(2,4-dichlorobenzyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl) urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethoxyphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-fluorobenzyl)urea; N-(cis-4-{[4-(diethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)urea; N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(4-chloro-2-methylphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-fluorobenzyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-methoxy-2-methylphenyl)urea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-[1-(4-bromophenyl)ethyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(5-methyl-3-phenylisoxazol-4-yl)urea; N-(2,3-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-methylphenyl)urea; N-(2,6-diisopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2,4,5-trichlorophenyl)urea; N-(2,5-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(4-bromo-2-chlorophenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea; N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea; ethyl N-({[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]-amino}cyclohexyl)methyl]amino}carbonyl)leucinate; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(4-fluorophenyl)urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-mesitylurea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea; N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)methyl]urea; N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)urea; N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea; N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)methyl]urea; and 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5,6,7,8-tetrahydro-quinazolin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

46. The compound according to claim 29 wherein R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: mono-C1-5 alkylamino, di-C1-5 alkylamino, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkoxy, heterocyclyl, (ii) C2-5 alkynyl, (iii) C2-5 alkenyl, (iv) C3-12 cycloalkyl, (v) carbocyclyl, (vi) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, and oxo, carboxy, C1-5 alkoxy carbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by nitro, mono-C1-5 alkylamino, di-C1-5 alkylamino, C1-5 alkoxy carbonylamino, carbocyclic aryl azo, carbocyclic aryl azo substituted by substituent(s) independently selected from the group consisting of: mono-C1-5 alkylamino, and di-C1-5 alkylamino, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by nitro, amino sulfonyl, heterocyclyl sulfonyl, C3-6 cycloalkyl, C3-6 cycloalkyl substituted by C1-5 alkyl, carbocyclic aryl, and heterocyclyl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy carbonyl, carbocyclic aryloxy, carbocyclic aryl, and heterocyclyl; L is Formula (VII); Y is —C(S)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is indanyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, or adamantly; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, 4,5,6,7-tetrahydro-benzo[b]thienyl, benzo[1,3]dioxolyl, benzo[2,1,3]thiadiazolyl, furyl, isoxazolyl, morpholinyl, oxazolyl, phenanthro[9,10-d]oxazolyl, piperidyl, pyrazolyl, pyridyl, tetrahydrofuryl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

47. The compound according to claim 46 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—: R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

48. The compound according to claim 47 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by carbocyclic aryl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, mono-C1-5 alkylamino, and di-C1-5 alkylamino; wherein carbocyclic aryl is phenyl or naphthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

49. The compound according to claim 1 selected from the group consisting of: N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea; N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea; N-[4-(dimethylamino)-1-naphthyl]-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-methoxy-5-methylphenyl)thiourea; N-(4-bromo-2-chlorophenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(4-iodophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2,4,6-tribromophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-(2,4,6-trichlorophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′-mesitylthiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,4-dimethylphenyl)thiourea; N-(2,6-diethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(4-bromo-2-methylphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-[4-bromo-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea; N-(4-chloro-2-methylphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea; N-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}-cyclohexyl)-N′4-fluoro-2-methylphenyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-4-methoxy-2-methylphenyl)thiourea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(2,4-dichloro-6-methylphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2-ethoxyphenyl)thiourea; N-[4-bromo-2-(trifluoromethoxy)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}cyclohexyl)thiourea; N-(4-chloro-2,5-dimethoxyphenyl)-N′-(cis4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin2-yl]amino}cyclohexyl)thiourea; and N-(cis-4-{[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino}-cyclohexyl)-N′-(2,2-diphenylethyl)thiourea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

50. The compound according to claim 29 wherein R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (ii) C2-5 alkenyl, (iii) carbocyclyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy; L is Formula (VII); Y is —(O)O—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 9H-fluorenyl or menthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

51. The compound according to claim 50 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

52. The compound according to claim 2 wherein Q is Formula (IV); p is 0; R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by nitro, carbocyclic aryloxy substituted by C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, mono-C1-5 alkylamino substituted by carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by carbocyclic aryl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino, di-carbocyclic arylamino substituted by C1-5 alkyl, C1-5 alkoxycarbonylamino, carbocyclic arylcarbonylamino, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by halogen, and carbocyclic aryl substituted by C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by nitro, heterocyclylthio substituted by C1-5 alkyl, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C2-5 alkenyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (iii) C2-5 alkynyl, and C2-5 alkynyl substituted by carbocyclic aryl, (iv) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by oxo, C1 5 alkyl substituted by carbocyclic aryl, and carbocyclic aryl, (v) carbocyclyl, (vi) carocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and halogenated carbocyclic aryl, C2-5 alkenyloxy, C34 cycloalkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, C1-5 alkoxycarbonyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by cyano, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, carbocyclic aryl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and halogenated carbocyclic aryl, (vii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, and C1-5 alkyl substituted by halogen, heterocyclyl; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-fluorenyl, 9-oxo-9H-fluorenyl, bicyclo[2.2.1]heptyl, indenyl, or menthyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 3,4-dihydro-2H-benzot[b][1,4]dioxepinyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 4-oxo-benzopyranyl, 9H-carbazolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, iniidazo[2,1-b]thiazolyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

53. The compound according to claim 52 wherein R1 is selected from the group consisting of: (i) C1-7 alkyl, and C1-7 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, mono-C1-5 alkylamino, mono-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, di-C1-5 alkylamino, di-C1-5 alkylamino substituted by substituent(s) independently selected from the group consisting of: cyano, and carbocyclic aryl, monocarbocyclic arylamino, di-carbocyclic arylamino, monocarbocyclic arylamino substituted by C1-5 alkyl, di-carbocyclic arylamino substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkoxy, (ii) C2-7 alkenyl, and C2-7 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkoxy, (iii) C2-5 alkynyl, and C2-5 alkynyl substituted by carbocyclic aryl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and carbocyclic aryl substituted by halogen, C2-5 alkenyloxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, di-C1-5 alkylamino substituted by cyano, C1-5 alkylthio, and C1-5 alkylthio substituted by halogen, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by hydroxy, C1-5 alkoxy, carbocyclic arylthio, carbocyclic arylthio substituted by C1-5 alkoxycarbonyl, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen; L is Formula (VII); Y is a single bond or —CH2—; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzo[1,4]dioxinyl, 4-oxo-benzopyranyl, 9H-carbazolyl, benzo[1,3]dioxolyl, benzo[b]thienyl, furyl, imidazo[2,1-b]thiazolyl, pyrazolyl, pyridyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

54. The compound according to claim 53 wherein R2 is methylamino, or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

55. The compound according to claim 54 wherein R1 is selected from the group consisting of: (i) C2-5 alkenyl, and C2-5 alkenyl substituted by carbocyclic aryl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, carbocyclic aryl, and carbocyclic aryl substituted by halogen, C2-5 alkenyloxy, mono-C1-5 alkylamino, di-C-1-5 alkylamino, mono-C1-5 alkylamino substituted by cyano, and di-C1-5 aikylamino substituted by cyano, (iii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 9H-carbazolyl, benzo[1,3]dioxolyl, pyrazolyl, or pyridyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

56. The compound according to claim 55 wherein R1 is selected from the group consisting of: (i) C2-5 alkenyl, and C2-5 alkenyl substituted by carbocyclic aryl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C2-5 alkenyloxy, (iii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxycarbonyl, carbocyclic aryl, carbocyclic aryl substituted by C1-5 alkyl, and carbocyclic aryl substituted by halogenated C1-5 alkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 1H-indolyl, 9H-carbazolyl, benzo[1,3]dioxolyl, or pyrazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

57. The compound according to claim 1 selected from the group consisting of: N2-(cis-4-{[(5-bromo-1H-indol-3-yl)methyl]amino}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[5-(4-fluorophenyl)pyridin-3-yl]methyl}amino)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)amino]methyl}-1H-indole-2-carboxylate; N2-(cis-4-{[(2,6-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine2,4-diamine; N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[(5-methoxy-1H-indol3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; 4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]amino}methyl)-6-methoxyphenol; N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(3,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)-2-iodo-6-methoxyphenol; 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2,6-dimethylphenol; N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine2,4-diamine; N2-[cis-4-({[4-(diethylamino)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[(9-ethyl-9H-carbazol3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diaamine; N2-(cis-4-{[(4-isopropoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2-ethoxyphenol; N2-{cis-4-[({[4-(dimethylamino)-1-naphthyl]methyl}amino)methyl]-cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N2-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,4-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine2,4-diamine; N4,N4-dimethyl-N2-[cis-4-({[(1-methyl-1H-indol3-yl)methyl]amino}-methyl)cyclohexyl]pyrimidine-2,4-diamine; N2-[cis-4-({[(7-methoxy-1,3-benzodioxol5-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(4-methoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(4-methoxy-2,5-dimethylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; 3-[[4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]amino}methyl)phenyl](methyl)amino]propanenitrile; N2-{cis-4-[({4-[(4-bromobenzyl)oxy]benzyl}amino)methyl]cyclohexyl}-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[4-(4-bromo-2-trifluoromethoxy-benzyl)amino-cyclohexyl]-N4,N4-dimethyl-pyrimidine2,4-iamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4,N4-dimethyl-pyrimidine-2,4-diamine; and N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4,N4-dimethyl-pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

58. The compound according to claim 57 selected from the group consisting of: ethyl 4,6-dichloro-3-{[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)amino]methyl}-1H-indole-2-carboxylate; N2-[cis-4-({[(4-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[(2-methoxy-1-naphthyl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; 4-bromo-2-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]amino}methyl)-6-methoxyphenol; N2-[cis-4-({[(5-bromo-1H-indol-3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,3,4-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N2-(cis-4-{[(3-ethoxy-4-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[({3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl}methyl)amino]methyl}cyclohexyl)pyrimidine-2,4-diamine; 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2-iodo6-methoxyphenol; 4-({[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-amino}methyl)-2,6-dimethylphenol; N2-(cis-4-{[(5-bromo-2,4-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(5-bromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine2,4-diamine; N2-[cis-4-({[(9-ethyl-9H-carbazol3-yl)methyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,3-diphenylprop-2-en-1-yl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,6-trimethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine2,4-diamine; N2-(cis-4-{[(5-bromo-2-ethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,4-dimethoxy-3-methylbenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(2,5-diethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3,5-dibromo-2-methoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N4,N4-dimethyl-N2-(cis-4-{[(2,4,5-triethoxybenzyl)amino]methyl}-cyclohexyl)pyrimidine-2,4-diamine; N2-[cis-4-({[2-(allyloxy)benzyl]amino}methyl)cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-[cis-4-({[(7-methoxy-1,3-benzodioxol5-yl)methyl]amino}methyl)-cyclohexyl]-N4,N4-dimethylpyrimidine-2,4-diamine; N2-(cis-4-{[(3-bromo-4,5-dimethoxybenzyl)amino]methyl}cyclohexyl)-N4,N4-dimethylpyrimidine-2,4-diamine; N2-{cis-4-[2-(4-bromo-2-trifluoromethoxy-phenyl)-ethylamino]-cyclohexyl}-N4,N4-dimethyl-pyrimidine-2,4-diamine; and N2-{cis-4-[(4-bromo-2-trifluoromethoxy-benzyl)amino-methyl]-cyclohexyl}-N4,N4-dimethyl-pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

59. The compound according to claim 52 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, C1-5 alkylcarbonyloxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by nitro, carbocyclic aryloxy substituted by C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by C1-5 alkyl, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by halogen, carbocyclic arylcarbonylamino, C1-5 alkoxycarbonylamino, C1-5 alkylthio, C1-5 alkylthio substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, carbocyclic arylthio, heterocyclylthio, heterocyclylthio substituted by C1-5 alkyl, heterocyclylthio substituted by nitro, C3-6 cycloalkyl, C3-6 cycloalkenyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkoxy, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryl, and heterocyclyl, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and nitro, (iii) C3-6 cycloalkyl, and C3-6 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, *C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, and carbocyclic aryl, and carbocyclic aryl, (iv) carbocyclyl, (v) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, carbocyclic aryloxy, carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkyl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, amino, mono-C1-5 alkylamino, di-C1-5 alkylamino, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, (carbocyclic aryl)NHC(O)NH, (carbocyclic aryl)NHC(O)NH substituted by C1-5 alkoxy, (carbocyclic aryl)NHC(O)NH substituted by haloganated C1-5 alkoxy, C1-5 alkylthio, C1-5 alkylthio substituted by halogen, carbocyclic arylthio, carbocyclic arylthio substituted by cyano, mono-C1-5 alkylaminosulfonyl, di-C1-5 alkylaminosulfonyl, and carbocyclic aryl, carbocyclic aryl substituted by halogen, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and halogenated carbocyclic aryl, (vi) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C2-5 alkenylthio, carbocyclic arylthio, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkyl, heterocyclyl; L is Forrnula (VII); Y is —C(O)—; wherein carbocyclic aryl is phenyl, naphthyl, or anthranyl; carbocyclyl is 1,2,3,4-tetrahydronaphthyl, 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-1-oxo-isoindolyl, 2,3-dihydro-benzofuryl, 2,4-dihydro-3-oxo-pyrazolyl, 2H-benzopyranyl, 2-oxo-benzopyranyl, 4-oxo-1,5,6,7-tetrahydro-indolyl, 9H-xanthenyl, benzo[1,3]dioxolyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, benzofuryl, benzothiazolyl, furyl, imidazolyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, pyrimidyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

60. The compound according to claim 59 wherein R2 is hydrogen, trifluoromethyl, methoxy, methylamino, dimethylamino, ethylamino, ethylmethylamino, or hydroxylethylmethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

61. The compound according to claim 60 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-arbocyclic arylamino substituted by halogen, carbocyclic arylcarbonylamino, C1-5 alkylthio, C3-6 cycloalkyl, carbocyclyl, carbocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by C1-5 alkylsulfinyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, and heterocyclyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carbocyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and nitro, (iii) carbocyclyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, oxo, and carbocyclic aryl, C1-5 alkoxy, C1-5 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, mono-C1-5 alkylamino, di-C1-5 alkylamino, C2-5 alkynylcarbonylamino, C2-5 alkynylcarbonylamino substituted by carbocyclic aryl, mono-C1-5 alkylaminosulfonyl, and di-C1-5 alkylaminosulfonyl, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryl, carbocyclic aryl substituted by halogen, and heterocyclyl, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, C1-5 alkylthio, C1-5 alkylsulfonyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkyl, heterocyclyl; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 1-oxo-indanyl, 9-oxo-9H-fluorenyl, or indenyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzofuryl, 2H-benzopyranyl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, morpholino, pyrazolyl, pyridyl, quinolyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

62. The compound according to claim 61 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylamino, di-C1-5 alkylamino, mono-carbocyclic arylamino, di-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, di-carbocyclic arylamino substituted by halogen, C1-5 alkylthio, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, C1-5 alkyl, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, carboyclic aryl, and carbocyclic aryl substituted by halogen, (ii) C2-5 alkenyl, and C2-5 alkenyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by nitro, (iii) carbocyclyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by C1-5 alkoxy, mono-C1-5 alkylaminocarbonyl, di-C1-5 alkylaminocarbonyl, Mono-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, di-C1-5 alkylaminocarbonyl substituted by carbocyclic aryl, mono-C1-5 alkylaminosulfonyl, and di-C1-5 alkylaminosulfonyl, (v) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkylthio, C1-5 alkylthio substituted by carbocyclic aryl, and C1-5 alkylthio substituted by halogenated carbocyclic aryl, carbocyclic aryloxy, carbocyclic aryloxy substituted by halogen, carbocyclic aryloxy substituted by C1-5 alkyl, carbocyclic aryl, carbocyclic aryl substituted by halogen, carbocyclic aryl substituted by nitro, and heterocyclyl; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 1-oxo-indanyl; heterocyclyl is 1,2,3-triazolyl, 1H-indolyl, 1H-pyrrolyl, 2,3-dihydro-benzofuryl, 9H-xanthenyl, benzo[2,1,3]oxadiazolyl, benzo[1,2,5]oxadiazolyl, benzo[b]thienyl, furyl, isoxazolyl, pyridyl, quinoxalyl, thiazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

63. The compound according to claim 1 selected from the group consisting of: N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxanide; 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-methyl-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybutanamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,5-dimethyl-3-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; 2,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene3-carboxamide; 1-benzyl-3-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-1H-pyrazole-5-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-naphthyl)acetamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)cyclopentanecarboxamide; 3-(2-chloro-6-fluorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrirmidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl2H1,2,3-triazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxyacetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(pentafluorophenoxy)acetamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxynicotinamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methylphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide; 2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide; 3-tert-butyl-1-(2,4-dichlorobenzyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-pyrazole-5-carboxamide; 6-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2H-chromene-3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide; 5-(4chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-iodo-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(4-methyl-2-nitrophenyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene2-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide; 1-benzyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1H-indole-3-carboxamide; 3-acetyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide; 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiophene2-carboxamide; 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide; N2,N6-dibenzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)lysinamide; 3-(dimethylamino)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(5-methyl-2-phenyl1,3-thiazol-4-yl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)-4-oxo-4-phenylbutanamide; 4-(4-bromophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-(1H-indol-3-yl)-4-oxobutanamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-[(3-phenylprop-2-ynoyl)amino]benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol3-yl)-4-(4-methylphenyl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1-(3-morpholin4-ylpropyl)-5-phenyl-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(4-nitrophenyl)butanamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl1H-indol3-yl)acetamide; N2-benzoyl-N5-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-N1,N1-dipropylglutamamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-phenoxybenzamide; 3-benzoyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide; N-(cis-4-1[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-[(1R)-1-(1-naphthyl)ethyl]phthalamide; (2S)-2-(3-benzoylphenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)propanamide; N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis [(1S)-1-phenylethyl]phthalamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-{(1E)-5-fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-[4-(2-thienylcarbonyl)phenyl]propanamide; 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl1H-pyrrole-3-carboxamide; 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-5-pheny-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenoxybenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-phenylquinoline-4-carboxamide; 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole-3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-(3-nitrophenyl)-2-furamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodo4-(isopropylsulfonyl)-5-(methylthio)thiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro1H-pyrrole-2-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethyl-4-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-mesityl-2-oxoacetamide; 3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hydroxybenzamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide; (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-phenylacrylamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-nitrobenzamide; 2-(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]acetamide; 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide; 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide; 2,4-dichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]-5-fluorobenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenoxybutanamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(3-methoxyphenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(4-methoxyphenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide; (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino]cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide; 2-(2-bromophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]2-(propylthio)nicotinamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]2-(1-naphthyl)acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]9-oxo9H-fluorene-4-carboxamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,4,6-trimethylbenzamide; 2,4,6-trichloro-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)methyl]benzamide; (2E)-3-(2-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acrylamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,3-diphenylpropanamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-5-iodo2-furamide; (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]3-oxoindane1-carboxamide; 2-benzyl-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]benzamide; 2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]3-methyl-4-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]3-methoxy-4-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]9H-xanthene9-carboxamide; 2-(1-benzothien3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide; 5-bromo-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-nicotinamide; 3-chloro-4-fluoro-N-[cis-4-(4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide; 3-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexylmethyl]-3,4-difluoro-benzamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide; and N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

64. The compound according to claim 63 selected from the group consisting of: 3-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2,1,3-benzoxadiazole-5-carboxamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-benzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-iodobenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methyl-2-phenyl2H1,2,3-triazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)-5-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-quinoxaline-2-carboxamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)acetamide; 3-(2,6-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl}2-(4-methylphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-4-[(dipropylamino)sulfonyl]benzamide; 2-(2,3-dihydro-1-benzofuran-5-yl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1,3-thiazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-thienyl)-1,3-thiazole-4-carboxamide; 5-(4-chloro-2-nitrophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-3-methoxy-4-nitrobenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-furamide; 5-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide; 2-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)acetamide; 4,5-dibromo-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1H-indol3-yl)-4-oxo-4-phenylbutanamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(1-methyl-1H-indol3-yl)-4-(4-methylphenyl)-4-oxobutanamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(2-phenyl1H-indol3-yl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-(ethylthio)-2,2-diphenylacetamide; N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N,N-bis[(1S)-1-phenylethyl]phthalamide; 3-(benzyloxy)-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,5-diphenyl1H-pyrrole-3-carboxamide; 1-{2-[(2-chloro-6-fluorobenzyl)thio]ethyl}-N-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)-2-methyl-5-phenyl-1H-pyrrole-3-carboxamide; 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-5-nitrothiophene-3-carboxamide; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-1-methyl-4-nitro1H-pyrrole-2-carboxamide; 3,5-di-tert-butyl-N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)-4-hydroxybenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2,2-diphenylacetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-phenylbutanamide; (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(4-nitrophenyl)acrylamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]2-(1-naphthyl)acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-2-(2,3,6-trichlorophenyl)acetamide; (2E)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-methyl]-3-(3-nitrophenyl)acrylamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]3-oxoindane-1-carboxamide; 2,2-bis(4-chlorophenyl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]3-methyl-4-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methoxy-4-nitrobenzamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl}methyl]-2-[2-(trifluoromethoxy)phenyl]acetamide; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]9H-xanthene-9-carboxamide; 2-(1-benzothien3-yl)-N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]acetamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(4-fluoro-phenoxy)-nicotinamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; C-[cis-(4-chloro-phenyl)-ethyl-amino]-N-[4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; 4-chloro-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; 2-(3,4-dichloro-phenoxy)-N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-2-(3-methoxy-phenoxy)-acetamide; and N-[cis-4-(4-dimethylamino-pyrimidin-2-ylamino)-cyclohexyl]-C-(ethyl-phenyl-amino)-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

65. The compound according to claim 52 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkoxy carbonyl, C1-5 alkylthio, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C2-5 alkenyl, (ii) C3-6 cycloalkyl, C3-6 cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy carbonyl, C1-5 alkoxy, C3-6 cycloalkoxy, carbocyclic aryloxy, C1-5 alkylthio, and carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkyl substituted by halogen, and carbocyclic aryl; L is Formula (VII); Y is —C(O)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl,3,4-dihydro-2H-benzo[b][1,4]dioxepinyl, benzo[1,3]dioxolyl, furyl, or isoxazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

66. The compound according to claim 65 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—: R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

67. The compound according to claim 66 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by carbocyclic aryl, (ii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C3-6 cycloalkoxy, (iii) heterocyclyl, and heterocyclyl substituted by C1-5 alkyl, and heterocyclyl substituted by carbocyclic aryl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is isoxazolyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

68. The compound according to claim 1 selected from the group consisting of: N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-mesitylurea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)urea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(diphenylmethyl)urea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-[1-(1-naphthyl)ethyl]urea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl}-N′-(3,4,5-trimethoxyphenyl)urea; N-(4-chloro-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)urea; N-(4-bromo-2-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)urea; N-(2,6-dibromo-4-isopropylphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)urea; N-[3-(cyclopentyloxy)-4-methoxyphenyl]-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,6-dimethylphenyl)urea; N-(2,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-methylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(4-fluorophenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-mesitylurea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-trichlorophenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,4,6-tribromophenyl)urea; N-(2,4-dibromo-6-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl)urea; N-(2,6-diethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-(2-chloro-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-ethyl-6-isopropylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-isopropyl-6-methylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-3-nitrophenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-propylphenyl)urea; N-(2-tert-butyl-6-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-(2-tert-butylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-(3-chloro-2-methylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-(4-bromo-2,6-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[4-chloro-2-(trifluoromethyl)phenyl]-N′-[(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(diphenylmethyl)urea; N-(4-bromo-2,6-dimethylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(3-methyl-5-phenylisoxazol-4-yl)urea; N-(3,5-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; N-(2,3-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; N-(2,6-diisopropylphenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2,3-dimethyl-6-nitrophenyl)urea; N-(2,6-dibromo-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; N-(2,6-dichlorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methoxy-5-methylphenyl)urea; N-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]-N′-(2-methyl-6-nitrophenyl)urea; N-(3,4-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; N-(3,5-difluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)methyl]urea; and N-(3-chloro-4-fluorophenyl)-N′-[(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)methyl]urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

69. The compound according to claim 52 wherein R1 is selected from the group consisting of: (i) C1-5 alkyl, and C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, (ii) carbocyclyl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy carbonyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, mono-C1-5 alkylamino, di-C1-5 alkylamino, and carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, C1-5 alkoxy carbonyl, and carbocyclic aryl; L is Formula (VII); Y is —C(S)NR5—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is bicyclo[2.2.1]heptyl; heterocyclyl is 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, isoxazolyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

70. The compound according to claim 69 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—; R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

71. The compound according to claim 70 wherein R1 is selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, C1-5 alkyl, C1-5 alkoxy, mono-C1-5 alkylamino, and di-C1-5 alkylamino; wherein carbocyclic aryl is phenyl or naphthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

72. The compound according to claim 1 selected from the group consisting of: N-(4-cyanophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}-cyclohexyl)thiourea; N-(2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(3,4,5-trimethoxyphenyl)thiourea; N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]-amino}cyclohexyl)thiourea; N-[4-(dimethylamino)-1-naphthyl]-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)thiourea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-tribromophenyl)thiourea; N-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)-N′-mesitylthiourea; N-(4-bromo-2,6-dimethylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea; N-(5-chloro-2,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-pyrimidin-2-yl]amino}cyclohexyl)thiourea; N-(2,4-dibromo-6-fluorophenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimiidin-2-yl]amino}cyclohexyl)thiourea; and N-(2,4-dichloro-6-methylphenyl)-N′-(cis-4-{[4-(dimethylamino)pyrimidin-2-yl]amino}cyclohexyl)thiourea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

73. The compound according to claim 52 wherein R1 is selected from the group consisting of: (i) C1-8 alkyl, and C1-8 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, C1-5 alkoxy substituted by carbocyclic aryl, carbocyclyl, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, and C1-5 alkoxy, (ii) C2-5 alkenyl, (iii) carbocycyl, (iv) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy; L is Formula (VII); Y is —C(O)O—; wherein carbocyclic aryl is phenyl or naphthyl; carbocyclyl is 9H-fluorenyl or menthyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

74. The compound according to claim 73 wherein R2 is methylamino or dimethylamino; p is 0; R3 and R4 are hydrogen; A is a single bond; B is a single bond or —CH2—: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

75. The compound according to claim 2 wherein Q is Formula (IV); p is 1 or 2; R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, oxo, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, mono-carbocyclic arylamino, monocarbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, and C1-5 alkyl, carbocyclic arylsulfinyl, carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkylcarbonylamino, C3-6 cycloalkylcarbonylauino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, and heterocyclyl, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of: C1-5 alkoxy, halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, and hydroxy, C1-9 alkoxy, C1-9 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, carboxy, C1-5 alkoxycarbonyl, di-C1-5 alkylamino, C1-5 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, C1-5 alkylthio, C1-5 alkylsulfinyl, C1-5 alkylsulfonyl, carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, amino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by halogen, heterocyclyl sulfonyl, heterocyclyl sulfonyl substituted by C1-5 alkyl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, C1-5 alkylthio, C1-5 alkylsulfinyl, carbocyclic arylsulfinyl, carbocyclic arylsulfinyl substituted by halogen, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, C1-5 alkyl, and C1-5 alkyl substituted by halogen, R2 is selected from the group consisting of: amino, C1-5 alkyl, C1-5 alkoxy, —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl or C3-6 cycloalkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 3,4-dihydro-1H-isoquinolinyl, benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

76. The compound according to claim 75 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: oxo, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, (ii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic arylsulfinyl, and carbocyclic arylsulfinyl substituted by halogen, L is Formula (VII); Y is a single bond or —CH2—; R2 is —N(R2a)(R2b), wherein R2a is C1-5 alkyl and R2b is C1-5 alkyl; carbocyclic aryl is phenyl; heterocyclyl is pyrazinyl; and halogen is fluoro, chloro, or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

77. The compound according to claim 76 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, (ii) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic arylsulfinyl, and carbocyclic arylsulfinyl substituted by halogen, R2 is —N(R2a)(R2b), wherein R2a is C1-5 alkyl and R2b is C1-5 alkyl; carbocyclic aryl is phenyl; heterocyclyl is pyrazinyl; and halogen is fluoro or bromo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

78. The compound according to claim 77 wherein R1 is selected from the group consisting of: heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic arylsulfinyl, and carbocyclic arylsulfinyl substituted by halogen, R2 is —N(R2a)(R2b), wherein R2a is C1-5 alkyl and R2b is C1-5 alkyl; carbocyclic aryl is phenyl; heterocyclyl is pyrazinyl; and halogen is fluoro; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

79. The compound according to any one of claims 76 to 78 wherein p is 1 and T is C1-5 alkyl; R3 and R4 are both hydrogen; A and B are both single bonds: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

80. The compound according to claim 1 selected from the group consisting of: N2-{cis-4-[(3,5-dimethoxybenzyl)amino]cyclohexyl}-N4,N4,5-trimethylpyrimidine-2,4-diamine; N2-{cis-4-[(3-bromobenzyl)amino]cyclohexyl}-N4,N4,5,6-tetramethylpyrimidine-2,4-diamine; N2-{cis-4-[(3,4-difluorobenzyl)amino]cyclohexyl}-N4,N4,5,6-tetramethylpyrimidine-2,4-diamine; and N2-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin2-yl}amino)cyclohexyl]-N4,N4,5-trimethylpyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

81. The compound according to claim 1 is: N2-[cis-4-({6-[(3,4-difluorophenyl)sulfinyl]pyrazin2-yl}amino)cyclohexyl]-N4,N4,5-trimethylpyrimidine-2,4-diamine; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

82. The compound according to claim 75 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, and C1-5 alkyl, carbocyclic arylsulfinyl, carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of: C1-5 alkoxy, halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, and hydroxy, C1-9 alkoxy, C1-9 alkoxy substituted by halogen, carboxy, C1-5 alkoxycarbonyl, di-C1-5 alkylamino, C1-5 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, C1-5 alkylsulfonyl, and carbocyclic aryl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, amino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by halogen, heterocyclyl sulfonyl, heterocyclyl sulfonyl substituted by C1-5 alkyl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, C1-5 alkylthio, C1-5 alkylsulfinyl, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, C1-5 alkyl, and C1-5 alkyl substituted by halogen, L is Formula (VII); Y is —C(O)—; R2 is selected from the group consisting of: amino, C1-5 alkyl, C1-5 alkoxy, —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl or C3-6 cycloalkyl; wherein carbocyclic aryl is phenyl; heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyrimidyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

83. The compound according to claim 82 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by halogen, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, and C1-5 alkyl, carbocyclic arylsulfinyl, carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituent(s) independently selected from the group consisting of: C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of: C1-5 alkoxy, halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, and hydroxy, C1-9 alkoxy, C1-9 alkoxy substituted by halogen, carboxy, C1-5 alkoxycarbonyl, and C1-5 alkylsulfonyl, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by halogen, heterocyclyl sulfonyl, heterocyclyl sulfonyl substituted by C1-5 alkyl, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by halogen, C1-5 alkylthio, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by substituents(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, R2 is selected from the group consisting of: C1-5 alkoxy, —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl; heterocyclyl is benzo[1,3]dioxolyl, furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

84. The compound according to claim 83 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: hydroxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, heterocyclyloxy, heterocyclyloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, mono-carbocyclic arylamino, mono-carbocyclic arylamino substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkoxy, and C1-5 alkyl, carbocyclic arylsulfinyl, carbocyclic arylsulfinyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by substitutent(s) independently selected from the group consisting of: C1-5 alkoxy, halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, cyano, nitro, C1-10 alkyl, C1-10 alkyl substituted by halogen, C1-9 alkoxy, and C1-9 alkoxy substituted by halogen, (iv) heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, C1-5 alkyl substituted by halogen, and C1-5 alkoxy, C1-5 alkylthio, carbocyclic arylsulfonyl, carbocyclic arylsulfonyl substituted by halogen, R2 is selected from the group consisting of: —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl; heterocyclyl is benzo[1,3]dioxolyl, furyl, pyrazolyl, pyridyl, or thienyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

85. The compound according to any one of claims 82 to 84 wherein p is 1 and T is C1-5 alkyl; R3 and R4 are both hydrogen; A is a single bond and B is a single bond or —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

86. The compound according to claim 1 selected from the group consisting of: N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide; N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide; N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide; 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,4-difluorobenzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]3-fluoro-4-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethoxy)benzamide; 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrim-idin-2-yl]amino}cyclohexyl)methyl]3-methylbenzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]3-fluoro-4-(trifluoromethyl)benzamide; 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; 4-chloro-N-[(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-dimethoxybenzamide; 4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-ylamino}methyl)cyclohexyl]benzamide; 4-bromo-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]3-methylbenzamide; 3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide; 3,4-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide; N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,5-bis(trifluoromethyl)benzamide; N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]-3,4-difluorobenzamide; 4-bromo-N-[cis-4-({[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide; 4-bromo-N-[cis-4-({[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide; N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide; 2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide; 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide; 2-(3,4-dichiorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-ethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-[cis-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide; 2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(5-chloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; 2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy2-(4-methoxyphenyl)acetamide; 2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy2-[3-(trifluoromethyl)phenyl]acetamide; N-(cis-4-{[4-(dimethyiamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]sulfinyl}acetamide; 2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(3,4-difluorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 2-[(3,4-dichlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfinyl}acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide; 2-(tert-butylthio)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclobexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(methylsulfonyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide; 4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]aminol}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino}-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methoxybenzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylisoxazole-3-carboxamide; 2-(3,5-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-methyl-1,3-oxazole-4-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; 4-bromo-N-(cis-4-{[4-dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-5-methylthiophene-2-carboxamide N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-6-(trifluoromethyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl}3,5-diethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide; 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxanide; 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]benzamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)propanamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide; N2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methyl-N2-(3-methylphenyl)glycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-fluorophenyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(4-fluorophenyl)-N2-methylglycinamide; N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-methoxyphenyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(4-methoxyphenyl)-N2-methylglycinamide; 2-[(3,4-difluorophenyl)amino]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-[(4-bromophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}acetamide; 2-[(2-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-[(3-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 3,4-dichloro-N-{cis-4-[(4-methoxy-5-methylpyrimridin-2-yl)amino]cyclohexyl}benzamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; 3-chloro-N-[cis-4-(4-dimethylamino5-methyl-pyrimidin-2-ylamino)-cyclohexyl]4-fluoro-benzamide; 4-chloro-N-[cis-4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]3-fluoro-benzamide; 3-chloro-N-[cis-4-(4-dimethylamino6-methyl-pyrimidin-2-ylamino)-cyclohexyl]5-fluoro-benzamide; N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide; 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide; and 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

87. The compound according to claim 1 selected from the group consisting of: N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-bis(trifluoromethyl)benzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3,5-dimethoxybenzamide; N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-(trifluoromethyl)benzamide; 4-bromo-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]-3-methylbenzamide; 3,5-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; 3,4-dichloro-N-[(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)methyl]benzamide; 3,5-dichloro-N-[cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}methyl)cyclohexyl]benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-fluorophenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino}-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4,5-trimethoxybenzamide; N-(4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-nitrobenzamide; N-cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-diphenylacetamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methylphenoxy)nicotinamide; 2-(4-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(4-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-fluorophenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)nicotinamide; 2-(2-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinanide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-methoxyphenoxy)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(4-iodophenoxy)nicotinamide; 2-(3,4-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-(2,3-dichlorophenoxy)-N-(cis-4-{[5-methyl-4-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(3,4-difluorophenyl)sulfonyl]-N-(cis-4-({[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-[cis-4-({4-[ethyl(methyl)amino]-5-methylpyrimidin-2-yl}amino)cyclohexyl]-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(2-methoxyphenoxy)nicotinamide; 2-(2-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 2-(3-bromophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-fluorophenoxy)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(3-methoxyphenoxy)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-[3-(trifluoromethyl)phenoxy]acetamide; 2-(3-chlorophenoxy)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; 2-[(5-hloropyridin-3-yl)oxy]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino]cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-(4-methoxyphenyl)acetamide; 2-(2,3-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxy-2-[3-(trifluoromethyl)phenyl]acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[2-(trifluoromethyl)phenyl]sulfinyl}acetamide; 2-[(2-chlorophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cydohexyl)acetamide; 2-[(3-bromophenyl)sulfinyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluorobenzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,4-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,5-difluorobenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,3,4-trifluorobenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-cyano-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(isopropylthio)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-(propylthio)nicotinamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-yano-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrinmidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 3-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-dimethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-cyano-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-2,6-dimethoxynicotinamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethyl)benzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclobexyl)-5-methylthiophene-2-carboxamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzarwde; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 4-bromo-N-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-bis(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-(trifluoromethyl)benzamide; N-cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluorobenzamide; N-(cis-4-{[4-(dimethylaryino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-fluoro-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-4-methylbenzamide; 3,5-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-difluorobenzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-methylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethylbenzamide; 4-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-ethylbenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-3-isopropoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; 5-chloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-fluoro-5-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2,2-difluoro-1,3-benzodioxole-5-carboxamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-ethoxybenzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-furamide; N-cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3,5-diethoxybenzamide; 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-3-(trifluoromethyl)benzamide; 5-bromo-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; 3,4-dichloro-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)benzamide; 3-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-(trifluoromethoxy)benzamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide; N-(cis-4-{[4-(dimethylainno)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-4-methoxy-3-(trifluoromethyl)benzamide; 2-(4-chlorophenyl)-N-cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 1-4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide; 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-2-methylpropanamide 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 1-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclobutanecarboxamide; 1-(2,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)acetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methylphenyl)cyclopropanecarboxamide; 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)propanamide 2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-hydroxyacetamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-1-(4-methoxyphenyl)cyclopropanecarboxamide; N2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methyl-N2-(3-methylphenyl)glycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-fluorophenyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(4-fluorophenyl)-N2-methylglycinamide; N2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-methylglycinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N2-(3-methoxyphenyl)-N2-methylglycinamide; 2-(3,4-dichlorophenoxy)-N-(cis-4-{[4-methyl-6-(methylamino)pyrimidin-2-yl]amino}cyclohexyl)acetamide; trans-2-(4-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3-chlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3,4-difluorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-(3,4-dichlorophenyl)-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; trans-2-[3,5-bis(trifluoromethyl)phenyl]-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)cyclopropanecarboxamide; 2-[(4-chlorophenyl)sulfonyl]-N-(cis-4-{[4-(dimethylamino}-5-methylpyrimidin-2-yl]amino}cyclohexyl)nicotinamide; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-2-{[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy}acetamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-2-phenoxy-nicotinamide; 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-4-fluoro-benzamide; 4-chloro-N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide; 3-chloro-N-[cis-4-(4-dimethylano-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide; N-[cis-4-(4-dimethylamino-6-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; 3-chloro-4-fluoro-N-[cis-4-(5-methyl-4-methylamino-pyrimidin-2-ylamino)-cyclohexyl]-benzamide; 4-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3-fluoro-benzamide; 3-chloro-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-5-fluoro-benzamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,4,5-trifluoro-benzamide; N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-3,5-difluoro-benzamide; and 2-(3,4-difluoro-phenyl)-N-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexyl]-acetamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

88. The compound according to claim 75 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkylcarbonylamino, C3-6 cycloalkylcarbonylamino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-10 alkyl, C1-10 alkyl substituted by halogen, C1-9 alkoxy, and C1-5 alkylthio, (iv) heterocyclyl, L is Formula (XV); Y is —C(O)NR5—; R2 is selected from the group consisting of: —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

89. The compound according to claim 88 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkoxy, and C1-5 alkoxy substituted by halogen, (ii) C3-12 cycloalkyl, and C3-12 cycloalkyl substituted by carbocyclic aryl, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-10 alkyl, C1-10 alkyl substituted by halogen, and C1-9 alkoxy; R2 is selected from the group consisting of: —N(R2a)(R2b), wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is 3,4-dihydro-1H-isoquinolinyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

90. The compound according to any one of claims 75, 88, and 89 wherein p is 1 and T is C1-5 alkyl; R3 and R4 are both hydrogen; and A and B are both single bonds; R5 is hydrogen: or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

91. The compound according to claim 1 selected from the group consisting of: cis-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide; cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarboxamide; cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[3-(trifluoromethyl)benzyl]cyclohexanecarboxamide; cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide; cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxanide; cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-phenylethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxanide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-fluorophenyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide; cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-benzyl-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-fluorobenzyl)cyclohexanecarboxamide; cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethylcyclohexanecarboxamide; cis-N-[(1R)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(2-fluorophenyl)ethyl}cyclohexanecarboxamide; cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1R)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide; cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[1-(4-ciorophenyl)-1-methylethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino)cyclohexanecarboxamide; and cis-N-{1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

92. The compound according to claim 1 selected from the group consisting of: cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-iodobenzyl)cyclohexanecarboxamide; cis-N-(2,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(4-methylbenzyl)cyclohexanecarboxamide; cis-N-(3,5-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,5-dimethoxybenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[3,5-bis(trifluoromethyl)benzyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methoxybenzyl)cyclohexanecarboxamide; cis-N-(4-chlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,4-dichlorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,5-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,3-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(4-bromo-2-fluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(2,4-ifluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-(3-methylbenzyl)cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[2-(trifluoromethoxy)benzyl]cyclohexanecarboxamide; cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methylphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-fluorophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-[1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(4-nitrophenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-(3-methoxyphenyl)cyclohexanecarboxamide; cis-N-(3-chlorophenyl)-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S,2R)-2-phenylcyclopropyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[4-(trifluoromethyl)phenyl]cyclohexanecarboxamide; cis-N-[(1S)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino}-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-N-(3,4-difluorobenzyl)-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(4-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(3-methoxyphenyl)ethyl]cyclohexanecarboxamide; cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1S)-1-(1-naphthyl)ethyl]cyclohexanecarboxamide; cis-N-[(1S)-1-(4-bromophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-((1S)-1-[4-(trifluoromethoxy)phenyl]ethyl}cyclohexanecarboxamide; cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-[(1R)-1-(2-fluorophenyl)ethyl]cyclohexanecarboxamide; cis-N-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[3-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; 4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}-N-{(1S)-1-[2-(trifluoromethyl)phenyl]ethyl}cyclohexanecarboxamide; and cis-N-[(1R)-1-(4-chlorophenyl)ethyl]-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexanecarboxamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

93. The compound according to claim 75 wherein R1 is selected from the group consisting of: (i) C1-16 alkyl, and C1-16 alkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-5 alkyl, and C1-5 alkyl substituted by halogen, (ii) C3-12 cycloalkyl, and C312 cycloalkyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryl, and carbocyclic aryl substituted by halogen, (iii) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-10 alkyl, C1-10 alkyl substituted by halogen, C1-9 alkoxy, C1-9 alkoxy substituted by substituent(s) independently selected from the group consisting of: halogen, and carbocyclic aryl, L is Formula (VII); Y is —C(O)NR5—; R2 is —N(R2a)(R2b) wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

94. The compound according to claim 75 or 93 wherein p is 1 or 2 and each T is independently C1-5 alkyl; R3 is hydrogen; R4 is hydrogen or C1-5 alkyl; A and B are both single bonds; R5 is hydrogen; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

95. The compound according to claim 1 selected from the group consisting of: N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea; N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea; N-1-[3,5-bis(trifluoromethyl)phenyl]-1-methylethyl}-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-[1-(4-chlorophenyl)cyclopropyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2-methoxyphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(3-methoxyphenyl)urea; N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea; N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea; N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2-methylphenyl)urea; N-benzyl-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[2-chloro-6-(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea; N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea; N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea; N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(2-fluorophenyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-[2-(trifluoromethoxy)phenyl]urea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-phenylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

96. The compound according to claim 1 selected from the group consisting of: N-(3,4-dimethoxyphenyl)-N′-(cis-4-{[4-(dimethylamino)-5,6-dimethylpyrimidin-2-yl)amino}cyclohexyl)urea; N-(3-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(3,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(3-methylphenyl)urea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-(4-methylphenyl)urea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-fluorophenyl)-N-methylurea; N′-(cis-4-{[4-dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-fluorophenyl)-N-methylurea; N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(3,4-difluorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(3-methoxyphenyl)-N-methylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-(4-methoxyphenyl)-N-methylurea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-6-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-[1-(4-chlorophenyl)-1-methylethyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(4-fluorophenyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-[2-(trifluoromethoxy)phenyl]urea; N-(4-bromophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2-methylphenyl)urea; N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N′-(2,4,6-trichlorophenyl)urea; N-(2,4-dichlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methylurea; N′-(cis-4-{[4{dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-methyl-N-[2-(trifluoromethoxy)phenyl]urea; N-(4-chlorophenyl)-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea; N-[3,5-bis(trifluoromethyl)phenyl]-N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-phenylurea; N′-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)-N-ethyl-N-(3-methylphenyl)urea; and 1-(2,3-dichloro-phenyl)-3-[cis-4-(4-dimethylamino-5-methyl-pyrimidin-2-ylamino)-cyclohexylmethyl]-urea; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

97. The compound according to claim 75 wherein R1 is selected from the group consisting of: heterocyclyl, and heterocyclyl substituted by substituent(s) independently selected from the group consisting of: carbocyclic aryloxy, carbocyclic aryloxy substituted by substituent(s) independently selected from the group consisting of: halogen, and C1-5 alkoxy, L is Formula (X) or (XI); Y is —C(O)—; R2 is —N(R2a)(R2b) wherein R2a is C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl; heterocyclyl is pyridyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

98. The compound according to claim 75 or 97 wherein p is 1 and T is C1-5 alkyl; R3 and R4 are both hydrogen; A is a single bond and B is —CH2—; or a pharmaceutically acceptable salt, hydrate, or solvate thereof

99. The compound according to claim 75 wherein R1 is selected from the group consisting of: (i) carbocyclic aryl, and carbocyclic aryl substituted by substituent(s) independently selected from the group consisting of: halogen, C1-10 alkyl, and C1-10 alkyl substituted by halogen, (ii) heterocyclyl, L is Formula (VII); and Y is —S(O)2—; R2 is —N(R2a)(R2b) wherein R2a is C1-5 alkyl and R2b is C1-5 alkyl; wherein carbocyclic aryl is phenyl or naphthyl; heterocyclyl is furyl; and halogen is fluoro, chloro, bromo, or iodo; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

100. The compound according to any one of claims 75 or 99 wherein p is 1 and T is C1-5 alkyl; R3 and R4 are both hydrogen, and A and B are both single bonds; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

101. The compound according to claim 1 is: 4-chloro-N-(cis-4-{[4-(dimethylamino)-5-methylpyrimidin-2-yl]amino}cyclohexyl)benzenesulfonamide; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

102. The compound according to claim 1 wherein R1 is selected from hydrogen, —CO2tBu, or —CO2Bn (Bn is a benzyl group); R2 is selected from the group consisting of: hydrogen, halogen, hydroxy, carboxy, carbamoyl, amino, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkyl substituted by hydroxy, C1-5 alkyl substituted by carboxy, C1-5 alkyl substituted by carbamoyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, —N(R2a)(R2b); wherein R2a is hydrogen or C1-5 alkyl and R2b is C1-5 alkyl, C3-6 cycloalkyl, or C1-5 alkyl substituted by substituent(s) independently selected from the group consisting of: halogen, hydroxy, carboxy, carbamoyl, C1-5 alkoxy, amino, and C3-6 cycloalkyl; or R2 is methylamino or dimethylamino when Q is Formula (II); Each T is independently selected from the group consisting of halogen, hydroxy, carboxy, carbamoyl, amino, cyano, nitro, C1-5 alkyl, C1-5 alkyl substituted by halogen, C1-5 alkyl substituted by hydroxy, C1-5 alkyl substituted by carboxy, C1-5 alkyl substituted by carbamoyl, C2-5 alkenyl, C2-5 alkynyl, C3-6 cycloalkyl, C1-5 alkoxy, C1-5 alkoxy substituted by halogen, carbocyclic aryl, heterocyclyl, and —N(R2a)(R2b); p is 0, 1, 2, 3, 4 or 5; L is selected from the group consisting of Formula (VII), (X), (XI), (XV), (XVIII), or (XIX): wherein R3 and R4 are independently hydrogen or C1-5 alkyl; and A and B are independently a single bond or —CH2—; and Y is a single bond; or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

103. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 102 in combination with a pharmaceutically acceptable carrier.

104. A method for the prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103.

105. A method for the prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103.

106. A method for the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy comprising administering to an individual suffering from said condition a therapeutically effective amount of a compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103.

107. A compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103 for use in a method of treatment of the human or animal body by therapy.

108. A compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103 for use in a method of prophylaxis or treatment of an eating disorder, obesity or an obesity related disorder of the human or animal body by therapy.

109. A compound according to any one of claims 1 to 102 or a pharmaceutical composition according to claim 103 for use in a method of prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy of the human or animal body by therapy.

110. A compound according to any one of claims 1 to 102 for the manufacture of a medicament for use in the prophylaxis or treatment of an eating disorder, obesity or obesity related disorders.

111. A compound according to any one of claims 1 to 102 for the manufacture of a medicament for use in the prophylaxis or treatment of anxiety, depression, schizophrenia, addiction, or epilepsy.

112. A method of producing a pharmaceutical composition comprising admixing a compound according to any one of claims 1 to 102 and a pharmaceutically acceptable carrier.